

Medical Control Board

Treatment Protocols

for

EMS System for Metropolitan Oklahoma City & Tulsa





#### **Preface**

Patients for whom EMS is summoned, EMS professionals providing life-sustaining and life-saving care, EMS professionals supporting field care through dispatch, education, quality improvement, and administrative leadership, and EMS physicians supporting all aspects of EMS through clinical leadership all deserve the finest clinical treatment protocols available. This protocol set was developed in that exact spirit to achieve that exact mission.

While no single set of EMS protocols can prove exhaustive, this particular compilation of protocols reflects essential care for the wide spectrum of patient ages, conditions, and acuities encountered by EMS professionals in metropolitan Oklahoma City and Tulsa. For 2025, we continue to incorporate an analysis of the peer-reviewed, published medical research within the past year so that our protocols remain current and evidenced-based. This set reflects that even the research of note over the past 12 months doesn't mandate tangible changes at this time, though additional advances are certainly on the horizon. This 2025 set continues to include every protocol identified as essential by the National Association of State EMS Officials.

Protocols are sectioned in easy to anticipate groupings (e.g. airway, cardiac arrest, trauma) and are formatted for brevity whenever possible. When appropriate, flowchart algorithms are utilized for easy to read care directives. Extensive use of pictures and diagrams are included in procedural protocols to promote clarity of understanding and accuracy of performance. Scopes of practice by EMS certification/licensure are clearly designated and use of color coding by scope of practice is consistent throughout all protocols.

With the exception of non-traumatic cardiac arrest, wherein patient return of spontaneous circulation is most often dependent upon effective, immediate interventions on scene, transport should be initiated as soon as possible.

EMS professionals should never perform emergency medical care outside of their individual scope of practice established by professional medical training, certification/licensure, and as credentialed by the Medical Control Board/Office of the Medical Director. When encountering patient conditions requiring care unspecified in these protocols, seek appropriate direction from on-line medical control, always delivering care with prudence and reasonable regard for safety of the patient, peers, and the public.

When possible, medication alternatives are indicated in these protocols in light of current and anticipated future medication supply shortages affecting EMS systems throughout the United States.

The Medical Control Board/Office of the Medical Director protocols development team has taken exhaustive efforts in developing and reviewing these protocols for accuracy. Despite every human effort, unintended typographical errors may persist. EMS professionals are directed to always deliver care with the highest regard for patient safety and when questions arise to care directives, care sequences, and/or medication selections and dosages, answers should be sought via on-line medical control during real-time patient care and via the Chief Medical Officers/OMD personnel during protocol training and review events.

In addition to this "Reference Edition" of these protocols, a "Field Edition" can be found at the Medical Control Board/Office of the Medical Director website (www.okctulomd.com). The Field Edition excludes the extensive medical literature references organized by individual protocol that reflect the evidence-based medicine used in protocol development in an effort to make the field edition more usable as a real-time clinical care resource.

It is the sincere hope that these protocols will guide EMS professionals serving metropolitan Oklahoma City and Tulsa in achieving the best clinical outcome possible for each and every patient receiving their dedicated care.





### **Index** of **Protocols**

### SECTION 1 GENERAL ASSESSMENT & GENERAL SUPPORTIVE CARE

- 1A Medical General Assessment Adult & Pediatric
- 1B Trauma General Assessment Adult & Pediatric
- 1C General Supportive Care Adult & Pediatric
- 1D Trauma and Hypovolemic Shock Supportive Care Adult & Pediatric
- 1E Neonatal Resuscitation- Pediatric

#### SECTION 2 AIRWAY

- 2A Airway Assessment Adult & Pediatric
- 2B Airway Establishment/Obstruction Management Adult & Pediatric
- 2C Airway Suctioning Adult & Pediatric
- 2D Bag Valve Mask (BVM) Management Adult & Pediatric
- 2E Supraglottic Airways Adult & Pediatric
- 2F Oral Intubation Adult
- 2G Medication Assisted Intubation Adult
- 2H Nasal Intubation Adult
- 2I Cricothyrotomy Adult
- 2] Confirmation of Endotracheal Airway Placement Adult & Pediatric
- 2K Laryngectomy/Tracheostomy Management Adult & Pediatric

### SECTION 3 PULMONARY/RESPIRATORY

- 3A Respiratory Arrest Adult & Pediatric
- 3B Dyspnea Uncertain Etiology Adult & Pediatric
- 3C Dyspnea Asthma Adult & Pediatric
- 3D Dyspnea Chronic Obstructive Pulmonary Disease (COPD) Adult
- 3E Dyspnea Congestive Heart Failure (CHF) Adult & Pediatric
- 3F Dyspnea Brief Resolve Unexplained Event (BRUE) Pediatric
- 3G Pulse Oximetry Adult & Pediatric
- 3H Waveform Capnography Adult & Pediatric
- 3I Oxygen Administration Adult & Pediatric
- 3J Nebulization Therapy Adult & Pediatric
- 3K Non-Invasive Positive Pressure Ventilation (NIPPV) Adult
- 3L Mechanical Ventilation Adult
- 3M Acute Dyspnea Croup Pediatric



**SECTION 5** 

# EMS System for Metropolitan Oklahoma City and Tulsa 2025 Medical Control Board Treatment Protocols



### **Index** of **Protocols**

#### **SECTION 4 CARDIAC ARREST**

4A	Resuscitation (CPR) – Adult & Pediatric
4B	Resuscitation Team Roles - Adult & Pediatric
4C	Automated External Defibrillation (AED) - Adult & Pediatric
4D	Manual Defibrillation – Adult & Pediatric
4E	Double Sequential External Defibrillation - Adult
4F	Asystole– Adult & Pediatric
4G	Ventricular Fibrillation/Pulseless Ventricular Tachycardia –
	Adult & Pediatric
4H	Pulseless Electrical Activity (PEA) – Adult & Pediatric
4I	Specific Causes of Cardiac Arrest – Adult & Pediatric
4J	Post Cardiac Arrest Treatment – Adult & Pediatric
4K	"Do Not Resuscitate"/Advanced Directive Orders, Futility of
	Resuscitation Initiation & Termination of Resuscitation –
	Adult & Pediatric
4L	Intra-Arrest Wakefulness - Adult
4M	Active Compression Decompression CPR - Adult
4N	EleGARD Head UP CPR - Adult
CARI	DIAC (NON-ARREST)
5A	Chest Pain – Uncertain Etiology – Adult & Pediatric
5B	Acquiring & Transmitting 12-Lead ECGs – Adult & Pediatric
5C	Acute Coronary Syndrome – Adult
5D	Bradycardia – Adult & Pediatric
5E	Transcutaneous Pacing – Adult & Pediatric
5F	Tachycardia – Stable – Adult & Pediatric
5G	Tachycardia – Unstable – Adult & Pediatric
5H	Synchronized Cardioversion – Adult & Pediatric
5I	Implantable Pacemaker Management – Adult & Pediatric
5J	Implantable Cardioverter/Defibrillator (ICD) Management –
٥,	Adult & Pediatric
5K	Premature Ventricular Contractions – Adult & Pediatric
5L	Hypertensive Emergency – Adult & Pediatric
5M	Ventricular Assist Device (VAD) Management – Adult
5N	Intra-Aortic Balloon Pump (IABP) Monitoring – Adult
50	Zoll Lifevest Wearable Defibrillator
_ 0	
MITTI	DOLOGIC / ALTERED MENTAL CTATUS

#### SECTION 6 NEUROLOGIC/ALTERED MENTAL STATUS

- 6A Stroke - Adult & Pediatric Altered Mental Status - Adult & Pediatric 6B
- Glucometry (Blood Glucose Determination) 6C
- Seizure Adult & Pediatric 6D





### **Index** of **Protocols**

SECTION 6	NEUROLOGIC/ALTERED MENTAL STATUS (CONTINUED)
	6E Syncope – Adult & Pediatric 6F Dystonic Reactions – Adult & Pediatric
SECTION 7	PSYCHIATRIC/BEHAVIORAL DISORDERS
	<ul> <li>7A Behavioral Disorder - Adult &amp; Pediatric</li> <li>7B Physical Restraint - Adult &amp; Pediatric</li> <li>7C Chemical Restraint - Adult &amp; Pediatric</li> <li>7D Emergency Mental Hold Issues - Adult &amp; Pediatric</li> </ul>
SECTION 8	TOXICOLOGIC/POISONINGS
	Poisonings – General Management – Adult & Pediatric  Toxidromes – Adult & Pediatric  Oklahoma Poison Control Center Use  Acute Allergic Reactions – Adult & Pediatric  Snakebites Pit Vipers (Rattlesnakes, Copperheads, & Mocassins)  (Crotalinae Envenomation) – Adult & Pediatric  Bee/Wasp Stings & Fire Ant Bites  (Hymenoptera Envenomation) – Adult & Pediatric  Hazardous Materials Response  Hydrofluoric Acid – Adult & Pediatric
SECTION 9	MEDICAL
	<ul> <li>Abdominal Pain/Nausea/Vomiting/Diarrhea - Adult &amp; Pediatric</li> <li>Sepsis - Adult &amp; Pediatric</li> <li>Epistaxis - Adult &amp; Pediatric</li> <li>Pain Management (Acute Onset &amp; Chronic Type) - Adult &amp; Pediatric</li> <li>Dialysis-Related Issues - Adult &amp; Pediatric</li> </ul>





### **Index** of **Protocols**

9F	Infectious Disease Precaution Recommendations – EMS Professionals
9G	Post-Exposure Prophylaxis Recommendations – Adult & Pediatric
9H	Vascular Access – Intravenous – Adult & Pediatric
9I	Vascular Access – Intraosseous – Adult & Pediatric
9J	Indwelling Central Vascular Device Management - Adult & Pediatric
9K	Medication Administration - Adult & Pediatric
	9Ka – Intravenous/Intraosseous – Adult & Pediatric
	9Kb – Intramuscular/Subcutaneous– Adult & Pediatric
	9Kc – Intranasal – Adult & Pediatric
	9Kd – Sublingual/Oral – Adult & Pediatric
	9Ke – Intraocular – Adult & Pediatric
	9Kf – Intravascular Infusion Management – Adult & Pediatric
9L	Nasogastric/Orogastric Tube- Adult
9M	Suspected Abuse/Neglect - Adult & Pediatric

### SECTION 10 TRAUMA

10A	Head/Neck/Spine Injury - Adult & Pediatric
10B	Eye Injury – Adult & Pediatric
10C	Dental Injury/Pain - Adult & Pediatric
10D	Chest/Abdomen/Pelvis Injury - Adult & Pediatric
10E	Needle Thoracostomy (Tension Pneumothorax Decompression) -
	Adult & Pediatric
10F	Chest Tube Monitoring - Adult & Pediatric
10G	Extremity/Amputation Injury - Adult & Pediatric
10H	Tourniquet - Adult & Pediatric
10I	Hemostatic Agents – Adult & Pediatric
10J	Compartment Syndrome - Adult & Pediatric
10K	Crush Injury Syndrome - Adult & Pediatric
10L	Burns – Adult & Pediatric
10M	Conductive Energy Weapon Related Management - Adult & Pediatric
10N	"Less Lethal" Weapon Related Management - Adult & Pediatric
100	Splinting of Injuries – Adult & Pediatric
	100a – Spinal Motion Restriction – Adult & Pediatric
	100b – Extremity – Adult & Pediatric
10P	Blast Injury – Adult & Pediatric
10Q	Field Amputation





### **Index** of **Protocols**

#### SECTION 11 ENVIRONMENTAL

- 11A Heat Illness Adult & Pediatric
- 11B Cold Illness/Injury Adult & Pediatric
- 11C Electrical/Lightning Injury Adult & Pediatric
- 11D Water Submersion Events Adult & Pediatric
- 11 E Heat Stroke Athletic Participants with Field Cooling Capabilities On-Site at Events

#### SECTION 12 FIREGROUND-RELATED

- 12A Fireground Rehabilitation Concepts Adult
- 12B Smoke Inhalation Adult & Pediatric
- 12C Carbon Monoxide Adult & Pediatric
- 12D Hyperbaric Oxygen Therapy Considerations Adult & Pediatric
- 12E Cyanide Adult & Pediatric

### SECTION 13 OBSTETRIC/GYNECOLOGIC

- 13A Childbirth Routine
- 13B Childbirth Complicated
- 13C Vaginal Bleeding/Discharge Adult & Pediatric
- 13D Complications of Pregnancy Adult
- 13E Pelvic Pain Adult & Pediatric
- 13F Alleged Sexual Assault Adult & Pediatric

### SECTION 14 RESPONSE, SCENE ISSUES & PATIENT TRANSPORTATION

- 14A Staging Considerations
- 14B Actions to Preserve Crime Scenes
- 14C Other Health Care Professionals on Scene
- 14D Informed Patient Consent/Refusal
- 14E On-Line Medical Control Physicians
- 14F Helicopter EMS (HEMS) Considerations
- 14G Patient Prioritization
- 14H Radio Report Communications
- 14I Interhospital Transfers
- 14J Scene Coordination





### **Index** of **Protocols**

### SECTION 15 MASS CASUALTY/DISASTER/TERRORIST EVENTS

Multiple Patient Scenes/Mass Casualty Event Concepts 15A Regional EMS System (REMSS) Activation Procedure 15B 15C **Chemical Weapons** ChemPack Deployment Activation Procedure 15D Nerve Agents 15E 15F **Biological Weapons** 15Fa Suspicious Powder Response Procedure Radiological Weapons 15G **Nuclear Weapons** 15H

### SECTION 16 FORMULARY

16A	Activated Charcoal
16B	Adenosine (Adenocard®)
16C	Albuterol (Proventil®, Ventolin®)
16D	Amiodarone (Cordarone®, Nexterone®)
16E	Aspirin
16F	Atropine Sulfate
16G	Calcium Chloride
16H	Dextrose (50% as D50 and 25% as D25 and 10% as D10)
16I	Diazepam (Valium®)
16J	Diltiazem (Cardizem®)
16K	Diphenhydramine (Benadryl®)
16L	Dopamine (Intropin®)
16M	DuoDote® Auto-Injector
16N	Epinephrine 1:1,000 & 1:10,000
160	Epinephrine Auto-Injector (Epipen®, Auvi-Q®)
16P	Etomidate (Amidate®)
16Q	Fentanyl (Sublimaze®)
16R	Glucagon
16S	Glucose (Oral)
16T	Haloperidol (Haldol®)





		Index of Protocols				
SECTION 16		FORMULARY (CONTINUED)				
	16U	Hydralazine (Apresoline®)				
	16V	Hydromorphone (Dilaudid®)				
		Hydroxocobalamin (CyanoKit®)				
		Ipratropium Bromide (Atrovent®)				
		Labetalol (Normodyne®, Trandate®)				
	16Z	Lidocaine 2% Intravascular (Xylocaine®)				
		Lidocaine Viscous Gel (Xylocaine®)				
		Lorazepam (Ativan®) Magnesium Sulfate				
		Methylprednisolone (Solu-Medrol®)				
		Midazolam (Versed®)				
		Morphine Sulfate				
		Naloxone (Narcan®)				
		Nitroglycerin – Nitroglycerin (Nitrolingual®, Nitromist®, Nitrostat®,				
		Nitroquick <sup>®</sup> , Tridil (IV Infusion), Nitro-Bid <sup>®</sup> - Dermal)				
	16II	Norepinephrine (Levophed®)				
	16JJ	Ondansetron (Zofran®)				
	16KK	Phenylephrine 2% (NeoSynephrine®)				
	16LL Pralidoxime Chloride (2-PAM)					
	16MM Sodium Bicarbonate					
	16NN	Calcium Gluconate				
	1600	Dexamethasone				
	16PP	Levalbuterol (Xopenex®)				
SECTION 17	RESEI	RVED FOR AGENCY SPECIFIC USE				
02011011.27	112021					
	17A	MCB: Destination Determination				
	17B	MCB: Table: Categorization of Hospitals				
	17C	MCB: EMS Diversion from Hospitals				
	17D	MCB: "No Fly Zones"				
	17E	MCB: Advanced Airway Management: Pediatric Oral Intubation				
	17F	MCB: Medication-Assisted Intubation – Pediatric				
	17G	MCB: Confirmation of Endotracheal Airway Placement – Pediatric				
	17H	MCB: Helmet Removal				
	17I	MCB: Controlled Substance Handling & Documentation – Field Paramedics				
	17J	MCB: Seasonal Influenza Vaccine Administration				
	17K	MCB: Tranexamic Acid (TXA) Formulary				
	17L	MCB: Positive End Expiratory Pressure (PEEP)				
	17M	MCB: Blood Sample Collection For Law Enforcement Adult & Pediatric MCB: Interim Guidance for Covid-19 Vaccine Administration				
	17N	MCB: Interim Guidance for Covid-19 Vaccine Administration				

MCB: Low Titer O+ Whole Blood (LTOWB) Metropolitan Oklahoma City

170





### **Index** of **Protocols**

### SECTION 18 RESERVED FOR AGENCY SPECIFIC USE - PILOT PROGRAMS/RESEARCH

### SECTION 19 APPENDICES

- 19A Approved Abbreviations
- 19B Oklahoma State Department of Health Communicable Disease Risk Exposure Report, OSDH 207
- 19C Oklahoma Model Trauma Triage Algorithm, Adult & Pediatric
- 19D Sample Fireground Rehabilitation Policies Tulsa Fire Department; Oklahoma City Fire Department





Approved 9/04/24, Effective 1/15/25, replaces all prior versions

### 1A – MEDICAL GENERAL ASSESSMENT ADULT & PEDIATRIC

### TREATMENT PRIORITIES

- Assessment:
  - ➤ SCENE SAFETY
- **▶PROTECTIVE EQUIPMENT**
- ➤ Primary Survey
- ➤ Secondary Survey (when appropriate)
- 2. Primary Survey Care:
  - >Initiate cardiopulmonary resuscitation if indicated
  - ➤Open airway
  - ➤ Support oxygenation/ventilation
  - >Support circulation Dysrhythmia care? Rate control?
    Hypotension care?
- 3. Minimize scene time in critical case unless working cardiac arrest
- 4. Enroute Care:
  - ➤ Reassess all primary care
  - ➤ Support oxygenation/ventilation
  - ➤ Vascular access
  - ➤ Secondary Survey (if able)
  - >Keep patient warm/avoid hypothermia
- 5. Hospital per destination protocol..

In general, approach the assessment of medical (non-trauma) patients, in A-B-C order:

**Airway**: Evaluate the patency and mechanics of the airway. Is the patient able to oxygenate and ventilate? Rapid intervention may be required during the assessment phase if airway patency and protection is compromised.

**Breathing:** Expose the chest as required to accurately assess the mechanics of respiration (taking into account patient privacy/modesty if in public location). Note the rate, depth, and pattern of respirations and if any degree of respiratory distress or effort. Auscultate breath sounds bilaterally.

Liberally obtain pulse oximetry readings and in patients with respiratory difficulties, waveform capnography readings (if equipped, \*\*Mandatory use if the patient is intubated).

**Circulation:** The adequacy of a patient's circulation is best assessed first by evaluating their level of consciousness and mental status. Next assess the location, rate, and character of the pulse. Then check a blood pressure – preferably, manually for at least the first reading. Apply the cardiac monitor (if equipped) liberally.

Cardiac Arrest is an exception to the above order. Aggressively initiate chest compressions and search for shockable rhythms at the appropriate intervals per Section 4 protocols.





Approved 9/04/24, Effective 1/15/25, replaces all prior versions

### Protocol 1A: Medical General Assessment – Adult & Pediatric, cont.

Many treatment decisions regarding airway management involve calculating the adult patient's Glasgow Coma Scale score using the following table:

Eyes Open		Best Motor Response		Best Verbal Response	
Spontaneously	4	Obeys verbal orders	6	Oriented, conversant	-
To command	3	Localizes painful stimuli	5	Disoriented, conversant	4
To pain	2	Withdraws	4	Inappropriate words	3
No response	1	Painful stimulus, flexion	3	Inappropriate sounds	1
		Painful stimulus, extension	2	No response	1
7		No response	1		
				Maximum 15 points	

After addressing the A-B-C order in most medical patients, including evaluating and addressing any life-threatening conditions, minimize scene time and initiate timely transport to an appropriate emergency department in any setting of a time-sensitive medical condition.

Complete a head-to-toe assessment of the patient if the patient is relatively medically stable. Obtain relevant history of past and current medical problems, medications, allergies, and physicians/hospitals used in care plans to help guide further assessment.

Reassess patients frequently, typically at least every 10 minutes, and more often if critical illness is discovered and being treated. In the situations of an unstable patient, vital signs should be assessed every 5 minutes, especially if hemodynamic changes are occurring.

Assess and treat per symptom or illness specific protocols that follow in this protocol set.

# Pediatric ("Pediatric" equals less than 18 years of age for all protocols unless specified) Assessment Comments:

1. Pediatric respiratory distress may look just like adult respiratory distress, presenting with:

slowing respirations cyanosis accessory muscle use pallor

nasal flaring lethargy/listlessness

retractions – intercostal or subcostal irritability tachypnea stridor mottling grunting





Approved 9/04/24, Effective 1/15/25, replaces all prior versions

### Protocol 1A: Medical General Assessment - Adult & Pediatric, cont.

2. Vital signs vary with age. In general, the younger the patient, the faster the respiratory rate, the faster the heart rate, and the lower the blood pressure:

AGE	HEART RATE (BPM)	RESP. RATE (BPM)	SYSTOLIC BP (mmHg)
Premature	100-190	40-60	
Neonate	90-190	30-60	50-70
6 months	80-180	25-40	60-110
1 year	80-150	20-40	70-110
3-4 years	80-140	20-30	80-115
5-6 years	70-120	20-25	80-115
7-8 years	70-110	20-25	85-120
11-12 years	60-110	15-20	95-135

The average normal systolic BP can also be estimated by:  $80 + (2 \times age)$  in years. Lower limits of normal systolic BP can also be estimated by:  $70 + (2 \times age)$  in years.

3. The following table can be used to calculate Glasgow Coma Scale scores in pediatric patients, especially those under 4 years of age. Most pediatric patients above the age of 4 years will be able to be assessed for Glasgow Coma Scale scores using the adult table.

Pediatric Glasgow Coma Scale Scores

Points*	Best eye	Best verba	Best Motor	
6	Q+.**		obeys	
5		localizes pain		
-7		Crying	Interaction	
4	spontaneous	consolable	inappropriate	withdraws to pain
3	3 to speech inconsistently consolable moani		moaning	flexion (decorticate)
2	2 to pain inconsolable restless		extensor (decerebrate)	
1	none	none none		none

\* Range of total points: 3 (worst) to 15 (normal)





# Medical Literature References 1A – Medical General Assessment – Adult & Pediatric

- Travers AH, Perkins GD, Berg RA, Castren M, Considine J, Escalante R, Gazmuri RJ, Koster RW, Lim SH, Nation KJ, Olasveengen TM, Sakamoto T, Sayre MR, Sierra A, Smyth MA, Stanton D, Vaillancourt C; Basic Life Support Chapter Collaborators. Part 3: Adult Basic Life Support and Automated External Defibrillation: 2015 International Consensus on Cardiopulmonary Resuscitation and Emergency Cardiovascular Care Science With Treatment Recommendations. *Circulation*. 2015 Oct 20;132(16 Suppl 1):S51-83.
- Callaway CW, Soar J, Aibiki M, Böttiger BW, Brooks SC, Deakin CD, Donnino MW, Drajer S, Kloeck W, Morley PT, Morrison LJ, Neumar RW, Nicholson TC, Nolan JP, Okada K, O'Neil BJ, Paiva EF, Parr MJ, Wang TL, Witt J; Advanced Life Support Chapter Collaborators. Part 4: Advanced Life Support: 2015 International Consensus on Cardiopulmonary Resuscitation and Emergency Cardiovascular Care Science With Treatment Recommendations. *Circulation*. 2015 Oct 20;132(16 Suppl 1):S84-145.
- Welsford M, Nikolaou NI, Beygui F, Bossaert L, Ghaemmaghami C, Nonogi H, O'Connor RE, Pichel DR, Scott T, Walters DL, Woolfrey KG; Acute Coronary Syndrome Chapter Collaborators.
   Part 5: Acute Coronary Syndromes: 2015 International Consensus on Cardiopulmonary Resuscitation and Emergency Cardiovascular Care Science With Treatment Recommendations.
   *Circulation*. 2015 Oct 20;132(16 Suppl 1):S146-76.
- 4. Lavonas EJ, Drennan IR, Gabrielli A, Heffner AC, Hoyte CO, Orkin AM, Sawyer KN, Donnino MW. Part 10: Special Circumstances of Resuscitation: 2015 American Heart Association Guidelines Update for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. *Circulation*. 2015 Nov 3;132(18 Suppl 2):S501-18.
- de Caen AR, Maconochie IK, Aickin R, Atkins DL, Biarent D, Guerguerian AM, Kleinman ME, Kloeck DA, Meaney PA, Nadkarni VM, Ng KC, Nuthall G, Reis AG, Shimizu N, Tibballs J, Veliz Pintos R; Pediatric Basic Life Support and Pediatric Advanced Life Support Chapter Collaborators. Part 6: Pediatric Basic Life Support and Pediatric Advanced Life Support: 2015 International Consensus on Cardiopulmonary Resuscitation and Emergency Cardiovascular Care Science With Treatment Recommendations. *Circulation*. 2015 Oct 20;132(16 Suppl 1):S177-203.
- 6. Murphy MF, Walls RM. Identification of the Difficult Airway. In Walls RM, Murphy MF, eds. Manual of Emergency Airway Management. Philadelphia, PA: Lippincott Williams & Wilkins, pp. 81-93, 2008.





Approved 9/04/24, Effective 1/15/25, replaces all prior versions

#### **1B - TRAUMA GENERAL ASSESSMENT ADULT & PEDIATRIC**

#### TREATMENT PRIORITIES Assessment: ➤ SCENE SAFETY >PROTECTIVE EQUIPMENT ▶Primary Survey >"Trauma Alert" to receiving ED if indicated Secondary Survey (when appropriate) 2. Primary Survey Care Control arterial bleeding ➤Open airway ➤ Seal "sucking" chest wound(s) > Needle thoracostomy for closed chest tension pneumothorax Minimize scene time in critical case. 4. Enroute Care: ➤ Reassess all primary care

- ➤ Support oxygenation/ventilation
- ➤Vascular access
- ➤ Secondary Survey (if able) ➤ Keep patient warm/avoid hypothermia
- Hospital per destination protocol..

Before entering any trauma scene, ensure your personal safety. Do not attempt patient contact until hazards can be appropriately mitigated. In addition to scene safety, factor mechanisms of injury, number of patients, and special equipment/extrication needs.

All trauma patients should be assessed utilizing primary, secondary, and reassessment surveys.

The **primary survey** is to be conducted on all trauma patients. It is designed to rapidly identify lifethreatening or potentially life-threatening injuries. The primary survey should be completed within 2 minutes of patient contact. THE PRIMARY SURVEY IS ONLY INTERRUPTED FOR LIFE-THREATENING ARTERIAL BLEEDING, AIRWAY OBSTRUCTION, OR RESPIRATORY/CARDIAC ARREST. The following are the steps of the **primary survey**:

- 1) Manually stabilize the cervical spine while assessing the airway and level of consciousness.
- 2) Evaluate breathing present? rapid? normal? slow? shallow?
- 3) Evaluate circulation carotid and radial pulses? Control external hemorrhage.
- 4) Exam the head for deformity, contusions, abrasions, penetrations, burns, lacerations, or swelling ("DCAP-BLS").
- 5) Exam the neck for deformity, contusions, abrasions, penetrations, burns, lacerations, swelling ("DCAP-BLS"), or subcutaneous emphysema.
- 6) Exam the chest for deformity, contusions, abrasions, penetrations, burns, lacerations, swelling ("DCAP-BLS"), or paradoxical movement.
- 7) Auscultate the chest for breath sounds in the mid-axilla bilaterally present? equal?
- 8) Exam the abdomen and pelvis for deformity, contusions, abrasions, penetrations, burns, lacerations, or swelling ("DCAP-BLS").
- 9) Exam the extremities for deformity, contusions, abrasions, penetrations, burns, lacerations, or swelling ("DCAP-BLS"), and pulse, movement, sensation.





Approved 9/04/24, Effective 1/15/25, replaces all prior versions

#### Protocol 1B: Trauma General Assessment - Adult & Pediatric, cont.

Primary survey interventions include airway management (See Section 2 Protocols – Airway), sealing open chest wounds, needle thoracostomy for suspected tension pneumothorax (See Protocol 10E – Needle Thoracostomy), oxygen administration and controlling any obvious external hemorrhage. Remember to expose the patient as needed to conduct an appropriate exam.

Any trauma patient with altered level of consciousness, abnormal respiration, abnormal circulation, or signs/conditions likely to lead to shock (distended abdomen, pelvic instability, bilateral femur fractures) should be rapidly immobilized and transported after completing the primary survey. These are "LOAD & GO" patients.

The **secondary survey** is always done enroute on critical patients. If no critical conditions are found in the primary survey, the secondary survey may be conducted on the scene and should be completed within 5 minutes after the primary survey is completed. The following are the steps of the **secondary survey**:

- 1) Obtain vital signs (pulse, respiratory rate, blood pressure, pulse oximetry)
- 2) Obtain history of traumatic event and pertinent patient medical history (allergies, medications, past illness/injury, last oral intake)
- 3) Head to toe exam look for "DCAP-BLS" in every body area. Calculate GCS score
- 4) Perform indicated bandaging and splinting

The **reassessment survey** is an abbreviated exam after interventions and done at least every five minutes for critical patients (and approximately every ten minutes for non-critical patients). The following are the steps of the **reassessment survey**:

- 1) Repeat the primary survey
- 2) Repeat vital signs
- 3) Repeat GCS score calculation
- 4) Check every intervention proper placement of intubation? Proper placement of IV/IO?
- 5) Check results of every intervention improved oxygenation/ventilation? Improved blood pressure?

Pediatric ("Pediatric" equals less than 18 years of age for all protocols unless specified) trauma assessment mirrors adult strategies above.





# Medical Literature References 1B – Trauma General Assessment – Adult & Pediatric

- Lavonas EJ, Drennan IR, Gabrielli A, Heffner AC, Hoyte CO, Orkin AM, Sawyer KN, Donnino MW. Part 10: Special Circumstances of Resuscitation: 2015 American Heart Association Guidelines Update for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. *Circulation*. 2015 Nov 3;132(18 Suppl 2):S501-18.
- Sasser SM, Hunt RC, Faul M, Sugerman D, Pearson WS, Dulski T, Wald MM, Jurkovich GJ, Newgard CD, Lerner EB; Centers for Disease Control and Prevention (CDC). Guidelines for field triage of injured patients: recommendations of the National Expert Panel on Field Triage, 2011. MMWR Recomm Rep. 2012 Jan 13;61(RR-1):1-20.
- 3. Wigginton JG, Roppolo L, Pepe PE. Advances in resuscitative trauma care. *Minerva Anestesiol.* 2011 Oct;77(10):993-1002.
- 4. Murphy MF, Walls RM. Identification of the Difficult Airway. In Walls RM, Murphy MF, eds. Manual of Emergency Airway Management. Philadelphia, PA: Lippincott Williams & Wilkins, pp. 81-93, 2008.
- 5. Badjatia N, Carney N, Crocco TJ, Fallat ME, Hennes HM, Jagoda AS, Jernigan S, Letarte PB, Lerner EB, Moriarty TM, Pons PT, Sasser S, Scalea T, Schleien CL, Wright DW; Brain Trauma Foundation; BTF Center for Guidelines Management. Guidelines for prehospital management of traumatic brain injury 2nd edition. *Prehosp Emerg Care*. 2008;12Suppl 1:S1-52.
- 6. Shibahashi, K., Sugiyama, K., & Hamabe, Y. (2020). Pediatric Out-of-Hospital Traumatic Cardiopulmonary Arrest After Traffic Accidents and Termination of Resuscitation. Annals of Emergency Medicine, 75(1), 57–65.





Approved 9/04/24, Effective 1/15/25, replaces all prior versions

# 1C - GENERAL SUPPORTIVE CARE ADULT & PEDIATRIC

#### TREATMENT PRIORITIES

- 1. Assessment:
  - > SCENE SAFETY
  - ▶ PROTECTIVE EQUIPMENT
  - > ABCs unless cardiac arrest
  - ➤ CAB if cardiac arrest
  - ➤ Early vital signs
- Get best history possible
- Evaluate/treat underlying medical cause per protocol(s)
- Early transport & ED notification for patients with time sensitive conditions (Resp Failure, STEMI, Stroke)

### EMD

IF CHIEF COMPLAINT IS <u>MEDICAL</u> IN NATURE, CHOOSE THE PROTOCOL THAT BEST FITS THE PATIENT'S FOREMOST SYMPTOMS, WITH PRIORITY SYMPTOMS TAKING PRECEDENCE

QUESTIONS TO ADDRESS SCENE SAFETY ISSUES

### EMERGENCY MEDICAL DISPATCHER

EMERGENCY MEDICAL RESPONDER

**EMT** 

**EMT-INTERMEDIATE 85** 

**ADVANCED EMT** 

**PARAMEDIC** 

EMR EMT

AIRWAY MANAGEMENT SUPPORT OXYGENATION/VENTILATION

**OBTAIN VITAL SIGNS** 

APPLY CARDIAC MONITOR/OBTAIN 12-LEAD ECG (when indicated & if equipped)
TRANSMIT 12-LEAD ECG TO RECEIVING HOSPITAL
MONITOR END – TIDAL CO<sub>2</sub> & WAVEFORM CAPNOGRAPHY
(when indicated & if equipped, \*\*Mandatory use if pt intubated)

ASSIST PT WITH PT'S OWN MEDICATION IF DIRECTED BY PROTOCOL(S)

DETERMINE BLOOD GLUCOSE/TREAT HYPOGLYCEMIA PER PROTOCOL

EMT-185 AEMT

INTUBATE IF INDICATED

IV/IO ACCESS IF INDICATED
FLUID BOLUS AS DIRECTED BY SPECIFIC MEDICAL PROTOCOL(S)

MEDICATION ADMINISTRATION PER SPECIFIC MEDICAL PROTOCOL(S)

#### **PARAMEDIC**

CONTINUOUS TREATMENT AND ASSESSMENT PER SPECIFIC MEDICAL PROTOCOL(S) INTERPRETATION OF 12-LEAD ECGS (when indicated & if equipped)

#### Clinical Operational Notes (All Field Provider Levels):

- 1. The practice of EMS medicine is built upon the foundation of "taking medical care to the patient". To achieve this objective, appropriate equipment (airway equipment kit, med/trauma equipment kit, suction device, AED/Cardiac Monitor/Defibrillator, patient packaging equipment) should be brought to the patient's side per Protocol 14J Scene Coordination to minimize critical treatment delays.
- 2. Minimize active movement on the patient's part in settings of suspected myocardial ischemia, stroke, and dyspnea. Move and package the patient for transport with safety considerations for all involved.
- 3. Maximum pediatric medication dosing equals standard adult dosing.





# Medical Literature References 1C – General Supportive Care – Adult & Pediatric


- Cicero, M. X., Adelgais, K., Hoyle, J. D., Lyng, J. W., Harris, M., Moore, B., & Gausche-Hill, M. (2020). Medication Dosing Safety for Pediatric Patients: Recognizing Gaps, Safety Threats, and Best Practices in the Emergency Medical Services Setting. A Position Statement and Resource Document from NAEMSP. *Prehospital Emergency Care*, 25(2), 294–306. https://doi.org/10.1080/10903127.2020.1794085
- Self, W. H., Semler, M. W., Wanderer, J. P., Wang, L., Byrne, D. W., Collins, S. P., ... Rice, T. W. (2018). Balanced Crystalloids versus Saline in Noncritically III Adults. New England Journal of Medicine. https://doi.org/10.1056/NEJMoa1711586.
- 3. Semler, M. W., Self, W. H., Wanderer, J. P., Ehrenfeld, J. M., Wang, L., Byrne, D. W., ... Rice, T. W. for the S. I. and the P. C. C. R. G. (2018). Balanced Crystalloids versus Saline in Critically III Adults. New England Journal of Medicine. https://doi.org/10.1056/NEJMoa1711584.
- 4. Lavonas EJ, Drennan IR, Gabrielli A, Heffner AC, Hoyte CO, Orkin AM, Sawyer KN, Donnino MW. Part 10: Special Circumstances of Resuscitation: 2015 American Heart Association Guidelines Update for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. *Circulation*. 2015 Nov 3;132(18 Suppl 2):S501-18.
- Travers AH, Perkins GD, Berg RA, Castren M, Considine J, Escalante R, Gazmuri RJ, Koster RW, Lim SH, Nation KJ, Olasveengen TM, Sakamoto T, Sayre MR, Sierra A, Smyth MA, Stanton D, Vaillancourt C; Basic Life Support Chapter Collaborators. Part 3: Adult Basic Life Support and Automated External Defibrillation: 2015 International Consensus on Cardiopulmonary Resuscitation and Emergency Cardiovascular Care Science With Treatment Recommendations. *Circulation*. 2015 Oct 20;132(16 Suppl 1):S51-83.
- Callaway CW, Soar J, Aibiki M, Böttiger BW, Brooks SC, Deakin CD, Donnino MW, Drajer S, Kloeck W, Morley PT, Morrison LJ, Neumar RW, Nicholson TC, Nolan JP, Okada K, O'Neil BJ, Paiva EF, Parr MJ, Wang TL, Witt J; Advanced Life Support Chapter Collaborators. Part 4: Advanced Life Support: 2015 International Consensus on Cardiopulmonary Resuscitation and Emergency Cardiovascular Care Science With Treatment Recommendations. *Circulation*. 2015 Oct 20;132(16 Suppl 1):S84-145.
- Welsford M, Nikolaou NI, Beygui F, Bossaert L, Ghaemmaghami C, Nonogi H, O'Connor RE, Pichel DR, Scott T, Walters DL, Woolfrey KG; Acute Coronary Syndrome Chapter Collaborators.
   Part 5: Acute Coronary Syndromes: 2015 International Consensus on Cardiopulmonary Resuscitation and Emergency Cardiovascular Care Science With Treatment Recommendations.
   Circulation. 2015 Oct 20;132(16 Suppl 1):S146-76.
- 8. de Caen AR, Maconochie IK, Aickin R, Atkins DL, Biarent D, Guerguerian AM, Kleinman ME, Kloeck DA, Meaney PA, Nadkarni VM, Ng KC, Nuthall G, Reis AG, Shimizu N, Tibballs J, Veliz Pintos R; Pediatric Basic Life Support and Pediatric Advanced Life Support Chapter Collaborators. Part 6: Pediatric Basic Life Support and Pediatric Advanced Life Support: 2015 International Consensus on Cardiopulmonary Resuscitation and Emergency Cardiovascular Care Science With Treatment Recommendations. *Circulation*. 2015 Oct 20;132(16 Suppl 1):S177-203.
- 9. Murphy MF, Walls RM. Identification of the Difficult Airway. In Walls RM, Murphy MF, eds. Manual of Emergency Airway Management. Philadelphia, PA: Lippincott Williams & Wilkins, pp. 81-93, 2008.
- 10. Moore, B., Shah, M. I., Owusu-Ansah, S., Gross, T., Brown, K., Gausche-Hill, M., ... Leonard, J. C. (2020). Pediatric Readiness in Emergency Medical Services Systems. Pediatrics, 145(1).





Approved 9/05/24, Effective 1/15/25, replaces all prior versions

# 1D - TRAUMA AND HYPOVOLEMIC SHOCK SUPPORTIVE CARE ADULT & PEDIATRIC



- 1. Clinical Operational Note (All Field Provider Levels): The practice of EMS medicine is built upon the foundation of "taking medical care the patient". To achieve this objective, appropriate equipment (airway equipment kit, med/trauma equipment kit, suction device, patient packaging equipment) should be brought to the patient's side per Protocol 14J Scene Coordination to minimize critical treatment delays.
- 2. Maximum pediatric medication dosing equals standard adult dosing.





# Medical Literature References 1D- Trauma and Hypovolemic Shock Supportive Care – Adult & Pediatric

- Self, W. H., Semler, M. W., Wanderer, J. P., Wang, L., Byrne, D. W., Collins, S. P., ... Rice, T. W. (2018). Balanced Crystalloids versus Saline in Noncritically III Adults. New England Journal of Medicine. https://doi.org/10.1056/NEJMoa1711586.
- 2. Semler, M. W., Self, W. H., Wanderer, J. P., Ehrenfeld, J. M., Wang, L., Byrne, D. W., ... Rice, T. W. for the S. I. and the P. C. C. R. G. (2018). Balanced Crystalloids versus Saline in Critically III Adults. New England Journal of Medicine. https://doi.org/10.1056/NEJMoa1711584.
- 3. Sasser SM, Hunt RC, Faul M, Sugerman D, Pearson WS, Dulski T, Wald MM, Jurkovich GJ, Newgard CD, Lerner EB; Centers for Disease Control and Prevention (CDC). Guidelines for field triage of injured patients: recommendations of the National Expert Panel on Field Triage, 2011. MMWR Recomm Rep. 2012 Jan 13;61(RR-1):1-20.
- 4. Wigginton JG, Roppolo L, Pepe PE. Advances in resuscitative trauma care. *Minerva Anestesiol*. 2011 Oct;77(10):993-1002.
- 5. Stuke LE, Pons PT, Guy JS, Chapleau WP, Butler FK, McSwain NE. Prehospital spine immobilization for penetrating trauma--review and recommendations from the Prehospital Trauma Life Support Executive Committee. *J Trauma*. 2011 Sep;71(3):763-9; discussion 769-70.
- 6. Williams-Johnson J, Williams E, Watson H. Management and treatment of pelvic and hip injuries. Emerg Med Clin North Am. 2010 Nov;28(4):841-59.
- 7. Lavonas EJ, Drennan IR, Gabrielli A, Heffner AC, Hoyte CO, Orkin AM, Sawyer KN, Donnino MW. Part 10: Special Circumstances of Resuscitation: 2015 American Heart Association Guidelines Update for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. *Circulation*. 2015 Nov 3;132(18 Suppl 2):S501-18.
- 8. Ben-Galim P, Dreiangel N, Mattox KL, Reitman CA, Kalantar SB, Hipp JA. Extrication collars can result in abnormal separation between vertebrae in the presence of a dissociative injury. *J Trauma*. 2010 Aug;69(2):447-50.
- 9. Cotton BA, Jerome R, Collier BR, Khetarpal S, Holevar M, Tucker B, Kurek S, Mowery NT, Shah K, Bromberg W, Gunter OL, Riordan WP Jr; Eastern Association for the Surgery of Trauma Practice Parameter Workgroup for Prehospital Fluid Resuscitation. Guidelines for prehospital fluid resuscitation in the injured patient. *J Trauma*. 2009 Aug;67(2):389-402.
- 10. Murphy MF, Walls RM. Identification of the Difficult Airway. In Walls RM, Murphy MF, eds. Manual of Emergency Airway Management. Philadelphia, PA: Lippincott Williams & Wilkins, pp. 81-93, 2008.
- 11. Badjatia N, Carney N, Crocco TJ, Fallat ME, Hennes HM, Jagoda AS, Jernigan S, Letarte PB, Lerner EB, Moriarty TM, Pons PT, Sasser S, Scalea T, Schleien CL, Wright DW; Brain Trauma Foundation; BTF Center for Guidelines Management. Guidelines for prehospital management of traumatic brain injury 2nd edition. *Prehosp Emerg Care*. 2008;12Suppl 1:S1-52.
- 12. Stiell IG, Clement CM, McKnight RD, Brison R, Schull MJ, Rowe BH, Worthington JR, Eisenhauer MA, Cass D, Greenberg G, MacPhail I, Dreyer J, Lee JS, Bandiera G, Reardon M, Holroyd B, Lesiuk H, Wells GA. The Canadian C-spine rule versus the NEXUS low-risk criteria in patients with trauma. *N Engl J Med.* 2003 Dec 25;349(26):2510-8.
- 13. Domeier RM, Swor RA, Evans RW, Hancock JB, Fales W, Krohmer J, Frederiksen SM, Rivera-Rivera EJ, Schork MA. Multicenter prospective validation of prehospital clinical spinal clearance criteria. *J Trauma*. 2002 Oct;53(4):744-50.
- 14. Pepe PE, Mosesso VN Jr, Falk JL. Prehospital fluid resuscitation of the patient with major trauma. *Prehosp Emerg Care*. 2002 Jan-Mar;6(1):81-91.





Approved 9/04/24, Effective 1/15/25, replaces all prior versions

# 1E – NEONATAL RESUSCITATION PEDIATRIC

#### TREATMENT PRIORITIES

- 1. Preserve patient warmth/avoid hypothermia
- 2. Assessment:
  - ▶Primary Survey
  - ➤ Secondary Survey (when appropriate)
- 3. Primary Survey Care:
  - ➤ Initiate cardiopulmonary resuscitation if indicated
  - ➤Open airway
  - ➤ Support oxygenation/ventilation
  - ➤ Support circulation
- 4. Minimize scene time in critical case unless working cardiac arrest
- Enroute Care:
  - ➤ Reassess all primary care
  - ➤ Support oxygenation/ventilation
  - ➤ Secondary Survey (if able)
- 6. Hospital per destination protocol..

In general, approach the resuscitation of the newborn or infant within the first 30 days of life focusing on basic life support interventions. Invasive, advanced procedures are rarely warranted and are rarely more effective than simple, yet important basic interventions.

**Warmth (Body Temperature Conservation):** Due to high surface to body weight ratios, the neonate rapidly loses body heat which can lead to respiratory and circulatory distress. Keep the neonate warm and minimize skin exposures unless absolutely warranted during care events.

**Airway**: Evaluate the patency and mechanics of the airway. Is the patient able to oxygenate and ventilate? Simple positioning intervention may be required during the assessment phase if airway patency and protection is compromised.

**Breathing:** Briefly expose the chest as required to accurately assess the mechanics of respiration. Note the rate, depth, and pattern of respirations and if any degree of respiratory distress or effort. Auscultate breath sounds bilaterally in the axilla to avoid confusing breath sounds from the other side of the chest. Gentle tactile stimulation (e.g. rubbing of the back, flicking the soles of the feet) may be required early in the assessment and often proves very effective in improving breathing activity.

Liberally obtain pulse oximetry readings and in patients with respiratory difficulties, waveform capnography readings (if equipped with neonatal sized equipment, \*\*Mandatory use if the patient is intubated).





Approved 9/04/24, Effective 1/15/25, replaces all prior versions

Protocol 1E: Neonatal Resuscitation – Pediatric, cont.

**Circulation:** The adequacy of a neonate's circulation is best assessed first by evaluating their level of activity and general body warmth. Next assess the rate and character of the brachial pulse. Pulse rates less than 100/minute are abnormal and a cause for concern of impending cardiovascular collapse. Pulse rates less than 60/minute indicate cardiovascular collapse and chest compressions should be initiated.

Cardiac Arrest is an exception to the above order. Aggressively initiate chest compressions, while still conserving warmth and initiating supplemental oxygenation and ventilation.

After addressing the Warmth-A-B-C order in most neonates, including evaluating and addressing any life-threatening conditions, minimize scene time and initiate timely transport to an appropriate emergency department.

Reassess patients frequently, typically at least every 5 minutes, and more often if critical illness is discovered and being treated. Assess and treat per symptom or illness specific protocols.

#### **Neonatal Assessment Comments:**

1. Respiratory distress may or may not look just like adult respiratory distress, presenting with:

slowing or increasing respirations cyanosis accessory muscle use pallor

nasal flaring lethargy/listlessness

retractions – intercostal or subcostal grunting tachypnea mottling

- 2. Vital signs vary with age. In general, the younger the patient, the faster the respiratory rate, the faster the heart rate, and the lower the blood pressure. In most neonates, blood pressure is difficult to measure and often unreliable in attempts to do so in the field. Rather than focus extended time on blood pressure measurements, evaluate perfusion by overall activity level, skin temperature/color, capillary refill (normally < 3 seconds), and muscular tone.</p>
- Use APGAR scoring at 1 and 5 minutes post-birth, continue every 5 mins if APGAR < 7:</li>

APGAR SCORING (SIGN)	0	1	2
APPEARANCE	BLUE OR PALE	BODY PINK, EXTREMITIES BLUE	COMPLETELY PINK
HEART RATE (BPM)	ABSENT	≤100	>100
GRIMACE (REACTION TO CATHETER IN NARES)	NO RESPONSE	GRIMACE	COUGH OR SNEEZE
MUSCLE TONE	LIMP	SOME FLEXION	ACTIVE MOTION
RESPIRATORY RATE	ABSENT	SLOW/IRREGULAR	GOOD, CRYING





# Medical Literature References 1E – Neonatal Resuscitation – Pediatric


- de Caen AR, Maconochie IK, Aickin R, Atkins DL, Biarent D, Guerguerian AM, Kleinman ME, Kloeck DA, Meaney PA, Nadkarni VM, Ng KC, Nuthall G, Reis AG, Shimizu N, Tibballs J, Veliz Pintos R; Pediatric Basic Life Support and Pediatric Advanced Life Support Chapter Collaborators. Part 6: Pediatric Basic Life Support and Pediatric Advanced Life Support: 2015 International Consensus on Cardiopulmonary Resuscitation and Emergency Cardiovascular Care Science With Treatment Recommendations. Circulation. 2015 Oct 20;132(16 Suppl 1):S177-203.
- Perlman JM, Wyllie J, Kattwinkel J, Wyckoff MH, Aziz K, Guinsburg R, Kim HS, Liley HG, Mildenhall L, Simon WM, Szyld E, Tamura M, Velaphi S; Neonatal Resuscitation Chapter Collaborators.
   Part 7: Neonatal Resuscitation: 2015 International Consensus on Cardiopulmonary Resuscitation and Emergency Cardiovascular Care Science With Treatment Recommendations. *Circulation*. 2015 Oct 20;132(16 Suppl 1):S204-41.
- 3. JWyckoff MH, Perlman JM. Effective ventilation and temperature control are vital to outborn resuscitation. *Prehosp Emerg Care*. 2004 Apr-Jun;8(2):191-5.
- 4. Escobedo, M. B., Aziz, K., Kapadia, V. S., Lee, H. C., Niermeyer, S., Schmölzer, G. M., ... Zaichkin, J. G. (2019). 2019 American Heart Association Focused Update on Neonatal Resuscitation: An Update to the American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation, 140(24), E922–E930.





Approved 9/04/24, Effective 1/15/25, replaces all prior versions

### 2A – AIRWAY ASSESSMENT ADULT & PEDIATRIC



The following principles should be followed to allow optimum assessment and care of the airway without unnecessary intervention.

- 1. Use the least invasive method of airway management appropriate to the patient.
- 2. Use a method of airway management with which you are procedurally comfortable.
- 3. Use meticulous suctioning to keep the airway clear of debris.
- 4. Monitor continuously to be sure that oxygenation/ventilation is as effective as intended and as needed.
- 5. Understand the difference between these various aspects of airway management:
  - A. Patency: how open and clear is the airway, free of foreign substances, blood, vomitus, and tongue obstruction?
  - B. Ventilation: the amount of air the patient is able to inhale and exhale in a given time, promoting exhalation of carbon dioxide. Use waveform capnography if equipped.
  - C. Oxygenation: the amount of oxygen the patient is able to convey to the circulation for tissue/organ perfusion. Use pulse oximetry when available.

Although the dynamics of EMS care often dictate rapid decisions in critical skill performance, assessment for difficult airway characteristics should precede intubation attempt(s). Several methods of evaluating airway-related anatomy exist. One commonly used mnemonic in emergency airway care is "LEMON", which stands for:

Look externally (Heavy perioral facial hair? Mis-shaped or missing dentition?)

Evaluate 3-3-2 (Can at least three fingers be placed in the vertical axis of the mouth? Can at least three fingers be placed in the space between the chin apex and the top of the neck? Can at least 2 fingers fit between the top of thyroid cartilage and the top of the neck? Three "yes" answers predicts lesser anatomical difficulty in establishing intubation.)

**M**allampati scoring – see Images A and B (View of posterior pharyngeal structures correlated to anticipated laryngeal view.)

**O**bstructions (Oral or upper neck masses? Large tongue?)

Neck mobility (Unable to assess if concerns of cervical spine injury.)






Approved 9/04/24, Effective 1/15/25, replaces all prior versions

#### Protocol 2A - Airway Assessment - Adult & Pediatric, cont.

Mallampati Scoring:



The LEMON criteria, including Mallampati scoring, is easiest to apply to compliant patients without acute respiratory distress and without need for emergent intubation. By nature, these are NOT the patients that EMS professionals are tasked with managing. However, the concepts expressed in these criteria can help in predicting more difficult invasive airway management. EMS professionals should always work in developing "Plan B" approaches in airway management to anticipate and be capable of effective care when facing obstacles to usually successful airway management methods.

The following directives guide the approach to typical medical and trauma-related airway problems. They assume the treating EMS professional is skilled in the various procedures appropriate for their scope of practice. Advanced procedures should only be attempted if clinically indicated after less invasive measures fail or are futile to attempt. Individual cases may require modification of these protocols. Airway management decisions and actions should always be thoroughly documented in the patient care report.

#### Medical Respiratory Arrest:

- 1. Open airway using head tilt-chin lift.
- 2. Oxygenate/ventilate with Bag-Valve-Mask (BVM) with supplemental O<sub>2</sub> near 100% FiO<sub>2</sub>.
- 3. Insert nasopharyngeal airway(s) and/or oropharyngeal airway as needed for patency.
- 4. Suction as needed.
- 5. Intubate per applicable protocols. If unable to successfully intubate or intubation is not within the scope of practice of available EMS professionals, place supraglottic airway per Protocol 2E Supraglottic Airways.





Approved 9/04/24, Effective 1/15/25, replaces all prior versions

#### Protocol 2A - Airway Assessment - Adult & Pediatric, cont.

### Trauma Respiratory Arrest:

- 1. Open airway using jaw thrust maneuver with another EMS professional applying in-line stabilization of cervical spine.
- 2. Oxygenate/ventilate with Bag-Valve-Mask (BVM) with supplemental O<sub>2</sub> near 100% FiO<sub>2</sub>.
- 3. Insert nasopharyngeal airway(s) only if no head/facial trauma and/or oropharyngeal airway as needed for patency.
- 4. Suction as needed.
- Intubate per applicable protocols. If unable to successfully intubate or intubation is not within the scope of practice of available EMS professionals, place supraglottic airway per Protocol 2E – Supraglottic Airways.

#### Medical Respiratory Insufficiency (Oxygenation, Ventilation, or Both):

- 1. Establish patency either spontaneously by patient, patient positioning, or with nasopharyngeal airway(s).
- 2. Suction as needed.
- 3. Apply supplemental O<sub>2</sub> by nasal cannula, non-rebreather mask, BVM, or if EMT license or higher, NIPPV if patient condition indicates need for oxygenation assist.
- 4. Assist ventilations by BVM, or if EMT license or higher, NIPPV if patient condition indicates need for ventilation assist.
- 5. If actions in steps 1-4 do not achieve needed oxygenation/ventilation AND if licensed as EMT-I85 or higher, intubate.

### Trauma Respiratory Insufficiency (Oxygenation, Ventilation, or Both):

- 1. Establish patency either spontaneously by patient, patient positioning, or if no head/facial trauma with nasopharyngeal airway(s).
- 2. Suction as needed.
- 3. Apply supplemental O<sub>2</sub> by nasal cannula, non-rebreather mask, BVM as patient condition indicates need for oxygenation assist.
- 4. Assist ventilations by BVM as patient condition indicates need for ventilation assist.
- 5. If actions in steps 1-4 do not achieve needed oxygenation/ventilation AND if licensed as EMT-I85 or higher, intubate.





### Medical Literature References 2A – Airway Assessment – Adult & Pediatric

- Travers AH, Perkins GD, Berg RA, Castren M, Considine J, Escalante R, Gazmuri RJ, Koster RW, Lim SH, Nation KJ, Olasveengen TM, Sakamoto T, Sayre MR, Sierra A, Smyth MA, Stanton D, Vaillancourt C; Basic Life Support Chapter Collaborators. Part 3: Adult Basic Life Support and Automated External Defibrillation: 2015 International Consensus on Cardiopulmonary Resuscitation and Emergency Cardiovascular Care Science With Treatment Recommendations. Circulation. 2015 Oct 20;132(16 Suppl 1):S51-83.
- Callaway CW, Soar J, Aibiki M, Böttiger BW, Brooks SC, Deakin CD, Donnino MW, Drajer S, Kloeck W, Morley PT, Morrison LJ, Neumar RW, Nicholson TC, Nolan JP, Okada K, O'Neil BJ, Paiva EF, Parr MJ, Wang TL, Witt J; Advanced Life Support Chapter Collaborators. Part 4: Advanced Life Support: 2015 International Consensus on Cardiopulmonary Resuscitation and Emergency Cardiovascular Care Science With Treatment Recommendations. *Circulation*. 2015 Oct 20;132(16 Suppl 1):S84-145.
- 3. de Caen AR, Maconochie IK, Aickin R, Atkins DL, Biarent D, Guerguerian AM, Kleinman ME, Kloeck DA, Meaney PA, Nadkarni VM, Ng KC, Nuthall G, Reis AG, Shimizu N, Tibballs J, Veliz Pintos R; Pediatric Basic Life Support and Pediatric Advanced Life Support Chapter Collaborators. Part 6: Pediatric Basic Life Support and Pediatric Advanced Life Support: 2015 International Consensus on Cardiopulmonary Resuscitation and Emergency Cardiovascular Care Science With Treatment Recommendations. Circulation. 2015 Oct 20;132(16 Suppl 1):S177-203.
- 4. Nielsen K, Hansen CM, Rasmussen LS. Airway management in unconscious non-trauma patients. *Emerg Med J.* 2012 Nov;29(11):887-9.
- 5. Murphy MF, Walls RM. Identification of the Difficult Airway. In Walls RM, Murphy MF, eds. Manual of Emergency Airway Management. Philadelphia, PA: Lippincott Williams & Wilkins, pp. 81-93, 2008.
- 6. Soroudi A, Shipp HE, Stepanski BM, Ray LU, Murrin PA, Chan TC, Davis DP, Vilke GM. Adult foreign body airway obstruction in the prehospital setting. *Prehosp Emerg Care*. 2007 Jan-Mar;11(1):25-9.
- 7. Vilke GM, Smith AM, Ray LU, Steen PJ, Murrin PA, Chan TC. Airway obstruction in children aged less than 5 years: the prehospital experience. *Prehosp Emerg Care*. 2004 Apr-Jun;8(2):196-9.
- 8. Levitan RM, Everett WW, Ochroch AE. Limitations of difficult airway prediction in emergency department intubated patients. *Ann Emerg Med* 44: 307-13, 2004.





Approved 9/04/24, Effective 1/15/25, replaces all prior versions

# 2B - AIRWAY ESTABLISHMENT / OBSTRUCTION MANAGEMENT ADULT & PEDIATRIC

### **EMERGENCY MEDICAL DISPATCHER** TREATMENT PRIORITIES **EMD EMERGENCY MEDICAL** 1, Remove obstruction RESPONDER 2. Oxygenation/Ventilation support VERIFY IF PATIENT IS CHOKING 3. NGT/OGT with iGel or intubation **EMT** AVOID BACK SLAPS ENCOURAGE COUGHING AND BREATHING EFFORTS INSTRUCT CALLER IN HEIMLICH MANEUVER IF INDICATED **EMT-INTERMEDIATE 85 ADVANCED EMT PARAMEDIC EMR EMT** GENERAL SUPPORTIVE CARE ADULTS: HEIMLICH MANEUVER OR ABDOMINAL THRUSTS IF SUPINE (CHEST COMPRESSIONS IF PREGNANT OR MORBID OBESITY) PEDIATRIC: HEIMLICH MANEUVER OR ABDOMINAL THRUSTS IF SUPINE (CHEST COMPRESSIONS IF < 1 YR OLD) **OBTAIN VITAL SIGNS** O2 VIA NC, NRB, OR BVM AS APPROPRIATE APPLY CARDIAC MONITOR (if equipped) **EMT OR HIGHER LICENSE:** MEASURE END - TIDAL CO₂ & MONITOR WAVEFORM CAPNOGRAPHY (if equipped, \*\*Mandatory use if pt intubated) PLACE SUPRAGLOTTIC AIRWAY IF INDICATED & ONLY IF BVM VENTILATIONS INEFFECTIVE **EMT-185 AEMT** DIRECT LARYNGOSCOPY & REMOVAL OF FOREIGN BODY **ADULT: INTUBATE IF INDICATED** IV ACCESS (IF NEEDED) **PARAMEDIC ADULT: MEDICATION ASSISTED INTUBATION IF INDICATED** ADULT: CRICOTHYROTOMY FOR COMPLETE, INTRACTABLE OBSTRUCTION PEDIATRIC: PT > 6 YRS OLD, CRICOTHYROTOMY FOR COMPLETE, INTRACTABLE OBSTRUCTION CONTINUOUS ASSESSMENT & TREATMENT PER APPLICABLE PROTOCOL(S) CONSULT OLMC IF AIRWAY OBSTRUCTION PERSISTS DESPITE ABOVE MEASURES





# Medical Literature References 2B Airway Establishment/Obstruction Management – Adult & Pediatric


- Travers AH, Perkins GD, Berg RA, Castren M, Considine J, Escalante R, Gazmuri RJ, Koster RW, Lim SH, Nation KJ, Olasveengen TM, Sakamoto T, Sayre MR, Sierra A, Smyth MA, Stanton D, Vaillancourt C; Basic Life Support Chapter Collaborators. Part 3: Adult Basic Life Support and Automated External Defibrillation: 2015 International Consensus on Cardiopulmonary Resuscitation and Emergency Cardiovascular Care Science With Treatment Recommendations. *Circulation*. 2015 Oct 20;132(16 Suppl 1):S51-83.
- Callaway CW, Soar J, Aibiki M, Böttiger BW, Brooks SC, Deakin CD, Donnino MW, Drajer S, Kloeck W, Morley PT, Morrison LJ, Neumar RW, Nicholson TC, Nolan JP, Okada K, O'Neil BJ, Paiva EF, Parr MJ, Wang TL, Witt J; Advanced Life Support Chapter Collaborators. Part 4: Advanced Life Support: 2015 International Consensus on Cardiopulmonary Resuscitation and Emergency Cardiovascular Care Science With Treatment Recommendations. *Circulation*. 2015 Oct 20;132(16 Suppl 1):S84-145.
- de Caen AR, Maconochie IK, Aickin R, Atkins DL, Biarent D, Guerguerian AM, Kleinman ME, Kloeck DA, Meaney PA, Nadkarni VM, Ng KC, Nuthall G, Reis AG, Shimizu N, Tibballs J, Veliz Pintos R; Pediatric Basic Life Support and Pediatric Advanced Life Support Chapter Collaborators. Part 6: Pediatric Basic Life Support and Pediatric Advanced Life Support: 2015 International Consensus on Cardiopulmonary Resuscitation and Emergency Cardiovascular Care Science With Treatment Recommendations. *Circulation*. 2015 Oct 20;132(16 Suppl 1):S177-203.
- 4. Hart KL, Thompson SH. Emergency cricothyrotomy. *Atlas Oral Maxillofac Surg Clin North Am.* 2010 Mar;18(1):29-38.
- 5. Soroudi A, Shipp HE, Stepanski BM, Ray LU, Murrin PA, Chan TC, Davis DP, Vilke GM. Adult foreign body airway obstruction in the prehospital setting. *Prehosp Emerg Care*. 2007 Jan-Mar;11(1):25-9.
- Rouillon I, Charrier JB, Devictor D, Portier F, Lebret IK, Attal P, Le Pajolec C, Bobin S. Lower respiratory tract foreign bodies: a retrospective review of morbidity, mortality and first aid management. *Int J Pediatr Otorhinolaryngol.* 2006 Nov;70(11):1949-55.
- 7. Vilke GM, Smith AM, Ray LU, Steen PJ, Murrin PA, Chan TC. Airway obstruction in children aged less than 5 years: the prehospital experience. *Prehosp Emerg Care*. 2004 Apr-Jun;8(2):196-9.





Approved 9/04/24, Effective 1/15/25, replaces all prior versions

# 2C - AIRWAY SUCTIONING ADULT & PEDIATRIC



#### Indications:

- 1. Trauma to the face and/or upper airway, with potential or actual airway obstruction.
- 2. Vomitus, food boluses or other liquid foreign material in airway.
- 3. Excess secretions or pulmonary edema fluid in upper airway (or lungs with endotracheal tube in place).
- 4. Amniotic fluid in naso/oropharynx of newborn with obvious obstruction to spontaneous breathing or who require positive-pressure ventilation.
- 5. Meconium in naso/oropharynx of non-vigorous newborn.

### **Contraindications:**

- 1. Airway patency effective without additional suctioning assistance.
- 2. Amniotic fluid or meconium in naso/oropharynx of vigorous, non-dyspneic newborn.

#### Technique:

- A. Open airway and inspect for visible foreign material.
- B. Turn patient on side if possible to facilitate clearance of liquid foreign material.
- C. Remove large or obvious foreign particulates with gloved hands. Sweep finger ACROSS posterior pharynx and clear material out of mouth in adults or if visible material in pediatrics.
- D. Power on suction machine.
- E. Suction of oropharynx:
  - 1. Attach suction catheter (or use open end of suction tubing for large amounts of debris).
  - 2. Oxygenate and ventilate the patient prior to the procedure as needed.
  - 3. Insert tip into oropharynx under direct vision, with sweeping motion.
  - 4. Continue intermittent suction interspersed with active oxygenation by mask. Use positive pressure ventilation if needed.
  - 5. If suction becomes clogged, dilute by suctioning water or normal saline to clean tubing. If suction clogs repeatedly, use connecting tubing alone, or manually remove large debris.





Approved 9/04/24, Effective 1/15/25, replaces all prior versions

PROTOCOL 2C: Airway Suctioning – Adult & Pediatric, cont.

### Technique, cont.:

### F. Catheter suction of endotracheal tube:

- 1. Attach suction catheter to tubing of suction device (leaving suction end in sterile container).
- 2. Ventilate patient 4 5 times for pre-suction oxygenation.
- 3. Detach bag from endotracheal tube and insert sterile tip of suction catheter <u>without</u> suction.
- 4. When catheter tip has been <u>gently</u> advanced to estimated carina depth, apply suction and withdraw catheter slowly.
- 5. Rinse catheter tip in sterile water or normal saline.
- 6. Ventilate patient before each suction attempt.

### **Precautions:**

- Suctioning, particularly through endotracheal tubes, always risks suctioning the available oxygen as well as the fluid from the airway. In most situations, limit the suction time to a few seconds while the catheter is being withdrawn. This precaution should NOT be followed when vomitus or other material continues to well up and completely obstruct airway. Then suctioning must be continued until an airway is reestablished, with intermittent oxygenation and ventilation performed to avoid prolonged lack of oxygen.
- Use equipment large enough for the job at hand. Large, solid matter will not be cleared out with suction catheters. Large amounts of particulate matter require open-ended suction using connecting tubing and physical removal with a gloved hand (using bite precautions) or use of Magill forceps.
- 3. The catheter and tubing will require frequent rinsing with water or normal saline to permit continued suctioning. Have a container of water or normal saline at hand before you begin. Use gauze to remove large material from the end of the catheter.
- 4. Do not <u>insert</u> a suction catheter with the suction functioning. Suction only on <u>withdrawal</u> of the catheter.

### **Complications:**

- 1. Hypoxia due to excessive suctioning time without adequate ventilation between attempts.
- 2. Persistent obstruction due to inadequate tubing size for removal of debris.
- 3. Lung injury from aspiration of stomach contents due to inadequate suctioning.
- 4. Asphyxia due to recurrent obstruction if airway is not monitored after initial suctioning.
- 5. Trauma to the posterior pharynx from forced use of equipment.
- 6. Vomiting and aspiration from stimulation of gag reflex.
- 7. Induction of cardio-respiratory arrest from vagal stimulation.





### Medical Literature References 2C Airway Suctioning—Adult & Pediatric


- Travers AH, Perkins GD, Berg RA, Castren M, Considine J, Escalante R, Gazmuri RJ, Koster RW, Lim SH, Nation KJ, Olasveengen TM, Sakamoto T, Sayre MR, Sierra A, Smyth MA, Stanton D, Vaillancourt C; Basic Life Support Chapter Collaborators. Part 3: Adult Basic Life Support and Automated External Defibrillation: 2015 International Consensus on Cardiopulmonary Resuscitation and Emergency Cardiovascular Care Science With Treatment Recommendations. *Circulation*. 2015 Oct 20;132(16 Suppl 1):S51-83.
- Callaway CW, Soar J, Aibiki M, Böttiger BW, Brooks SC, Deakin CD, Donnino MW, Drajer S, Kloeck W, Morley PT, Morrison LJ, Neumar RW, Nicholson TC, Nolan JP, Okada K, O'Neil BJ, Paiva EF, Parr MJ, Wang TL, Witt J; Advanced Life Support Chapter Collaborators. Part 4: Advanced Life Support: 2015 International Consensus on Cardiopulmonary Resuscitation and Emergency Cardiovascular Care Science With Treatment Recommendations. *Circulation*. 2015 Oct 20;132(16 Suppl 1):S84-145.
- 3. de Caen AR, Maconochie IK, Aickin R, Atkins DL, Biarent D, Guerguerian AM, Kleinman ME, Kloeck DA, Meaney PA, Nadkarni VM, Ng KC, Nuthall G, Reis AG, Shimizu N, Tibballs J, Veliz Pintos R; Pediatric Basic Life Support and Pediatric Advanced Life Support Chapter Collaborators. Part 6: Pediatric Basic Life Support and Pediatric Advanced Life Support: 2015 International Consensus on Cardiopulmonary Resuscitation and Emergency Cardiovascular Care Science With Treatment Recommendations. *Circulation*. 2015 Oct 20;132(16 Suppl 1):S177-203.
- Perlman JM, Wyllie J, Kattwinkel J, Wyckoff MH, Aziz K, Guinsburg R, Kim HS, Liley HG, Mildenhall L, Simon WM, Szyld E, Tamura M, Velaphi S; Neonatal Resuscitation Chapter Collaborators.
   Part 7: Neonatal Resuscitation: 2015 International Consensus on Cardiopulmonary Resuscitation and Emergency Cardiovascular Care Science With Treatment Recommendations. *Circulation*. 2015 Oct 20;132(16 Suppl 1):S204-41.
- 5. Gungor S, Kurt E, Teksoz E, Goktolga U, Ceyhan T, Baser I. Oronasopharyngeal suction versus no suction in normal and term infants delivered by elective cesarean section: a prospective randomized controlled trial. *Gynecol Obstet Invest.* 2006;61:9–14.
- 6. Kozak RJ, Ginther BE, Bean WS.Difficulties with portable suction equipment used for prehospital advanced airway procedures. *Prehosp Emerg Care*. 1997 Apr-Jun;1(2):91-5.





Approved 9/04/24, Effective 1/15/25, replaces all prior versions

### 2D - BAG VALVE MASK (BVM) MANAGEMENT ADULT & PEDIATRIC



### **Indications**:

- 1. Respiratory arrest.
- 2. Inadequate oxygenation/ventilation not improved by non-positive pressure methods or immediately obvious that will not improve by non-positive pressure methods.

#### **Contraindications:**

- 1. Acute dyspnea of lesser severity able to be managed without BVM management
- 2. Active or suspected impending emesis

#### Technique:

Utilize the following mnemonic to guide correct BVM management:

- C Hold mask by **c-clamp** (now referred to as EC-clamp) formed by one, preferably both hands
- O Use an oropharyngeal and/or nasopharyngeal airway(s)
- P Place in a sniffing position to open the airway (\*\*\*unless spinal injury suspected)
- **E Elevate the jaw** to additionally open the airway
- S Seal the mask over the mouth and nose without excessive downward force
- S Use **Sellick maneuver** if indicated (**BURP** = backward, upward, rightward pressure) on the cricoid cartilage to partially occlude the esophagus in the unconscious patient. Do not utilize if ventilations are effective and without onset of gastric distention. Be ready for emesis when releasing Sellick maneuver.
- O Use 100% oxygen concentration (FiO2 = 1.0) to start and titrate down as indicated
- S Squeeze the bag slowly and smoothly (over 1 second ventilation periods) delivering adequate ventilation volume (approx. 6-8 mL of air/kg if respiratory/cardiac arrest or shock; 8-10 mL of air/kg up to 1000 mL if non-shock hemodynamics) and provide adequate exhalation time.






Approved 9/04/24, Effective 1/15/25, replaces all prior versions


PROTOCOL 2D: Bag Valve Mask (BVM) Management - Adult & Pediatric, cont.

BVM technique that promotes optimal oxygenation/ventilation takes two, sometimes three EMS professionals to achieve.

Utilization of the above technique will promote improved oxygenation/ventilation, while reducing potential for gastric insufflation, vomiting, and aspiration. For gastric insufflation in adults compromising BVM ventilations, utilize a nasogastric/orogastric tube per Protocol 9L – Nasogastric/Orogastric Tube.

Utilize the flowchart below to guide BVM management ventilation rates. Use of an adjustable rate metronome can promote delivery at the indicated rate(s).









### Medical Literature References 2D – Bag Valve Mask (BVM) Management – Adult & Pediatric


- Travers AH, Rea TD, Bobrow BJ, Edelson DP, Berg RA, Sayre MR, Berg MD, Chameides L, O'Connor RE, Swor RA. Part 4: CPR overview: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. *Circulation*. 2010;122(suppl 3):S676–S684.
- Berg RA, Hemphill R, Abella BS, Aufderheide TP, Cave DM, Hazinski MF, Lerner EB, Rea TD, Sayre MR, Swor RA. Part 5: Adult basic life support: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. *Circulation*. 2010;122(suppl 3):S685–S705.
- Neumar RW, Otto CW, Link MS, Kronick SL, Shuster M, Callaway CW, Kudenchuk PJ, Ornato JP, McNally B, Silvers SM, Passman RS, White RD, Hess EP, Tang W, Davis D, Sinz E, Morrison LJ. Part 8: adult advanced cardiovascular life support: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. *Circulation*. 2010;122(suppl 3):S729–S767.
- Berg MD, Schexnayder SM, Chameides L, Terry M, Donoghue A, Hickey RW, Berg RA, Sutton RM, Hazinski MF. Part 13: pediatric basic life support: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. *Circulation*. 2010;122(suppl 3):S862–S875.
- Kleinman ME, Chameides L, Schexnayder SM, Samson RA, Hazinski MF, Atkins DL, Berg MD, de Caen AR, Fink EL, Freid EB, Hickey RW, Marino BS, Nadkarni VM, Proctor LT, Qureshi FA, Sartorelli K, Topjian A, van der Jagt EW, Zaritsky AL. Part 14: pediatric advanced life support: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation. 2010;122(suppl 3):S876–S908.
- 6. Hinchey PR, Myers JB, Lewis R, De Maio VJ, Reyer E, Licatese D, Zalkin J, Snyder G; Capital County Research Consortium. Improved out-of-hospital cardiac arrest survival after the sequential implementation of 2005 AHA guidelines for compressions, ventilations, and induced hypothermia: the Wake County experience. *Ann Emerg Med.* 2010 Oct;56(4):348-57.
- 7. Hanif MA, Kaji AH, Niemann JT. Advanced airway management does not improve outcome of out-of-hospital cardiac arrest. *Acad Emerg Med.* 2010 Sep;17(9):926-31.
- 8. Stockinger ZT, McSwain NE Jr. Prehospital endotracheal intubation for trauma does not improve survival over bag-valve-mask ventilation. *J Trauma*. 2004 Mar;56(3):531-6.
- 9. Wayne MA, Delbridge TR, Ornato JP, Swor RA, Blackwell T; Turtle Creek Conference II. Concepts and application of prehospital ventilation. *Prehosp Emerg Care*. 2001 Jan-Mar;5(1):73-8.
- 10. Kroll M, Das J, Siegler J. Can Altering Grip Technique and Bag Size Optimize Volume Delivered with Bag-Valve-Mask by Emergency Medical Service Providers? *Prehospital Emergency Care*. 2019;23(2):210-214. doi:10.1080/10903127.2018.1489020





Approved 9/04/24, Effective 1/15/25, replaces all prior versions

## 2E – SUPRAGLOTTIC AIRWAYS ADULT & PEDIATRIC



#### Indications:

- 1. Hypoxia and/or hypoventilation refractory to non-invasive airway/respiratory management.
- 2. Airway protection to reduce aspiration in the setting of sustained altered mental status with a Glasgow Coma Scale Score < 8.
- 3. Three unsuccessful oral and/or nasal intubation attempts in the above settings. An intubation attempt has occurred when the tip of the endotracheal tube is advanced beyond the gum line or into a nare. Attempts are counted per patient not per intubator. It is not necessary to first attempt intubation if a difficult airway is anticipated or visualized. A supraglottic airway may be used as the first–line airway in these cases.

#### Contraindications:

- 1. Ability to maintain oxygenation and ventilation by less invasive methods, such as Bag-Valve-Mask ventilation.
- 2. Intact gag reflex
- 3. Known esophageal disease
- 4. Ingestion of caustic substance (e.g. lye, acids) or extensive airway burns
- 5. Tracheotomy or laryngectomy
- 6. Suspected Foreign Body Airway Obstruction
- 7. (Relative Contraindication): Patient size outside of manufacturer recommended range for airway size used. The supraglottic airway may be utilized in such patients if the fit of the airway allows for appropriate oxygenation and ventilation of the patient.

#### **Precaution:**

Medical literature indicates concerns regarding reduction in cerebral arterial flow and impedance of cerebral venous return due to pressure effects of supraglottic airways. Supraglottic airways should not be utilized when other methods of airway management are capable of achieving needed oxygenation/ventilation.





Approved 9/04/24, Effective 1/15/25, replaces all prior versions

### PROTOCOL 2E: Supraglottic Airways - Adult & Pediatric, cont.

#### Technique (I-gel™):

Patient Size	I-gel™ Size	Color	Nasogastric Tube Size			
Neonate 2-5 kg	1	Pink	N/A			
Infant 5-12 kg	1.5	Light Blue	10			
Small Pediatric 10-25 kg	2	Grey	12			
Large Pediatric 25-35 kg	2.5	White	12			
Small Adult 30-60 kg	3	Yellow	12			
Medium Adult 50-90 kg	4	Green	12			
Large Adult 90+ kg	5	Orange	14			



Illustration of Correct Placement I-gel™ Airway (Size 4 Shown)


#### To prepare the I-gel<sup>™</sup> Airway:

- Open the package and take out the protective cradle containing the device.
- Remove the accessory pack containing the lubricant and airway support strap from the protective cradle and place the support strap aside.
- Open the lubricant and place a small amount in the OG suction port and the remainder in the cradle. **Preload OG tube into suction port.**
- Grasp the I-gel<sup>™</sup> along the integrated bite block and lubricate the back, sides and front of the cuff with a thin layer of lubricant.
- When lubricant is applied take care to avoid the introduction of lubricant in or near the ventilation portal in the airway.






Approved 9/04/24, Effective 1/15/25, replaces all prior versions **PROTOCOL 2E: Supraglottic Airways – Adult & Pediatric, cont.** 




Grasp the lubricated I-gel<sup>™</sup> along the integrated bite block (tube portion of the device). Position the device so that the I-gel<sup>™</sup> cuff outlet is facing toward the chin of the patient. **(Figure 1)** 

The patient should be in the "sniffing" position, with head extended and neck slightly flexed forward. If cervical injury is suspected, use modified "jaw thrust" instead of any flexion at the neck. The chin should be gently pressed down/inferior before proceeding to insert the I-gel<sup>TM</sup>.





Introduce the leading soft tip into the mouth of the patient in a direction toward the hard palate. Glide the device downwards and backwards along the hard palate with a continuous, but gentile push until a definitive resistance is felt. (**Figure 2**)

WARNING: Do not apply excessive force on the device during insertion It is not necessary to insert your fingers or thumbs into the oral cavity of the patient during insertion of the device. If there is resistance during insertion, a 'jaw thrust' and slight rotation of the device is recommended.



At this point, the tip of the device should be located into the upper esophageal opening and the cuff should be located against the laryngeal framework. The incisors should be resting on the integrated bite block. (**Figure 3**)





Once I-gel<sup>TM</sup> is in place advance OG to appropriate position, apply suction to decompress the stomach and secure the tube with strap provided. (**Figure 4**)





Approved 9/04/24, Effective 1/15/25, replaces all prior versions


### PROTOCOL 2E: Supraglottic Airways - Adult & Pediatric, cont.


#### Removal of the I-gel™ Airway:

- 1. Ensure suctioning equipment is ready, roll patient onto left side
- 2. Carefully remove I-gel™ airway with gentle, but firm traction. Suction as needed.
- 3. Insert an oropharyngeal or nasopharyngeal adjunct, as needed Protocol Title: I-gel™ Airway Placement Procedure
- 4. Continue ventilations with a BVM at 10-15 LPM flow, as needed or place on non-rebreather mask at 10-15 LPM
- 5. Document time of removal and ongoing vitals

#### Additional Information:

- 1. If unable to place an I-gel™ Airway in three attempts, utilize BVM ventilation.
- 2. Ventilation portal of the I-gel<sup>™</sup> Airway must align with the laryngeal inlet for adequate oxygenation and ventilation. Insertion depth should be adjusted to optimize ventilation.
- 3. Preload the correct size OG tube prior to insertion. (OG will need to be lubricated prior to loading into I-gel<sup>™</sup>).
- 3. Most unsuccessful insertion attempts relate to the failure to keep the tube in a midline position during insertion.
- 4. Do not force the tube during insertion; this may result in trauma to the airway or esophagus.
- 5. Document any complications as well as all methods used to ensure appropriate placement of the I-gel<sup>™</sup> Airway including auscultation of absence of epigastric sounds and presence of lung sounds, physiologic changes (chest rise and fall, improved oxygenation, condensation in I-gel<sup>™</sup> Airway with exhalations), and waveform capnography readings (if applied).
- 6. Assess and document placement verification of the I-gel<sup>™</sup> Airway after patient movement and periodically throughout care and transportation.
- 7. Alternative method of securing as shown below. (Figure 5)
- 8. If strap is unavailable use tape as pictured (Figure 6)









### Medical Literature References 2E – Supraglottic Airways – Adult & Pediatric


- Callaway CW, Soar J, Aibiki M, Böttiger BW, Brooks SC, Deakin CD, Donnino MW, Drajer S, Kloeck W, Morley PT, Morrison LJ, Neumar RW, Nicholson TC, Nolan JP, Okada K, O'Neil BJ, Paiva EF, Parr MJ, Wang TL, Witt J; Advanced Life Support Chapter Collaborators. Part 4: Advanced Life Support: 2015 International Consensus on Cardiopulmonary Resuscitation and Emergency Cardiovascular Care Science With Treatment Recommendations. *Circulation*. 2015 Oct 20;132(16 Suppl 1):S84-145.
- 2. Szarpak L, Kurowski A, Truszewski Z, Robak O, Frass M. Comparison of 4 supraglottic devices used by paramedics during simulated CPR: a randomized controlled crossover trial. *Am J Emerg Med.* 2015 Aug;33(8):1084-8.
- 3. White JM, Braude DA, Lorenzo G, Hart BL. Radiographic evaluation of carotid artery compression in patients with extraglottic airway devices in place. *Acad Emerg Med.* 2015;22:636-8.
- 4. Gruber C, Nabecker S, Wohlfarth P, Ruetzler A, Roth D, Kimberger O, Fischer H, Frass M, Ruetzler K. Evaluation of airway management associated hands-off time during cardiopulmonary resuscitation: a randomised manikin follow-up study. *Scand J Trauma Resusc Emerg Med.* 2013 Feb 25:21:10.
- 5. Voscopoulos C, Barker T, Listwa T, Nelson S, Pozner C, Liu X, Zane R, Antoine JA. A comparison of the speed, success rate, and retention of rescue airway devices placed by first-responder emergency medical technicians: a high-fidelity human patient simulation study. *J Emerg Med.* 2013 Apr:44(4):784-9.
- 6. Wang HE, Szydlo D, Stouffer J, Lin S, Carlson J, Vaillancourt C, Sears G, Verbeek R, Fowler R, Idris A, Koenig K, Christenson J, Minokadeh A, Brandt J, Rea T; the ROC Investigators. Endotracheal Intubation versus Supraglottic Airway Insertion in Out-of-Hospital Cardiac Arrest. *Resuscitation*. 2012:83:1061-1066.
- 7. <u>Mitchell MS, Lee White M, King WD, Wang HE</u>. Paramedic King Laryngeal Tube airway insertion versus endotracheal intubation in simulated pediatric respiratory arrest. *Prehosp Emerg Care*. 2012 Apr-Jun;16(2):284-8.
- 8. Segal N, Yannopoulos D, Mahoney BD, Frascone RJ, Matsuura T, Cowles CG, McKnite SH, Chase DG. Impairment of carotid artery blood flow by supraglottic airway use in a swine model of cardiac arrest. *Resuscitation*. 2012;83:1025-1030.
- 9. Gahan K, Studnek JR, Vandeventer S. King LT-D use by urban basic life support first responders as the primary airway device for out-of-hospital cardiac arrest. *Resuscitation*. 2011 Dec;82(12):1525-8.
- 10. Frascone RJ, Russi C, Lick C, Conterato M, Wewerka SS, Griffith KR, Myers L, Conners J, Salzman JG. Comparison of prehospital insertion success rates and time to insertion between standard endotracheal intubation and a supraglottic airway. *Resuscitation*. 2011 Dec;82(12):1529-36.
- 11. Timmermann A. Supraglottic airways in difficult airway management: successes, failures, use and misuse. *Anaesthesia*. 2011 Dec;66 Suppl 2:45-56. doi: 10.1111/j.1365-2044.2011.06934.x.
- 12. <u>Ritter SC</u>, <u>Guyette FX</u>. Prehospital pediatric King LT-D use: a pilot study. *Prehosp Emerg Care*. 2011 Jul-Sep;15(3):401-4.
- 13. Gaither JB, Matheson J, Eberhardt A, Colwell CB. Tongue engorgement associated with prolonged use of the King-LT laryngeal tube device. *Ann Emerg Med.* 2010 Apr;55(4):367-9
- 14. <u>Burns JB Jr</u>, <u>Branson R</u>, <u>Barnes SL</u>, <u>Tsuei BJ</u>. Emergency airway placement by EMS providers: comparison between the King LT supralaryngeal airway and endotracheal intubation. *Anaesthesia*. 2010 Jan-Feb;25(1):92-5.
- 15. <u>Frascone RJ</u>, <u>Wewerka SS</u>, <u>Griffith KR</u>, <u>Salzman JG</u>. Use of the King LTS-D during medication-assisted airway management. *Prehosp Emerg Care*. 2009 Oct-Dec;13(4):5415.
- 16. Braude, D., Steuerwald, M., Wray, T., & Galgon, R. (2019). Managing the Out-of-Hospital Extraglottic Airway Device. Annals of Emergency Medicine, 74(3), 416–422. https://doi.org/10.1016/j.annemergmed.2019.03.002





Approved 9/04/24, Effective 1/15/25, replaces all prior versions

# 2F – ORAL INTUBATION ADULT



#### **Indications**:

- 1. Hypoxia and/or hypoventilation refractory to non-invasive airway/respiratory management.
- 2. Airway protection to minimize aspiration in the setting of sustained altered mental status with a Glasgow Coma Scale Score <8.
- 3. Impending airway edema in the setting of respiratory tract burns or anaphylaxis.

#### Contraindications:

- 1. A total of three unsuccessful oral and/or nasal intubation attempts in the above settings. An intubation attempt has occurred when the tip of the endotracheal tube is advanced beyond the gum line or into a nostril. Attempts are counted per patient not per intubator.
- 2. Waveform capnography not immediately available.

#### Direct Laryngoscopy Technique:

- 1. Throughout the period pre-, during, post-intubation the patient must be continually monitored for hypoxia, bradycardia, or hypotension. Corrective measures, including BVM oxygenation should take priority over continuing the current intubation attempts.
- 2. In pulsatile (non-cardiac arrest) patients, provide supplemental oxygenation throughout the intubation process with nasal cannula oxygen delivery at 15 lpm flow. While this flow rate is much higher than typical nasal cannula oxygen flow rates, the additional force of 15 lpm will help to reduce intra-intubation oxygen desaturation/hypoxia.
- 3. Walk the laryngoscope down the tongue to avoid placing the laryngoscope in the esophagus.
- 4. If unable to lift the mandible with the laryngoscope, place your left forearm on the pt's head for leverage.
- 5. If the vocal cords are poorly visualized in any patient, manipulate the thyroid cartilage with your right hand until appropriate visualization is achieved. Have a colleague hold the thyroid cartilage in this place while you finish intubating. This technique is referred to as "bimanual laryngoscopy" and works much more reliably than cricoid pressure.
- 6. If the vocal cords are still poorly visualized in obese patients without suspected spinal injury, elevate their head/neck/shoulders. Place blankets or pillows under the head/neck/shoulders until the patient's chin or nose is level with the chest.





Approved 9/04/24, Effective 1/15/25, replaces all prior versions

#### PROTOCOL 2F: Oral Intubation – Adult, cont.

- 7. If ambient light inhibits visualization of the larynx, block this light by any means possible, including a blanket stretched over your head and the patient's head and neck.
- 8. In adult patients of appropriate size, strong preference is given for using the 8.0 mm endotracheal tube for orotracheal intubation. Use of this sized tube enables inpatient pulmonary care unable to be performed with smaller sized tubes.
- 9. It is strongly recommended the Flex-Guide™ introducer be used during any second intubation attempt.
- 10. It is required the Flex-Guide™ introducer be used during the third intubation attempt.

#### Video Laryngoscopy (VL) Technique:

- 1. Throughout the period pre-, during, post-intubation the patient must be continually monitored for hypoxia, bradycardia, or hypotension. Corrective measures, including BVM oxygenation should take priority over continuing the current intubation attempts.
- 2. In pulsatile (non-cardiac arrest) patients, provide supplemental oxygenation throughout the intubation process with nasal cannula oxygen delivery at 15 lpm flow. While this flow rate is much higher than typical nasal cannula oxygen flow rates, the additional force of 15 lpm will help to reduce intra-intubation oxygen desaturation/hypoxia.
- 3. Select appropriate UE Scope blade for patient size and attach to monitor.
- 4. Assure monitor is on and recording.
- 5. Open patient's mouth using scissor technique (index/thumb).
- 6. Insert blade midline along the tongue and identify the epiglottis (do not deliver tube if unable to visualize (epiglottis).
- 7. Insert blade into vallecula and lift to achieve 50/50 view of the vocal cords.
- 8. Perform head-lift or ELM to maximize view if necessary.
- 9. Deliver bougie and railroad ETT over bougie.
- 10. If resistance to passage, rotate ETT clockwise or counterclockwise.
- 11. Check insertion depth and inflate ETT cuff, then remove bougie first and then VL device.






Approved 9/04/24, Effective 1/15/25, replaces all prior versions

#### PROTOCOL 2F: Oral Intubation – Adult, cont.

The Flex-Guide™ Introducer (also known as the Gum Elastic Bougie):

The Flex-Guide™ Introducer is a single patient use, semi-rigid plastic rod with an angled tip, promoting glottic passage when the vocal cords are incompletely visible during laryngoscopy. A 1 cm wide black band is located along the Flex-Guide™ to help determine correct placement depth. The Flex-Guide™ shape and elasticity allow the intubator to feel a "washboard" sensation as the anteriorly angled tip is advanced down the tracheal rings. Failure to feel a "washboard" sensation indicates inadvertent esophageal placement and the Flex-Guide™ must be fully withdrawn before reattempting placement. The Flex-Guide™ length allows it to be advanced to the carina where resistance is met, also a means of confirming tracheal rather than esophageal placement. Avoid storing the Flex-Guide™ coiled, as it works best in these regards when it is straight. The Flex-Guide™ is contraindicated in patients < 16 years of age.



### Flex-Guide™ Introducer Technique:

- 1. Advance the angled tip facing anteriorly, with continual visualization by laryngoscopy. Anytime resistance is met, stop advancing and reassess placement forceful passage can result in perforation of soft tissues.
- 2. Stabilize the Flex-Guide™ when in place, while maintaining laryngoscopy.
- 3. Direct a colleague to slide the endotracheal tube over the Flex-Guide<sup>™</sup>. He or she stabilizes the proximal end of the Flex-Guide<sup>™</sup> as it emerges from the sliding endotracheal tube.
- 4. Take control of the endotracheal tube, sliding it down the Flex-Guide™ length, while being careful to avoid Flex-Guide™ migration. Once the endotracheal tube has passed to an appropriate estimated endotracheal depth, stabilize it while your colleague withdraws the Flex-Guide™ prior to laryngoscope removal.





Approved 9/04/24, Effective 1/15/25, replaces all prior versions

#### PROTOCOL 2F: Oral Intubation - Adult, cont.

#### Confirmation of Oral Endotracheal Placement:

The following sequence is to be used (and its use documented) to verify and maintain correct oral endotracheal placement without fail:

- 1. Visualization of endotracheal tube passage between the vocal cords.
- 2. **Detection of End-tidal carbon dioxide.** End-tidal carbon dioxide (EtCO<sub>2</sub>) detection shall be confirmed within 60 seconds of endotracheal tube placement. The capnography adaptor is to be placed at the bag-valve device-endotracheal tube interface for the first ventilation. The normal waveform indicating correct endotracheal placement reflects a rapid upstroke with the beginning of exhalation, the exhalation plateau ending at the point of EtCO<sub>2</sub> measurement, and a rapid downstroke with the beginning of inhalation.

Any waveform that does not show rhythmic rise and fall correlating with assisted ventilations indicates incorrect tube placement and the tube must be withdrawn. To be perfectly clear, the use of an endotracheal tube for ongoing oxygenation and ventilation is dependent upon continuously measurable capnography waveforms. See Protocol 3H-Capnography for discussion of EtCO<sub>2</sub> values.

- 3. Auscultation. Auscultate the epigastrium. If epigastric sounds are heard, intubation is to be reattempted. The endotracheal tube placed in the esophagus may be left in place, at the intubator's discretion, until another endotracheal tube is correctly placed and verified. If no epigastric sounds are heard, proceed to auscultation of the thorax bilaterally. Breath sounds are best auscultated in the anterior to mid axillary lines. If breath sounds are present on the right and absent on the left, this suggests a right main stem intubation. Withdraw the endotracheal tube 1cm and repeat auscultation. If necessary, the tube may be withdrawn an additional 1-2cm.
- 4. **Assessment of physiologic changes.** These include equal rise and fall of the chest, condensation in the endotracheal tube on exhalation, improvement in the patient's color, and improvement in the patient's respiratory distress or failure.
- 5. Secure the endotracheal tube with a tube holder and place a cervical collar. When intubated patients are moved during EMS care, waveform capnography must be rechecked for any change. If the waveform continues to show a normal pattern of rapid upstroke with exhalation, exhalation plateau, and rapid downstroke with inhalation, no further repeat confirmation is required. If at any time, the capnography waveform is abnormal, steps 2-5 must be rechecked and documented. If at any time during patient care there is doubt as to correct endotracheal placement of intubation, you must either re-verify by this sequence or reattempt correct endotracheal placement. While the intubator may delegate confirmation steps to his/her colleagues, he or she is ultimately responsible to ensure that a complete confirmation sequence is performed. If the intubator accompanies the patient to the hospital, he or she remains ultimately responsible for ongoing endotracheal tube placement confirmation. If the intubator does not accompany the patient to the hospital by ambulance or helicopter ambulance transport, the primary transporting/treating paramedic or RN assumes ultimate responsibility for ongoing endotracheal tube placement confirmation.





Approved 9/04/24, Effective 1/15/25, replaces all prior versions

### PROTOCOL 2F: Oral Intubation - Adult, cont.

### Post-Endotracheal Intubation Additional Care:

Place a nasogastric or orogastric tube to intermittent suction to alleviate gastric air/distension. This will improve oxygenation/ventilation and decrease risk of aspiration.





#### Medical Literature References 2F – Oral Intubation – Adult

- 1. Jaber, S., Rollé, A., Godet, T., Terzi, N., Riu, B., Asfar, P., Bourenne, J., Ramin, S., Lemiale, V., Quenot, J. P., Guitton, C., Prudhomme, E., Quemeneur, C., Blondonnet, R., Biais, M., Muller, L., Ouattara, A., Ferrandiere, M., Saint-Léger, P., ... Dellamonica, J. (2021). Effect of the use of an endotracheal tube and stylet versus an endotracheal tube alone on first-attempt intubation success: a multicentre, randomised clinical trial in 999 patients. *Intensive Care Medicine*.
- Walker, R. G., White, L. J., Whitmore, G. N., Esibov, A., Levy, M. K., Cover, G. C., ... Nania, J. M. (2018). Evaluation of Physiologic Alterations during Prehospital Paramedic-Performed Rapid Sequence Intubation. Prehospital Emergency Care, 22(3), 300–311. https://doi.org/10.1080/10903127.2017.1380095
- 3. Oliveira J. e Silva, L., Cabrera, D., Barrionuevo, P., Johnson, R. L., Erwin, P. J., Murad, M. H., & Bellolio, M. F. (2017). Effectiveness of Apneic Oxygenation During Intubation: A Systematic Review and Meta-Analysis. Annals of Emergency Medicine, 70(4), 483–494.e11. https://doi.org/10.1016/j.annemergmed.2017.05.001
- Driver, B., Dodd, K., Klein, L. R., Buckley, R., Robinson, A., McGill, J. W., ... Prekker, M. E. (2017). The Bougie and First-Pass Success in the Emergency Department. Annals of Emergency Medicine, 70(4), 473–478.e1. https://doi.org/10.1016/j.annemergmed.2017.04.033
- Driver, B. E., Prekker, M. E., Klein, L. R., Reardon, R. F., Miner, J. R., Fagerstrom, E. T., ... Cole, J. B. (2018). Effect of use of a bougie vs endotracheal tube and stylet on first-attempt intubation success among patients with difficult airways undergoing emergency intubation a randomized clinical trial. JAMA - Journal of the American Medical Association. https://doi.org/10.1001/jama.2018.6496
- 6. Tennyson J, Ford-Webb T, Weisberg S, LeBlanc D. Endotracheal tube cuff pressures in patients intubated prior to helicopter EMS transport. Western J Emerg Med. 2016 Nov;17(6):721-5.
- 7. Myers LA, Gallet CG, Kolb LJ, Lohse CH, Russi CS. Determinants of success and failure in prehospital endotracheal intubation. Western J Emerg Med. 2016 Sept;17(5):640-7.
- 7. Sime J, Bailitz J, Moskoff J. The bougie: an inexpensive lifesaving airway device. J Emerg Med. 2012 Dec;43(6):e393-5.
- 8. Davis DP, Koprowicz KM, Newgard CD, Daya M, Bulger EM, Stiell I, Nichol G, Stephens S, Dreyer J, Minei J, Kerby JD. The relationship between out-of-hospital airway management and outcome among trauma patients with Glasgow Coma Scale Scores of 8 or less. Prehosp Emerg Care. 2011Apr-Jun;15(2):184-92.
- 9. Combes X, Jabre P, Margenet A, Merle JC, Leroux B, Dru M, Lecarpentier E, Dhonneur G. Unanticipated difficult airway management in the prehospital emergency setting: prospective validation of an algorithm. Anesthesiology. 2011 Jan;114(1):105-10.
- 10. Thomas S, Judge T, Lowell MJ, MacDonald RD, Madden J, Pickett K, Werman HA, Shear ML, Patel P, Starr G, Chesney M, Domeier R, Frantz P, Funk D, Greenberg RD. Airway management success and hypoxemia rates in air and ground critical care transport: a prospective multicenter study. Prehosp Emerg Care. 2010 Jul-Sep;14(3):283.
- 11. Kupas DF, Kauffman KF, Wang HE. Effect of airway-securing method on prehospital endotracheal tube dislodgment. Prehosp Emerg Care. 2010 Jan-Mar;14(1):26-30.
- 12. Davis DP, Fisher R, Buono C, Brainard C, Smith S, Ochs G, Poste JC, Dunford JV. Predictors of intubation success and therapeutic value of paramedic airway management in a large, urban EMS system. Prehosp Emerg Care. 2006 Jul-Sep;10(3):356-62.
- 13. Levitan RM, Kinkle WC, Levin WJ, Everett WW. Laryngeal view during laryngoscopy: a randomized trial comparing cricoid pressure, backward-upward-rightward pressure, and bimanual laryngoscopy. Ann Emerg Med. 2006 Jun;47(6):548-55.
- 14. Wang HE, Davis DP, O'Connor RE, Domeier RM. Drug-assisted intubation in the prehospital setting (resource document to NAEMSP position statement). Prehosp Emerg Care. 2006 Apr-Jun;10(2):261-71.





Medical Literature References 2F – Oral Intubation – Adult (cont.)

- 15. Silvestri S, Ralls GA, Krauss B, Thundiyil J, Rothrock SG, Senn A, Carter E, Falk J. The effectiveness of out-of-hospital use of continuous end-tidal carbon dioxide monitoring on the rate of unrecognized misplaced intubation within a regional emergency medical services system. Ann Emerg Med. 2005 May;45(5):497-503.
- Davis DP, Hoyt DB, Ochs M, Fortlage D, Holbrook T, Marshall LK, Rosen P. The effect of paramedic rapid sequence intubation on outcome in patients with severe traumatic brain injury. J Trauma. 2003 Mar;54(3):444-53.
- 17. Katz SH, Falk JL. Misplaced endotracheal tubes by paramedics in an urban emergency medical services system. Ann Emerg Med. 2001 Jan;37(1):32-7.





Approved 9/04/24, Effective 1/15/25, replaces all prior versions

## 2G - MEDICATION ASSISTED INTUBATION ADULT

TREATMENT PRIORITIES

1, Oxygenation/Ventilation support



#### **PARAMEDIC**

 ${\tt MEDICATION\text{-}ASSISTED\ INTUBATION\ IF\ INDICATED}\\ {\tt FOLLOW\ PROTOCOL\ 2F-ORAL\ INTUBATION\ FOR\ TECHNIQUE\ \&\ CONFIRMATION\ OF\ INTUBATION\ }$ 

#### FOR FACILITATING ORAL INTUBATION:

ADULT: ETOMIDATE 0.3 mg/kg IVP/IOP SINGLE DOSE OR ADULT: MIDAZOLAM 0.1 mg/kg TO MAX OF 5 mg  $\,$  IVP/IOP

MAY REPEAT ONCE IF ADULT SYS BP ≥ 100 mmHg

#### FOR POST-ORAL INTUBATION SEDATION TO PREVENT EXTUBATION (IF INDICATED):

ADULT: MIDAZOLAM 0.1 mg/kg TO MAX OF 5 mg IVP/IOP MAY REPEAT ONCE IF ADULT SYS BP ≥ 100 mmHg OR

ADULT: DIAZEPAM 0.1 mg/kg TO MAX OF 5 mg IVP/IOP MAY REPEAT ONCE IF ADULT SYS BP ≥ 100 mmHg OR

ADULT: LORAZEPAM 0.1 mg/kg TO MAX OF 2 mg IVP/IOP MAY REPEAT ONCE IF ADULT SYS BP ≥ 100 mmHg

CONTINUOUS ASSESSMENT & TREATMENT PER APPLICABLE PROTOCOL(S)





#### Medical Literature References 2G – Medication Assisted Intubation – Adult

- Bruder ED, Ball IM, Ridi S, Pickett W, Hohl C. Single induction dose of etomidate versus other induction agents for endotracheal intubation in critically ill patients. *Cochrane Database Syst Rev.* 2015 Jan8;1:CD010225.
- Flower O, Hellings S. Sedation in traumatic brain injury. Emerg Med Int. 2012;2012:637171. doi: 10.1155/2012/637171. Epub 2012 Sep 20. PubMed PMID: 23050154; PubMed Central PMCID: PMC3461283.
- 3. Hunter BR, Kirschner J. In patients with severe sepsis, does a single dose of etomidate to facilitate intubation increase mortality? *Ann Emerg Med.* 2013 May; 61(5):571-2.
- 4. Banh KV, James S, Hendey GW, Snowden B, Kaups K. Single-Dose Etomidate for Intubation in the Trauma Patient. *J Emerg Med.* 2012;43(5):e277-e282.
- 5. Dmello D, Taylor S, O'Brien J, Matuschak GM. Outcomes of etomidate in severe sepsis and septic shock. *Chest.* 2010 Dec;138(6):1327-32.
- Tekwani KL, Watts HF, Sweis RT, Rzechula KH, Kulstad EB. A comparison of the effects of etomidate and midazolam on hospital length of stay in patients with suspected sepsis: a prospective, randomized study. *Ann Emerg Med.* 2010 Nov;56(5):481-9. Epub 2010 Sep 15.
- 7. Davis DP, Fakhry SM, Wang HE, Bulger EM, Domeier RM, Trask AL, Bochicchio GV, Hauda WE, Robinson L. Paramedic rapid sequence intubation for severe traumatic brain injury: perspectives from an expert panel. *Prehosp Emerg Care*. 2007 Jan-Mar;11(1):1-8.
- 8. Wang HE, Davis DP, O'Connor RE, Domeier RM. Drug-assisted intubation in the prehospital setting (resource document to NAEMSP position statement). *Prehosp Emerg Care*. 2006 Apr-Jun;10(2):261-71.
- 9. Bozeman WP, Kleiner DM, Huggett V. A comparison of rapid-sequence intubation and etomidate-only intubation in the prehospital air medical setting. *Prehosp Emerg Care.* 2006 Jan-Mar;10(1):8-13.
- 10. Davis DP, Stern J, Sise MJ, Hoyt DB. A follow-up analysis of factors associated with head-injury mortality after paramedic rapid sequence intubation. *J Trauma*. 2005 Aug;59(2):486-90.
- 11. Swanson ER, Fosnocht DE, Jensen SC. Comparison of etomidate and midazolam for prehospital rapid-sequence intubation. *Prehosp Emerg Care*. 2004 Jul-Sep;8(3):273-9.
- 12. Davis DP, Dunford JV, Poste JC, Ochs M, Holbrook T, Fortlage D, Size MJ, Kennedy F, Hoyt DB. The impact of hypoxia and hyperventilation on outcome after paramedic rapid sequence intubation of severely head-injured patients. *J Trauma*. 2004 Jul;57(1):1-8; discussion 8-10.
- 13. Deitch S, Davis DP, Schatteman J, Chan TC, Vilke GM. The use of etomidate for prehospital rapid-sequence intubation. *Prehosp Emerg Care*. 2003 Jul-Sep;7(3):380-3.
- Davis DP, Hoyt DB, Ochs M, Fortlage D, Holbrook T, Marshall LK, Rosen P. The effect of paramedic rapid sequence intubation on outcome in patients with severe traumatic brain injury. *J Trauma*. 2003 Mar;54(3):444-53.
- 15. Bozeman WP, Young S. Etomidate as a sole agent for endotracheal intubation in the prehospital air medical setting. *Air Med J.* 2002 Jul-Aug;21(4):32-5; discussion 35-7.
- 16. Davis BD, Fowler R, Kupas DF, Roppolo LP. Role of rapid sequence induction for intubation in the prehospital setting: helpful or harmful? *Curr Opin Crit Care*. 2002 Dec;8(6):571-7.
- 17. Reed DB, Snyder G, Hogue TD. Regional EMS experience with etomidate for facilitated intubation. *Prehosp Emerg Care*. 2002 Jan-Mar;6(1):50-3.
- 18. Davis DP, Kimbro TA, Vilke GM. The use of midazolam for prehospital rapid-sequence intubation may be associated with a dose-related increase in hypotension. *Prehosp Emerg Care*. 2001 Apr-Jun;5(2):163-8.
- 19. Kociszewski C, Thomas SH, Harrison T, Wedel SK. Etomidate versus succinylcholine for intubation in an air medical setting. *Am J Emerg Med.* 2000 Nov;18(7):757-63.
- 20. Wang HE, O'Connor RE, Megargel RE, Bitner M, Stuart R, Bratton-Heck B, Lamborn M, Tan L. The utilization of midazolam as a pharmacologic adjunct to endotracheal intubation by paramedics. *Prehosp Emerg Care*. 2000 Jan-Mar;4(1):14-8.





Approved 9/04/24, Effective 1/15/25, replaces all prior versions

## 2H – NASAL INTUBATION ADULT



#### Indications:

- 1. Hypoxia and/or hypoventilation refractory to non-invasive airway/respiratory management, including refractory to NIPPV.
- 2. Airway protection to minimize aspiration in the setting of sustained altered mental status with a Glasgow Coma Scale Score <8.
- 3. Impending airway edema in the setting of respiratory tract burns or anaphylaxis.
- 4. Patients more compliant with intubation attempts in a sitting position.
- 5. Oral anatomy, injury, or jaw clenching preventing indicated orotracheal intubation.

#### **Contraindications:**

- 1. Apnea.
- 2. Pediatric patients (age ≤12 years).
- 3. Suspected basilar skull fracture.
- 4. Mid-facial injuries with bony instability.
- 5. Combativeness preventing patient compliance.
- 6. Anticoagulant use (Warfarin/Coumadin, Plavix, or Aspirin) Relative contraindication orotracheal intubation preferred to minimize bleeding complications.
- 7. Three unsuccessful oral and/or nasal intubation attempts in the above settings. An intubation attempt has occurred when the tip of the endotracheal tube is advanced beyond the gum line or into a nostril. Attempts are counted per patient not per intubator.
- 8. Waveform capnography not immediately available.

#### Technique:

- 1. Apply two sprays of phenylephrine 2% in each nostril to induce local vasoconstriction. This will enlarge the nostril and decrease epistaxis complications.
- 2. Apply lidocaine 2% gel to the endotracheal tube cuff.
- 3. Insert the well-lubricated tube along the floor of the most patent nostril, bevel side facing inward toward the septum. This positioning will prevent a turbinate from being trapped in the tube and subsequently being sheared off as the tube is advanced. Pass the tube straight back (not angulated upward) with constant, gentle pressure. Do not use an endotracheal stylet in nasotracheal intubations.
- 4. As the tube is advanced, there is a loss of resistance as the tube passes from the nasopharynx into the oropharynx. Continue advancing the tube.





Approved 9/04/24, Effective 1/15/25, replaces all prior versions

#### PROTOCOL 2H: Nasal Intubation - Adult, cont.

- 5. As the tube nears the glottis, guide the tube by listening at the adaptor. The awake patient should be instructed to deeply inspire to help guide the tube through the vocal cords and into the trachea. Correct endotracheal placement may also be assisted by rotating the tube 90 degrees so that the bevel is up and facing the glottis.
- 6. Once the tube has been placed, the patient should not be capable of phonation. The ability to speak after "nasotracheal intubation" actually denotes "nasoesophageal intubation." In such cases, the tube is to be slightly withdrawn and correct placement reattempted. The Flex-Guide™ may NOT be used for difficult nasotracheal intubations.

#### <u>Confirmation of Nasal Endotracheal Placement:</u>

The following sequence is to be used (and its use documented) to verify and maintain correct nasal endotracheal placement without fail:

- 1. Detection of End-tidal carbon dioxide. End-tidal carbon dioxide (EtCO<sub>2</sub>) detection shall be confirmed within 60 seconds of endotracheal tube placement. The capnography adaptor is to be placed at the bag-valve device-endotracheal tube interface for the first ventilation. The normal waveform indicating correct endotracheal placement reflects a rapid upstroke with the beginning of exhalation, the exhalation plateau ending at the point of EtCO<sub>2</sub> measurement, and a rapid down stroke with the beginning of inhalation. Any waveform that does not show rhythmic rise and fall correlating with assisted ventilations indicates incorrect tube placement and the tube must be withdrawn. To be perfectly clear, the use of an endotracheal tube for ongoing oxygenation and ventilation is dependent upon continuously measurable capnography waveforms. See Protocol 3H -Capnography for discussion of EtCO<sub>2</sub> values.
- 2. Auscultation. Auscultate the epigastrum. If epigastric sounds are heard, intubation is to be reattempted. If no epigastric sounds are heard, proceed to auscultation of the thorax bilaterally. Breath sounds are best auscultated in the anterior to mid axillary lines. If breath sounds are present on the right and absent on the left, this suggests a right main stem intubation. Withdraw the endotracheal tube 1 cm and repeat breath sound auscultation. If necessary, the tube may be withdrawn an additional 1-2 cm.
- 3. **Assessment of physiologic changes.** These include equal rise and fall of the chest, condensation in the endotracheal tube on exhalation, improvement in the patient's color, and improvement in the patient's respiratory distress or failure.
- 4. Secure the endotracheal tube with tape and place a cervical collar. When intubated patients are moved during EMS care, waveform capnography must be rechecked for any change. If the waveform continues to show a normal pattern of rapid upstroke with exhalation, exhalation plateau, and rapid down stroke with inhalation, no further repeat confirmation is required. If at any time, the capnography waveform is abnormal, steps 1-4 must be rechecked and documented. If at any time during patient care there is doubt as to correct endotracheal placement of intubation, you must either re-verify by

this sequence or reattempt correct endotracheal placement.





Approved 9/04/24, Effective 1/15/25, replaces all prior versions

### PROTOCOL 2H: Nasotracheal Intubation - Adult, cont.

### Confirmation of Nasal Endotracheal Placement (cont.):

While the intubator may delegate confirmation steps to his/her colleagues, he or she is ultimately responsible to ensure that a complete confirmation sequence is performed. If the intubator accompanies the patient to the hospital, he or she remains ultimately responsible for ongoing endotracheal tube placement confirmation. If the intubator does not accompany the patient to the hospital by ambulance or helicopter ambulance transport, the primary transporting/treating paramedic or RN assumes ultimate responsibility for ongoing endotracheal tube placement confirmation.





#### Medical Literature References 2H – Nasal Intubation – Adult

- 1. Tennyson J, Ford-Webb T, Weisberg S, LeBlanc D. Endotracheal tube cuff pressures in patients intubated prior to helicopter EMS transport. Western J Emerg Med. 2016 Nov;17(6):721-5.
- Callaway CW, Soar J, Aibiki M, Böttiger BW, Brooks SC, Deakin CD, Donnino MW, Drajer S, Kloeck W, Morley PT, Morrison LJ, Neumar RW, Nicholson TC, Nolan JP, Okada K, O'Neil BJ, Paiva EF, Parr MJ, Wang TL, Witt J; Advanced Life Support Chapter Collaborators. Part 4: Advanced Life Support: 2015 International Consensus on Cardiopulmonary Resuscitation and Emergency Cardiovascular Care Science With Treatment Recommendations. *Circulation*. 2015 Oct 20;132(16 Suppl 1):S84-145.
- 3. Davis DP, Koprowicz KM, Newgard CD, Daya M, Bulger EM, Stiell I, Nichol G, Stephens S, Dreyer J, Minei J, Kerby JD. The relationship between out-of-hospital airway management and outcome among trauma patients with Glasgow Coma Scale Scores of 8 or less. PrehospEmerg Care. 2011 Apr-Jun;15(2):184-92.
- 4. Wang HE, Mann NC, Mears G, Jacobson K, Yealy DM. Out-of-hospital airway management in the United States. Resuscitation. 2011 Apr;82(4):378-85.
- 5. Combes X, Jabre P, Margenet A, Merle JC, Leroux B, Dru M, Lecarpentier E, Dhonneur G. Unanticipated difficult airway management in the prehospital emergency setting: prospective validation of an algorithm. Anesthesiology. 2011 Jan;114(1):105-10.
- 6. Thomas S, Judge T, Lowell MJ, MacDonald RD, Madden J, Pickett K, Werman HA, Shear ML, Patel P, Starr G, Chesney M, Domeier R, Frantz P, Funk D, Greenberg RD. Airway management success and hypoxemia rates in air and ground critical care transport: a prospective multicenter study. PrehospEmerg Care. 2010 Jul-Sep;14(3):283.
- 7. Kupas DF, Kauffman KF, Wang HE. Effect of airway-securing method on prehospital endotracheal tube dislodgment. PrehospEmerg Care. 2010 Jan-Mar;14(1):26-30.
- 8. Davis DP, Fisher R, Buono C, Brainard C, Smith S, Ochs G, Poste JC, Dunford JV. Predictors of intubation success and therapeutic value of paramedic airway management in a large, urban EMS system. PrehospEmerg Care. 2006 Jul-Sep;10(3):356-62.
- 9. Wang HE, Yealy DM. Out-of-Hospital Endotracheal Intubation: Where Are We? Ann Emerg Med 2006 47(6):532-541.
- Wang HE, Davis DP, O'Connor RE, Domeier RM. Drug-assisted intubation in the prehospital setting (resource document to NAEMSP position statement). PrehospEmerg Care. 2006 Apr-Jun;10(2):261-71
- 11. Silvestri S, Ralls GA, Krauss B, Thundiyil J, Rothrock SG, Senn A, Carter E, Falk J. The effectiveness of out-of-hospital use of continuous end-tidal carbon dioxide monitoring on the rate of unrecognized misplaced intubation within a regional emergency medical services system. Ann Emerg Med. 2005 May;45(5):497-503.
- Colwell CB, McVaney KE, Haukoos JS, Wiebe DP, Gravitz CS, Dunn WW, Bryan T. An evaluation of out-of-hospital advanced airway management in an urban setting. AcadEmerg Med. 2005 May;12(5):417-22.
- 13. Brown J, Thomas F. What happens with failed blind nasal tracheal intubations? Air Med J. 2001 Mar-Apr;20(2):13-6.
- 14. Katz SH, Falk JL. Misplaced endotracheal tubes by paramedics in an urban emergency medical services system. Ann Emerg Med. 2001 Jan;37(1):32-7.





Approved 9/04/24, Effective 1/15/25, replaces all prior versions

### 2I – CRICOTHYROTOMY ADULT

#### **PARAMEDIC**


#### Indications:

the front

 Upper airway obstruction (eg. facial or neck trauma occluding airway patency, foreign body unable to be removed, angioedema) and inability to adequately oxygenate and ventilate using less invasive methods.

#### Contraindications:

- 1. Ability to oxygenate and ventilate using less invasive methods.
- 2. Infant and younger pediatrics airway anatomical size not conducive to successful cricothyrotomy in EMS care. Contact OLMC for direction in these ages.
- 3. Older pediatrics airway anatomical size MAY not be conducive to successful cricothyrotomy in EMS care. Contact OLMC for direction in these ages.
- 4. Suspected fractured larynx and/or cricoid cartilage.
- 5. Suspected tracheal transection with retraction of the trachea into the chest.
- 6. Inability to find anatomical landmarks



Do not confuse the hyoid bone for the thyroid cartilage.

Attempted placement of a cricothyrotomy airway superior to the thyroid cartilage will cause anatomical disruption and will NOT establish a secure airway capable of needed oxygenation and ventilation. The hyoid bone does NOT have the distinct notch of the thyroid cartilage.

Cricothyroid membrane





Approved 9/04/24, Effective 1/15/25, replaces all prior versions

#### PROTOCOL 2I: Emergency Cricothyrotomy - Adult, cont.

### Non-Surgical Technique (Control-Cric™):

- A. Position patent supine and identify the cricothyroid membrane.
- B. Stabilize the thyroid cartilage with the non-dominant hand (illustration shows the right hand as non-dominant). The dominant hand rests on the sternum, holding the device, with the scalpel oriented horizontal, across the neck at the cricothyroid membrane (illustration shows the left hand as dominant). (Figure 1)



C. Inserting the scalpel to its depth safety hub, make a horizontal incision through both the skin and the underlying cricothyroid membrane. (Figure 2)








Approved 9/04/24, Effective 1/15/25, replaces all prior versions

### PROTOCOL 2I: Emergency Cricothyrotomy – Adult, cont.

Non-Surgical Technique (Control-Cric™), cont:

D. Slide the included tracheal hook down the handle with the thumb placed at the knob, advancing the tip of the hook into the incision made in Step C/Figure 2. (Figure 3)



E. Free the tracheal hook from the handle by sliding it fully down the handle and transfer control of the hook to the non-dominant hand. The tracheal hook should now be able to stabilize movement of the trachea as it is pulled in a controlled force and manner, with the hook under the inferior edge of the thyroid cartilage. (Figure 4)







Approved 9/04/24, Effective 1/15/25, replaces all prior versions


#### PROTOCOL 2I: Emergency Cricothyrotomy – Adult, cont.

### Non-Surgical Technique (Control-Cric™), cont:

F. Insert the Cric-Key<sup>™</sup> through the cricothyroid membrane incision. Confirm placement by moving the Cric-Key<sup>™</sup> introducer along the anterior wall of the trachea to feel for the tracheal rings as partial confirmation of correct placement. (Figure 5)



G. Remove the Cric-Key™ introducer. (Figure 6) Inflate the cuff until resistance is met. Confirm placement with continuous waveform capnography. See also Protocol 3H: Waveform Capnography – Adult & Pediatric.








Approved 9/04/24, Effective 1/15/25, replaces all prior versions

#### PROTOCOL 2I: Emergency Cricothyrotomy – Adult, cont.

Non-Surgical Technique (Control-Cric™), cont:

G. Secure the cricothyrotomy airway with the included stabilizing strap. (Figure 7)



### Surgical Technique (6.0 endotracheal tube and tracheal hook):

- A. Establish adequate space and lighting. Do not attempt cricothyrotomy in poorly visualized conditions.
- B. If rapidly available, clean anterior neck with ChloraPrep®, Betadine®, or alcohol wipe.
- C. Definitively locate the following landmarks: thyroid cartilage ("Adam's apple") and cricoid cartilage. The cricothyroid membrane lies between these cartilages.
- D. Using the non-dominant hand, spread the overlying skin taut with the thumb and fingers, and slightly depress the skin over the cricothyroid membrane with the index finger to mark the site of cricothyrotomy. Do not release the non-dominant hand from the neck until the procedure is complete! Once the anatomy is found and defined, avoid movement of the anatomy to promote proper cricothyrotomy airway placement.
- E. Stabilization of the anatomy requires assistance from a second EMS professional, preferably licensed as a paramedic as well.
- F. Ask second EMS professional to aspirate all air from the endotracheal tube cuff.





Approved 9/04/24, Effective 1/15/25, replaces all prior versions

#### PROTOCOL 2I: Emergency Cricothyrotomy – Adult, cont.

#### Surgical Technique, cont.:

- G. Using a sterile scalpel, make a vertical incision in the mid-line of the neck extending from just above the lower edge of the thyroid cartilage to the middle of the cricoid cartilage. Make the depth of this incision sufficient to extend through the skin and fatty tissue underneath.
- H. Using sterile hemostats, spread the incision open horizontally to expose the cricothyroid membrane. Instruct the second EMS professional to hold the hemostats in this position.
- I. Using the same scalpel as in Step G, now make a short horizontal incision in the middle of the cricothyroid membrane. There is a small artery running vertically on each side of the cricothyroid membrane. Keeping the horizontal incision less than ½ inch (approx. 1 cm) will decrease bleeding that may occur.
- J. Pass the 6.0 mm endotracheal tube through the horizontal incision in the cricothyroid membrane, angling the tube inferior and posterior along the tracheal anatomy. A "washboard" sensation may be felt as the tube slides along the tracheal wall. Avoid excessive pressure in placing the endotracheal tube, but a moderate degree may be required to first pass the endotracheal tube through the cricothyroid membrane. If significant resistance is encountered (without suspicion of lower respiratory tract foreign body), the hemostats used in Step H may be used to spread the cricothyroid membrane incision vertically while the endotracheal tube is passed through it and/or use of the tracheal hook may better stabilize the anatomy to overcome resistance to airway passage.
- K. Inflate the endotracheal cuff and verify airway placement per Protocol 2J Confirmation of Artificial Airway Placement.
- L. Secure the airway using a cloth tie or commercial endotracheal tube restraint while continuing oxygenation and ventilation. Artificial ventilation will generally be easier if the endotracheal tube is cut to a shorter length. Be careful to cut the upper aspect of the endotracheal tube above the insertion site of the cuff inflation portal to avoid irreversible cuff deflation.





Approved 9/04/24, Effective 1/15/25, replaces all prior versions

#### PROTOCOL 2I: Emergency Cricothyrotomy – Adult, cont.

#### Modified Non-Surgical Technique (Control-Cric™):

In patients with neck edema, subcutaneous air, or fat/obesity preventing necessary tactile identification of anatomical landmarks to perform standard non-surgical cricothyrotomy, utilize the following modification:

A. Using the included scalpel, make a single, vertical, mid-line incision in the skin overlying the area that is estimated to contain the thyroid cartilage, cricothyroid membrane, and cricoid cartilage. When making the incision, make an incision approximately 2 inches (5 cm) in length and deep enough that the subcutaneous fat can be visualized. Using a gloved index finger palpate the structures through the incision and when identified, proceed as per standard non-surgical cricothyrotomy.





#### Medical Literature References 2I - Cricothyrotomy – Adult

- 1. Hessert MJ, Bennett BL. Optimizing emergent surgical cricothyrotomy for use in austere environments. *Wilderness Environ Med.* 2013 Mar;24(1):53-66.
- 2. Mabry RL. An analysis of battlefield cricothyrotomy in Iraq and Afghanistan. *J Spec Oper Med.* 2012 Spring;12(1):17-23.
- 3. Hubble MW, Wilfong DA, Brown LH, Hertelendy A, Benner RW. A meta-analysis of prehospital airway control techniques part II: alternative airway devices and cricothyrotomy success rates. *Prehosp Emerg Care*. 2010 Oct-Dec;14(4):515-30.
- 4. Keane MF, Brinsfield KH, Dyer KS, Roy S, White D. A laboratory comparison of emergency percutaneous and surgical cricothyrotomy by prehospital personnel. *Prehosp Emerg Care*. 2004 Oct-Dec;8(4):424-6.
- 5. Marcolini EG, Burton JH, Bradshaw JR, Baumann MR. A standing-order protocol for cricothyrotomy in prehospital emergency patients. *Prehosp Emerg Care*. 2004 Jan-Mar;8(1):23-8.
- 6. Fortune JB, Judkins DG, Scanzaroli D, McLeod KB, Johnson SB. Efficacy of prehospital surgical cricothyrotomy in trauma patients. *J Trauma*. 1997 May;42(5):832-6.





Approved 9/04/24, Effective 1/15/25, replaces all prior versions

# 2J – CONFIRMATION OF ENDOTRACHEAL AIRWAY PLACEMENT ADULT


EMT-INTERMEDIATE 85


ADVANCED EMT

PARAMEDIC

The following sequence is to be used (and its use documented) to verify and maintain correct endotracheal artificial airway placement without fail:

- 1. Visualization of endotracheal tube passage between vocal cords oral intubation only. (Figure 1)
- 2. Detection of End-tidal carbon dioxide. End-tidal carbon dioxide (EtCO<sub>2</sub>) detection shall be confirmed within 60 seconds of endotracheal tube placement. The capnography adaptor is to be placed at the bag-valve device-endotracheal tube interface for the first ventilation. The normal waveform indicating correct endotracheal placement reflects a rapid upstroke with the beginning of exhalation, the exhalation plateau ending at the point of EtCO<sub>2</sub> measurement, and a rapid downstroke with the beginning of inhalation. Any waveform that does not show rhythmic rise and fall correlating with assisted ventilations indicates incorrect tube placement and the tube must be withdrawn. To be perfectly clear, the use of an endotracheal tube for ongoing oxygenation and ventilation is dependent upon continuously measurable capnography waveforms. See Protocol 3H -Capnography for discussion of EtCO<sub>2</sub> values and waveforms. (Figure 2)
- 3. Auscultation. Auscultate the epigastrium. (Figure 3) If epigastric sounds are heard, intubation is to be reattempted. The endotracheal tube placed in the esophagus may be left in place, at the intubator's discretion, until another endotracheal tube is correctly placed and verified. If no epigastric sounds are heard, proceed to auscultation of the thorax bilaterally. Breath sounds are best auscultated in the anterior to midaxillary lines. If breath sounds are present on the right and absent on the left, this suggests a right mainstem intubation. Withdraw the endotracheal tube 1 cm and repeat breath sound auscultation. If necessary, the tube may be withdrawn an additional 1-2 cm.












Approved 9/04/24, Effective 1/15/25, replaces all prior versions

### PROTOCOL 2J: Confirmation of Endotracheal Artificial Airway Placement – Adult

- 4. **Assessment of physiologic changes.** These include equal rise and fall of the chest, condensation in the endotracheal tube on exhalation, improvement in the patient's color, and improvement in the patient's respiratory distress/failure.
- 5. Secure the endotracheal tube with a tube holder and place a cervical collar. (Figure 4)



When intubated patients are moved during EMS care, waveform capnography must be rechecked for any change. If the waveform continues to show a normal pattern of rapid upstroke with exhalation, exhalation plateau, and rapid downstroke with inhalation, no further repeat confirmation is required. If at any time, the capnography waveform is abnormal, steps 2-5 must be rechecked and documented. If at any time during patient care there is doubt as to correct endotracheal placement of intubation, either re-verify by this sequence or reattempt correct endotracheal placement. While the intubator may delegate confirmation steps to his/her colleagues, he or she is ultimately responsible to ensure that a complete confirmation sequences performed. If the intubator accompanies the patient to the hospital, he or she remains ultimately responsible for ongoing endotracheal tube placement confirmation. If the intubator does not accompany the patient to the hospital by ambulance or helicopter ambulance transport, the primary transporting/treating paramedic or RN assumes ultimate responsibility for ongoing endotracheal tube placement confirmation.

Upon delivery of the patient at treatment destination or at subsequent transport (eg. helicopter transport), a waveform capnograph will be obtained and documented after the patient has been physically transferred onto the destination's/subsequent transport's stretcher/bed/operating table to show confirmed, continued correct endotracheal tube placement at EMS transfer of patient care.





### Medical Literature References 2J – Confirmation of Endotracheal Artificial Airway Placement – Adult& Pediatric


- Callaway CW, Soar J, Aibiki M, Böttiger BW, Brooks SC, Deakin CD, Donnino MW, Drajer S, Kloeck W, Morley PT, Morrison LJ, Neumar RW, Nicholson TC, Nolan JP, Okada K, O'Neil BJ, Paiva EF, Parr MJ, Wang TL, Witt J; Advanced Life Support Chapter Collaborators. Part 4: Advanced Life Support: 2015 International Consensus on Cardiopulmonary Resuscitation and Emergency Cardiovascular Care Science With Treatment Recommendations. *Circulation*. 2015 Oct 20;132(16 Suppl 1):S84-145.
- 2. Phelan MP, Ornato JP, Peberdy MA, Hustey FM; American Heart Association's Get With The Guidelines-Resuscitation Investigators. Appropriate documentation of confirmation of endotracheal tube position and relationship to patient outcome from in-hospital cardiac arrest. *Resuscitation*. 2013 Jan;84(1):31-6.
- 3. Davis DP, Koprowicz KM, Newgard CD, Daya M, Bulger EM, Stiell I, Nichol G, Stephens S, Dreyer J, Minei J, Kerby JD. The relationship between out-of-hospital airway management and outcome among trauma patients with Glasgow Coma Scale Scores of 8 or less. *Prehosp Emerg Care*. 2011 Apr-Jun;15(2):184-92.
- 4. Wang HE, Mann NC, Mears G, Jacobson K, Yealy DM. Out-of-hospital airway management in the United States. *Resuscitation*. 2011 Apr;82(4):378-85.
- 5. Combes X, Jabre P, Margenet A, Merle JC, Leroux B, Dru M, Lecarpentier E, Dhonneur G. Unanticipated difficult airway management in the prehospital emergency setting: prospective validation of an algorithm. *Anesthesiology*. 2011 Jan;114(1):105-10.
- 6. Thomas S, Judge T, Lowell MJ, MacDonald RD, Madden J, Pickett K, Werman HA, Shear ML, Patel P, Starr G, Chesney M, Domeier R, Frantz P, Funk D, Greenberg RD. Airway management success and hypoxemia rates in air and ground critical care transport: a prospective multicenter study. *Prehosp Emerg Care*. 2010 Jul-Sep;14(3):283.
- 7. Kupas DF, Kauffman KF, Wang HE. Effect of airway-securing method on prehospital endotracheal tube dislodgment. *Prehosp Emerg Care*. 2010 Jan-Mar;14(1):26-30.
- 8. Davis DP, Fisher R, Buono C, Brainard C, Smith S, Ochs G, Poste JC, Dunford JV. Predictors of intubation success and therapeutic value of paramedic airway management in a large, urban EMS system. *Prehosp Emerg Care*. 2006 Jul-Sep;10(3):356-62.
- 9. Wang HE, Yealy DM. Out-of-Hospital Endotracheal Intubation: Where Are We? *Ann Emerg Med* 2006 47(6):532-541.
- 10. Silvestri S, Ralls GA, Krauss B, Thundiyil J, Rothrock SG, Senn A, Carter E, Falk J. The effectiveness of out-of-hospital use of continuous end-tidal carbon dioxide monitoring on the rate of unrecognized misplaced intubation within a regional emergency medical services system. *Ann Emerg Med.* 2005 May;45(5):497-503.
- Colwell CB, McVaney KE, Haukoos JS, Wiebe DP, Gravitz CS, Dunn WW, Bryan T. An evaluation of out-of-hospital advanced airway management in an urban setting. *Acad Emerg Med.* 2005 May;12(5):417-22.
- 12. Davis DP, Hoyt DB, Ochs M, Fortlage D, Holbrook T, Marshall LK, Rosen P. The effect of paramedic rapid sequence intubation on outcome in patients with severe traumatic brain injury. *J Trauma*. 2003 Mar;54(3):444-53.
- 13. Katz SH, Falk JL. Misplaced endotracheal tubes by paramedics in an urban emergency medical services system. *Ann Emerg Med.* 2001 Jan;37(1):32-7.
- 14. Gausche M, Lewis RJ, Stratton SJ, Haynes BE, Gunter CS, Goodrich SM, Poore PD, McCollough MD, Henderson DP, Pratt FD, Seidel JS. Effect of out-of-hospital pediatric endotracheal intubation on survival and neurological outcome: a controlled clinical trial. *JAMA*. 2000 Feb 9;283(6):783-90.





Approved 9/04/24, Effective 1/15/25, replaces all prior versions

## 2K – LARYNGECTOMY/TRACHEOSTOMY MANAGEMENT ADULT & PEDIATRIC



### Laryngectomy vs Tracheostomy

- Laryngectomy is the permanent surgical removal of the larynx. The trachea is brought to the skin surface as a stoma. The lungs no longer have anatomical connection with the oropharyngeal cavity. Laryngectomy patients may have a surgically created tracheoesophageal fistula with insertion of a voice prosthesis so that they may speak.
- Tracheostomy is the surgical opening of the tracheal lumen, with the entire larynx remaining intact. This is usually performed emergently to relieve an obstruction of the upper airway or electively when a tracheal tube is needed for a prolonged or even permanent timeframe. There is usually a tracheal tube in place.

### **Emergency Management**:

- Most adults and children with either a laryngectomy or tracheostomy are dependent on the laryngectomy stoma and/or tracheostomy tube as their primary airway.
   Cardiopulmonary arrest often results from obstruction of their surgical airway. Obstruction may be due to thick secretions/mucous plug, blood clot(s), a foreign body, or kinking or dislodgement of the tracheal tube. Assess expeditiously and deliberately to re-establish airway patency and support oxygenation/ventilation.
- Early warning signs of obstruction include tachypnea, tachycardia, and hypoxia.
   Cyanosis, bradycardia and apnea are late signs do not wait for these to develop before intervening.

#### **Complications:**

- Airway obstruction
- Aspiration
- Blocked tube
- Bleeding
- Tracheal trauma
- Pneumothorax
- Subcutaneous and mediastinal emphysema
- Respiratory and cardiovascular collapse
- Dislodged tube
- Tracheo-esophageal fistula
- Infection





Approved 9/04/24, Effective 1/15/25, replaces all prior versions

#### PROTOCOL 2K: Stoma/Tracheostomy Management- Adult & Pediatric, cont.

#### Tracheostomy Suctioning:

Suctioning is necessary to remove thick secretions/mucus, maintain a patent airway, and avoid blockages of the tracheostomy tube/ostomy. Indications for suctioning include:

- Audible or visual signs of secretions in the tube/ostomy
- Signs of respiratory distress
- Suspicion of blocked or partially blocked tube
- Inability to clear the tube by coughing out the secretions.
- Increases in required ventilation pressures (in ventilated patients)
- Request by patient for suction

Tracheal suctioning should be carried out regularly for patients with a tracheostomy. The frequency varies between patients and is based on individual assessment. Tracheal damage may be caused by suctioning. This can be minimized by using the appropriately sized suction catheter and limiting suctioning.

Table 1: recommended suction ca	theter	sizes								
Tracheostomy tube size (in mm)	3.0	3.5	4.0	4.5	5.0	6.0mm	7.0mm	7.5mm	8.0mm	9.0mm – 10mm
	mm	mm	mm	mm	mm					
Recommended suction catheter size (Fr)	7	8	8	10	10	10-12	14	14-16	14-16	16

#### Helpful Tips in Tracheostomy Suctioning:

- The suction depth is determined by the estimated length of the tracheostomy tube and no deeper than the estimated depth of the carina.
- The depth of insertion of the suction catheter needs to be determined prior to suctioning to avoid trauma.
- Using the patient's spare tracheostomy tube of the same size (if available) to estimate needed depth of suctioning.
- The pressure setting for tracheal suctioning (suction machine pressure) for small children is no more than 50-100 mmHg and for older children/adults is no more than 100-120 mmHg) to avoid tracheal damage.
- In most circumstances, it is best to limit the duration of suctioning (including passing the catheter and suctioning the tracheostomy tube) to 5-10 seconds.
- Routine use of normal saline is not necessary although there is anecdotal evidence it
  may thin secretions. In situations where this may be of benefit, only 1-2 mL is usually
  needed.





Approved 9/04/24, Effective 1/15/25, replaces all prior versions

### PROTOCOL 2K: Stoma/Tracheostomy Management– Adult & Pediatric, cont.

### **Tracheal Suctioning Procedure:**

- 1. Inform pt of intended action.
- 2. Maintain appropriate PPE throughout procedure.
- 3. Assemble needed suction equipment and power on suction device.
- 4. Instill small volume of sterile normal saline into the tracheostomy tube (if needed) for thick or dry secretions. Excessive use of saline is not recommended. Use saline only if the mucus is very thick, hard to cough up or difficult to suction. Recommended amount per instillation is approximately 1-2 mL.
- 5. Gently insert catheter into the tracheal tube/ostomy without applying suction, passing to the previously estimated needed depth.
- 6. Put thumb over opening in catheter to create suction and use a circular motion (twirl catheter between thumb and index finger) while withdrawing the catheter so that the mucus is removed well from all areas. Avoid suctioning longer than 10 seconds because of oxygen loss. Suction normal saline from a container if needed to clear catheter.
- For tracheostomy tubes with cuffs, it may be necessary to deflate the cuff periodically for suctioning to prevent pooling of secretions above tracheal cuff.
- 8. Let patient rest and breathe, then repeat suction if needed until clear (trying to allow about 30 seconds between suctioning).
- 9. Oxygenate/ventilate as needed.


#### Tracheostomy tube tie changes:

- There is a potential risk for tracheostomy tube dislodgment when attending to tie changes, therefore two personnel who are competent in tracheostomy care should undertake tracheostomy tie changes.
- During the tracheostomy tie change one person is to maintain the airway by securing the tracheostomy tube in place and not removing the hand until the new tracheostomy ties are applied. The other person is to change the ties and attend to stoma care.
- If the tie becomes loose, make it is a priority to re-secure the tracheostomy tube before it can become dislodged.






Approved 9/04/24, Effective 1/15/25, replaces all prior versions







Approved 9/04/24, Effective 1/15/25, replaces all prior versions







## Medical Literature References 2K - Laryngectomy/Tracheostomy Management— Adult & Pediatric

- Travers AH, Perkins GD, Berg RA, Castren M, Considine J, Escalante R, Gazmuri RJ, Koster RW, Lim SH, Nation KJ, Olasveengen TM, Sakamoto T, Sayre MR, Sierra A, Smyth MA, Stanton D, Vaillancourt C; Basic Life Support Chapter Collaborators. Part 3: Adult Basic Life Support and Automated External Defibrillation: 2015 International Consensus on Cardiopulmonary Resuscitation and Emergency Cardiovascular Care Science With Treatment Recommendations. *Circulation*. 2015 Oct 20:132(16 Suppl 1):S51-83.
- Callaway CW, Soar J, Aibiki M, Böttiger BW, Brooks SC, Deakin CD, Donnino MW, Drajer S, Kloeck W, Morley PT, Morrison LJ, Neumar RW, Nicholson TC, Nolan JP, Okada K, O'Neil BJ, Paiva EF, Parr MJ, Wang TL, Witt J; Advanced Life Support Chapter Collaborators. Part 4: Advanced Life Support: 2015 International Consensus on Cardiopulmonary Resuscitation and Emergency Cardiovascular Care Science With Treatment Recommendations. *Circulation*. 2015 Oct 20;132(16 Suppl 1):S84-145.
- de Caen AR, Maconochie IK, Aickin R, Atkins DL, Biarent D, Guerguerian AM, Kleinman ME, Kloeck DA, Meaney PA, Nadkarni VM, Ng KC, Nuthall G, Reis AG, Shimizu N, Tibballs J, Veliz Pintos R; Pediatric Basic Life Support and Pediatric Advanced Life Support Chapter Collaborators. Part 6: Pediatric Basic Life Support and Pediatric Advanced Life Support: 2015 International Consensus on Cardiopulmonary Resuscitation and Emergency Cardiovascular Care Science With Treatment Recommendations. *Circulation*. 2015 Oct 20;132(16 Suppl 1):S177-203.
- 4. Branson, RD. Secretion Management in the Mechanically-Ventilated Patient. *Respiratory Care*, 2007;52(100):1328-1347.
- Rouillon I, Charrier JB, Devictor D, Portier F, Lebret IK, Attal P, Le Pajolec C, Bobin S. Lower respiratory tract foreign bodies: a retrospective review of morbidity, mortality and first aid management. *Int J Pediatr Otorhinolaryngol*. 2006 Nov;70(11):1949-55.
- 6. Ridling D, Martin LD, Bratton S. Endotracheal Suctioning With or Without Instillation of Isotonic Sodium Chloride Solution in Critically III Children. *Am J Crit Care*. 2003.12(3):212-219.



TREATMENT PRIORITIES

2. Oxygenation/Ventilation

4. Dextrose for hypoglycemia

5. Naloxone for narcotic/opiate

(BVM prior to administration of

. Airway patency

Naloxone) 3. Vital signs

overdose

### EMS System for Metropolitan Oklahoma City and Tulsa 2025 Medical Control Board Treatment Protocols



Approved 9/04/24, Effective 1/15/25, replaces all prior versions

#### 3A - RESPIRATORY ARREST **EMERGENCY MEDICAL ADULT & PEDIATRIC DISPATCHER EMERGENCY MEDICAL** RESPONDER **EMD EMT CPR BY EMD INSTRUCTION EMT-INTERMEDIATE 85 ADVANCED EMT PARAMEDIC**

**EMT** 

ESTABLISH AIRWAY PATENCY (POSITIONING, OPA, NPA)  $\mathsf{O}_2$  VIA BVM AS APPROPRIATE GENERAL SUPPORTIVE CARE **OBTAIN VITAL SIGNS** DETERMINE BLOOD GLUCOSE APPLY CARDIAC MONITOR/OBTAIN 12-LEAD ECG (if equipped) TRANSMIT 12-LEAD ECG TO RECEIVING EMERGENCY DEPARTMENT

#### TOXINS/DRUG OVERDOSE - SUSPECTED NARCOTIC/OPIATE - APNEIC

ADDRESS OXYGENATION AND VENTILATION (SPO2 GOAL ≥ 94%) BEFORE ADMINISTERING NALOXONE ADULT: NALOXONE 2 mg IN, MAY REPEAT ONCE
PEDIATRIC: NALOXONE 0.5 mg IN, MAY REPEAT TO MAX OF 2 mg
USE NALOXONE TO RESTORE EFFECTIVE BREATHING; AVOID EXCESSIVE DOSING TO PREVENT WITHDRAWAL

#### **EMT OR HIGHER LICENSE:**

MEASURE END-TIDAL CO2 & MONITOR WAVEFORM CAPNOGRAPHY (if equipped, \*\*Mandatory use if pt intubated) PLACE SUPRAGLOTTIC AIRWAY IF INDICATED & ONLY IF BVM VENTILATIONS INEFFECTIVE

> **EMT-185 AEMT**

ADULT: INTUBATE IF INDICATED PER APPLICABLE PROTOCOLS DO NOT INTUBATE PATIENTS WITH RAPIDLY REVERSIBLE RESP ARREST ETIOLOGY (e.g. NARCOTIC/OPIATE OVERDOSE)

#### IV/IO ACCESS

ADULT: IV NS TKO IF SYS BP  $\geq$  100 mmHg WITHOUT HYPOTENSIVE SYMPTOMS ADULT: IV NS 250 mL BOLUS IF SYS BP <100 mmHg WITH HYPOTENSIVE SYMPTOMS & NO SIGNS OF PULMONARY EDEMA, ADULT: REPEAT UP TO 2 LITERS NS IF SYS BP REMAINS < 100 mmHg WITH HYPOTENSIVE SYMPTOMS & NO SIGNS OF PULMONARY EDEMA PEDIATRIC: IV NS TKO IF SYS BP > (70 + 2x age in years) mmHg

PEDIATRIC: IV NS TKO IF SYS BP > (70 + 2x age in years) mmHg

PEDIATRIC: IV NS 20 mL/kg BOLUS IF SYS BP < (70 + 2x age in years) mmHg IF NO SIGNS OF PULMONARY EDEMA

#### HYPOGLYCEMIA (GLUCOSE <50 mg/dL) - ADULT & PEDIATRIC

D10 5 mL/kg IVPB WIDE OPEN UP TO 250 mL OR D25 2 mL/kg IV/IO UP TO 100 mL (must be ≥ 1 year of age) OR D50 1 mL/kg IV/IO UP TO 50 mL (must be ≥ 25 kg) IF NO VASCULAR ACCESS OBTAINED & IF IO SEEMS EXCESSIVE TO CLINICAL STATUS: GLUCAGON: IF PT WT ≥25 kg, 1mg IM; <25 kg, 0.5 mg IM

ADULT & PEDIATRIC: REPEAT DETERMINATION OF BLOOD GLUCOSE POST-HYPOGLYCEMIA TREATMENT

#### ADVANCED EMT OR HIGHER LICENSE:

TOXINS/DRUG OVERDOSE - SUSPECTED NARCOTIC/OPIATE - APNEIC ADULT: NALOXONE 2 mg IVP/IOP/IN, MAY REPEAT ONCE PEDIATRIC: NALOXONE 0.5 mg IVP/IOP/IN, MAY REPEAT TO MAX OF 2 mg USE NALOXONE TO RESTORE EFFECTIVE BREATHING; AVOID EXCESSIVE DOSING TO PREVENT WITHDRAWAL

#### **PARAMEDIC**

ADULT: MEDICATION-ASSISTED INTUBATION IF INDICATED PER PROTOCOL 2G

CONTINUOUS ASSESSMENT & TREATMENT OF SUSPECTED RESP ARREST ETIOLOGY PER APPLICABLE PROTOCOL(S)





#### Medical Literature References 3A – Respiratory Arrest – Adult & Pediatric

- Travers AH, Perkins GD, Berg RA, Castren M, Considine J, Escalante R, Gazmuri RJ, Koster RW, Lim SH, Nation KJ, Olasveengen TM, Sakamoto T, Sayre MR, Sierra A, Smyth MA, Stanton D, Vaillancourt C; Basic Life Support Chapter Collaborators. Part 3: Adult Basic Life Support and Automated External Defibrillation: 2015 International Consensus on Cardiopulmonary Resuscitation and Emergency Cardiovascular Care Science With Treatment Recommendations. *Circulation*. 2015 Oct 20;132(16 Suppl 1):S51-83.
- Callaway CW, Soar J, Aibiki M, Böttiger BW, Brooks SC, Deakin CD, Donnino MW, Drajer S, Kloeck W, Morley PT, Morrison LJ, Neumar RW, Nicholson TC, Nolan JP, Okada K, O'Neil BJ, Paiva EF, Parr MJ, Wang TL, Witt J; Advanced Life Support Chapter Collaborators. Part 4: Advanced Life Support: 2015 International Consensus on Cardiopulmonary Resuscitation and Emergency Cardiovascular Care Science With Treatment Recommendations. *Circulation*. 2015 Oct 20;132(16 Suppl 1):S84-145.
- de Caen AR, Maconochie IK, Aickin R, Atkins DL, Biarent D, Guerguerian AM, Kleinman ME, Kloeck DA, Meaney PA, Nadkarni VM, Ng KC, Nuthall G, Reis AG, Shimizu N, Tibballs J, Veliz Pintos R; Pediatric Basic Life Support and Pediatric Advanced Life Support Chapter Collaborators. Part 6: Pediatric Basic Life Support and Pediatric Advanced Life Support: 2015 International Consensus on Cardiopulmonary Resuscitation and Emergency Cardiovascular Care Science With Treatment Recommendations. *Circulation*. 2015 Oct 20;132(16 Suppl 1):S177-203.
- 4. Wang HE, Szydlo D, Stouffer J, Lin S, Carlson J, Vaillancourt C, Sears G, Verbeek R, Fowler R, Idris A, Koenig K, Christenson J, Minokadeh A, Brandt J, Rea T; the ROC Investigators. Endotracheal Intubation versus SupraglotticAirway Insertion in Out-of-Hospital Cardiac Arrest. *Resuscitation*. 2012 Sep;83(9):1061-6.
- 5. Segal N, Yannopoulos D, Mahoney BD, Frascone RJ, Matsuura T, Cowles CG, McKnite SH, Chase DG. Impairment of carotid artery blood flow by supraglottic airway use in a swine model of cardiac arrest. *Resuscitation*. 2012 Aug;83(8):1025-30.
- 6. Gahan K, Studnek JR, Vandeventer S. King LT-D use by urban basic life support first responders as the primary airway device for out-of-hospital cardiac arrest. *Resuscitation*. 2011 Dec;82(12):1525-8.
- 7. Timmermann A. Supraglottic airways in difficult airway management: successes, failures, use and misuse. *Anaesthesia*. 2011 Dec;66Suppl 2:45-56. doi: 10.1111/j.1365-2044.2011.06934.x.
- 8. Davis DP, Fisher R, Buono C, Brainard C, Smith S, Ochs G, Poste JC, Dunford JV. Predictors of intubation success and therapeutic value of paramedic airway management in a large, urban EMS system. *Prehosp Emerg Care*. 2006 Jul-Sep;10(3):356-62.
- 9. Wang HE, Yealy DM. Out-of-Hospital Endotracheal Intubation: Where Are We? *Ann Emerg Med* 2006 47(6):532-541.
- Wang HE, Davis DP, O'Connor RE, Domeier RM. Drug-assisted intubation in the prehospital setting (resource document to NAEMSP position statement). Prehosp Emerg Care. 2006 Apr-Jun;10(2):261-71.
- Silvestri S, Ralls GA, Krauss B, Thundiyil J, Rothrock SG, Senn A, Carter E, Falk J. The
  effectiveness of out-of-hospital use of continuous end-tidal carbon dioxide monitoring on the rate of
  unrecognized misplaced intubation within a regional emergency medical services system. *Ann Emerg Med.* 2005 May;45(5):497-503.
- 12. Katz SH, Falk JL. Misplaced endotracheal tubes by paramedics in an urban emergency medical services system. *Ann Emerg Med.* 2001 Jan;37(1):32-7.
- 13. Gausche M, Lewis RJ, Stratton SJ, Haynes BE, Gunter CS, Goodrich SM, Poore PD, McCollough MD, Henderson DP, Pratt FD, Seidel JS. Effect of out-of-hospital pediatric endotracheal intubation on survival and neurological outcome: a controlled clinical trial. *JAMA*. 2000 Feb 9;283(6):783-90.





Approved 9/04/24, Effective 1/15/25, replaces all prior versions

## 3B – DYSPNEA – UNCERTAIN ETIOLOGY ADULT & PEDIATRIC

#### TREATMENT PRIORITIES

- 1. Vital signs (including EtCO2, if equipped)
- Oxygenation support
   O<sub>2</sub> by NC, NRB
  - BVM, Bi/CPAP, ETT if indicated
- 3. Ventilation support
  - BVM, Bi/CPAP, ETT if indicated
- 4. Nebulization therapy
  - Albuterol

#### **EMD**

ADVISE TO AVOID PHYSICAL EXERTION OR ENVIRONMENTAL STRESS (TEMP EXTREMES). ADVISE PT SELF-ADMINISTRATION OF MEDICATIONS (eg. ALBUTEROL INHALER)

IF PREVIOUSLY PRESCRIBED FOR SIMILAR SYMPTOMS

## EMERGENCY MEDICAL DISPATCHER

EMERGENCY MEDICAL RESPONDER

**EMT** 

**EMT-INTERMEDIATE 85** 

**ADVANCED EMT** 

**PARAMEDIC** 

EMR EMT

GENERAL SUPPORTIVE CARE
OBTAIN VITAL SIGNS
O<sub>2</sub> VIA NC, NRB, OR BVM AS APPROPRIATE
APPLY CARDIAC MONITOR (if equipped)

ADULT: OBTAIN 12-LEAD ECG & TRANSMIT TO RECEIVING EMERGENCY DEPARTMENT (if equipped)
ASSIST PT WITH PT'S OWN ALBUTEROL INHALER/NEBULIZER (when applicable)

#### **EMT OR HIGHER LICENSE:**

MEASURE END-TIDAL CO<sub>2</sub> & MONITOR WAVEFORM CAPNOGRAPHY (if equipped)

ADULT: APPLY Bi/CPAP IF INDICATED (if equipped)

ADULT & PEDIATRIC WEIGHT ≥15 kg: NEBULIZED ALBUTEROL 5 mg OR LEVALBUTEROL 2.5 mg
PEDIATRIC WEIGHT <15 kg: NEBULIZED ALBUTEROL 2.5 mg OR LEVALBUTEROL 1.25 mg
MAY REPEAT ALBUTEROL OR LEVALBUTEROL ENROUTE X 1 AS NEEDED

PLACE SUPRAGLOTTIC AIRWAY IF INDICATED & ONLY IF BVM VENTILATIONS INEFFECTIVE

EMT-185 AEMT

**ADULT: INTUBATE IF INDICATED PER APPLICABLE PROTOCOLS** 

#### IV ACCESS

ADULT: IV NS TKO IF SYS BP ≥ 100 mmHg WITHOUT HYPOTENSIVE SYMPTOMS
ADULT: IV NS 250 mL BOLUS IF SYS BP <100 mmHg WITH HYPOTENSIVE SYMPTOMS & NO SIGNS OF PULMONARY EDEMA,

ADULT: REPEAT UP TO 2 LITERS NS IF SYS BP REMAINS < 100 mmHg WITH HYPOTENSIVE SYMPTOMS & NO SIGNS OF PULMONARY EDEMA
PEDIATRIC: IV NS TKO IF SYS BP ≥ (70 + 2x age in years) mmHg

PEDIATRIC: IV NS 20 mL/kg BOLUS IF SYS BP < (70 + 2x age in years) mmHg IF NO SIGNS OF PULMONARY EDEMA

#### **PARAMEDIC**

ADULT: MEDICATION-ASSISTED INTUBATION IF INDICATED PER PROTOCOL 2G CONTINUOUS ASSESSMENT & TREATMENT PER APPLICABLE PROTOCOL(S)





## Medical Literature References 3B – Dyspnea – Uncertain Etiology - Adult & Pediatric

- Callaway CW, Soar J, Aibiki M, Böttiger BW, Brooks SC, Deakin CD, Donnino MW, Drajer S, Kloeck W, Morley PT, Morrison LJ, Neumar RW, Nicholson TC, Nolan JP, Okada K, O'Neil BJ, Paiva EF, Parr MJ, Wang TL, Witt J; Advanced Life Support Chapter Collaborators. Part 4: Advanced Life Support: 2015 International Consensus on Cardiopulmonary Resuscitation and Emergency Cardiovascular Care Science With Treatment Recommendations. *Circulation*. 2015 Oct 20;132(16 Suppl 1):S84-145.
- Welsford M, Nikolaou NI, Beygui F, Bossaert L, Ghaemmaghami C, Nonogi H, O'Connor RE, Pichel DR, Scott T, Walters DL, Woolfrey KG; Acute Coronary Syndrome Chapter Collaborators.
   Part 5: Acute Coronary Syndromes: 2015 International Consensus on Cardiopulmonary Resuscitation and Emergency Cardiovascular Care Science With Treatment Recommendations.
   Circulation. 2015 Oct 20;132(16 Suppl 1):S146-76.
- 3. Williams TA, Finn J, Perkins GD, Jacobs IG. Prehospital continuous positive airway pressure for acute respiratory failure: a systematic review and meta-analysis. *Prehosp Emerg Care*. 2013 Apr-Jun;17(2):261-73.
- 4. Wesley K, Wayne M, Richards M. Many benefits of CPAP. *J Emerg Med Srvcs.* 2011 Jan. s12-s19.
- 5. Bledsoe BE, Anderson E, Hodnick R, Johnson L, Johnson S, Dievendorf E. Low-fractional oxygen concentration continuous positive airway pressure is effective in the prehospital setting. *Prehosp Emerg Care*. 2012 Apr-Jun;16(2):217-21.
- Maak CA, Tabas, JA, McClintock DE. Should Acute Treatment with Inhaled Beta Agonists be Withheld from Patients with Dyspnea Who May Have Heart Failure? *J Emerg Med*. 2011 40(2):135-145.
- 7. Warner GS. Evaluation of the effect of prehospital application of continuous positive airway pressure therapy in acute respiratory distress. *Prehosp Disaster Med.* 2010 Jan-Feb; 25(1): 87-91.
- 8. McKinney J, Brywczynski J, Slovis CM. Med under scrutiny: the declining roles of furosemide, morphine & beta blockers in prehospital care. *JEMS*. 2009 Jan;34(1):10-2.
- 9. Hubble MW, Richards ME, Jarvis R, Millikan T, Young D. Effectiveness of prehospital continuous positive airway pressure in the management of acute pulmonary edema. *Prehosp Emerg Care*. 2006 Oct-Dec;10(4):430-9.
- 10. Jaronik J, Mikkelson P, Fales W, Overton DT. Evaluation of prehospital use of furosemide in patients with respiratory distress. *Prehosp Emerg Care*. 2006 Apr-Jun;10(2):194-7.
- 11. Markenson D, Foltin G, Tunik M, Cooper A, Treiber M, Caravaglia K. Albuterol sulfate administration by EMT-basics: results of a demonstration project. *Prehosp Emerg Care*. 2004 Jan-Mar;8(1):34-40.





Approved 9/04/24, Effective 1/15/25, replaces all prior versions

#### TREATMENT PRIORITIES

- 1. Vital signs
  - (including EtCO2, if equipped)
- 2. Oxygenation support
  - → O₂ by NC, NRB
  - > BVM, Bi/CPAP, ETT if indicated
- 3. Ventilation support
  - ▶ BVM, Bi/CPAP, ETT if indicated
- 4. Nebulization therapy
  - Albuterol, Ipratropium bromide

### 3C – DYSPNEA – ASTHMA ADULT & PEDIATRIC

#### **EMD**

ADVISE TO AVOID PHYSICAL EXERTION
OR ENVIRONMENTAL STRESS (TEMP EXTREMES).
ADVISE PT SELF-ADMINISTRATION OF MEDICATIONS
(eg. ALBUTEROL INHALER)
AS PREVIOUSLY PRESCRIBED FOR ASTHMA SYMPTOMS

## EMERGENCY MEDICAL DISPATCHER

EMERGENCY MEDICAL RESPONDER

**EMT** 

**EMT-INTERMEDIATE 85** 

**ADVANCED EMT** 

**PARAMEDIC** 

EMR EMT

GENERAL SUPPORTIVE CARE
OBTAIN VITAL SIGNS
O₂ VIA NC, NRB, OR BVM AS APPROPRIATE
APPLY CARDIAC MONITOR (if equipped)
ASSIST PT WITH PT'S OWN ALBUTEROL INHALER/NE BULIZER (when applicable)

#### **EMT OR HIGHER LICENSE:**

MEASURE END-TIDAL CO<sub>2</sub> & MONITOR WAVEFORM CAPNOGRAPHY (if equipped, \*\*Mandatory use if pt intubated)

ADULT: APPLY Bi/CPAP IF INDICATED (if equipped)

ADULT & PEDIATRIC WEIGHT ≥15kg: NEBULIZED ALBUTEROL 5 mg OR LEVALBUTEROL 2.5 mg & IPRATROPIUM BROMIDE 0.5 mg
PEDIATRIC WEIGHT <15kg: NEBULIZED ALBUTEROL 2.5 mg OR LEVALBUTEROL 1.25 mg & IPRATROPIUM BROMIDE 0.25 mg
MAY REPEAT ALBUTEROL OR LEVALBUTEROL ENROUTE X 2 AS NEEDED

#### FOR SEVERE ASTHMA REFRACTORY TO NEBULIZATION:

ADULT: EPINEPHRINE 1mg/mL (1:1000) 0.3 mg (0.3 mL) AUTOINJECTOR INTRAMUSCULAR INJECTION IN THIGH PEDIATRIC: EPINEPHRINE 1mg/mL (1:1000) 0.15 mg (0.15 mL) AUTOINJECTOR INTRAMUSCULAR INJECTION IN THIGH OLMC ORDER ONLY FOR EPHINEPHRINE IF PT ≥50 YEARS OLD, HEART ILLNESS HISTORY, OR BLOOD PRESSURE >140/90 mmHg

PLACE SUPRAGLOTTIC AIRWAY IF INDICATED & ONLY IF BVM VENTILATIONS INEFFECTIVE

EMT-185 AEMT

ADULT: INTUBATE IF INDICATED PER APPLICABLE PROTOCOLS

#### IV ACCESS

ADULT: IV NS TKO IF SYS BP ≥ 100 mmHg WITHOUT HYPOTENSIVE SYMPTOMS

ADULT: IV NS 250 mL BOLUS IF SYS BP < 100 mmHg WITH HYPOTENSIVE SYMPTOMS & NO SIGNS OF PULMONARY EDEMA,
ADULT: REPEAT UP TO 2 LITERS NS IF SYS BP REMAINS < 100 mmHg WITH HYPOTENSIVE SYMPTOMS & NO SIGNS OF PULMONARY EDEMA
PEDIATRIC: IV NS TKO IF SYS BP ≥ (70 + 2x age in years) mmHg

PEDIATRIC: IV NS 20 mL/kg BOLUS IF SYS BP < (70 + 2x age in years) mmHg IF NO SIGNS OF PULMONARY EDEMA

#### **AEMT OR HIGHER LICENSE:**

#### FOR SEVERE ASTHMA REFRACTORY TO NEBULIZATION:

ADULT: EPINEPHRINE 1mg/mL (1:1000) at 0.3 mg (0.3 mL) IM

PEDIATRIC: EPINEPHRINE 1mg/mL (1:1000) at 0.01 mg/kg (0.01 mL/kg) NOT TO EXCEED 0.3 mg (0.3 mL) IM

OLMC CONSULT FOR EPHINEPHRINE IF PT ≥50 YEARS OLD, HEART ILLNESS HISTORY, OR BLOOD PRESSURE > 140/90 mmHg

#### **PARAMEDIC**

ADULT: METHYLPREDNISOLONE 125 mg IVP OR DEXAMETHASONE 10 mg IVP, MAY GIVE IM IF NO VASCULAR ACCESS OBTAINED.

PEDIATRIC: METHYLPREDNISOLONE 2 mg/kg NOT TO EXCEED 125 mg IVP OR DEXAMETHASONE 0.6 mg/kg NOT TO EXCEED 10 mg IVP

MAY GIVE IM IF NO VASCULAR ACCESS OBTAINED.

ADULT: MAGNESIUM SULFATE 1 gram VERY SLOW IVP OVER 10 MINS

#### AVOID/STOP IF HYPOTENSION OR KNOWN RENAL FAILURE

ADULT: MEDICATION-ASSISTED INTUBATION IF INDICATED PER PROTOCOL 2G CONTINUOUS ASSESSMENT & TREATMENT PER APPLICABLE PROTOCOL(S)





### Medical Literature References 3C– Dyspnea – Asthma - Adult & Pediatric

- Goodacre S, Cohen J, Bradburn M, Stevens J, Gray A, Benger J, Coats T; 3Mg Research Team. The 3Mg trial: a randomised controlled trial of intravenous or nebulised magnesium sulphate versus placebo in adults with acute severe asthma. *Health Technol Assess*. 2014 Apr;18(22):1-168.
- 2. Williams TA, Finn J, Perkins GD, Jacobs IG. Prehospital continuous positive airway pressure for acute respiratory failure: a systematic review and meta-analysis. *Prehosp Emerg Care*. 2013 Apr-Jun;17(2):261-73.
- 3. Shan Z, Rong Y, Yang W, Wang D, Yao P, Xie J, Liu L. Intravenous and nebulized magnesium sulfate for treating acute asthma in adults and children: a systematic review and meta-analysis. *Respir Med.* 2013 Mar;107(3):321-30.
- 4. VandenHoek TL, Morrison LJ, Shuster M, Donnino M, Sinz E, Lavonas EJ, Jeejeebhoy FM, Gabrielli A. Part 12: cardiac arrest in special situations: 2010 American Heart Association guidelines for cardiopulmonary resuscitation and emergency cardiovascular care. *Circulation*. 2010;122(suppl 3):S829–S861.
- 5. Walker DM. Update on epinephrine (adrenaline) for pediatric emergencies. *Curr Opin Pediatr*. 2009 Jun;21(3):313-9.
- 6. Simons FE, Lieberman PL, Read EJ Jr, Edwards ES, Simons FE, Lieberman PL, Read EJ Jr, Edwards ES. Hazards of unintentional injection of epinephrine from autoinjectors: a systematic review. *Ann Allergy Asthma Immunol.* 2009 Apr;102(4):282-7.
- 7. Myers JB, Slovis CM, Eckstein M, Goodloe JM, Isaacs SM, Loflin JR, Mechem CC, Richmond NJ, Pepe PE; U.S. Metropolitan Municipalities' EMS Medical Directors. Evidence-based performance measures for emergency medical services systems: a model for expanded EMS benchmarking. *Prehosp Emerg Care*. 2008 Apr-Jun;12(2):141-51.
- 8. Bryson D, Camargo CA, Domeier RM, Gaeta TJ, Hendeles L, Hise S, Nowak RM, Russotti R, Sapien R, Wallace D, Wright JL, Boss L, Greiling A, Redd S, Workgroup on EMS Management of Asthma Exacerbations. A model protocol for emergency medical services management of asthma exacerbations. *Prehosp Emerg Care*. 2006 Oct-Dec;10(4):418-429.
- 9. Rowe BH, Camargo CA Jr.Emergency department treatment of severe acute asthma. *Ann Emerg Med.* 2006 Jun;47(6):564-6.
- 10. Richmond NJ, Silverman R, Kusick M, Matallana L, Winokur J. Out-of-hospital administration of albuterol for asthma by basic life support providers. *Acad Emerg Med.* 2005 May;12(5):396-403.
- 11. Thompson M, Wise S, and Rodenberg H. A preliminary comparison of levalbuterol and albuterol in prehospital care. *J Emerg Med.* 2004; 26(3):271-277
- 12. Markenson D, Foltin G, Tunik M, Cooper A, Treiber M, Caravaglia K. Albuterol sulfate administration by EMT-basics: results of a demonstration project. *Prehosp Emerg Care*. 2004 Jan-Mar;8(1):34-40.
- 13. Delbridge T, Domeier R, Key CB. Prehospital asthma management. *Prehosp Emerg Care*. 2003 Jan-Mar;7(1):42-7.
- 14. Meduri GU, Cook TR, Turner RE, Cohen M, Leeper KV. Noninvasive positive pressure ventilation in status asthmaticus. *Chest.* 1996 Sep;110(3):767-74.





Approved 11/08/23, Effective 1/15/24, replaces all prior versions

## 3D – DYSPNEA – CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) ADULT

#### TREATMENT PRIORITIES

- 1. Vital signs
- (including EtCO2, if equipped)
- 2. Oxygenation support
  - → O₂ by NC, NRB
  - ▶ BVM, Bi/CPAP, ETT if indicated
- 3. Ventilation support
  - > BVM, Bi/CPAP, ETT if indicated
- 4. Nebulization therapy
  - Albuterol, Ipratropium bromide

#### **EMD**

ADVISE TO AVOID PHYSICAL EXERTION
OR ENVIRONMENTAL STRESS (TEMP EXTREMES).
ADVISE PT SELF-ADMINISTRATION OF MEDICATIONS
(eg. ALBUTEROL INHALER)
AS PREVIOUSLY PRESCRIBED FOR COPD SYMPTOMS

## EMERGENCY MEDICAL DISPATCHER

EMERGENCY MEDICAL RESPONDER

**EMT** 

**EMT-INTERMEDIATE 85** 

**ADVANCED EMT** 

**PARAMEDIC** 

EMR EMT

GENERAL SUPPORTIVE CARE
OBTAIN VITAL SIGNS
O<sub>2</sub> VIA NC, NRB, OR BVM AS APPROPRIATE
APPLY CARDIAC MONITOR/OBTAIN 12-LEAD ECG (if equipped)
TRANSMIT 12-LEAD ECG TO RECEIVING EMERGENCY DEPARTMENT
ASSIST PT WITH PT'S OWN ALBUTEROL INHALER/NEBULIZER (when applicable)

#### **EMT OR HIGHER LICENSE:**

MEASURE END-TIDAL CO<sub>2</sub> & MONITOR WAVEFORM CAPNOGRAPHY (if equipped)

APPLY BI/CPAP IF INDICATED (if equipped)

NEBULIZED ALBUTEROL 5 mg OR LEVALBUTEROL 2.5 mg & IPRATROPIUM BROMIDE 0.5 mg

MAY REPEAT ALBUTEROL OR LEVALBUTEROL ENROUTE X 2 AS NEEDED

PLACE SUPRAGLOTTIC AIRWAY IF INDICATED & ONLY IF BVM VENTILATIONS INEFFECTIVE

EMT-185 AEMT

INTUBATE IF INDICATED PER APPLICABLE PROTOCOLS

#### IV ACCESS

IV NS TKO IF SYS BP ≥ 100 mmHg WITHOUT HYPOTENSIVE SYMPTOMS

IV NS 250 mL BOLUS IF SYS BP <100 mmHg WITH HYPOTENSIVE SYMPTOMS & NO SIGNS OF PULMONARY EDEMA,

REPEAT UP TO 2 LITERS NS IF SYS BP REMAINS < 100 mmHg WITH HYPOTENSIVE SYMPTOMS & NO SIGNS OF PULMONARY EDEMA

#### **PARAMEDIC**

METHYLPREDNISOLONE 125 mg IVP OR DEXAMETHASONE 10 mg IVP, MAY GIVE IM IF NO VASCULAR ACCESS OBTAINED.

MEDICATION-ASSISTED INTUBATION IF INDICATED PER PROTOCOL 2G CONTINUOUS ASSESSMENT & TREATMENT PER APPLICABLE PROTOCOL(S)





### Medical Literature References 3D– Dyspnea – Chronic Obstructive Pulmonary Disease (COPD) - Adult

- 1. Williams TA, Finn J, Perkins GD, Jacobs IG. Prehospital continuous positive airway pressure for acute respiratory failure: a systematic review and meta-analysis. *Prehosp Emerg Care*. 2013 Apr-Jun;17(2):261-73.
- 2. Wijesinghe M, Perrin K, Healy B, Hart K, Clay J, Weatherall M, Beasley R. Pre-hospital oxygen therapy in acute exacerbations of chronic obstructive pulmonary disease. *Intern Med J.* 2011 Aug;41(8): 618-22.
- 3. Schmidbauer W, Ahlers O, Spies C, Dreyer A, Mager G, Kerner T. Early prehospital use of non-invasive ventilation improves acute respiratory failure in acute exacerbation of chronic obstructive pulmonary disease. *Emerg Med J.* 2011 Jul;28(7):626-7.
- 4. Austin MA, Wills KE, Blizzard L, Walters EH, Wood-Baker R. Effect of high flow oxygen on mortality in chronic obstructive pulmonary disease patients in prehospital setting: randomised controlled trial. *BMJ* 2010 Oct 18;341:c5462.
- 5. Myers JB, Slovis CM, Eckstein M, Goodloe JM, Isaacs SM, Loflin JR, Mechem CC, Richmond NJ, Pepe PE; U.S. Metropolitan Municipalities' EMS Medical Directors. Evidence-based performance measures for emergency medical services systems: a model for expanded EMS benchmarking. *Prehosp Emerg Care*. 2008 Apr-Jun;12(2):141-51.
- 6. Bryson D, Camargo CA, Domeier RM, Gaeta TJ, Hendeles L, Hise S, Nowak RM, Russotti R, Sapien R, Wallace D, Wright JL, Boss L, Greiling A, Redd S, Workgroup on EMS Management of Asthma Exacerbations. A model protocol for emergency medical services management of asthma exacerbations. *Prehosp Emerg Care*. 2006 Oct-Dec;10(4):418-429.
- 7. Perry E, Williams B. The quandary of prehospital oxygen administration in chronic obstructive pulmonary disease -- a review of the literature. *J Emerg Prim Health Care*. 2008: 6(1).
- 8. Richmond NJ, Silverman R, Kusick M, Matallana L, Winokur J. Out-of-hospital administration of albuterol for asthma by basic life support providers. *Acad Emerg Med.* 2005 May;12(5):396-403.
- 9. Thompson M, Wise S, and Rodenberg H. A preliminary comparison of levalbuterol and albuterol in prehospital care. *J Emerg Med.* 2004; 26(3):271-277.
- 10. Markenson D, Foltin G, Tunik M, Cooper A, Treiber M, Caravaglia K. Albuterol sulfate administration by EMT-basics: results of a demonstration project. *Prehosp Emerg Care*. 2004 Jan-Mar;8(1):34-40.
- 11. Kopsaftis, Z., Carson-Chahhoud, K. V., Austin, M. A., & Wood-Baker, R. (2020). Oxygen therapy in the pre-hospital setting for acute exacerbations of chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews.





Approved 9/04/24, Effective 1/15/25, replaces all prior versions

3E – DYSPNEA – CONGESTIVE HEART FAILURE (CHF)
ADULT & PEDIATRIC

#### TREATMENT PRIORITIES

- 1. Vital signs (including EtCO2, if equipped)
- 2. Oxygenation support
  - → O₂ by NC, NRB
  - > BVM, Bi/CPAP, ETT if indicated
- 3. Ventilation support
  - ▶ BVM, Bi/CPAP, ETT if indicated
- 4. Cardiac pre-load & after-load reduction
  - Adult: Nitroglycerin
  - Pediatric: OLMC CONSULT

#### **EMD**

ADVISE TO AVOID PHYSICAL EXERTION
OR ENVIRONMENTAL STRESS (TEMP EXTREMES).
ADVISE PT SELF-ADMINISTRATION OF MEDICATIONS
(eg. NITROGLYCERIN SPRAY/TABS)
AS PREVIOUSLY PRESCRIBED FOR CHF SYMPTOMS

## EMERGENCY MEDICAL DISPATCHER

EMERGENCY MEDICAL RESPONDER

**EMT** 

**EMT-INTERMEDIATE 85** 

**ADVANCED EMT** 

**PARAMEDIC** 

EMR EMT

GENERAL SUPPORTIVE CARE
OBTAIN VITAL SIGNS
O<sub>2</sub> VIA NC, NRB, OR BVM AS APPROPRIATE
APPLY CARDIAC MONITOR/OBTAIN 12-LEAD ECG (if equipped)
TRANSMIT 12-LEAD ECG TO RECEIVING EMERGENCY DEPARTMENT

#### **EMT OR HIGHER LICENSE:**

MEASURE END-TIDAL  ${\rm CO_2}$  & MONITOR WAVEFORM CAPNOGRAPHY (if equipped)

ADULT: APPLY Bi/CPAP IF INDICATED (if equipped)

ADULT: ASSIST PT WITH PT OWN NITROGLYCERIN AS PREVIOUSLY PRESCRIBED FOR CHF SYMPTOMS IF SYS BP ≥ 100 mmHg
PLACE SUPRAGLOTTIC AIRWAY IF INDICATED & ONLY IF BVM VENTILATIONS INEFFECTIVE

EMT-I85 AEMT

**ADULT: INTUBATE IF INDICATED PER APPLICABLE PROTOCOLS** 

#### **IV ACCESS**

**ADULT**: IV NS TKO IF SYS BP ≥ 100 mmHg WITHOUT HYPOTENSIVE SYMPTOMS

ADULT: IV NS 250 mL BOLUS IF SYS BP <100 mmHg WITH HYPOTENSIVE SYMPTOMS & NO SIGNS OF PULMONARY EDEMA,

ADULT: REPEAT UP TO 2 LITERS NS IF SYS BP REMAINS < 100 mmHg WITH HYPOTENSIVE SYMPTOMS & NO SIGNS OF PULMONARY EDEMA

**PEDIATRIC:** IV NS TKO IF SYS BP ≥ (70 + 2x age in years) mmHg

PEDIATRIC: IV NS 20 mL/kg BOLUS IF SYS BP < (70 + 2x age in years) mmHg IF NO SIGNS OF PULMONARY EDEMA

#### **PARAMEDIC**

ADULT: MEDICATION-ASSISTED INTUBATION IF INDICATED PER PROTOCOL 2G

#### ADULT: PHARMACOLOGIC TREATMENT IF SYS BP ≥ 100 mmHg:

NITROGLYCERIN 0.4 mg SUBLINGUAL EVERY 5 MINS OR

IF PATIENT ON NIPPV, USE NITROGLYCERIN 2% OINTMENT 1½ INCHES APPLIED TO CHEST WALL

ADULT: PHARMACOLOGIC TREATMENT IF SYS BP < 100 mmHg:

NOREPINEPHRINE 2-4 mcg/min TITRATE to SYS ≥ 100 mmHg **OR** 

DOPAMINE 5-20 mcg/kg/min TITRATE TO SYS BP ≥ 100 mmHg

PEDIATRIC: OLMC CONSULT FOR PHARMACOLOGIC TREATMENT

TREAT PER PROTOCOL 5C - ACUTE CORONARY SYNDROME AND/OR DYSRHYTHMIA PROTOCOL(S) AS INDICATED CONTINUOUS ASSESSMENT & TREATMENT PER APPLICABLE PROTOCOL(S)

TRANSPORT ASAP PER DESTINATION PROTOCOL





### Medical Literature References 3E- Dyspnea - Congestive Heart Failure (CHF) - Adult & Pediatric

- Callaway CW, Soar J, Aibiki M, Böttiger BW, Brooks SC, Deakin CD, Donnino MW, Drajer S, Kloeck W, Morley PT, Morrison LJ, Neumar RW, Nicholson TC, Nolan JP, Okada K, O'Neil BJ, Paiva EF, Parr MJ, Wang TL, Witt J; Advanced Life Support Chapter Collaborators. Part 4: Advanced Life Support: 2015 International Consensus on Cardiopulmonary Resuscitation and Emergency Cardiovascular Care Science With Treatment Recommendations. *Circulation*. 2015 Oct 20;132(16 Suppl 1):S84-145.
- Welsford M, Nikolaou NI, Beygui F, Bossaert L, Ghaemmaghami C, Nonogi H, O'Connor RE, Pichel DR, Scott T, Walters DL, Woolfrey KG; Acute Coronary Syndrome Chapter Collaborators.
   Part 5: Acute Coronary Syndromes: 2015 International Consensus on Cardiopulmonary Resuscitation and Emergency Cardiovascular Care Science With Treatment Recommendations.
   Circulation. 2015 Oct 20;132(16 Suppl 1):S146-76.
- 3. Scott MC, Winters ME. Congestive Heart Failure. *Emerg Med Clin North Am.* 2015 Aug;33(3):553-62.
- 4. Williams TA, Finn J, Celenza A, Teng TH, Jacobs IG. Paramedic Identification of Acute Pulmonary Edema in a Metropolitan Ambulance Service. *Prehosp Emerg Care*. 2013 July-Sep;17(3):339-47.
- 5. Williams TA, Finn J, Perkins GD, Jacobs IG. Prehospital continuous positive airway pressure for acute respiratory failure: a systematic review and meta-analysis. *Prehosp Emerg Care*. 2013 Apr-Jun;17(2):261-73.
- 6. Williams B, Boyle M, Robertson N, Giddings C. When pressure is positive: a literature review of the prehospital use of continuous positive airway pressure. *Prehosp Disaster Med.* 2013 Feb;28(1):52-60.
- 7. Dib JE, Matin SA, Luckert A. Prehospital Use of Continuous Positive Airway Pressure for Acute Severe Congestive Heart Failure. *J Emerg Med.* 2012 42(5):553-558.
- 8. Bledsoe BE, Anderson E, Hodnick R, Johnson L, Johnson S, Dievendorf E. Low-fractional oxygen concentration continuous positive airway pressure is effective in the prehospital setting. *Prehosp Emerg Care*. 2012 Apr-Jun;16(2):217-21.
- Maak CA, Tabas, JA, McClintock DE. Should Acute Treatment with Inhaled Beta Agonists be Withheld from Patients with Dyspnea Who May Have Heart Failure? <u>J Emerg Med</u>. 2011 40(2):135-145.
- De Backer D, Biston P, Devriendt J, Madl C, Chochrad D, Aldecoa C, Brasseur A, Defrance P, Cottignies P, Vincent J for the SOAP II Invesigators. Comparison of dopamine and norepinephrine in the treatment of shock. *NEJM*. 2010;362:779-89.
- 11. Warner GS. Evaluation of the effect of prehospital application of continuous positive airway pressure therapy in acute respiratory distress. *Prehosp Disaster Med.* 2010 Jan-Feb; 25(1): 87-91.
- 12. McKinney J, Brywczynski J, Slovis CM. Med under scrutiny: the declining roles of furosemide, morphine & beta blockers in prehospital care. *JEMS*. 2009 Jan;34(1):10-2.
- 13. <u>Mattu</u> A, Lawner B. Prehospital Management of Congestive Heart Failure. In Management of Heart Failure in the Emergent Situation. *Heart Failure Clinics* 2009 5(1):19-24.
- 14. Hubble MW, Richards ME, Jarvis R, Millikan T, Young D. Effectiveness of prehospital continuous positive airway pressure in the management of acute pulmonary edema. *Prehosp Emerg Care*. 2006 Oct-Dec;10(4):430-9.
- 15. Jaronik J, Mikkelson P, Fales W, Overton DT. Evaluation of prehospital use of furosemide in patients with respiratory distress. *Prehosp Emerg Care*. 2006 Apr-Jun;10(2):194-7.





Approved 9/04/24, Effective 1/15/25, replaces all prior versions

## 3F – DYSPNEA – BRIEF RESOLVE UNEXPLAINED EVENT (BRUE) PEDIATRIC LESS THAN 1 YEAR OF AGE

### **EMERGENCY MEDICAL** TREATMENT PRIORITIES DISPATCHER **EMD EMERGENCY MEDICAL** 1. Vital signs RESPONDER (including EtCO2, if equipped) 2. Oxygenation support KEEP PATIENT FREE FROM INJURY HAZARDS ➢ O₂ by NC, NRB AVOID PLACING ANYTHING IN MOUTH **EMT** BVM if indicated PLACE IN POSITION OF RESPIRATORY COMFORT 3. Ventilation support **EMT-INTERMEDIATE 85** BVM if indicated 4. Transport for further evaluation **ADVANCED EMT PARAMEDIC EMR EMT** GENERAL SUPPORTIVE CARE **OBTAIN VITAL SIGNS** O2 VIA NC, NRB, OR BVM AS APPROPRIATE HISTORY TO DEFINE IF BRUE - CYANOSIS? CHANGE IN BREATHING? MOTOR TONE LOSS OR STIFFNESS? ALTERED MENTAL STATUS? NO OTHER EXPLANATION FOR SYMPTOMS? DOES BRUE = LOW RISK? - SINGLE EVENT TODAY? EVENT LESS THAN 1 MINUTE? NO PRIOR EVENT? GESTATIONAL AGE AT BIRTH >32 WEEKS? AGE NOW > 2 MOS? NO CPR GIVEN? NORMAL EXAM? DOES BRUE = HIGH RISK? - "NO" TO A LOW RISK ITEM ABOVE? FAM HX OF SUDDEN CARDIAC DEATH? SOCIAL ENVIRONMENT CONCERNING FOR POSSIBLE CHILD ABUSE? \*\*\*OLMCP CONSULT REQUIRED IF PARENT/GUARDIAN REFUSAL OF TRANSPORT IF BRUE = HIGH RISK APPLY CARDIAC MONITOR (if equipped) **EMT OR HIGHER LICENSE:** MEASURE END-TIDAL CO<sub>2</sub> & MONITOR WAVEFORM CAPNOGRAPHY (if equipped) **EMT-185 AEMT** IV ACCESS IF INDICATED IV NS TKO IF SYS BP ≥ (70 + 2x age in years) mmHg IV NS 20 mL/kg BOLUS IF SYS BP < (70 + 2x age in years) mmHg IF NO SIGNS OF PULMONARY EDEMA **PARAMEDIC** MEDICATION-ASSISTED INTUBATION IF INDICATED PER PROTOCOL 2G

CONTINUOUS ASSESSMENT & TREATMENT PER APPLICABLE PROTOCOL(S)





## Medical Literature References 3F – Dyspnea – Apparent Life Threatening Event – Pediatric


- 1. Tieder JS, Altman RL, Bonkowsky JL, Brand DA, Claudius I, Cunningham DJ, Dewolfe C, Percelay JM, Pitetti RD, Smith MB. Management of Apparent Life-Threatening Events in Infants: A Systematic Review. *J Pediatr.* 2013 Feb 14.
- 2. Kaji AH, Claudius I, Santillanes G, Mittal MK, Hayes K, Lee J, Gausche-Hill M. Apparent life-threatening event: multicenter prospective cohort study to develop a clinical decision rule for admission to the hospital. *Ann Emerg Med.* 2013 Apr;61(4):379-387.e4.
- 3. Kaji AH, Santillanes G, Claudius I, Mittal MK, Hayes K, Lee J, Gausche-Hill M. Do infants less than 12 months of age with an apparent life-threatening event need transport to a pediatric critical care center? *Prehosp Emerg Care*. 2013 Jul-Sep;17(3):304-11.
- Romaneli MT, Fraga AM, Morcillo AM, Tresoldi AT, Baracat EC. Factors associated with infant death after apparent life-threatening event (ALTE). J Pediatr (Rio J). 2010 Nov-Dec;86(6):515-9.
- 5. Zuckerbraun NS, Zomorrodi A, Pitetti RD. Occurrence of serious bacterial infection in infants aged 60 days or younger with an apparent life-threatening event. *Pediatr Emerg Care*. 2009 Jan;25(1):19-25.
- 6. Kaji AH, Gausche-Hill M. Managing infants after an apparent life-threatening event. *Emerg Med.* 2008;40(10): 15-9
- 7. Santiago-Burruchaga M, Sánchez-Etxaniz J, Benito-Fernández J, Vázquez-Cordero C, Mintegi-Raso S, Labayru-Echeverría M, Vega-Martín MI. Assessment and management of infants with apparent life-threatening events in the pediatric emergency department. *Eur J Emerg Med.* 2008 Aug;15(4):203-8.
- 8. McGovern MC, Smith MB. Causes of apparent life threatening events in infants: a systematic review. *Arch Dis Child*. 2004 Nov;89(11):1043-8.
- 9. Stratton SJ, Taves A, Lewis RJ, Clements H, Henderson D, McCollough. Apparent life-threatening events in infants. High risk in the out-of-hospital environment. *Ann Emerg Med.* 2004 43(6):711-717.
- 10. De Piero AD, Teach SJ, Chamberlain JM. ED evaluation of infants after an apparent life-threatening event. *Am J Emerg Med*. 2004 Mar;22(2):83-6.
- 11. Davies F, Gupta R. Apparent life threatening events in infants presenting to an emergency department. *Emerg Med J.* 2002 Jan;19(1):11-6.





Approved 9/04/24, Effective 1/15/25, replaces all prior versions

## 3G – PULSE OXIMETRY ADULT & PEDIATRIC



#### **Indications:**

- 1. Medical General Assessment/General Supportive Care.
- 2. Trauma General Assessment/Trauma & Hypovolemic Shock Supportive Care.
- 3. Acute Dyspnea (Uncertain Etiology, Asthma, COPD, CHF, BRUE).
- 4. Cardiovascular Disorders (Chest Pain, Acute Coronary Syndrome, Dysrhythmias).
- 5. Neurologic Disorders/Altered Mental Status (Stroke, Seizure, Syncope).
- 6. Toxicologic/Poisonings (Altered Mental Status, Dyspnea).
- 7. Trauma (Head, Face, Neck, Chest Injuries).

Contraindications: None

#### Technique:

- A. Power on the pulse oximeter (may be included with monitor/defibrillator).
- B. Select an appropriate site for measurement.
  - 1. Best skin color on hand (or foot/ear if pediatric).
  - 2. Not distal to acute suspected orthopedic injuries.
- C. Place the infrared sensor on the patient.
- D. Read the pulse rate and oximetry reading (SpO<sub>2</sub>).

#### Precautions:

- A. Pulse oximetry values may be inaccurate in hemodynamically compromised patients (shock), patients with peripheral vascular constriction, carbon monoxide poisonings/smoke inhalations, and any conditions that may cause methemoglobinemia or sulfhemoglobinemia. Always correlate the patient's clinical condition with SpO<sub>2</sub> readings.
- B. Trends prove more informative than a single measurement. At least two measurements should be performed and documented when using pulse oximetry. In the setting of artificial airway placement, pulse oximetry should be utilized continuously.





## Medical Literature References 3G– Pulse Oximetry - Adult

- 1. Aguilar SA, Davis DP. Latency of pulse oximetry signal with use of digital probes associated with inappropriate extubation during prehospital rapid sequence intubation in head injury patients: case examples. *J Emerg Med.* 2012 Apr;42(4):424-8.
- 2. Wijesinghe M, Perrin K, Healy B, Hart K, Clay J, Weatherall M, Beasley R. Pre-hospital oxygen therapy in acute exacerbations of chronic obstructive pulmonary disease. *Intern Med J.* 2011 Aug;41(8): 618-22.
- 3. Langhan ML, Ching K, Northrup V, Alletag M, Kadia P, Santucci K, Chen L. A randomized controlled trial of capnography in the correction of simulated endotracheal tube dislodgement. *Acad Emerg Med.* 2011 Jun;18(6):590-6.
- 4. Davis DP, Aguilar S, Sonnleitner C, Cohen M, Jennings M. Latency and loss of pulse oximetry signal with the use of digital probes during prehospital rapid-sequence intubation. *Prehosp Emerg Care*. 2011 Jan-Mar;15(1):18-22.
- 5. Austin MA, Wills KE, Blizzard L, Walters EH, Wood-Baker R. Effect of high flow oxygen on mortality in chronic obstructive pulmonary disease patients in prehospital setting: randomised controlled trial. *BMJ* 2010 Oct 18;341:c5462.
- Smithline HA, Rudnitzky N, Macomber S, Blank FS. Pulse oximetry using a disposable finger sensor placed on the forehead in hypoxic patients. *J Emerg Med.* 2010 Jul;39(1):121-5.
- 7. Callahan JM. Pulse oximetry in emergency medicine. *Emerg Med Clin North Am.* 2008 Nov;26(4):869-79, vii.
- 8. Perry E, Williams B. The quandary of prehospital oxygen administration in chronic obstructive pulmonary disease -- a review of the literature. *J Emerg Prim Health Care*. 2008; 6(1).
- 9. Davis DP, Hwang JQ, Dunford JV. Rate of decline in oxygen saturation at various pulse oximetry values with prehospital rapid sequence intubation. *Prehosp Emerg Care*. 2008 Jan-Mar;12(1):46-51.
- 10. Van Dyk NT, Cloyd DJ, Rea TD, Eisenberg MS. The effect of pulse oximetry on emergency medical technician decision making. *Prehosp Emerg Care* 2004 8(4):417-419.




EMERGENCY
MEDICINE
UNIVERSITY OF OKLAHOMA

\* EMS SECTION

Approved 9/04/24, Effective 1/15/25, replaces all prior versions

## 3H – WAVEFORM CAPNOGRAPHY ADULT & PEDIATRIC



#### Indications:

- 1.Medical General Assessment/General Supportive Care.
- 2.Trauma General Assessment/Trauma & Hypovolemic Shock Supportive Care.
- 3. Acute Dyspnea (Uncertain Etiology, Asthma, COPD, CHF, BRUE).
- 4.Confirmation of Endotracheal Airway Placement EARLY USE INDICATED; SEE PROTOCOL 2J.
- 5.Mechanical Ventilation
- 6. Termination of Resuscitation; SEE PROTOCOL 4K
- 7. Neurologic Disorders/Altered Mental Status (Stroke, Seizure, Syncope).
- 8. Toxicologic/Poisonings (Altered Mental Status, Dyspnea).
- 9. Trauma (Head, Face, Neck, Chest Injuries).

Contraindications: None

#### Technique:

#### (Physio-Control LifePak® 12/15) to Monitor EtCO<sub>2</sub>:

- 1. Make sure the monitor is ON.
- 2. Select the appropriate EtCO<sub>2</sub> accessory for the patient.
- 3. Open the CO<sub>2</sub> port door and insert the FilterLine® connector; turn connector clockwise until tight.
- 4. Verify that the CO<sub>2</sub> area is displayed. The EtCO<sub>2</sub> monitor performs the autozero routine as part of the initialization self-test.
- 5. Display CO<sub>2</sub> waveform in Channel 3 on the LifePak screen.
- 6. Connect the CO<sub>2</sub> FilterLine<sup>®</sup> set to the patient.
- 7. Confirm that the EtCO<sub>2</sub> value and waveform are displayed.



**Note:** Do not connect the FilterLine<sup>®</sup> set to the patient/ventilation system until the EtCO<sub>2</sub> monitor has completed its self-test and warm-up.





Approved 9/04/24, Effective 1/15/25, replaces all prior versions

### PROTOCOL 3H: Waveform capnography – Adult & Pediatric, cont.

#### **Critical Comment:**

When CO<sub>2</sub> is **NOT** detected, four factors must be quickly assessed:

- 1. Loss of airway apnea? esophageal endotracheal tube placement/migration? obstruction?
- 2. Circulatory collapse cardiac arrest? massive pulmonary embolism? exsanguination?
- 3. Equipment failure disconnected or malfunctioning bag-valve or ventilator?
- 4. Adjust EtCO2 scale to 0-20 and print 6 second strip to verify waveform capnography.


#### Interpreting Capnography:

The figure below shows a normal capnography waveform display. There are 4 phases of the waveform that require analysis. The flat  $\mathbf{A} - \mathbf{B}$  baseline segment (Respiratory Baseline) represents the beginning of exhalation of  $CO_2$  – free gas that is contained in dead space from the conduction airways (trachea, bronchi). This value normally is zero. The  $\mathbf{B} - \mathbf{C}$  segment (Expiratory Upstroke), a sharp rise, represents exhalation of a mixture of dead space gases and alveolar gases. The  $\mathbf{C} - \mathbf{D}$  segment represents the alveolar plateau, characterized by exhalation of mostly alveolar gas. Point  $\mathbf{D}$  is the end-tidal (EtCO<sub>2</sub>) value that is recorded and displayed by the monitor, (peak concentration of  $CO_2$  occurring at the end of expiration). The  $\mathbf{D} - \mathbf{E}$  segment (Inspiratory Downstroke), a sharp fall, reflects the inhalation of gases that are  $CO_2$  – free (room air or supplemental oxygen). Alterations of the normal capnograph or  $EtCO_2$  values are the result of changes in metabolism, circulation, ventilation, or equipment function.

A normal range for  $EtCO_2$  is **35 – 45 mmHg**, similar to the range of  $CO_2$  in arterial blood.

#### Normal Waveform:

Normal Capnography Waveform








Approved 9/04/24, Effective 1/15/25, replaces all prior versions

PROTOCOL 3H: Waveform capnography – Adult & Pediatric, cont.

#### **Abnormal Waveforms:**




Possible Causes:

### 1.Endotracheal tube in esophagus.


#### 2.Apnea.

- 3. Endotracheal tube or supraglottic not connected to capnography detector.
- 4. Total obstruction/mucus plugging.
- 5. Capnography malfunction if abnormal waveform persists with change in capnography adaptor, the endotracheal tube or supraglottic MUST be withdrawn and intubation or supraglottic placement reattempted.



#### Possible Causes:

- 1. Hyperventilation (due to underlying illness/injury or excessive assisted ventilations).
- 2. Hypothermia (Decrease in Metabolism).



#### Possible causes:

- 1. Bronchospasm of asthma or COPD exacerbation.
- 2. Incomplete obstruction/mucus plugging.






Approved 9/04/24, Effective 1/15/25, replaces all prior versions


### PROTOCOL 3H: Waveform capnography - Adult & Pediatric, cont.

#### **Abnormal Waveforms:**




#### Possible causes:

- 1. Hypoventilation (due to underlying illness/injury or inadequate assisted ventilations).
- 2. Hyperthermia, pain, shivering (Increase in Metabolism).



#### Possible causes:

- 1. Hypoventilation (due to underlying illness/injury or inadequate assisted ventilations).
- 2. Rising body temperature, increasing pain (Increasing Metabolism).



### Possible causes:

- Cardiopulmonary arrest.
- 2. Pulmonary embolism.
- 3. Sudden hypotension, massive blood loss, cardiopulmonary bypass.







Approved 9/04/24, Effective 1/15/25, replaces all prior versions

PROTOCOL 3H: Waveform capnography – Adult & Pediatric, cont.

**Abnormal Waveforms:** 



Cardiogenic oscillations are caused by changes in thoracic volume secondary to expansion and contraction of the myocardium with each heartbeat. They are usually seen in patients with small tidal volumes and slow respiratory rates, and are of little physiologic consequence.



Spontaneous breathing efforts may be evident on the CO2 waveform display. The patient on the top demonstrates poorer quality spontaneous breathing effort than the patient on the bottom.



Approved 9/04/24, Effective 1/15/25, replaces all prior versions PROTOCOL 3H: Waveform capnography – Adult & Pediatric, cont.

## <u>Troubleshooting Tips for EtCO2 monitoring:</u>

Observation/Message	Possible Cause	Corrective Action
ALARM APNEA	No breath has been detected for 30 seconds since last valid breath	Check the patient, then ventilation equipment for leaks/disconnected tubing
CO2 FILTERLINE OFF	FilterLine®, or any other CO2 accessories disconnected or not securely connected to the LifePak® EtCO2 connector	Connect FilterLine®, or any other CO2 accessories, to input connector or tighten connection
CO2 FILTERLINE BLOCKAGE	FilterLine® is twisted or clogged. The message appears after 30 seconds of unsuccessful purging	Check the FilterLine® and if necessary replace it
	Airway Adapter clogged	Check the Airway Adapter and necessary, replace it
CO2 FILTERLINE PURGING	FilterLine <sup>®</sup> tube twisted or clogged with water	Check the FilterLine® and if necessary, untwist or reconnect it
EtCO2 values erratic	A leak in the tubing  Assisted ventilated patient breaths spontaneously	Check for connection leaks and line leaks to patient and correct if necessary
EtCO2 values are consistently higher or lower than expected	Physiological cause  Ventilator/Assisted ventilation error	Check patient (pulse?)  Check ventilator &/or assisted ventilation rate
		Adjust EtCO2 scale to 0- 20mmHg to reflect lower than anticipated value
		Print 6 second strip for verification of waveform
XXX appears in place of EtCO2 value	CO2 module not calibrated successfully	Notify appropriate supervisor/materials agent of critical
	CO2 module failed	equipment failure





### Medical Literature References 3H - Capnography - Adult & Pediatric


- Callaway CW, Soar J, Aibiki M, Böttiger BW, Brooks SC, Deakin CD, Donnino MW, Drajer S, Kloeck W, Morley PT, Morrison LJ, Neumar RW, Nicholson TC, Nolan JP, Okada K, O'Neil BJ, Paiva EF, Parr MJ, Wang TL, Witt J; Advanced Life Support Chapter Collaborators. Part 4: Advanced Life Support: 2015 International Consensus on Cardiopulmonary Resuscitation and Emergency Cardiovascular Care Science With Treatment Recommendations. *Circulation*. 2015 Oct 20;132(16 Suppl 1):S84-145.
- 2. Phelan MP, Ornato JP, Peberdy MA, Hustey FM; American Heart Association's Get With The Guidelines-Resuscitation Investigators. Appropriate documentation of confirmation of endotracheal tube position and relationship to patient outcome from in-hospital cardiac arrest. *Resuscitation*. 2013 Jan;84(1):31-6.
- 3. Goodloe JM. Basic Capnography. JEMS. 2012 Mar: s4-s7
- 4. Isbell CL, Batchinsky AI, Hetz KM, Baker WL, Cancio LC. Correlation between capnography and arterial carbón dioxide before, during, and after severe chest injury in swine. *Shock*. 2012 Jan;37(1):103-9.
- 5. White RD, Goodman BW, Arendt CJ. Neurologically Intact Survival Following Prolonged Cardiac Arrest Monitored With Continuous Capnography and Subsequent Treatment With Therapeutic Hypothermia. *Mayo Clin Proc.* November 2011;86(11):1124-1126
- 6. Langhan ML, Ching K, Northrup V, Alletag M, Kadia P, Santucci K, Chen L. A randomized controlled trial of capnography in the correction of simulated endotracheal tube dislodgement. *Acad Emerg Med.* 2011 Jun;18(6):590-6.
- 7. Einav S, Bromiker R, Weiniger CF, Matot I. Mathematical modeling for prediction of survival from resuscitation based on computerized continuous capnography: proof of concept. *Acad Emerg Med.* 2011 May;18(5):468-75.
- 8. Kartal M, Eray O, Rinnert S, Goksu E, Bektas F, Eken C. ETCO<sub>2</sub>: a predictive tool for excluding metabolic disturbances in nonintubated patients. *Am J Emerg Med.* 2011 Jan;29(1):65-9.
- 9. Delerme S, Freund Y, Renault R, Devilliers C, Castro S, Chopin S, Juillien G, Riou B, Ray P. Concordance between capnography and capnia in adults admitted for acute dyspnea in an ED. *Am J Emerg Med*. 2010 Jul;28(6):711-4.
- 10. Jabre P, Jacob L, Auger H, Jaulin C, Monribot M, Aurore A, Margenet A, Marty J, Combes X.Capnography monitoring in nonintubated patients with respiratory distress. *Am J Emerg Med.* 2009 Nov;27(9):1056-9.
- 11. Moses JM, Alexander JL, Agus MS. The correlation and level of agreement between end-tidal and blood gas pCO2 in children with respiratory distress: a retrospective analysis. *BMC Pediatr.* 2009 Mar 12:9:20.
- 12. Warner KJ, Cuschieri J, Garland B, Carlbom D, Baker D, Copass MK, Jurkovich GJ, Bulger EM. The utility of early end-tidal capnography in monitoring ventilation status after severe injury. *J Trauma*. 2009 Jan;66(1):26-31.
- 13. Silvestri S, Ralls GA, Krauss B, Thundiyil J, Rothrock SG, Senn A, Carter E, Falk J. The effectiveness of out-of-hospital use of continuous end-tidal carbon dioxide monitoring on the rate of unrecognized misplaced intubation within a regional emergency medical services system. *Ann Emerg Med.* 2005 May;45(5):497-503.
- 14. Katz SH, Falk JL. Misplaced endotracheal tubes by paramedics in an urban emergency medical services system. *Ann Emerg Med.* 2001 Jan;37(1):32-7.





Approved 9/04/24, Effective 1/15/25, replaces all prior versions

## 3I – OXYGEN ADMINISTRATION ADULT & PEDIATRIC



#### Indications:

#### Use in chronic conditions to include:

COPD – chronic bronchitis or emphysema

Chronic lung disease – lung cancer, sarcoidosis, pulmonary fibrosis, pulmonary hypertension.

EMS administration of O<sub>2</sub> may be at usual concentrations (e.g. nasal cannula flow at 2-3 liters per minute) or at higher concentrations than usual during acute dyspnea episodes (e.g. non-rebreather mask flow at 12 liters per minute) if the chronic pulmonary disease patient exhibits more than typical dyspnea or more than typical hypoxemia.

#### Use in acute conditions to include:

Respiratory arrest

Dyspnea – uncertain etiology, asthma, COPD, CHF, BRUE, acute allergic reaction Cardiac arrest

Acute coronary syndrome (if associated with dyspnea or pulse oximetry< 94%) Stroke (if associated with dyspnea or pulse oximetry< 94%)

Stroke (If associated with dysphea or pulse oximetry< 94%

Multi-systems trauma

EMS administration of O<sub>2</sub> should be goal-directed to achieve oxygen saturation levels, based on pulse oximetry, with a target level of 94–98% in most patients, or 88–92% in COPD patients.

#### Precautions:

Excessive oxygen levels can impair the respiratory drive in chronic pulmonary disease patients and paradoxically contribute to as much tissue disease as hypoxemia. Multiple studies show that **hyper**oxemia in certain ischemic tissue disease events (e.g. cardiac arrest, stroke) can lead to worse outcomes than normal oxygen levels. Treat hypoxemia, but avoid excessive oxygen levels that are unneeded in addressing patient symptoms of dyspnea or signs of respiratory failure (e.g. low pulse oximetry readings).





Approved 9/04/24, Effective 1/15/25, replaces all prior versions PROTOCOL 3I: Oxygen Administration – Adult & Pediatric, cont.

#### Supplemental oxygen concentration capabilities of different devices:

Via nasal cannula (NC) at 1-6 liters per minute (lpm), yields 24-44% concentration of inhaled oxygen (FiO<sub>2</sub> of 0.24-0.40). Typically, each additional liter flow will increase the concentration of inhaled oxygen by 4%. With higher lpm flows (5-6 lpm) via NC, nasal irritation and drying of mucosa can occur without use of humidified O<sub>2</sub>.

There are a number of face mask options, such as the simple face mask, often used between 6 and 12 lpm, resulting in a concentration of oxygen to the patient between 40% and 50%. This is closely related to the more controlled air-entrainment masks, also known as Venturi masks, which can accurately deliver a predetermined oxygen concentration in a range of 24 - 50%.

In some instances, a partial rebreathing mask can be used, which is based on a non-rebreather mask, but with the valves over the exhalation ports removed. The partial rebreathing mask can provide oxygen concentration in the 40 - 70% using up to 15 lpm flow.

Non-rebreather masks draw oxygen from an attached reservoir bag, with one-way valves that direct exhaled air out of the mask. When properly fitted and used at flow rates of 10-15 LPM or higher, they deliver 60 - 80% oxygen concentrations and occasionally higher, depending upon mask/face interface and valve function. Minimum lpm flow through a non-rebreather (even when using for presumed psychogenic hyperventilation) should be 10 lpm.





## Medical Literature References 3I – Oxygen Administration – Adult & Pediatric


- Travers AH, Perkins GD, Berg RA, Castren M, Considine J, Escalante R, Gazmuri RJ, Koster RW, Lim SH, Nation KJ, Olasveengen TM, Sakamoto T, Sayre MR, Sierra A, Smyth MA, Stanton D, Vaillancourt C; Basic Life Support Chapter Collaborators. Part 3: Adult Basic Life Support and Automated External Defibrillation: 2015 International Consensus on Cardiopulmonary Resuscitation and Emergency Cardiovascular Care Science With Treatment Recommendations. *Circulation*. 2015 Oct 20;132(16 Suppl 1):S51-83.
- Callaway CW, Soar J, Aibiki M, Böttiger BW, Brooks SC, Deakin CD, Donnino MW, Drajer S, Kloeck W, Morley PT, Morrison LJ, Neumar RW, Nicholson TC, Nolan JP, Okada K, O'Neil BJ, Paiva EF, Parr MJ, Wang TL, Witt J; Advanced Life Support Chapter Collaborators. Part 4: Advanced Life Support: 2015 International Consensus on Cardiopulmonary Resuscitation and Emergency Cardiovascular Care Science With Treatment Recommendations. *Circulation*. 2015 Oct 20;132(16 Suppl 1):S84-145.
- de Caen AR, Maconochie IK, Aickin R, Atkins DL, Biarent D, Guerguerian AM, Kleinman ME, Kloeck DA, Meaney PA, Nadkarni VM, Ng KC, Nuthall G, Reis AG, Shimizu N, Tibballs J, Veliz Pintos R; Pediatric Basic Life Support and Pediatric Advanced Life Support Chapter Collaborators. Part 6: Pediatric Basic Life Support and Pediatric Advanced Life Support: 2015 International Consensus on Cardiopulmonary Resuscitation and Emergency Cardiovascular Care Science With Treatment Recommendations. Circulation. 2015 Oct 20;132(16 Suppl 1):S177-203.
- 4. Cameron L, Pilcher J, Weatherall M, Beasley R, Perrin K. The risk of serious adverse outcomes associated with hypoxaemia and hyperoxaemia in acute exacerbations of COPD. *Postgrad Med J*. 2012 Dec;88(1046):684-9.
- 5. Martin DS, Grocott MP. Oxygen therapy in critical illness: precise control of arterial oxygenation and permissive hypoxemia. *Crit Care Med.* 2013 Feb;41(2):423-32.
- 6. Chu DK, Kim LH-Y, Young PJ, et al. Mortality and morbidity in acutely ill adults treated with liberal versus conservative oxygen therapy (IOTA): a systematic review and meta-analysis. *The Lancet*. 2018;391(10131):1693-1705. doi:10.1016/S0140-6736(18)30479-3





Approved 9/04/24, Effective 1/15/25, replaces all prior versions

### 3J – NEBULIZATION THERAPY ADULT & PEDIATRIC



EMR may only assist with patient's own nebulizer

### Indications:

- 1. Dyspnea Uncertain Etiology
- 2. Dyspnea Asthma
- 3. Dyspnea Chronic Obstructive Pulmonary Disease (COPD)
- 4. Acute Allergic Reactions
- 5. Bronchospasm from toxic inhalations

#### **Contraindications:**

1. Non-bronchospastic respiratory distress (e.g., clear presentation of CHF)

#### Technique:

- A. Assemble nebulization device.
- B. Fill nebulization chamber with medication to be nebulized.
- C. Initiate 6-10 lpm O<sub>2</sub> flow if using hand-held nebulization device or via face mask.
- D. Place nebulization chamber "in-line" with respiratory circuit if using nebulization via NIPPV, supraglottic airway or endotracheal tube. Use continuing pre-nebulization lpm flow of O<sub>2</sub> to deliver nebulized medication through the respiratory circuit.

Repeat steps B – D as patient condition indicates per applicable protocol(s).





## Medical Literature References 3J – Nebulization Therapy - Adult & Pediatric


- Myers JB, Slovis CM, Eckstein M, Goodloe JM, Isaacs SM, Loflin JR, Mechem CC, Richmond NJ, Pepe PE; U.S. Metropolitan Municipalities' EMS Medical Directors. Evidence-based performance measures for emergency medical services systems: a model for expanded EMS benchmarking. *Prehosp Emerg Care*. 2008 Apr-Jun;12(2):141-51.
- 2. Bryson D, Camargo CA Domeier RM, Gaeta TJ, Hendeles L, Hise S, Nowak RM, Russotti R, Sapien R, Wallace D, Wright JL, Boss L, Greiling A, Redd S, Workgroup on EMS Management of Asthma Exacerbations. A model protocol for emergency medical services management of asthma exacerbations. *Prehosp Emerg Care*. 2006 Oct-Dec;10(4):418-429.
- 3. Rowe BH, Camargo CA Jr. Emergency department treatment of severe acute asthma. *Ann Emerg Med.* 2006 Jun;47(6):564-6.
- 4. Richmond NJ, Silverman R, Kusick M, Matallana L, Winokur J. Out-of-hospital administration of albuterol for asthma by basic life support providers. *Acad Emerg Med.* 2005 May;12(5):396-403.
- 5. Markenson D, Foltin G, Tunik M, Cooper A, Treiber M, Caravaglia K. Albuterol sulfate administration by EMT-basics: results of a demonstration project. *Prehosp Emerg Care*. 2004 Jan-Mar;8(1):34-40.
- 6. Delbridge T, Domeier R, Key CB. Prehospital asthma management. *Prehosp Emerg Care*. 2003 Jan-Mar;7(1):42-7.





Approved 9/04/24, Effective 1/15/25, replaces all prior versions

## 3K – NON-INVASIVE POSITIVE PRESSURE VENTILATION (NIPPV) ADULT & INTER- FACILITY PEDIATRIC



### Indications:

- 1. Dyspnea Uncertain Etiology Adult.
- 2. Dyspnea Asthma Adult.
- 3. Dyspnea Chronic Obstructive Pulmonary Disease (COPD) Adult.
- 4. Dyspnea Congestive Heart Failure (CHF) Adult.
- 5. Acute Allergic Reactions Adult (Dyspnea).
- 6. Water Submersion Event Adult (Dyspnea).
- 7. Pediatric Dyspnea Inter-Facility Continuation of Care.

#### Contraindications:

- 1. Apnea.
- 2. Pediatric dyspnea- Non-Inter-Facility/Non-Continuation of Care.
- 3. Adult dyspnea of lesser severity able to be managed without NIPPV.
- 4. Adult dyspnea of greater severity requiring invasive airway management.
- 5. Altered mental status preventing patient cooperation with NIPPV.
- 6. Active or suspected impending emesis.
- 7. High risk of aspiration/Impaired gag reflex.
- 8. Facial trauma/features impairing a tight NIPPV mask-face seal.






Approved 9/04/24, Effective 1/15/25, replaces all prior versions

PROTOCOL 3K: Non – Invasive Positive Pressure Ventilation (NIPPV) - Adult & Inter-Facility Pediatric, cont.

#### Bi-Level/CPAP Ventilation Algorithm



#### Special Considerations/Complications

- Patients requiring bronchodilator therapy?
  - ✓ Bronchodilators via nebulizer t-piece in line with NIPPV
- It is very important to achieve a tight seal between face and NIPPV mask to deliver anticipated levels of NIPPV
- Monitor closely for nausea/impending emesis be prepared to quickly remove facemask to avoid aspiration of emesis






Approved 9/04/24, Effective 1/15/25, replaces all prior versions

PROTOCOL 3K: Non – Invasive Positive Pressure Ventilation (NIPPV) - Adult & Inter-Facility Pediatric, cont.

#### Technique (ZoLL Z Vent):

#### Circuits:



- Zoll Z ventilator circuits feature a low dead space design that minimizes CO2 rebreathing.
- 2. Note: dead space (circuit and HME) should never be greater than 25% of the patient's tidal volume (set or spontaneous.
- 3. The 2 standard ventilator circuits cover the range of patient from infant through adult.


➤ Pediatric/adult – patients 20 kg through adult, minimum tidal volume 200mL.

\*\*\*Ventilator use in pediatrics restricted to inter-facility transport only.\*\*\*

➤ Infant/pediatric – 5 through 30 kg, maximum tidal volume 300 mL. \*\*\*Ventilator use in pediatrics restricted to inter-facility transport only.\*\*\*

### Connections - check the ventilator for proper operation before connecting to patient:

<u>Step 1</u>: Connect ventilator circuit (use test lung whenever possible) oxygen hose to 55 psi regulated output.



Clear hose to exhalation valve

Patient circuit corrugated tubing to gas





Approved 9/04/24, Effective 1/15/25, replaces all prior versions

## PROTOCOL 3K: Non - Invasive Positive Pressure Ventilation (NIPPV) - Adult & Inter-Facility Pediatric, cont.

Step 2: Power



Turn power switch to "ON"

- Unit performs a Self-Check and AUTO-CAL of the internal transducers.
- Zoll Z then begins operation using the default settings.
- AUTO-CAL is performed every 5 minutes thereafter or when an altitude or temperature change is detected.
- Start-up settings may be changed during operation at any time.

#### Factory Defaults:

FiO2: 21%
High PIP Limit: 35 cm H2O
PEEP: 5 cm H2O
Vt: 450 ml
BPM: 12
I:E 1:3
Mode: AC (V)

Step 3: Changing a Primary Parameter:



- 1. Current value is highlighted.
- Turn rotary encoder to desired value.
  - Adult
  - Pediatric
  - ➤ NIPPV
  - Custom (Cardiac Arrest)
  - Last setting

Remember: "Touch, Turn, Confirm"™





Medical Literature References 3K – Non-Invasive Positive Pressure Ventilation (NIPPV) – Adult


- 1. Finn, J. C., Brink, D., McKenzie, N., Garcia, A., Tohira, H., Perkins, G. D., Arendts, G., Fatovich, D. M., Hendrie, D., McQuillan, B., Summers, Q., Celenza, A., Mukherjee, A., Smedley, B., Pereira, G., Ball, S., Williams, T., & Bailey, P. (2022). Prehospital continuous positive airway pressure (CPAP) for acute respiratory distress: A randomised controlled trial. *Emergency Medicine Journal*, *39*(1), 37–44. https://doi.org/10.1136/emermed-2020-210256
- 2. Goodacre S, Stevens JW, Pandor A, Poku E, Ren S, Cantrell A, Bounes V, Mas A, Payen D, Petrie D, Roessler MS, Weitz G, Ducros L, Plaisance P. Prehospital noninvasive ventilation for acute respiratory failure: systematic review, network meta-analysis, and individual patient data meta-analysis. *Acad Emerg Med.* 2014 Sep; 21(9):960-70.
- 3. Williams TA, Finn J, Perkins GD, Jacobs IG. Prehospital continuous positive airway pressure for acute respiratory failure: a systematic review and meta-analysis. *Prehosp Emerg Care*. 2013 Apr-Jun;17(2):261-73.
- 4. Williams B, Boyle M, Robertson N, Giddings C. When pressure is positive: a literature review of the prehospital use of continuous positive airway pressure. *Prehosp Disaster Med.* 2013 Feb;28(1):52-60.
- 5. Cheskes S, Thomson S, Turner L. Feasibility of Continuous Positive Airway Pressure by Primary Care Paramedics. *Prehosp Emerg Care*. 2012 Oct-Dec;16(4):535-40.
- 6. Bledsoe BE, Anderson E, Hodnick R, Johnson L, Johnson S, Dievendorf E. Low-fractional oxygen concentration continuous positive airway pressure is effective in the prehospital setting. *Prehosp Emerg Care*. 2012 Apr-Jun;16(2):217-21.
- 7. Dib JE, Matin SA, Luckert A. Prehospital use of continuous positive airway pressure for acute severe congestive heart failure. *J Emerg Med*. 2012 May;42(5):553-8.
- 8. Frontin P, Bounes V, Houzé-Cerfon CH, Charpentier S, Houzé-Cerfon V, Ducassé JL. Continuous positive airway pressure for cardiogenic pulmonary edema: a randomized study. *Am J Emerg Med.* 2011 Sep;29(7):775-81.
- 9. Daily JC, Wang HE. Noninvasive positive pressure ventilation: resource document for the National Association of EMS Physicians position statement. *Prehosp Emerg Care*. 2011 Jul-Sep;15(3):432-8.
- 10. Warner GS. Evaluation of the effect of prehospital application of continuous positive airway pressure therapy in acute respiratory distress. *Prehosp Disaster Med.* 2010 Jan-Feb;25(1):87-91.
- 11. Hubble MW, Richards ME, Wilfong DA. Estimates of cost-effectiveness of prehospital continuous positive airway pressure in the management of acute pulmonary edema. *Prehosp Emerg Care*. 2008 Jul-Sep;12(3):277-85.
- 12. Hubble MW, Richards ME, Jarvis R, Millikan T, Young D. Effectiveness of prehospital continuous positive airway pressure in the management of acute pulmonary edema. *Prehosp Emerg Care*. 2006 Oct-Dec;10(4):430-9.





Approved 9/04/24, Effective 1/15/25, replaces all prior versions

## 3L – MECHANICAL VENTILATION ADULT & INTER-FACILITY PEDIATRIC



#### Indications:

- 1. Respiratory/Cardiac Arrest Adult.
- 2. Any Medical Etiology of Dyspnea or Airway Management Requiring Intubation Adult
- 3. Any Trauma Etiology of Dyspnea or Airway Management Requiring Intubation (except suspected pneumothorax) Adult.
- 4. Pediatric Dyspnea Requiring Intubation Inter-Facility Continuation of Care.

### **Contraindications:**

- 1. Pediatric Dyspnea Non-Inter-Facility/Non-Continuation of Care.
- 2. Adult dyspnea of lesser severity able to be managed without mechanical ventilation.
- 3. Suspected or impending pneumothorax/tension pneumothorax.

#### Technique (Zoll Z Vent):

#### Controls:








Approved 9/04/24, Effective 1/15/25, replaces all prior versions

PROTOCOL 3L: Mechanical Ventilation - Adult & Inter-Facility Pediatric, cont.


#### Circuits:



- 1. Zoll Z ventilator circuits feature a low dead space design that minimizes CO2 re-breathing.
- Note: dead space (circuit and HME) should never be greater than <u>25%</u> of the patient's tidal volume (set or spontaneous).
- 3. The 2 standard ventilator circuits cover the range of patient from infant through adult.
  - Pediatric/adult patients 20 kg through adult, minimum tidal volume 200 mL; \*\*\*Ventilator use in pediatrics restricted to inter-facility transport only.\*\*\*
  - Infant/pediatric 5 through 30 kg, maximum tidal volume 300 mL. \*\*\*Ventilator use in pediatrics restricted to inter-facility transport only.\*\*\*

#### Connections- check the ventilator for proper operation before connecting to patient:

<u>Step 1</u>: Connect ventilator circuit (use test lung whenever possible) oxygen hose to 55 psi regulated output.







Approved 9/04/24, Effective 1/15/25, replaces all prior versions

### PROTOCOL 3L: Mechanical Ventilation - Adult & Inter-Facility Pediatric, cont.

#### Step 2: Power:



Turn power switch to "ON"

- Unit performs a Self-Check and AUTO-CAL of the internal transducers.
- Zoll Z then begins operation using the default settings.
- AUTO-CAL is performed every 5 minutes thereafter or when an altitude or temperature change is detected.
- Start-up settings may be changed during operation at any time.

### Factory Defaults:

FiO2: 21%
High PIP Limit: 35 cm H2O
PEEP: 5 cm H2O
Vt: 450 ml
BPM: 12
I:E 1:3
Mode: AC (V)

Step 3: Changing a Primary Parameter:



- 1. Current value is highlighted.
- 2. Turn rotary encoder to desired value.
  - > Adult
  - Pediatric
    - ➤ NIPPV
    - Custom (Cardiac Arrest)
    - Last setting

Remember: "Touch, Turn, Confirm"™





Approved 9/04/24, Effective 1/15/25, replaces all prior versions

PROTOCOL 3L: Mechanical Ventilation - Adult & Inter-Facility Pediatric, cont.

## <u>"Custom" (For Adult Cardiac Arrest ONLY)</u>: (Figure 1)

• FiO2: 100%

• PIP: 25 cm H2O (Max

50 cm H2O)

• PEEP: 3 cm H2O

• Vt: 400-500 ml (titrate PIP to keep tidal volume within this

range.)

BPM: 10
 I:E 1:3
 Mode: SIMV (P)

#### Once Ventilator Powered On;

- Select "Custom" from Start Menu
- Press select "√" green check twice (double tap) at startup
- Confirm Correct Pre-programmed Settings
- Titrate only PIP, other settings remain as specified above



### Safety notes:

- A. Initial airway management and ventilation must not be compromised while preparing mechanical ventilation equipment.
- B. If problems arise during Zoll Z vent use or if there is uncertainty about the adequacy of oxygenation and ventilations with the Zoll Z vent, then STOP and ensure oxygenation and ventilation with the usual methods.
- C. Using the Zoll Z vent mechanical ventilation device will give the ability to determine early changes in pulmonary compliance, such as may be detected using a bag-ventilation technique.
- D. The incidence of a pneumothorax is increased in the presence of chest trauma with any form of positive pressure ventilation.
- E. Gastric distention can cause resistance to mechanical ventilation. Gastric distention should be suspected in patients with an acutely distended abdomen after non-intubate positive pressure ventilation. Relieve gastric distention impairing respiratory mechanics with either a nasogastric or orogastric tube with low suction until distention is relieved.
- F. Continuous waveform capnography is indicated for mechanical ventilation utilizing the Zoll Z. If transporting a patient with a home ventilator that remains on baseline settings the use of continuous waveform capnography is optional.





#### Medical Literature References 3L – Mechanical Ventilation – Adult

- 1. Cheskes S, Thomson S, Turner L. Feasibility of Continuous Positive Airway Pressure by Primary Care Paramedics. *Prehosp Emerg Care*. 2012 Oct-Dec;16(4):535-40.
- 2. Bledsoe BE, Anderson E, Hodnick R, Johnson L, Johnson S, Dievendorf E. Low-fractional oxygen concentration continuous positive airway pressure is effective in the prehospital setting. *Prehosp Emerg Care*. 2012 Apr-Jun;16(2):217-21.
- 3. Dib JE, Matin SA, Luckert A. Prehospital use of continuous positive airway pressure for acute severe congestive heart failure. *J Emerg Med*. 2012 May;42(5):553-8.
- 4. Frontin P, Bounes V, Houzé-Cerfon CH, Charpentier S, Houzé-Cerfon V, Ducassé JL. Continuous positive airway pressure for cardiogenic pulmonary edema: a randomized study. *Am J Emerg Med.* 2011 Sep;29(7):775-81.
- 5. Daily JC, Wang HE. Noninvasive positive pressure ventilation: resource document for the National Association of EMS Physicians position statement. *Prehosp Emerg Care*. 2011 Jul-Sep;15(3):432-8.
- 6. Warner GS. Evaluation of the effect of prehospital application of continuous positive airway pressure therapy in acute respiratory distress. *Prehosp Disaster Med.* 2010 Jan-Feb;25(1):87-91.
- 7. Hubble MW, Richards ME, Wilfong DA. Estimates of cost-effectiveness of prehospital continuous positive airway pressure in the management of acute pulmonary edema. *Prehosp Emerg Care*. 2008 Jul-Sep;12(3):277-85.
- 8. Hubble MW, Richards ME, Jarvis R, Millikan T, Young D. Effectiveness of prehospital continuous positive airway pressure in the management of acute pulmonary edema. *Prehosp Emerg Care*. 2006 Oct-Dec;10(4):430-9.





Approved 9/04/24, Effective 1/15/25, replaces all prior versions

#### TREATMENT PRIORITIES

- 1. Vital signs (including EtCO2, if equipped)
- 2. Oxygenation support
  - O₂ by NC, NRB
  - BVM, ETT if indicated
- 3. Ventilation support
  - > BVM, ETT if indicated
- 4. Nebulization therapy
  - Epinephrine 1mg/mL 1:1,000 at 3ml

Consider Foreign body as a cause of stridor

### 3M – DYSPNEA – CROUP PEDIATRIC

#### **EMD**

ADVISE TO AVOID PHYSICAL EXERTION
OR ENVIRONMENTAL STRESS (TEMP EXTREMES).
ADVISE PT SELF-ADMINISTRATION OF MEDICATIONS
(eg. ALBUTEROL INHALER)
AS PREVIOUSLY PRESCRIBED FOR DYSPENA SYMPTOMS

## EMERGENCY MEDICAL DISPATCHER

EMERGENCY MEDICAL RESPONDER

**EMT** 

**EMT-INTERMEDIATE 85** 

**ADVANCED EMT** 

**PARAMEDIC** 

EMR EMT

CROUP MOSTLY OCCURS IN INFANTS AND YOUNG CHILDREN BETWEEN SIX MONTHS AND THREE YEARS OF AGE, AND IS LESS COMMONLY SEEN IN CHILDREN OLDER THAN SIX YEARS

GENERAL SUPPORTIVE CARE
OBTAIN VITAL SIGNS
O₂ VIA NC, NRB, OR BVM AS APPROPRIATE
APPLY CARDIAC MONITOR (if equipped)
ATTEMPT TO KEEP CHILD CALM WHILE PROPERLY SECURING THE CHILD FOR TRANSPORT

#### **EMT OR HIGHER LICENSE:**

MEASURE END-TIDAL CO<sub>2</sub> & MONITOR WAVEFORM CAPNOGRAPHY (if equipped.\*\*Mandatory use if pt intubated)

EMT-185 AEMT

PEDIATRIC: INTUBATE IF INDICATED PER PROTOCOL 17E

IV ACCESS

**PEDIATRIC:** IV NS TKO IF SYS BP ≥ (70 + 2x age in years) mmHg **PEDIATRIC:** IV NS 20 mL/kg BOLUS IF SYS BP < (70 + 2x age in years) mmHg IF NO SIGNS OF PULMONARY EDEMA

#### **PARAMEDIC**

PEDIATRIC: METHYLPREDNISOLONE 2 mg/kg NOT TO EXCEED 125 mg IVP or DEXAMETHASONE 0.6 mg/kg NOT TO EXCEED 10 mg IVP, MAY GIVE IM IF NO VASCULAR ACCESS OBTAINED.

FOR SIGNIFICANT INSPIRATORY STRIDOR AT REST, DECREASED RESPONSIVENESS, POOR PERFUSION, APNEA OR CYANOSIS PEDIATRIC: NEBULIZED EPINEPHRINE 1mg/mL (1:1000) at 3mg/3mL VIA NEBULIZER

PEDIATRIC: MEDICATION-ASSISTED INTUBATION IF INDICATED PER PROTOCOL 17F CONTINUOUS ASSESSMENT & TREATMENT PER APPLICABLE PROTOCOL(S)





Medical Literature References 3M – Dyspnea-Croup – Pediatric

- 1. Eghbali A, Sabbagh A, Bagheri B, Taherahmadi H, Kahbazi M. Efficacy of nebulized L-epinephrine for treatment of croup: A randomized, double-blind study. Fundam Clin Pharmacol. 2016. doi:10.1111/fcp.12158.
- 2. Petrocheilou A, Tanou K, Kalampouka E, Malakasioti G, Giannios C, Kaditis AG. Viral croup: Diagnosis and a treatment algorithm. Pediatr Pulmonol. 2014. doi:10.1002/ppul.22993.
- 3. Bjornson C, Russell KF, Vandermeer B, Durec T, Klassen TP, Johnson DW. Nebulized epinephrine for croup in children. Evidence-Based Child Heal. 2012. doi:10.1002/ebch.1856.
- 4. Argent AC, Hatherill M, Newth CJL, Klein M. The effect of epinephrine by nebulization on measures of airway obstruction in patients with acute severe croup. Intensive Care Med. 2008. doi:10.1007/s00134-007-0855-0.
- 5. Stannard W, O'Callaghan C. Management of croup. Pediatr Drugs. 2002. doi:10.2165/00128072-200204040-00003.
- 6. Wright RB, Pomerantz WJ, Luria JW. New approaches to respiratory infections in children: Bronchiolitis and croup. Emerg Med Clin North Am. 2002. doi:10.1016/S0733-8627(03)00053-1.
- Waisman Y, Klein BL, Boenning DA, et al. Prospective randomized double-blind study comparing L-epinephrine and racemic epinephrine aerosols in the treatment of laryngotracheitis (croup). Pediatrics. 1992.



Approved 9/04/24. Effective 1/15/25, replaces all prior versions



### **4A - RESUSCITATION (CPR) ADULT & PEDIATRIC**

**EMD** 

CPR BY EMD INSTRUCTION

#### TREATMENT PRIORITIES:

- 1. Circulatory support
  - Apply ResQCPR® within 2 minutes
- Chest compression rate 80/min ResQCPR®
- Chest compression rate 110/min standard CPR
- Appropriate compression depth & full recoil
- Limit pauses in compressions
- Timely defibrillation (if indicated)
- Utilize Res-Q-Pod®
- 2. Oxygenation/Ventilation support
  - > Avoid hyperventilation in rate & volume
  - Use waveform capnography (if equipped)
    - \*\*Mandatory use if patient intubated

### **DISPATCHER** EMERGENCY MEDICAL

RESPONDER

**EMERGENCY MEDICAL** 

**EMT** 

**EMT-INTERMEDIATE 85** 

**ADVANCED EMT** 

**PARAMEDIC** 

**EMT** 

POSITION PATIENT FOR EFFECTIVE RESUSCITATION. FOR ADULT NONTRAUMATIC CARDIAC ARREST ONLY: CHEST COMPRESSIONS AT 80/MINUTE USING ResQCPR® CHEST COMPRESSIONS AT 110 COMPRESSIONS/MINUTE USING HANDS ONLY USE METRONOME THROUGHOUT TO GUIDE COMPRESSION RATE LIMIT PAUSES IN CHEST COMPRESSIONS - AVOID PAUSES WHENEVER PHYSICALLY POSSIBLE.

APPLY AED (OR MANUAL DEFIBRILLATION PADS IF PARAMEDIC PRESENT) PLACE PADS ANTERIOR-POSTERIOR.

IF CARDIAC ARREST DURATION ESTIMATED > 4 MINS AND WITHOUT GOOD QUALITY BYSTANDER CPR. PERFORM CPR FOR 2 MINUTES PRIOR TO AED/RHYTHM ANALYSIS FOR DEFIBRILLATION DETERMINATION.

IF CARDIAC ARREST DURATION ESTIMATED ≤ 4 MINS, IMMEDIATE AED/RHYTHM ANALYSIS FOR DEFIBRILLATION DETERMINATION.

ADULT: 110 COMPRESSIONS/MINUTE WITH 8-10 VENTILATIONS/MINUTE WITHOUT PAUSE IN COMPRESSIONS. ATTACH RES-Q-POD® TO BVM.

PEDIATRIC: 15 COMPRESSION: 2 VENTILATION CYCLES WITH 110 COMPRESSIONS/MINUTE RATE ASYNCHRONOUS 10 VENTILATIONS AND 110 COMPRESSIONS PER MINUTE IF ADVANCED AIRWAY IN PLACE ATTACH ResQPOD® TO BVM IF PT ≥ 12 YEARS OF AGE AND ESTIMATED WEIGHT ≥ 50 kg.

FOLLOW AED PROMPTS FOR RHYTHM ANALYSIS & DEFIBRILLATION IF INDICATED (USING 2015 AHA STANDARDS). AFTER AED SHOCK (IF APPLICABLE), IMMEDIATELY RESUME CPR FOR 2 MINUTES. IF NO AED SHOCK ADVISED, IMMEDIATELY RESUME CPR FOR 2 MINUTES.

#### **EMT OR HIGHER LICENSE ONLY:**

PLACE SUPRAGLOTTIC AIRWAY IF INDICATED & ONLY IF BVM VENTILATIONS INEFFECTIVE. IF RETURN OF SPONTANEOUS CIRCULATION, REFER TO PROTOCOL 4J - POST CARDIAC ARREST TREATMENT

> AT 20 MINS OF RESUSCITATIVE MEASURES (IF APPLICABLE): CONTACT OLMC FOR TERMINATION OF RESUSCITATION CONSULTATION (IF APPLICABLE PER PROTOCOL 4K - TERMINATION OF RESUSCITATION)

#### **EMT-185 AEMT**

ADULT: INTUBATE AFTER CPR INITIATED - FIRST ATTEMPT WITHOUT PAUSE IN COMPRESSIONS LIMIT INTUBATION COMPRESSION PAUSE TO MAXIMUM OF 10 SECONDS

IV / IO ACCESS

#### **PARAMEDIC**

ASSESS FOR UNDERLYING ETIOLOGY OF CARDIAC ARREST & TREAT PER APPLICABLE PROTOCOL(S) RHYTHM ANALYSIS AT NEXT APPROPRIATE RHYTHM CHECK LIMIT RHYTHM ANALYSIS COMPRESSION PAUSE TO MAXIMUM OF 5 SECONDS RHYTHM SPECIFIC MANAGEMENT PER APPLICABLE PROTOCOL(S) 4F - 4H





Medical Literature References 4A – Resuscitation (CPR) – Adult & Pediatric (cont)

- Goodloe, J. M., Topjian, A., Hsu, A., Dunne, R., Panchal, A. R., Levy, M., McEvoy, M., Vaillancourt, C., Cabanas, J. G., Eisenberg, M. S., Rea, T. D., Kudenchuk, P. J., Gienapp, A., Flores, G. E., Fuchs, S., Adelgais, K. M., Owusu-Ansah, S., Terry, M., Sawyer, K. N., ... Sayre, M. R. (2021). Interim Guidance for Emergency Medical Services Management of Out-of-Hospital Cardiac Arrest During the COVID-19 Pandemic. In *Circulation: Cardiovascular Quality and Outcomes* (Vol. 14, Issue 7, p. E007666). Lippincott Williams and Wilkins. https://doi.org/10.1161/CIRCOUTCOMES.120.007666
- 2. Grunau, B., Kime, N., Leroux, B., Rea, T., van Belle, G., Menegazzi, J. J., Kudenchuk, P. J., Vaillancourt, C., Morrison, L. J., Elmer, J., Zive, D. M., Le, N. M., Austin, M., Richmond, N. J., Herren, H., & Christenson, J. (2020). Association of Intra-arrest Transport vs Continued On-Scene Resuscitation with Survival to Hospital Discharge among Patients with Out-of-Hospital Cardiac Arrest. *JAMA Journal of the American Medical Association*, 324(11), 1058–1067.
- 3. Benger, J. R., Lazaroo, M. J., Clout, M., Voss, S., Black, S., Brett, S. J., Kirby, K., Nolan, J. P., Reeves, B. C., Robinson, M., Scott, L. J., Smartt, H., South, A., Taylor, J., Thomas, M., Wordsworth, S., & Rogers, C. A. (2020). Randomized trial of the i-gel supraglottic airway device versus tracheal intubation during out of hospital cardiac arrest (AIRWAYS-2): Patient outcomes at three and six months. *Resuscitation*, *157*, 74–82.
- 4. Ji, C., Lall, R., Quinn, T., Kaye, C., Haywood, K., Horton, J., ... Perkins, G. D. (2017). Post-admission outcomes of participants in the PARAMEDIC trial: A cluster randomised trial of mechanical or manual chest compressions. Resuscitation. https://doi.org/10.1016/j.resuscitation.2017.06.026
- 5. Scales, D. C., Cheskes, S., Verbeek, P. R., Pinto, R., Austin, D., Brooks, S. C., ... Morrison, L. J. (2017). Prehospital cooling to improve successful targeted temperature management after cardiac arrest: A randomized controlled trial. Resuscitation.https://doi.org/10.1016/j.resuscitation.2017.10.002
- Brooks SC, Anderson ML, Bruder E, Daya MR, Gaffney A, Otto CW, Singer AJ, Thiagarajan RR, Travers AH. Part 6: Alternative Techniques and Ancillary Devices for Cardiopulmonary Resuscitation: 2015 American Heart Association Guidelines Update for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. *Circulation*. 2015 Nov 3;132(18 Suppl 2):S436-43.
- 7. Lavonas EJ, Drennan IR, Gabrielli A, Heffner AC, Hoyte CO, Orkin AM, Sawyer KN, Donnino MW. Part 10: Special Circumstances of Resuscitation: 2015 American Heart Association Guidelines Update for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. *Circulation*. 2015 Nov 3;132(18 Suppl 2):S501-18.
- 8. Travers AH, Perkins GD, Berg RA, Castren M, Considine J, Escalante R, Gazmuri RJ, Koster RW, Lim SH, Nation KJ, Olasveengen TM, Sakamoto T, Sayre MR, Sierra A, Smyth MA, Stanton D, Vaillancourt C; Basic Life Support Chapter Collaborators. Part 3: Adult Basic Life Support and Automated External Defibrillation: 2015 International Consensus on Cardiopulmonary Resuscitation and Emergency Cardiovascular Care Science With Treatment Recommendations. *Circulation*. 2015 Oct 20:132(16 Suppl 1):S51-83.
- Callaway CW, Soar J, Aibiki M, Böttiger BW, Brooks SC, Deakin CD, Donnino MW, Drajer S, Kloeck W, Morley PT, Morrison LJ, Neumar RW, Nicholson TC, Nolan JP, Okada K, O'Neil BJ, Paiva EF, Parr MJ, Wang TL, Witt J; Advanced Life Support Chapter Collaborators. Part 4: Advanced Life Support: 2015 International Consensus on Cardiopulmonary Resuscitation and Emergency Cardiovascular Care Science With Treatment Recommendations. *Circulation*. 2015 Oct 20;132(16 Suppl 1):S84-145.





Medical Literature References 4A – Resuscitation (CPR) – Adult & Pediatric (cont)

- 10. de Caen AR, Maconochie IK, Aickin R, Atkins DL, Biarent D, Guerguerian AM, Kleinman ME, Kloeck DA, Meaney PA, Nadkarni VM, Ng KC, Nuthall G, Reis AG, Shimizu N, Tibballs J, Veliz Pintos R; Pediatric Basic Life Support and Pediatric Advanced Life Support Chapter Collaborators. Part 6: Pediatric Basic Life Support and Pediatric Advanced Life Support: 2015 International Consensus on Cardiopulmonary Resuscitation and Emergency Cardiovascular Care Science With Treatment Recommendations. Circulation. 2015 Oct 20;132(16 Suppl 1):S177-203.
- McMullan J, Gerecht R, Bonomo J, Robb R, McNally B, Donnelly J, Wang HE; CARES Surveillance Group. Airway management and out-of-hospital cardiac arrest outcome in the CARES registry. Resuscitation. 2014 May;85(5):617-22.
- 12. Vadeboncoeur T, Stolz U, Panchal A, Silver A, Venuti M, Tobin J, Smith G, Nunez M, Karamooz M, Spaite D, Bobrow B. Chest compression depth and survival in out-of-hospital cardiac arrest. *Resuscitation*. 2014 Feb;85(2):182-8.
- 13. Frascone RJ, Wayne MA, Swor RA, Mahoney BD, Domeier RM, Olinger ML, Tupper DE, Setum CM, Burkhart N, Klann L, Salzman JG, Wewerka SS, Yannopoulos D, Lurie KG, O'Neill BJ, Holcomb RG, Aufderheide TP. Treatment of non-traumatic out-of-hospital cardiac arrest with active compression decompression cardiopulmonary resuscitation plus an impedance threshold device. Resuscitation. 2013 Sep;84(9):1214-22.
- 14. Maertens VL, De Smedt LE, Lemoyne S, Huybrechts SA, Wouters K, Kalmar AF, Monsieurs KG. Patients with cardiac arrest are ventilated two times faster than guidelines recommend: an observational prehospital study using tracheal pressure measurement. Resuscitation. 2013 Jul;84(7):921-6.
- 15. Cunningham LM, Mattu A, O'Connor RE, Brady WJ. Cardiopulmonary resuscitation for cardiac arrest: the importance of uninterrupted chest compressions in cardiac arrest resuscitation. *Am J Emerg Med.* 2012 Oct;30(8):1630-8.
- 16. Monsieurs KG, De Regge M, Vansteelandt K, De Smet J, Annaert E, Lemoyne S, Kalmar AF, Calle PA. Excessive chest compression rate is associated with insufficient compression depth in prehospital cardiac arrest. *Resuscitation*. 2012 Nov;83(11):1319-23.
- 17. İdris AH, Guffey D, Aufderheide TP, Brown S, Morrison LJ, Nichols P, Powell J, Daya M, Bigham BL, Atkins DL, Berg R, Davis D, Stiell I, Sopko G, Nichol G. The Relationship Between Chest Compression Rates and Outcomes from Cardiac Arrest. *Circulation*. 2012 Jun 19;125(24):3004-12.
- 18. Vaillancourt C, Everson-Stewart S, Christenson J, Andrusiek D, Powell J, Nichol G, Cheskes S, Aufderheide TP, Berg R, Stiell IG; Resuscitation Outcomes Consortium Investigators. The impact of increased chest compression fraction on return of spontaneous circulation for out-of-hospital cardiac arrest patients not in ventricular fibrillation. *Resuscitation*. 2011 Dec;82(12):1501-7.
- 19. Aufderheide TP, Frascone RJ, Wayne MA, Mahoney BD, Swor RA, Domeier RM, Olinger ML, Holcomb RG, Tupper DE, Yannopoulos D, Lurie KG. Standard cardiopulmonary resuscitation versus active compression-decompression cardiopulmonary resuscitation with augmentation of negative intrathoracic pressure for out-of-hospital cardiac arrest: a randomised trial. Lancet. 2011 Jan22:377(9762):301-11.
- 20. Yannopoulos D, Aufderheide TP, Abella BS, et al. Quality of CPR: An important effect modifier in cardiac arrest clinical outcomes and intervention effectiveness trials. *Resuscitation*. 2015;94:106-113. doi:10.1016/j.resuscitation.2015.06.004
- 21. Banerjee PR, Ganti L, Pepe PE, Singh A, Roka A, Vittone RA. Early On-Scene Management of Pediatric Out-of-Hospital Cardiac Arrest Can Result in Improved Likelihood for Neurologically-Intact Survival. *Resuscitation*. 2019;135:162-167. doi:10.1016/j.resuscitation.2018.11.002





Medical Literature References 4A – Resuscitation (CPR) – Adult & Pediatric (cont)

- 22. Duval, S., Pepe, P. E., Aufderheide, T. P., Goodloe, J. M., Debaty, G., Labarère, J., ... Yannopoulos, D. (2019). Optimal Combination of Compression Rate and Depth During Cardiopulmonary Resuscitation for Functionally Favorable Survival. *JAMA Cardiology*. https://doi.org/10.1001/jamacardio.2019.2717
- 23. Benoit, J. L., McMullan, J. T., Wang, H. E., Xie, C., Xu, P., Hart, K. W., ... Lindsell, C. J. (2019). Timing of Advanced Airway Placement after Witnessed Out-of-Hospital Cardiac Arrest. *Prehospital Emergency Care*. https://doi.org/10.1080/10903127.2019.1595236
- 24. Wang, C. H., Lee, A. F., Chang, W. T., Huang, C. H., Tsai, M. S., Chou, E., ... Chen, W. J. (2020). Comparing Effectiveness of Initial Airway Interventions for Out-of-Hospital Cardiac Arrest: A Systematic Review and Network Meta-analysis of Clinical Controlled Trials. Annals of Emergency Medicine, 75(5), 627–636.
- 25. Panchal, A. R., Berg, K. M., Cabanãs, J. G., Kurz, M. C., Link, M. S., Del Rios, M., ... Kudenchuk, P. J. (2019). 2019 American Heart Association Focused Update on Systems of Care: Dispatcher-Assisted Cardiopulmonary Resuscitation and Cardiac Arrest Centers: An Update to the American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation, 140(24), E895–E903.
- 26. Panchal, A. R., Berg, K. M., Hirsch, K. G., Kudenchuk, P. J., Del Rios, M., Cabanãs, J. G., ... Donnino, M. W. (2019). 2019 American Heart Association Focused Update on Advanced Cardiovascular Life Support: Use of Advanced Airways, Vasopressors, and Extracorporeal Cardiopulmonary Resuscitation during Cardiac Arrest: An Update to the American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation, 140(24), E881–E894.
- 27. Duff, J. P., Topjian, A. A., Berg, M. D., Chan, M., Haskell, S. E., Joyner, B. L., ... Atkins, D. L. (2019). 2019 American Heart Association Focused Update on Pediatric Advanced Life Support: An Update to the American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation, 140(24), E904–E914.
- 28. Duff, J. P., Topjian, A. A., Berg, M. D., Chan, M., Haskell, S. E., Joyner, B. L., ... Atkins, D. L. (2019). 2019 American Heart Association Focused Update on Pediatric Basic Life Support: An Update to the American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation, 140(24), 915–921.
- 29. Soar, J., MacOnochie, I., Wyckoff, M. H., Olasveengen, T. M., Singletary, E. M., Greif, R., ... Fran Hazinski, M. (2019). 2019 International Consensus on Cardiopulmonary Resuscitation and Emergency Cardiovascular Care Science with Treatment Recommendations: Summary from the Basic Life Support; Advanced Life Support; Pediatric Life Support; Neonatal Life Support; Education, Implementation, and Teams; And First Aid Task Forces. In Circulation (Vol. 140).
- 30. Pepe, P. E., Duval, S., Aufderheide, T. P., Goodloe, J. M., Debaty, G., Labarère, J., ... Yannopoulos, D. (2019). Optimal Combination of Compression Rate and Depth during Cardiopulmonary Resuscitation for Functionally Favorable Survival. JAMA Cardiology. https://doi.org/10.1001/jamacardio.2019.2717





Approved 9/04/24, Effective 1/15/25, replaces all prior versions

### **4B - RESUSCITATION TEAM ROLES ADULT & PEDIATRIC**

#### Four + Rescuers/ Compression & Ventilation Leader/ Position 4 (P4) Always outside CPR "triangle"

- Monitors time intervals
  - Calls for compressor change every 60 seconds
  - Calls for rhythm analysis every 2 minutes
- Monitors quality of CPR and use of metronome
- 80 compressions per minute ResQCPR
- 110 compressions per minute if standard CPR
- Assures manual defibrillator in "paddles" mode
- Monitors for use of proper equipment/adjuncts
- Gathers concise history from family/bystanders
- Keeps resuscitation area quiet so team members can hear
- Monitors for DNR issues
- Avoids direct patient care to maintain supervisory duties if greater than four rescuers throughout EMS resuscitation.
- Directs "staging" of personnel beyond six rescuers away from immediate resuscitation area to prevent crowding

#### Three + Rescuers/Airway/Position 3 (P3) Always at patient's head

- Airway management per protocol(s)
  - for BVM ventilations, applies mask seal with both hands while P1 and P2 alternate bag squeezing during their respective compression off cycles. Squeezes bag only when P1 AND P2 busy with other tasks.
  - assists EMT-I/AEMT/paramedic during intubation as needed (if not EMT-I/AEMT/ paramedic)
- Avoids compression interruptions for airway procedures.

#### Single Rescuer/ Circulation 1/ Position 1 (P1) Always on patient's right

- If more than two rescuers:
  - o continuous chest compressions 1 min Adult non-trauma 80/minResQCPR® Adult/Pediatric:110/min standard CPR


  - alternates compressions with P2 charges manual defib (if applicable)last 15 seconds of P2 compressions analyzes rhythm (by AED or paramedic) if AED is used and defib indicated, resume chest

  - compressions while AED is charging. Clear for defib. Resume compressions immediately after P2 delivers AED defib or paramedic delivers manual
  - defib (if paramedic present &defib indicated) if BVM ventilations by P3 & when able, squeeze bag with ResQPod® light at 10/min rate in off compression cycle (while P2 compressing) as P3 maintains mask seal
- If two rescuers:
  - continuous chest compressions 1 min Adult non-trauma 80/min ResQCPR®
  - Adult/Pediatric:110/min standard CPR
    adult passive oxygenation with NRB O2 in second minute when P2 compressing (passive oxygenation limited to first 6 mins of EMS resuscitation)
  - pediatric: alternate 15:2 (asynchronous vents if
  - advanced airway) with P2 charges manual defib (if applicable) last 15 seconds of P2 compressions
  - if AED is used and defib indicated, resume chest compressions while AED is charging. Clear for defib. Resume compressions immediately after P2 delivers AED defib or paramedic delivers manual defib (if paramedic present &defib indicated)
- If alone and cardiac arrest duration estimated ≤ 4 mins:
  o apply AED/manual defibrillator

  - analyze rhythm (by AED or paramedic)
  - defib if indicated (by AED or paramedic) with compressions during AED or manual defib charging. Clear for defib.
  - call for additional help
  - continuous chest compressions

Adult non-trauma 80/min ResQCPR®
Adult/Pediatric:110/min standard CPR

- maintain compressions and analyze rhythm by AED or paramedic every 2 minutes (with defib if indicated as above) until additional help arrives
- If alone and cardiac arrest duration estimated >4 mins:
  - call for additional help
  - continuous chest compressions 2 mins Adult non-trauma 80/min ResQCPR<sup>®</sup>
    Adult/Pediatric:110/min standard CPR
  - apply AED/manual defibrillator
  - analyze rhythm (by AED or paramedic) defib if indicated (by AED or paramedic) with
  - compressions during AED or manual defib charging. Clear for defib.
  - maintain compressions and analyze rhythm by AED or paramedic every 2 minutes (with defib if indicated as above) until additional help arrives



#### Five + Rescuers/ Vascular and Medication/ Position 5 (P5) **Paramedic**

#### Always outside CPR "triangle" at lower 1/2 of patient

- Initiates IV/IO access
- Administers medications per protocol(s) in consult with P6 Delivers manual defib (when indicated) if both P1 and P2 nonparamedic - in this situation monitor/manual defib moved from patient upper left to P5 location

#### Two + Rescuers/ Circulation 2/ Position 2(P2) Always on patient's left

- If more than two rescuers
  - o applies AED/manual defibrillator in first minute while P1 compressing
  - if good bystander CPR for arrest estimated arrest ≤4 mins. charges manual defib (if applicable) last 15 seconds of P1 compressions & prepares to deliver compressions after
  - analyzes rhythm (by AED or paramedic) starts chest compressions immediately
  - if no defib indicated or immediately after defib (if indicated)
  - continuous chest compressions 1 min Adult non-trauma 80/min ResQCPR® (deploy ResQPUMP within 2 minutes)
  - Adult/Pediatric110/min standard CPR if no/poor bystander CPR for arrest or estimated arrest time > 4 mins, alternate compressions with P1 starts compression metronome as soon
  - as possible when P1 compressing (priority goes to AED/manual defibrillator attachment)
  - if BVM ventilations by P3 & when able, squeezes bag with ResQPod® light at 10/min rate in off compression cycle (while P1 compressing) as P3 maintains
- - applies AED/manual defibrillator in first minute while P1 compressing
  - if good bystander CPR for arrest or estimated arrest time ≤4 mins, charges manual defib (if applicable) last 15 seconds of P1 compressions & prepare to deliver compressions after rhythm analysis
  - analyzes rhythm (by AED or paramedic) starts chest compressions immediately it
  - no defib indicated or immediately after defib (if indicated)
  - continuous chest compressions 1 min Adult non-trauma 80/min ResQCPR® (deploy ResQPUMP within 2 minutes) Adult/Pediatric110/min standard CPR pediatric: alternate 15:2 (asynchronous
  - vents if advanced airway) with P1
  - if no/poor bystander CPR for arrest or estimated arrest time > 4 mins. alternate compressions with P
  - starts compression metronome as soon as possible when P1 compressing (priority goes to AED/manual defibrillator

## Six + Rescuers/ Resuscitation Leader/ Position 6 (P6)

#### Always outside CPR "triangle" at lower 1/2 of patient

- Maintains overall awareness of resuscitation dynamics "Busiest mental activity" position on team dictates little
- to no physical activity for success
- Interfaces with P1-5 as situation dictates
  Prioritizes communication with P1-3 through P4
- Assesses for etiologies of cardiac arrest
- Determines if termination of resuscitation appropriate
  - consult OLMC when indicated by protocol communicates with family/bystanders if
  - indicated





## Medical Literature References 4B – Resuscitation Team Roles – Adult & Pediatric

- 1. Okubo, M., Komukai, S., Callaway, C. W., & Izawa, J. (2021). Association of Timing of Epinephrine Administration With Outcomes in Adults With Out-of-Hospital Cardiac Arrest. *JAMA Network Open*, 4(8), e2120176. https://doi.org/10.1001/jamanetworkopen.2021.20176
- 2. Benoit JL, Gerecht RB, Steuerwald MT, McMullan JT. Endotracheal intubation versus supraglottic airway placement in out-of-hospital cardiac arrest: a meta-analysis. *Resuscitation*. 2015 Aug;93:20-6.
- 3. Lemkin DL, Witting MD, Allison MG, Farzad A, Bond MC, Lemkin MA. Electrical exposure risk associated with hands-on defibrillation. *Resuscitation*. 2014 Oct;85(10):1330-6.
- Cheskes S, Common MR, Byers PA, Zhan C, Morrison LJ. Compressions during defibrillation charging shortens shock pause duration and improves chest compression fraction during shockable out of hospital cardiac arrest. *Resuscitation*. 2014 Aug:85(8):1007-11.
- 5. Conover K, Kern KB, Silver AE, Bobrow BJ, Spaite DW, Indik JH. Resumption of chest compressions after successful defibrillation and risk for recurrence of ventricular fibrillation in out-of-hospital cardiac arrest. *Circ Arrhythm Electrophysiol.* 2014 Aug;7(4):633-9.
- Cheskes S, Schmicker RH, Verbeek PR, Salcido DD, Brown SP, Brooks S, Menegazzi JJ, Vaillancourt C, Powell J, May S, Berg RA, Sell R, Idris A, Kampp M, Schmidt T, Christenson J; Resuscitation Outcomes Consortium (ROC) Investigators. The impact of peri-shock pause on survival from out-of-hospital shockable cardiac arrest during the Resuscitation Outcomes Consortium PRIMED trial. Resuscitation. 2014;85(3):336-42
- Cunningham LM, Mattu A, O'Connor RE, Brady WJ. Cardiopulmonary resuscitation for cardiac arrest: the importance of uninterrupted chest compressions in cardiac arrest resuscitation. Am J Emerg Med. 2012 Oct;30(8):1630-8.
- 8. Roosa JR, Vadeboncoeur TF, Dommer PB, Panchal AR, Venuti M, Smith G, Silver A, Mullins M, Spaite D, Bobrow BJ. CPR variability during ground ambulance transport of patients in cardiac arrest. *Resuscitation*. 2013 May;84(5):592-5.
- 9. Idris AH, Guffey D, Aufderheide TP, Brown S, Morrison LJ, Nichols P, Powell J, Daya M, Bigham BL, Atkins DL, Berg R, Davis D, Stiell I, Sopko G, Nichol G. The Relationship Between Chest Compression Rates and Outcomes from Cardiac Arrest. *Circulation*. 2012 Jun 19;125(24):3004-12.
- 10. Field RA, Soar J, Davies RP, Akhtar N, Perkins GD. The impact of chest compression rates on quality of chest compressions a manikin study. *Resuscitation*. 2012 Mar;83(3):360-4.
- 11. Vaillancourt C, Everson-Stewart S, Christenson J, Andrusiek D, Powell J, Nichol G, Cheskes S, Aufderheide TP, Berg R, Stiell IG; Resuscitation Outcomes Consortium Investigators. The impact of increased chest compression fraction on return of spontaneous circulation for out-of-hospital cardiac arrest patients not in ventricular fibrillation. *Resuscitation*. 2011 Dec;82(12):1501-7.
- 12. Aufderheide TP, Nichol G, Rea TD, Brown SP, Leroux BG, Pepe PE, Kudenchuk PJ, Christenson J, Daya MR, Dorian P, Callaway CW, Idris AH, Andrusiek D, Stephens SW, Hostler D, Davis DP, Dunford JV, Pirrallo RG, Stiell IG, Clement CM, Craig A, Van Ottingham L, Schmidt TA, Wang HE, Weisfeldt ML, Ornato JP, Sopko G; Resuscitation Outcomes Consortium (ROC) Investigators. A trial of an impedance threshold device in out-of-hospital cardiac arrest. N Engl J Med. 2011 Sep 1;365(9):798-806.
- 13. Cheskes S, Schmicker RH, Christenson J, Salcido DD, Rea T, Powell J, Edelson DP, Sell R, May S, Menegazzi JJ, Van Ottingham L, Olsufka M, Pennington S, Simonini J, Berg RA, Stiell I, Idris A, Bigham B, Morrison L; Resuscitation Outcomes Consortium (ROC) Investigators. Perishock pause: an independent predictor of survival from out-of-hospital shockable cardiac arrest. *Circulation*. 2011 Jul 5;124(1):58-66.
- 14. Sell RE, Sarno R, Lawrence B, Castillo EM, Fisher R, Brainard C, Dunford JV, Davis DP. Minimizing preand post-defibrillation pauses increases the likelihood of return of spontaneous circulation (ROSC). *Resuscitation*. 2010 Jul;81(7):822-5.
- 15. Kern KB, Stickney RE, Gallison L, Smith RE. Metronome improves compression and ventilation rates during CPR on a manikin in a randomized trial. *Resuscitation*. 2010 Feb;81(2):206-10.
- 16. Jäntti H, Silfvast T, Turpeinen A, Kiviniemi V, Uusaro A. Influence of chest compression rate guidance on the quality of cardiopulmonary resuscitation performed on manikins. *Resuscitation*. 2009 Apr;80(4):453-7.





## Medical Literature References 4B – Resuscitation Team Roles – Adult & Pediatric (cont)


- 17. Bobrow BJ, Ewy GA, Clark L, Chikani V, Berg RA, Sanders AB, Vadeboncoeur TF, Hilwig RW, Kern KB. Passive oxygen insufflation is superior to bag-valve-mask ventilation for witnessed ventricular fibrillation out-of-hospital cardiac arrest. *Ann Emerg Med.* 2009 Nov;54(5):656-662.e1.
- 18. Bertrand C, Hemery F, Carli P, Goldstein P, Espesson C, Rüttimann M, Macher JM, Raffy B, Fuster P, Dolveck F, Rozenberg A, Lecarpentier E, Duvaldestin P, Saissy JM, Boussignac G, Brochard L; Boussignac Study Group. Constant flow insufflation of oxygen as the sole mode of ventilation during out-of-hospital cardiac arrest. *Intensive Care Med.* 2006 Jun;32(6):843-51.
- 19. Pepe PE, Roppolo LP, Fowler RL. The detrimental effects of ventilation during low-blood-flow states. *Curr Opin Crit Care*. 2005 Jun;11(3):212-8.





Approved 9/04/24, Effective 1/15/25, replaces all prior versions

## 4C – AUTOMATED EXTERNAL DEFIBRILLATION (AED) ADULT & PEDIATRIC



### Indications:

Adults and pediatrics that are unresponsive, apneic or agonally breathing, and pulseless.


### **Contraindications:**

None, though futile in obvious death (decapitation, rigor mortis, dependent lividity, and/or decomposition).

### Technique (Physio-Control LifePak®1000):

- 1. Turn ON AED. (Figure 1)
- 2. Apply AED. Follow illustration for correct defibrillation pad placement. (Figure 2)
  - a. Avoid air spaces/incomplete skin contact under pads.
  - b. Avoid placing pads over suspected implanted pacemakers and/or implanted defibrillators.
  - c. NOTE (Pediatric): If victim is less than 8 years old or under 25 kg (55 lbs), connect the Infant/Child Reduced Energy Defibrillation Electrodes to the AED and proceed to STEP 3. If Infant/Child Reduced Energy Defibrillation Electrodes are unavailable, place pads in anterior left chest and posterior left chest position when using a standard AED.
  - d. NOTE (Infant <1 year of age): Manual defibrillation preferred. Follow STEP 2c if manual defibrillation/paramedic unavailable.









Approved 9/04/24, Effective 1/15/25, replaces all prior versions

### Protocol 4C: Automated External Defibrillation (AED) – Adult& Pediatric, cont.

- 3. Follow AED visual and voice prompts.
  - a. If cardiac arrest duration estimated >4 minutes and without good quality bystander CPR, perform CPR for 2 minutes prior to AED analysis for defibrillation determination.
  - b. If cardiac arrest duration estimated ≤4 minutes, immediate AED analysis for defibrillation determination.
- 4. Follow all AED manufacturer recommendations for safe, effective, and accurate rhythm analysis and defibrillation.
- 5. Restart chest compressions while the AED is charging. **DO NOT CONTINUE TO PROVIDE CHEST COMPRESSIONS WHEN THE AED IS DISCHARGING / DEFIBRILLATING.**
- 6. Resuscitate victims of cardiac arrest per applicable protocol(s), minimizing pauses in chest compressions (see Protocol 4B Resuscitation Team Roles).





## Medical Literature References 4C–Automated External Defibrillation (AED) – Adult & Pediatric

- Nichol, G., Sayre, M. R., Guerra, F., & Poole, J. (2017). Defibrillation for Ventricular Fibrillation: A Shocking Update. Journal of the American College of Cardiology. https://doi.org/10.1016/i.jacc.2017.07.778
- Olsen J, Brunborg C, Steinberg M, Persse D, Sterz F, Lozano Jr M, Westfall M, Travis DT, Lerner EB, Brouwer MA, Wik L. Pre-shock chest compression pause effects on termination of ventricular fibrillation/tachycardia and return of organized rhythm within mechanical and manual cardiopulmonary resuscitation. *Resuscitation*. 93 (2015):158-163.
- 3. Travers AH, Perkins GD, Berg RA, Castren M, Considine J, Escalante R, Gazmuri RJ, Koster RW, Lim SH, Nation KJ, Olasveengen TM, Sakamoto T, Sayre MR, Sierra A, Smyth MA, Stanton D, Vaillancourt C; Basic Life Support Chapter Collaborators. Part 3: Adult Basic Life Support and Automated External Defibrillation: 2015 International Consensus on Cardiopulmonary Resuscitation and Emergency Cardiovascular Care Science With Treatment Recommendations. *Circulation*. 2015 Oct 20;132(16 Suppl 1):S51-83.
- Welsford M, Nikolaou NI, Beygui F, Bossaert L, Ghaemmaghami C, Nonogi H, O'Connor RE, Pichel DR, Scott T, Walters DL, Woolfrey KG; Acute Coronary Syndrome Chapter Collaborators.
   Part 5: Acute Coronary Syndromes: 2015 International Consensus on Cardiopulmonary Resuscitation and Emergency Cardiovascular Care Science With Treatment Recommendations.
   Circulation. 2015 Oct 20;132(16 Suppl 1):S146-76.
- 5. de Caen AR, Maconochie IK, Aickin R, Atkins DL, Biarent D, Guerguerian AM, Kleinman ME, Kloeck DA, Meaney PA, Nadkarni VM, Ng KC, Nuthall G, Reis AG, Shimizu N, Tibballs J, Veliz Pintos R; Pediatric Basic Life Support and Pediatric Advanced Life Support Chapter Collaborators. Part 6: Pediatric Basic Life Support and Pediatric Advanced Life Support: 2015 International Consensus on Cardiopulmonary Resuscitation and Emergency Cardiovascular Care Science With Treatment Recommendations. *Circulation*. 2015 Oct 20;132(16 Suppl 1):S177-203.
- 6. Winship C, Williams B, Boyle MJ. Cardiopulmonary resuscitation before defibrillation in the out-of-hospital setting: a literature review. *Emerg Med J.* 2012 Oct;29(10):826-9.
- Cheskes S, Schmicker RH, Christenson J, Salcido DD, Rea T, Powell J, Edelson DP, Sell R, May S, Menegazzi JJ, Van Ottingham L, Olsufka M, Pennington S, Simonini J, Berg RA, Stiell I, Idris A, Bigham B, Morrison L; Resuscitation Outcomes Consortium (ROC) Investigators. Perishock pause: an independent predictor of survival from out-of-hospital shockable cardiac arrest. *Circulation*. 2011 Jul 5;124(1):58-66.
- 8. Edelson DP, Robertson-Dick BJ, Yuen TC, Eilevstjønn J, Walsh D, Bareis CJ, VandenHoek TL, Abella BS. Safety and efficacy of defibrillator charging during ongoing chest compressions: a multicenter study. *Resuscitation*. 2010 Nov;81(11):1521-6.
- Edelson DP, Abella BS, Kramer-Johansen J, Wik L, Myklebust H, Barry AM, Merchant RM, Hoek TL, Steen PA, Becker LB. Effects of compression depth and pre-shock pauses predict defibrillation failure during cardiac arrest. *Resuscitation*. 2006 Nov;71(2):137-45.
- 10. Einav S, Weissman C, Kark J, Lotan C, Matot I. Future shock: automatic external defibrillators. *Curr Opin Anaesthesiol.* 2005 Apr;18(2):175-80.
- 11. Vilke GM, Chan TC, Dunford JV, Metz M, Ochs G, Smith A, Fisher R, Poste JC, McCallum-Brown L, Davis DP. The three-phase model of cardiac arrest as applied to ventricular fibrillation in a large, urban emergency medical services system. *Resuscitation*. 2005 Mar;64(3):341-6.
- 12. Wik L, Hansen TB, Fylling F, Steen T, Vaagenes P, Auestad BH, Steen PA. Delaying defibrillation to give basic cardiopulmonary resuscitation to patients with out-of-hospital ventricular fibrillation: a randomized trial. *JAMA*. 2003 Mar 19:289(11):1389-95.
- Cobb LA, Fahrenbruch CE, Walsh TR, Copass MK, Olsufka M, Breskin M, Hallstrom AP. Influence of cardiopulmonary resuscitation prior to defibrillation in patients with out-of-hospital ventricular fibrillation. *JAMA*. 1999 Apr 7;281(13):1182-8.





Approved 9/04/24, Effective 1/15/25, replaces all prior versions

## 4D – MANUAL DEFIBRILLATION ADULT & PEDIATRIC

#### PARAMEDIC

### Indication:

Ventricular Fibrillation/Pulseless Ventricular Tachycardia


### **Contraindications**:


Spontaneous pulse.


All cardiac rhythms except ventricular fibrillation/pulseless ventricular tachycardia.

### Technique:


1. Power **ON**. (Figure 1)



















Approved 9/04/24, Effective 1/15/25, replaces all prior versions

### Protocol 4D: Manual Defibrillation, Adult & Pediatric, cont.


- Press CHARGE. While the monitor/defibrillator is charging, a charging bar appears and a ramping tone sounds, indicating the charging energy level. When the monitor/defibrillator is fully charged, the screen displays available energy. (Figure 5).
- 6. Make certain all personnel, including the operator of the monitor/defibrillator, are physically clear of the patient, stretcher, bed and any equipment connected to the patient.
- 7. Confirm ECG rhythm of ventricular fibrillation or pulseless ventricular tachycardia. Confirm available energy.
- 8. Press the (shock) button on the monitor/defibrillator to defibrillate the patient. (Figure 6)
- NOTE: To disarm (cancel the charge), press the SPEED DIAL. The
  monitor/defibrillator disarms automatically if shock buttons are not pressed
  within 60 seconds, or if the energy selection is pressed after charging begins. IF
  DEFIBRILLATION NOT INDICATED UPON A RHYTHM CHECK, DISARM (CANCEL
  THE CHARGE) BEFORE RESUMING CHEST COMPRESSIONS TO PREVENT
  INADVERTANT ELECTRICAL EXPOSURE TO EMS PERSONNEL.
- 10. Repeat procedure starting from Step 4, when indicated.



If patient is less than 4 years of age and/or under 15 kg weight, connect the Quik-Combo<sup>®</sup> Pediatric Electrodes to the monitor/defibrillator and proceed to Step 3. **NOTE**: Pediatric: Initial defibrillation 2 joules/kg with second and subsequent defibrillations at 4 joules/kg. Prior to determining manual defibrillation settings count prior AED defibrillations.

### **DEFIBRILLATION CLINICAL PEARLS:**

- 1. In an emergency resuscitation setting that requires defibrillation, if unfamiliar with monitor/ defibrillator available, look for 1-2-3 sequence (Figure 7) that all monitor/defibrillators are labeled with by industry practice. 1 turns on the device; 2 selects energy; 3 charges the device. Typically, immediately next to 3 is the shock or discharge button.
- In an emergency resuscitation setting that requires defibrillation, do not interrupt or pause chest compressions unless absolutely necessary. Continue to provide chest compressions while a monitor/defibrillator operator is powering on the monitor/defibrillator, selecting energy and charging the device.
- 3. DO NOT CONTINUE TO PROVIDE CHEST COMPRESSIONS WHEN THE MONITOR/DEFIBRILLATOR IS DISCHARGING / DEFIBRILLATING.











### Medical Literature References 4D–Manual Defibrillation – Adult & Pediatric

- Sinclair, J. E., Austin, M., Froats, M., Leduc, S., Maloney, J., Dionne, R., Reed, A., & Vaillancourt, C. (2019). Characteristics, Prehospital Management, and Outcomes in Patients Assessed for Hypoglycemia: Repeat Access to Prehospital or Emergency Care. *Prehospital Emergency Care*, 23(3), 364–376. https://doi.org/10.1080/10903127.2018.1504150
- 2. Brooks SC, Anderson ML, Bruder E, Daya MR, Gaffney A, Otto CW, Singer AJ, Thiagarajan RR, Travers AH. Part 6: Alternative Techniques and Ancillary Devices for Cardiopulmonary Resuscitation: 2015 American Heart Association Guidelines Update for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. *Circulation*. 2015 Nov 3;132(18 Suppl 2):S436-43.
- 3. Lavonas EJ, Drennan IR, Gabrielli A, Heffner AC, Hoyte CO, Orkin AM, Sawyer KN, Donnino MW. Part 10: Special Circumstances of Resuscitation: 2015 American Heart Association Guidelines Update for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. *Circulation*. 2015 Nov 3;132(18 Suppl 2):S501-18.
- 4. Travers AH, Perkins GD, Berg RA, Castren M, Considine J, Escalante R, Gazmuri RJ, Koster RW, Lim SH, Nation KJ, Olasveengen TM, Sakamoto T, Sayre MR, Sierra A, Smyth MA, Stanton D, Vaillancourt C; Basic Life Support Chapter Collaborators. Part 3: Adult Basic Life Support and Automated External Defibrillation: 2015 International Consensus on Cardiopulmonary Resuscitation and Emergency Cardiovascular Care Science With Treatment Recommendations. *Circulation*. 2015 Oct 20;132(16 Suppl 1):S51-83.
- Callaway CW, Soar J, Aibiki M, Böttiger BW, Brooks SC, Deakin CD, Donnino MW, Drajer S, Kloeck W, Morley PT, Morrison LJ, Neumar RW, Nicholson TC, Nolan JP, Okada K, O'Neil BJ, Paiva EF, Parr MJ, Wang TL, Witt J; Advanced Life Support Chapter Collaborators. Part 4: Advanced Life Support: 2015 International Consensus on Cardiopulmonary Resuscitation and Emergency Cardiovascular Care Science With Treatment Recommendations. *Circulation*. 2015 Oct 20;132(16 Suppl 1):S84-145.
- 6. de Caen AR, Maconochie IK, Aickin R, Atkins DL, Biarent D, Guerguerian AM, Kleinman ME, Kloeck DA, Meaney PA, Nadkarni VM, Ng KC, Nuthall G, Reis AG, Shimizu N, Tibballs J, Veliz Pintos R; Pediatric Basic Life Support and Pediatric Advanced Life Support Chapter Collaborators. Part 6: Pediatric Basic Life Support and Pediatric Advanced Life Support: 2015 International Consensus on Cardiopulmonary Resuscitation and Emergency Cardiovascular Care Science With Treatment Recommendations. *Circulation*. 2015 Oct 20;132(16 Suppl 1):S177-203.
- 7. Winship C, Williams B, Boyle MJ. Cardiopulmonary resuscitation before defibrillation in the out-of-hospital setting: a literature review. *Emerg Med J.* 2012 Oct;29(10):826-9.
- 8. Cheskes S, Schmicker RH, Christenson J, Salcido DD, Rea T, Powell J, Edelson DP, Sell R, May S, Menegazzi JJ, Van Ottingham L, Olsufka M, Pennington S, Simonini J, Berg RA, Stiell I, Idris A, Bigham B, Morrison L; Resuscitation Outcomes Consortium (ROC) Investigators. Perishock pause: an independent predictor of survival from out-of-hospital shockable cardiac arrest. *Circulation*. 2011 Jul 5;124(1):58-66.
- 9. Edelson DP, Robertson-Dick BJ, Yuen TC, Eilevstjønn J, Walsh D, Bareis CJ, VandenHoek TL, Abella BS. Safety and efficacy of defibrillator charging during ongoing chest compressions: a multicenter study. *Resuscitation*. 2010 Nov;81(11):1521-6.
- 10. Edelson DP, Abella BS, Kramer-Johansen J, Wik L, Myklebust H, Barry AM, Merchant RM, Hoek TL, Steen PA, Becker LB. Effects of compression depth and pre-shock pauses predict defibrillation failure during cardiac arrest. *Resuscitation*. 2006 Nov;71(2):137-45.
- 11. Vilke GM, Chan TC, Dunford JV, Metz M, Ochs G, Smith A, Fisher R, Poste JC, McCallum-Brown L, Davis DP. The three-phase model of cardiac arrest as applied to ventricular fibrillation in a large, urban emergency medical services system. *Resuscitation*. 2005 Mar;64(3):341-6.





- 12. Wik L, Hansen TB, Fylling F, Steen T, Vaagenes P, Auestad BH, Steen PA. Delaying defibrillation to give basic cardiopulmonary resuscitation to patients with out-of-hospital ventricular fibrillation: a randomized trial. *JAMA*. 2003 Mar 19;289(11):1389-95.
- 13. Cobb LA, Fahrenbruch CE, Walsh TR, Copass MK, Olsufka M, Breskin M, Hallstrom AP. Influence of cardiopulmonary resuscitation prior to defibrillation in patients with out-of-hospital ventricular fibrillation. *JAMA*. 1999 Apr 7;281(13):1182-8.





Approved 9/04/24, Effective 1/15/25, replaces all prior versions

## 4E – DOUBLE SEQUENTIAL EXTERNAL DEFIBRILLATION ADULT

#### **PARAMEDIC**

#### Indication:

**Adult** refractory Ventricular Fibrillation/Pulseless Ventricular Tachycardia. See also Protocol 4G - Ventricular Fibrillation & Pulseless Ventricular Tachycardia.

### Contraindications:

Spontaneous pulse.

All cardiac rhythms except ventricular fibrillation/pulseless ventricular tachycardia

### Technique:

- 1. If two LifePak12 or 15 monitor/defibrillators are available, power the second one ON.
- 2. Connect therapy electrodes (defibrillation pads) to therapy cable and confirm cable connection to monitor/defibrillator per Protocol 4D.
- Prepare the patient's skin and apply second set of therapy electrodes (defibrillation pads) to the patient, in the right parasternal and cardiac apex positions next to, but NOT overlapping the anterior pad of the first set of therapy electrodes (defibrillation pads). (Figure 1)
- 4. Proceed to charge each defibrillator to 360J. Once fully charged, have either one paramedic discharge both defibrillators or if using two paramedics, using a 3-2-1 verbal countdown, discharge the defibrillators sequentially using a very specific count of "one thousand one" between the discharge of defibrillator one and the discharge of defibrillator two. FAILURE TO ALLOW A ONE SECOND PAUSE BETWEEN SEQUENTIAL DEFIBRILLATIONS CAN IRREVERSIBLY HARM A DEFIBRILLATOR, RENDERING IT PERMANENTLY INOPERABLE.
- 5. Throughout the use of double sequential external defibrillation, follow all standard safety measures as with routine defibrillation as outlined in Protocol 4D.

### **CLINICAL PEARLS:**

DO NOT CONTINUE TO PROVIDE CHEST COMPRESSIONS WHEN THE MONITOR/ DEFIBRILLATOR IS DISCHARGING / DEFIBRILLATING.









## Medical Literature References 4E – Double Seguential External Defibrillation - Adult

- 1. Pound J, Verbeek PR, Cheskes S. CPR induced consciousness during out-of-hospital cardiac arrest: a case report on an emerging phenomenon. *Prehosp Emerg Care*. 2017:21(2);252-256.
- 2. Merlin MA, Tagore A, Bauter R, Arshad FH. A case series of double sequence defibrillation. *Prehosp Emerg Care.* 2016:20(4);550-553.
- 3. Johnston M, Cheskes S, Ross G, Verbeek PR. Double sequential external defibrillation and survival from out-of-hospital cardiac arrest: a case report. *Prehosp Emerg Care*. 2017:20(5);662-666.
- 4. Esibov A, Chapman FW, Melnick SB, Sullivan JL, Walcott GP. Minor variations in electrode pad placement impact defibrillation success. *Prehosp Emerg Care*. 2017:20(2);292-298.
- 5. Cortez E, Krebs W, Davis J, Keseg DP, Panchal AR. Use of double sequential external defibrillation for refractory ventricular fibrillation during out-of-hospital cardiac arrest. *Resuscitation*. 108 (2016) 82-86.
- 6. Lybeck AM, Moy HP, Tan DK. Double sequential defibrillation for refractory ventricular fibrillation: a case report. *Prehosp Emerg Care*. 2015:19(4);554-557.
- 7. Cabañas JG, Myers JB, Williams JG, et al. Double sequential external defibrillation in out-of-hospital refractory ventricular fibrillation: a report of ten cases. *Prehosp Emerg Care*. 2015:19(1);126-130.
- 8. Gerstein NS, Shah MB, Jorgensen KM. Simulatneous use of two defibrillators for the conversion of refractory ventricular fibrillation. Journ Cardiothoracic Vasc Anesthesia. 29(2):421-424. April 2015.
- 9. Leacock BW. Double simultaneous defibrillators for refractory ventricular fibrillation. *Journ Emerg Med.* 2014. 46(4):742-474. Eifling M, Razavi M, Massumi A. The evaluation and management of electrical storm. *Tex Heart Inst J.* 2011:32(8):111-121.
- 10. Hoch DH, Batsford WP, Greenberg SM, et al. Double sequential external shocks for refractory ventricular fibrillation. *J Am Coll Cardiol*. 1994:2;1141-1145.
- 11. Delorenzo A, Nehme Z, Yates J, Bernard S, Smith K. Double sequential external defibrillation for refractory ventricular fibrillation out-of-hospital cardiac arrest: A systematic review and meta-analysis. *Resuscitation*. 2019;135:124-129. doi:10.1016/j.resuscitation.2018.10.025
- 12. Mapp JG, Hans AJ, Darrington AM, et al. Prehospital Double Sequential Defibrillation: A Matched Case-Control Study. *Acad Emerg Med.* December 2018:acem.13672. doi:10.1111/acem.13672
- 13. Hamilton, R. J., Ramzy, M., Teufel, J., Laub, G., & Kresh, J. Y. (2020). Dual Defibrillation is Highly Variable: An Analysis of Pulse Interval Delivered in Dual Defibrillation. Prehospital Emergency Care, 24(2), 232–237. https://doi.org/10.1080/10903127.2019.1621411
- 14. Bero, M., Sochor, M., Wong, S., & Brady, W. (2020). Changing the management of refractory ventricular fibrillation: The consideration of earlier utilization of dual sequential defibrillation. American Journal of Emergency Medicine, 38(3), 545–548.





Approved 9/04/24, Effective 1/15/25, replaces all prior versions

### **4F - ASYSTOLE ADULT & PEDIATRIC**

#### TREATMENT PRIORITIES:

- 1. Continuous chest compressions Apply ResQCPR® within 2 minutes 80/min ResQCPR® 110/min standard CPR
- 2. Evaluate and treat underlying cause(s)
- 3. Timely vasopressor administration4. Resuscitation per Protocols 4A & 4B



#### **PARAMEDIC**

VASOPRESSOR ADMINISTRATION: ADULT: EPINEPHRINE 1 mg IVP/IOP. REPEAT EVERY 3 – 5 MINUTES PEDIATRIC: EPINEPHRINE 0.1mg/mL (1:10,000) at 0.01 mg/kg (0.1 mL/kg) IVP/IOP. REPEAT EVERY 3-5 MINUTES





Medical Literature References 4F - Asystole – Adult & Pediatric

- Tomio, J., Nakahara, S., Takahashi, H., Ichikawa, M., Nishida, M., Morimura, N., & Sakamoto, T. (2017). Effectiveness of Prehospital Epinephrine Administration in Improving Long-term Outcomes of Witnessed Out-of-hospital Cardiac Arrest Patients with Initial Non-shockable Rhythms. Prehospital Emergency Care, 21(4), 432–441. https://doi.org/10.1080/10903127.2016.1274347
- 2. Brooks SC, Anderson ML, Bruder E, Daya MR, Gaffney A, Otto CW, Singer AJ, Thiagarajan RR, Travers AH. Part 6: Alternative Techniques and Ancillary Devices for Cardiopulmonary Resuscitation: 2015 American Heart Association Guidelines Update for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. *Circulation*. 2015 Nov 3;132(18 Suppl 2):S436-43.
- 3. Lavonas EJ, Drennan IR, Gabrielli A, Heffner AC, Hoyte CO, Orkin AM, Sawyer KN, Donnino MW. Part 10: Special Circumstances of Resuscitation: 2015 American Heart Association Guidelines Update for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. *Circulation*. 2015 Nov 3;132(18 Suppl 2):S501-18.
- 4. Travers AH, Perkins GD, Berg RA, Castren M, Considine J, Escalante R, Gazmuri RJ, Koster RW, Lim SH, Nation KJ, Olasveengen TM, Sakamoto T, Sayre MR, Sierra A, Smyth MA, Stanton D, Vaillancourt C; Basic Life Support Chapter Collaborators. Part 3: Adult Basic Life Support and Automated External Defibrillation: 2015 International Consensus on Cardiopulmonary Resuscitation and Emergency Cardiovascular Care Science With Treatment Recommendations. *Circulation*. 2015 Oct 20;132(16 Suppl 1):S51-83.
- Callaway CW, Soar J, Aibiki M, Böttiger BW, Brooks SC, Deakin CD, Donnino MW, Drajer S, Kloeck W, Morley PT, Morrison LJ, Neumar RW, Nicholson TC, Nolan JP, Okada K, O'Neil BJ, Paiva EF, Parr MJ, Wang TL, Witt J; Advanced Life Support Chapter Collaborators. Part 4: Advanced Life Support: 2015 International Consensus on Cardiopulmonary Resuscitation and Emergency Cardiovascular Care Science With Treatment Recommendations. *Circulation*. 2015 Oct 20:132(16 Suppl 1):S84-145.
- Welsford M, Nikolaou NI, Beygui F, Bossaert L, Ghaemmaghami C, Nonogi H, O'Connor RE, Pichel DR, Scott T, Walters DL, Woolfrey KG; Acute Coronary Syndrome Chapter Collaborators.
   Part 5: Acute Coronary Syndromes: 2015 International Consensus on Cardiopulmonary Resuscitation and Emergency Cardiovascular Care Science With Treatment Recommendations. Circulation. 2015 Oct 20;132(16 Suppl 1):S146-76.
- de Caen AR, Maconochie IK, Aickin R, Atkins DL, Biarent D, Guerguerian AM, Kleinman ME, Kloeck DA, Meaney PA, Nadkarni VM, Ng KC, Nuthall G, Reis AG, Shimizu N, Tibballs J, Veliz Pintos R; Pediatric Basic Life Support and Pediatric Advanced Life Support Chapter Collaborators.
   Part 6: Pediatric Basic Life Support and Pediatric Advanced Life Support: 2015 International Consensus on Cardiopulmonary Resuscitation and Emergency Cardiovascular Care Science With Treatment Recommendations. Circulation. 2015 Oct 20:132(16 Suppl 1):S177-203.
- 8. Lin S, Callaway CW, Shah PS, Wagner JD, Beyene J, Ziegler CP, Morrison LJ. Adrenaline for out-of-hospital cardiac arrest resuscitation: a systematic review and meta-analysis of randomized controlled trials. *Resuscitation*. 2014 Jun;85(6):732-40.
- 9. Larabee TM, Liu KY, Campbell JA, Little CM. Vasopressors in cardiac arrest: a systematic review. *Resuscitation*. 2012 Aug;83(8):932-9.
- 10. Idris AH, Guffey D, Aufderheide TP, Brown S, Morrison LJ, Nichols P, Powell J, Daya M, Bigham BL, Atkins DL, Berg R, Davis D, Stiell I, Sopko G, Nichol G. The Relationship Between Chest Compression Rates and Outcomes from Cardiac Arrest. *Circulation*. 2012 Jun 19;125(24):3004-12.
- 11. Mentzelopoulos SD, Zakynthinos SG, Siempos I, Malachias S, Ulmer H, Wenzel V. Vasopressin for cardiac arrest: meta-analysis of randomized controlled trials. *Resuscitation*. 2012 Jan;83(1):32-9.
- Vaillancourt C, Everson-Stewart S, Christenson J, Andrusiek D, Powell J, Nichol G, Cheskes S, Aufderheide TP, Berg R, Stiell IG; Resuscitation Outcomes Consortium Investigators. The impact of increased chest compression fraction on return of spontaneous circulation for out-of-hospital cardiac arrest patients not in ventricular fibrillation. *Resuscitation*. 2011 Dec;82(12):1501-7.
- 13. Cody P, Lauderdale S, Hogan DE, Frantz RR. Comparison of two protocols for pulseless cardiopulmonary arrest: vasopressin combined with epinephrine versus epinephrine alone. *Prehosp Disaster Med.* 2010 Sep-Oct;25(5):420-3.






Approved 9/04/24, Effective 1/15/25 replaces all prior versions

### 4G VENTRICULAR FIBRILLATION & PULSELESS VENTRICULAR TACHYCARDIA ADULT & PEDIATRIC

#### TREATMENT PRIORITIES

- Continuous chest compressions
   Apply ResQCPR® within 2 minutes
   80/min ResQCPR® 110/min standard CPR
- 2. Timely defibrillation
- 3. Evaluate and treat underlying cause(s)
- 4. Timely vasopressor administration
- Timely antiarrhythmic administration 6. Resuscitation per Protocols 4A & 4B



#### **PARAMEDIC**

#### MANUAL DEFIBRILLATION:

PAUSE CPR FOR A SINGLE SHOCK. LIMIT DEFIBRILLATION COMPRESSION PAUSE TO MAXIMUM OF 10 SECONDS. ADULT: IF PT ESTIMATED WEIGHT < 100 kg ESCALATING DEFIBS AT 200J, 300J, 360J FOURTH & SUBSEQUENT DEFIBS UTILIZING DOUBLE SEQUENTIAL EXTERNAL DEFIBRILLATION PER PROTOCOL 4E

ADULT: IF PT ESTIMATED WEIGHT ≥ 100 kg FIRST DEFIB AT 360 JOULES SECOND & SUBSEQUENT DEFIBS UTILIZING DOUBLE SEQUENTIAL EXTERNAL DEFIBRILLATION PER PROTOCOL 4E

PEDIATRIC: INITIAL DEFIB 2 JOULES/kg, SECOND & SUBSEQUENT DEFIBS 4 JOULES/kg COUNT AED DEFIBRILLATIONS PRIOR TO DETERMINING MANUAL DEFIBRILLATION SETTING

#### VASOPRESSOR ADMINISTRATION:

ADULT: EPINEPHRINE 1 mg IVP/IOP. REPEAT EVERY 3-5 MINUTES. MAXIMUM CUMULATIVE DOSE 3mg PEDIATRIC: EPINEPHRINE 0.1mg/mL (1:10,000) at 0.01 mg/kg (0.1 mL/kg) IVP/IOP. REPEAT EVERY 3-5 MINUTES

#### ANTIARRHYTHMIC ADMINISTRATION:

ADULT: AMIODARONE 300 mg IVP/IOP. REPEAT AT 150 mg IVP/IOP IN 5 MINUTES. MAXIMUM CUMULATIVE DOSE 450 mg. EPINEPHRINE 1 mg IVP/IOP WITH EVERY AMIODARONE ADMINISTRATION

ADULT: MAGNESIUM SULFATE 1 gram IVP/IOP IF TORSADES (POLYMORPHIC PULSELESS VENTRICULAR TACHYCARDIA)

PEDIATRIC: AMIODARONE 5 mg/kg IVP/IOP SINGLE DOSE. EPINEPHRINE 0.01 mg/kg (1:10,000. 0.1 mL/kg) WITH AMIODARONE ADMINISTRATION.

IF SUCCESSFUL CONVERSION TO SUSTAINED PULSATILE RHYTHM (RETURN OF SPONTANEOUS CIRCULATION): ADULT: AMIODARONE 150mg IVPB (ADD TO 100mL NS BAG, INFUSE OVER 10 MINUTES) PEDIATRIC: OLMC CONSULT





## Medical Literature References 4G - Ventricular Fibrillation/Pulseless Ventricular Tachycardia – Adult & Pediatric

- Kudenchuk, P. J., Leroux, B. G., Daya, M., Rea, T., Vaillancourt, C., Morrison, L. J., ... Dorian, P. (2017). Antiarrhythmic Drugs for Nonshockable-Turned-Shockable Out-of-Hospital Cardiac Arrest:The ALPS Study (Amiodarone, Lidocaine, or Placebo). Circulation. https://doi.org/10.1161/CIRCULATIONAHA.117.028624
- Kudenchuk PJ, Brown SP, Daya M, Rea T, Nichol G, Morrison LJ, Leroux B, Vaillancourt C, Wittwer L, Callaway CW, Christenson J, Egan D, Ornato JP, Weisfeldt ML, Stiell IG, Idris AH, Aufderheide TP, Dunford JV, Colella MR, Vilke GM, Brienza AM, Desvigne-Nickens P, Gray PC, Gray R, Seals N, Straight R, Dorian P for the Resuscitation Outcomes Consortium Investigators. Amiodarone, lidocaine, or placebo in out-of-hospital cardiac arrest. NEJM. 2016:374:1711-22.
- 3. Osei-Ampofo M, Cheskes S, Byers A, Drennan IR, Buick JE, Verbeek PR. A novel approach to improve time to first shock in prehospital STEMI complicated by ventricular fibrillation. *Prehosp Emerg Care* 20(2):278-82.
- 4. Brooks SC, Anderson ML, Bruder E, Daya MR, Gaffney A, Otto CW, Singer AJ, Thiagarajan RR, Travers AH. Part 6: Alternative Techniques and Ancillary Devices for Cardiopulmonary Resuscitation: 2015 American Heart Association Guidelines Update for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. *Circulation*. 2015 Nov 3;132(18 Suppl 2):S436-43.
- 5. Lavonas EJ, Drennan IR, Gabrielli A, Heffner AC, Hoyte CO, Orkin AM, Sawyer KN, Donnino MW. Part 10: Special Circumstances of Resuscitation: 2015 American Heart Association Guidelines Update for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. *Circulation*. 2015 Nov 3;132(18 Suppl 2):S501-18.
- Travers AH, Perkins GD, Berg RA, Castren M, Considine J, Escalante R, Gazmuri RJ, Koster RW, Lim SH, Nation KJ, Olasveengen TM, Sakamoto T, Sayre MR, Sierra A, Smyth MA, Stanton D, Vaillancourt C; Basic Life Support Chapter Collaborators. Part 3: Adult Basic Life Support and Automated External Defibrillation: 2015 International Consensus on Cardiopulmonary Resuscitation and Emergency Cardiovascular Care Science With Treatment Recommendations. *Circulation*. 2015 Oct 20;132(16 Suppl 1):S51-83.
- Callaway CW, Soar J, Aibiki M, Böttiger BW, Brooks SC, Deakin CD, Donnino MW, Drajer S, Kloeck W, Morley PT, Morrison LJ, Neumar RW, Nicholson TC, Nolan JP, Okada K, O'Neil BJ, Paiva EF, Parr MJ, Wang TL, Witt J; Advanced Life Support Chapter Collaborators. Part 4: Advanced Life Support: 2015 International Consensus on Cardiopulmonary Resuscitation and Emergency Cardiovascular Care Science With Treatment Recommendations. *Circulation*. 2015 Oct 20;132(16 Suppl 1):S84-145.
- Welsford M, Nikolaou NI, Beygui F, Bossaert L, Ghaemmaghami C, Nonogi H, O'Connor RE, Pichel DR, Scott T, Walters DL, Woolfrey KG; Acute Coronary Syndrome Chapter Collaborators.
   Part 5: Acute Coronary Syndromes: 2015 International Consensus on Cardiopulmonary Resuscitation and Emergency Cardiovascular Care Science With Treatment Recommendations.
   Circulation. 2015 Oct 20;132(16 Suppl 1):S146-76.
- de Caen AR, Maconochie IK, Aickin R, Atkins DL, Biarent D, Guerguerian AM, Kleinman ME, Kloeck DA, Meaney PA, Nadkarni VM, Ng KC, Nuthall G, Reis AG, Shimizu N, Tibballs J, Veliz Pintos R; Pediatric Basic Life Support and Pediatric Advanced Life Support Chapter Collaborators. Part 6: Pediatric Basic Life Support and Pediatric Advanced Life Support: 2015 International Consensus on Cardiopulmonary Resuscitation and Emergency Cardiovascular Care Science With Treatment Recommendations. Circulation. 2015 Oct 20;132(16 Suppl 1):S177-203.
- 10. Idris AH, Guffey D, Aufderheide TP, Brown S, Morrison LJ, Nichols P, Powell J, Daya M, Bigham BL, Atkins DL, Berg R, Davis D, Stiell I, Sopko G, Nichol G. The Relationship Between Chest Compression Rates and Outcomes from Cardiac Arrest. *Circulation*. 2012 Jun 19;125(24):3004-12.
- 11. Freese JP, Jorgenson DB, Liu PY, Innes J, Matallana L, Nammi K, Donohoe RT, Whitbread M, Silverman RA, Prezant DJ. Waveform analysis-guided treatment versus a standard shock-first protocol for the treatment of out-of-hospital cardiac arrest presenting in ventricular fibrillation: results of an international randomized, controlled trail. *Circulation*. 2013 Aug 27;128(9):995-1002.
- 12. Larabee TM, Liu KY, Campbell JA, Little CM. Vasopressors in cardiac arrest: A systematic review. *Resuscitation*. 2012 Aug;83(8):932-9.





## Medical Literature References 4G - Ventricular Fibrillation/Pulseless Ventricular Tachycardia – Adult & Pediatric (cont)

- 13. Idris AH, Guffey D, Aufderheide TP, Brown S, Morrison LJ, Nichols P, Powell J, Daya M, Bigham BL, Atkins DL, Berg R, Davis D, Stiell I, Sopko G, Nichol G. The Relationship Between Chest Compression Rates and Outcomes from Cardiac Arrest. *Circulation*. 2012 Jun 19:125(24):3004-12.
- 14. Vaillancourt C, Everson-Stewart S, Christenson J, Andrusiek D, Powell J, Nichol G, Cheskes S, Aufderheide TP, Berg R, Stiell IG; Resuscitation Outcomes Consortium Investigators. The impact of increased chest compression fraction on return of spontaneous circulation for out-of-hospital cardiac arrest patients not in ventricular fibrillation. *Resuscitation*. 2011 Dec;82(12):1501-7.
- 15. Ong ME, Pellis T, Link MS. The use of antiarrhythmic drugs for adult cardiac arrest: a systematic review. *Resuscitation*. 2011 Jun;82(6):665-70.
- 16. Cody P, Lauderdale S, Hogan DE, Frantz RR. Comparison of two protocols for pulseless cardiopulmonary arrest: vasopressin combined with epinephrine versus epinephrine alone. *Prehosp Disaster Med.* 2010 Sep-Oct;25(5):420-3.
- 17. Ristango G, Tang W, Huang L, et al. Epinephrine reduces cerebral perfusion during cardiopulmonary resuscitation. Crit Care Med. 2009;37(4):1408-1415.
- 18. Wik L, Hansen TB, Fylling F, Steen T, Vaagenes P, Auestad BH, Steen PA. Delaying defibrillation to give basic cardiopulmonary resuscitation to patients with out-of-hospital ventricular fibrillation: a randomized trial. *JAMA*. 2003 Mar 19;289(11):1389-95.
- 19. Tang W, Weil MH, Sun S, et al. Epinephrine increases the severity of postresuscitation myocardial dysfunction. *Circulation*. 1995;92(10):3089-3093.
- 20. Daya, M. R., Leroux, B. G., Dorian, P., Rea, T. D., Newgard, C. D., Morrison, L. J., ... Kudenchuk, P. J. (2020). Survival after intravenous versus intraosseous amiodarone, lidocaine, or placebo in out-of-hospital shock-refractory cardiac arrest. Circulation, 188–198.
- 21. Miraglia, D., Miguel, L. A., & Alonso, W. (2020). The evolving role of novel treatment techniques in the management of patients with refractory VF/pVT out-of-hospital cardiac arrest. American Journal of Emergency Medicine, 38(3), 648–654.






Approved 9/04/24, Effective 1/15/25, replaces all prior versions

### **4H - PULSELESS ELECTRICAL ACTIVITY ADULT & PEDIATRIC**

#### TREATMENT PRIORITIES:

- Continuous chest compressions
   Apply ResQCPR® within 2 minutes
   80/min ResQCPR® 110/min standard CPR
- Evaluate and treat underlying cause(s)
   Timely vasopressor administration
   Resuscitation per Protocols 4A & 4B



#### **PARAMEDIC**

VASOPRESSOR ADMINISTRATION: ADULT: EPINEPHRINE 1 mg IVP/IOP. REPEAT EVERY 3 – 5 MINUTES

PEDIATRIC: EPINEPHRINE 0.1mg/mL (1:10,000) at 0.01 mg/kg (0.1 mL/kg) IVP/IOP. REPEAT EVERY 3-5 MINUTES





## Medical Literature References 4H - Pulseless Electrical Activity – Adult & Pediatric

- Tomio, J., Nakahara, S., Takahashi, H., Ichikawa, M., Nishida, M., Morimura, N., & Sakamoto, T. (2017). Effectiveness of Prehospital Epinephrine Administration in Improving Long-term Outcomes of Witnessed Out-of-hospital Cardiac Arrest Patients with Initial Non-shockable Rhythms. Prehospital Emergency Care, 21(4), 432–441. https://doi.org/10.1080/10903127.2016.1274347
- 2. Brooks SC, Anderson ML, Bruder E, Daya MR, Gaffney A, Otto CW, Singer AJ, Thiagarajan RR, Travers AH. Part 6: Alternative Techniques and Ancillary Devices for Cardiopulmonary Resuscitation: 2015 American Heart Association Guidelines Update for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. *Circulation*. 2015 Nov 3;132(18 Suppl 2):S436-43.
- 3. Lavonas EJ, Drennan IR, Gabrielli A, Heffner AC, Hoyte CO, Orkin AM, Sawyer KN, Donnino MW. Part 10: Special Circumstances of Resuscitation: 2015 American Heart Association Guidelines Update for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. *Circulation*. 2015 Nov 3;132(18 Suppl 2):S501-18.
- 4. Travers AH, Perkins GD, Berg RA, Castren M, Considine J, Escalante R, Gazmuri RJ, Koster RW, Lim SH, Nation KJ, Olasveengen TM, Sakamoto T, Sayre MR, Sierra A, Smyth MA, Stanton D, Vaillancourt C; Basic Life Support Chapter Collaborators. Part 3: Adult Basic Life Support and Automated External Defibrillation: 2015 International Consensus on Cardiopulmonary Resuscitation and Emergency Cardiovascular Care Science With Treatment Recommendations. *Circulation*. 2015 Oct 20;132(16 Suppl 1):S51-83.
- Callaway CW, Soar J, Aibiki M, Böttiger BW, Brooks SC, Deakin CD, Donnino MW, Drajer S, Kloeck W, Morley PT, Morrison LJ, Neumar RW, Nicholson TC, Nolan JP, Okada K, O'Neil BJ, Paiva EF, Parr MJ, Wang TL, Witt J; Advanced Life Support Chapter Collaborators. Part 4: Advanced Life Support: 2015 International Consensus on Cardiopulmonary Resuscitation and Emergency Cardiovascular Care Science With Treatment Recommendations. *Circulation*. 2015 Oct 20;132(16 Suppl 1):S84-145.
- Welsford M, Nikolaou NI, Beygui F, Bossaert L, Ghaemmaghami C, Nonogi H, O'Connor RE, Pichel DR, Scott T, Walters DL, Woolfrey KG; Acute Coronary Syndrome Chapter Collaborators.
   Part 5: Acute Coronary Syndromes: 2015 International Consensus on Cardiopulmonary Resuscitation and Emergency Cardiovascular Care Science With Treatment Recommendations.
   Circulation. 2015 Oct 20:132(16 Suppl 1):S146-76.
- 7. de Caen AR, Maconochie IK, Aickin R, Atkins DL, Biarent D, Guerguerian AM, Kleinman ME, Kloeck DA, Meaney PA, Nadkarni VM, Ng KC, Nuthall G, Reis AG, Shimizu N, Tibballs J, Veliz Pintos R; Pediatric Basic Life Support and Pediatric Advanced Life Support Chapter Collaborators. Part 6: Pediatric Basic Life Support and Pediatric Advanced Life Support: 2015 International Consensus on Cardiopulmonary Resuscitation and Emergency Cardiovascular Care Science With Treatment Recommendations. Circulation. 2015 Oct 20;132(16 Suppl 1):S177-203.
- 8. Idris AH, Guffey D, Aufderheide TP, Brown S, Morrison LJ, Nichols P, Powell J, Daya M, Bigham BL, Atkins DL, Berg R, Davis D, Stiell I, Sopko G, Nichol G. The Relationship Between Chest Compression Rates and Outcomes from Cardiac Arrest. *Circulation*. 2012 Jun 19;125(24):3004-12.
- 9. Larabee TM, Liu KY, Campbell JA, Little CM. Vasopressors in cardiac arrest: A systematic review. *Resuscitation.* 2012 Aug;83(8):932-9.
- Vaillancourt C, Everson-Stewart S, Christenson J, Andrusiek D, Powell J, Nichol G, Cheskes S, Aufderheide TP, Berg R, Stiell IG; Resuscitation Outcomes Consortium Investigators. The impact of increased chest compression fraction on return of spontaneous circulation for out-of-hospital cardiac arrest patients not in ventricular fibrillation. *Resuscitation*. 2011 Dec;82(12):1501-7.
- 11. Cody P, Lauderdale S, Hogan DE, Frantz RR. Comparison of two protocols for pulseless cardiopulmonary arrest: vasopressin combined with epinephrine versus epinephrine alone. *Prehosp Disaster Med.* 2010 Sep-Oct;25(5):420-3.
- 12. Olasveengen TM, Samdal M, Steen PA, Wik L, Sunde K. Progressing from initial non-shockable rhythms to a shockable rhythm is associated with improved outcome after out-of-hospital cardiac arrest. Resuscitation. 2009 Jan;80(1):24-9.
- 13. Väyrynen T, Kuisma M, Määttä T, Boyd J. Who survives from out-of-hospital pulseless electrical activity? *Resuscitation*. 2008 Feb;76(2):207-13.





Approved 9/04/24, Effective 1/15/25, replaces all prior versions

#### 4I - SPECIFIC CAUSES OF CARDIAC ARREST **ADULT & PEDIATRIC**

#### TREATMENT PRIORITIES:

- 1. Circulatory support
  - Apply ResQCPR® within 2 minutes
  - Chest compression rate 80/min ResQCPR®
  - Chest compression rate 110/min
  - Appropriate compression depth & full recoil
  - Limit pauses in compressions
  - Timely defibrillation (if indicated)
  - Utilize Res-Q-Pod<sup>©</sup>
  - If hyperkalemia, calcium chloride first medication
- 2. Oxygenation/Ventilation support
  - Avoid hyperventilation in rate & volume
  - Use waveform capnography (if equipped) \*Mandatory use if patient intubated



**EMR** 

FIND POSSIBLE CAUSES OF CARDIOPULMONARY ARREST & TREAT WHERE APPROPRIATE:

**HYPOXIA** – OXYGENATION/VENTILATION WITH 100% O2 HYPOKALEMIA – RAPID TRANSPORT

PRE-EXISTING ACIDOSIS – OXYGENATION/VENTILATION WITH 100% O2 PRE-EXISTING HYPOTHERMIA (PROLONGED COLD EXPOSURE) – REWARM PATIENT CARDIAC TAMPONADE - RAPID TRANSPORT THROMBOSIS (AMI OR PE) – RAPID TRANSPORT
TRAUMA – SEE APPROPRIATE TRAUMA PROTOCOLS TOXINS/DRUG OVERDOSE - SUSPECTED NARCOTIC/OPIATE ADULT: NALOXONE 2 mg IN, MAY REPEAT ONCE PEDIATRIC: NALOXONE 0.5 mg IN, MAY REPEAT ONCE

> **EMT-185 AEMT**

FIND POSSIBLE CAUSES OF CARDIOPULMONARY ARREST & TREAT WHERE APPROPRIATE:

HYPOVOLEMIA

ADULT: 1 LITER NS IV/IO BOLUS IF NO SIGNS OF PULMONARY EDEMA PEDIATRIC: 20 mL/kg NS IV/IO BOLUS IF NO SIGNS OF PULMONARY EDEMA HYPOGLYCEMIA (GLUCOSE <50 mg/dL) - ADULT & PEDIATRIC
D10 5 mL/kg IVPB WIDE OPEN UP TO 250 mL OR
D25 2 mL/kg IV/IO UP TO 100 mL (must be ≥ 1 year of age) OR D50 1 mL/kg IV/IO UP TO 50 mL (must be ≥ 25 kg)

CARDIAC TAMPONADE

ADULT: 500 mL NS IV/IO BOLUS IF NO SIGNS OFPULMONARY EDEMA PEDIATRIC: 10 mL/kg NS IV/IO BOLUS IF NO SIGNS OF PULMONARY EDEMA

#### ADVANCED EMT OR HIGHER LICENSE:

TOXINS/DRUG OVERDOSE - SUSPECTED NARCOTIC/OPIATE ADULT: NALOXONE 2 mg IVP/IOP, MAY REPEAT ONCE PEDIATRIC: NALOXONE 0.5 mg IVP/IOP, MAY REPEAT ONCE

#### **PARAMEDIC**

FIND POSSIBLE CAUSES OF CARDIOPULMONARY ARREST & TREAT WHERE APPROPRIATE:

HYPERKALEMIA – CALCIUM CHLORIDE 10 mg/kg IVP/IOP (MAX 1 gram) & SODIUM BICARBONATE 1 mEq/kg IVP/IOP (MAX 50 mEq)
TOXINS/DRUG OVERDOSE – SUSPECTED TRICYCLIC ANTIDEPRESSANT - SODIUM BICARBONATE 1 mEq/kg IVP/IOP (MAX 50 mEq)
TOXINS/DRUG OVERDOSE – SUSPECTED BETA BLOCKERS

ADULT: GLUCAGON 1 mg IVP/IOP
PEDIATRIC: GLUCAGON 0.5 mg IVP/IOP

TOXINS/DRUG OVERDOSE - SUSPECTED CALCIUM CHANNEL BLOCKERS - CALCIUM CHLORIDE 10 mg/kg IVP/IOP (MAX 1 gram) TENSION PNEUMOTHORAX - NEEDLE THORACOSTOMY (CHEST DECOMPRESSION)





## Medical Literature References 4I – Specific Causes of Cardiac Arrest – Adult & Pediatric

- Brooks SC, Anderson ML, Bruder E, Daya MR, Gaffney A, Otto CW, Singer AJ, Thiagarajan RR, Travers AH. Part 6: Alternative Techniques and Ancillary Devices for Cardiopulmonary Resuscitation: 2015 American Heart Association Guidelines Update for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. *Circulation*. 2015 Nov 3;132(18 Suppl 2):S436-43.
- Lavonas EJ, Drennan IR, Gabrielli A, Heffner AC, Hoyte CO, Orkin AM, Sawyer KN, Donnino MW. Part 10: Special Circumstances of Resuscitation: 2015 American Heart Association Guidelines Update for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. *Circulation*. 2015 Nov 3;132(18 Suppl 2):S501-18.
- 3. Travers AH, Perkins GD, Berg RA, Castren M, Considine J, Escalante R, Gazmuri RJ, Koster RW, Lim SH, Nation KJ, Olasveengen TM, Sakamoto T, Sayre MR, Sierra A, Smyth MA, Stanton D, Vaillancourt C; Basic Life Support Chapter Collaborators. Part 3: Adult Basic Life Support and Automated External Defibrillation: 2015 International Consensus on Cardiopulmonary Resuscitation and Emergency Cardiovascular Care Science With Treatment Recommendations. *Circulation*. 2015 Oct 20;132(16 Suppl 1):S51-83.
- Callaway CW, Soar J, Aibiki M, Böttiger BW, Brooks SC, Deakin CD, Donnino MW, Drajer S, Kloeck W, Morley PT, Morrison LJ, Neumar RW, Nicholson TC, Nolan JP, Okada K, O'Neil BJ, Paiva EF, Parr MJ, Wang TL, Witt J; Advanced Life Support Chapter Collaborators. Part 4: Advanced Life Support: 2015 International Consensus on Cardiopulmonary Resuscitation and Emergency Cardiovascular Care Science With Treatment Recommendations. *Circulation*. 2015 Oct 20;132(16 Suppl 1):S84-145.
- Welsford M, Nikolaou NI, Beygui F, Bossaert L, Ghaemmaghami C, Nonogi H, O'Connor RE, Pichel DR, Scott T, Walters DL, Woolfrey KG; Acute Coronary Syndrome Chapter Collaborators.
   Part 5: Acute Coronary Syndromes: 2015 International Consensus on Cardiopulmonary Resuscitation and Emergency Cardiovascular Care Science With Treatment Recommendations.
   Circulation. 2015 Oct 20;132(16 Suppl 1):S146-76.
- 6. de Caen AR, Maconochie IK, Aickin R, Atkins DL, Biarent D, Guerguerian AM, Kleinman ME, Kloeck DA, Meaney PA, Nadkarni VM, Ng KC, Nuthall G, Reis AG, Shimizu N, Tibballs J, Veliz Pintos R; Pediatric Basic Life Support and Pediatric Advanced Life Support Chapter Collaborators. Part 6: Pediatric Basic Life Support and Pediatric Advanced Life Support: 2015 International Consensus on Cardiopulmonary Resuscitation and Emergency Cardiovascular Care Science With Treatment Recommendations. *Circulation*. 2015 Oct 20;132(16 Suppl 1):S177-203.
- 7. Lin CH, Tu YF, Chiang WC, Wu SY, Chang YH, Chi CH. Electrolyte abnormalities and laboratory findings in patients with out-of-hospital cardiac arrest who have kidney disease. *Am J Emerg Med.* 2013 Mar;31(3):487-93.
- 8. Papastylianou A, Mentzelopoulos S. Current pharmacological advances in the treatment of cardiac arrest. *Emerg Med Int.* 2012;2012:815857.
- 9. Williamson K, Breed M, Alibertis K, Brady WJ. The impact of the code drugs: cardioactive medications in cardiac arrest resuscitation. *Emerg Med Clin North Am.* 2012 Feb;30(1):65-75. doi: 10.1016/j.emc.2011.09.008.
- 10. Aschner JL, Poland RL. Sodium bicarbonate: basically useless therapy. *Pediatrics*. 2008 Oct;122(4):831-5.
- 11. Srinivasan V, Morris MC, Helfaer MA, Berg RA, Nadkarni VM; American Heart Association National Registry of CPR Investigators. Calcium use during in-hospital pediatric cardiopulmonary resuscitation: a report from the National Registry of Cardiopulmonary Resuscitation. *Pediatrics*. 2008 May;121(5):e1144-51.
- 12. Martin GB, Nowak RM, Cisek JE, Carden DL, Tomlanovich MC. Hyperkalemia during human cardiopulmonary resuscitation: incidence and ramifications. *J Emerg Med.* 1989 Mar-Apr;7(2):109-13.





Approved 9/04/24, Effective 1/15/25, replaces all prior versions

## 4J - POST CARDIAC ARREST TREATMENT ADULT & PEDIATRIC

#### TREATMENT PRIORITIES

- 1. Support oxygenation/ventilation. Avoid hyperventilation. Avoid hyperoxemia (when possible).
- 2. Identify & treat underlying cause of cardiopulmonary arrest.
- 3. Achieve systolic blood pressure ≥ 100 mmHg (Adult) using cold saline and / or vasopressor infusion.
- 4. Initiate therapeutic induced hypothermia (if applicable receiving hospital must have capability for same).

#### INCLUSION CRITERIA FOR INDUCTION OF HYPOTHERMIA

- AGE ≥ 18 YEARS OF AGE
- > RETURN OF SPONTANEOUS CIRCULATION
- NON-TRAUMATIC CARDIAC ARREST
- > SUPRAGLOTTIC OR INTUBATION AIRWAY IN PLACE
- NO PURPOSEFUL RESPONSE TO PAIN

EMERGENCY MEDICAL
DISPATCHER

EMERGENCY MEDICAL
RESPONDER

EMT

ADVANCED EMT

**PARAMEDIC** 

EMR EMT

GENERAL SUPPORTIVE CARE
OBTAIN VITAL SIGNS
O<sub>2</sub> NRB or BVM AS APPLICABLE
APPLY CARDIAC MONITOR/OBTAIN 12-LEAD ECG (if equipped))
TRANSMIT 12-LEAD ECG TO RECEIVING EMERGENCY DEPARTMENT

#### IF PATIENT MEETS CRITERIA FOR INDUCED HYPOTHERMIA:

EXPOSE PATIENT AND COVER WITH SHEET PACK AXILLA AND GROIN WITH ICE/COLD PACKS

#### **EMT OR HIGHER LICENSE ONLY:**

 $\label{eq:measure end-tidal co2} \mbox{MONITOR WAVEFORM CAPNOGRAPHY (if equipped, ** Mandatory use if patient intubated))} \\ \mbox{PLACE SUPRAGLOTTIC AIRWAY ONLY IF INDICATED \& BVM VENTILATIONS INEFECTIVE}$ 

EMT-I85 AEMT

ADULT: INTUBATE IF INDICATED

IV/IO ACCESS

IF PATIENT MEETS CRITERIA FOR INDUCED HYPOTHERMIA:

IV/IO COLD (4 DEGREE CELSIUS) NS 30 mL/kg BOLUS UP TO 1 LITER IF NO SIGNS OF PULMONARY EDEMA

#### **PARAMEDIC**

ADULT: MEDICATION ASSISTED INTUBATION IF INDICATED INTERPRET ECG/12-LEAD ECG – TREAT PER PROTOCOL 5C - ACUTE CORONARY SYNDROME AND/OR DYSRHYTHMIA PROTOCOL(S) AS APPLICABLE

ADULT: ACHIEVE SYSTOLIC BLOOD PRESSURE MINIMUM OF 100 mmHg

IV FLUID: NS BOLUS (MAY USE COLD SALINE) UP TO 1 LITER TO ACHIEVE SYS BP ≥ 100 mmHg IF NO SIGNS OF PULMONARY EDEMA

NOREPINEPHRINE 2-4 mcg/min IVPB/IOPB IF IV FLUID INEFFECTIVE OR CONTRAINDICATED

DOPAMINE 10-20 mcg/kg/min IVPB/IOPB IF IV FLUID INEFFECTIVE OR CONTRAINDICATED

PEDIATRIC: ACHIEVE MINIMUM SYSTOLIC BLOOD PRESSURE OF (70 + 2 x age in years) mmHg IV FLUID: NS BOLUS OF 20 mL/kg UP TO 60 mL/kg IF NO SIGNS OF PULMONARY EDEMA

OLMC CONSULT FOR PHARMACOLOGIC TREATMENT IF IV FLUID INEFFECTIVE OR CONTRAINDICATED

### IF PATIENT MEETS CRITERIA FOR INDUCED HYPOTHERMIA:

SHIVERING CONTROL: MIDAZOLAM 0.1 mg/kg IVP/IOP MAXIMUM DOSE 5 mg

CONTINUOUS ASSESSMENT & TREATMENT PER APPLICABLE PROTOCOL(S)





## Medical Literature References 4J – Post Cardiac Arrest Treatment – Adult & Pediatric

- Baldi, E., Schnaubelt, S., Caputo, M. L., Klersy, C., Clodi, C., Bruno, J., Compagnoni, S., Benvenuti, C., Domanovits, H., Burkart, R., Fracchia, R., Primi, R., Ruzicka, G., Holzer, M., Auricchio, A., & Savastano, S. (2021). Association of Timing of Electrocardiogram Acquisition After Return of Spontaneous Circulation With Coronary Angiography Findings in Patients With Out-of-Hospital Cardiac Arrest. *JAMA Network Open*, 4(1), e2032875. https://doi.org/10.1001/jamanetworkopen.2020.32875
- Donnino MW, Andersen LW, Berg KM, Reynolds JC, Nolan JP, Morley PT, Lang E, Cocchi MN, Xanthos T, Callaway CW, Soar J; ILCOR ALS Task Force. Temperature Management After Cardiac Arrest: An Advisory Statement by the Advanced Life Support Task Force of the International Liaison Committee on Resuscitation and the American Heart Association Emergency Cardiovascular Care Committee and the Council on Cardiopulmonary, Critical Care, Perioperative and Resuscitation. Circulation. 2015 Dec 22;132(25):2448-56.
- 3. Perman SM, Grossestreuer AV, Wiebe DJ, Carr BG, Abella BS, Gaieski DF. The utility of therapeutic hypothermia for post-cardiac arrest syndrome patients with an initial non-shockable rhythm. *Circulation*. 2015 Dec 1;132(22):2146-51.
- 4. Callaway CW, Donnino MW, Fink EL, Geocadin RG, Golan E, Kern KB, Leary M, Meurer WJ, Peberdy MA, Thompson TM, Zimmerman JL. Part 8: Post-Cardiac Arrest Care: 2015 American Heart Association Guidelines Update for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. *Circulation*. 2015 Nov 3;132(18 Suppl 2):S465-82.
- Travers AH, Perkins GD, Berg RA, Castren M, Considine J, Escalante R, Gazmuri RJ, Koster RW, Lim SH, Nation KJ, Olasveengen TM, Sakamoto T, Sayre MR, Sierra A, Smyth MA, Stanton D, Vaillancourt C; Basic Life Support Chapter Collaborators. Part 3: Adult Basic Life Support and Automated External Defibrillation: 2015 International Consensus on Cardiopulmonary Resuscitation and Emergency Cardiovascular Care Science With Treatment Recommendations. *Circulation*. 2015 Oct 20;132(16 Suppl 1):S51-83.
- 6. Callaway CW, Soar J, Aibiki M, Böttiger BW, Brooks SC, Deakin CD, Donnino MW, Drajer S, Kloeck W, Morley PT, Morrison LJ, Neumar RW, Nicholson TC, Nolan JP, Okada K, O'Neil BJ, Paiva EF, Parr MJ, Wang TL, Witt J; Advanced Life Support Chapter Collaborators. Part 4: Advanced Life Support: 2015 International Consensus on Cardiopulmonary Resuscitation and Emergency Cardiovascular Care Science With Treatment Recommendations. *Circulation*. 2015 Oct 20;132(16 Suppl 1):S84-145.
- de Caen AR, Maconochie IK, Aickin R, Atkins DL, Biarent D, Guerguerian AM, Kleinman ME, Kloeck DA, Meaney PA, Nadkarni VM, Ng KC, Nuthall G, Reis AG, Shimizu N, Tibballs J, Veliz Pintos R; Pediatric Basic Life Support and Pediatric Advanced Life Support Chapter Collaborators. Part 6: Pediatric Basic Life Support and Pediatric Advanced Life Support: 2015 International Consensus on Cardiopulmonary Resuscitation and Emergency Cardiovascular Care Science With Treatment Recommendations. *Circulation*. 2015 Oct 20;132(16 Suppl 1):S177-203.
- 8. Spaite DW, Bobrow BJ, Stolz U, Berg RA, Sanders AB, Kern KB, Chikani V, Humble W, Mullins T, Stapczynski JS, Ewy GA; Arizona Cardiac Receiving Center Consortium. Statewide regionalization of postarrest care for out-of-hospital cardiac arrest: association with survival and neurologic outcome. Ann Emerg Med. 2014 Nov;64(5):496-506.
- 9. Kim F, Nichol G, Maynard C, Hallstrom A, Kudenchuk PJ, Rea T, Copass MK, Carlbom D, Deem S, Longstreth WT Jr, Olsufka M, Cobb LA. Effect of prehospital induction of mild hypothermia on survival and neurological status among adults with cardiac arrest: a randomized clinical trial. JAMA. 2014 Jan 1;311(1):45-52.





Medical Literature References
4J – Post Cardiac Arrest Treatment – Adult & Pediatric (cont)


- 10. Nielsen N, Wetterslev J, Cronberg T, Erlinge D, Gasche Y, Hassager C, Horn J, Hovdenes J, Kjaergaard J, Kuiper M, Pellis T, Stammet P, Wanscher M, Wise MP, Aneman A, Al-subaie N, Boesgaard S, Bro-Jeppesen J, Brunetti I, Bugge JF, Hingston DC, Juffermans NP, Koopmans M, Kober L, Langorgen J, Lilja G, Moller JE, Rundgren M, Rylander C, Smid O, Werer C, Winkel P, Friberg H; TTM Trial Investigators. Targeted temperature management at 33C versus 36C after cardiac arrest. N Engl J Med. 2013 Dec 5;369(23):2197-206.
- 11. Fugate JE, Moore SA, Knopman DS, Claassen DO, Wijdicks EF, White RD, Rabinstein AA. Cognitive outcomes of patients undergoing therapeutic hypothermia after cardiac arrest. *Neurology*. 2013 May 17. [Epub ahead of print] PubMed PMID: 23685933.
- 12. Bernard SA, Smith K, Cameron P, Masci K, Taylor DM, Cooper DJ, Kelly AM, Silvester W; Rapid Infusion of Cold Hartmanns Investigators. Induction of prehospital therapeutic hypothermia after resuscitation from nonventricular fibrillation cardiac arrest. *Crit Care Med.* 2012 Mar;40(3):747-53.
- 13. Testori C, Sterz F, Behringer W, Haugk M, Uray T, Zeiner A, Janata A, Arrich J, Holzer M, Losert H. Mild therapeutic hypothermia is associated with favourable outcome in patients after cardiac arrest with non-shockable rhythms. *Resuscitation*. 2011 Sep;82(9):1162-7.
- 14. Cabanas JG, Brice JH, De Maio VJ, Myers B, Hinchey PR. Field-induced therapeutic hypothermia for neuroprotection after out-of hospital cardiac arrest: a systematic review of the literature. *J Emerg Med* 2011 Apr;40(4):400-9.
- 15. Hinchey PR, Myers JB, Lewis R, De Maio VJ, Reyer E, Licatese D, Zalkin J, Snyder G; Capital County Research Consortium. Improved out-of-hospital cardiac arrest survival after the sequential implementation of 2005 AHA guidelines for compressions, ventilations, and induced hypothermia: the Wake County experience. *Ann Emerg Med.* 2010 Oct;56(4):348-57.
- 16. Bernard SA, Smith K, Cameron P, Masci K, Taylor DM, Cooper DJ, Kelly AM, Silvester W; Rapid Infusion of Cold Hartmanns (RICH) Investigators. Induction of therapeutic hypothermia by paramedics after resuscitation from out-of-hospital ventricular fibrillation cardiac arrest: a randomized controlled trial. *Circulation*. 2010 Aug 17;122(7):737-42.
- 17. Mechem CC, Goodloe JM, Richmond NJ, Kaufman BJ, Pepe PE; U.S. Metropolitan Municipalities EMS Medical Directors Consortium. Resuscitation center designation: recommendations for emergency medical services practices. *Prehosp Emerg Care*. 2010 Jan-Mar;14(1):51-61.
- 18. Pepe PE, Roppolo LP, Fowler RL. The detrimental effects of ventilation during low-blood-flow states. *Curr Opin Crit Care*. 2005 Jun;11(3):212-8.
- 19. Bernard SA, Gray TW, Buist MD, Jones BM, Silvester W, Gutteridge G, Smith K. Treatment of comatose survivors of out-of-hospital cardiac arrest with induced hypothermia. *N Engl J Med.* 2002 Feb 21;346(8):557-63.
- Hypothermia after Cardiac Arrest Study Group. Mild therapeutic hypothermia to improve the neurologic outcome after cardiac arrest. N Engl J Med. 2002 Feb 21;346(8):549-56. Erratum in N Engl J Med 2002 May 30;346(22):1756.





Approved 9/04/24, Effective 1/15/25, replaces all prior versions

4K - "Do Not Resuscitate"/Advanced Directive Orders,
Futility of Resuscitation Initiation, & Termination of Resuscitation
Adult & Pediatric



#### "Do Not Resuscitate" & Advanced Directive Orders

Emergency Medical Responders, EMTs and Paramedics shall follow a physician's written Do-Not-Resuscitate (DNR) order, an Oklahoma DNR Consent Form, or an Advanced Health Care Directive accompanied by a written statement from two physicians that the patient is a "qualified" patient.

In many instances of advanced directives/DNR wishes communicated by the patient's family or caregivers, DNR paperwork is missing or incomplete. In such circumstances, contact the Chief Medical Officer or Assistant Chief Medical Officer early in resuscitation (within 2-3 minutes of initiating resuscitation) to review the situation. In most of these situations, the Chief Medical Officer or Assistant Chief Medical Officer will be able to determine further resuscitation is NOT warranted and will be able to cease further resuscitation in concordance with the patient's/family's wishes.

In any of the above confirmed situations, cease or withhold BVM ventilations, advanced airway placement, defibrillation, CPR, and antiarrhythmic and/or vasopressor medication administration. Provide all other appropriate care in accordance with applicable treatment protocols and procedures if the patient is not in respiratory or cardiac arrest, specifically addressing non-cardiopulmonary arrest conditions and maintaining appropriate comfort care for the patient.





Approved 9/04/24, Effective 1/15/25, replaces all prior versions

### **Futility of Resuscitation Initiation**

CPR should not be initiated (or continued if initiated by bystanders prior to arrival) by Emergency Medical Responders, EMTs, and paramedics in the following clinical conditions representing "obvious death" (regardless of cause of cardiac arrest):

No pulse AND
No spontaneous respirations AND
Pupils fixed (unreactive to light) AND
One or more of the following:

Rigor mortis. Decomposition. Decapitation. Dependent lividity.

PROTOCOL 4K: "Do Not Resuscitate" Advanced Directive Orders, Futility of Resuscitation, & Termination of Resuscitation – Adult & Pediatric, cont Futility of Resuscitation Initiation, cont.

In <u>blunt traumatic cardiac arrest</u>, CPR should not be initiated (or continued if initiated by bystanders prior to arrival) by Emergency Medical Responders, EMTs, and Paramedics in the following clinical conditions:

No pulse AND
No spontaneous respirations AND
No shockable rhythm AND
No organized ECG activity, i.e., (patient is asystolic or PEA <40 beats per minute)

In <u>penetrating traumatic cardiac arrest</u>, CPR should not be initiated (or continued if initiated by bystanders prior to arrival) by Emergency Medical Responders, EMTs, & paramedics in the following clinical conditions:

No pulse AND
No spontaneous respirations AND
Pupils fixed (unreactive to light) AND
No spontaneous movement AND
No organized ECG activity (asystole or PEA <40 beats per minute)

Unless the above death criteria are clearly met, CPR and other resuscitative efforts should be initiated and aggressively delivered to promote the best chance of patient survival. In cases involving relative hypothermia (often involved in water submersion situations), ensure full resuscitative efforts are delivered as outlined in Protocol 11B - Cold Illness/Injury. In cases of lightning strike (without signs of "obvious death" as previously listed in this protocol), ensure full resuscitative efforts.





Approved 9/04/24, Effective 1/15/25, replaces all prior versions

PROTOCOL 4K: "Do Not Resuscitate" Advanced Directive Orders, Futility of Resuscitation Initiation, & Termination of Resuscitation – Adult & Pediatric, cont.

#### **Termination of Resuscitation**

Evidence-based medicine supports the practice of field CPR termination in the following:

Adult, non-traumatic cardiac arrest patients who have not responded to full resuscitative efforts delivered consistent with the 2025 Medical Control Board Treatment Protocols in the following circumstance in which Paramedic (or higher level) care is available within 20 minutes of first EMS contact with the patient:

An adult patient who has a **non-EMS witnessed**, **non-traumatic cardiac arrest** and is **found in asystole or PEA upon Paramedic arrival** may be considered a candidate for field termination of resuscitation if they do not respond to full resuscitation efforts AND:

- 1) Location of cardiac arrest is a private residence or healthcare facility (e.g. nursing home).
- 2) ALS resuscitative efforts (CPR, successful placement of advanced airway, successful vascular access IV or IO, and medication administration) have been continuously performed for at least 20 minutes without return of spontaneous circulation (ROSC) or conversion of asystole or PEA to Ventricular Fibrillation/Ventricular Tachycardia at any time during the 20+ minutes of advanced life support.
  - 3) End-tidal carbon dioxide <20 mmHg at time of resuscitation termination.
- 4) The cardiac arrest did not occur in absolute or relative hypothermia.
- 5) The cardiac arrest did not occur due to apparent toxic agent exposure.

Adult, non-traumatic cardiac arrest patients who have not responded to full resuscitative efforts delivered consistent with the 2025 Medical Control Board Treatment Protocols in the following circumstance in which Paramedic (or higher level) care is <u>NOT</u> available within 20 minutes of first EMS contact with the patient:

An adult patient who has a **non-EMS witnessed**, **non-traumatic cardiac arrest** and is **found in a non-AED shockable rhythm upon first care arrival** may be considered a candidate for field termination of resuscitation if they do not respond to full resuscitation efforts AND:

- 1) Location of cardiac arrest is a private residence or healthcare facility (e.g. nursing home).
- 2) BLS/ALS (non-Paramedic level) resuscitative efforts (CPR, and the possible inclusion of successful placement of advanced airway, successful vascular access IV or IO, and limited medication administration) have been continuously performed for at least 20 minutes without return of spontaneous circulation (ROSC) or conversion of a non-AED shockable rhythm to an AED-shockable rhythm at any time during the 20+ minutes of resuscitation.
  - 3) The cardiac arrest did not occur in absolute or relative hypothermia.
- 4) The cardiac arrest did not occur due to apparent toxic agent exposure.





Approved 9/04/24, Effective 1/15/25, replaces all prior versions

### Termination of Resuscitation, cont.

To be perfectly clear, only after <u>ALL</u> of the above criteria are met, then an online medical control physician or the patient's personal physician may be consulted for field termination of cardiac arrest resuscitation. The physician's order may be either by direct voice communication or in writing if the physician is present at the scene. The order is based upon the physician's decision that the patient's condition is terminal, cardiovascular unresponsiveness has been established despite optimal out-of-hospital ALS emergency medical care, and biologic death has occurred. The EMS professional's decision to stop the resuscitation then shall be based on this physician's order, though such order cannot contradict the conditions specified for termination of resuscitation.

In the event that all of the above field termination criteria are not met, and on scene personnel identify extenuating circumstances that could supersede the stated criteria, the Office of the Medical Director shall be contacted for consultation.

Prior to field termination of resuscitation order requests, logistical factors should be considered such as family expectations, safety of crew and public if resuscitation is halted on scene, factors inhibiting safe patient movement, non-English-speaking family/cultural barriers, private physician order to continue resuscitation and transport, possible correctable causes of cardiac arrest yet untreated. EMS providers on-scene should consider the family member(s) access to resources including clergy, crisis workers, social workers, and other necessary personnel to ensure field termination of resuscitation can be achieved in an efficient, humane manner. Additionally, Oklahoma legal requirements for unattended death must be follow.





# Medical Literature References 4K – "Do Not Resuscitate"/Advanced Directive Orders, Futility of Resuscitation Initiation & Termination of Resuscitation – Adult & Pediatric

- Kashiura M, Hamabe Y, Akashi A, Sakurai A, Tahara Y, Yonemoto N, Nagao K, Yaguchi A, Morimura N, SOS-KANTO 2012 Study Group. Applying the termination of resuscitation rules to out-of-hospital cardiac arrests of both cardiac and non-cardiac etiologies: a prospective cohort study. *Crit Care*. 2016;20(49)
- National Association of EMS Physicians and American College of Surgeons Committee on Trauma. Position Statement: Withholding of resuscitation for adult traumatic cardiopulmonary arrest. *Prehosp Emerg Care*. 2013 Apr-Jun;17(2):291.
- 3. Wampler DA, Collett L, Manifold CA, Velasquez C, McMullan JT. Cardiac arrest survival is rare without prehospital return of spontaneous circulation. *Prehosp Emerg Care*. 2012 Oct-Dec;16(4):4515.
- 4. National Association of EMS Physicians. Termination of resuscitation in nontraumatic cardiopulmonary arrest. *Prehosp Emerg Care*. 2011 Oct-Dec;15(4):542.
- Millin MG, Khandker SR, Malki A. Termination of resuscitation of nontraumatic cardiopulmonary arrest: resource document for the National Association of EMS Physicians position statement. *Prehosp Emerg Care*, 2011 Oct-Dec:15(4):547-54.
- Mollberg NM, Wise SR, Berman K, Chowdhry S, Holevar M, Sullivan R, Vafa A. The consequences of noncompliance with guidelines for withholding or terminating resuscitation in traumatic cardiac arrest patients. *J Trauma*. 2011 Oct;71(4):997-1002.
- 7. Eckstein M, Hatch L, Malleck J, McClung C, Henderson SO. End-tidal CO2 as a predictor of survival in out-of-hospital cardiac arrest. *Prehosp Disaster Med.* 2011 Jun;26(3):148-50.
- 8. Ponce A, Swor R, Quest TE, Macy M, Meurer W, Sasson C. Death notification training for prehospital providers: a pilot study. *Prehosp Emerg Care*. 2010 Oct-Dec;14(4):537-42.
- Sasson C, Forman J, Krass D, Macy M, Hegg AJ, McNally BF, Kellermann AL. A qualitative study to understand barriers to implementation of national guidelines for prehospital termination of unsuccessful resuscitation efforts. *Prehosp Emerg Care*. 2010 Apr-Jun;14(2):250-8.
- Sherbino J, Keim SM, Davis DP; Best Evidence In Emergency Medicine (BEEM) Group. Clinical decision rules for termination of resuscitation in out-of-hospital cardiac arrest. *J Emerg Med.* 2010 Jan;38(1):80-6.
- 11. Ruygrok ML, Byyny RL, Haukoos JS; Colorado Cardiac Arrest & Resuscitation Collaborative Study Group and the Denver Metro EMS Medical Directors. Validation of 3 termination of resuscitation criteria for good neurologic survival after out-of-hospital cardiac arrest. *Ann Emerg Med.* 2009 Aug;54(2):239-47.
- 12. Sasson C, Forman J, Krass D, Macy M, Kellermann AL, McNally BF. A qualitative study to identify barriers to local implementation of prehospital termination of resuscitation protocols. *Circ Cardiovasc Qual Outcomes*. 2009 Jul;2(4):361-8.
- 13. Morrison LJ, Verbeek PR, Zhan C, Kiss A, Allan KS. Validation of a universal prehospital termination of resuscitation clinical prediction rule for advanced and basic life support providers. *Resuscitation*. 2009 Mar:80(3):324-8.
- 14. Morrison LJ, Bigham BL, Kiss A, Verbeek PR. Termination of resuscitation: a guide to interpreting the literature. *Resuscitation*. 2008 Dec;79(3):387-90.
- Richman PB, Vadeboncoeur TF, Chikani V, Clark L, Bobrow BJ. Independent evaluation of an out-of-hospital termination of resuscitation (TOR) clinical decision rule. *Acad Emerg Med.* 2008
   Jun:15(6):517-21.
- 16. Morrison LJ, Verbeek PR, Vermeulen MJ, Kiss A, Allan KS, Nesbitt L, Stiell I. Derivation and evaluation of a termination of resuscitation clinical prediction rule for advanced life support providers. *Resuscitation*. 2007 Aug;74(2):266-75.
- Morrison LJ, Visentin LM, Vermeulen M, Kiss A, Theriault R, Eby D, Sherbino J, Verbeek R; TOR investigators. Inter-rater reliability and comfort in the application of a basic life support termination of resuscitation clinical prediction rule for out of hospital cardiac arrest. *Resuscitation*. 2007 Jul;74(1):150-7.
- Morrison LJ, Visentin LM, Kiss A, Theriault R, Eby D, Vermeulen M, Sherbino J, Verbeek PR; TOR Investigators. Validation of a rule for termination of resuscitation in out-of-hospital cardiac arrest. *N Engl J Med.* 2006 Aug 3;355(5):478-87.





Medical Literature References
4K – "Do Not Resuscitate"/Advanced Directive Orders, Futility of Resuscitation Initiation
& Termination of Resuscitation – Adult & Pediatric

- Reynolds JC, Grunau BE, Rittenberger JC, Sawyer KN, Kurz MC, Callaway CW. Association Between Duration of Resuscitation and Favorable Outcome After Out-of-Hospital Cardiac Arrest: Implications for Prolonging or Terminating Resuscitation. *Circulation*. 2016;134(25):2084-2094. doi:10.1161/CIRCULATIONAHA.116.023309
- Tataris, K. L., Richards, C. T., Stein-Spencer, L., Ryan, S., Lazzara, P., & Weber, J. M. (2017). EMS
  Provider Perceptions on Termination of Resuscitation in a Large, Urban EMS System. *Prehospital Emergency Care*. https://doi.org/10.1080/10903127.2017.1317891
- 21. Grunau B, Puyat J, Wong H, et al. Gains of Continuing Resuscitation in Refractory Out-of-hospital Cardiac Arrest: A Model-based Analysis to Identify Deaths Due to Intra-arrest Prognostication. *Prehospital Emergency Care.* 2018;22(2):198-207. doi:10.1080/10903127.2017.1356412
- 22. Ebell, M. H., Vellinga, A., Masterson, S., & Yun, P. (2019). Meta-analysis of the accuracy of termination of resuscitation rules for out-of-hospital cardiac arrest. Emergency Medicine Journal, 36(8), 479–484.





Approved 9/04/24, Effective 1/15/25, replaces all prior versions

## **4L-INTRA-ARREST WAKEFULNESS**

#### TREATMENT PRIORITIES

- 1. Safety of self
- 2. Safety of public safety professionals
- 3. Safety of patient
- 4. Continuity of resuscitation

## **ADULT**



**EMR EMT** 

ASSIST IN PHYSICAL CONTROL OF PATIENT, INCLUDING APPLYING PHYSICAL RESTRAINTS ANY RESTRAINT(S) SHOULD MINIMIZE ANY DETRIMENT TO RESPIRATORY OR PERFUSION MECHANICS

> USE ADEQUATE NUMBERS OF PUBLIC SAFETY PROFESSIONALS TO MINIMIZE RISK OF INJURY TO SELF AND OTHERS

SPEAK CALMLY TO PATIENT WITH REASSURANCE THAT HELP IS BEING PROVIDED

CONTINUE RESUCITATION CARE PER APPLICABLE PROTOCOLS

**EMT-185 AEMT** 

IV/IO ACCESS DO NOT RISK SELF INJURY WITH NEEDLESTICK IN IV ACCESS IF PT COMBATIVE

### **PARAMEDIC**

### CHEMICAL RESTRAINT:

ALL PATIENTS REQUIRING CHEMICAL RESTRAINT ARE TO BE PHYSICALLY RESTRAINED AS WELL

ADULT: MIDAZOLAM 0.1 mg/kg IVP/IOP TO MAX OF 5 mg. MAY REPEAT ONCE. OR

ADULT: DIAZEPAM 5 mg IVP/IOP IF MIDAZOLAM NOT AVAILABLE. MAY REPEAT ONCE.

OR ADULT: LORAZEPAM 2 mg IVP/IOP IF MIDAZOLAM NOT AVAILABLE. MAY REPEAT ONCE.

(MIDAZOLAM STRONGLY PREFERRED DUE TO MOST RAPID ONSET OF ACTION OF BENZODIAZEPINE OPTIONS)


CONTINUOUS ASSESSMENT & TREATMENT PER APPLICABLE PROTOCOL(S)





Approved 9/04/24, Effective 1/15/25, replaces all prior versions

## 4M – ACTIVE COMPRESSION DECOMPRESSION CPR ADULT



#### **Indication**:

Adult non-traumatic cardiac arrest.

#### **Contraindications:**

Spontaneous circulation/pulse.

Traumatic cardiac arrest (hanging/strangulation is NOT considered traumatic in this context). Sternotomy less than estimated 6 months time.

#### Technique:

- 1. The correct compression/decompression rate is 80 cycles/minute when using the ResQPUMP<sup>®</sup>. Either the built-in two-tone metronome or an external metronome set to 80 should guide the rate.
- 2. The correct compression depth is 2 inches in adults when using the ResQPUMP<sup>®</sup>. Excessive depths can lead to chest wall trauma and chest wall trauma can lead to tension pneumothorax.
- 3. The correct compression force is whatever occurs at no more than 2 inches of depth in adults when using the ResQPUMP®. In many adults, this will be at or very near 40kg of force as measured on the device's force gauge (which should read as 0kg of force when pulled out for patient use), but let the depth determine the force. Do not start out trying to achieve a certain force regardless of depth. Excessive force can lead to chest wall trauma and chest wall trauma can lead to tension pneumothorax.
- 4. Any compression with the ResQPUMP® should be directly midline of the sternum. Avoid placing the ResQPUMP® laterally to the sternum. Improper placement can lead to chest wall trauma and chest wall trauma can lead to tension pneumothorax.






Approved 9/04/24, Effective 1/15/25, replaces all prior versions

#### Protocol 4M: Active Compression Decompression CPR, Adult, cont.

Technique (cont):

- 5. The correct compression technique with the ResQPUMP® involves the compressor's shoulders being over and in line with the sternum, producing a direct down (compression) and up (decompression) cycle. Even slight lateral movements of the ResQPUMP® can cause loss of suction between the device and the patient's chest, losing the active decompression advantage of the ResQPUMP®.
- 6. The correct decompression force of the ResQPUMP® is at 10kg as measured on the device's force gauge. Additional decompression force is unnecessary and could lead to chest wall trauma and chest wall trauma can lead to tension pneumothorax.
- 7. Avoid any ResQPUMP® use when standing. All ResQPUMP®-assisted compressions should be performed when kneeling immediately next to the patient's side.
- 8. Avoid any ResQPUMP® use when the patient is in motion. This includes during movement of the patient to the ambulance for transport. This includes during ambulance transport of the patient to an Emergency Department.
- 9. If unable to achieve consistent chest wall suction and active decompression with the ResQPUMP®, discontinue its use and revert to manual chest compressions at 110 compressions/minute. Strategies to improve chest wall suction include wiping away any moisture on the chest and avoiding placement of therapy electrodes (defibrillation pads) in the compression/decompression site.









### Medical Literature References 4M – Active Compression Decompression CPR - Adult


- 1. Frascone RJ. HemoDynamic Duo. Improving survival from cardiac arrest using active compression-decompression CPR (ACD-CPR) with an ITD. *JEMS*. 2014 Dec; Suppl:8-13.
- Frascone RJ, Wayne MA, Swor RA, Mahoney BD, Domeier RM, Olinger ML, Tupper DE, Setum CM, Burkhart N, Klann L, Salzman JG, Wewerka SS, Yannopoulos D, Lurie KG, O'Neil BJ, Holcomb RG, Aufderheide TP. Treatment of non-traumatic out-of-hospital cardiac arrest with active compression decompression cardiopulmonary resuscitation plus an impedance threshold device. *Resuscitation*. 2013 Sep;84(9):1214-22.
- 3. Luo XR, Zhang HL, Chen GJ, Ding WS, Huang L. Active compression-decompression cardiopulmonary resuscitation (CPR) versus standard CPR for cardiac arrest patients: a meta-analysis. *World J Emerg Med.* 2013;4(4):266-72.
- Aufderheide TP, Frascone RJ, Wayne MA, Mahoney BD, Swor RA, Domeier RM, Olinger ML, Holcomb RG, Tupper DE, Yannopoulos D, Lurie KG. Standard cardiopulmonary resuscitation versus active compression-decompression cardiopulmonary resuscitation with augmentation of negative intrathoracic pressure for out-of-hospital cardiac arrest: a randomised trial. *Lancet*. 2011 Jan 22;377(9762):301-11.





Approved 9/04/24, Effective 1/15/25, Replaces All Prior Versions

### 4N – EleGARD<sup>®</sup> HEAD UP CPR ADULT



#### Indication:

Adult non-traumatic cardiac arrest (includes isolated hanging or strangulation)

### **Contraindications:**

Spontaneous circulation
Traumatic cardiac arrest
Patient size/body habitus prevents correct positioning
Sternotomy less than 6 months old – by history or best estimate if history unconfirmed

#### Technique:

- 1. Move patient to area allowing approximately 3 feet of space in all directions (if applicable).
- 2. Position EleGARD® near the patient's head. DO NOT apply c-collar when using EleGARD®
- 3. Power on EleGARD® device by depressing the #1 button.
- 4. 'Coordinate lifting the patient's torso (to no more than approximately 45 degrees) and sliding the lower edge of EleGARD® under the patient until that edge comes to the approximate line of the patient's tailbone, with the patient's head being cradled within the head rest of EleGARD®.
- 5. Lower the patient and EleGARD® together, aligning the patient with their armpits above the compression backplate (yellow board) ensuring the neck rest is at the base of the neck. This may involve pulling EleGARD® back while lowering to ensure proper alignment. While not always possible, the goal for completion of steps 4 & 5 is within 10 seconds.
- 6. Place a superglottic airway with a ResQPOD® and continue ResQPUMP® CPR. Once ResQPOD® is in place on the airway, press #2 button and continue with 2 minutes of CPR. Begin manual CPR if the ResQPUMP® is either not available or not effective.





Approved 9/04/24, Effective 1/15/25, Replaces All Prior Versions

#### Protocol 4N: EleGARD® Head Up CPR, Adult, (cont.)

#### Technique (cont.):

- 7. Adjust patient position as necessary. DO NOT stop CPR until the timer flashes indicating the end of the 2-minute CPR cycle.
- 8. Activate the head/neck/upper trunk elevation sequence by depressing the #3 button. The sequence is automatic once the #3 button is depressed and will take 2 minutes. The battery lights will illuminate in an upward cascade as the head/neck/upper trunk are being elevated. Limit any interruptions in compressions while EleGARD® is elevating. Continue standard resuscitative measures.
- 9. In instances of ROSC and a mean arterial blood pressure of 65mmHg or greater or a systolic blood pressure of 90mmHg or greater, the head of the patient should remain elevated in the head-up device. In instances where the mean arterial pressure is below 65mmHg or systolic BP below 90 mmHg, the head-up device should be lowered to the lowest position in the device.
- 10. If transporting, lift EleGARD® horizontally just enough to slide a Mega Mover under the patient's torso. Lift the patient's legs to assure Mega Mover extends the complete length of the patient. Before and after any patient move, check patient positioning for correctness in EleGARD®.
- 11. When patient transfer of care occurs or termination of resuscitation occurs, EleGARD<sup>®</sup> is lowered to its resting position by depressing the gray "DOWN" button.
- 12. Complete decontamination of EleGARD® and ready its next use following departmental/OMD instructions.








**4N - RESUSCITATION TEAM ROLES** EleGARD® HEAD UP CPR-ADULT

#### TREATMENT PRIORITIES PRIOR TO PRIMING PHASE < 2 MINUTES:

- 1. Circulatory Support
  - Apply ResQCPR®, and place EleGARD®
    - Continuous chest compression: 110/min standard CPR
    - Place i-gel® with ResQPOD®, inline EtCO2/waveform capnography, & OGT
    - Once i-gel®, and ResQPod® in place: 80 chest compression decompression cycles/min ResQCPR® with ResQPUMP®
  - Prior to priming phase, rhythm analysis, and timely defibrillation (if indicated)
  - ➤ Start priming phase by pressing button # 2
    - Priming phase is 2 min uninterrupted CPR with, i-gel®, ResQPod®, ResQPUMP®, and EleGARD®
- 2. Oxygenation/Ventilation support
  - Avoid hyperventilation in rate & volume
  - Use waveform capnography \*\*mandatory use if patient intubated

#### Position 3 (P3) always at patient's head Position 4 (P4) post EleGARD® Position 4 (P4) initial location always Preps and places i-gel®, ResQPOD®, deployment always outside CPR outside CPR "triangle" inline EtCO2/waveform capnography, "triangle" • States "EleGARD® is ready" when inline airway filter (if using), and BVM Assist P3 with prepping/placing i-gel® ready to deploy Assist with placing posterior & OGT (after EleGARD® is in place) Places EleGARD® defibrillation pad • 8-10 ventilations without pause in compressions **Post Initial Location ELeGARD®** Deployment Airway Bag Position 2(P2) always on patient's left Position 1 (P1) always on patient's right • Starts metronome for P1 (if attached • Starts chest compression and voices to to the monitor) start metronome (chest compressions at

- 110 compressions/minute using hands
- Helps guide EleGARD® (grabs LUCAS back plate to guide under axillae)
- Initiates ResQPUMP® CPR once ResQPOD® is placed on i-gel®



Anterior-Posterior Pad Placement (1st defibrillator) 2<sup>nd</sup> defibrillator per protocol 4E

- Places anterior defibrillation pad, positions posterior defibrillation pad so that P3 can access during patient lift, and attaches cable to LP15
- Straddles patient, grabs both arms and lifts patient's torso so EleGARD® can be placed
- When EleGARD® is placed, events EleGARD®, and pre-charges monitor
- Does not interrupt priming phase

#### Post Deployment of EleGARD® Follow

- Protocol 4B Resuscitation Team Roles
- 4N EleGARD® HEAD UP CPR ADULT






#### Medical Literature References 4N - EleGARD Head Up CPR Adult

- 1. Duhem, H., Moore, J. C., Rojas-Salvador, C., Salverda, B., Lick, M., Pepe, P., Labarere, J., Debaty, G., & Lurie, K. G. (2021). Improving post-cardiac arrest cerebral perfusion pressure by elevating the head and thorax. *Resuscitation*, *159*, 45–53.
- 2. Moore, J. C., Salverda, B., Rojas-Salvador, C., Lick, M., Debaty, G., & G. Lurie, K. (2021). Controlled sequential elevation of the head and thorax combined with active compression decompression cardiopulmonary resuscitation and an impedance threshold device improves neurological survival in a porcine model of cardiac arrest. *Resuscitation*, *158*, 220–227.
- 3. Holley, J., Moore, J. C., Jacobs, M., Rojas-Salvador, C., Lick, C., Salverda, B. J., Lick, M. C., Frascone, R. J., Youngquist, S. T., & Lurie, K. G. (2020). Supraglottic airway devices variably develop negative intrathoracic pressures: A prospective cross-over study of cardiopulmonary resuscitation in human cadavers. *Resuscitation*, *148*, 32–38.
- 4. Moore, J. C., Salverda, B., Lick, M., Rojas-Salvador, C., Segal, N., Debaty, G., & Lurie, K. G. (2020). Controlled progressive elevation rather than an optimal angle maximizes cerebral perfusion pressure during head up CPR in a swine model of cardiac arrest. *Resuscitation*, 150, 23–28.
- Pepe, P. E., Aufderheide, T. P., Lamhaut, L., Davis, D. P., Lick, C. J., Polderman, K. H., Scheppke, K. A., Deakin, C. D., O'Neil, B. J., van Schuppen, H., Levy, M. K., Wayne, M. A., Youngquist, S. T., Moore, J. C., Lurie, K. G., Bartos, J. A., Bachista, K. M., Jacobs, M. J., Rojas-Salvador, C., ... Yannopoulos, D. (2020). Rationale and Strategies for Development of an Optimal Bundle of Management for Cardiac Arrest. *Critical Care Explorations*, 2(10), e0214.
- 6. Rojas-Salvador, C., Moore, J. C., Salverda, B., Lick, M., Debaty, G., & Lurie, K. G. (2020). Effect of controlled sequential elevation timing of the head and thorax during cardiopulmonary resuscitation on cerebral perfusion pressures in a porcine model of cardiac arrest. *Resuscitation*, 149, 162–169.
- 7. Pepe, P. E., Scheppke, K. A., Antevy, P. M., Crowe, R. P., Millstone, D., Coyle, C., Prusansky, C., Garay, S., Ellis, R., Fowler, R. L., & Moore, J. C. (2019). Confirming the Clinical Safety and Feasibility of a Bundled Methodology to Improve Cardiopulmonary Resuscitation Involving a Head-Up/Torso-Up Chest Compression Technique. *Critical Care Medicine*, 47(3), 449–455.
- 8. Moore, J. C., Holley, J., Segal, N., Lick, M. C., Labarère, J., Frascone, R. J., Dodd, K. W., Robinson, A. E., Lick, C., Klein, L., Ashton, A., McArthur, A., Tsangaris, A., Makaretz, A., Makaretz, M., Debaty, G., Pepe, P. E., & Lurie, K. G. (2018). Consistent head up cardiopulmonary resuscitation haemodynamics are observed across porcine and human cadaver translational models. *Resuscitation*, *132*, 133–139.
- 9. Ryu, H. H., Moore, J. C., Yannopoulos, D., Lick, M., McKnite, S., Shin, S. do, Kim, T. Y., Metzger, A., Rees, J., Tsangaris, A., Debaty, G., & Lurie, K. G. (2016). The Effect of Head Up Cardiopulmonary Resuscitation on Cerebral and Systemic Hemodynamics. *Resuscitation*, 102, 29–34. https://doi.org/10.1016/j.resuscitation.2016.01.033





Approved 9/04/24, Effective 1/15/25, replaces all prior versions



ADULT: IF CHEST PAIN NOT IMPROVED WITH INITIAL NTG: MAY TREAT WITH OPIOID OPTION ABOVE IF INDICATED PEDIATRIC: CONSULT FOR TREATMENT DIRECTIVE(S) IF INDICATED





### Medical Literature References 5A – Chest Pain – Uncertain Etiology – Adult& Pediatric


- 1. Hofmann R, et al for the DETO2X-SWEDEHEART Investigators. Oxygen therapy in suspected acute myocardial infarction. NEJM, published Aug 28, 2017. doi: 10.1056/NEJMoa1706222.
- 2. Nehme Z, Stub D, Bernard S, Stephenson M, Bray JE, Cameron P, Meredith IT, Barger B, Ellims AH, Taylor AJ, Kaye DM, Smith K; AVOID Investigators. Effect of supplemental oxygen exposure on myocardial injury in ST-elevation myocardial infarction. Heart. 2016 Mar;102(6):444-51.
- 3. Thang ND, Karlson BW, Bergman B, Santos M, Karlsson T, Bengtson A, Johanson P, Rawshani A, Herlitz J. Characteristics of and outcome for patients with chest pain in relation to transport by the emergency medical services in a 20-year perspective. *Am J Emerg Med.* 2012 Nov;30(9):1788-95.
- 4. Verbeek PR, Ryan D, Turner L, Craig AM. Serial prehospital 12-lead electrocardiograms increase identification of ST-segment elevation myocardial infarction. *Prehosp Emerg Care*. 2012 Jan;16(1):109-14.
- Wright RS, Anderson JL, Adams CD, Bridges CR, Casey DE Jr, Ettinger SM, Fesmire FM, Ganiats TG, Jneid H, Lincoff AM, Peterson ED, Philippides GJ, Theroux P, Wenger NK, Zidar JP. 2011 ACCF/AHA focused update of the guidelines for the management of patients with unstable angina/non–ST-elevation myocardial infarction (updating the 2007 guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am CollCardiol. 2011;57:1920–59.
- 6. Werman HA, Newland R, Cotton B. Transmission of 12-lead electrocardiographic tracings by Emergency Medical Technician-Basics and Emergency Medical Technician-Intermediates: a feasibility study. *Am J Emerg Med.* 2011 May;29(4):437-40.
- 7. Trivedi K, Schuur JD, Cone DC. Can paramedics read ST-segment elevation myocardial infarction on prehospital 12-lead electrocardiograms? *Prehosp Emerg Care*. 2009 Apr-Jun;13(2):207-14.
- 8. Lin CH, Lin WC, Ho YJ, Chang JS. Children with chest pain visiting the emergency department. *Pediatr Neonatol.* 2008 Apr;49(2):26-9.
- 9. Bradley EH, Herrin J, Wang Y, Barton BA, Webster TR, Mattera JA, Roumanis SA, Curtis JP, Nallamothu BK, Magid DJ, McNamara RL, Parkosewich J, Loeb JM, Krumholz HM. Strategies for reducing the door-to-balloon time in acute myocardial infarction. *N Engl J Med.* 2006 Nov 30;355(22):2308-20.





Approved 9/04/24, Effective 1/15/25, replaces all prior versions

### 5B – ACQUIRING & TRANSMITTING 12–LEAD ECGS ADULT & PEDIATRIC



### Indications:

- 1. Respiratory Arrest
- 2. Dyspnea Uncertain Etiology
- 3. Dyspnea Chronic Obstructive Pulmonary Disease
- 4. Dyspnea Congestive Heart Failure
- 5. Dyspnea Apparent Life-Threatening Event
- 6. Post Return of Spontaneous Circulation from Cardiac Arrest
- 7. Chest Pain Uncertain Etiology
- 8. Acute Coronary Syndrome
- 9. Bradycardia
- 10. Tachycardia Stable
- 11. Tachycardia Unstable
- 12. Premature Ventricular Contractions
- 13. Hypertensive Emergency
- 14. Stroke
- 15. Syncope
- 16. Poisonings
- 17. Conductive Energy Weapon Related Management
- 18. "Less Lethal" Weapon Related Management
- 19. Lightning/Electrical Injury

#### Contraindications:

If transferring facility has already obtained 12-Lead ECG confirming STEMI prior to EMS arrival, transport is not to be delayed in an effort to obtain additional 12-Lead ECG by arriving EMS professionals. Serial 12-Lead ECG(s) for transmission to receiving facilities is/are to be obtained during transport.







Approved 9/04/24, Effective 1/15/25, replaces all prior versions


### Protocol 5B: Acquiring & Transmitting 12-Lead ECGs - Adult & Pediatric, cont.

#### Technique (applicable to all 12-Lead ECG devices):

- 1. Prepare skin for electrode application. This may include hair removal with razor and/or rubbing the skin with a gauze (sterile or non-sterile) to remove oil and sweat. Both actions contribute to better electrode adhesion, leading to better quality 12-Lead ECGs.
- 2. For standard 12-Lead ECG, apply leads/electrodes as follows (Figures 1 & 2):
  - a. RA lead on right upper extremity, preferably distal on the extremity near the wrist on the palm side.
  - b. LA lead (mirror image of RA) on the left upper extremity, preferably distal on the extremity near the wrist on the palm side.
  - c. RL lead on the right lower extremity, preferably distal on the extremity near the ankle on the outside of the leg.
  - d. LL lead (mirror image of RL) on the left lower extremity, preferably distal on the extremity near the ankle on the outside of the leg.
  - e. V1 lead to the right of the sternum in the 4<sup>th</sup> intercostal space.
  - f. V2 lead (mirror image of V1) to the left of the sternum in the 4<sup>th</sup> intercostal space.
  - g. V4 lead is placed next and in the mid-clavicular line in the left 5<sup>th</sup> intercostal space.
  - h. V3 lead in the middle of the line now created between leads V2 and V4.
  - i. V5 lead in horizontal line with V4 at anterior axillary line of the left axilla.
  - j. V6 lead in horizontal line with V5 at mid-axillary line of the left axilla.
- 3. For a "right-sided" 12-lead ECG to evaluate for right ventricular myocardial infarction in the setting of suspected left ventricular inferior wall ST segment elevation myocardial infarction, simply apply four additional electrodes on the right chest, mirroring V3, V4, V5, and V6. Then move the leads off of V3-V6 and place on their right-sided mirror electrode to create V3R, V4R, V5R, and V6R (Figure 2).












Approved 9/04/24, Effective 1/15/25, replaces all prior versions

Protocol 5B: Acquiring & Transmitting 12-Lead ECGs - Adult & Pediatric, cont.


### Technique (Physio-Control LifePak® 15):

To acquire and transmit a 12-lead ECG:


- 1. Press ON. (Figure 4)
- 2. Insert the lead attachments into the main cable. (Figure 5)
- 3. Insert the cable connector into the monitor's green ECG connector. (Figure 6)
- 4. Prepare patient's skin as described above.
- 5. Apply leads/electrodes as described above.
- Instruct patient to remain still as possible during 12-Lead ECG acquisition to reduce movement artifact (to improve quality of 12-Lead ECG sent to emergency department).
- 7. Press **12-LEAD** to acquire ECG and enter patient demographic information of last name, first name, age, sex (gender), incident number (if applicable) using the speed dial. (Figures 7 & 8)
- 8. Once 12-Lead ECG acquired, press **TRANSMIT**. (Figure 9)
- 9. In the TRANSMIT window, select 12-Lead **REPORT** to be sent. (Figure 10)
- 10. In the TRANSMIT window, select **SITE**.
- 11. In the SITE window, select desired transmission destination, typically a hospital's emergency department. (Figure 11)
- 12. In the TRANSMIT window, select **SEND**. (Figure 12)
- 13. The Physio-Control LifePak®15 should connect to the selected destination.
- 14. Once the transmission is completed a transaction message is automatically printed.
- 15. If the transmission fails, make at least one additional attempt at transmission.























Approved 9/04/24, Effective 1/15/25, replaces all prior versions

Protocol 5B: Acquiring &Transmitting 12-Lead ECGs - Adult & Pediatric, cont.

**NOTE:** There are limitations with transmitting data by telecommunications. Successful transmission depends on the access to public or private network services that may or may not always be available. This is especially true for cellular communication that is influenced by many factors, such as:

- Geography
- Location
- Weather
- Cellular service activity load (volume of active users)
- Cellular service availability

Treatment protocols take into account the fact that data transmissions cannot be assured with the use of cellular communications. Therefore, early voice communication with the receiving facility is an essential contingency plan for interrupted data transmissions.

Multiple methods of transmitting 12-Lead ECG data exist (proprietary cellular/satellite network systems, data fax transmission, cellular transmission of images, e.g. photographs of the 12-Lead ECG sent via smartphone). Check with local EMS administration officials and medical oversight physician(s) to ensure local practices are understood and follow all applicable laws relating to protected health information.





### Medical Literature References 5B – Acquiring & Transmitting 12-Lead ECGs – Adult& Pediatric

- Welsford M, Nikolaou NI, Beygui F, Bossaert L, Ghaemmaghami C, Nonogi H, O'Connor RE, Pichel DR, Scott T, Walters DL, Woolfrey KG; Acute Coronary Syndrome Chapter Collaborators. Part 5: Acute Coronary Syndromes: 2015 International Consensus on Cardiopulmonary Resuscitation and Emergency Cardiovascular Care Science With Treatment Recommendations. Circulation. 2015 Oct 20;132(16 Suppl 1):S146-76.
- 2. Mencl F, Wilber S, Frey J, Zalewski J, Maiers JF, Bhalla MC. Paramedic ability to recognize ST-segment elevation myocardial infarction on prehospital electrocardiograms. *Prehosp Emerg Care*. 2013 Apr-Jun;17(2):203-10.
- 3. Bhalla MC, Mencl F, Gist MA, Wilber A, Zalewski J. Prehospital electrocardiographic computer identification of ST-segment elevation myocardial infarction. *Prehosp Emerg Care*. 2013 Apr-Jun;17(2):211-16.
- 4. Boothroyd LJ, Segal E, Bogaty P, Nasmith J, Eisenberg MJ, Boivin JF, Vadeboncœur A, de Champlain F. Information on myocardial ischemia and arrhythmias added by prehospital electrocardiograms. *Prehosp Emerg Care*. 2013 Apr-Jun;17(2):187-92.
- Verbeek PR, Ryan D, Turner L, Craig AM. Serial prehospital 12-lead electrocardiograms increase identification of ST-segment elevation myocardial infarction. *Prehosp Emerg Care*. 2012 Jan-Mar;16(1):109-14.
- 6. Werman HA, Newland R, Cotton B. Transmission of 12-lead electrocardiographic tracings by Emergency Medical Technician-Basics and Emergency Medical Technician-Intermediates: a feasibility study. *Am J Emerg Med.* 2011 May;29(4):437-40.
- 7. Kushner FG, Hand M, Smith SC Jr, King SB 3rd, Anderson JL, Antman EM, Bailey SR, Bates ER, Blankenship JC, Casey DJ Jr, Green LA, Hochman JS, Jacobs AK, Krumholz HM, Morrison DA, Ornato JP, Pearle DL, Peterson ED, Sloan MA, Whitlow PL, Williams DO. 2009 Focused updates: ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction (updating the 2004 guideline and 2007 focused update) and ACC/AHA/SCAI guidelines on percutaneous coronary intervention (updating the 2005 guideline and 2007 focused update): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2009;120:2271–2306.
- 8. Trivedi K, Schuur JD, Cone DC. Can paramedics read ST-segment elevation myocardial infarction on prehospital 12-lead electrocardiograms? *Prehosp Emerg Care*. 2009 Apr-Jun;13(2):207-14.
- 9. Bradley EH, Herrin J, Wang Y, Barton BA, Webster TR, Mattera JA, Roumanis SA, Curtis JP, Nallamothu BK, Magid DJ, McNamara RL, Parkosewich J, Loeb JM, Krumholz HM. Strategies for reducing the door-to-balloon time in acute myocardial infarction. *N Engl J Med.* 2006 Nov 30;355(22):2308-20.




HOURS OR CIALIS® WITHIN 48 HOURS

WITHOUT OLMC CONSULT.

### EMS System for Metropolitan Oklahoma City and Tulsa 2025 Medical Control Board Treatment Protocols



Approved 9/04/24, Effective 1/15/25, replaces all prior versions







Determines appropriate destination of ACS patient

STEMI alert via telephone contact via recorded line to receiving facility

Approved 9/04/24, Effective 1/15/25, replaces all prior versions

## 5C – ACS TEAM ROLES ADULT & PEDIATRIC

#### Position 3 (P3) Manage Airway Position 4 (P4) Scene Coordination Always outside ACS "triangle" Applies capnography Applies O2 ONLY if indicated Monitors time intervals of interventions and time from first medical contact Airway management as indicated by Avoids direct patient care to maintain supervisory duties if greater than four clinical presentation of patient rescuers throughout. Directs "staging" of personnel beyond six rescuers away from immediate treatment area to prevent crowding. Assumes duties of P5/P6 if limited to four rescuers throughout (if paramedic) and positions self in P5 or P6 position. Anterior-Posterior Pad Placement Position 1 (P1) Interventional Paramedic Position 2 (P2) Efficient Data Acquisition Always on patient's right Always on patients's left Vital signs ASA Applies 4 lead cables NTG Enters patient demographics into Fentanyl only if indicated monitor/defibrillator Obtains 12-Lead ECG Fluid and vasopressor management Applies defibrillation pads ANT-POST Scene Coordination **Transport Logistics Efficient Data Acquisition** Position 6 (P6) Treatment Implementation Paramedic Manage Airway Always outside ACS"triangle" at lower 1/2 of patient Interventional Physical and verbal assessment of patient Gathers concise history from patient/family/bystanders Position 5 (P5) Transport Logistics Maintains overall awareness of ACS dynamics, Always outside ACS "triangle" implements treatment plan based on clinical Ingress/Egress formulation Reviews 12-Lead ECG, determines presence of diagnostic quality and confirms STEMI criteria Assists in equipment management Transmission of diagnostic 12-Lead ECG to receiving






Medical Literature References 5C – Acute Coronary Syndromes – Adult

- Tanguay, A., Lebon, J., Lau, L., Hébert, D., & Bégin, F. (2018). Detection of STEMI Using Prehospital Serial 12-Lead Electrocardiograms. Prehospital Emergency Care, 22(4), 419–426. https://doi.org/10.1080/10903127.2017.1399185
- 2. Hofmann R, et al for the DETO2X-SWEDEHEART Investigators. Oxygen therapy in suspected acute myocardial infarction. NEJM, published Aug 28, 2017. doi: 10.1056/NEJMoa1706222.
- 3. Nehme Z, Stub D, Bernard S, Stephenson M, Bray JE, Cameron P, Meredith IT, Barger B, Ellims AH, Taylor AJ, Kaye DM, Smith K; AVOID Investigators. Effect of supplemental oxygen exposure on myocardial injury in ST-elevation myocardial infarction. Heart. 2016 Mar:102(6):444-51.
- 4. A Novel Approach to Improve Time to First Shock in Prehospital STEMI Complicated by Ventricular Fibrillation. Osei-Ampofo M, Cheskes S, Byers A, Drennan IR, Buick JE, Verbeek PR. Prehosp Emerg Care. 2016;20(2):278-82.
- Welsford M, Nikolaou NI, Beygui F, Bossaert L, Ghaemmaghami C, Nonogi H, O'Connor RE, Pichel DR, Scott T, Walters DL, Woolfrey KG; Acute Coronary Syndrome Chapter Collaborators. Part 5: Acute Coronary Syndromes: 2015 International Consensus on Cardiopulmonary Resuscitation and Emergency Cardiovascular Care Science With Treatment Recommendations. Circulation. 2015 Oct 20;132(16 Suppl 1):S146-76.
- 6. Nam J, Caners K, Bowen JM, Welsford M, O'ReillyD. Systematic review and meta-analysis of the benefits of out-of-hospital 12-lead ECG and advance notification in ST-segment elevation myocardial infarction patients. Ann Emerg Med. 2014 Aug;64(2):176-86.
- Cone DC, Lee CH, Van Gelder C. EMS Activation of the Cardiac Catheterization Laboratory Is Associated with Process Improvements in the Care of Myocardial Infarction Patients. *Prehosp Emerg Care*. 2013 Jul-Sep;17(3):293-8
- 8. Mencl F, Wilber S, Frey J, Zalewski J, Maiers JF, Bhalla MC. Paramedic ability to recognize ST-segment elevation myocardial infarction on prehospital electrocardiograms. *Prehosp Emerg Care*. 2013 Apr-Jun;17(2):203-10.
- Bhalla MC, Mencl F, Gist MA, Wilber A, Zalewski J. Prehospital electrocardiographic computer identification of ST-segment elevation myocardial infarction. *Prehosp Emerg Care*. 2013 Apr-Jun;17(2):211-16.
- 10. Ryan D, Craig AM, Turner L, Verbeek PR. Clinical events and treatment in prehospital patients with ST-segment elevation myocardial infarction. *Prehosp Emerg Care*. 2013 Apr-Jun;17(2):181-86.
- 11. Cantor WJ, Hoogeveen P, Robert A, Elliott K, Goldman LE, Sanderson E, Plante S, Prabhakar M, Miner S. Prehospital diagnosis and triage of ST-elevation myocardial infarction by paramedics without advanced care training. *Am Heart J*. 2012 Aug;164(2):201-6.
- 12. Verbeek PR, Ryan D, Turner L, Craig AM. Prehospital 12-lead electrocardiograms increase identification of ST-segment elevation myocardial infarction. *Prehosp Emerg Care*. 2012 Jan-Mar;16(1):109-14.
- 13. Mathews R, Peterson ED, Li S, Roe MT, Glickman SW, Wiviott SD, Saucedo JF, Antman EM, Jacobs AK, Wang TY. Use of emergency medical service transport among patients with ST-segment-elevation myocardial infarction: findings from the National Cardiovascular Data Registry Acute Coronary Treatment Intervention Outcomes Network Registry-Get With the Guidelines. *Circulation*. 2011 Jul 12;124(2):154-63.
- 14. Kushner FG, Hand M, Smith SC Jr, King SB 3rd, Anderson JL, Antman EM, Bailey SR, Bates ER, Blankenship JC, Casey DJ Jr, Green LA, Hochman JS, Jacobs AK, Krumholz HM, Morrison DA, Ornato JP, Pearle DL, Peterson ED, Sloan MA, Whitlow PL, Williams DO. 2009 Focused updates: ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction (updating the 2004 guideline and 2007 focused update) and ACC/AHA/SCAI guidelines on percutaneous coronary intervention (updating the 2005 guideline and 2007 focused update): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2009;120:2271–2306.
- Bradley EH, Herrin J, Wang Y, Barton BA, Webster TR, Mattera JA, Roumanis SA, Curtis JP, Nallamothu BK, Magid DJ, McNamara RL, Parkosewich J, Loeb JM, Krumholz HM. Strategies for reducing the doorto-balloon time in acute myocardial infarction. N Engl J Med. 2006 Nov 30;355(22):2308-20.





Approved 9/04/24, Effective 1/15/25, replaces all prior versions







#### Medical Literature References 5D - Bradycardia – Adult & Pediatric

- Link MS, Atkins DL, Passman RS, Halperin HR, Samson RA, White RD, Cudnik MT, Berg MD, Kudenchuk PJ, Kerber RE. Part 6: electrical therapies: automated external defibrillators, defibrillation, cardioversion, and pacing: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. *Circulation*. 2010;122(suppl 3):S706–S719.
- Neumar RW, Otto CW, Link MS, Kronick SL, Shuster M, Callaway CW, Kudenchuk PJ, Ornato JP, McNally B, Silvers SM, Passman RS, White RD, Hess EP, Tang W, Davis D, Sinz E, Morrison LJ. Part 8: adult advanced cardiovascular life support: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. *Circulation*. 2010;122(suppl 3):S729–S767.
- 3. O'Connor RE, Brady W, Brooks SC, Diercks D, Egan J, Ghaemmaghami C, Menon V, O'Neil BJ, Travers AH, Yannopoulos D. Part 10: acute coronary syndromes: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. *Circulation*. 2010;122(suppl 3):S787–S817.
- Kleinman ME, Chameides L, Schexnayder SM, Samson RA, Hazinski MF, Atkins DL, Berg MD, de Caen AR, Fink EL, Freid EB, Hickey RW, Marino BS, Nadkarni VM, Proctor LT, Qureshi FA, Sartorelli K, Topjian A, van der Jagt EW, Zaritsky AL. Part 14: pediatric advanced life support: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation. 2010;122(suppl 3):S876–S908.
- 5. Sherbino J, Verbeek PR, MacDonald RD, Sawadsky BV, McDonald AC, Morrison LJ. Prehospital transcutaneous cardiac pacing for symptomatic bradycardia or bradyasystolic cardiac arrest: a systematic review. *Resuscitation*. 2006 Aug;70(2):193-200.





Approved 9/04/24, Effective 1/15/25, replaces all prior versions

### 5E – TRANSCUTANEOUS PACING ADULT & PEDIATRIC

#### **PARAMEDIC**

#### Indications:

- 1. Symptomatic 2nd Degree AV Block-Type II (Classic)
- 2. Symptomatic 3rd Degree AV Block (Complete)
- 3. Symptomatic Bradycardia in Acute Coronary Syndrome in preference to atropine use
- 4. Symptomatic Bradycardia unresponsive to non-electrical interventions
- 5. Symptomatic Bradycardia in pediatric patients (when approved by OLMCP consultation)


#### **Contraindications:**


1. Asymptomatic Bradycardia


#### Technique:

#### (Physio-Control LifePak® 15):

- 1. Maintain standard ECG monitoring using electrodes/cable.
- Apply Quik–Combo<sup>™</sup>pads in anterior/posterior chest wall location illustrated in (Figure 1). Excessive diaphoresis may require drying and/or excessive chest hair may require partial removal to achieve appropriate pad-chest wall adhesion.
- 3. Connect Quik-Combo<sup>™</sup> pad set to LifePak<sup>®</sup> monitor/defibrillator via attached cable.
- 4. Advise patient of impending therapy. Administer sedation if patient condition allows, adults to receive 2-5 mg midazolam IVP as individual patient weight and hemodynamics dictate.
- 5. Power on the pacing function by pressing the "PACER" button (Figure 2).
- 6. Confirm ECG rhythm is sensed by Quik-Combo™ pads, looking for triangular "sense markers" marking QRS complexes (Figure 3). If sense markers do not appear, check for correct Quik-Combo™ pad attachment to LifePak monitor/defibrillator. If sense markers are inconsistently tracking QRS complexes and/or tracking T waves, adjust ECG size or select alternate monitoring lead to achieve correct QRS complex tracking.













Approved 9/04/24, Effective 1/15/25, replaces all prior versions

#### PROTOCOL 5E: Transcutaneous Pacing, Adult & Pediatric, cont.

#### Technique (cont):

- 7. Set pacing **rate** at 60 paces per minute (adults) either by pressing the "RATE" switch up arrow to increase rate or down arrow to decrease rate or by rotating the "SPEED DIAL" knob (Figure 4). The "RATE" switch will allow changes in 10 paces per minute increments; the "SPEED DIAL" knob will allow changes in 5 paces per minute increments.
- 8. Set pacing **current** at minimum level achieving electrical AND mechanical capture. Deliver electrical pacing current either by pressing the "CURRENT" switch up arrow to increase milliAmp (mA) current or down arrow to decrease mA current or by rotating the "SPEED DIAL" knob (Figure 5). The "CURRENT" switch will allow changes in 10 mA increments; the "SPEED DIAL" knob will allow changes in 5 mA increments.
- Pressing the "PAUSE" button will cause the set pacing rate to decrease by 25% (eg. rate of 60 paces per minute changes to rate of 45 paces per minute) while it is being depressed. This function should not be used without directive from OLMC.
- 10. If pacing therapy termination is required, power off the pacing function by pressing the "PACER" button (Figure 2).





## Pacing-Related Considerations: (Physio-Control LifePak® 15):

- 1. In the event of ventricular fibrillation or pulseless ventricular tachycardia, pressing the yellow "CHARGE" button will automatically stop the pacing function. Proceed with defibrillation.
- 2. If the monitor displays "ECG LEAD OFF" during transcutaneous pacing, pacing automatically switches to non demand and continues at the fixed rate until the ECG lead(s) is reattached. During non demand pacing, the pacemaker delivers pulses at the set pace rate regardless of any intrinsic beats that the patient may have. The monitor continues to display the pacing rate and the current. To reestablish demand pacing, reattach the ECG lead(s).
- 3. If the Quik-Combo<sup>™</sup> electrodes detach during pacing, the monitor will display "CONNECT ELECTRODES" and "PACING STOPPED" messages and sound an alarm. The set pacing rate is maintained, but the current resets to 0 mA. Reattaching the Quik-Combo<sup>™</sup> electrodes silences the alarm and removes the messages. The current remains at 0 mA until manually adjusted as described above.






Approved 9/04/24, Effective 1/15/25, replaces all prior versions

### PROTOCOL 5E: Transcutaneous Pacing, Adult & Pediatric, cont.

#### Pacing-Related Considerations (cont):

- 4. Proper electrical capture is displayed by depolarization of the ventricles, reflected as a wide QRS, followed by a distinct, broad T wave (Figures 6 & 7). Absence of these findings immediately following pacing spikes generally indicates failure of consistent electrical and mechanical capture (Figures 8 & 9).
- 5. With transcutaneous pacing, it may be difficult to see the paced QRS complex due to washout from the pacing stimulus. It is imperative to confirm capture by a physiologic measure such as a pulse.








### Medical Literature References 5E – Transcutaneous Pacing – Adult & Pediatric

- Callaway CW, Soar J, Aibiki M, Böttiger BW, Brooks SC, Deakin CD, Donnino MW, Drajer S, Kloeck W, Morley PT, Morrison LJ, Neumar RW, Nicholson TC, Nolan JP, Okada K, O'Neil BJ, Paiva EF, Parr MJ, Wang TL, Witt J; Advanced Life Support Chapter Collaborators. Part 4: Advanced Life Support: 2015 International Consensus on Cardiopulmonary Resuscitation and Emergency Cardiovascular Care Science With Treatment Recommendations. *Circulation*. 2015 Oct 20;132(16 Suppl 1):S84-145.
- Welsford M, Nikolaou NI, Beygui F, Bossaert L, Ghaemmaghami C, Nonogi H, O'Connor RE, Pichel DR, Scott T, Walters DL, Woolfrey KG; Acute Coronary Syndrome Chapter Collaborators.
   Part 5: Acute Coronary Syndromes: 2015 International Consensus on Cardiopulmonary Resuscitation and Emergency Cardiovascular Care Science With Treatment Recommendations.
   *Circulation*. 2015 Oct 20;132(16 Suppl 1):S146-76.
- de Caen AR, Maconochie IK, Aickin R, Atkins DL, Biarent D, Guerguerian AM, Kleinman ME, Kloeck DA, Meaney PA, Nadkarni VM, Ng KC, Nuthall G, Reis AG, Shimizu N, Tibballs J, Veliz Pintos R; Pediatric Basic Life Support and Pediatric Advanced Life Support Chapter Collaborators. Part 6: Pediatric Basic Life Support and Pediatric Advanced Life Support: 2015 International Consensus on Cardiopulmonary Resuscitation and Emergency Cardiovascular Care Science With Treatment Recommendations. Circulation. 2015 Oct 20;132(16 Suppl 1):S177-203.
- 4. Morrison LJ, Long J, Vermeulen M, Schwartz B, Sawadsky B, Frank J, Cameron B, Burgess R, Shield J, Bagley P, Mausz V, Brewer JE, Dorian P. A randomized controlled feasibility trial comparing safety and effectiveness of prehospital pacing versus conventional treatment: 'PrePACE'. *Resuscitation*. 2008 Mar;76(3):341-9.
- 5. Cummins RO, Graves JR, Larsen MP, Hallstrom AP, Hearne TR, Ciliberti J, Nicola RM, Horan S. Out-of-hospital transcutaneous pacing by emergency medical technicians in patients with asystolic cardiac arrest. *N Engl J Med.* 1993 May 13;328(19):1377-82.





Approved 9/04/24, Effective 1/15/25, replaces all prior versions








### Medical Literature References 5F – Tachycardia - Stable – Adult & Pediatric

- 1. Çorbacıoğlu, Ş. K., Akıncı, E., Çevik, Y., Aytar, H., Öncül, M. V., Akkan, S., & Uzunosmanoğlu, H. (2017). Comparing the success rates of standard and modified Valsalva maneuvers to terminate PSVT: A randomized controlled trial. American Journal of Emergency Medicine. https://doi.org/10.1016/j.aiem.2017.05.034
- Callaway CW, Soar J, Aibiki M, Böttiger BW, Brooks SC, Deakin CD, Donnino MW, Drajer S, Kloeck W, Morley PT, Morrison LJ, Neumar RW, Nicholson TC, Nolan JP, Okada K, O'Neil BJ, Paiva EF, Parr MJ, Wang TL, Witt J; Advanced Life Support Chapter Collaborators. Part 4: Advanced Life Support: 2015 International Consensus on Cardiopulmonary Resuscitation and Emergency Cardiovascular Care Science With Treatment Recommendations. *Circulation*. 2015 Oct 20;132(16 Suppl 1):S84-145.
- 3. Welsford M, Nikolaou NI, Beygui F, Bossaert L, Ghaemmaghami C, Nonogi H, O'Connor RE, Pichel DR, Scott T, Walters DL, Woolfrey KG; Acute Coronary Syndrome Chapter Collaborators. Part 5: Acute Coronary Syndromes: 2015 International Consensus on Cardiopulmonary Resuscitation and Emergency Cardiovascular Care Science With Treatment Recommendations. *Circulation*. 2015 Oct 20;132(16 Suppl 1):S146-76.
- 4. de Caen AR, Maconochie IK, Aickin R, Atkins DL, Biarent D, Guerguerian AM, Kleinman ME, Kloeck DA, Meaney PA, Nadkarni VM, Ng KC, Nuthall G, Reis AG, Shimizu N, Tibballs J, Veliz Pintos R; Pediatric Basic Life Support and Pediatric Advanced Life Support Chapter Collaborators. Part 6: Pediatric Basic Life Support and Pediatric Advanced Life Support: 2015 International Consensus on Cardiopulmonary Resuscitation and Emergency Cardiovascular Care Science With Treatment Recommendations. *Circulation*. 2015 Oct 20;132(16 Suppl 1):S177-203.
- 5. Luk JH, Walsh B, Yasbin P. Safety and efficacy of prehospital diltiazem. *West J Emerg Med.* 2013 May;14(3):296-300.
- 6. Lim SH, Anantharaman V, Teo WS, Chan YH. Slow infusion of calcium channel blockers compared with intravenous adenosine in the emergency treatment of supraventricular tachycardia. Resuscitation. 2009 May;80(5):523-8.
- Riccardi A, Arboscello E, Ghinatti M, Minuto P, Lerza R. Adenosine in the treatment of supraventricular tachycardia: 5 years of experience (2002-2006). Am J Emerg Med. 2008 Oct;26(8):879-82.
- 8. DiMarco JP, Miles W, Akhtar M, Milstein S, Sharma AD, Platia E, McGovern B, Scheinman MM, Govier WC.Adenosine for paroxysmal supraventricular tachycardia: dose ranging and comparison with verapamil. Assessment in placebo-controlled, multicenter trials. The Adenosine for PSVT Study Group. *Ann Intern Med.* 1990 Jul 15;113(2):104-10.





Approved 9/04/24, Effective 1/15/25, replaces all prior versions







Medical Literature References 5G – Tachycardia - Unstable – Adult & Pediatric

- Lavonas EJ, Drennan IR, Gabrielli A, Heffner AC, Hoyte CO, Orkin AM, Sawyer KN, Donnino MW. Part 10: Special Circumstances of Resuscitation: 2015 American Heart Association Guidelines Update for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. *Circulation*. 2015 Nov 3;132(18 Suppl 2):S501-18.
- Callaway CW, Soar J, Aibiki M, Böttiger BW, Brooks SC, Deakin CD, Donnino MW, Drajer S, Kloeck W, Morley PT, Morrison LJ, Neumar RW, Nicholson TC, Nolan JP, Okada K, O'Neil BJ, Paiva EF, Parr MJ, Wang TL, Witt J; Advanced Life Support Chapter Collaborators. Part 4: Advanced Life Support: 2015 International Consensus on Cardiopulmonary Resuscitation and Emergency Cardiovascular Care Science With Treatment Recommendations. *Circulation*. 2015 Oct 20;132(16 Suppl 1):S84-145.
- Welsford M, Nikolaou NI, Beygui F, Bossaert L, Ghaemmaghami C, Nonogi H, O'Connor RE, Pichel DR, Scott T, Walters DL, Woolfrey KG; Acute Coronary Syndrome Chapter Collaborators.
   Part 5: Acute Coronary Syndromes: 2015 International Consensus on Cardiopulmonary Resuscitation and Emergency Cardiovascular Care Science With Treatment Recommendations.
   *Circulation*. 2015 Oct 20;132(16 Suppl 1):S146-76.
- 4. de Caen AR, Maconochie IK, Aickin R, Atkins DL, Biarent D, Guerguerian AM, Kleinman ME, Kloeck DA, Meaney PA, Nadkarni VM, Ng KC, Nuthall G, Reis AG, Shimizu N, Tibballs J, Veliz Pintos R; Pediatric Basic Life Support and Pediatric Advanced Life Support Chapter Collaborators. Part 6: Pediatric Basic Life Support and Pediatric Advanced Life Support: 2015 International Consensus on Cardiopulmonary Resuscitation and Emergency Cardiovascular Care Science With Treatment Recommendations. *Circulation*. 2015 Oct 20;132(16 Suppl 1):S177-203.
- 5. Ong ME, Pellis T, Link MS. The use of antiarrhythmic drugs for adult cardiac arrest: a systematic review. *Resuscitation*. 2011 Jun;82(6):665-70.
- 6. Marill KA, deSouza IS, Nishijima DK, Stair TO, Setnik GS, Ruskin JN. Amiodarone is poorly effective for the acute termination of ventricular tachycardia. *Ann Emerg Med.* 2006 Mar;47(3):217-24.
- 7. Somberg JC, Bailin SJ, Haffajee CI, Paladino WP, Kerin NZ, Bridges D, Timar S, Molnar J; Amio-Aqueous Investigators. Intravenous lidocaine versus intravenous amiodarone (in a new aqueous formulation) for incessant ventricular tachycardia. *Am J Cardiol*. 2002 Oct 15;90(8):853-9.





Approved 9/04/24, Effective 1/15/25, replaces all prior versions

## 5H – SYNCHRONIZED CARDIOVERSION ADULT & PEDIATRIC

#### **PARAMEDIC**

#### Indication:

Unstable, symptomatic tachycardia (adult heart rate > 150 beats per minute; afebrile pediatric heart rate > 180 beats per minute) AND hemodynamic compromise adult systolic blood pressure <100 mmHg; pediatric systolic blood pressure < (70 + 2x age in years) mmHg.


#### Contraindications:


- 1. Stable tachycardia (Treatment per Protocol 5F Stable Tachycardia)
- 2. Normal sinus rhythm
- 3. Bradycardia
- 4. Ventricular fibrillation/pulseless ventricular tachycardia

#### Technique (Physio-Control LifePak® 15):

- 1. Power **ON**. (Figure 1)
- 2. Attach patient ECG cable and ECG electrodes. ECG electrodes and cable must be used to monitor the ECG when paddles are used for synchronized cardioversion.
- 3. Select lead with the greatest QRS complex amplitude positive or negative deflection. (Figure 2)
- 4. Press **SYNC**. The **SYNC MODE** message appears in the message area when **SYNC** is active. (Figure 3)
  - a. **NOTE:** To deactivate **SYNC MODE** when not synchronized cardioverting, press **SYNC** again.













Approved 9/04/24, Effective 1/15/25, replaces all prior versions


Protocol 5H: Synchronized Cardioversion, Adult & Pediatric, cont.

Technique (cont):


- 5. Observe the ECG rhythm. Confirm that a triangle sense marker (▼) appears near the MIDDLE of each QRS complex. (Figure 4)
  - a. If the sense markers DO NOT appear or are displayed in the wrong location (for example on the T wave) adjust ECG SIZE or select another lead. It is normal for the sense marker location to vary slightly on each QRS.
- Connect the therapy electrodes to the therapy cable and confirm cable connection to the monitor/defibrillator. (Figure 5)
- 7. Prepare the patient's skin and apply therapy electrodes to the patient in the anterior-posterior chest wall position. (Figure 6)
- 8. Press **ENERGY SELECT** or rotate the **SPEED DIAL** to select the desired energy. (Figure 7) Per Protocol 5G Tachycardia Unstable, for adult synchronized cardioversion, begin at 100 joules energy. If unstable tachydysrhythmia persists, repeat synchronized cardioversion at escalating energy settings of 200 joules, 300 joules, 360 joules. For pediatric synchronized cardioversion, consult on-line medical control for treatment plan and energy settings.
- Press CHARGE. While the monitor/defibrillator is charging a charging bar appears and a ramping tone sounds, indicating the charging energy level. When the monitor/defibrillator is fully charged, the screen displays available energy. (Figure 8)

















Approved 9/04/24, Effective 1/15/25, replaces all prior versions

Protocol 5H: Synchronized Cardioversion, Adult & Pediatric, cont.

#### Technique (cont):

- 10. Make certain all personnel, including the operator, stand clear of the patient, bed, and any equipment connected to the patient.
- 11. Confirm ECG rhythm. Confirm available energy. Prior to delivering synchronized cardioversion, it is paramount to ensure that the SYNC MODE message continues to appear. Failure to deliver a "synchronized" cardioversion in this setting could cause ventricular fibrillation cardiac arrest in the patient. (Figure 9)
- 12. Press and hold the (shock) button on the monitor/defibrillator until the **ENERGY DELIVERED** message appears on the screen. (Figure 10)
  - a. NOTE: To disarm (cancel the charge), press the SPEED DIAL. The energy disarms automatically if shock buttons are not pressed within 60 seconds, or if the energy selection after charging begins.
- 13. Observe patient and ECG rhythm. Repeat procedure starting from Step 4, if necessary.









### Medical Literature References 5H – Synchronized Cardioversion – Adult & Pediatric

- Callaway CW, Soar J, Aibiki M, Böttiger BW, Brooks SC, Deakin CD, Donnino MW, Drajer S, Kloeck W, Morley PT, Morrison LJ, Neumar RW, Nicholson TC, Nolan JP, Okada K, O'Neil BJ, Paiva EF, Parr MJ, Wang TL, Witt J; Advanced Life Support Chapter Collaborators. Part 4: Advanced Life Support: 2015 International Consensus on Cardiopulmonary Resuscitation and Emergency Cardiovascular Care Science With Treatment Recommendations. *Circulation*. 2015 Oct 20;132(16 Suppl 1):S84-145.
- de Caen AR, Maconochie IK, Aickin R, Atkins DL, Biarent D, Guerguerian AM, Kleinman ME, Kloeck DA, Meaney PA, Nadkarni VM, Ng KC, Nuthall G, Reis AG, Shimizu N, Tibballs J, Veliz Pintos R; Pediatric Basic Life Support and Pediatric Advanced Life Support Chapter Collaborators. Part 6: Pediatric Basic Life Support and Pediatric Advanced Life Support: 2015 International Consensus on Cardiopulmonary Resuscitation and Emergency Cardiovascular Care Science With Treatment Recommendations. *Circulation*. 2015 Oct 20;132(16 Suppl 1):S177-203.
- 3. Marill KA, deSouza IS, Nishijima DK, Stair TO, Setnik GS, Ruskin JN. Amiodarone is poorly effective for the acute termination of ventricular tachycardia. *Ann Emerg Med.* 2006 Mar;47(3):217-24.
- 4. Slovis CM, Kudenchuk PJ, Wayne MA, Aghababian R, Rivera-Rivera EJ. Prehospital management of acute tachyarrhythmias. *Prehosp Emerg Care*. 2003 Jan-Mar;7(1):2-12.
- 5. Somberg JC, Bailin SJ, Haffajee CI, Paladino WP, Kerin NZ, Bridges D, Timar S, Molnar J; Amio-Aqueous Investigators. Intravenous lidocaine versus intravenous amiodarone (in a new aqueous formulation) for incessant ventricular tachycardia. *Am J Cardiol*. 2002 Oct 15;90(8):853-9.





Approved 9/04/24, Effective 1/15/25, replaces all prior versions

## 5I - IMPLANTABLE PACEMAKER MANAGEMENT ADULT & PEDIATRIC

#### **PARAMEDIC**

### Clinical Pearls:

- 1. Correlate electrical pacing activity with mechanical heart activity (eg. pulses).
- 2. If electrical pacer spikes seen on the ECG monitor are not consistently and immediately followed by electrical activity of atrial, ventricular, or both atrial and ventricular depolarization, then the pacemaker may be intermittently functioning. This may be normal if the patient's heart rate is above 60 beats per minute, since most pacemakers will be set to a demand mode (pacing only when needed). Alternately, if the patient is bradycardic, the pacemaker may be non-functional (eg. battery failure).
- 3. The "sensor function" of a pacemaker attempts to anticipate increased metabolic needs and raises heart rate. The most commonly used sensor is an accelerometer which raises pacing rate when motion is detected. Thus, physical motion of the patient (including motion created by riding on the ambulance stretcher enroute to the hospital) can stimulate increasing rates of pacing. If the paced rate is noticeably higher than usual set rates of 60-80 beats per minute, attempt to minimize the patient's physical motion and observe if pacing rates decline.
- 4. Due to the variety of pacemaker types and settings, pacemaker manufacturers supply patients with a card to be carried (usually in wallet or purse) that identifies the pacemaker by manufacturer, type, and date of implantation.
- 5. Specific types of pacemaker malfunction include the following:
  - a. Failure to pace/output no pacing spikes seen in a bradycardic patient. (example, oversensing of myopotentials, dead battery)
  - b. Failure to sense pacing becomes asynchronous. (example, patient's heart voltage too low for pacer to sense)
  - c. Failure to capture pacing spikes seen without capture. (examples, lead becomes dislodged from myocardium or breaks)
  - d. Overpacing or "runaway pacing" pacemaker pacing at fast rates without clear reason. (examples, sensor-driven pacing from motion, pacemaker-mediated tachycardia)
- 6. In the setting of sustained, symptomatic rapid pacing suspected to be related to overpacing (see Item 4 above) tachycardia may be able to be controlled by placing a doughnut-shaped medical magnet over the generator.
- 7. In the setting of cardiac arrest, treat per usual resuscitation, but avoid placing defibrillation pads over the pacemaker generator.
- 8. Consult on-line medical control early in the course of suspected pacemaker management issues for further guidance.





### Medical Literature References 5I – Pacemaker Management – Adult & Pediatric

- Callaway CW, Soar J, Aibiki M, Böttiger BW, Brooks SC, Deakin CD, Donnino MW, Drajer S, Kloeck W, Morley PT, Morrison LJ, Neumar RW, Nicholson TC, Nolan JP, Okada K, O'Neil BJ, Paiva EF, Parr MJ, Wang TL, Witt J; Advanced Life Support Chapter Collaborators. Part 4: Advanced Life Support: 2015 International Consensus on Cardiopulmonary Resuscitation and Emergency Cardiovascular Care Science With Treatment Recommendations. *Circulation*. 2015 Oct 20;132(16 Suppl 1):S84-145.
- 2. Allison MG, Mallemat HA. Emergency care of patients with pacemakers and defibrillators. *Emerg Med Clin North Am.* 2015 Aug;33(3):653-7.
- 3. Neuenschwander JF 2nd.Cardiac devices in emergency department heart failure patients. *Heart Fail Clin.* 2009 Jan;5(1):63-73, vi-vii.
- 4. McMullan J, Valento M, Attari M, Venkat A. Care of the pacemaker/implantable cardioverter defibrillator patient in the ED. *Am J Emerg Med.* 2007 Sep;25(7):812-22.





Approved 9/04/24, Effective 1/15/25, replaces all prior versions

## 5J - IMPLANTABLE CARDIOVERTER/DEFIBRILLATOR (ICD) MANAGEMENT ADULT & PEDIATRIC

#### **PARAMEDIC**

#### Clinical Pearls:

- 1. Correlate ICD activity with ECG rhythm ventricular fibrillation/tachycardia?
- Due to the variety of ICDs, manufacturers supply patients with a card to be carried (usually in wallet or purse) that identifies the ICD by manufacturer, type, and date of implantation.
- 3. All ICDs have pacemaker function. Some patients have pacing indications and may have normal or abnormal pacemaker function (see 5I Pacemaker Management) associated with their ICD. Many patients with ICDs, however, do not have a pacemaker indication.
- 4. Specific types of ICD malfunction include the following:
  - a. Inappropriate ICD shocks Patient is shocked without evidence of arrhythmia (examples, lead fracture, oversensing of t-waves)
  - Failure to shock ventricular tachycardia/fibrillation (examples, undersensing of small fibrillatory waves, slow ventricular tachycardia below the ICD's programmed VT zone)
- 5. If the patient is hemodynamically stable, acquire and transmit a 12-Lead ECG prior to attempting any change in ICD function.
- 6. In the setting of oversensing, especially if multiple apparently inappropriate ICD discharges occur, the ICD may be temporarily deactivated by placing a doughnut-shaped medical magnet over the ICD generator. Depending upon the exact model of ICD, a beep or sustained tone may be heard with successful magnet application.
- 7. While the magnet is applied to the ICD, no therapies will be delivered even when needed for life-threatening arrhythmias. Therefore, PRIOR TO DEACTIVATING AN ICD WITH A MAGNET, THE PATIENT MUST BE ON CONTINUOUS ECG MONITORING AND A DEFIBRILLATOR MUST BE IMMEDIATELY AVAILABLE.
- 8. In the setting of cardiac arrest, treat per usual resuscitation, but avoid placing defibrillation pads over the ICD generator.
- 9. Consult on-line medical control early in the course of suspected ICD management issues for further guidance.





### Medical Literature References 5J – Implantable Cardioverter/Defibrillator (AICD) Management – Adult & Pediatric

- Travers AH, Perkins GD, Berg RA, Castren M, Considine J, Escalante R, Gazmuri RJ, Koster RW, Lim SH, Nation KJ, Olasveengen TM, Sakamoto T, Sayre MR, Sierra A, Smyth MA, Stanton D, Vaillancourt C; Basic Life Support Chapter Collaborators. Part 3: Adult Basic Life Support and Automated External Defibrillation: 2015 International Consensus on Cardiopulmonary Resuscitation and Emergency Cardiovascular Care Science With Treatment Recommendations. *Circulation*. 2015 Oct 20;132(16 Suppl 1):S51-83.
- Callaway CW, Soar J, Aibiki M, Böttiger BW, Brooks SC, Deakin CD, Donnino MW, Drajer S, Kloeck W, Morley PT, Morrison LJ, Neumar RW, Nicholson TC, Nolan JP, Okada K, O'Neil BJ, Paiva EF, Parr MJ, Wang TL, Witt J; Advanced Life Support Chapter Collaborators. Part 4: Advanced Life Support: 2015 International Consensus on Cardiopulmonary Resuscitation and Emergency Cardiovascular Care Science With Treatment Recommendations. *Circulation*. 2015 Oct 20;132(16 Suppl 1):S84-145.
- 3. Protocol expert consultant: David Sandler, MD. Oklahoma Heart Institute, Tulsa. Board certified in clinical cardiac electrophysiology, cardiovascular disease, and internal medicine by the American Board of Internal Medicine.
- 4. Lee JK, Blossfield K. Chapter 24. Automatic Implantable Cardioverter-Defibrillator Assessment. In: Reichman EF, Simon RR, eds. Emergency Medicine Procedures. New York: McGraw-Hill; 2004. http://www.accessemergencymedicine.com/content.aspx?aID=48546. Accessed June 30, 2012.
- Piktel JS. Chapter 22. Cardiac Rhythm Disturbances. In: Tintinalli JE, Kelen GD, Stapczynski JS, eds. Tintinalli's Emergency Medicine: A Comprehensive Study Guide. 7th ed. New York: McGraw-Hill; 2011. http://www.accessemergencymedicine.com/content.aspx?aID=6357092. Accessed June 29, 2012.
- 6. Neuenschwander JF 2nd. Cardiac devices in emergency department heart failure patients. *Heart Fail Clin.* 2009 Jan;5(1):63-73, vi-vii.
- 7. McMullan J, Valento M, Attari M, Venkat A. Care of the pacemaker/implantable cardioverter defibrillator patient in the ED. *Am J Emerg Med.* 2007 Sep;25(7):812-22.
- 8. Munter DW, DeLacey WA. Automatic implantable cardioverter-defibrillators. *Emerg Med Clin North Am.* 1994 Aug;12(3):579-95.





Approved 9/04/24, Effective 1/15/25, replaces all prior versions


#### **5K - PREMATURE VENTRICULAR CONTRACTIONS ADULT & PEDIATRIC**

#### TREATMENT PRIORITIES

- 1. O2 via NC or NRB if indicated
- 2. 12-Lead ECG
- 3. Rhythm Analysis

UNSTABLE (SYMPTOMATIC) premature ventricular contractions are defined by any of the following symptoms:

- 1. Dyspnea
- Chest pain
- 3. Weakness
- Altered mental status
- 5. Hypoxemia6. Pulmonary Pulmonary edema



#### **PARAMEDIC**

ASYMPTOMATIC PVCs DO NOT REQUIRE ANTI-DYSRHYTHMIC MEDICATION.

TREAT IF UNSTABLE WITH SYMPTOMS AND ADULT SYS BP < 100 mmHg

DO NOT PHARMACOLOGICALLY SUPPRESS PVCs IN 2<sup>nd</sup> / 3<sup>rd</sup> DEGREE HEART BLOCKS ADULT: AMIODARONE 150mg VERY SLOW IVP/IVPB OVER 10 MINUTES.

PEDIATRIC: OLMC CONSULT





### Medical Literature References 5K – Premature Ventricular Contractions – Adult & Pediatric

- Callaway CW, Soar J, Aibiki M, Böttiger BW, Brooks SC, Deakin CD, Donnino MW, Drajer S, Kloeck W, Morley PT, Morrison LJ, Neumar RW, Nicholson TC, Nolan JP, Okada K, O'Neil BJ, Paiva EF, Parr MJ, Wang TL, Witt J; Advanced Life Support Chapter Collaborators. Part 4: Advanced Life Support: 2015 International Consensus on Cardiopulmonary Resuscitation and Emergency Cardiovascular Care Science With Treatment Recommendations. *Circulation*. 2015 Oct 20;132(16 Suppl 1):S84-145.
- de Caen AR, Maconochie IK, Aickin R, Atkins DL, Biarent D, Guerguerian AM, Kleinman ME, Kloeck DA, Meaney PA, Nadkarni VM, Ng KC, Nuthall G, Reis AG, Shimizu N, Tibballs J, Veliz Pintos R; Pediatric Basic Life Support and Pediatric Advanced Life Support Chapter Collaborators. Part 6: Pediatric Basic Life Support and Pediatric Advanced Life Support: 2015 International Consensus on Cardiopulmonary Resuscitation and Emergency Cardiovascular Care Science With Treatment Recommendations. *Circulation*. 2015 Oct 20;132(16 Suppl 1):S177-203.
- 3. Omar AR, Lee LC, Seow SC, Teo SG, Poh KK. Managing ventricular ectopics: are ventricular ectopic beats just an annoyance? *Singapore Med J.* 2011 Oct;52(10):707-13.
- 4. Van Herendael H, Dorian P. Amiodarone for the treatment and prevention of ventricular fibrillation and ventricular tachycardia. *Vasc Health Risk Manag.* 2010 Aug 9;6:465-72.
- 5. Marill KA, deSouza IS, Nishijima DK, Stair TO, Setnik GS, Ruskin JN. Amiodarone is poorly effective for the acute termination of ventricular tachycardia. *Ann Emerg Med.* 2006 Mar;47(3):217-24.
- 6. Somberg JC, Bailin SJ, Haffajee CI, Paladino WP, Kerin NZ, Bridges D, Timar S, Molnar J; Amio-Aqueous Investigators. Intravenous lidocaine versus intravenous amiodarone (in a new aqueous formulation) for incessant ventricular tachycardia. *Am J Cardiol*. 2002 Oct 15;90(8):853-9.
- 7. Dorian P, Cass D, Schwartz B, Cooper R, Gelaznikas R, Barr A. Amiodarone as compared with lidocaine for shock-resistant ventricular fibrillation. *N Engl J Med.* 2002 Mar 21;346(12):884-90.





Removed by MCB September 11, 2013

5L - HYPERTENSIVE EMERGENCY ADULT & PEDIATRIC





#### Medical Literature References 5L – Hypertensive Emergency – Adult& Pediatric


- 1. Peacock WF 4th, Hilleman DE, Levy PD, Rhoney DH, Varon J. A systematic review of nicardipine vs labetalol for the management of hypertensive crises. *Am J Emerg Med.* 2012 Jul;30(6):981-93.
- 2. Marik PE, Rivera R. Hypertensive emergencies: an update. *Curr Opin Crit Care*. 2011 Dec;17(6):569-80.
- 3. Baumann BM, Cline DM, Pimenta E. Treatment of hypertension in the emergency department. *J Am Soc Hypertens*. 2011 Sep-Oct;5(5):366-77.
- 4. Mayer SA, Kurtz P, Wyman A, Sung GY, Multz AS, Varon J, Granger CB, Kleinschmidt K, Lapointe M, Peacock WF, Katz JN, Gore JM, O'Neil B, Anderson FA; STAT Investigators. Clinical practices, complications, and mortality in neurological patients with acute severe hypertension: the Studying the Treatment of Acute Hypertension Registry. *Crit Care Med.* 2011 Oct;39(10):2330-6.
- 5. Jauch EC, Cucchiara B, Adeoye O, Meurer W, Brice J, Chan Y-F, Gentile N, Hazinski MF. Part 11: adult stroke: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. *Circulation*. 2010;122(suppl 3):S818–S828.



Approved 9/04/24, Effective 1/15/25, replaces all prior versions




### 5M – VENTRICULAR ASSIST DEVICE (VAD) MANAGEMENT ADULT & PEDIATRIC



A **Ventricular Assist Device**, or **VAD**, is a mechanical device used to support circulation in a patient with significant cardiac ventricular dysfunction. The VAD, most commonly, is used to support the left side of the heart and provide extra cardiac output to the body. This device is called an LVAD or left ventricular assist device. An LVAD can be placed for short term use to bridge patients until they can receive a heart transplant (bridge to transplant) or long term use for those patients that are not candidates for heart transplant (destination therapy). A destination therapy patient will live for months to years at home with the device in place. A VAD is <u>not</u> a total artificial heart (TAH), which completely supports circulation in a patient whose native heart has been removed.

VADs can assist either the right (RVAD) or left (LVAD) ventricle, or both at once (BiVAD). The choice of device depends on underlying heart disease and the function of the right side of the heart. The most common type of device used is an LVAD.

In Oklahoma the most common VAD in use is the HeartMate<sup>®</sup> 3 LVAD which is replacing the LVAD II models. The Heart Mate<sup>®</sup> II and 3 uses a continuous flow pumping action to produce forward circulation. Because of the continuous flow nature of the pump, a patient with a HeartMate II and 3<sup>®</sup> may not have a palpable pulse even though they are alive. The lack of pulse can also make it difficult, or impossible to obtain a blood pressure.



- 1) Implanted Pump
- 2) Inflow Cannula
- 3) Outflow Conduit
- 4) Percutaneous Cable
- 5) Controller
- 6) Wearable Battery



MEDICINE
UNIVERSITY OF OKLAHOMA

\*\* EMS SECTION

Approved 9/04/24, Effective 1/15/25, replaces all prior versions

PROTOCOL 5M: Ventricular Assist Device (VAD) Management – Adult and Ped. cont.

#### Hospital Resources in Oklahoma for Patients with a VAD and TAH:

Oklahoma City: Integris Baptist Medical Center OU Children's Hospital

Tulsa: Hillcrest Hospital

St. Francis (coming online at the end of 2024)

Upon arrival to the scene, contact a VAD coordinator for assistance with VAD/TAH related questions. An RN coordinator is available 24-hours a day.

24-hour Integris Baptist Medical Center VAD/TAH phone number: 405-713-7040 24-hour OU Children's Hospital VAD/TAH phone number: 572-568-1048 24-hour Hillcrest Hospital VAD/TAH phone number: 918-370-6948

#### Cardiac Arrest Care in Patients with a VAD:

Follow same BLS and ACLS protocols (including defibrillation and cardioversion). OU Children's requests NO CPR Hillcrest Hospital requests NO CPR if VAD is working

Perform chest compressions only after all other treatments have been applied.

Because of the assistance from the LVAD, patients may not be symptomatic with ventricular arrhythmias. Be sure to assess the patient first prior to intervention.

The LVAD does NOT interfere with the patient's heart rhythm. The native rhythm will appear on the monitor.

#### Non-Cardiac Arrest Care in Patients with a VAD:

Emergencies in a patient with a VAD can arise due to:

- Problems directly related to the VAD:
  - → Power Failure
  - Suspected mechanical malfunctions characterized by frequent alarms emitting from the system controller, an increase or decrease in flow rates
- Focus on switching out the system controller. (see directions below)
- Illness/Injury not related to the VAD treat per applicable protocol. (i.e. stroke, bleeding, etc.)

#### Power Failure of a VAD - EMS Assessment & Care:

- A patient experiencing a power failure with their VAD system will present with signs and symptoms of circulatory collapse (dyspnea, hypoxemia, hypotension, dysrhythmias, altered mental status).
- Focus on restoring power to the VAD by switching batteries in the battery pack, connecting to an AC power source, or switching out the system controller.





Approved 9/04/24, Effective 1/15/25, replaces all prior versions

PROTOCOL 5M: Ventricular Assist Device (VAD) Management – Adult and Ped. cont.

TROUBLESHOOTING: Heart Mate® II or 3

#### When the Pump Has Stopped

- Check the connections between the controller and the pump and the power source and fix any loose connections.
- If the pump does not restart and the patient is connected to batteries replace the current batteries with a new, fully-charged pair.
- If pump does not restart, change controllers.

#### **Changing Controllers:**



1. To insert the driveline, slide the safety tab back to unlock and expose the red button



2. Align the arrow on the controller to the arrow on the driveline cable until they connect, and firmly insert the driveline until it snaps into place



3. Be sure to slide the safety tab back over the red button, locking the driveline in place.



4. Tug gently on the metal portion of the driveline to ensure it is fully engaged.





Approved 9/04/24, Effective 1/15/25, replaces all prior versions

PROTOCOL 5M: Ventricular Assist Device (VAD) Management – Adult & Ped. cont.

#### **Alarms: Emergency Procedures**

#### Low Battery Alarm

The red low battery symbol illuminates when less than 5 minutes of battery power remain (applicable only during 14 Volt Lithium-Ion battery-powered operation).



This is a **Hazard** alarm. When the red battery symbol illuminates, immediately replace the depleted batteries with a fully-charged pair, or switch to the Power Module.

#### Yellow Wrench Alarm

The yellow wrench symbol illuminates when the System Controller detects a mechanical, electrical, or software issue with the system.




This is an **Advisory** alarm. When the yellow wrench illuminates, check the screen for troubleshooting instructions.

#### Red Heart Alarm

The red heart symbol illuminates when the System Controller detects a problem that could cause serious injury or death.



This is a **Hazard** alarm. When the red heart illuminates, check the screen for instructions and take immediate action to resolve the problem.










Approved 9/04/24, Effective 1/15/25, replaces all prior versions

PROTOCOL 5M: Ventricular Assist Device (VAD) Management – Adult & Ped. cont.

TROUBLESHOOTING: Heart Mate® II or 3

#### **Changing Batteries**

- 1. Warning: At least one power lead must be connected to a power source at all times.
- 2. **DO NOT remove** both batteries at the same time or the pump will stop.
- 3. Obtain two charged batteries from patient's black bag.
- 4. Check the charge of the battery by pressing the battery gauge button on the end and top of the battery. (Figure 1)
- 5. Remove <u>only one battery</u> from the clip by pressing the tab on the battery clip to release the battery.
- 6. Controller will start beeping and flashing green lights.
- 7. Replace with new fully charged battery by lining up the arrows on the battery and the clip and pressing until you hear a "click."
- 8. Repeat previous steps with the second battery and battery clip. Remove only one battery from the clip by pressing the tab on the battery clip to release the battery.










Approved 9/04/24, Effective 1/15/25, replaces all prior versions

PROTOCOL 5M: Ventricular Assist Device (VAD) Management - Adult and Ped. cont.

#### HeartMate II® or 3 LVAD Patient Assessment protocol







Approved 9/04/24, Effective 1/15/25, replaces all prior versions

PROTOCOL 5M: Ventricular Assist Device (VAD) Management – Adult & Ped, cont.

### Always transport black "GO BAG" with patient to hospital

#### HeartMate 3" LVAS SYSTEM OVERVIEW

### System Components



10007367.C | filem approved for U.S. use only.






Approved 9/04/24, Effective 1/15/25, replaces all prior versions

PROTOCOL 5M: Ventricular Assist Device (VAD) Management – Adult & Ped, cont.

#### **Total Artificial Heart**

#### Overview:



#### **Basic Operations**

- 1. Pump is connected to 2 drivelines (air lines) that are attached to the driver, which runs the pump
- 2. Do not kink the drivelines.
- 3. The electrical conduction system of the heart has been removed so a heart rhythm cannot be viewed on the ECG.
- 4. Batteries last approximately 2 hours for a set.
- 5. Plug the driver into an outlet as often as possible for power.



EMERGENCY
MEDICINE
UNIVERSITY OF OKLAHOMA

\*\* EMS SECTION

Approved 9/04/24, Effective 1/15/25, replaces all prior versions

PROTOCOL 5M: Ventricular Assist Device (VAD) Management – Adult & Ped, cont.

#### **Total Artificial Heart**

# When the Pump Has Stopped: Immediately switch to the back-up driver.

### **Changing to the Back-Up Driver**


- With the Wire Cutter Tool, cut the Wire Tie under the metal release button of the CPC Connector that secures the red TAH Cannula to the red Freedom Driveline. DO NOT DISCONNECT THE CANNULA FROM THE DRIVELINE YET.
- With the Wire Cutter Tool, cut the Wire Tie under the metal release button of the CPC Connector that secures the blue TAH Cannula to the blue Freedom Driveline. DO NOT DISCONNECT THE CANNULA FROM THE DRIVELINE YET.



CAUTION: Before disconnecting the Drivelines of the primary Freedom Driver, you must have the Drivelines of the backup Freedom Driver within reach. The backup Driver must be turned on by inserting 2 batteries. Perform steps 3 and 4 simultaneously.

- 3. Disconnect the **red** Cannula from the **red** Driveline of the primary Freedom Driver.
- 4. Press and hold down the metal release button. (Fig. 11)
- 5. Pull the **red** Cannula away from the **red** Driveline (Figure 12). **Immediately** insert the **red** Cannula into the new **red** Driveline from the backup Freedom Driver until you hear a click.
- **6. Simultaneously** disconnect the **blue** Cannula from the **blue** Driveline of the primary Freedom Driver.
- 7. Press and hold down the metal release button.
- **8.** Pull the **blue** Cannula away from the **blue** Driveline.
- Immediately insert the blue Cannula into the new blue Driveline from the back-up Freedom Driver until you hear a click.









Approved 9/04/24, Effective 1/15/25, replaces all prior versions

PROTOCOL 5M: Ventricular Assist Device (VAD) Management – Adult & Ped, cont.

#### **Total Artificial Heart**

#### Treatment Considerations:

- 1. External chest compressions cannot be performed on a patient with a Total Artificial Heart. Changing to the back-up driver is essential to maintaining circulation. There's no "hand-pump" to operate the Total Artificial Heart manually.
- 2. If the pump stops, a red fault alarm along with a continuous audio tone will sound.
- 3. All device settings are preset and cannot be changed in the field.
- Since the electrical conduction system of the heart has been removed the underlying ECG rhythm will show asystole. The patient with a Total Artificial Heart should not be defibrillated.
- 5. If the driver pump is connected and functioning properly, the patient will have a pulse.
- 6. A measurable blood pressure is obtainable using a manual or automated blood pressure device.
- 7. Use alternative ways to assess the adequacy of perfusion such as pale vs. pink, dry vs. diaphoretic, and alert vs. confused.
- 8. Incorporate device into assessment.
- 9. General Supportive Care and initiate treatment per applicable protocol.
- 10. Listen just below the heart to hear if the device is running and assess for a palpable pulse.
- 11. If there is no palpable pulse detected, consider the following:
  - The device is not running: Troubleshoot the device and treat per protocol.
  - The device is running, but the patient is still unconscious or unstable:
    - o Neurological evaluation: Possible Stroke
    - Expose the patient:
      - Be cautious with trauma shears; don't cut a driveline or cable exiting the patient's body that might be hidden under an article of clothing;
      - Assess the dressings over the driveline exit site (found in the abdominal area) for signs of infection.





### Medical Literature References 5M – Ventricular Assist Device Management – Adult

- 1. Stenberg, R., & Shenvi, C. (2020). Targeted Evaluation of Patients With Left Ventricular Assist Devices and Shock or Hypotension. In *Annals of Emergency Medicine* (Vol. 76, Issue 1, pp. 34–41). Mosby Inc. https://doi.org/10.1016/j.annemergmed.2020.01.003
- The Emergency Management of Ventricular Assist Devices. Robertson J, Long B, Koyman A. Am J Emerg Med. 2016 Jul; 34(7):1294-301
- 3. Mechem CC. Prehospital assessment and management of patients with ventricular-assist devices. *Prehosp Emerg Care*. 2013 Apr-Jun;17(2):223-9.
- 4. Integris Baptist VAD Program Nurse Coordinators Review of Protocol in June of 2012.
- 5. Patel P, Williams JG, Brice JH. Sustained ventricular fibrillation in an alert patient: preserved hemodynamics with a left ventricular assist device. *Prehosp Emerg Care*. 2011 Oct-Dec;15(4):533-6.
- 6. Keseg DP. Pumping life into failing hearts. What EMS providers should know about ventricular assist devices. *EMS World*. 2011 Mar;40(3):55-9.
- 7. Busch MC, Haap M, Kristen A, Haas CS. Asymptomatic sustained ventricular fibrillation in a patient with left ventricular assist device. *Ann Emerg Med.* 2011 Jan;57(1):25-8.
- 8. Walters WA, Wydro GC, Hollander T, Brister N. Transport of the ventricular assist device-supported patient: a case series. *Prehosp Emerg Care*. 2005 Jan-Mar;9(1):90-7.
- 9. Bramstedt KA, Simeon DJ. The challenges of responding to "high-tech" cardiac implant patients in crisis. *Prehosp Emerg Care*. 2002 Oct-Dec;6(4):425-32.
- 10. Goebel, M., Tainter, C., Kahn, C., Dunford, J. V., Serra, J., Pierce, J., & Donofrio, J. J. (2019). An Urban 9-1-1 System's Experience with Left Ventricular Assist Device Patients. *Prehospital Emergency Care*.
- 11. Long, B., Robertson, J., Koyfman, A., & Brady, W. (2019). Left ventricular assist devices and their complications: A review for emergency clinicians. American Journal of Emergency Medicine, 37(8), 1562–1570.





Approved 9/04/24, Effective 1/15/25, replaces all prior versions

#### 5N - INTRA-AORTIC BALLOON PUMP (IABP) MONITORING - ADULT


#### **PARAMEDIC**

#### **Introduction**:

Transfer of patients between hospitals is and will be an increasing demand due to an aging society and the increasing invasiveness of recommended therapies. Intra-aortic balloon pumps are used in mechanical circulatory support. The reduction in size and weight of the respective devices now allows an increasing number of interfacility transfers with continuing mechanical circulation support.

#### Indications for Intra-Aortic Balloon Pump (IABP):

IABP counter-pulsation support is a recommended option for patients with cardiac failure, mainly due to coronary artery disease or congestive heart failure. Early IABP support is used to accompany acute percutaneous coronary intervention (PCI) or cardiac surgery. In addition, IABP support may function as a bridge prior to invasive procedures if these specialties are unavailable at the initial hospital of admission. If in such a situation inter-hospital transfer is mandatory, IABP support must be maintained in clinical settings that may include refractory unstable angina, impending or acute myocardial infarction, ventricular failure, acute valvular disease, and cardiogenic shock.





#### Objective of the Transport Team:

1. Provide skilled personnel and the equipment to deliver specialized care needed to stabilize, maintain, and transport critically ill patients with IABP support.

**NOTE**: Paramedic may provide or assist in providing mechanical circulatory support during interfacility transport only if they have completed special additional training in the use of IABP including appropriate continuing education and are properly credentialed by the appropriate local medical oversight physician(s) to operate or assist with IABP.





Approved 9/04/24, Effective 1/15/25, replaces all prior versions

Protocol 5N: Intra – Aortic Balloon Pump Monitoring (IABP) – Adult, cont.

#### Before transport of the patient:

- Together with physician, nurse, or cardiovascular technical staff (as appropriate), ensure
  that intra-aortic balloon catheter is properly secured, check intra-aortic balloon insertion site
  for bleeding or drainage, confirm adequacy of distal pulses and perfusion, and record pretransport intra-aortic balloon pump settings.
  - NOTE: IT MAY BE NECESSARY TO USE A DOPPLER STETHOSCOPE TO CONFIRM PULSATILE FLOW IF CARDIOGENIC SHOCK IS SEVERE.
- 2. Measure and record augmented systolic, mean, and diastolic blood pressure in addition to standard vital signs.
- 3. If the transport is not accompanied by a physician or nurse, obtain written order for intraacrtic balloon pump settings to be used enroute.
  - NOTE: IF YOU ARE NOT FAMILIAR WITH THE TYPE OF INTRA-AORTIC BALLOON PUMP BEING USED, OR DO NOT FEEL COMFORTABLE WITH THE INTRA-AORTIC BALLOON PUMP SETTINGS PRESCRIBED BY THE SENDING PHYSICIAN, DO NOT ATTEMPT TRANSPORT. CONTACT ON-LINE MEDICAL CONTROL FOR FURTHER INSTRUCTIONS.
- 4. Ensure that the intra-aortic balloon pump being used is properly functioning, that an acceptable ECG trigger is present, and that all settings are correct.

#### During transport of the patient:

- 1. Connect IABP power cable to the ambulance power supply during transport. The battery gauge of the IABP is in the right lower corner of the console screen.
- 2. Continuously monitor augmented systolic, mean, and diastolic blood pressure in addition to standard vital signs.
- 3. In the event of mechanical failure, and the patient remains stable, attempt to identify and correct the problem.
- 4. In the event of a clinical emergency, and a physician, nurse practitioner, or physician surrogate IS present, assist with intra-aortic balloon pump management on request, and contact on-line medical control (or duly authorized agent) as soon as possible (without compromising patient safety).
- 5. In the event of a clinical emergency, and a physician, nurse practitioner, or physician surrogate is **NOT** present, proceed with cardiopulmonary resuscitation as indicated, and contact on-line medical control as soon as possible (without compromising patient safety).
  - **NOTE**: CARDIOPULMONARY RESUSCITATION AND DEFIBRILLATION MAY BE PERFORMED WHILE THE INTRA-AORTIC BALLOON PUMP IS FUNCTIONING.

#### After transport of the patient:

Record type and model of intra-aortic balloon pump used, settings employed in-transport, and augmented systolic, mean and diastolic blood pressures obtained post-transport, as well as any changes in patient condition, modifications in intra-aortic balloon pump settings, and unusual incidents occurring enroute.






Approved 9/04/24, Effective 1/15/25, replaces all prior versions

Protocol 5N: Intra – Aortic Balloon Pump Monitoring (IABP) – Adult, cont.

Troubleshooting the Maquet CS300™ IABP – (see protocol Special Note):








Approved 9/04/24, Effective 1/15/25, replaces all prior versions

Protocol 5N: Intra - Aortic Balloon Pump Monitoring (IABP) - Adult, cont.

Troubleshooting the Maquet CS 300™ IABP, cont:








Approved 9/04/24, Effective 1/15/25, replaces all prior versions

Protocol 5N: Intra – Aortic Balloon Pump Monitoring (IABP) – Adult, cont.

Troubleshooting the Maquet CS300™ IABP, cont:









Approved 9/04/24, Effective 1/15/25, replaces all prior versions

Protocol 5N: Intra – Aortic Balloon Pump Monitoring (IABP) – Adult, cont.

Troubleshooting the Maguet CS300™ IABP, cont:









#### Medical Literature References 5N – Intra-Aortic Balloon Pump (IABP) Monitoring – Adult


- Callaway CW, Soar J, Aibiki M, Böttiger BW, Brooks SC, Deakin CD, Donnino MW, Drajer S, Kloeck W, Morley PT, Morrison LJ, Neumar RW, Nicholson TC, Nolan JP, Okada K, O'Neil BJ, Paiva EF, Parr MJ, Wang TL, Witt J; Advanced Life Support Chapter Collaborators. Part 4: Advanced Life Support: 2015 International Consensus on Cardiopulmonary Resuscitation and Emergency Cardiovascular Care Science With Treatment Recommendations. *Circulation*. 2015 Oct 20;132(16 Suppl 1):S84-145.
- 2. Sinclair TD, Werman HA. Transfer of patients dependent on an intra-aortic balloon pump using critical care services. *Air Med J.* 2009 Jan-Feb;28(1):40-6.
- 3. MacDonald RD, Farquhar S. Transfer of intra-aortic balloon pump-dependent patients by paramedics. *Prehosp Emerg Care*. 2005 Oct-Dec;9(4):449-53.
- 4. Hatlestad DC, Van Horn J. Air transport of the IABP patient. Intra-Aortic Balloon Pump. *Air Med J.* 2002 Sep-Oct;21(5):42-8.





Approved 9/04/24, Effective 1/15/25, replaces all prior versions

#### 50-ZOLL LIFEVEST WEARABLE DEFIBRILLATOR



The following will help guide you through your assessment and care of the Zoll LifeVest.

- 1. The LifeVest wearable cardioverter defibrillator is worn by patients at risk for sudden cardiac arrest, providing protection during their changing condition and while permanent sudden cardiac arrest risk has not been established.
- 2. Before delivering a treatment shock, the LifeVest tests to see if a patient is conscious by providing the patient an opportunity to press the response buttons to prevent a treatment shock. It is important that only the patient press the response button.
- 3. The LifeVest therapy pads release a Blue gel prior to a treatment shock to both improve shock conduction and mitigate burning. The gel should remain on the patient as long as the patient is wearing the LifeVest in case additional treatment shocks are required. If you choose to remove the LifeVest from the patient and monitor the patient with external equipment, the gel can be removed with water.
- 4. After the LifeVest detects a treatable arrhythmia, the time to treatment will be between 25 and 60 seconds depending on the type and rate of the arrhythmia and whether the patient presses the response buttons.
- 5. No one should touch the patient while a shock is delivered. The LifeVest will warn bystanders with a tactile vibration alarm, a two tone siren alert and a voice command stating "electrical shock possible, do not touch patient," or "bystanders do not interfere" before a shock is delivered.
- 6. The monitor should be disconnected from the electrode belt prior to delivering an external defibrillation. The garment and belt do not need to be removed.
- 7. Never do CPR with the LifeVest turned on. Pull the battery out of the monitor to turn the device off. The garment can be opened from the front if CPR needs to be performed.
- 8. The tactile vibration alert, the two tone alarm, the voice prompts, and the display on the monitor screen are part of the LifeVest consciousness test, which requires the patient to press the response buttons to avoid a shock. It is important that only the patient press the response buttons.
- 9. Look at the monitor display if the LifeVest is giving gong alerts. Follow the prompts on the monitor screen. No treatment will be given for gong alerts.





Approved 9/04/24, Effective 1/15/25, replaces all prior versions

#### Protocol 50: Zoll Lifevest Wearable Defibrillator - Cont.

- 10. The patient should always bring the LifeVest system, the wireless modem / battery charger, and the extra external battery to the hospital. This will allow the patient to download any stored event data from the monitor and change the battery as required.
- 11. If the LifeVest needs to be turned off, remove the battery from the end of the black monitor. Removing the battery will shut the system off. To turn the system back on, put the battery back in and press the response button to activate device.
- 12. It is best to leave a patient in their LifeVest if at all possible. Do not remove the LifeVest unless absolutely necessary.
- 13. This device is a patient belonging and should be treated as a patient valuable. It is a rented durable medical equipment item that must be returned to Zoll and the patient is held liable for missing components. Please keep components in a personal belonging bag and make sure the equipment is kept with the patient or a family member.

Contact Zoll LifeVest to report where the patient was transported and if the patient had alarms or was defibrillated.

1-800-543-3267





Approved 9/04/24, Effective 1/15/25, replaces all prior versions

#### Protocol 50: Zoll Lifevest Wearable Defibrillator - Cont.

#### Photo 1:

(Boxed in red) is the monitor worn in a holster around the waist and collects ECG data from the sensing electrodes which can later be sent to a doctor via modem.



#### Photo 2:

(Circled in red) Dry, non-adhesive sensing electrodes on this electrode belt continuously monitor patient's heart.

(Boxed in green) These dry therapeutic electrodes will automatically deploy conductive gel prior to delivering a shock.







Approved 9/04/24, Effective 1/15/25, replaces all prior versions

#### TREATMENT PRIORITIES

3 in 5 minutes of patient contact:

- 1. Vital signs
- 2. O<sub>2</sub> ONLY if indicated
- 3. Los Angeles Prehospital Stroke Screen

Early transport & ED notification if symptoms <23 hours

#### 6A - STROKE ADULT & PEDIATRIC

#### **EMD**

ADVISE TO AVOID PHYSICAL EXERTION
OR ENVIRONMENTAL STRESS (TEMP EXTREMES).
CONDUCT STROKE SCREENING QUERY IF AUTHORIZED BY
LOCAL MEDICAL DISPATCH PROTOCOL.

#### EMERGENCY MEDICAL DISPATCHER EMERGENCY MEDICAL RESPONDER

**EMT** 

**EMT-INTERMEDIATE 85** 

**ADVANCED EMT** 

**PARAMEDIC** 

#### EMR EMT

GENERAL SUPPORTIVE CARE
OBTAIN VITAL SIGNS
O<sub>2</sub> VIA NC, NRB, OR BVM ONLY IF DYSPNEA OR PULSE OX <94% AT ROOM AIR

#### LOS ANGELES PREHOSPITAL STROKE SCREEN

AGE OVER 45 YEARS?
NO PRIOR HX OF SEIZURE DISORDER?
NEW ONSET OF NEUROLOGIC SYMPTOMS IN LAST 24 HRS?
PATIENT AMBULATORY AT BASELINE [PRIOR TO EVENT]?
BLOOD GLUCOSE 50 TO 400 mg/dL?
FACIAL DROOP; ARM DRIFT; IMPAIRED SPEECH?

EARLY "STROKE ALERT" NOTIFICATION TO RECEIVING EMERGENCY DEPARTMENT
WITH DEFINITIVE STROKE SYMPTOMS IF LESS THAN 23 HOURS DURATION
ADVISE TIME OF LAST ACCURATELY KNOWN BASELINE NEUROLOGICAL STATUS (LAST "NORMAL" FOR PT)
OBTAIN CELLPHONE NUMBER(S) OF FAMILY MEMBER(S) TO PROVIDE ED STAFF UPON ARRIVAL

APPLY CARDIAC MONITOR/OBTAIN 12-LEAD ECG (if equipped)
TRANSMIT 12-LEAD ECG TO RECEIVING EMERGENCY DEPARTMENT

#### **EMT OR HIGHER LICENSE:**

MEASURE END-TIDAL CO<sub>2</sub> & MONITOR WAVEFORM CAPNOGRAPHY (if equipped, \*\*Mandatory use if pt intubated) PLACE SUPRAGLOTTIC AIRWAY IF INDICATED & ONLY IF BVM VENTILATIONS ARE INEFFECTIVE

EMT-185 AEMT

**ADULT: INTUBATE IF INDICATED** 

#### IV ACCESS

IV NS TKO IF SYS BP ≥ 100 mmHg WITHOUT HYPOTENSIVE SYMPTOMS
IV NS 250 mL BOLUS IF SYS BP <100 mmHg WITH HYPOTENSIVE SYMPTOMS & NO SIGNS OF PULMONARY EDEMA,
REPEAT UP TO 2 LITERS NS IF SYS BP REMAINS < 100 mmHg WITH HYPOTENSIVE SYMPTOMS & NO SIGNS OF PULMONARY EDEMA

#### **PARAMEDIC**

ADULT: MEDICATION-ASSISTED INTUBATION IF INDICATED

EVALUATE FOR OTHER ALTERED MENTAL STATUS ETIOLOGIES. TREAT PER APPROPRIATE PROTOCOL(S) CONTINUOUS ASSESSMENT & TREATMENT PER APPLICABLE PROTOCOL(S)





Medical Literature References 6A – Stroke – Adult & Pediatric

- Medoro, I., & Cone, D. C. (2017). An Analysis of EMS and ED Detection of Stroke. Prehospital Emergency Care, 21(4), 476–480. https://doi.org/10.1080/10903127.2017.1294222
- 2. Saver JL, Starkman S, Eckstein M, Stratton SJ, Pratt FD, Hamilton S, Conwit R, Liebeskind DS, Sung G, Kramer I, Moreau G, Goldweber R, Sanossian N; FAST-MAG Investigators and Coordinators. Prehospital use of magnesium sulfate as neuroprotection in acute stroke. *NEJM.* 2015 Feb 5;372(6):528-36.
- 3. Rincon F, Kang J, Maltenfort M, Vibbert M, Urtecho J, Athar MK, Jallo J, Pineda CC, Tzeng D, McBride W, Bell R. Association between hyperoxia and mortality after stroke: a multicenter cohort study. *Crit Care Med.* 2014 Feb;42(2):387-96.
- 4. McKinney JS, Mylavarapu K, Lane J, Roberts V, Ohman-Strickland P, Merlin MA. Hospital prenotification of stroke patients by emergency medical services improves stroke time targets. *J Stroke Cerebrovasc Dis.* 2013 Feb;22(2):113-8.
- 5. Chenaitia H, Lefevre O, Ho V, Squarcioni C, Pradel V, Fournier M, Toesca R, Michelet P, Auffray JP. Emergency medical service in the stroke chain of survival. *Eur J Emerg Med.* 2013 Feb;20(1):39-44.
- 6. McKinney JS, Mylavarapu K, Lane J, Roberts V, Ohman-Strickland P, Merlin MA. Hospital Prenotification of Stroke Patients by Emergency Medical Services Improves Stroke Time Targets. J Stroke Cerebrovasc Dis. 2013 Feb;22(2):113-8.
- 7. Lin CB, Peterson ED, Smith EE, Saver JL, Liang L, Xian Y, Olson DM, Shah BR, Hernandez AF, Schwamm LH, Fonarow GC. Emergency medical service hospital prenotification is associated with improved evaluation and treatment of acute ischemic stroke. *Circ Cardiovasc Qual Outcomes*. 2012 Jul 1;5(4):514-22.
- 8. Protocol expert consultant: Lawrence Davis, MD. Oklahoma City. Board certified in neurology and vascular neurology by the American Board of Psychiatry and Neurology.
- 9. The ESCORTT group. The identification of acute stroke: an analysis of emergency calls. *Int J Stroke*. 2012 Feb 15.doi: 10.1111/j.1747-4949.2011.00749.x.
- 10. Jauch EC, Cucchiara B, Adeoye O, Meurer W, Brice J, Chan Y-F, Gentile N, Hazinski MF. Part 11: adult stroke: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. *Circulation*. 2010;122(suppl 3):S818–S828.
- 11. Alberts MJ, Latchaw RE, Jagoda A, Wechsler LR, Crocco T, George MG, Connolly ES, Mancini B, Prudhomme S, Gress D, Jensen ME, Bass R, Ruff R, Foell K, Armonda RA, Emr M, Warren M, Baranski J, Walker MD; Brain Attack Coalition. Revised and updated recommendations for the establishment of primary stroke centers: a summary statement from the brain attack coalition. *Stroke*. 2011 Sep;42(9):2651-65.
- 12. Patel MD, Rose KM, O'Brien EC, Rosamond WD. Prehospital notification by emergency medical services reduces delays in stroke evaluation: findings from the North Carolina stroke care collaborative. *Stroke*. 2011 Aug;42(8):2263-8.
- 13. Fonarow GC, Smith EE, Saver JL, Reeves MJ, Bhatt DL, Grau-Sepulveda MV, Olson DM, Hernandez AF, Peterson ED, Schwamm LH. Timeliness of tissue-type plasminogen activator therapy in acute ischemic stroke: patient characteristics, hospital factors, and outcomes associated with door-to-needle times within 60 minutes. *Circulation*. 2011 Feb 22;123(7):750-8.
- 14. Brice JH, Evenson KR, Lellis JC, Rosamond WD, Aytur SA, Christian JB, Morris DL. Emergency medical services education, community outreach, and protocols for stroke and chest pain in North Carolina. *Prehosp Emerg Care*. 2008 Jul-Sep;12(3):366-71.
- 15. Adams HP Jr, del Zoppo G, Alberts MJ, Bhatt DL, Brass L, Furlan A, Grubb RL, Higashida RT, Jauch EC, Kidwell C, Lyden PD, Morgenstern LB, Qureshi AI, Rosenwasser RH, Scott PA, Wijdicks EF. Guidelines for the early management of adults with ischemic stroke: a guideline from the American Heart Association/American Stroke Association Stroke Council, Clinical Cardiology Council, Cardiovascular Radiology and Intervention Council, and the Atherosclerotic Peripheral Vascular Disease and Quality of Care Outcomes in Research Interdisciplinary Working Groups. Stroke. 2007 May;38(5):1655-711. Erratum in Stroke. 2007 Sep;38(9):e96. Stroke. 2007 Jun;38(6):e38.
- 16. Kidwell CS, Starkman S, Eckstein M, Weems K, Saver JL. Identifying stroke in the field. Prospective validation of the Los Angeles prehospital stroke screen (LAPSS). *Stroke*. 2000 Jan;31(1):71-6.





Medical Literature References 6A – Stroke – Adult & Pediatric

- 17. Krebs, W., Sharkey-Toppen, T. P., Cheek, F., Cortez, E., Larrimore, A., Keseg, D., & Panchal, A. R. (2018). Prehospital Stroke Assessment for Large Vessel Occlusions: A Systematic Review. *Prehospital Emergency Care*. https://doi.org/10.1080/10903127.2017.1371263
- 18. Adeoye, O., Nyström, K. V., Yavagal, D. R., Luciano, J., Nogueira, R. G., Zorowitz, R. D., ... Jauch, E. C. (2019). Recommendations for the Establishment of Stroke Systems of Care: A 2019 Update: A Policy Statement From the American Stroke Association. *Stroke*. https://doi.org/10.1161/STR.000000000000173





Approved 9/04/24, Effective 1/15/25, replaces all prior versions

#### TREATMENT PRIORITIES

- 1. Vital signs
- 2. O<sub>2</sub>
- 3. Dextrose for hypoglycemia
- 4. Benzodiazepine for sustained, active seizure (refer to 6D Seizure if applicable)
- 5.BVM prior to administration of Naloxone

#### Evaluate differential diagnosis

- of AMS & treat per protocol(s): Hypoxemia (Shock)
  - Head Injury
  - Stroke
  - Seizure
  - Infection (Sepsis/ Meningitis)
  - Medication/Alcohol
  - Heat or Cold Illness

#### **6B - ALTERED MENTAL STATUS ADULT & PEDIATRIC**

#### **EMD**

KEEP PATIENT FREE FROM INJURY HAZARDS AVOID PLACING ANYTHING IN MOUTH PLACE IN RECOVERY POSITION POST SEIZURE

#### **EMR**

GENERAL SUPPORTIVE CARE & OBTAIN VITAL SIGNS O2 VIA NC, NRB, OR BVM AS APPROPRIATE

#### TOXINS/DRUG OVERDOSE - SUSPECTED NARCOTIC/OPIATE

ADDRESS OXYGENATION AND VENTILATION (SPO2 GO AL ≥ 94%) BEFORE ADMINISTERING NALOXONE APNEIC/AGONALLY BREATHING

ADULT: NALOXONE 2 mg IN, MAY REPEAT ONCE

PEDIATRIC: NALOX ONE 0.5 mg IN, MAY REPEAT TO MAX OF 2 mg INEFFECTIVE BREATHING ACTIVITY

ADULT & PEDIATRIC: NALOXONE 0.5 mg IN, MAY REPEAT TO MAX OF 2 mg
USE NALOXONE TO RESTORE EFFECTIVE BREATHING: AVOID EXCESSIVE DOSING TO PREVENT WITHDRAWAL

> DETERMINE BLOOD GLUCOSE FOR PATIENT ABLE TO SWALLOW

ADULT & PEDIATRIC WEIGHT ≥25 kg HYPOGLYCEMIA CARE:

IF GLUCOSE <50 mg/dL, 1 tube ORAL GLUCOSE (15 grams) PO
PEDIATRIC WEIGHT <25 kg HYPOGLYCEMIA CARE:

IF GLUCOSE <50 mg/dL, ½ tube ORAL GLUCOSE (7.5 grams) PO

APPLY CARDIAC MONITOR (if equipped)

MEASURE END-TIDAL CO2 & MONITOR WAVEFORM CAPNOGRAPHY (if equipped, \*\*Mandatory use if pt intubated)
PLACE SUPRAGLOTTIC AIRWAY IF INDICATED & ONLY IF BVM VENTILATIONS INEFFECTIVE

EMERGENCY MEDICAL **DISPATCHER** 

EMERGENCY MEDICAL RESPONDER

**EMT** 

**EMT-INTERMEDIATE 85** 

ADVANCED EMT

**PARAMEDIC** 

**EMT-185 AEMT** 

**IV ACCESS** 

ADULT: IV NS TKO IF SYS BP ≥ 100 mmHg WITHOUT HYPOTENSIVE SYMPTOMS

ADULT: IV NS 250 mL BOLUS IF SYS BP < 100 mmHg WITH HYPOTENSIVE SYMPTOMS & NO SIGNS OF PULMONARY EDEMA, ADULT: REPEAT UP TO 2 LITERS NS IF SYS BP REMAINS < 100 mmHg WITH HYPOTENSIVE SYMPTOMS & NO SIGNS OF PULMONARY EDEMA PEDIATRIC: IV NS TKO IF SYS BP ≥ (70 + 2x age in years) mmHg

PEDIATRIC: IV NS 20 mL/kg BOLUS IF SYS BP < (70 + 2x age in years) mmHg IF NO SIGNS OF PULMONARY EDEMA

HYPOGLYCEMIA (GLUCOSE <50 mg/dL) - ADULT & PEDIATRIC

D10 5 mL/kg IVPB WIDE OPEN UP TO 250 mL OR

D25 2 mL/kg IV/IO UP TO 100 mL (must be ≥ 1 year of age) OR D50 1 mL/kg IV/IO UP TO 50 mL (must be ≥ 25 kg)

IF NO VASCULAR ACCESS OBTAINED & IF IO SEEMS EXCESSIVE TO CLINICAL STATUS:

GLUCAGON: IF PT WT ≥25 kg, 1mg IM; <25 kg, 0.5 mg IM ADULT & PEDIATRIC: REPEAT DETERMINATION OF BLOOD GLUCOSE POST-HYPOGLYCEMIA TREATMENT

ADULT: INTUBATE IF INDICATED; DO NOT INTUBATE PATIENTS WITH RAPIDLY REVERSIBLE ETIOLOGY (eg. HYPOGLYCEMIA, OPIATES)

#### ADVANCED EMT OR HIGHER LICENSE:

TOXINS/DRUG OVERDOSE - SUSPECTED NARCOTIC/OPIATE - APNEIC/AGONALLY BREATHING ADULT: NALOXONE 2 mg IVP/IOP/IN, MAY REPEAT ONCE
PEDIATRIC: NALOXONE 0.5 mg IVP/IOP/IN, MAY REPEAT TO MAX OF 2 mg

TOXINS/DRUG OVERDOSE - SUSPECTED NARCOTIC/OPIATE - INEFFECTIVE BREATHING ACTIVITY

ADULT & PEDIATRIC: NALOXONE 0.5 mg IVP/IOP/IN, MAY REPEAT TO MAX OF 2 mg USE NALOXONE TO RESTORE EFFECTIVE BREATHING; AVOID EXCESSIVE DOSING TO PREVENT WITHDRAWAL

**PARAMEDIC** 

ADULT: MEDICATION-ASSISTED INTUBATION IF INDICATED

CONTINUOUS ASSESSMENT & TREATMENT OF SUSPECTED AMS ETIOLOGY PER APPLICABLE PROTOCOL(S) CONSULT OLMC IF ABOVE TREATMENT INEFFECTIVE FOR HYPOGLYCEMIA OR NARCOTIC/OPIATE ETIOLOGY CONSULT OLMC IF UNCERTAIN OF ETIOLOGY AND TREATMENT PLAN OF AMS





#### Medical Literature References 6B – Altered Mental Status – Adult & Pediatric


- 1. Hern HG, Kiefer M, Louie D, Barger J, Alter HJ. D10 in the treatment of prehospital hypoglycemia a 24 month observational cohort study. Prehosp Emerg Care, 2017, 21(1): 63-67
- 2. Zuckerman M, Weisberg SN, Boyer EW. Pitfalls of intranasal naloxone. *Prehosp Emerg Care*. 2014 Oct-Dec;18(4):550-4.
- 3. Robinson A, Wermeling DP. Intranasal naloxone administration for treatment of opioid overdose. *Am J Health Syst Pharm.* 2014 Dec 15:71(24):2129-35.
- 4. Davis CS, Southwell JK, Niehaus VR, Walley AY, Dailey MW. Emergency medical services naloxone access: a national systematic legal review. *Acad Emerg Med.* 2014 Oct;21(10):1173-7.
- 5. Merlin MA, Carluccio A, Raswant N, Dossantos F, Ohman-Strickland P, Lehrfeld DP. Comparison of Prehospital glucose with or without IV thiamine. *West J Emerg Med.* 2012 Nov;13(5):406-9.
- 6. Weber JM, Tataris KL, Hoffman JD, Aks SE, Mycyk MB. Can nebulized naloxone be used safely and effectively by emergency medical services for suspected opioid overdose? *Prehosp Emerg Care*. 2012 Apr-Jun;16(2):289-92.
- Silbergleit R, Durkalski V, Lowenstein D, Conwit R, Pancioli A, Palesch Y, Barsan W; NETT Investigators. Intramuscular versus intravenous therapy for prehospital status epilepticus. N Engl J Med. 2012 Feb 16;366(7):591-600.
- 8. Somani R, Baranchuk A, Guzman JC, Morillo CA. The role of Emergency Medical Services in the assessment and management of syncope. *Int J Cardiol*. 2012 Feb 9;154(3):368-9.
- 9. Grossman SA, Babineau M, Burke L, Kancharla A, Mottley L, Nencioni A, Shapiro NI. Do outcomes of near syncope parallel syncope? *Am J Emerg Med*. 2012 Jan;30(1):203-6.
- 10. Quinn J, McDermott D. Electrocardiogram findings in emergency department patients with syncope. *Acad Emerg Med.* 2011 Jul;18(7):714-8.
- 11. Shearer P, Riviello J. Generalized convulsive status epilepticus in adults and children: treatment guidelines and protocols. *Emerg Med Clin North Am.* 2011 Feb;29(1):51-64.
- 12. Jauch EC, Cucchiara B, Adeoye O, Meurer W, Brice J, Chan Y-F, Gentile N, Hazinski MF. Part 11: adult stroke: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. *Circulation*. 2010;122(suppl 3):S818–S828.
- 13. Meehan TJ, Bryant SM, Aks SE. Drugs of abuse: the highs and lows of altered mental states in the emergency department. *Emerg Med Clin North Am.* 2010 Aug;28(3):663-82.
- 14. Barton ED, Colwell CB, Wolfe T, Fosnocht D, Gravitz C, Bryan T, Dunn W, Benson J, Bailey J. Efficacy of intranasal naloxone as a needleless alternative for treatment of opioid overdose in the prehospital setting. *J Emerg Med.* 2005 Oct;29(3):265-71.
- 15. Vilke GM, Castillo EM, Ray LU, Murrin PA, Chan TC. Evaluation of pediatric glucose monitoring and hypoglycemic therapy in the field. *Pediatr Emerg Care*. 2005 Jan;21(1):1-5.
- Brieger D, Eagle KA, Goodman SG, Steg PG, Budaj A, White K, Montalescot G; GRACE Investigators. Acute coronary syndromes without chest pain, an underdiagnosed and undertreated high-risk group: insights from the Global Registry of Acute Coronary Events. *Chest.* 2004 Aug;126(2):461-9.
- 17. Seger DL. Flumazenil—treatment or toxin. J Toxicol Clin Toxicol. 2004;42(2):209-16.
- 18. Bledsoe BE. No more coma cocktails. Using science to dispel myths & improve patient care. *JEMS*. 2002 Nov;27(11):54-60.
- 19. Hoffman RS, Goldfrank LR. The poisoned patient with altered consciousness. Controversies in the use of a 'coma cocktail'. *JAMA*. 1995 Aug 16;274(7):562-9.
- 20. Hoffman JR, Schriger DL, Luo JS. The empiric use of naloxone in patients with altered mental status: a reappraisal. *Ann Emerg Med.* 1991 Mar;20(3):246-52.





Approved 9/04/24, Effective 1/15/25, replaces all prior versions

### 6C - GLUCOMETRY (BLOOD GLUCOSE DETERMINATION) ADULT & PEDIATRIC



#### Indications:

- 1. Suspected stroke (as part of Los Angeles Prehospital Stroke Screen)
- 2. Altered mental status unclear etiology
- 3. Seizure
- 4. Known or suspected diabetes

Contraindications: None

#### Technique:

- 1. Calibrate the meter per manufacturer instructions.
- 2. Use only manufacturer approved test strips.
  - a. Run a control test every time a new box of test strips is used.
  - b. Store unused test strips in original container and do not use **EXPIRED** test strips.
  - c. Do not apply blood to the test strip before inserting the test strip into the meter. If the meter displays a result before applying blood **DO NOT** use that result.
  - d. Do not reuse test strips. Once blood is applied to test strip discard it.
  - e. If another glucometry reading is required, use a new test strip.
  - f. Do not expose strips to heat outside the recommended range, moisture, or humidity.

#### **Determining Blood Glucose:**

- 1. Using universal precautions, power on the meter.
- 2. Insert a test strip into the meter per manufacturer instructions.
- 3. Position hand palm-side up; choose whichever finger is least calloused.
- 4. Apply intermittent pressure to the finger to help the blood to flow.
- 5. Clean the fingertip with alcohol. Start in the middle and work outward to prevent contaminating the area. Allow area to dry.
- 6. Hold the finger and firmly place a new, sterile lancet <u>off-center</u> on the fingertip and firmly press the lancet to puncture the fingertip.
- 7. Wipe away the first drop of blood with a sterile gauze pad, then apply blood to test strip.
- 8. Properly dispose of all contaminated supplies.






Medical Literature References
6C – Glucometry (Blood Glucose Determination) – Adult & Pediatric

- 1. Shearer P, Riviello J. Generalized convulsive status epilepticus in adults and children: treatment guidelines and protocols. *Emerg Med Clin North Am.* 2011 Feb;29(1):51-64.
- 2. Jauch EC, Cucchiara B, Adeoye O, Meurer W, Brice J, Chan Y-F, Gentile N, Hazinski MF. Part 11: adult stroke: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. *Circulation*. 2010;122(suppl 3):S818–S828.
- 3. Vilke GM, Castillo EM, Ray LU, Murrin PA, Chan TC. Evaluation of pediatric glucose monitoring and hypoglycemic therapy in the field. *Pediatr Emerg Care*. 2005 Jan;21(1):1-5.
- 4. Bledsoe BE. No more coma cocktails. Using science to dispel myths & improve patient care. *JEMS*. 2002 Nov;27(11):54-60.
- 5. Holstein A, Kühne D, Elsing HG, Thiessen E, Plaschke A, Widjaja A, Vogel MY, Egberts EH. Practicality and accuracy of prehospital rapid venous blood glucose determination. *Am J Emerg Med.* 2000 Oct;18(6):690-4.
- 6. Hoffman RS, Goldfrank LR. The poisoned patient with altered consciousness. Controversies in the use of a 'coma cocktail'. *JAMA*. 1995 Aug 16;274(7):562-9.
- 7. Jones JL, Ray VG, Gough JE, Garrison HG, Whitley TW. Determination of prehospital blood glucose: a prospective, controlled study. *J Emerg Med*. 1992 Nov-Dec;10(6):679-82.





Approved 9/04/24, Effective 1/15/25, replaces all prior versions



**EMT-185 AEMT** 

IV ACCESS

ADULT: IV NS TKO IF SYS BP ≥ 100 mmHg WITHOUT HYPOTENSIVE SYMPTOMS

ADULT: IV NS 250 mL BOLUS IF SYS BP < 100 mmHg WITH HYPOTENSIVE SYMPTOMS & NO SIGNS OF PULMONARY EDEMA, ADULT: REPEAT UP TO 2 LITERS NS IF SYS BP REMAINS < 100 mmHg WITH HYPOTENSIVE SYMPTOMS & NO SIGNS OF PULMONARY EDEMA

**PEDIATRIC:** IV NS TKO IF SYS BP ≥ (70 + 2x age in years) mmHg PEDIATRIC: IV NS 20 mL/kg BOLUS IF SYS BP < (70 + 2x age in years) mmHg IF NO SIGNS OF PULMONARY EDEMA

HYPOGLYCEMIA (GLUCOSE <50 mg/dL) - ADULT & PEDIATRIC D10 5 mL/kg IVPB WIDE OPEN UP TO 250 mL OR

D25 2 mL/kg IV/IO UP TO 100 mL (must be ≥ 1 year of age) OR D50 1 mL/kg IV/IO UP TO 50 mL (must be ≥ 25 kg) IF NO VASCULAR ACCÈSS OBTAINED & IF IO SEEMS EXCESSIVE TO CLINICAL STATUS:

GLUCAGON: IF PT WT ≥25 kg, 1mg IM; <25 kg, 0.5 mg IM
ADULT & PEDIATRIC: REPEAT DETERMINATION OF BLOOD GLUCOSE POST-HYPOGLYCEMIA TREATMENT

#### **PARAMEDIC**

EVALUATE FOR OTHER ALTERED MENTAL STATUS ETIOLOGIES. TREAT PER APPROPRIATE PROTOCOL(S)

ADULT: MIDAZOLAM 0.1 mg/kg IM/IVP/IOP TO MAX OF 5 mg FOR ACTIVE SEIZURE. MAY REPEAT X 1 IN 5 MINS IF STILL SEIZING. ADULT: DIAŽEPAM 5 mg IVP/IOP or 10 mg IM FOR ACTIVE SEIZURE IF MIDAZOLAM NOT AVAILABLE.

MAY REPEAT X 1 IN 5 MINS IF STILL SEIZING. OR

ADULT: LORAZEPAM 2 mg IVP/IOP/IM FOR ACTIVE SEIZURE IF MIDAZOLAM NOT AVAILABLE. MAY REPEAT X 1 IN 10 MINS IF STILL SEIZING.

PEDIATRIC: MIDAZOLAM 0.1 mg/kg IM/IVP/IOP TO MAX OF 5 mg FOR ACTIVE SEIZURE. MAY REPEAT X 1 IN 5 MINS IF STILL SEIZING. PEDIATRIC: DIAZEPAM 0.1 mg/kg TO MAX OF 5 mg IVP/IOP/IM FOR ACTIVE SEIZURE IF MIDAZOLAM NOT AVAILABLE.

MAY REPEAT X 1 IN 5 MINS IF STILL SEIZING. OR PEDIATRIC: LORAZEPAM 0.1 mg/kg TO MAX OF 2 mg IVP/IOP/IM FOR ACTIVE SEIZURE IF MIDAZOLAM NOT AVAILABLE MAY REPEAT X 1 IN 10 MINS IF STILL SEIZING.

**OLMC CONSULT IF SEIZURE CONTINUES DESPITE ABOVE TREATMENT** 

CONTINUOUS ASSESSMENT & TREATMENT PER APPLICABLE PROTOCOL(S)





#### Medical Literature References 6D – Seizure – Adult & Pediatric

- 1. Clemency BM, Ott JA, Tanski CT, Bart JA, Lindstrom HA. Parenteral midazolam is superior to diazepam for treatment of prehospital seizures. *Prehosp Emerg Care*. 2015 Apr-Jun;19(2):218-23.
- Brophy GM, Bell R, Claassen J, Alldredge B, Bleck TP, Glauser T, Laroche SM, Riviello JJ Jr, Shutter L, Sperling MR, Treiman DM, Vespa PM; Neurocritical Care Society Status Epilepticus Guideline Writing Committee. Guidelines for the Evaluation and Management of Status Epilepticus. *Neurocrit Care*. 2012 Aug;17(1):3-23
- Silbergleit R, Durkalski V, Lowenstein D, Conwit R, Pancioli A, Palesch Y, Barsan W; NETT Investigators. Intramuscular versus intravenous therapy for prehospital status epilepticus. N Engl J Med. 2012 Feb 16;366(7):591-600.
- 4. Shearer P, Riviello J. Generalized convulsive status epilepticus in adults and children: treatment guidelines and protocols. *Emerg Med Clin North Am.* 2011 Feb;29(1):51-64.
- 5. Vilke GM, Castillo EM, Ray LU, Murrin PA, Chan TC. Evaluation of pediatric glucose monitoring and hypoglycemic therapy in the field. *Pediatr Emerg Care*. 2005 Jan;21(1):1-5.
- 6. Vilke GM, Sharieff GQ, Marino A, Gerhart AE, Chan TC. Midazolam for the treatment of out-of-hospital pediatric seizures. *Prehosp Emerg Care*. 2002 Apr-Jun;6(2):215-7.
- 7. Alldredge BK, Gelb AM, Isaacs SM, Corry MD, Allen F, Ulrich S, Gottwald MD, O'Neil N, Neuhaus JM, Segal MR, Lowenstein DH. A comparison of lorazepam, diazepam, and placebo for the treatment of out-of-hospital status epilepticus. *N Engl J Med.* 2001 Aug 30;345(9):631-7.
- 8. Alldredge BK, Wall DB, Ferriero DM. Effect of prehospital treatment on the outcome of status epilepticus in children. *Pediatr Neurol.* 1995 Apr;12(3):213-6.
- Kay, L., Merkel, N., von Blomberg, A., Willems, L. M., Bauer, S., Reif, P. S., ... Strzelczyk, A. (2019). Intranasal midazolam as first-line inhospital treatment for status epilepticus: a pharmaco-EEG cohort study. Annals of Clinical and Translational Neurology, 6(12), 2413–2425. https://doi.org/10.1002/acn3.50932





Approved 9/04/24, Effective 1/15/25, replaces all prior versions

#### **6E - SYNCOPE ADULT & PEDIATRIC**

#### TREATMENT PRIORITIES

- 1. Vital signs
- 2. O<sub>2</sub>
- 3. Dextrose for hypoglycemia
- 4. Benzodiazepine for sustained, active seizure (refer to 6D Seizure if applicable)
- 5. BVM prior to administration of Naloxone

Evaluate differential diagnosis of Syncope & treat per protocol(s):

- Acute Coronary Syndrome
- Cardiac Dysrhythmia
- Hypotension (Shock)
- Hypoxemia (Shock)
- Head Injury
- Stroke
- Seizure
- Infection (Sepsis/ Meningitis)
- Medication/Alcohol
- Heat or Cold Illness
- Psychogenic/Emotion

#### **EMD**

KEEP PATIENT FREE FROM INJURY HAZARDS AVOID PLACING ANYTHING IN MOUTH ADVISE TO AVOID PHYSICAL EXERTION OR ENVIRONMENTAL STRESS (TEMP EXTREMES) PLACE IN RECOVERY POSITION/POSITION OF COMFORT

GENERAL SUPPORTIVE CARE; OBTAIN VITAL SIGNS O<sub>2</sub> VIA NC, NRB, OR BVM AS APPROPRIATE DETERMINE BLOOD GLUCOSE FOR PATIENT ABLE TO SWALLOW

ADULT & PEDIATRIC WEIGHT ≥ 25 kg HYPOGLYCEMIA CARE:

IF GLUCOSE < 50 mg/dL, 1 tube ORAL GLUCOSE (15 grams) PO PEDIATRIC WEIGHT <25 kg HYPOGLYCEMIA CARE:

IF GLUCOSE <50 mg/dL, 1/2 tube ORAL GLUCOSE (7.5 grams) PO

TOXINS/DRUG OVERDOSE - SUSPECTED NARCOTIC/OPIATE

ADDRESS OXYGENATION AND VENTILATION (SP02 ≥ 94%) BEFORE ADMINSTRATION OF NALOXONE

APNEIC/AGONALLY BREATHING

ADULT: NALOXONE 2 mg IN, MAY REPEAT ONCE PEDIATRIC: NALOXONE 0.5 mg IN, MAY REPEAT TO MAX OF 2 mg
INEFFECTIVE BREATHING ACTIVITY

ADULT & PEDIATRIC: NALOXONE 0.5 mg IN, MAY REPEAT TO MAX OF 2 mg
USE NALOXONE TO RESTORE EFFECTIVE BREATHING:

AVOID EXCESSIVE DOSING TO PREVENT WITHDRAWAL APPLY CARDIAC MONITOR/OBTAIN 12-LEAD ECG (if equipped) TRANSMIT 12-LEAD ECG TO RECEIVING EMERGENCY DEPARTMENT

EMT OR HIGHER LICENSE MEASURE END-TIDAL CO<sub>2</sub> & MONITOR WAVEFORM CAPNOGRAPHY
(if equipped, \*\*Mandatory use if pt intubated)
PLACE SUPRAGLOTTIC AIRWAY IF INDICATED & ONLY IF BVM VENTILATIONS INEFFECTIVE

**EMERGENCY MEDICAL DISPATCHER** 

EMERGENCY MEDICAL RESPONDER

**EMT** 

**EMT-INTERMEDIATE 85** 

ADVANCED EMT

**PARAMEDIC** 

**EMT-185 AEMT** 

IV ACCESS

**ADULT:** IV NS TKO IF SYS BP  $\geq$  100 mmHg WITHOUT HYPOTENSIVE SYMPTOMS

ADULT: IV NS 250 mL BOLUS IF SYS BP < 100 mmHg WITH HYPÖTENSIVE SYMPTOMS & NO SIGNS OF PULMONARY EDEMA ADULT: REPEAT UP TO 2 LITERS NS IF SYS BP REMAINS < 100 mmHg WITH HYPOTENSIVE SYMPTOMS & NO SIGNS OF PULMONARY EDEMA
PEDIATRIC: IV NS TKO IF SYS BP ≥ (70 + 2x age in years) mmHg
PEDIATRIC: IV NS 20 mL/kg BOLUS IF SYS BP < (70 + 2x age in years) mmHg IF NO SIGNS OF PULMONARY EDEMA

HYPOGLYCEMIA (GLUCOSE <50 mg/dL) - ADULT & PEDIATRIC D10 5 mL/kg IVPB WIDE OPEN UP TO 250 mL OR

D25 2 mL/kg IV/IO UP TO 100 mL (must be ≥ 1 year of age) OR D50 1 mL/kg IV/IO UP TO 50 mL (must be ≥ 25 kg) IF NO VASCULAR ACCESS OBTAINED & IF IO SEEMS EXCESSIVE TO CLINICAL STATUS:

GLUCAGON: IF PT WT 225 kg, 10 mg IM; <25 kg, 0.5 mg IM

ADULT & PEDIATRIC: REPEAT DETERMINATION OF BLOOD GLUCOSE POST-HYPOGLYCEMIA TREATMENT

ADULT: INTUBATE IF INDICATED; DO NOT INTUBATE PATIENTS WITH RAPIDLY REVERSIBLE AMS ETIOLOGY (eg. HYPOGLYCEMIA, OPIATES) ADVANCED EMT OR HIGHER LICENSE:

> TOXINS/DRUG OVERDOSE - SUSPECTED NARCOTIC/OPIATE - APNEIC/AGONALLY BREATHING ADULT: NALOXONE 2 mg IVP/IOP/IN MAY REPEAT ONCE

PEDIATRIC: NALOXONE 0.5 mg IVP/IOP/IN, MAY REPEAT TO MAX OF 2 mg

TOXINS/DRUG OVERDOSE - SUSPECTED NARCOTIC/OPIATE - INEFFECTIVE BREATHING ACTIVITY

ADULT & PEDIATRIC: NALOXONE 0.5 mg IVP/IOP/IN, MAY REPEAT TO MAX OF 2 mg

USE NALOXONE TO RESTORE EFFECTIVE BREATHING; AVOID EXCESSIVE DOSING TO PREVENT WITHDRAWAL

#### **PARAMEDIC**

ADULT: MEDICATION-ASSISTED INTUBATION IF INDICATED

CONTINUOUS ASSESSMENT & TREATMENT OF SUSPECTED AMS ETIOLOGY PER APPLICABLE PROTOCOL(S) CONSULT OLMC IF ABOVE TREATMENT INEFFECTIVE FOR HYPOGLYCEMIA OR NARCOTIC/OPIATE ETIOLOGY CONSULT OLMC IF UNCERTAIN OF ETIOLOGY AND TREATMENT PLAN OF AMS





#### Medical Literature References 6E – Syncope – Adult & Pediatric

- 1. Weber JM, Tataris KL, Hoffman JD, Aks SE, Mycyk MB. Can nebulized naloxone be used safely and effectively by emergency medical services for suspected opioid overdose? *Prehosp Emerg Care*. 2012 Apr-Jun;16(2):289-92.
- 2. Silbergleit R, Durkalski V, Lowenstein D, Conwit R, Pancioli A, Palesch Y, Barsan W; NETT Investigators. Intramuscular versus intravenous therapy for prehospital status epilepticus. *N Engl J Med.* 2012 Feb 16;366(7):591-600.
- 3. Somani R, Baranchuk A, Guzman JC, Morillo CA. The role of Emergency Medical Services in the assessment and management of syncope. *Int J Cardiol.* 2012 Feb 9;154(3):368-9.
- 4. Grossman SA, Babineau M, Burke L, Kancharla A, Mottley L, Nencioni A, Shapiro NI. Do outcomes of near syncope parallel syncope? *Am J Emerg Med.* 2012 Jan;30(1):203-6.
- 5. Quinn J, McDermott D. Electrocardiogram findings in emergency department patients with syncope. *Acad Emerg Med.* 2011 Jul;18(7):714-8.
- 6. Shearer P, Riviello J. Generalized convulsive status epilepticus in adults and children: treatment guidelines and protocols. *Emerg Med Clin North Am.* 2011 Feb;29(1):51-64.
- 7. Jauch EC, Cucchiara B, Adeoye O, Meurer W, Brice J, Chan Y-F, Gentile N, Hazinski MF. Part 11: adult stroke: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. *Circulation*. 2010;122(suppl 3):S818–S828.
- 8. Meehan TJ, Bryant SM, Aks SE. Drugs of abuse: the highs and lows of altered mental states in the emergency department. *Emerg Med Clin North Am.* 2010 Aug;28(3):663-82.
- 9. Barton ED, Colwell CB, Wolfe T, Fosnocht D, Gravitz C, Bryan T, Dunn W, Benson J, Bailey J. Efficacy of intranasal naloxone as a needleless alternative for treatment of opioid overdose in the prehospital setting. *J Emerg Med.* 2005 Oct;29(3):265-71.
- 10. Vilke GM, Castillo EM, Ray LU, Murrin PA, Chan TC. Evaluation of pediatric glucose monitoring and hypoglycemic therapy in the field. *Pediatr Emerg Care*. 2005 Jan;21(1):1-5.
- 11. Brieger D, Eagle KA, Goodman SG, Steg PG, Budaj A, White K, Montalescot G; GRACE Investigators. Acute coronary syndromes without chest pain, an underdiagnosed and undertreated high-risk group: insights from the Global Registry of Acute Coronary Events. *Chest.* 2004 Aug;126(2):461-9.
- 12. Seger DL. Flumazenil--treatment or toxin. J Toxicol Clin Toxicol. 2004;42(2):209-16.
- 13. Bledsoe BE. No more coma cocktails. Using science to dispel myths & improve patient care. *JEMS*. 2002 Nov;27(11):54-60.
- 14. Hoffman RS, Goldfrank LR. The poisoned patient with altered consciousness. Controversies in the use of a 'coma cocktail'. *JAMA*. 1995 Aug 16;274(7):562-9.
- 15. Hoffman JR, Schriger DL, Luo JS. The empiric use of naloxone in patients with altered mental status: a reappraisal. *Ann Emerg Med.* 1991 Mar;20(3):246-52.





**EMERGENCY MEDICAL DISPATCHER** 

**EMERGENCY MEDICAL** RESPONDER

**EMT** 

**EMT-INTERMEDIATE 85** 

ADVANCED EMT

**PARAMEDIC** 

Approved 9/04/24, Effective 1/15/25, replaces all prior versions

#### **6F - DYSTONIC REACTIONS ADULT & PEDIATRIC** TREATMENT PRIORITIES 1. Vital signs **EMD** 3. Dextrose for hypoglycemia 4. Benzodiazepine for

Evaluate differential diagnosis of AMS & treat per protocol(s):

sustained, active seizure

(refer to 6D Seizure if

- Hypoxemia (Shock)
- Head Injury
- Stroke

applicable)

- Seizure
- Infection (Sepsis/ Meningitis)
- Medication/Alcohol
- Heat or Cold Illness

#### **EMR EMT**

KEEP PATIENT FREE FROM INJURY HAZARDS

AVOID PLACING ANYTHING IN MOUTH

GENERAL SUPPORTIVE CARE OBTAIN VITAL SIGNS O2 VIA NC, NRB, AS APPROPRIATE

DETERMINE BLOOD GLUCOSE

ADULT & PEDIATRIC WEIGHT ≥25 kg HYPOGLYCEMIA CARE: IF GLUCOSE <50 mg/dL, 1 tube ORAL GLUCOSE (15 grams) PO PEDIATRIC WEIGHT <25 kg HYPOGLYCEMIA CARE: IF GLUCOSE <50 mg/dL, ½ tube ORAL GLUCOSE (7.5 grams) PO

**EMT OR HIGHER LICENSE:** 

MEASURE END-TIDAL CO<sub>2</sub> & MONITOR CAPNOGRAPH (if equipped)

**EMT-185 AEMT** 

#### IV ACCESS

ADULT: IV NS TKO IF SYS BP ≥ 100 mmHg WITHOUT HYPOTENSIVE SYMPTOMS ADULT: IV NS 250 mL BOLUS IF SYS BP <100 mmHg WITH HYPOTENSIVE SYMPTOMS & NO SIGNS OF PULMONARY EDEMA, ADULT: REPEAT UP TO 2 LITERS NS IF SYS BP REMAINS < 100 mmHg WITH HYPOTENSIVE SYMPTOMS & NO SIGNS OF PULMONARY EDEMA PEDIATRIC: IV NS TKO IF SYS BP ≥ (70 + 2x age in years) mmHg

PEDIATRIC: IV NS 20 mL/kg BOLUS IF SYS BP < (70 + 2x age in years) mmHg IF NO SIGNS OF PULMONARY EDEMA

HYPOGLYCEMIA (GLUCOSE <50 mg/dL) - ADULT & PEDIATRIC

D10 5 mL/kg IVPB WIDE OPEN UP TO 250 mL OR

D25 2 mL/kg IV/IO UP TO 100 mL (must be ≥ 1 year of age) OR D50 1 mL/kg IV/IO UP TO 50 mL (must be ≥ 25 kg) IF NO VASCULAR ACCÈSS OBTAINED & IF IO SEEMS EXCESSIVE TO CLINICAL STATUS: GLUCAGON: IF PT WT ≥25 kg, 1mg IM; <25 kg, 0.5 mg IM

ADULT & PEDIATRIC: REPEAT DETERMINATION OF BLOOD GLUCOSE POST-HYPOGLYCEMIA TREATMENT

#### **PARAMEDIC**

ADULT: DIPHENHYDRAMINE 50 mg IM/IVP PEDIATRIC: DIPHENHYDRAMINE 1 mg/kg IM/IVP TO MAX OF 50 mg

IF NO IMPROVEMENT 15 MINUTES AFTER DIPHENHYDRAMINE ADMINISTRATION & MARKED MUSCLE SPASM/TONE:

ADULT: MIDAZOLAM 2.5 mg IVP/IM/IN OR ADULT: DIAZEPAM 5 mg IVP OR ADULT: LORAZEPAM 2 mg IVP/IM.

PEDIATRIC: MIDAZOLAM 0.1 mg/kg IM/IVP/IN TO MAX OF 2,5 mg OR PEDIATRIC: DIAZEPAM 0.1 mg/kg TO MAX OF 5 mg IVP/IM OR PEDIATRIC: LORAZEPAM 0.1 mg/kg TO MAX OF 2 mg IVP/IM

CONTINUOUS ASSESSMENT & TREATMENT OF SUSPECTED ETIOLOGY PER APPLICABLE PROTOCOL(S) CONSULT OLMC IF ABOVE TREATMENT INEFFECTIVE





#### Medical Literature References 6F – Dystonic Reactions – Adult & Pediatric

- 1. Derinoz O, Caglar AA. Drug-induced movement disorders in children at pediatric emergency department: 'dystonia'. *Emerg Med J.* 2013 Feb;30(2):130-3.
- 2. Jacobsen RC. Out-of-hospital lingual dystonia resulting in airway obstruction. *Prehosp Emerg Care*. 2011 Oct-Dec;15(4):537-40.
- 3. Clark GT, Ram S. Four oral motor disorders: bruxism, dystonia, dyskinesia and drug-induced dystonic extrapyramidal reactions. *Dent Clin North Am.* 2007 Jan;51(1):225-43, viii-ix.
- 4. Rodnitzky RL. Drug-induced movement disorders in children and adolescents. *Expert Opin Drug Saf.* 2005 Jan;4(1):91-102.
- 5. Barach E, Dubin LM, Tomlanovich MC, Kottamasu S. Dystonia presenting as upper airway obstruction. *J Emerg Med*. 1989 May-Jun;7(3):237-40.





Approved 9/04/24, Effective 1/15/25, replaces all prior versions

#### TREATMENT PRIORITIES

- . Assess scene safety
- 2. Safety of self
- 3. Safety of public safety professionals
- 4. Safety of patient
- 5. Observe for uncontrolled agitation, combativeness, AMS impeding necessary medical care or pulling at necessary medical interventions (IV lines, endotracheal tubes)
- Employ alternative methods to avoid physically restraining the patient
- Restrain patient if alternatives fail and/or it is necessary to maintain necessary medical intervention or to carry out treatment protocols
- Treat Hyperactive Delirium with severe agitation

#### 7A - BEHAVIORAL DISORDERS **ADULT & PEDIATRIC**

#### **EMD**

KEEP VIOLENT OR SUICIDAL PATIENT ON THE LINE. IN VOLATILE/CRIMINAL SITUATIONS, FOLLOW APPLICABLE LAW ENFORCEMENT PROTOCOL

FOR JUMPERS, NOTIFY LAW AND FIRE/RESCUE RESOURCES.

## EMERGENCY MEDICAL DISPATCHER **EMT EMT-INTERMEDIATE 85** ADVANCED EMT **PARAMEDIC**

**EMT** 

GENERAL SUPPORTIVE CARE - DO NOT LEAVE PATIENT ALONE OBTAIN VITAL SIGNS O2 VIA NC or NRB AS APPROPRIATE APPLY CARDIAC MONITOR (if equipped)

IF RESTRAINTS ARE REQUIRED USE SOFT RESTRAINTS and / or KERLIX RESTRAIN PATIENT TO LONG SPINE BOARD OR ORTHOPEDIC SCOOP

> DO NOT TRANSPORT PATIENTS "SANDWICHED" BETWEEN TWO BACKBOARDS

DURING TRANSPORT OF PATIENTS IN POLICE INSTITUTED LOCKING RESTRAINTS, A POLICE OFFICER SHOULD EITHER ACCOMPANY THE PATIENT OR PROVIDE EMS PERSONNEL MEANS TO UNLOCK THE RESTRAINTS

DETERMINE BLOOD GLUCOSE

ADULT & PEDIATRIC WEIGHT ≥25 kg HYPOGLYCEMIA CARE: IF GLUCOSE <50 mg/dL, 1 tube ORAL GLUCOSE (15 grams) PO PEDIATRIC WEIGHT <25 kg HYPOGLYCEMIA CARE: IF GLUCOSE <50 mg/dL, ½ tube ORAL GLUCOSE (7.5 grams) PO

#### **EMT OR HIGHER LICENSE:**

MEASURE END – TIDAL CO<sub>2</sub> & MONITOR WAVEFORM CAPNOGRAPHY (if equipped, \*\*Mandatory use if pt intubated)

**EMT - 185 AEMT** 

#### IV ACCESS

ADULT: IV NS TKO IF SYS BP ≥ 100 mmHg WITHOUT HYPOTENSIVE SYMPTOMS

ADULT: IV NS 250 mL BOLUS IF SYS BP <100 mmHg WITH HYPOTENSIVE SYMPTOMS & NO SIGNS OF PULMONARY EDEMA, ADULT: REPEAT UP TO 2 LITERS IF SYS BP REMAINS < 100 mmHg WITH HYPOTENSIVE SYMPTOMS & NO SIGNS OF PULMONARY EDEMA PEDIATRIC: IV NS TKO IF SYS BP ≥ (70 + 2x age in years) mmHg

PEDIATRIC: IV NS 20 mL/kg BOLUS IF SYS BP < (70 + 2x age in years) mmHg IF NO SIGNS OF PULMONARY EDEMA

HYPOGLYCEMIA (GLUCOSE <50 mg/dL) - ADULT & PEDIATRIC D10 5 mL/kg IVPB WIDE OPEN UP TO 250 mL OR

D25 2 mL/kg IV/IO UP TO 100 mL (must be ≥ 1 year of age) OR D50 1 mL/kg IV/IO UP TO 50 mL (must be ≥ 25 kg) IF NO VASCULAR ACCÈSS OBTAINÉD & IF IO SEEMS EXCESSIVE TO CLINICAL STATUS: GLUCAGON: IF PT WT ≥25 kg, 1mg IM; <25 kg, 0.5 mg IM

ADULT & PEDIATRIC: REPEAT DETERMINATION OF BLOOD GLUCOSE POST-HYPOGLYCEMIA TREATMENT

**PARAMEDIC** 

CHEMICAL RESTRAINT: SEE PROTOCOL 7C

CONSULT OLMCP IF UNCERTAIN OF ETIOLOGY AND TREATMENT PLAN FOR PSYCHIATRIC PROBLEM OR IF ADDITIONAL RESTRAINT MEASURES NEEDED

CONTINUOUS ASSESSMENT & TREATMENT PER APPLICABLE PROTOCOL(S)





## Medical Literature References 7A – Behavior Disorder – Adult & Pediatric


- 1. Kupas, D. F., Wydro, G. C., Tan, D. K., Kamin, R., Harrell, A. J., & Wang, A. (2021). Clinical Care and Restraint of Agitated or Combative Patients by Emergency Medical Services Practitioners. *Prehospital Emergency Care*, *25*(5), 721–723. https://doi.org/10.1080/10903127.2021.1917736
- Gonin, P., Beysard, N., Yersin, B., & Carron, P. (2017). CME Information: Excited Delirium: A Systematic Review. Continuing Medical Education in Academic Emergency Medicine. https://doi.org/10.1111/acem.13330
- 3. Swickhamer C, Colvig C, Chan SB. Restraint use in the elderly emergency department patient. *J Emerg Med.* 2013 Apr;44(4):869-74.
- 4. Vilke GM, Bozeman WP, Dawes DM, Demers G, Wilson MP. Excited delirium syndrome (ExDS): treatment options and considerations. *J Forensic Leg Med*. 2012 Apr;19(3):117-21.
- Weiss S, Peterson K, Cheney P, Froman P, Ernst A, Campbell M. The Use of Chemical Restraints Reduces Agitation in Patients Transported by Emergency Medical Service. *J Emerg Med.* 2012 Nov;43(5):820-8
- Vilke GM, Debard ML, Chan TC, Ho JD, Dawes DM, Hall C, Curtis MD, Costello MW, Mash DC, Coffman SR, McMullen MJ, Metzger JC, Roberts JR, Sztajnkrcer MD, Henderson SO, Adler J, Czarnecki F, Heck J, Bozeman WP. Excited Delirium Syndrome (ExDS): Defining Based on a Review of the Literature. *J Emerg Med.* 2012 Nov;43(5):897-905.
- 7. Ho JD, Dawes DM, Nelson RS, Lundin EJ, Ryan FJ, Overton KG, Zeiders AJ, Miner JR. Acidosis and catecholamine evaluation following simulated law enforcement "use of force" encounters. *Acad Emerg Med.* 2010 Jul;17(7):e60-8.
- 8. Otahbachi M, Cevik C, Bagdure S, Nugent K. Excited delirium, restraints, and unexpected death: a review of pathogenesis. *Am J Forensic Med Pathol.* 2010 Jun;31(2):107-12.
- 9. Strote J, Verzemnieks E, Walsh M, Hutson HR. Use of force by law enforcement: an evaluation of safetyand injury. *J Trauma*. 2010 Nov;69(5):1288-93.
- 10. Rossi J, Swan MC, Isaacs ED. The violent or agitated patient. *Emerg Med Clin North Am.* 2010 Feb;28(1):235-56, x.
- 11. Coburn VA, Mycyk MB. Physical and chemical restraints. *Emerg Med Clin North Am.* 2009 Nov;27(4):655-67, ix.
- 12. Cheney PR, Gossett L, Fullerton-Gleason L, Weiss SJ, Ernst AA, Sklar D. Relationship of restraint use, patient injury, and assaults on EMS personnel. *Prehosp Emerg Care*. 2006 Apr-Jun;10(2):207-12
- 13. Brice JH, Pirrallo RG, Racht E, Zachariah BS, Krohmer J. Management of the violent patient. *Prehosp Emerg Care*. 2003 Jan-Mar;7(1):48-55.





Approved 9/04/24, Effective 1/15/25, replaces all prior versions

## 7B – PHYSICAL RESTRAINT ADULT & PEDIATRIC



#### Indications:

- 1. Reducing likelihood of patient doing harm to self.
- 2. Reducing likelihood of patient doing harm to others (including EMS professionals).
- 3. Reducing likelihood of patient disrupting medically necessary interventions.
- 4. Patient requires/required chemical restraint per Protocol 7C.

Alternatives to physical restraint as outlined below are to be utilized so as to minimize the use of physical restraints. However, if alternatives to physical restraints are unsuccessful, then physical restraints will be applied in an effective and compassionate manner. Throughout the use of alternatives to physical restraint and physical restraint, the patient and the patient's concerned parties (family, friends, co-workers, etc.) shall be treated with respect and informed of the need for these procedures. This protocol is not intended to place EMS professionals at higher risk for injury. If personal safety is compromised or threatened during the course of patient care, appropriate law enforcement personnel should be summoned for assistance. If at any time questions arise as to appropriateness of using alternatives to physical restraint or physical restraint, OLMC should be consulted for direction.

#### Contraindications:

- 1. Patient (or patient's legal guardian or medical power of attorney) possesses medical decision making capacity and is refusing evaluation, treatment, and/or transport (in the absence of threatened or actual harm to self or others).
- 2. Patient is compliant with medically necessary interventions.
- 3. Reducing likelihood of patient doing harm to self and/or others and reducing likelihood of patient disrupting medically necessary interventions can be successfully accomplished with alternatives to physical restraint in the best judgment of the EMS professional(s) treating the patient.





Approved 9/04/24, Effective 1/15/25, replaces all prior versions

PROTOCOL 7B: Physical Restraint – Adult & Pediatric, cont.

#### Technique:

The following steps shall be taken and documented in determining the need for physical restraints:

- 1. **Assessment of mental status** Observe for uncontrolled agitation, combativeness, threats of violence to self or others, disorientation, altered mental status impeding medically necessary interventions, or pulling at necessary medical interventions (eg. oxygen, IV lines, endotracheal tubes).
- 2. **Alternatives to physical restraint** Reassurance, support of concerned parties (family, friends, coworkers, etc.), reorientation, diversionary activity, explanation of illness, injury, and medically necessary interventions.
- Justification for physical restraint- Failure of alternatives to physical restraint, reduce likelihood of
  patient harm to self, reduce likelihood of patient harm to others, enable medically necessary
  interventions per EMS protocols.
- 4. Inform patient and concerned parties of physical restraint use.
- 5. Apply physical restraints.

Restraints are to be soft and are not to impede airway patency, respiratory mechanics, or circulation. Patients will not be restrained prone unless an impaled object or airway patency necessitates such positioning. Restraints will be applied in an effective, yet compassionate manner. Every effort should be made to avoid injury to the patient during application of physical restraints.

Humane restraints that reduce potential for patient injury from the restraints are those made from roll gauze, soft leather, and those designed as single-patient use, disposable foam with cloth ties. Restraints are to be non-locking unless applied by law enforcement officers in appropriate circumstances and able to be released rapidly if patient condition mandates.

During treatment and transport of a patient in law enforcement-instituted restraints (including handcuffs), EMS professionals should monitor for and advocate for change in restraints that compromise airway patency, respiratory mechanics, or circulation. Patients will not be transported with wrists cuffed to ankles either directly or indirectly (also referred to as "hog-tying"). These positions have been shown to impair respiratory mechanics and pose significant obstacles to definitive airway management if required enroute. During transport of patients in law enforcement-instituted locking restraints, a law enforcement officer should either accompany the patient in the ambulance or provide the treating EMS professionals means to unlock the restraints. This policy allows rapid restraint release should the patient deteriorate to a condition requiring restraint release to properly treat.

Patients restrained using this protocol should generally be restrained to a backboard. This facilitates patient transfer in the emergency department and in the case of airway secretions or vomiting, enables rapid positioning of the patient to reduce aspiration. Patients will not be transported "sandwiched" between two backboards; this positioning impedes patient care and increases risk of aspiration.





Approved 9/04/24, Effective 1/15/25, replaces all prior versions

PROTOCOL 7B: Physical Restraint – Adult & Pediatric, cont.

Once physical restraints are applied, they will be left in place until the patient is transferred to emergency department personnel. This policy prevents recurrent harm to self, harm to others, and disruption of intact medical devices and treatment. Despite assurance from the patient that they will comply with treatment, restraints are to be left in place unless a direct order from OLMC is given to release the physical restraints. Such an order must be clearly documented on the patient care form.





## Medical Literature References 7B – Physical Restraints – Adult & Pediatric

- 1. Swickhamer C, Colvig C, Chan SB. Restraint use in the elderly emergency department patient. *J Emerg Med.* 2013 Apr;44(4):869-74.
- Vilke GM, Debard ML, Chan TC, Ho JD, Dawes DM, Hall C, Curtis MD, Costello MW, Mash DC, Coffman SR, McMullen MJ, Metzger JC, Roberts JR, Sztajnkrcer MD, Henderson SO, Adler J, Czarnecki F, Heck J, Bozeman WP. Excited Delirium Syndrome (ExDS): Defining Based on a Review of the Literature. J Emerg Med. 2012 Nov;43(5):897-905.
- 3. Vilke GM, Bozeman WP, Dawes DM, Demers G, Wilson MP. Excited delirium syndrome (ExDS): treatment options and considerations. *J Forensic Leg Med*. 2012 Apr;19(3):117-21.
- 4. Otahbachi M, Cevik C, Bagdure S, Nugent K. Excited delirium, restraints, and unexpected death: a review of pathogenesis. *Am J Forensic Med Pathol.* 2010 Jun;31(2):107-12.
- 5. Rossi J, Swan MC, Isaacs ED. The violent or agitated patient. *Emerg Med Clin North Am.* 2010 Feb;28(1):235-56, x.
- 6. Coburn VA, Mycyk MB. Physical and chemical restraints. *Emerg Med Clin North Am.* 2009 Nov;27(4):655-67, ix.
- Cheney PR, Gossett L, Fullerton-Gleason L, Weiss SJ, Ernst AA, Sklar D. Relationship of restraint use, patient injury, and assaults on EMS personnel. *Prehosp Emerg Care*. 2006 Apr-Jun;10(2):207-12.
- 8. Brice JH, Pirrallo RG, Racht E, Zachariah BS, Krohmer J. Management of the violent patient. *Prehosp Emerg Care*. 2003 Jan-Mar;7(1):48-55.
- 9. Guerrero, P., & Mycyk, M. B. (2020). Physical and Chemical Restraints (an Update). Emergency Medicine Clinics of North America, 38(2), 437–451.





Approved 9/04/24, Effective 1/15/25, replaces all prior versions

#### TREATMENT PRIORITIES

- 1. Asses scene safety
- 2. Safety of self
- Safety of public safety professionals
- 4. Safety of patient
- 5. Treat Hyperactive Delirium with severe agitation

## 7C – CHEMICAL RESTRAINT ADULT & PEDIATRIC



EMR EMT

ASSIST IN PHYSICAL CONTROL OF PATIENT FOR PARAMEDIC TO ADMINISTER CHEMICAL RESTRAINT

USE ADEQUATE NUMBERS OF PUBLIC SAFETY PROFESSIONALS TO MINIMIZE RISK OF INJURY TO SELF AND OTHERS

**EMT OR HIGHER LICENSE:** 

MEASURE END-TIDAL CO<sub>2</sub> & MONITOR WAVEFORM CAPNOGRAPHY (if equipped, \*\*Mandatory use if pt intubated))

EMT-185 AEMT

IV ACCESS IF PT TEMPORARILY COOPERATIVE DO NOT RISK SELF INJURY WITH NEEDLESTICK IN IV ACCESS IF PT COMBATIVE

#### **PARAMEDIC**

#### CHEMICAL RESTRAINT:

ALL PATIENTS REQUIRING CHEMICAL RESTRAINT ARE TO BE PHYSICALLY RESSTRAINED AS WELL

ADULT: MIDAZOLAM 0.1 mg/kg IM/IVP/IN/IOP TO MAX OF 5 mg. MAY REPEAT ONCE.  $\mathbf{OR}$ 

**ADULT:** DIAZEPAM 5 mg IVP/IOP or 10 mg IM IF MIDAZOLAM NOT AVAILABLE. MAY REPEAT ONCE.  $\mathbf{OR}$ 

ADULT: LORAZEPAM 2 mg IVP/IOP/IM IF MIDAZOLAM NOT AVAILABLE. MAY REPEAT ONCE.

(MIDAZOLAM STRONGLY PREFERRED DUE TO MOST RAPID ONSET OF ACTION OF BENZODIAZEPINE OPTIONS)
PLUS.

ADULT: HALOPERIDOL 5 mg IM

PEDIATRIC: MIDAZOLAM 0.1 mg/kg IM/IVP/IN/IOP TO MAX OF 5 mg.

OR
PEDIATRIC: DIAZEPAM 0.1 mg/kg TO MAX OF 5 mg IVP/IOP/IM FOR ACTIVE SEIZURE IF MIDAZOLAM NOT AVAILABLE.
OR

PEDIATRIC: LORAZEPAM 0.1 mg/kg TO MAX OF 2 mg IVP/IOP/IM FOR ACTIVE SEIZURE IF MIDAZOLAM NOT AVAILABLE.

CONSULT OLMCP IF UNCERTAIN OF ETIOLOGY AND TREATMENT PLAN FOR PSYCHIATRIC PROBLEM OR IF ADDITIONAL CHEMICAL RESTRAINT MEASURES NEEDED

CONTINUOUS ASSESSMENT & TREATMENT PER APPLICABLE PROTOCOL(S)





## Medical Literature References 7C – Chemical Restraint – Adult & Pediatric


- 1. Swickhamer C, Colvig C, Chan SB. Restraint use in the elderly emergency department patient. *J Emerg Med.* 2013 Apr;44(4):869-74.
- 2. Weiss S, Peterson K, Cheney P, Froman P, Ernst A, Campbell M. The Use of Chemical Restraints Reduces Agitation in Patients Transported by Emergency Medical Service. *J Emerg Med.* 2012 Nov;43(5):820-8.
- 3. Wilson MP, Macdonald K, Vilke GM, Feifel D. A Comparison of the Safety of Olanzapine and Haloperidol in Combination with Benzodiazepines in Emergency Department Patients with Acute Agitation. *J Emerg Med.* 2012 Nov;43(5):790-7
- Vilke GM, Debard ML, Chan TC, Ho JD, Dawes DM, Hall C, Curtis MD, Costello MW, Mash DC, Coffman SR, McMullen MJ, Metzger JC, Roberts JR, Sztajnkrcer MD, Henderson SO, Adler J, Czarnecki F, Heck J, Bozeman WP. Excited Delirium Syndrome (ExDS): Defining Based on a Review of the Literature. *J Emerg Med.* 2012 Nov;43(5):897-905.
- 5. Vilke GM, Bozeman WP, Dawes DM, Demers G, Wilson MP. Excited delirium syndrome (ExDS): treatment options and considerations. *J Forensic Leg Med*. 2012 Apr;19(3):117-21.
- 6. Strote J, Verzemnieks E, Walsh M, Hutson HR. Use of force by law enforcement: an evaluation of safety and injury. *J Trauma*. 2010 Nov;69(5):1288-93.
- 7. Ho JD, Dawes DM, Nelson RS, Lundin EJ, Ryan FJ, Overton KG, Zeiders AJ, Miner JR. Acidosis and catecholamine evaluation following simulated law enforcement "use of force" encounters. *Acad Emerg Med.* 2010 Jul;17(7):e60-8.
- 8. Otahbachi M, Cevik C, Bagdure S, Nugent K. Excited delirium, restraints, and unexpected death: a review of pathogenesis. *Am J Forensic Med Pathol.* 2010 Jun;31(2):107-12.
- 9. Rossi J, Swan MC, Isaacs ED. The violent or agitated patient. *Emerg Med Clin North Am.* 2010 Feb;28(1):235-56, x.
- 10. Coburn VA, Mycyk MB. Physical and chemical restraints. *Emerg Med Clin North Am.* 2009 Nov;27(4):655-67, ix.
- 11. Miller JL, Ashford JW, Archer SM, Rudy AC, Wermeling DP. Comparison of intranasal administration of haloperidol with intravenous and intramuscular administration: a pilot pharmacokinetic study. *Pharmacotherapy.* 2008 Jul;28(7):875-82.
- 12. Cheney PR, Gossett L, Fullerton-Gleason L, Weiss SJ, Ernst AA, Sklar D. Relationship of restraint use, patient injury, and assaults on EMS personnel. *Prehosp Emerg Care*. 2006 Apr-Jun;10(2):207-12
- 13. Brice JH, Pirrallo RG, Racht E, Zachariah BS, Krohmer J. Management of the violent patient. *Prehosp Emerg Care*. 2003 Jan-Mar;7(1):48-55.
- 14. Guerrero, P., & Mycyk, M. B. (2020). Physical and Chemical Restraints (an Update). Emergency Medicine Clinics of North America, 38(2), 437–451.





Approved 9/04/24, Effective 1/15/25, replaces all prior versions

## 7D – EMERGENCY MENTAL HOLD ISSUES ADULT & PEDIATRIC



EMS professionals should utilize this protocol and its principles and directives to promote and protect the safety of mentally ill patients, drug or alcohol dependent patients, and other involved parties who may be endangered by the patient's disturbed or altered psychological state to the extent of being subject to an immediate likelihood of serious harm.

#### **Definitions:**

- "Drug Dependent Patient" for the purpose of this protocol means: A patient who is using a controlled substance as presently defined in Section 102 of the Federal Controlled Substances Act and who is in a state of psychic or physical dependence, or both, arising from administration of that controlled substance on an intermittent or continuous basis.
- 2. "Alcohol Dependent Patient" for the purpose of this protocol means: A patient who uses alcoholic beverages to an extent that it impairs mental or physical health, family life, occupational life, and potentially compromises the health and safety of the community.
- 3. "Mentally III Patient" for the purpose of this protocol means: A patient afflicted with a substantial disorder of thought, mood, perception, psychological orientation or memory that significantly impairs judgment, behavior, capacity to recognize reality or ability to meet the ordinary demands of life. Mental illness may be reflected in a sustained altered mentation secondary to chronic medical condition or prior physical injury.
- 4. "Immediate likelihood of serious harm" posed by patients either to self or others for the purpose of this protocol means:
  - a) a substantial risk of physical harm to self, manifested by active threats of, or attempts at, suicide or intentional bodily harm; **OR**
  - b) a substantial risk of physical harm to others manifested by active threats of, or attempts at, homicide or intentional bodily harm; **OR**
  - c) actively placing others in reasonable fear of imminent violent behavior or serious physical harm; **OR**





Approved 9/04/24, Effective 1/15/25, replaces all prior versions

#### PROTOCOL 7D: Emergency Mental Hold Issues – Adult & Pediatric, cont.

d) causing a prudent EMS professional to believe with reasonable certainty that without immediate medical treatment, severe physical impairment or injury would be sustained by the patient or other involved party as a result of the patient's apparent inability to prevent suicidal activity, homicidal activity, or significant risk of harm to self or others through distorted reality (eg. driving while acutely psychotic or clinically intoxicated).

#### **Emergency Mental Hold Procedures:**

- 1. Upon dispatch to and/or subsequent assessment of a patient representing, in the EMS professional's best judgment, "immediate likelihood of serious harm", the EMS professional should notify dispatch to immediately request the appropriate law enforcement authority. It is the duty of the responding law enforcement officer(s) to determine if the affected person appears to be mentally unstable, alcohol dependent or drug dependent to a degree that immediate emergency action is necessary to prevent the patient from harming self or others. If the law enforcement officer determines that immediate emergency action is necessary, under Oklahoma law, the law enforcement officer must take the person into protective custody. The law enforcement officer(s) can base their decision upon personal observation of the actions of the patient or upon the statement of either EMS professionals or other parties deemed credible.
- 2. If EMS professionals at the scene believe the patient to be actively mentally ill, alcohol dependent, and/or drug dependent to the extent of being subject to an "immediate likelihood of serious harm" to self or others, representing a medical need to be taken into protective custody by law enforcement, the primary assessing EMS professional shall fill out the "Individual's Affidavit for Emergency Detention" and submit to the law enforcement officer(s) at the scene as may be required to effect such detention.
- 3. If EMS professionals and the law enforcement officer(s) at the scene cannot reach agreement whether the patient is actively mentally ill, alcohol dependent, and/or drug dependent to the extent of representing an "immediate likelihood of serious harm" to self or others, representing a medical need to be taken into protective custody by law enforcement, the appropriate EMS supervisor(s) and corresponding law enforcement supervisor(s) should be contacted. Supervisor presence at the scene could be required to achieve consensus of actions that promote the patient's and others' safety.
- 4. If the EMS supervisor determines the patient is actively mentally ill, alcohol dependent, and/or drug dependent to the extent of representing an "immediate likelihood of serious harm" to self or others, representing a medical need to be taken into protective custody by law enforcement and therefore is in need of immediate medical attention, this shall be conveyed to the appropriate law enforcement supervisor. If the law enforcement supervisor does not subsequently place the patient on mental hold, notify the appropriate receiving hospital's On-Line Medical Control Physician (or the System EMS Chief Medical Officer) for formal physician consultation, complete an agency-specified Incident Report, and submit it to the Chief Medical Officer for review.





Approved 9/04/24, Effective 1/15/25, replaces all prior versions PROTOCOL 7D: Emergency Mental Hold Issues – Adult & Pediatric, cont.

5. If it appears that the affected person is mentally ill or suffers chronic altered mentation and does not require emergency medical attention, EMS personnel will stay on scene only until it can be reasonably determined that the person does not suffer from an apparent serious physical condition, illness, or injury requiring emergency medical attention and/or until the law enforcement officers at the scene indicate that they no longer require assistance from EMS.

#### Emergency Detention (previously referred to as Emergency Order of Detention or EOD) Issues:

- 1. An affidavit that is completed by anyone (including an EMS professional) who is concerned about the patient's safety or who witnessed concerned behavior that could impact the safety of others, that details the observations and impressions that serve as the basis for involuntary detention of the patient in the safety interests of the patient and others has been commonly referred to as an "EOD" or "Emergency Order of Detention". This is no longer used as a legal term. The correct terminology is a "third party statement" and the statement form as displayed in state documents can be found immediately following this protocol.
- 2. The "third party statement" must have sufficiently detailed information to justify placing the patient, at least temporarily, into law enforcement custody. (eg. "suicidal" is not enough). A law enforcement officer can refuse to take a patient into custody if he or she determines there is insufficient written evidence contained within the "third party statement".
- 3. The "third party statement" is the legally recognized documentation that compels a patient to be placed into Emergency Detention (ED) in the safety interests of self and others until emergency psychiatric assessment (and stabilization when applicable) can be conducted. Medical facilities in Oklahoma that can conduct emergency psychiatric assessment and stabilization are referred to as "Emergency Detention (formerly EOD) designated facilities".
- 4. A patient that is under Emergency Detention by use of a "third party statement" cannot refuse transport to receive an appropriate physician evaluation. EMS professionals treating and transporting patients under Emergency Detention should not let the patient flee from EMS care and supervision, unless the patient poses an immediate, serious physical threat to the EMS professional(s). Utilize law enforcement officers, physical restraint, and if licensed as a paramedic, chemical restraint, as warranted to prevent patients under Emergency Detention from fleeing.
- 5. Once an appropriate physician, typically a psychiatrist, has evaluated the patient under Emergency Detention through use of a "third party statement", he or she may validate continued involuntary detention of the patient or may release the patient from further involuntary medical detention.
- 6. EMS professionals should work with their system Chief Medical Officer, local medical professionals, and local law enforcement officers to review applicable emergency mental hold issues and resources.

# THIRD PARTY STATEMENT the undersigned being \_\_\_\_\_\_ years of age, declare: That on the day of 20 , I observed (name) County, Oklahoma, and that at \_\_\_\_\_o'clock \_\_\_\_m. Statement of observation (describe activity or incident personally observed): That upon such basis, I have a reasonable belief that this person has a mental illness or is alcohol- or drug-dependent to a degree that immediate emergency action is necessary. I, the undersigned attest to the above statement to be factual and true to the best of my knowledge and that I will testify to the above in court. Any false statement given to the officer by the person upon whose statement of the officer relies shall be a misdemeanor and subject to the sanctions of Title 21 of the Oklahoma State Statute. Name (please print) Signature Address

IN RE: THE PROTECTIVE CUSTODY OF:





## Medical Literature References 7D – Emergency Mental Hold Issues -Adult & Pediatric

- 1. Protocol expert consultant: Gerard Clancy, MD. President, University of Oklahoma Tulsa. Department of Psychiatry, University of Oklahoma School of Community Medicine, Tulsa. Board certified in psychiatry by the American Board of Psychiatry and Neurology.
- 2. Protocol expert consultant: Lori Whelan, MD. Department of Emergency Medicine, University of Oklahoma School of Community Medicine, Tulsa. Board certified in emergency medicine by the American Board of Emergency Medicine.
- 3. Oklahoma Department of Mental Health and Substance Abuse Services. Accessed website on 6/25/12: www.ok.gov/odmhsas accessed on 6/25/12.
- 4. Oklahoma State Law Title 43A.Mental Health. Accessed website on 6/25/12: http://www.ok.gov/odmhsas/documents/2010%20-%2043A.pdf.
- 5. Trivedi TK, Glenn M, Hern G, Schriger DL, Sporer KA. Emergency Medical Services Use Among Patients Receiving Involuntary Psychiatric Holds and the Safety of an Out-of-Hospital Screening Protocol to "Medically Clear" Psychiatric Emergencies in the Field, 2011 to 2016. *Annals of Emergency Medicine*. 2019;73(1):42-51. doi:10.1016/j.annemergmed.2018.08.422





**EMERGENCY MEDICAL** 

**DISPATCHER** 

**EMT** 

**EMT-INTERMEDIATE 85** 

**ADVANCED EMT** 

**PARAMEDIC** 

RESPONDER

Approved 9/04/24, Effective 1/15/25, replaces all prior versions

#### TREATMENT PRIORITIES

- Self/Others/Scene Safety
- Vital signs
- Oxygenation/Ventilation
   Identify & treat toxin
   BVM prior to administration of
- Poison Center/OLMC consult if needed . Manage shock, altered mental status seizures, arrhythmias; CO Poisoning per specific protocol
- 8. Transport ASAP

#### **8A - POISONINGS-GENERAL MANAGEMENT ADULT & PEDIATRIC**

#### **EMD**

ADVISE TO AVOID PHYSICAL EXERTION OR ENVIRONMENTAL STRESS (TEMP EXTREMES). DO NOT MOVE THE PATIENT UNLESS IN DANGER. OPEN AIRWAY IF NOT ALERT AND INEFFECTIVE BREATHING. DETERMINE NUMBER OF PATIENTS INVOLVED

DECIDE IF ADDITIONAL RESOURCES ARE NEEDED

**EMT** 

GENERAL SUPPORTIVE CARE; OBTAIN VITAL SIGNS O2 VIA NC, NRB, OR BVM AS APPROPRIATE

TOXINS/DRUG OVERDOSE - SUSPECTED NARCOTIC/OPIATE - APNEIC/AGONALLY BREATHING (see opiate toxidrome in Protocol 8B)

ADDRESS OXYGENATION AND VE NTILATION (SP02 GOAL ≥ 94% BEFORE ADMINISTERING NALOXONE ADULT: NALOXONE 2 mg IN, MAY REPEAT ONCE

PEDIATRIC: NALOXONE 0.5 mg IN, MAY REPEAT TO MAX OF 2 mg
TOXINS/DRUG OVERDOSE - SUSPECTED NARCOTIC/OPIATE - INEFFECTIVE BREATHING ACTIVITY (see opiate toxidrome in Protocol 8B)

ADULT & PEDIATRIC: NALOXONE 0.5 mg IN, MAY REPEAT TO MAX OF 2 mg
USE NALOXONE TO RESTORE EFFECTIVE BREATHING; AVOID EXCESSIVE DOSING TO PREVENT WITHDRAWAL

APPLY CARDIAC MONITOR/OBTAIN 12-LEAD ECG (if equipped) TRANSMIT 12-LEAD ECG TO RECEIVING EMERGENCY DEPARTMENT

EMT OR HIGHER LICENSE

MEASURE END - TIDAL CO2 & MONITOR WAVEFORM CAPNOGRAPHY (if equipped, \*\*Mandatory use if pt intubated) PLACE SUPRAGLOTTIC AIRWAY IF INDICATED ONLY IF BVM VENTILATIONS INEFFECTIVE

USE OF ACTIVATED CHARCOAL FOR ACUTE INGESTED POISONS, (i.e., Acetaminophen, ASA, TCA, Barbiturates)

ADULT/PEDIATRIC: ACTIVATED CHARCOAL 1 gram/kg PO (OLMC ORDER ONLY; USE ONLY IF TRANSPORT TIME WILL EXCEED 30 MINS)

#### **EMT-185**

IV ACCESS

ADULT: INTUBATE IF INDICATED; DO NOT INTUBATE PATIENTS WITH RAPIDLY REVERSIBLE TOXICOLOGY ETIOLOGY (eg. OPIATES) ADVANCED EMT OR HIGHER LICENSE:

TOXINS/DRUG OVERDOSE - SUSPECTED NARCOTIC/OPIATE - APNEIC/AGONALLY BREATHING (see opiate toxidrome in Protocol 8B) ADULT: NALOXONE 2 mg IVP/IOP/IN, MAY REPEAT ONCE

PEDIATRIC: NALOXONE 0.5 mg IVP/IOP/IN, MAY REPEAT TO MAX OF 2 mg

TOXINS/DRUG OVERDOSE - SUSPECTED NARCOTIC/OPIATE - INEFFECTIVE BREATHING ACTIVITY (see opiate toxidrome in Protocol 8B) ADULT & PEDIATRIC: NALOXONE 0.5 mg IVP/IOP/IN, MAY REPEAT TO MAX OF 2 mg

USE NALOXONE TO RESTORE EFFECTIVE BREATHING, AVOID EXCESSIVE DOSING TO PREVENT WITHDRAWAL

#### **PARAMEDIC**

**ADULT: MEDICATION ASSISTED INTUBATION IF INDICATED** 

TOXINS/DRUG OVERDOSE - SUSPECTED ORGANOPHOSPHATE (see cholinergic toxidrome in Protocol 8B)

ADULT: ATROPINE 2 mg IVP/IOP/IM, USE IVP FOR MORE SEVERE PRESENTATIONS. REPEAT EVERY 3-5 MINS IF SYMPTOMS PROGRESSIVE PEDIATRIC: ATROPINE 0.05 mg/kg IVP/IOP/IM, USE IVP FOR MORE SEVERE PRESENTATIONS. MINIMUM DOSE 0.1 mg. OLMC FOR REPEAT. ADULT/PEDIATRIC (> 12 years): PRALIDOXIME CHLORIDE 600 mg (1 AUTOINJECTOR) IM, MAY REPEAT TWICE FOR A TOTAL OF 1800 mg; ADMINISTER EACH DOSE 15 MINUTES APART FOR MILD SYMPTOMS OR IN RAPID SUCCESSION FOR MODERATE TO SEVERE SYMPTOMS

TOXINS/DRUG OVERDOSE - SUSPECTED TRICYCLIC ANTIDEPRESSANT (VENTRICULAR DYSRHYTHMIAS, SEIZURES) (see anticholinergic toxidrome in Protocol 8B)

ADULT/PEDIATRIC: SODIUM BICARBONATE 1 mEq/kg IVP/IOP MAX DOSE 50 mEq

TOXINS/DRUG OVERDOSE - SUSPECTED STIMULANT (SEVERE AGITATION, HTN, TACHYCARDIA, DIAPHORESIS)

(see hallucinogenic and sympathomimetic toxidromes in Protocol 8B)

ADULT: MIDAZOLAM 0.1 mg/kg IVP/IN/IM TO MAX 5 mg OR DIAZEPAM 2.5-5 mg IVP OR LORAZEPAM 1-2 mg IVP/IM PEDIATRIC: OLMCP ORDER ONLY

TOXINS/DRUG OVERDOSE - SUSPECTED CALCIUM CHANNEL BLOCKER

ADULT: CALICUM CHLORIDE 10 mg/kg IVP/IOP MAX DOSE 1 gram

TOXINS/DRUG OVERDOSE - SUSPECTED BETA-BLOCKER

ADULT: GLUCAGON 1 mg IVP/IOP PEDIATRIC: GLUCAGON 0.5 mg IVP/IOP

CONSULT OLMC IF ABOVE TREATMENT INEFFECTIVE FOR TOXINS/DRUG OVERDOSE ETIOLOGY Poison Information Center Specialists are authorized to direct medical care related to the medical toxicology and/or hazardous material exposure aspects of patient care if contacted for directives





#### Medical Literature References 8A - Poisonings–General Management - Adult & Pediatric


- Lavonas EJ, Drennan IR, Gabrielli A, Heffner AC, Hoyte CO, Orkin AM, Sawyer KN, Donnino MW. Part 10: Special Circumstances of Resuscitation: 2015 American Heart Association Guidelines Update for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. *Circulation*. 2015 Nov 3;132(18 Suppl 2):S501-18.
- 2. Shannon MW. Emergency Management of Poisoning: A General Approach to Poisoning. In: Shannon MW, Borron SW, Burns MJ, eds. Haddad and Winchester's Clinical Management of Poisoning and Drug Overdose. 4th Ed. Philadelphia, PA: Saunders Elsevier; 2007: 13-30.
- 3. Eldridge DL, Van Eyk J, Kornegay C. Pediatric toxicology. *Emerg Med Clin North Am.* 2007 May;25(2):283-308.
- 4. Mokhlesi B, Corbridge T. Toxicology in the critically ill patient. *Clin Chest Med.* 2003 Dec;24(4):689-711.
- 5. Isbister GK, Dawson AH, Whyte IM. Feasibility of prehospital treatment with activated charcoal: Who could we treat, who should we treat? *Emerg Med J.* 2003 Jul;20(4):375-8.





Approved 9/04/24, Effective 1/15/25, replaces all prior versions

### 8B - TOXIDROMES ADULT & PEDIATRIC



### Toxidromes as a Diagnostic Guide in Suspected Overdose

Toxidrome	Signs and symptoms	Vital sign	Classic agents
anticholinergic	delirium, flushed skin, dilated pupils, urinary retention, decreased bowel sounds, memory loss, seizures (mnemonic: "hot as a hare, dry as a bone, red as a beet, blind as a bat, mad as a hatter")	tachycardia hyperthermia hypertension	atropine antihistamines scopolamine tricyclic antidepressants
cholinergic	confusion, weakness, salivation, lacrimation, urination, defecation, gastrointestinal motility, emesis, disphoresis, muscle fasciculations, miosis, seizures, "Killer Bs": bradycardia, bronchorrhea, bronchospasm	bradycardia hypothermia tachypnea	organophosphates carbamates
hallucinogenic	disorientation, hallucinations, visual illusions, panic reaction, moist skin, hyperactive bowel sounds, seizures	tachycardia tachypnea hypertension	phencyclidine lysergic acid diethylamide cannabis
opiate/narcotic	altered mental status, unresponsiveness, miosis, shock, decreased respiration	bradypnea bradycardia hypothermia hypotension	dextromethorphan opiates: morphine propoxyphene
sedative/hypnotic	coma, stupor, confusion, sedation, CNS dsyfunction	apnea	ethanol barbiturates benzodiazepines anticonvulsants
sympathomimetic	delusions, paranoia, diaphoresis, piloerection, mydriasis, hyperreflexia, seizures, anxiety	tachycardia hypertension hyperthermia	cocaine amphetamines methamphetamine phenylpropanolamine ephedrine pseudoephedrine





#### Medical Literature References 8B - Toxidromes- Adult & Pediatric


- 1. Florida Poison Information Center, Jacksonville. Toxidromes. FPICjax.org. http://www.fpicjax.org/toxidromes.htm. Accessed June 17, 2012.
- 2. Goldstein S. Four steps to diagnosing drug overdose. Emergency Medicine Magazine. emedmag.com. April 2009:17-22.
- 3. Shannon MW. Emergency Management of Poisoning: A General Approach to Poisoning. In: Shannon MW, Borron SW, Burns MJ, eds. Haddad and Winchester's Clinical Management of Poisoning and Drug Overdose. 4th Ed. Philadelphia, PA: Saunders Elsevier; 2007: 13-30.
- 4. Mokhlesi B, Corbridge T. Toxicology in the critically ill patient. *Clin Chest Med.* 2003 Dec;24(4):689-711.





Approved 9/04/24, Effective 1/15/25, replaces all prior versions

#### **8C - OKLAHOMA POISON CONTROL CENTER USE**



#### **Indications**:

- A. Real-time consultation on toxic severity of exposure/inhalation/ingestion/snakebites.
- B. Real-time consultation regarding no/minimal toxicity exposures for patient follow-up contact and self-treatment advice.
- C. Real-time consultation regarding needed hospital resources for patient toxicity.
- D. Identification of pills (using imprint letters/numbers on pills).
- E. Product ingredient identification and toxic severity potential.

#### Contraindications:

None

#### Technique:

To contact the Oklahoma Poison Control Center in Oklahoma City:

# Healthcare Professional Access Number: 1-877-271-6998

When calling, identify yourself by name, EMS certification level, and agency/apparatus identification. Have as much patient information and substance/exposure/snake information possible readily available to share with the poison center specialist.

The University of Oklahoma College of Pharmacy administers all operations of the Oklahoma Poison Control Center in cooperation with The Children's Hospital at OU Medical Center.

Calls are answered 24 hours a day by pharmacists and nurses intensively trained in clinical toxicology and designated as specialists in poison information.





Approved 9/04/24, Effective 1/15/25, replaces all prior versions

## 8D - ACUTE ALLERGIC REACTIONS **ADULT & PEDIATRIC**

## **EMERGENCY MEDICAL DISPATCHER**

EMERGENCY MEDICAL **RESPONDER** 

**EMT** 

**EMT-INTERMEDIATE 85** 

ADVANCED EMT

**PARAMEDIC** 

## TREATMENT PRIORITIES

- 1. Vital signs
- 2. Epinephrine for anaphylaxis \*\* First two epi doses are standing order. Any additional epi dose requires OLMC consult.
- 3. Oxygen administration
- 4. Bronchodilator for bronchospasm

#### **EMD**

ADVISE TO USE EPINEPHRINE AUTOINJECTOR IF AVAILABLE AND PATIENT'S PHYSICIAN HAS PRESCRIBED TO USE FOR SAME SYMPTOMS

ADVISE TO AVOID PHYSICAL EXERTION OR ENVIRONMENTAL STRESS (TEMP EXTREMES). DO NOT MOVE THE PATIENT UNLESS IN DANGER OPEN AIRWAY IF NOT ALERT AND INEFFECTIVE BREATHING

**EMT** 

GENERAL SUPPORTIVE CARE **OBTAIN VITAL SIGNS** O2 VIA NC, NRB, OR BVM AS APPROPRIATE APPLY CARDIAC MONITOR (if equipped)

ASSIST PT WITH PT'S OWN ALBUTEROL INHALER/NEBULIZER (when applicable)

#### **EMT OR HIGHER LICENSE:**

#### FOR ANAPHYLAXIS ONLY

ADULT: \*\*EPINEPHRINE 1mg/mL 1:1000 0.5 mg (0.5 mL) IM OR AUTOINJECTOR ANTERIOR/LATERAL THIGH PEDIATRIC: \*\*EPINEPHRINE 1mg/mL 1:1000, 0.15 mg (0.15 mL) IM OR AUTOINJECTOR ANTERIOR/LATERAL THIGH OLMC ORDER ONLY FOR EPINEPHRINE IF PT ≥ 50 YEARS OLD, HEART ILLNESS HISTORY, OR BLOOD PRESSURE > 140/90 mmHg

MEASURE END-TIDAL CO<sub>2</sub> & MONITOR WAVEFORM CAPNOGRAPHY (if equipped, \*\*\* Mandatory use if pt intubated) **ADULT:** APPLY Bi/CPAP IF INDICATED (if equipped)

PLACE SUPRAGLOTTIC AIRWAY IF INDICATED & ONLY IF BVM VENTILATIONS INEFFECTIVE

ADULT & PEDIATRIC WEIGHT ≥15 kg: NEBULIZED ALBUTEROL 5 mg or LEVALBUTEROL 2.5 mg & IPRATROPIUM BROMIDE 0.5 mg PEDIATRIC WEIGHT <15 kg: NEBULIZED ALBUTEROL 2.5 mg or LEVALBUTEROL 1.25 mg & IPRATROPIUM BROMIDE 0.25 mg MAY REPEAT ALBUTEROL OR LEVALBUTEROL ENROUTE X 2 AS NEEDED

> **EMT-185 AEMT**

> > **ADULT: INTUBATE IF INDICATED**

IV ACCESS

ADULT: IV NS TKO IF SYS BP ≥ 100 mmHg WITHOUT HYPOTENSIVE SYMPTOMS

ADULT: IV NS 250 mL BOLUS IF SYS BP <100 mmHg WITH HYPOTENSIVE SYMPTOMS & NO SIGNS OF PULMONARY EDEMA, ADULT: REPEAT UP TO 2 LITERS NS IF SYS BP REMAINS < 100 mmHg WITH HYPOTENSIVE SYMPTOMS & NO SIGNS OF PULMONARY EDEMA

**PEDIATRIC:** IV NS TKO IF SYSBP  $\geq$  (70 + 2x age in years) mmHg

PEDIATRIC: IV NS 20 mL/kg BOLUS IF SYS BP < (70 + 2x age in years) mmHg & NO SIGNS OF PULMONARY EDEMA REPEAT UP TO 60 mL/kg IF SYS BP REMAINS < (70 + 2x age in years) mmHg & NO SIGNS OF PULMONARY EDEM

FOR ANAPHYLAXIS ONLY

ADULT: \*\*EPINEPHRINE 1 mg/mL 1:1000 0.5 mg (0.5 mL) IM ANTERIOR/LATERAL THIGH PEDIATRIC: \*\*EPINEPHRINE 1 mg/mL 1:1000, 0.01 mg/kg NOT TO EXCEED 0.3 mg IM ANTERIOR/LATERAL THIGH

OLMC ORDER ONLY FOR EPINEPHRINE IF PT ≥ 50 YEARS OLD, HEART ILLNESS HISTORY, OR BLOOD PRESSURE > 140/90 mmHg

#### PARAMEDIC

MILD REACTION (RASH, ITCH, HIVES) ANTIHISTAMINE

ADULT: DIPHENHYDRAMINE 50 mg IM/IVP

PEDIATRIC: DIPHENHYDRAMINE 1 mg/kg IM/IVP TO MAX OF 50 mg

#### MODERATE REACTION (SOB, WHEEZING) ANTIHISTAMINE + BRONCHODILATOR + STEROID

DIPHENHYDRAMINE ADMINISTRATION AS IN MILD REACTION & BRONCHODILATOR ADMINISTRATION AS IN EMT ABOVE

ADULT: METHYLPREDNISOLONE 125 mg IM/IVP or DEXAMETHASONE 10 mg IM/IVP

PEDIATRIC: METHYLPREDNISOLONE 2 mg/kg IM/IVP, MAX 125 mg or DEXAMETHASONE 0.6 mg/kg IM/IVP MAX 10 mg

SEVERE REACTION ANAPHYLAXIS SERIOUS DYSPNEA, GIDISTRESS, ANGIOEDEMA, OR SYSBP < 100 mmHg ADULT OR < (70 + 2x age in years) mmHg PEDIATRIC

VASO CONSTRICTOR + ANTIHISTAMINE + BRONCHODILATOR + STEROID

ADULT: \*\*EPINEPHRINE 1 mg/mL 1:1000 0.5 mg (0.5 mL) IM ANTERIOR/LATERAL THIGH PEDIATRIC: \*\*EPINEPHRINE 1 mg/mL 1:1000, 0.01 mg/kg NOT TO EXCEED 0.3 mg IM ANTERIOR/LATERAL THIGH

DIPHENHYDRAMINE ADMINISTRATION & BRONCHODILATOR ADMINISTRATION AS IN MILD REACTION; STEROID ADMINISTRATION AS ABOVE

IF REFRACTORY ANAPHYLAXIS, ADMINISTER INTRAVASCULAR EPINEPHRINE 1:10,000

ADULT: \*\*EPINEPHRINE 0.1 mg/mL 1:10,000 1 mg SLOW IV/IOP (OVER 3 MINUTES)

PEDIATRIC: \*\*EPINEPHRINE 0.1mg/mL 1:10,000, 0.01 mg/kg SLOW IV/IOP (OVER 3 MINUTES) NOT TO EXCEED 0.5 mg

ADULT: MEDICATION ASSISTED INTUBATION IF INDICATED

CONTINUOUS ASSESSMENT & TREATMENT PER APPLICABLE PROTOCOL(S)

## **EMR**

8D.1





#### Medical Literature References 8D – Allergic Reactions - Adult & Pediatric

- Latimer, A. J., Husain, S., Nolan, J., Doreswamy, V., Rea, T. D., Sayre, M. R., & Eisenberg, M. S. (2018). Syringe Administration of Epinephrine by Emergency Medical Technicians for Anaphylaxis. Prehospital Emergency Care, 22(3), 319–325. https://doi.org/10.1080/10903127.2017.1392667
- Lavonas EJ, Drennan IR, Gabrielli A, Heffner AC, Hoyte CO, Orkin AM, Sawyer KN, Donnino MW. Part 10: Special Circumstances of Resuscitation: 2015 American Heart Association Guidelines Update for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. *Circulation*. 2015 Nov 3;132(18 Suppl 2):S501-18.
- 3. Singer E, Zodda D. Allergy and anaphylaxis: principles of acute emergency management. *Emerg Med Pract*. 2015 Aug;17(8):1-19.
- 4. Nowak R, Farrar JR, Brenner BE, Lewis L, Silverman RA, Emerman C, Hay DP, Russell WS, Schmitz N, Miller J, Singer E, Camargo CA Jr, Wood J. Customizing anaphylaxis guidelines for emergency medicine. *J Emerg Med.* 2013 Aug;45(2):299-306.
- Jacobsen RC, Toy S, Bonham AJ, Salomone JA, Ruthstrom J, Gratton M. Anaphylaxis Knowledge among Paramedics: Results of a National Survey. *Prehosp Emerg Care*. 2012 Oct-Dec;16(4):527-34.
- 6. Simons FE, Ardusso LR, Bilo MB, Dimov V, Ebisawa M, El-Gamal YM, Ledford DK, Lockey RF, Ring J, Sanchez-Borges M, Senna GE, Sheikh A, Thong BY, Worm M. 2012 Update: World Allergy Organization guidelines for the assessment and management of anaphylaxis. *Curr Opin Allergy Clin Immunol.* 2012 Aug;12(4):389-99.
- 7. Jacobsen RC, Millin MG. The use of epinephrine for out-of-hospital treatment of anaphylaxis: resource document for the National Association of EMS Physicians position statement. *Prehosp Emerg Care*. 2011 Oct-Dec;15(4):570-6.
- 8. National Association of EMS Physicians. The use of epinephrine for out-of-hospital treatment of anaphylaxis. *Prehosp Emerg Care*. 2011 Oct-Dec;15(4):544.
- 9. Simons FE, Ardusso LR, Bilò MB, El-Gamal YM, Ledford DK, Ring J, Sanchez-Borges M, Senna GE, Sheikh A, Thong BY; World Allergy Organization. World Allergy Organization anaphylaxis guidelines: summary. *J Allergy Clin Immunol*. 2011 Mar;127(3):587-93.e1-22.
- 10. Walker DM. Update on epinephrine (adrenaline) for pediatric emergencies. *Curr Opin Pediatr*. 2009 Jun;21(3):313-9.
- 11. Simons FE, Lieberman PL, Read EJ Jr, Edwards ES. Simons FE, Lieberman PL, Read EJ Jr, Edwards ES. Hazards of unintentional injection of epinephrine from autoinjectors: a systematic review. *Ann Allergy Asthma Immunol.* 2009 Apr;102(4):282-7.
- Myers JB, Slovis CM, Eckstein M, Goodloe JM, Isaacs SM, Loflin JR, Mechem CC, Richmond NJ, Pepe PE; U.S. Metropolitan Municipalities' EMS Medical Directors. Evidence-based performance measures for emergency medical services systems: a model for expanded EMS benchmarking. <u>Prehosp Emerg Care.</u> 2008 Apr-Jun;12(2):141-51.
- 13. <u>Bryson D, Camargo CA Domeier RM, Gaeta TJ, Hendeles L, Hise S, Nowak RM, Russotti R, Sapien R, Wallace D, Wright JL, Boss L, Greiling A, Redd S, Workgroup on EMS Management of Asthma Exacerbations. A model protocol for emergency medical services management of asthma exacerbations. *Prehosp Emerg Care*. 2006 Oct-Dec;10(4):418-429.</u>
- 14. Richmond NJ, Silverman R, Kusick M, Matallana L, Winokur J. Out-of-hospital administration of albuterol for asthma by basic life support providers. *Acad Emerg Med.* 2005 May;12(5):396-403.
- 15. Thompson M, Wise S, and Rodenberg H. A preliminary comparison of levalbuterol and albuterol in prehospital care. *J Emerg Med*. 2004; 26(3):271-277
- 16. Markenson D, Foltin G, Tunik M, Cooper A, Treiber M, Caravaglia K. Albuterol sulfate administration by EMT-basics: results of a demonstration project. *Prehosp Emerg Care*. 2004 Jan-Mar;8(1):34-40.
- 17. Delbridge T, Domeier R, Key CB. Prehospital asthma management. *Prehosp Emerg Care*. 2003 Jan-Mar;7(1):42-7.
- 18. Meduri GU, Cook TR, Turner RE, Cohen M, Leeper KV. Noninvasive positive pressure ventilation in status asthmaticus. *Chest*, 1996 Sep:110(3):767-74.





Medical Literature References 8D – Allergic Reactions - Adult & Pediatric

- 19. Jacobsen, R. C., & Millin, M. G. (2011). The use of epinephrine for out-of-hospital treatment of anaphylaxis: Resource document for the national association of ems physicians position statement. *Prehospital Emergency Care*.
- 20. Lyng, J. W., White, C. C., Peterson, T. Q., Lako-Adamson, H., Goodloe, J. M., Dailey, M. W., ... Brown, L. H. (2019). Non-Auto-Injector Epinephrine Administration by Basic Life Support Providers: A Literature Review and Consensus Process. Prehospital Emergency Care, 23(6), 855–861.





Approved 9/04/24, Effective 1/15/25, replaces all prior versions

## **8E - SNAKEBITES - PIT VIPERS** (RATTLESNAKES, COPPERHEADS, & MOCASSINS) (CROTALINAE ENVENOMATION) ADULT & PEDIATRIC

**EMT-INTERMEDIATE 85** 

**EMT** 

**EMERGENCY MEDICAL** 

**DISPATCHER** 

RESPONDER

ADVANCED EMT

**PARAMEDIC** 

TREATMENT PRIORITIES

- Vital signs
- Epinephrine for anaphylaxis
- \*\* First two epi doses are standing order. Any additional epi dose requires OLMC consult.
- OK Poison Center consult
- Appropriate destination per OK Poison Center consult

**EMD** 

ADVISE TO AVOID PHYSICAL EXERTION OR ENVIRONMENTAL STRESS (TEMP EXTREMES). MOVE AWAY FROM SNAKE(S) IF ABLE OPEN AIRWAY IF NOT ALERT AND INEFFECTIVE BREATHING

**EMR EMT** 

GENERAL SUPPORTIVE CARE - MARK EDGE OF SWELLING/TENDERNESS EVERY 15 MINS TO DETERMINE SYMPTOM PROGRESSION OBTAIN VITAL SIGNS & ADMINISTER O<sub>2</sub> VIA NC, NRB, OR BVM AS APPROPRIATE
IMMOBILIZE/ELEVATE AND AVOID JOINT FLEXION IN EXTREMITY BITTEN TO MINIMIZE SWELLING OF EXTREMITY

DO NOT CUT THE BITE SITE OR ATTEMPT TO "EXTRACT THE VENOM" FROM BITE SITE WITH SUCTION/VACUUM DEVICES CONSULT OKLAHOMA POISON CONTROL CENTER PER PROTOCOL 8C – DESCRIBE SNAKE APPEARANCE/TYPE AS BEST ABLE APPLY CARDIAC MONITOR (if equipped)

ADULT/PEDIATRIC: N/V: ISOPROPYL ALCOHOL PADS HELD 1 TO 2 CM BELOW NARES (MAX 3 PADS EVERY 15 MINUTES)

FOR ANAPHYLAXIS ONLY (ANAPHYLAXIS FROM SNAKEBITE IS RARE):

ADULT: \*\*EPINEPHRINE 1mg/mL 1:1000 0.5 mg (0.5 mL) IM OR AUTOINJECTOR ANTERIOR/LATERAL THIGH.

PEDIATRIC: \*\*EPINEPHRINE 1mg/mL 1:1000 0.15 mg (0.15 mL) IM OR AUTOINJECTOR ANTERIOR/LATERAL THIGH.

OLMC ORDER ONLY FOR EPINEPHRINE IF PT ≥ 50 YEARS OLD, HEART ILLNESS HISTORY, OR BLOOD PRESSURE > 140/90 mmHg

MEASURE END-TIDAL CO<sub>2</sub> & MONITOR WAVEFORM CAPONGRAPHY (if equipped, \*\*\* Mandatory use if pt intubated)

ADULT: APPLY BI/CPAP IF INDICATED (if equipped)
PLACE SUPRAGLOTTIC AIRWAY IF INDICATED & ONLY IF BVM VENTILATIONS INEFFECTIVE

**EMT-185 AEMT** 

> **ADULT: INTUBATE IF INDICATED** IV ACCESS

ADULT: IV NS TKO IF SYS BP ≥ 100 mmHg WITHOUT HYPOTENSIVE SYMPTOMS

ADULT: IV NS 250 mL BOLUS IF SYS BP <100 mmHg WITH HYPOTENSIVE SYMPTOMS & NO SIGNS OF PULMONARY EDEMA ADULT: REPEAT UP TO 2 LITERS NS IF SYS BP REMAINS < 100 mmHg WITH HYPOTENSIVE SYMPTOMS & NO SIGNS OF PULMONARY EDEMA **PEDIATRIC:** IV NS TKO IF SYS BP ≥ (70 + 2x age in years) mmHg

PEDIATRIC: IV NS 20 mL/kg BOLUS IF SYS BP < (70 + 2x age in years) mmHg & NO SIGNS OF PULMONARY EDEMA REPEAT UP TO 60 mL/kg IF SYS BP REMAINS < (70 + 2x age in years) mmHg & NO SIGNS OF PULMONARY EDEMA

FOR ANAPHYLAXIS ONLY (ANAPHYLAXIS FROM SNAKEBITE IS RARE):

ADULT: \*\*EPINEPHRINE 1mg/mL 1:1000 0.5 mg (0.5 mL) IM ANTERIOR/LATERAL THIGH
PEDIATRIC: \*\*EPINEPHRINE 1mg/mL 1:1000, 0.01 mg/kg IM NOT TO EXCEED 0.3 mg IM ANTERIOR/LATERAL THIGH OLMC ORDER ONLY FOR EPINEPHRINE IF PT ≥ 50 YEARS OLD, HEART ILLNESS HISTORY, OR BLOOD PRESSURE > 140/90 mmHg

#### **PARAMEDIC**

ANTIEMETIC (IF REQUIRED); ADULT: ONDANSETRON 4 mg IVP/ODT. MAY REPEAT ONCE IN 10 MINUTES PEDIATRIC: ONDANSETRON 0.1 mg/kg IVP TO A MAXIMUM SINGLE DOSE OF 4 mg; IF AGE > 2 years, MAY GIVE ONDANSETRON 4 mg ODT

ANALGESIA (IF REQUIRED); OPIOID/OPIATE USE, ADULT MUST HAVE SYS BP ≥ 100 mmHg; PEDIATRIC MUST HAVE SYS BP ≥ (70 + 2x age in years) mmHg ADULT: FENTANYL 1 mcg/kg SLOW IVP/IM/IN, MAXIMUM DOSE 100 mcg. MAY REPEAT EVERY 10 MINUTES TO MAXIMUM CUMULATIVE DOSE OF 3 mcg/kg or 250 mcg WHICHEVER IS LESSER. OR

> ADULT: MORPHINE SULFATE 2 - 4 mg SLOW IVP, MAY REPEAT 2 - 4 mg EVERY 5 MINUTES TO A TOTAL OF 10 mg. OR

ADULT: HYDROMORPHONE 0.5 - 1 mg SLOW IVP, MAY REPEAT EVERY 10 MINUTES TO MAXIMUM CUMULATIVE DOSE OF 2 mg.

PEDIATRIC: OLMCP ORDER ONLY FOR OPIOID/OPIATE ANALGESIA

SEVERE REACTION/ANAPHYLAXIS SERIOUS DYSPNEA, GI DISTRESS, ANGIOEDEMA, OR SYS BP <100 mmHg ADULT OR < (70 + 2x age in years) mmHg PEDIATRIC

ADULT: \*\*EPINEPHRINE 1mg/mL 1:1000 0.5 mg (0.5 mL) IM ANTERIOR/LATERAL THIGH
\*EPINEPHRINE 1mg/mL 1:1000, 0.01 mg/kg IM NOT TO EXCEED 0.3 mg IM ANTERIOR/LATERAL THIGH

IF REFRACTORY ANAPHYLAXIS, ADMINISTER INTRAVASCULAR EPINEPHRINE 1:10,000 ADULT: \*\*EPINEPHRINE 0.1 mg/mL 1:10,000 1 mg SLOW IV/IOP (OVER 3 MINUTES)

PEDIATRIC: \*\*EPINEPHRINE 0.1mg/mL 1:10,000, 0.01 mg/kg SLOW IV/IOP (OVER 3 MINUTES) NOT TO EXCEED 0.5 mg
ADULT: MEDICATION ASSISTED INTUBATION IF INDICATED

CONTINUOUS ASSESSMENT & TREATMENT PER APPLICABLE PROTOCOL(S)

8E.1





#### Medical Literature References 8E – Snakebites (Crotalinae Envenomation)- Adult & Pediatric

- Latimer, A. J., Husain, S., Nolan, J., Doreswamy, V., Rea, T. D., Sayre, M. R., & Eisenberg, M. S. (2018). Syringe Administration of Epinephrine by Emergency Medical Technicians for Anaphylaxis. Prehospital Emergency Care, 22(3), 319–325. https://doi.org/10.1080/10903127.2017.1392667
- 2. Simons FE, Ardusso LR, Bilo MB, Dimov V, Ebisawa M, El-Gamal YM, Ledford DK, Lockey RF, Ring J, Sanchez-Borges M, Senna GE, Sheikh A, Thong BY, Worm M. 2012 Update: World Allergy Organization guidelines for the assessment and management of anaphylaxis. *Curr Opin Allergy Clin Immunol*. 2012 Aug;12(4):389-99.
- 3. Protocol expert consultant: William Banner, MD, PhD. Medical Director, Oklahoma Poison Control Center, Oklahoma City. Board certified in medical toxicology by the American Board of Medical Toxicology. Board certified in pediatrics and pediatric critical care medicine by the American Board of Pediatrics.
- Protocol expert consultant: Boyd Burns, DO. Department of Emergency Medicine, University of Oklahoma School of Community Medicine, Tulsa. Board certified in emergency medicine by the American Board of Emergency Medicine.
- Lavonas EJ, Ruha AM, Banner W, Bebarta V, Bernstein JN, Bush SP, Kerns WP 2nd, Richardson WH, Seifert SA, Tanen DA, Curry SC, Dart RC. Unified treatment algorithm for the management of crotaline snakebite in the United States: results of an evidence-informed consensus workshop. BMC Emerg Med. 2011 Feb 3;11:2.
- 6. Spiller HA, Bosse GM, Ryan ML. Use of antivenom for snakebites reported to United States poison centers. *Am J Emerg Med*. 2010 Sep;28(7):780-5.
- 7. Goto CS, Feng SY. Crotalidae polyvalent immune Fab for the treatment of pediatric crotaline envenomation. *Pediatr Emerg Care*. 2009 Apr;25(4):273-9.
- 8. Ahmed SM, Ahmed M, Nadeem A, Mahajan J, Choudhary A, Pal J. Emergency treatment of a snake bite: Pearls from literature. *J Emerg Trauma Shock*. 2008 Jul;1(2):97-105.
- 9. McNally J, Boesen K, Boyer L. Toxicologic information resources for reptile envenomations. *Vet Clin North Am Exot Anim Pract.* 2008 May;11(2):389-401, viii.
- 10. Wozniak EJ, Wisser J, Schwartz M. Venomous adversaries: a reference to snake identification, field safety, and bite-victim first aid for disaster-response personnel deploying into the hurricane-prone regions of North America. *Wilderness Environ Med.* 2006 Winter;17(4):246-66.
- 11. Singletary EM, Rochman AS, Bodmer JC, Holstege CP. Envenomations. *Med Clin North Am.* 2005 Nov;89(6):1195-224.
- 12. Lyng, J. W., White, C. C., Peterson, T. Q., Lako-Adamson, H., Goodloe, J. M., Dailey, M. W., ... Brown, L. H. (2019). Non-Auto-Injector Epinephrine Administration by Basic Life Support Providers: A Literature Review and Consensus Process. Prehospital Emergency Care, 23(6), 855–861.



1. Vital signs

## EMS System for Metropolitan Oklahoma City and Tulsa 2025 Medical Control Board Treatment Protocols



Approved 9/04/24, Effective 1/15/25, replaces all prior versions

#### (HYMENOPTERA ENVENOMATION) **ADULT & PEDIATRIC** TREATMENT PRIORITIES

**EMD** 

ADVISE TO USE EPINEPHRINE AUTOINJECTOR IF AVAILABLE AND PATIENT'S PHYSICIAN HAS PRESCRIBED TO USE FOR SAME SYMPTOMS

**8F - BEE/WASP STINGS & FIRE ANT BITES** 

ADVISE TO AVOID PHYSICAL EXERTION OR ENVIRONMENTAL STRESS (TEMP EXTREMES). DO NOT MOVE THE PATIENT UNLESS IN DANGER OPEN AIRWAY IF NOT ALERT AND INEFFECTIVE BREATHING EMERGENCY MEDICAL **DISPATCHER** 

> RESPONDER **EMT**

**EMT-INTERMEDIATE 85** 

**ADVANCED EMT** 

**PARAMEDIC** 

3. Oxygen administration 4. Bronchodilator for bronchospasm

2. Epinephrine for anaphylaxis

requires OLMC consult.

standing order. Any

additional epi dose

\*\* First two epi doses are

**EMT** 

GENERAL SUPPORTIVE CARE - REMOVE STINGER(S) WITHOUT SQUEEZING IF STILL EMBEDDED IN SKIN **OBTAIN VITAL SIGNS** 

O2 VIA NC, NRB, OR BVM AS APPROPRIATE APPLY CARDIAC MONITOR (if equipped)
ASSIST PT WITH PT'S OWN ALBUTEROL INHALER/NEBULIZER (when applicable)

#### **EMT OR HIGHER LICENSE:**

FOR ANAPHYLAXIS ONLY

ADULT: \*\*EPINEPHRINE 1mg/mL 1:1000 0.5 mg (0.5 mL) IM OR AUTOINJECTOR ANTERIOR/LATERAL THIGH. PEDIATRIC: \*\*\*EPINEPHRINE 1 mg/mL 1:1000 0.15 mg (0.15 mL) IM OR AUTOINJECTOR ANTERIOR/LATERAL THIGH.

OLMC ORDER ONLY FOR EPINEPHRINE IF PT ≥ 50 YEARS OLD, HEART ILLNESS HISTORY, OR BLOOD PRESSURE > 140/90 mmHg

MEASURE END-TIDAL CO₂ & MONITOR WAVEFORM CAPNOGRAPHY (if equipped, \*\*\* Mandatory use if pt intubated)

ADULT: APPLY Bi/CPAP IF INDICATED (if equipped)

PLACE SUPRAGLOTTIC AIRWAY IF INDICATED & ONLY IF BVM VENTILATIONS INEFFECTIVE ADULT & PEDIATRIC WEIGHT ≥15 kg: NEBULIZED ALBUTEROL 5 mg or LEVALBUTEROL 2.5 mg & IPRATROPIUM BROMIDE 0.5 mg PEDIATRIC WEIGHT <15 kg: NEBULIZED ALBUTEROL 2.5 mg or LEVALBUTEROL 1.25 mg & IPRATROPIUM BROMIDE 0.25 mg MAY REPEAT ALBUTEROL OR LEVALBUTEROL ENROUTE X 2 AS NEEDED

> **EMT-185 AEMT**

> > **ADULT: INTUBATE IF INDICATED** IV ACCESS

ADULT: IV NS TKO IF SYS BP ≥ 100 mmHg WITHOUT HYPOTENSIVE SYMPTOMS

ADULT: IV NS 250 mL BOLUS IF SYS BP < 100 mmHg WITH HYPOTENSIVE SYMPTOMS & NO SIGNS OF PULMONARY EDEMA, ADULT: REPEAT UP TO 2 LITERS NS IF SYS BP REMAINS < 100 mmHg WITH HYPOTENSIVE SYMPTOMS & NO SIGNS OF PULMONARY EDEMA **PEDIATRIC:** IV NS TKO IF SYS BP ≥ (70 + 2x age in years) mmHg

PEDIATRIC: IV NS 20 mL/kg BOLUS IF SYS BP < (70 + 2x age in years) mmHg & NO SIGNS OF PULMONARY EDEMA REPEAT UP TO 60 mL/kg IF SYS BP REMAINS < (70 + 2x age in years) mmHg & NO SIGNS OF PULMONARY EDEMA

#### FOR ANAPHYLAXIS ONLY

ADULT: \*\*EPINEPHRINE 1mg/mL 1:1000 0.5 mg (0.5 mL) IM ANTERIOR/LATERAL THIGH PEDIATRIC: \*\*EPINEPHRINE 1mg/mL 1:1000, 0.01 mg/kg NOT TO EX CEED 0.3 mg IM ANTERIOR/LATERAL THIGH

OLMC ORDER ONLY FOR EPINEPHRINE IF PT ≥ 50 YEARS OLD, HEART ILLNESS HISTORY, OR BLOOD PRESSURE > 140/90 mmHg

#### **PARAMEDIC**

#### MILD REACTION (RASH, ITCH, HIVES) ANTIHISTAMINE

ADULT: DIPHENHYDRAMINE 50 mg IM/IVP PEDIATRIC: DIPHENHYDRAMINE 1 mg/kg IM/IVP TO MAX OF 50 mg

MODERATE REACTION (SOB, WHEEZING) ANTIHISTAMINE + BRONCHODILATOR + STEROID

DIPHENHYDRAMINE ADMINISTRATION AS IN MILD REACTION & BRONCHODILATOR ADMINISTRATION AS IN EMT ABOVE ADULT: METHYLPREDNISOLONE 125 mg IM/IVP OR DEXAMETHASONE 10 mg IM/IVP

PEDIATRIC: METHYLPREDNISOLONE 2 mg/kg IM/IVP, MAX 125 mg or DEXAMETHASONE 0.6 mg/kg IM/IVP MAX 10 mg

SEVERE REACTION/ANAPHYLAXIS SERIOUS DYSNEA, GI DISTRESS, ANGIOEDEMA, OR SYS BP <100 mmHg ADULT OR < (70 + 2x age in years) mmHg PEDIATRIC VASOCONSTRICTOR + ANTIHISTAMINE + BRONCHODILATOR + STEROID

ADULT: \*\*EPINEPHRINE 1mg/mL 1:1000 0.5 mg (0.5 mL) IM ANTERIOR/LATERAL THIGH
PEDIATRIC: \*\*EPINEPHRINE 1mg/mL 1:1000, 0.01 mg/kg NOT TO EXCEED 0.3 mg IM ANTERIOR/LATERAL THIGH
DIPHENHYDRAMINE ADMINISTRATION & BRONCHODILATOR ADMINISTRATION AS IN MILD REACTION; STEROID ADMINISTRATION AS ABOVE

IF REFRACTORY ANAPHYLAXIS, ADMINISTER INTRAVASCULAR EPINEPHRINE 1:10,000 ADULT: \*\*EPINEPHRINE 0.1mg/mL 1:10,000 1 mg SLOW IV/IOP (OVER 3 MINUTES)

PEDIATRIC: \*\*EPINEPHRINE 0.1mg/mL 1:10,000, 0.01 mg/kg SLOW I/V/IOP (OVER 3 MINUTES) NOT TO EXCEED 0.5 mg
ADULT: MEDICATION ASSISTED INTUBATION IF INDICATED

CONTINUOUS ASSESSMENT & TREATMENT PER APPLICABLE PROTOCOL(S)





#### Medical Literature References 8F – Bee/Wasp Stings (Hymenoptera Envenomation)- Adult & Pediatric


- Latimer, A. J., Husain, S., Nolan, J., Doreswamy, V., Rea, T. D., Sayre, M. R., & Eisenberg, M. S. (2018). Syringe Administration of Epinephrine by Emergency Medical Technicians for Anaphylaxis. Prehospital Emergency Care, 22(3), 319–325. https://doi.org/10.1080/10903127.2017.1392667
- 2. Lavonas EJ, Drennan IR, Gabrielli A, Heffner AC, Hoyte CO, Orkin AM, Sawyer KN, Donnino MW. Part 10: Special Circumstances of Resuscitation: 2015 American Heart Association Guidelines Update for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. *Circulation*. 2015 Nov 3;132(18 Suppl 2):S501-18.
- 3. Jacobsen RC, Toy S, Bonham AJ, Salomone JA, Ruthstrom J, Gratton M. Anaphylaxis Knowledge among Paramedics: Results of a National Survey. *Prehosp Emerg Care*. 2012 Oct-Dec;16(4):527-34.
- 4. Simons FE, Ardusso LR, Bilo MB, Dimov V, Ebisawa M, El-Gamal YM, Ledford DK, Lockey RF, Ring J, Sanchez-Borges M, Senna GE, Sheikh A, Thong BY, Worm M. 2012 Update: World Allergy Organization guidelines for the assessment and management of anaphylaxis. *Curr Opin Allergy Clin Immunol*. 2012 Aug;12(4):389-99.
- 5. Jacobsen RC, Millin MG. The use of epinephrine for out-of-hospital treatment of anaphylaxis: resource document for the National Association of EMS Physicians position statement. *Prehosp Emerg Care*. 2011 Oct-Dec;15(4):570-6.
- 6. National Association of EMS Physicians. The use of epinephrine for out-of-hospital treatment of anaphylaxis. *Prehosp Emerg Care*. 2011 Oct-Dec;15(4):544.
- 7. Simons FE, Ardusso LR, Bilò MB, El-Gamal YM, Ledford DK, Ring J, Sanchez-Borges M, Senna GE, Sheikh A, Thong BY; World Allergy Organization. World Allergy Organization anaphylaxis guidelines: summary. *J Allergy Clin Immunol*. 2011 Mar;127(3):587-93.e1-22.
- 8. Walker DM. Update on epinephrine (adrenaline) for pediatric emergencies. *Curr Opin Pediatr.* 2009 Jun;21(3):313-9.
- 9. Simons FE, Lieberman PL, Read EJ Jr, Edwards ES. Simons FE, Lieberman PL, Read EJ Jr, Edwards ES. Hazards of unintentional injection of epinephrine from autoinjectors: a systematic review. *Ann Allergy Asthma Immunol.* 2009 Apr;102(4):282-7.
- Myers JB, Slovis CM, Eckstein M, Goodloe JM, Isaacs SM, Loflin JR, Mechem CC, Richmond NJ, Pepe PE; U.S. Metropolitan Municipalities' EMS Medical Directors. Evidence-based performance measures for emergency medical services systems: a model for expanded EMS benchmarking. <u>Prehosp Emerg Care.</u> 2008 Apr-Jun;12(2):141-51.
- 11. Markenson D, Foltin G, Tunik M, Cooper A, Treiber M, Caravaglia K. Albuterol sulfate administration by EMT-basics: results of a demonstration project. *Prehosp Emerg Care*. 2004 Jan-Mar;8(1):34-40.
- 12. Lyng, J. W., White, C. C., Peterson, T. Q., Lako-Adamson, H., Goodloe, J. M., Dailey, M. W., ... Brown, L. H. (2019). Non-Auto-Injector Epinephrine Administration by Basic Life Support Providers: A Literature Review and Consensus Process. Prehospital Emergency Care, 23(6), 855–861.





Approved 9/04/24, Effective 1/15/25, replaces all prior versions

#### **8G – HAZARDOUS MATERIALS RESPONSE**



This protocol contains generally accepted principles related to EMS response and activity relating to suspected or actual hazardous materials incidents. The overriding principle is safety, with an emphasis on minimizing, preferably preventing, further hazardous materials exposures and related illness.

Specific practices for individual hazardous material substances are beyond the capability of a general principle protocol and the EMS professional is directed to utilize hazardous material specialists within local fire services as well as hazardous material information found in resources such as:

- 1) Emergency Response Guidebook (ERG 2020 edition if available), developed jointly by the US Department of Transportation (DOT), Transport Canada, and the Secretariat of Communications and Transportation of Mexico.
- 2) Wireless Information System for Emergency Responders (WISER), maintained at the US National Library of Medicine Specialized Information Services. The webpage for WISER is http://wiser.nlm.nih.gov/ and according to this website, "WISER is available for download as a standalone application on Microsoft Windows PCs, Apple iPhone and iPod Touch, Google Android devices, Windows Mobile devices, BlackBerry devices, Palm OS PDAs, and via WebWISER.

When responding to individuals in hazardous materials environment(s) and/or contaminated by hazardous materials, real danger exist that EMS professionals, public safety apparatus, and hospitals may be unable to effectively function if not protected from this contamination. Therefore, appropriate efforts must be made to protect the already apparent patient(s), responding public safety professionals, at-risk citizenry, and the emergency healthcare system from further contamination.

Treatment by unprotected or inappropriately protected EMS professionals should not be attempted until appropriate protective measures can be accomplished and the patient is decontaminated or otherwise determined non-toxic by appropriate authority (eg. Fire Department Hazardous Materials specialist, Oklahoma Poison Control Center specialist, and/or on-line medical control physician).





Approved 9/04/24, Effective 1/15/25, replaces all prior versions **Protocol 8G: Hazardous Materials Response, cont.** 

#### Initial measures of protection for EMS professionals and equipment:

EMS professionals that are initially responding and arriving toward the incident location should perform the following:

- 1. Park in an anticipated safe area (typically upwind/uphill unless otherwise directed by Hazardous Materials specialists responding or already on-scene).
- 2. Determine and advise the appropriate communications center of the following (if not previously known):
  - a) The exact location of the incident.
  - b) The type of incident (transportation accident, fire, explosion, etc.).
  - c) Identification/nature of the hazardous materials, if known.
  - d) Environmental conditions (estimated wind direction and speed).
  - e) Recommended routes to and from the location.
  - f) Staging area.
  - g) Control line (perimeter) established or recommended to be established by fire service and/or law enforcement professionals.
  - h) Approximate number of patients (actual number preferred if known).
  - i) Number of ambulances needed (estimated transport resources).
- 3. **DO NOT** rush into a suspected hazardous/contaminated situation until appropriate safety measures are accomplished. If additional public safety professionals have not yet arrived, generally accepted safe practices include:
  - a) Do not drive any further into the area. Stay upwind and uphill.
  - b) Establish a control line at least 300 feet from the incident and stay outside of it
  - c) Tell approaching persons to stop where they are.
  - d) Designate a refuge area for victims already inside the control line and direct those ambulatory to this refuge area.

#### Additional measures of protection for EMS professionals and equipment:

- 1. Whenever possible, use portable or disposable medical equipment for treating hazardous materials victims. Check with local policy, but in general a safe practice is to leave any potentially contaminated equipment with the Hazardous Materials team to coordinate decontamination of any potentially contaminated equipment.
- 2. Open any windows to the patient compartment of the ambulance. Dangerous concentrations of chemicals can develop when unintentionally contaminated victims or rescuers are in the unventilated patient compartment of an ambulance.
- 3. After decontaminated patients have been treated and/or transported to the emergency department, the EMS professionals should be formally evaluated by emergency health care providers at an emergency department if exhibiting unusual signs or symptoms consistent with hazardous materials exposure since participating in the incident.





Medical Literature References 8G – Hazardous Materials Response

- 1. Emergency Response Guidebook. Website accessed 6/27/12 at: http://phmsa.dot.gov/hazmat/library/erg
- 2. Wireless Information System for Emergency Responders. Website accessed 6/27/12 at: http://wiser.nlm.nih.gov/





Approved 9/04/24, Effective 1/15/25, replaces all prior versions

#### **8H - HYDROFLUORIC ACID ADULT & PEDIATRIC EMERGENCY MEDICAL DISPATCHER EMD** TREATMENT PRIORITIES **EMERGENCY MEDICAL RESPONDER** 1. Personal safety – avoid exposure DIRECT TO MOVE AWAY FROM SUSPECTED SOURCE 2. Patient safety – remove exposure **EMT** IF SAFE TO DO SO 3. Irrigate if ocular exposure OCULAR EXPOSURE: 4. Irrigate & calcium gluconate topical application if DIRECT TO IRRIGATE WITH WATER & DON'T STOP dermal exposure **EMT-INTERMEDIATE 85** DERMAL EXPOSURE 5. Respiratory support if inhalation exposure 6. Water or milk consumption if ingestion exposure DIRECT TO REMOVE INVOLVED CLOTHING DIRECT TO IRRIGATE/SHOWER & DON'T STOP **ADVANCED EMT PARAMEDIC EMT** MAINTAIN PERSONAL & PATIENT SAFETY - UTILIZE HAZMAT SPECIALISTIS IF CONDITIONS WARRANT GENERAL SUPPORTIVE CARE & OBTAIN VITAL SIGNS O2 VIA NC. NRB. OR BVM AS APPROPRIATE APPLY CARDIAC MONITOR (if equipped) OCULAR EXPOSURE: START/CONTINUE IRRIGATION OF EYES FOR A MINIMUM OF 15 MINUTES USING TAP WATER OR NS DERMAL EXPOSURE: START/CONTINUE IRRIGATION FOR SEVERAL MINUTES THEN APPLY CALCIUM GLUCONATE 2.5% GEL (if available) LIBERALLY INHALATION EXPOSURE: RESPIRATORY SUPPORT - TREAT PER PROTOCOL 3B ACUTE DYSPNEA INGESTION EXPOSURE: IF AWAKE & AIRWAY INTACT, PATIENT TO CONSUME MINIMUM OF 8 OUNCES OF MILK OR WATER EMT OR HIGHER LICENSE: MEASURE END-TIDAL CO<sub>2</sub> & MONITOR WAVEFORM CAPNOGRAPHY (if equipped) ADULT: APPLY Bi/CPAP IF INDICATED (if equipped) PLACE SUPRAGLOTTIC AIRWAY IF INDICATED & ONLY IF BVM VENTILATIONS INEFFECTIVE **EMT-185 AEMT ADULT**: INTUBATE IF INDICATED

**PARAMEDIC** 

IV/IO ACCESS

ADULT: IV NS TKO IF SYS BP  $\geq$  100 mmHg WITHOUT HYPOTENSIVE SYMPTOMS

ADULT: IV NS 250 mL BOLUS IF SYS BP < 100 mmHg WITH HYPOTENSIVE SYMPTOMS & NO SIGNS OF PULMONARY EDEMA, PEDIATRIC: IV NS TKO IF SYS BP  $\geq$  (70 + 2x age in years) mmHg

PEDIATRIC: IV NS 20 mL/kg BOLUS IF SYS BP < (70 + 2x age in years) mmHg IF NO SIGNS OF PULMONARY EDEMA

ADULT: MEDICATION ASSISTED INTUBATION IF INDICATED

AVOID OPIATE/NARCOTIC ANALGESIA ADMINISTRATION – MONITOR EFFECTIVENESS OF ABOVE MEASURES FOR PAIN CONTROL

CONTINUOUS ASSESSMENT & TREATMENT PER APPLICABLE PROTOCOL(S)





Medical Literature References 8H – Hydrofluoric Acid - Adult & Pediatric

1. Scalzo AJ and Blume-Odom CM. Hydrofluoric Acid and Other Fluorides. In: Shannon MW, Borron SW, Burns MJ, eds. Haddad and Winchester's Clinical Management of Poisoning and Drug Overdose. 4th Ed. Philadelphia, PA: Saunders Elsevier; 2007:1323-1334.





Approved 9/04/24, Effective 1/15/25, replaces all prior versions

#### 9A ABDOMINAL PAIN/NAUSEA/VOMITING/DIARRHEA ADULT & PEDIATRIC

#### **EMERGENCY MEDICAL EMD DISPATCHER** TREATMENT PRIORITIES Supportive care **EMERGENCY MEDICAL** 2. IVF if needed for hypotension ADVISE TO REST IN COMFORTABLE POSITION **RESPONDER** 3. Antiemetic for active vomiting ADVISE NO FOOD OR DRINK ADVISE TO AVOID MOVEMENT UNLESS NECESSARY **EMT EMT-INTERMEDIATE 85 ADVANCED EMT PARAMEDIC EMR EMT** GENERAL SUPPORTIVE CARE **OBTAIN VITAL SIGNS** O2 VIA NC OR NRB AS APPROPRIATE NAUSEA/VOMITING ADULT/PEDIATRIC: ISOPROPYL ALCOHOL PADS HELD 1 TO 2 CM BELOW NARES (MAX 3 PADS EVERY 15 MINUTES)

**EMT-185 AEMT** 

IV ACCESS

ADULT: IV NS TKO IF SYS BP ≥ 100 mmHg WITHOUT HYPOTENSIVE SYMPTOMS

ADULT: IV NS 250 mL BOLUS IF SYS BP <100 mmHg WITH HYPOTENSIVE SYMPTOMS & NO SIGNS OF PULMONARY EDEMA, ADULT: REPEAT UP TO 2 LITERS NS IF SYS BP REMAINS < 100 mmHg WITH HYPOTENSIVE SYMPTOMS & NO SIGNS OF PULMONARY EDEMA PEDIATRIC: IV NS TKO IF SYS BP ≥ (70 + 2x age in years) mmHg
PEDIATRIC: IV NS 20 mL/kg BOLUS IF SYS BP < (70 + 2x age in years) mmHg IF NO SIGNS OF PULMONARY EDEMA

**PARAMEDIC** 

ANTIEMETIC (IF ACTIVELY VOMITING) ADULT: ONDANSETRON 4 mg IVP/ODT. MAY REPEAT ONCE IN 10 MINUTES PEDIATRIC: ONDANSETRON 0.1 mg/kg IVP TO A MAXIMUM SINGLE DOSE OF 4 mg

IF AGE >2 years, MAY GIVE ONDANSETRON 4 mg ODT

ANALGESIA (IF REQUIRED)

FOR OPIATE USE, ADULT MUST HAVE SYS BP ≥ 100 mmHg; PEDIATRIC MUST HAVE SYS BP ≥ (70 + 2x age in years) mmHg

ADULT: FENTANYL 1 mcg/kg SLOW IVP/IM/IN, MAXIMUM DOSE 100 mcg. MAY REPEAT EVERY 10 MINUTES TO MAXIMUM CUMULATIVE DOSE OF 3 mcg/kg or 250 mcg WHICHEVER IS LESSER.

OR

ADULT: MORPHINE SULFATE 2 - 4 mg SLOW IVP, MAY REPEAT 2 - 4 mg EVERY 5 MINUTES TO A TOTAL OF 10 mg. OR

ADULT: HYDROMORPHONE 0.5 - 1 mg SLOW IVP

MAY REPEAT EVERY 10 MINUTES TO MAXIMUM CUMULATIVE DOSE OF 2 mg.

PEDIATRIC: OLMCP ORDER ONLY

OLMCP CONSULT IF FURTHER ANALGESIA REQUIRED

CONTINUOUS ASSESSMENT & TREATMENT PER APPLICABLE PROTOCOL(S)






Medical Literature References
9A – Abdominal Pain/Nausea/Vomiting/Diarrhea – Adult& Pediatric

- 1. Salvucci AA, Squire B, Burdick M, Luoto M, Brazzel D, Vaezazizi R. Ondansetron is safe and effective for prehospital treatment of nausea and vomiting by paramedics. *Prehosp Emerg Care*. 2011 Jan-Mar;15(1):34-8.
- 2. Yuan Y, Chen JY, Guo H, Zhang Y, Liang DM, Zhou D, Zhao H, Lin F. Relief of abdominal pain by morphine without altering physical signs in acute appendicitis. *Chin Med J* (Engl). 2010 Jan 20;123(2):142-5.
- 3. Sharwood LN, Babl FE. The efficacy and effect of opioid analgesia in undifferentiated abdominal pain in children: a review of four studies. *Paediatr Anaesth*. 2009 May;19(5):445-51.
- 4. Warden CR, Moreno R, Daya M. Prospective evaluation of ondansetron for undifferentiated nausea and vomiting in the prehospital setting. *Prehosp Emerg Care*. 2008 Jan-Mar;12(1):87-91.
- 5. Bailey B, Bergeron S, Gravel J, Bussières JF, Bensoussan A. Efficacy and impact of intravenous morphine before surgical consultation in children with right lower quadrant pain suggestive of appendicitis: a randomized controlled trial. *Ann Emerg Med.* 2007 Oct;50(4):371-8.
- 6. Gallagher EJ, Esses D, Lee C, Lahn M, Bijur PE. Randomized clinical trial of morphine in acute abdominal pain. *Ann Emerg Med.* 2006 Aug;48(2):150-60, 160.e1-4.
- 7. Pointer JE, Harlan K. Impact of liberalization of protocols for the use of morphine sulfate in an urban emergency medical services system. *Prehosp Emerg Care*. 2005 Oct-Dec;9(4):377-81.





Approved 9/04/24, Effective 1/15/25, replaces all prior versions



PEDIATRIC: ONDANSETRON 0.1 mg/kg IVP TO A MAXIMUM SINGLE DOSE OF 4 mg
IF AGE >2 years, MAY GIVE ONDANSETRON 4 mg ODT

SEPTIC SHOCK UNRESPONSIVE TO IV/IO FLUIDS AS ABOVE? **ADULT: PHARMACOLOGIC TREATMENT IF SYS BP < 100 mmHg:** NOREPINEPHRINE 2-4 mcg/min TITRATE TO SYS  $\geq$  100 mmHg OR

DOPAMINE 5-20 mcg/kg/min TITRATE TO SYS BP ≥ 100 mmHg IF NOREPINEPHRINE NOT AVAILABLE PEDIATRIC: OLMC CONSULT FOR PHARMACOLOGIC TREATMENT

#### FEBRILE SEIZURE?

IF SOLITARY AND SHORT DURATION (< 5 MINUTES) – OBSERVE IF PROLONGED/STATUS EPILEPTICUS, TREAT PER PROTOCOL 6D – SEIZURE

MINIMIZE SCENE TIME IF SEPSIS SUSPECTED

IF CLINICAL CONCERN FOR SEPSIS, NOTIFY RECEIVING ED OF POSSIBLE SEPSIS IN RADIO REPORT

CONTINUOUS ASSESSMENT & TREATMENT PER APPLICABLE PROTOCOL(S)






Medical Literature References 9B – Sepsis - Adult & Pediatric

- 1. Yealy, D. M., Mohr, N. M., Shapiro, N. I., Venkatesh, A., Jones, A. E., & Self, W. H. (2021). Early Care of Adults With Suspected Sepsis in the Emergency Department and Out-of-Hospital Environment: A Consensus-Based Task Force Report. In *Annals of Emergency Medicine* (Vol. 78, Issue 1, pp. 1–19). Mosby Inc. https://doi.org/10.1016/j.annemergmed.2021.02.006
- 2. Loubani OM, Green RS. A systematic review of extravasation and local tissue injury from administration of vasopressors through peripheral intravenous catheters and central venous catheters. *J Crit Care*. 2015;30:653e9-e17.
- Ferguson-Myrthil N. Vasopressor use in adult patients. Cardiol Rev. 2012 May;20(3):153-8.
- Vasu TS, Cavallazzi R, Hirani A, Kaplan G, Leiby B, Marik PE. Norepinephrine or dopamine for septic shock: systematic review of randomized clinical trials. *J Intensive Care Med.* 2012 May;27(3):172-8.
- 5. De Backer D, Aldecoa C, Njimi H, Vincent JL. Dopamine versus norepinephrine in the treatment of septic shock: a meta-analysis. *Crit Care Med.* 2012 Mar;40(3):725-30.
- 6. Suffoletto B, Frisch A, Prabhu A, Kristan J, Guyette FX, Callaway CW. Prediction of serious infection during prehospital emergency care. *Prehosp Emerg Care*. 2011 Jul-Sep;15(3):325-30.
- 7. De Backer D, Biston P, Devriendt J, Madl C, Chochrad D, Aldecoa C, Brasseur A, Defrance P, Gottignies P, Vincent JL, SOAP II Investigators. Comparison of dopamine and norepinephrine in the treatment of shock. *N Engl J Med.* 2010 Mar 4;362(9):779-89.
- 8. De Backer D, Biston P, Devriendt J, Madl C, Chochrad D, Aldecoa C, Brasseur A, Defrance P, Cottignies P, Vincent J for the SOAP II Invesigators. Comparison of dopamine and norepinephrine in the treatment of shock. *NEJM*. 2010;362:779-89.
- 9. Robson W, Nutbeam T, Daniels R. Sepsis: a need for prehospital intervention? *Emerg Med J.* 2009 Jul;26(7):535-8.





Approved 9/04/24, Effective 1/15/25, replaces all prior versions







#### Medical Literature References 9C – Epistaxis – Adult& Pediatric

- 1. Smith J, Siddiq S, Dyer C, Rainsbury J, Kim D. Epistaxis in patients taking oral anticoagulant and antiplatelet medication: prospective cohort study. *J Laryngol Otol.* 2011 Jan;125(1):38-42.
- 2. Rainsbury JW, Molony NC. Clopidogrel versus low-dose aspirin as risk factors for epistaxis. *Clin Otolaryngol*. 2009 Jun;34(3):232-5.
- 3. Pallin DJ, Chng YM, McKay MP, Emond JA, Pelletier AJ, Camargo CA Jr. Epidemiology of epistaxis in US emergency departments, 1992 to 2001. *Ann Emerg Med.* 2005 Jul;46(1):77-81.
- 4. Leong SC, Roe RJ, Karkanevatos A. No frills management of epistaxis. *Emerg Med J.* 2005 Jul;22(7):470-2.
- 5. Middleton PM. Epistaxis. Emerg Med Australas. 2004 Oct-Dec;16(5-6):428-40.





Approved 9/04/24, Effective 1/15/25, replaces all prior versions

# 9D – PAIN MANAGEMENT MEDICAL (ACUTE ONSET & CHRONIC TYPE) ADULT & PEDIATRIC 1. Vital signs 2. Opioid/Opiate analgesia as clinically appropriate per protocol ADVISE TO AVOID PHYSICAL EXERTION OR ENVIRONMENTAL STRESS (TEMP EXTREMES). DO NOT MOVE THE PATIENT UNLESS IN DANGER DO NOT ATTEMPT TO SPLINT INJURIES

EMERGENCY MEDICAL
DISPATCHER

EMERGENCY MEDICAL
RESPONDER

EMT

EMT-INTERMEDIATE 85

ADVANCED EMT

PARAMEDIC

EMR EMT

GENERAL SUPPORTIVE CARE (MEDICAL PT) OR TRAUMA AND HYPOVOLEMIC SHOCK SUPPORTIVE CARE (TRAUMA PT) OBTAIN VITAL SIGNS

O<sub>2</sub> VIA NC, NRB, OR BVM AS APPROPRIATE APPLY CARDIAC MONITOR (when available)

#### **EMT OR HIGHER LICENSE:**

MEASURE END - TIDAL CO<sub>2</sub> & MONITOR WAVEFORM CAPNOGRAPHY (if equipped, \*\* Mandatory use if pt intubated)

EMT-185 AEMT

IV ACCESS

ADULT: IV NS TKO IF SYS BP ≥ 100 mmHg WITHOUT HYPOTENSIVE SYMPTOMS

ADULT: IV NS 250 mL BOLUS IF SYS BP <100 mmHg WITH HYPOTENSIVE SYMPTOMS & NO SIGNS OF PULMONARY EDEMA

ADULT: REPEAT UP TO 2 LITERS NS IF SYS BP REMAINS < 100 mmHg WITH HYPOTENSIVE SYMPTOMS & NO SIGNS OF PULMONARY EDEMA

PEDIATRIC: IV NS 20 mL/kg BOLUS IF SYS BP < (70 + 2x age in years) mmHg

REPEAT UP TO 60 mL/kg IF SYS BP REMAINS < (70 + 2x age in years) mmHg & NO SIGNS OF PULMONARY EDEMA

#### **PARAMEDIC**

ANALGESIA (IF REQUIRED - PARAMEDIC DISCRETION, PARTICULARLY WITH CHRONIC PAIN SYMPTOMS)

FOR OPIATE USE, ADULT MUST HAVE SYS BP ≥ 100 mmHg; PEDIATRIC MUST HAVE SYS BP ≥ (70 + 2x age in years) mmHg

ADULT: FENTANYL 1 mcg/kg SLOW IVP/IM/IN, MAXIMUM DOSE 100 mcg. MAY REPEAT EVERY 10 MINUTES TO MAXIMUM CUMULATIVE DOSE OF 3 mcg/kg or 250 mcg WHICHEVER IS LESSER.

OR

ADULT: MORPHINE SULFATE 2 - 4 mg SLOW IVP, MAY REPEAT 2 - 4 mg EVERY 5 MINUTES TO A TOTAL OF 10 mg.

ADULT: HYDROMORPHONE 0.5 - 1 mg SLOW IVP, MAY REPEAT EVERY 10 MINUTES TO MAXIMUM CUMULATIVE DOSE OF 2 mg.

PEDIATRIC: OLMCP ORDER ONLY

OLMCP CONSULT IF FURTHER ANALGESIA REQUIRED

CONTINUOUS ASSESSMENT & TREATMENT PER APPLICABLE PROTOCOL(S)





#### Medical Literature References 9D – Pain Management (Acute Onset & Chronic Type) – Adult & Pediatric

- 1. Karlsen AP, Pedersen DM, Trautner S, Dahl JB, Hansen MS. Safety of intranasal fentanyl in the out-of-hospital setting: a prospective observational study. *Ann Emerg Med.* 2014 Jun;63(6):699-703.
- 2. Auffret Y, Gouillou M, Jacob GR, Robin M, Jenvrin J, Soufflet F, Alavi Z. Does midazolam enhance pain control in prehospital management of traumatic severe pain? *Am J Emerg Med.* 2014 Jun;32(6):655-9.
- 3. Bendall JC, Simpson PM, Middleton PM. Effectiveness of prehospital morphine, fentanyl, and methoxyflurane in pediatric patients. *Prehosp Emerg Care*. 2011 Apr-Jun;15(2):158-65.
- 4. Park CL, Roberts DE, Aldington DJ, Moore RA. Prehospital analgesia: systematic review of evidence. *J R Army Med Corps*. 2010 Dec;156(4 Suppl 1):295-300.
- 5. Middleton PM, Simpson PM, Sinclair G, Dobbins TA, Math B, Bendall JC. Effectiveness of morphine, fentanyl, and methoxyflurane in the prehospital setting. *Prehosp Emerg Care*. 2010 Oct-Dec;14(4):439-47.
- 6. Yuan Y, Chen JY, Guo H, Zhang Y, Liang DM, Zhou D, Zhao H, Lin F. Relief of abdominal pain by morphine without altering physical signs in acute appendicitis. *Chin Med J* (Engl). 2010 Jan 20;123(2):142-5.
- 7. Sharwood LN, Babl FE. The efficacy and effect of opioid analgesia in undifferentiated abdominal pain in children: a review of four studies. *Paediatr Anaesth*. 2009 May;19(5):445-51.
- 8. Thomas SH, Shewakramani S. Prehospital trauma analgesia. J Emerg Med. 2008 Jul;35(1):47-57.
- 9. Bailey B, Bergeron S, Gravel J, Bussières JF, Bensoussan A. Efficacy and impact of intravenous morphine before surgical consultation in children with right lower quadrant pain suggestive of appendicitis: a randomized controlled trial. *Ann Emerg Med.* 2007 Oct;50(4):371-8.
- Rickard C, O'Meara P, McGrail M, Garner D, McLean A, Le Lievre P. A randomized controlled trial of intranasal fentanyl vs intravenous morphine for analgesia in the prehospital setting. Am J Emerg Med. 2007 Oct;25(8):911-7.
- 11. Gallagher EJ, Esses D, Lee C, Lahn M, Bijur PE. Randomized clinical trial of morphine in acute abdominal pain. *Ann Emerg Med.* 2006 Aug;48(2):150-60, 160.e1-4.
- 12. Kanowitz A, Dunn TM, Kanowitz EM, Dunn WW, Vanbuskirk K. Safety and effectiveness of fentanyl administration for prehospital pain management. *Prehosp Emerg Care*. 2006 Jan-Mar;10(1):1-7.
- 13. Pointer JE, Harlan K. Impact of liberalization of protocols for the use of morphine sulfate in an urban emergency medical services system. *Prehosp Emerg Care*. 2005 Oct-Dec;9(4):377-81.
- 14. Thomas SH, Rago O, Harrison T, Biddinger PD, Wedel SK. Fentanyl trauma analgesia use in air medical scene transports. *J Emerg Med*. 2005 Aug;29(2):179-87.
- 15. McManus JG Jr, Sallee DR Jr. Pain management in the prehospital environment. *Emerg Med Clin North Am.* 2005 May;23(2):415-31.
- 16. DeVellis P, Thomas SH, Wedel SK, Stein JP, Vinci RJ. Prehospital fentanyl analgesia in airtransported pediatric trauma patients. *Pediatr Emerg Care*. 1998 Oct;14(5):321-3.



EMERGENCY
MEDICINE
UNIVERSITY OF OKLAHOMA

\*\* EMS Section

Approved 9/04/24, Effective 1/15/25, replaces all prior versions

## 9E – DIALYSIS-RELATED ISSUES ADULT & PEDIATRIC

#### TREATMENT PRIORITIES:

- 1. Circulatory support
- External bleeding control
- Hypotension treatment with fluids and/or vasopressors
- If hyperkalemia, calcium chloride first medication
- Vascular access precaution: avoid fistulas/graft/shunt
- 2. Hypoglycemia care

#### **EMD**

CPR BY EMD INSTRUCTION (if applicable)
CONTROL ANY BLEEDING
WITH DIRECT PRESSURE
ADVISE REST

## EMERGENCY MEDICAL DISPATCHER

EMERGENCY MEDICAL RESPONDER

EMT

**EMT-INTERMEDIATE 85** 

**ADVANCED EMT** 

**PARAMEDIC** 

EMR EMT

GENERAL SUPPORTIVE CARE OBTAIN VS

#### DIALYSIS PORT/CATHETER/FISTULA BLEEDING?

DIRECT PRESSURE HEMOSTATIC AGENT

TOURNIQUET PROXIMAL TO FISTULA IF BLEEDING SEVERE & UNCONTROLLABLE ON EXTREMITY

#### ADULT & PEDIATRIC WEIGHT ≥25 kg HYPOGLYCEMIA CARE:

IF GLUCOSE <50 mg/dL, 1 tube ORAL GLUCOSE (15 grams) PO PEDIATRIC WEIGHT <25 kg HYPOGLYCEMIA CARE:

IF GLUCOSE <50 mg/dL, ½ tube ORAL GLUCOSE (7.5 grams) PO

EMT - 185 AEMT

#### VASCULAR ACCESS?

IN MANY SITUATIONS, DIALYSIS PROFESSIONALS WILL LEAVE CATHETER IN PLACE TO USE AS IV PRN DO NOT INITIATE IV USING EMS CATHETERS IN FISTULA/GRAFT/SHUNT – VASCULAR DAMAGE CAN OCCUR USE IO ACCESS IF IV ACCESS UNOBTAINABLE

#### SYMPTOMATIC HYPOTENSION?

ADULT & PEDIATRIC: 10 mL/kg (MAX OF 500 mL IF ANURIC) NS IV/IO BOLUS IF NO SIGNS OF PULMONARY EDEMA

 $\textbf{HYPOGLYCEMIA} \hspace{0.1cm} (\texttt{GLUCOSE} \hspace{0.1cm} \texttt{<} 50 \hspace{0.1cm} \texttt{mg/dL}) \hspace{0.1cm} \textbf{-} \hspace{0.1cm} \textbf{ADULT} \hspace{0.1cm} \textbf{\&} \hspace{0.1cm} \textbf{PEDIATRIC}$ 

D10 5 mL/kg IVPB WIDE OPEN UP TO 250 mL OR

D25 2 mL/kg IV/IO UP TO 100 mL (must be  $\geq$  1 year of age) OR D50 1 mL/kg IV/IO UP TO 50 mL (must be  $\geq$  25 kg) IF NO VASCULAR ACCESS OBTAINED & IF IO SEEMS EXCESSIVE TO CLINICAL STATUS:

GLUCAGON: IF PT WT ≥25 kg, 1mg IM; <25 kg, 0.5 mg IM

ADULT & PEDIATRIC: REPEAT DETERMINATION OF BLOOD GLUCOSE POST-HYPOGLYCEMIA TREATMENT

#### **PARAMEDIC**

#### CARDIAC ARREST OR VENTRICULAR DYSRHYTHMIA FROM KNOWN/SUSPECTED HYPERKALEMIA?

ADULT/PEDIATRIC: CALCIUM CHLORIDE 10 mg/kg IVP/IOP (MAX 1 gram) & SODIUM BICARBONATE 1 m Eq/kg IVP/IOP (MAX 50 m Eq)

CARDIAC ARREST FROM PRE-EXISTING METABOLIC ACIDOSIS?

ADULT/PEDIATRIC: SODIUM BICARBONATE 1 mEq/kg IVP/IOP (MAX 50 mEq)

#### SYMPTOMATIC HYPOTENSION WITHOUT IMPROVEMENT AFTER 10 mL/kg IVF (MAX 500 mL IF ANURIC)?

ADULT: PHARMACOLOGIC TREATMENT IF SYS BP < 100 mmHg:

NOREPINEPHRINE 2-4 mcg/min TITRATE to SYS ≥ 100 mmHg **OR**DOPAMINE 5-20 mcg/kg/min TITRATE TO SYS BP ≥ 100 mmHg **PEDIATRIC:** OLMC CONSULT FOR PHARMACOLOGIC TREATMENT

CONTINUOUS ASSESSMENT & TREATMENT PER APPLICABLE PROTOCOL(S)





Medical Literature References 9E – Dialysis-Related Issues - Adult & Pediatric


- Protocol expert consultant: Sunil Agrawal, MD. Nephrology Specialists of Oklahoma, Tulsa. Board certified in nephrology and internal medicine by the American Board of Internal Medicine.
- 2. Lin CH, Tu YF, Chiang WC, Wu SY, Chang YH, Chi CH. Electrolyte abnormalities and laboratory findings in patients with out-of-hospital cardiac arrest who have
- 3. kidney disease. Am J Emerg Med. 2013 Mar;31(3):487-93
- 4. De Backer D, Biston P, Devriendt J, Madl C, Chochrad D, Aldecoa C, Brasseur A, Defrance P, Cottignies P, Vincent J for the SOAP II Invesigators. Comparison of dopamine and norepinephrine in the treatment of shock. *NEJM*. 2010;362:779-89.
- 5. <u>Davis TR, Young BA, Eisenberg MS, Rea TD, Copass MK, Cobb LA</u>. Outcome of cardiac arrests attended by emergency medical services staff at community outpatient dialysis centers. *Kidney Int.* 2008 Apr;73(8):933-9.
- 6. Venkat A, Kaufmann KR, Venkat K. Care of the end-stage renal disease patient on dialysis in the ED. *Am J Emerg Med*. 2006 Nov;24(7):847-58.
- 7. Lafrance JP, Nolin L, Senécal L, Leblanc M. Predictors and outcome of cardiopulmonary resuscitation (CPR) calls in a large haemodialysis unit over a seven-year period. *Nephrol Dial Transplant*. 2006 Apr;21(4):1006-12.
- 8. Wald DA. ECG manifestations of selected metabolic and endocrine disorders. *Emerg Med Clin North Am.* 2006 Feb;24(1):145-57, vii.
- 9. Loran MJ, McErlean M, Eisele G, Raccio-Robak N, Verdile VP. The emergency department care of hemodialysis patients. *Clin Nephrol.* 2002 Jun;57(6):439-43.





Approved 9/04/24, Effective 1/15/25, replaces all prior versions

## 9F – INFECTIOUS DISEASE PRECAUTION RECOMMENDATIONS EMS PROFESSIONALS



In the course of EMS care of a patient (from time of emergency services request through transport of the patient to the destination location), EMS professionals should be informed, aware, and proactive regarding practices that reduce their exposure to infectious diseases, with a goal of preventing transmission of those infectious diseases to and/or through EMS professionals.

The following recommendations are general guidelines that will assist in reducing exposure to infectious diseases in the commission of EMS treatment of patients.

- 1. Follow immunization recommendations from Centers for Disease Control Advisory Committee on Immunization Practices (ACIP) (eg. Hepatitis B and Flu vaccinations).
- 2. Always be prepared for isolation from body substances (blood, respiratory secretions, sputum, saliva, emesis, fecal matter).
- 3. Wear examination gloves (in most situations, non-sterile type) during patient care activities.
- 4. If patient conditions tolerate, reduce exposure of suspected infectious respiratory droplets by covering the patient's nose and mouth in oxygen administration (eg. non-rebreather mask) or with a face mask (eg. surgical type face mask) if oxygen administration is not required.
- 5. When providing airway assessment and management, maximize the functional distance between the patient's nose and mouth and the EMS professional's nose and mouth. The greater the possible distance, the lesser the risk of respiratory illness transmission.
- 6. Wear appropriate body substance isolation (eye splash protection, mask over nose/mouth, gloves as previously noted, gown to protect personal uniform contamination) as patient suspected illness/injury may dictate.
- 7. During treatment of the patient, avoid likely trajectories of bleeding, coughing, spitting, vomiting, defecating whenever possible.
- 8. Exercise extremely diligent action when handling or around the handling of contaminated sharps (eg. IV/IO needles, needle/syringe, glucometry lancets) and have appropriate sharps container readily present at patient side and on ambulance.
- 9. For all exposures, wash exposed area(s) as soon as possible with copious irrigation and/or antibacterial solution approved for that area(s) use.
- 10. In the event of exposure, follow general principles as listed in Protocol 9G Post-Exposure Prophylaxis Recommendations as well as agency-specific policies. Do not delay in reporting and seeking treatment for an infectious disease/body substance exposure of concern.





## Medical Literature References 3F – Dyspnea – Apparent Life Threatening Event – Pediatric


- 1. Tieder JS, Altman RL, Bonkowsky JL, Brand DA, Claudius I, Cunningham DJ, Dewolfe C, Percelay JM, Pitetti RD, Smith MB. Management of Apparent Life-Threatening Events in Infants: A Systematic Review. *J Pediatr.* 2013 Feb 14.
- 2. Kaji AH, Claudius I, Santillanes G, Mittal MK, Hayes K, Lee J, Gausche-Hill M. Apparent life-threatening event: multicenter prospective cohort study to develop a clinical decision rule for admission to the hospital. *Ann Emerg Med.* 2013 Apr;61(4):379-387.e4.
- 3. Kaji AH, Santillanes G, Claudius I, Mittal MK, Hayes K, Lee J, Gausche-Hill M. Do infants less than 12 months of age with an apparent life-threatening event need transport to a pediatric critical care center? *Prehosp Emerg Care*. 2013 Jul-Sep;17(3):304-11.
- Romaneli MT, Fraga AM, Morcillo AM, Tresoldi AT, Baracat EC. Factors associated with infant death after apparent life-threatening event (ALTE). J Pediatr (Rio J). 2010 Nov-Dec;86(6):515-9.
- 5. Zuckerbraun NS, Zomorrodi A, Pitetti RD. Occurrence of serious bacterial infection in infants aged 60 days or younger with an apparent life-threatening event. *Pediatr Emerg Care*. 2009 Jan;25(1):19-25.
- 6. Kaji AH, Gausche-Hill M. Managing infants after an apparent life-threatening event. *Emerg Med.* 2008;40(10): 15-9
- 7. Santiago-Burruchaga M, Sánchez-Etxaniz J, Benito-Fernández J, Vázquez-Cordero C, Mintegi-Raso S, Labayru-Echeverría M, Vega-Martín MI. Assessment and management of infants with apparent life-threatening events in the pediatric emergency department. *Eur J Emerg Med.* 2008 Aug;15(4):203-8.
- 8. McGovern MC, Smith MB. Causes of apparent life threatening events in infants: a systematic review. *Arch Dis Child*. 2004 Nov;89(11):1043-8.
- 9. Stratton SJ, Taves A, Lewis RJ, Clements H, Henderson D, McCollough. Apparent life-threatening events in infants. High risk in the out-of-hospital environment. *Ann Emerg Med.* 2004 43(6):711-717.
- 10. De Piero AD, Teach SJ, Chamberlain JM. ED evaluation of infants after an apparent life-threatening event. *Am J Emerg Med*. 2004 Mar;22(2):83-6.
- 11. Davies F, Gupta R. Apparent life threatening events in infants presenting to an emergency department. *Emerg Med J.* 2002 Jan;19(1):11-6.





Approved 9/04/24, Effective 1/15/25, replaces all prior versions

## 9G – POST-EXPOSURE PROPHYLAXIS RECOMMENDATIONS ADULT & PEDIATRIC



Preventing an exposure is always better than the "cure" for an exposure. Despite careful practices, EMS professionals can experience at least one concerning infectious disease exposure in a career.

Every EMS organization should have a pre-planned course of rapid, clinically-effective action steps (regardless of time of day, day of week) to be followed in the event of EMS professionals sustaining concerning occupational exposures to infectious diseases. The Chief Medical Officer should be involved in the planning of post-exposure evaluation and post-exposure prophylaxis (PEP) care.

The following recommendations are general guidelines that can assist in post-exposure evaluation and PEP care:

- 1. Wash exposed area(s) as soon as possible with copious irrigation and/or antibacterial solution approved for that area(s) use.
- 2. Gather as much information about the exposure of concern as possible what body substance (eg. blood, saliva), what route of exposure, timing/amount of exposure, patient demographics, location of the exposure source (e.g. in the emergency department at "any town" hospital), and any related infectious disease medical history of the patient (eg. known HIV or Hepatitis C?).
- 3. Do not delay in reporting and seeking treatment for an infectious disease/body substance exposure of concern. Regardless of time of day or day or week, seek direction from the appropriate EMS supervisor and/or report to the employer's pre-designated PEP health care facility immediately after the patient's care can be transferred to other healthcare providers. Time to treatment (in hours) is of the essence to reduce transmission of infectious disease.
- 4. A national resource exists for real-time PEP care. This clinical resource is maintained at the University of California at San Francisco/San Francisco General Hospital. Treating physicians can access phone advice (PEP line) at 1-888-448-4911 in the evaluation and treatment for occupational events concerning for exposure to HIV, hepatitis, and other blood-borne pathogens. The PEP line is answered from 0800-0100 Central Standard Time except on holidays. Messages left during unanswered hours are returned during the next operational morning.





Approved 9/04/24, Effective 1/15/25, replaces all prior versions PROTOCOL 9G: Post-Exposure Prophylaxis Recommendations – Adult & Pediatric, cont

- 5. Additional information on PEP care can be obtained at the following website: http://www.nccc.ucsf.edu/clinical-resources/prep-guidelines-and-resources/
- 6. The Oklahoma State Department of Health has a policy and reporting form for EMS professional use in the event of an occupational exposure to infectious disease of concern. The information and form can be accessed at the following website: https://www.ok.gov/health2/documents/HIV-CommunicableDiseaseRiskExposureReport.pdf A copy of this form (OSDH Form 207) can be found in Section 19 of these protocols.





## Medical Literature References 9G – Post-Exposure Prophylaxis Recommendations – Adult & Pediatric

- 1. National HIV/AIDS Clinicians' Consultation Center at http://www.nccc.ucsf.edu/home/ accessed 7/1/12.
- 2. Oklahoma State Department of Health (OSDH) OAC 310:555 at http://www.ok.gov/health/documents/HIV-Statute%20555-504.pdf accessed 7/1/12.
- 3. OSDH Form 207 at http://www.ok.gov/health/documents/HIV-Communicable%20Disease%20Risk%20Exposure%20Report.pdf accessed 7/1/12.
- 4. Centers for Disease Control (CDC) resources to prevent Healthcare Associate Infections (HAIs) at http://www.cdc.gov/HAI/prevent/ppe.html accessed 7/1/12.
- Occupational Safety Health Administration Bloodborne Pathogens Standard. 29 CFR 1910.1030 at http://www.osha.gov/pls/oshaweb/owadisp.show\_document?p\_table=STANDARDS&p\_id=10051 accessed 7/1/12.
- 6. Henderson DK. Management of needlestick injuries: a house officer who has a needlestick. *JAMA*. 2012 Jan 4;307(1):75-84.
- 7. El Sayed M, Kue R, McNeil C, Dyer KS. A descriptive analysis of occupational health exposures in an urban emergency medical services system: 2007-2009. *Prehosp Emerg Care*. 2011 Oct-Dec;15(4):506-10.
- 8. CDC. Immunization of Health-Care Personnel: Recommendations of the Advisory Committee on Immunization Practices (ACIP). *MMWR*, 2011; 60(RR-7).
- 9. Chin RL. Postexposure prophylaxis for HIV. Emerg Med Clin North Am. 2010 May;28(2):421-9.
- 10. Boal WL, Leiss JK, Ratcliffe JM, Sousa S, Lyden JT, Li J, Jagger J. The national study to prevent blood exposure in paramedics: rates of exposure to blood. *Int Arch Occup Environ Health*. 2010 Feb;83(2):191-9.
- 11. Merchant RC, Nettleton JE, Mayer KH, Becker BM. Blood or body fluid exposures and HIV postexposure prophylaxis utilization among first responders. *Prehosp Emerg Care*. 2009 Jan-Mar;13(1):6-13.
- 12. Chapman LE, Sullivent EE, Grohskopf LA, Beltrami EM, Perz JF, Kretsinger K, Panlilio AL, Thompson ND, Ehrenberg RL, Gensheimer KF, Duchin JS, Kilmarx PH, Hunt RC. Postexposure interventions to prevent infection with HBV, HCV, or HIV, and tetanus in people wounded during bombings and other mass casualty events--United States, 2008: recommendations of the Centers for Disease Control and Prevention and Disaster Medicine and Public Health Prep. 2008 Oct;2(3):150-65.
- 13. Panlilio AL, Cardo DM, Grohskopf LA, Heneine W, Ross CS; U.S. Public Health Service. Updated U.S. Public Health Service guidelines for the management of occupational exposures to HIV and recommendations for postexposure prophylaxis. *MMWR Recomm Rep.* 2005 Sep 30:54(RR-9):1-17.
- 14. Miller NL, Gudmestad T, Eisenberg MS. Development of model infectious disease protocols for fire and EMS personnel. *Prehosp Emerg Care*. 2005 Jul-Sep;9(3):326-32.
- Datta SD, Armstrong GL, Roome AJ, Alter MJ. Blood exposures and hepatitis C virus infections among emergency responders. Arch Intern Med. 2003 Nov 24;163(21):2605-10.
- 16. Rinnert KJ, O'Connor RE, Delbridge T. Risk reduction for exposure to blood-borne pathogens in EMS. National Association of Emergency Medical Services Physicians. *Prehosp Emerg Care*. 1998 Jan-Mar;2(1):62-6.





Approved 9/04/24, Effective 1/15/25, replaces all prior versions

## 9H - VASCULAR ACCESS - INTRAVENOUS ADULT & PEDIATRIC



#### Indications:

- 1. Vascular access for intravenous administration of crystalloid fluids in hypotension and/or volume insufficiency.
- 2. Vascular access for intravenous administration of medications for a multitude of medically indicated effects.
- 3. Vascular access in a patient with an increased potential for needing either of the above indications.

#### Contraindications:

- None absolute, though despite aseptic technique and using sterile angiocatheters, there is always a risk of introducing infection when the skin integrity is violated. Do not establish IV access unless directed by applicable treatment protocol(s) or the patient meets one of the indications above.
- 2. Venous sites distal to a fracture.
- 3. Venous site underlying cellulitis/abscess.

#### Technique:

#### A. Extremity:

- 1. Apply IV tourniquet proximal to proposed vascular access site.
- 2. Clean insertion site with ChloraPrep®, Betadine®, or alcohol prep.
- 3. Stabilize vein in place by applying gentle traction on vein distal to point of entry.
- 4. Puncture the skin with the bevel of the needle upward about 0.5 1 cm from the vein and enter the vein from the side or from above.
- 5. Note blood return and advance the catheter over the needle.
- 6. Remove needle and connect IV line. Note: venous blood for laboratory work may be drawn with syringe before connecting IV line.
- 7. Release IV tourniquet.
- 8. Open IV tubing clamp full to check flow and placement, then slow rate to TKO or as indicated by applicable treatment protocol.
- 9. Secure catheter and tubing with tape or commercial device in a manner that reduces traction upon the catheter.
- 10. Anchor with an arm board or splint if the catheter is likely to be dislodged.
- 11. Recheck IV patency periodically to minimize occurrence of unrecognized fluid/medication extravasation.





Approved 9/04/24, Effective 1/15/25, replaces all prior versions

#### PROTOCOL 9H: Vascular Access - Intravenous - Adult & Pediatric, cont.

#### Technique:

- B. External Jugular Vein for peripheral venous access in a patient in extremis only.

  Anatomical landmarks, including the vein, must be visible no "blind" sticks.

  Avoid multiple attempts and avoid attempts on both sides use IO access prn.
  - 1. Position the patient supine, head down (this may not be necessary or desirable if congestive heart failure or respiratory distress present). Turn patient's head to opposite side from procedure. (Maintain cervical spine alignment if cervical spinal injury suspected; do not attempt external jugular vein cannulation in suspected cervical spine injury patients.)
  - 2. Expose vein by having patient bear down if possible, and "tourniquet" vein with finger pressure just above clavicle.
  - 3. Clean insertion site with ChloraPrep<sup>®</sup>, Betadine<sup>®</sup>, or alcohol prep.
  - 4. Stabilize vein in place by applying gentle traction on vein distal to point of entry.
  - 5. Align the cannula in the direction of the vein, with the point aimed toward the shoulder on the same side.
  - 9. Puncture skin over vein first, then puncture vein itself. Use other hand to traction vein near clavicle to prevent rolling.
  - 10. Proceed as with extremity vein. Do not wrap any tape/retaining device around the circumference of neck to stabilize IV catheter/line.

#### **Complications**:

- 1. Local: hematoma formation, infection, thrombosis, phlebitis.
- 2. Systemic: bacteremia/sepsis, catheter fragment embolus.

#### Additional Notes:

- A. Antecubital veins are useful access sites for patients in shock, but if possible, avoid areas near joints (or splint well!).
- B. The point between the junction of two veins is more stable and often easier to use.
- C. Start distally and, if successive attempts are necessary, make more proximal attempts.
- D. The most difficult problem with IV insertion is to know when to try and when to stop trying. If the procedure is not accomplished after two attempts or two minutes, the EMT I85 or higher licensed EMS professional must consider expediting other care, including transport to the emergency department, with further attempts enroute. This does not pertain to the trauma patient where rapid transport is advised with IV's performed enroute to the hospital.
- E. Renal dialysis fistulas and surgically implanted ports should not be used for vascular access. Use IO access in critical patient situations otherwise.
- F. Saline locks may be utilized in place of crystalloid infusions/IV lines in conditions less likely to require rapid administration of IV fluid.





## Medical Literature References 9H - Vascular Access – Intravenous - Adult & Pediatric

- 1. Fields JM, Piela NE, Au AK, Ku BS. Risk factors associated with difficult venous access in adult ED patients. *Am J Emerg Med*. 2014 Oct;32(10):1179-82.
- 2. Aulagnier J, Hoc C, Mathieu E, Dreyfus JF, Fischler M, Le Guen M. Efficacy of AccuVein to facilitate peripheral intravenous placement in adults presenting to an emergency department: a randomized clinical trial. *Acad Emerg Med.* 2014 Aug;21(8):858-63.
- 3. Merlin MA, Kaplan E, Schlogl J, Suss H, DosSantos FD, Ohman-Strickland P, Shiroff A. Study of placing a second intravenous line in trauma. *Prehosp Emerg Care*. 2011 Apr-Jun;15(2):208-13.
- 4. Cotton BA, Jerome R, Collier BR, Khetarpal S, Holevar M, Tucker B, Kurek S, Mowery NT, Shah K, Bromberg W, Gunter OL, Riordan WP Jr; Eastern Association for the Surgery of Trauma Practice Parameter Workgroup for Prehospital Fluid Resuscitation. Guidelines for prehospital fluid resuscitation in the injured patient. *J Trauma*. 2009 Aug;67(2):389-402.
- 5. Carr BG, Brachet T, David G, Duseja R, Branas CC. The time cost of prehospital intubation and intravenous access in trauma patients. *Prehosp Emerg Care*. 2008 Jul-Sep;12(3):327-32.]
- Spaite DW, Valenzuela TD, Criss EA, Meislin HW, Hinsberg P. A prospective in-field comparison of intravenous line placement by urban and nonurban emergency medical services personnel. *Ann Emerg Med.* 1994 Aug;24(2):209-14.
- 7. Boyle MF, Kuntz B. Saline locks in prehospital care. *Prehosp Disaster Med.* 1994 Jul-Sep;9(3):190-2
- 8. Slovis CM, Herr EW, Londorf D, Little TD, Alexander BR, Guthmann RJ. Success rates for initiation of intravenous therapy en route by prehospital care providers. *Am J Emerg Med.* 1990 Jul;8(4):305-7.





Approved 9/04/24, Effective 1/15/25, replaces all prior versions

## 9I - VASCULAR ACCESS - INTRAOSSEOUS ADULT & PEDIATRIC



#### **Indications**:

- 1. First-choice access in cardio/pulmonary arrest (unless IV access can be achieved as timely).
- 2. Second-choice access in dynamic, life-threatening shock or respiratory failure (if IV access cannot be achieved in clinically needed time).

#### **Contraindications:**

- 1. Inability to locate anatomical landmarks (blind insertion contraindicated).
- 2. Suspected cellulitis at insertion site.
- 3. Suspected acute or non-healed fracture proximal to foot in same leg (proximal tibial insertion) or proximal to forearm in same arm (humeral head insertion).
- 4. Suspected total knee arthroplasty/replacement (proximal tibial insertion).
- 5. Suspected markedly poor circulation extremity (history of amputation, gangrene, bypass).

#### Technique (EZ-IO® System):

- A. Assemble following materials:
  - Driver with Needle Set based on patient size and weight: 15mm 3-39 kg (PINK); 25mm 40 kg and greater (BLUE);


45mm 40 kg and greater (excessive tissue) (YELLOW).

- 2. EZ-Connect® 90 degree connection set.
- 3. Alcohol wipe (or ChloraPrep® or equivalent if available).
- 4. Saline flush syringe.
- 5. 1 mg/kg Lidocaine (up to 40mg) for intraosseous push if patient responsive.
- 6. Pressure infuser.
- 7. EZ-IO®Stabilizer (optional if proximal tibia insertion; required if humeral head insertion).



- 1. Proximal tibia site (Figure 1).
- 2 Palpate patella (1). Palpate tibial tuberosity (2) approximately two fingers widths below patella in adults and adolescents, or one finger width below patella in smaller pediatrics. Insertion (3) at one finger width medial to tibial tuberosity in the tibial plateau.











Approved 9/04/24, Effective 1/15/25, replaces all prior versions PROTOCOL 9I: Vascular Access - Intraosseous, Adult & Pediatric, cont.

- B. Locate insertion site (cont.)
  - 3. Humeral head site. Extra precision should be taken when utilizing this site. The anatomy proves more difficult to locate, the insertion area is smaller, and the IO needle is more prone to dislodgement due to a thinner bony cortex and higher likelihood of inadvertent EMS provider contact with the IO line.

Position arm in 90 degree flexion, with elbow kept to side of trunk (Figure 2). This position helps to gain maximal "exposure" of the humeral head.

Palpate and identify the mid-shaft humerus and continue palpating with a thumb proximal toward the humeral head. Near the shoulder, note a small protrusion. This is the base of the greater tubercle insertion site. With the opposite hand "pinching" the anterior and inferior aspects of the humeral head, confirm the identification of the greater tubercle in the midline of the humerus. (Figure 3).






- C. Clean insertion site with alcohol wipe, or preferably with ChloraPrep<sup>®</sup> or equivalent swab.
- D. Access the intraosseous space.
  - 1. Stabilize anatomy near the insertion site with non-dominant hand.
  - 2. Position driver at insertion site with needle at 90 degree angle to the surface of the bone. Use driver to insert needle through the skin at the insertion site until you feel the needle tip encounter bone. Allow the driver to perform its function of progressively inserting the needle. Avoid strong, downward pressure on the needle and maintain constant driver drilling speed. (Figure 4 next page proximal tibia insertion site depicted)
  - 3. Once the bone cortex feels encountered, ensure use of proper sized needle by checking for visualization of at least one 5 mm mark line (solid black circumferential line on the needle). If at least one 5mm mark line is not visible, a longer needle will be required to achieve useable intraosseous access. (Figure 5 next page)





Approved 9/04/24, Effective 1/15/25, replaces all prior versions **PROTOCOL 9I: Vascular Access - Intraosseous, Adult & Pediatric, cont.** 




- 4. Resume use of driver to insert a properly-sized needle through the bony cortex and into the bony marrow (evident with a sudden decrease in resistance to needle insertion), maintaining the 90 degree angle to the surface of the skin. Most typically, properly-sized needles will have their hub resting on the skin surface at the time the needle tip is correctly in the marrow space.
- E. While stabilizing the needle hub with a thumb and an index finger, disengage the driver from the needle in a gentle, upward motion.
- F. While still stabilizing the needle hub with a thumb and an index finger, remove the stylet by rotating it counterclockwise until disengaged.
- G. Do NOT attempt aspiration of blood or marrow via the catheter. Pulling marrow into the catheter may clog the catheter and prevent its use for needed fluid and/or medication administration. Do confirm proper EZ-IO® catheter placement using a combination of the following signs:
  - a. IO catheter rests at 90 degree angle and feels firmly in bone when grasping hub.
  - b. Blood-tinged marrow oozes spontaneously from hub (may often be absent, yet the catheter is still correctly placed).
  - c. Fluid and medication administration is possible without significant resistance and without extravasation.
- H. When using the proximal tibia insertion site, use of the EZ-Stabilizer® (Figure 6 next page) is optional and its use is determined by the EMT-Intermediate's or EMT-Paramedic's judgment. When using the humeral head insertion site, use of the EZ-Stabilizer® is required to reduce the chances of inadvertent dislodgement (refer to earlier discussion of humeral head insertion site). If the EZ-Stabilizer® is used, it must be applied prior to connecting the 90 degree connector set to the catheter hub.





Approved 9/04/24, Effective 1/15/25, replaces all prior versions **PROTOCOL 9I: Vascular Access - Intraosseous, Adult & Pediatric, cont.** 



- The EZ-Connect® 90 degree connector set (also seen in Figure 6) is used to prevent excessive pressure on the catheter when infusing fluids or administering medications. Failure to use the 90 degree connector set can cause inadvertent dislodgement due to excessive pressure down the catheter. Flush the EZ-Connect® set with Normal Saline prior to attaching it to the catheter hub and then flush the line to flush the catheter with 10mL Normal Saline if patient unresponsive or Lidocaine 2% 1 mg/kg up to 40mg slow intraosseous push if the patient is responsive and clearly able to sense pain. If using Lidocaine as directed, follow with 10mL Normal Saline flush.
- J. Medication administration is given in the same dosing as with IV administrations.
- K. Fluid administration will require the use of a pressure infuser on the IV fluid bag. Due to the increased pressure of the marrow space, IV fluid will not infuse without assistance of the pressure infuser. Inflate pressure infuser until IV fluid is seen infusing with constant flow. Monitor for extravasation and monitor for need to reinflate pressure infuser. Fluid delivery rate may be as high as 1 liter per hour at tibial site and up to 5 liters per hour at humeral head site.
- L. In determining the site for IO access, consider knowledge of the anatomy, prior training and comfort in accessing that particular site, and how IO access at that site may or may not interfere with other care events (eg. use of the humeral head site for medication administration in cardiac arrest could disrupt the continuity of chest compressions).

#### Complications of intraosseous line placement attempts:

Through and through bone penetration – avoid by using correct needle and insertion technique. Extravasation – avoid by using correct needle and insertion technique. Monitor ongoing use and stop at early signs of extravasation. Fracture of bone – avoid by using correct insertion technique (avoid excessive pressure). Infection – avoid by using aseptic technique and do not insert through suspected cellulitis. Growth plate injury in pediatrics – avoid by choosing correct insertion site.





## Medical Literature References 9I - Vascular Access – Intraosseous - Adult & Pediatric

- 1. Vidacare.com accessed on May 5-6, 2012.
- 2. Santos D, Carron PN, Yersin B, Pasquier M. EZ-IO(®) intraosseous device implementation in a pre-hospital emergency service: A prospective study and review of the literature. *Resuscitation*. 2013 Apr;84(4):440-5.
- 3. Wampler D, Schwartz D, Shumaker J, Bolleter S, Beckett R, Manifold C. Paramedics successfully perform humeral EZ-IO intraosseous access in adult out-of-hospital cardiac arrest patients. *Am J Emerg Med.* 2012 Sep;30(7):1095-9.
- 4. Tan BKK, Chong S, Koh ZX, Ong MEH. EZ-IO in the ED: an observational, prospective study comparing flow rates with proximal and distal tibia intraosseous access in adults. *Am J of Emerg Med.* 2012; doi.10.1016/j.ajem.2011.10.025.
- 5. Gazin N, Auger H, Jabre P et al. Efficacy and safety of the EZ-IO<sup>™</sup> intraosseous device: Out-of-hospital implementation of a management algorithm for difficult vascular access. *Resuscitation* 2011;82(1):126-9.
- 6. Hoskins SL, Nascimento P Jr., Lima RM, Espana-Tenorio, JM, Kramer GC. Pharmacokinetics of intraosseous and central venous drug delivery during cardiopulmonary resuscitation. *Resuscitation* 2011;doi:10.1016/j.resuscitation. 2011.07.041.
- 7. Reades R, Studneck J, Garrett J, Vandeventer S, Blackwell T. Comparison of first-attempt success between tibial and humeral intraosseous insertions during out-of-hospital cardiac arrest. *Prehosp Emerg Care*. 2011;15(2):278-81.
- 8. Reades R, Studnek JR, Vandeventer S, Garrett J. Intraosseous versus intravenous vascular access during out-of-hospital cardiac arrest: a randomized controlled trial. *Ann Emerg Med* 2011;doi:10.1016/i.annemergmed.2011.07.020.
- 9. Wampler D, Schwartz D, Shumaker J, Bolleter S, Beckett R, Manifold C. Paramedics successfully perform humeral EZ-IO intraosseous access in adult out-of-hospital cardiac arrest patients. *Am J of Emerg Med.* 2011; doi:10.1016/j.ajem.2011.07.010.
- 10. Weiser G, Hoffmann Y, Galbraith R, Shavit I. Current advances in intraosseous infusion a systematic review. *Resuscitation*. 2011;doi:10.1016/j.resuscitation.2011.07.020.
- 11. Frascone RJ, Jensen J, Wewerka SS, Salzman JG. Use of the pediatric EZ-IO needle by emergency medical services providers. *Pediatr Emerg Care*. 2009; 25: 329-32.
- 12. Fowler R, Gallagher JV, Isaacs SM, Ossman E et al. The role of intraosseous vascular access in the out-of-hospital environment (resource document to NAEMSP position statement). *Prehosp Emerg Care*. 2007; 11: 63-6.





Approved 9/04/24, Effective 1/15/25, replaces all prior versions

## 9J – INDWELLING CENTRAL VASCULAR DEVICE MANAGEMENT ADULT & PEDIATRIC

#### **PARAMEDIC**

#### Indications:

Use and/or monitoring of indwelling central venous devices.

#### **Contraindications:**

- 1. Central venous ports easily permanently damaged with wrong needle or infected.
- 2. Suspected infection in the indwelling central venous devices.
- 3. Easy peripheral venous access available or already established.

#### Technique:

Indwelling central venous devices may become irreversibly damaged if wrong needles and techniques occur. In general, avoid the use of indwelling central venous devices unless already in use (during an interfacility transfer) or in the case of a peripherally inserted central catheter (PICC) line, peripheral venous access is not readily available or already established.

In the setting of interfacility transfer, indwelling central venous device(s) must be reviewed with either the transferring practitioner/physician or appropriate nursing personnel prior to conducting the interfacility transfer. Potential complications during transfer should be discussed and contingency plans reviewed.

During packaging, patient movement, and throughout the interfacility transfer, perform periodic inspection and assessment of indwelling central venous devices and take precautions to avoid inadvertent dislodgement of such devices.

If the need arises to access a PICC line, clean the port with ChloraPrep<sup>®</sup>, Betadine<sup>®</sup>, or an alcohol wipe. Aspirate 4 - 5 mL of fluid and discard (to remove any anticoagulant in the line) prior to infusing fluid or administering medication. Flush 10 mL of saline in the PICC line after administering a medication. Maintain aseptic technique throughout all handling of the PICC line.

If a closed cap on the line is required to be removed to access the indwelling central venous device, make sure the line is clamped to avoid introduction of an air embolus.

Contact OLMC early for any needed advice or direction in the use of an indwelling central venous device.





Medical Literature References
9J – Indwelling Central Vascular Device Management – Adult & Pediatric

- 1. Feldman R. Chapter 39. Troubleshooting Indwelling Central Venous Lines. In: Reichman EF, Simon RR, eds. Emergency Medicine Procedures. New York: McGraw-Hill; 2004. http://www.accessemergencymedicine.com/content.aspx?aID=50037. Accessed July 1, 2012.
- 2. Feldman R. Chapter 40. Accessing Indwelling Central Venous Lines. In: Reichman EF, Simon RR, eds. Emergency Medicine Procedures. New York: McGraw-Hill; 2004. http://www.accessemergencymedicine.com/content.aspx?aID=50147. Accessed July 1, 2012.





Approved 9/04/24, Effective 1/15/25, replaces all prior versions


## 9K – MEDICATION ADMINISTRATION ADULT & PEDIATRIC

Prior to all medication administrations, assure the "5 Rights" are reviewed:

- 1. Right Patient
- 2. Right Route
- 3. Right Dose
- 4. Right Time
- 5. Right Medication

If any one of these "rights" is "wrong", stop and do not administer the medication!

#### **Specific routes of medication administration:**



#### 9Ka: Intravenous / Intraosseous – Adult & Pediatric:


- 1. Assure that the IV / IO line is patent.
- 2. Cleanse the access port nearest the IV / IO site with alcohol prep.
- 3. Eject any air from syringe and insert needle or adapter into access port.
- 4. Pinch the IV /IO line above the medication port. This prevents the medication from traveling toward the IV bag, forcing it instead toward the patient.
- 5. Inject the medication as specified per appropriate treatment protocol.
- 6. Remove the needle or adapter and release the tubing.
- 7. Open the flow regulator to allow 10 20 mL fluid flush.






Approved 9/04/24, Effective 1/15/25, replaces all prior versions

#### PROTOCOL 9K: Medication Administration – Adult & Pediatric, cont.



#### 9Kb: Intramuscular/Subcutaneous Injection - Adult & Pediatric:

- 1. Use a 1 inch to 1.5 inch long 21 to 25 gauge needle on a syringe.
- 2. Select injection site (if IM, deltoid, lateral thigh, or upper/outer quadrant of gluteus; if SubQ, arm or lateral thigh).
- 3. Cleanse the injection site with alcohol prep.
- 4. Eject any air from syringe.
- 5. If IM, stretch skin over injection site and insert needle 90 degrees to skin surface, through skin into muscle, aspirate and if no blood return, inject medication.
- 6. If SubQ, pinch skin in a fold over injection site and insert needle 45 degrees to skin surface, through skin into subcutaneous fatty tissue, aspirate and if no blood return, inject medication.
- 7. Remove needle and put bandage over the injection site.



#### 9Kc: Intranasal - Adult & Pediatric, technique:


- 1. Use a medication nasal atomization device on a syringe.
- 2. Eject any air from syringe.
- 3. Place the atomizer tip approximately 1.5 cm within the nostril.
- 4. Briskly compress the syringe plunger to spray atomized solution into the nasal cavity/onto the nasal mucosa (gently pushing the plunger will not result in atomization).





Approved 9/04/24, Effective 1/15/25, replaces all prior versions

#### PROTOCOL 9K: Medication Administration – Adult & Pediatric, cont.



#### 9Kd: Sublingual/Oral – Adult & Pediatric:

1. Instruct, assist, or place the tablet or spray under the tongue (sublingual) or in the mouth (oral)/on the tongue (oral dissolving).

## **PARAMEDIC**

#### 9Ke: Ocular - Adult & Pediatric:

- 1. Don't touch the tip of the medication container to any part of the eye or face.
- 2. Pull the lower eyelid down while avoiding any ocular (eyeball) pressure.
- 3. Instill eye drop(s) in the space between the eyelid and the eyeball.

## PARAMEDIC

#### 9Kf: Intravascular Infusion Management - Adult & Pediatric:

- 1. Assure that the IV / IO line is patent.
- 2. Cleanse the access port nearest the IV / IO site with alcohol prep.
- 3. Flush any air from infusion line/set and insert needle or adapter into access port.
- 4. Unless simultaneously giving an IV fluid bolus, close off the IV line above the medication port. This prevents the medication from traveling toward the IV bag, forcing it instead toward the patient.
- 5. Infuse the medication as specified per appropriate treatment protocol.





#### Medical Literature References 9K–Medication Administration– Adult & Pediatric


- 1. Rech MA, Barbas B, Chaney W, Greenhalgh E, Turck C. When to pick the nose: out-of-hospital and emergency department intranasal administration of medications. *Ann Emerg Med.* 2017;70:203-211.
- 2. Arthur AO, Goodloe JM, Thomas SH. Subcutaneous fluid administration: a potentially useful tool in prehospital care. *Emerg Med Int.* 2012;2012:904521. Epub 2012 May 9.
- 3. Göransson KE, Johansson E. Indication and usage of peripheral venous catheters inserted in adult patients during emergency care. *J Vasc Access*. 2011 Jul-Sep;12(3):193-9. doi: 10.5301/JVA.2010.5967.
- 4. Vilke GM, Tornabene SV, Stepanski B, Shipp HE, Ray LU, Metz MA, Vroman D, Anderson M, Murrin PA, Davis DP, Harley J. Paramedic self-reported medication errors. *Prehosp Emerg Care*. 2006 Oct-Dec;10(4):457-62.
- 5. Abarbanell NR. Prehospital pharmacotherapeutic interventions: recommendations for medication administration by EMT-A and EMT-I personnel. *Am J Emerg Med.* 1994 Nov;12(6):625-30.





Approved 9/04/24, Effective 1/15/25, replaces all prior versions

#### PROTOCOL 9L - Nasogastric/Orogastric Tube - Adult & Pediatric



#### Indications:

- 1. I-gel<sup>™</sup> placement only.
- 2. Decompression of ventilated air in stomach (reduction of gastric distension) in the cardiac arrest patient.
- 3. Decompression of ventilated air in stomach (reduction of gastric distension), compromising oxygenation/ventilation in the unconscious, I-gel<sup>™</sup> patient.

#### Technique:

- 1. Choice proper NG tube size from chart in protocol 2E.1 (page 2E.2).
- 2. Lubricate NG tube prior to insertion into I-gel™ NG tube portal.
- 3. Place NG tube through the I-gel™ NG tube portal into the stomach.
- 4. Confirm correct gastric placement of gastric tube by injecting 10 to 20 mL of air while auscultating over the stomach for a "swoosh" or "burping/bubbling" indicating the gastric tube tip lies within the stomach. Confirm absence of similar sounds in the lungs by auscultating in the mid-axillary line bilaterally while repeating the injection of small mL volumes of air.
- 5. Attach gastric tube to low pressure suction and observe for gastric decompression.


#### **PARAMEDIC**

#### Indications:

- 1. Decompression of ventilated air in stomach (reduction of gastric distension) in the cardiac arrest patient. (may be placed pre or post intubation)
- 2. Decompression of ventilated air in stomach (reduction of gastric distension), compromising oxygenation/ventilation in the unconscious, intubated patient.

#### Contraindications:

- 1. Suspected basilar skull fracture
- 2. Suspected mid-facial fractures
- 3. Known or suspected actively bleeding esophageal varices







Approved 9/04/24, Effective 1/15/25, replaces all prior versions

#### PROTOCOL 9L - Nasogastric/Orogastric Tube - Adult & Pediatric cont.'

#### Technique:

- 1. Select correct size gastric tube. Adult patients typically require size 16 to 18 French gastric tubes.
- 2. Measure length of gastric tube to pass by starting with tip just at xiphoid process, then using distance to earlobe and over to tip of nose (Figure).
- 3. Mark the measured length of tube with a piece of tape.
- 4. Lubricate tip of tube with water soluble lubricant if inserting nasally.
- 5. Nasal insertion: direct gastric tube along the floor of nostril to the posterior nasopharynx, then feed the gastric tube through the oropharynx down the esophagus and into the stomach, stopping when taped mark nears nostril.
- 6. Oral insertion: direct gastric tube along tongue to posterior oropharynx, then feed the gastric tube down the esophagus and into the stomach, stopping when taped mark nears lips.
- 7. Confirm correct gastric placement of gastric tube by injecting 10 to 20 mL of air while auscultating over the stomach for a "swoosh" or "burping/bubbling" indicating the gastric tube tip lies within the stomach. Confirm absence of similar sounds in the lungs by auscultating in the mid-axillary line bilaterally while repeating the injection of small mL volumes of air.
- 8. Tape the tube in place on the nose or on around the mouth. Alternatively, some commercial types of endotracheal tube holders can be used to secure gastric tubes if passed orally.
- 9. Attach gastric tube to low pressure suction and observe for gastric decompression.

#### Troubleshooting:

- Abort gastric tube passage attempts if unsuccessful in three attempts.
- 2. Repetitive coughing indicates the gastric tube is erroneously passing down the trachea. Tracheal/bronchial stimulation in gastric tube passage will typically provoke strong coughing reflex. Promptly withdraw tracheally placed gastric tubes to avoid aspiration. An endotracheal tube will not prevent inadvertent passage of a gastric tube down the trachea.
- 3. Avoid lavage or medications via gastric tube. Use is for gastric decompression.





Medical Literature References
9L - Nasogastric/Orogastric Tube – Adult


- Leschke RR. Chapter 47. Nasogastric Intubation. In: Reichman EF, Simon RR, eds. Emergency Medicine Procedures. New York: McGraw-Hill; 2004. http://www.accessemergencymedicine.com/content.aspx?aID=50768. Accessed June 30, 2012.
- 2. Witting MD. "You wanna do what?!" Modern indications for nasogastric intubation. *J Emerg Med.* 2007 Jul;33(1):61-4.
- 3. Metheny N. Achieving successful nasogastric tube placements in emergency situations. *Am J Crit Care*. 2000 Sep;9(5):303-4, 306.





Approved 9/04/24, Effective 1/15/25, replaces all prior versions

## 9M – SUSPECTED ABUSE/NEGLECT ADULT & PEDIATRIC



#### **Indications:**

- 1. Concern for child abuse and/or neglect.
- 2. Concern for adult/elder abuse and/or neglect.

#### Contraindications:

None

In the course of EMS care of a patient (from time of emergency services request through transport of the patient to the destination location), EMS professionals that become concerned regarding actual or perceived abuse and/or neglect occurring to persons of any age should directly inform any receiving health care professionals and/or involved law enforcement officers of the concerns. If the concerns are regarding abuse and/or neglect of the patient, document such concerns in the patient care report, including specific comments that the receiving health care professional(s) and/or law enforcement officers were directly informed of such concerns in appropriate detail.

If EMS professionals believe an adult or child is being abused or neglected, and/or have concerns regarding the imminent safety of an adult or child due to possible abuse or neglect, there is a legal responsibility to report the beliefs and/or concerns.

# Oklahoma Department of Human Services Abuse and Neglect Hotline (Calls Answered 24 Hours a Day/7 Days a Week)

1-800-522-3511

When calling, identify yourself by name, EMS certification level, and agency/apparatus identification. Have as much patient/person information and situational/observation information possible readily available to share with the abuse and neglect hotline specialist.





Approved 9/04/24, Effective 1/15/25, replaces all prior versions

#### TREATMENT PRIORITIES

- 1. Spinal stabilization; Avoid spinal traction
- 2. Hemorrhage control
- 3. Assessment/Care for lifethreatening injuries/ shock/high intracranial pressure
- 4. Vital signs
- 5. Appropriate trauma care destination selection

#### 10A - HEAD/NECK/SPINE INJURY ADULT & PEDIATRIC

#### **EMD**

DO NOT MOVE THE PATIENT UNLESS IN DANGER STABILIZE HEAD AND NECK IN POSITION FOUND OPEN AIRWAY IF NOT ALERT & INEFFECTIVE BREATHING CONTROL BLEEDING ONLY IF SERIOUS DO NOT ATTEMPT TO SPLINT INJURIES

## EMERGENCY MEDICAL DISPATCHER

EMERGENCY MEDICAL RESPONDER

**EMT** 

**EMT-INTERMEDIATE 85** 

**ADVANCED EMT** 

**PARAMEDIC** 

EMR EMT

TRAUMA AND HYPOVOLEMIC SHOCK SUPPORTIVE CARE
SPINAL "STABILIZATION" - DO NOT APPLY SPINAL "TRACTION" DURING MOTION RESTRICTION OR IMMOBILIZATION (if applicable)
STABILIZE IMPALED OBJECTS

O<sub>2</sub> VIA NC, NRB, OR BVM AS APPROPRIATE APPLY CARDIAC MONITOR (if equipped)

#### **EMT OR HIGHER LICENSE:**

MEASURE END – TIDAL CO<sub>2</sub> & MONITOR WAVEFORM CAPNOGRAPHY (if equipped, \*\* Mandatory use if pt intubated) MAINTAIN EtCO<sub>2</sub> LEVELS 35 – 40 mmHg

DURING SIGNS SUGGESTIVE OF INCREASING INTRACRANIAL PRESSURE
(PROGRESSIVE DECLINE IN MENTAL STATUS, POSTURING, SEIZING, DILATING/NON-REACTIVE/ASYMMETRIC PUPILS)
CONTROLLED HYPERVENTILATION TO ACHIEVE EtCO2 LEVELS 30-35 mmHg

PLACE SUPRAGLOTTIC AIRWAY IF INDICATED & ONLY IF BVM VENTILATIONS INEFFECTIVE.

EMT-185 AEMT

**ADULT: INTUBATE IF INDICATED** 

IV ACCESS (IO IF INDICATED) (TWO LINES IF POSSIBLE)

ADULT: IV / IO NS 250 mL BOLUS TO MAINTAIN SYS BP ≥ 100mmHg

ADULT: REPEAT UP TO 2 LITERS IF SYS BP REMAINS < 100 mmHg & NO SIGNS OF PULMONARY EDEMA PEDIATRIC: IV / IO NS 20 mL/kg BOLUS IF SYS BP < (70 + 2x age in years) mmHg & NO SIGNS OF PULMONARY EDEMA

#### **PARAMEDIC**

EVALUATE FOR OTHER ALTERED MENTAL STATUS ETIOLOGIES. TREAT PER APPROPRIATE PROTOCOL(S)

ADULT: MEDICATION ASSISTED INTUBATION IF INDICATED

ADULT: MIDAZOLAM 5 mg IM/IVP/IN/IOP FOR ACTIVE SEIZURE. MAY REPEAT X 1 IN 5 MINS IF STILL SEIZING OR ADULT: DIAZEPAM 5 mg IVP/IOP or 10 mg IM FOR ACTIVE SEIZURE. MAY REPEAT X 1 IN 5 MINS IF STILL SEIZING OR ADULT: LORAZEPAM 1 mg IVP/IM/IOP FOR ACTIVE SEIZURE. MAY REPEAT X 1 IN 5 MINS IF STILL SEIZING

PEDIATRIC: MIDAZOLAM 0.1 mg/kg IM/IVP/IN/IOP TO MAX OF 5mg FOR ACTIVE SEIZURE. MAY REPEAT X 1 IN 5 MINS IF STILL SEIZING OR PEDIATRIC: DIAZEPAM 0.1 mg/kg TO MAX OF 5 mg IVP/IOP/IM FOR ACTIVE SEIZURE. MAY REPEAT X 1 IN 5 MINS IF STILL SEIZING OR PEDIATRIC: LORAZEPAM 0.1 mg/kg IVP/IM/IOP for ACTIVE SEIZURE. MAY REPEAT X 1 IN 5 MINS IF STILL SEIZING

OLMC CONSULT IF SEIZURE CONTINUES DESPITE ABOVE TREATMENT

CONTINUOUS ASSESSMENT & TREATMENT PER APPLICABLE PROTOCOL(S)






#### Medical Literature References 10A – Head/Neck/Spine Injury – Adult & Pediatric

- Lulla A, Lumba-Brown A, Totten AM, Maher PJ, Badjatia N, Bell R, Donayri CTJ, Fallat ME, Hawryluk GWJ, Goldberg SA, Hennes HMA, Ignell SP, Ghajar J, Krzyzaniak BP, Lerner EB, Nishijima D, Schleien C, Shackelford S, Swartz E, Wright DW, Zhang R, Jagoda A, Bobrow BJ. Prehospital Guidelines for the Management of Traumatic Brain Injury 3rd Edition. Prehosp Emerg Care. 2023;27(5):507-538. doi: 10.1080/10903127.2023.2187905. Epub 2023 Apr 20. PMID: 37079803.
- Fischer, P. E., Perina, D. G., Delbridge, T. R., Fallat, M. E., Salomone, J. P., Dodd, J., ... Gestring, M. L. (2018). Spinal Motion Restriction in the Trauma Patient A Joint Position Statement. Prehospital Emergency Care, 3127, 1–3. https://doi.org/10.1080/10903127.2018.1481476
- 3. Kempena J, Trust MD, Ali S, Cabana JG, Hinchey PR, Brown LH, Brown CV. Prehospital endotracheal intubation vs extraglottic airway device in blunt trauma. *Am J Emerg Med.* 2015 Aug;33(8):1080-3.
- 4. Wang HE, Brown SP, MacDonald RD, Dowling SK, Lin S, Davis D, Schreiber MA, Powell J, van Heest R, Daya M. Association of out-of-hospital advanced airway management with outcomes after traumatic brain injury and hemorrhagic shock in the ROC hypertonic saline trial. *Emerg Med J.* 2014 Mar;31(3):186-91.
- 5. Franschman G, Peerdeman SM, Andriessen TM, Greuters S, Toor AE, Vos PE, Bakker FC, Loer SA, Boer C; Amsterdam Lifeliner: Analysis of Results and Methods--Traumatic Brain Injury (ALARM-TBI) Investigators. Effect of secondary prehospital risk factors on outcome in severe traumatic brain injury in the context of fast access to trauma care. *J Trauma*. 2011 Oct;71(4):826-32.
- Davis DP, Koprowicz KM, Newgard CD, Daya M, Bulger EM, Stiell I, Nichol G, Stephens S, Dreyer J, Minei J, Kerby JD. The relationship between out-of-hospital airway management and outcome among trauma patients with Glasgow Coma Scale Scores of 8 or less. *Prehosp Emerg Care*. 2011 Apr-Jun;15(2):184-92.
- 7. Swartz EE, Hernandez AE, Decoster LC, Mihalik JP, Burns MF, Reynolds C. Prehospital emergency removal of football helmets using two techniques. *Prehosp Emerg Care*. 2011 Apr-Jun;15(2):166-74.
- 8. Irvin CB, Szpunar S, Cindrich LA, Walters J, Sills R. Should trauma patients with a Glasgow Coma Scale score of 3 be intubated prior to hospital arrival? *Prehosp Disaster Med.* 2010 Nov-Dec;25(6):541-6.
- 9. Haut ER, Kalish BT, Cotton BA, Efron DT, Haider AH, Stevens KA, Kieninger AN, Cornwell EE 3rd, Chang DC. Prehospital intravenous fluid administration is associated with higher mortality in trauma patients: a National Trauma Data Bank analysis. *Ann Surg.* 2011 Feb;253(2):371-7.
- 10. Dumont TM, Visioni AJ, Rughani AI, Tranmer BI, Crookes B. Inappropriate prehospital ventilation in severe traumatic brain injury increases in-hospital mortality. *J Neurotrauma*. 2010 Jul;27(7):1233-41.
- 11. Zebrack M, Dandoy C, Hansen K, Scaife E, Mann NC, Bratton SL. Early resuscitation of children with moderate-to-severe traumatic brain injury. *Pediatrics*. 2009 Jul;124(1):56-64.
- 12. Berlot G, La Fata C, Bacer B, Biancardi B, Viviani M, Lucangelo U, Gobbato P, Torelli L, Carchietti E, Trillò G, Daniele M, Rinaldi A. Influence of prehospital treatment on the outcome of patients with severe blunt traumatic brain injury: a single-centre study. *Eur J Emerg Med.* 2009 Dec;16(6):312-7.
- Badjatia N, Carney N, Crocco TJ, Fallat ME, Hennes HM, Jagoda AS, Jernigan S, Letarte PB, Lerner EB, Moriarty TM, Pons PT, Sasser S, Scalea T, Schleien CL, Wright DW; Brain Trauma Foundation; BTF Center for Guidelines Management. Guidelines for prehospital management of traumatic brain injury 2nd edition. *Prehosp Emerg Care*. 2008;12Suppl 1:S1-52.





Approved 9/04/24, Effective 1/15/25, replaces all prior versions



EVALUATE FOR OTHER ALTERED MENTAL STATUS ETIOLOGIES. TREAT PER APPROPRIATE PROTOCOL(S)

ANALGESIA (IF REQUIRED)

FOR OPIATE USE, ADULT MUST HAVE SYS BP ≥ 100 mmHg; PEDIATRIC MUST HAVE SYS BP ≥ (70 + 2x age in years) mmHg

ADULT: FENTANYL 1 mcg/kg SLOW IVP/IM/IN, MAXIMUM DOSE 100 mcg. MAY REPEAT EVERY 10 MINUTES TO MAXIMUM CUMULATIVE DOSE OF 3 mcg/kg or 250 mcg WHICHEVER IS LESSER. OR

ADULT: MORPHINE SULFATE 2 - 4 mg SLOW IVP, MAY REPEAT 2 - 4 mg EVERY 5 MINUTES TO A TOTAL OF 10 mg.

OR ADULT: HYDROMORPHONE 0.5 - 1 mg SLOW IVP, MAY REPEAT EVERY 10 MINUTES TO MAXIMUM CUMULATIVE DOSE OF 2 mg.

PEDIATRIC: OLMCP ORDER ONLY

OLMCP CONSULT IF FURTHER ANALGESIA REQUIRED

CONTINUOUS ASSESSMENT & TREATMENT PER APPLICABLE PROTOCOL(S)






#### Medical Literature References 10B – Eye Injury – Adult & Pediatric

- 1. Khare GD, Symons RC, Do DV. Common ophthalmic emergencies. *Int J Clin Pract.* 2008 Nov;62(11):1776-84.
- 2. Spector J, Fernandez WG. Chemical, thermal, and biological ocular exposures. *Emerg Med Clin North Am.* 2008 Feb;26(1):125-36, vii.
- 3. Bord SP, Linden J. Trauma to the globe and orbit. *Emerg Med Clin North Am.* 2008 Feb;26(1):97-123, vi-vii.
- 4. Bledsoe BE, Ho B. Sight-threatening eye injuries: prehospital management of ophthalmological emergencies. *JEMS*. 2004 Oct;29(10):94-106





Approved 9/04/24, Effective 1/15/25, replaces all prior versions



ANALGESIA (IF REQUIRED)

FOR OPIATE USE, ADULT MUST HAVE SYS BP ≥ 100 mmHg, PEDIATRIC MUST HAVE SYS BP ≥ (70 + 2x age in years) mmHg

ADULT: FENTANYL 1 mcg/kg SLOW IVP/IM/IN, MAXIMUM DOSE 100 mcg. MAY REPEAT EVERY 10 MINUTES TO MAXIMUM CUMULATIVE DOSE OF 3 mcg/kg or 250 mcg WHICHEVER IS LESSER.

OR ADULT: MORPHINE SULFATE 2 - 4 mg SLOW IVP, MAY REPEAT 2 - 4 mg EVERY 5 MINUTES TO A TOTAL OF 10 mg.

OR

ADULT: HYDROMORPHONE 0.5 - 1 mg SLOW IVP, MAY REPEAT EVERY 10 MINUTES TO MAXIMUM CUMULATIVE DOSE OF 2 mg.

PEDIATRIC: OLMCP ORDER ONLY

OLMCP CONSULT IF FURTHER ANALGESIA REQUIRED

CONTINUOUS ASSESSMENT & TREATMENT PER APPLICABLE PROTOCOL(S)





Medical Literature References 10C – Dental Injury/Pain– Adult & Pediatric

- Andersson L, Andreasen JO, Day P, Heithersay G, Trope M, Diangelis AJ, Kenny DJ, Sigurdsson A, Bourguignon C, Flores MT, Hicks ML, Lenzi AR, Malmgren B, Moule AJ, Tsukiboshi M; International Association of Dental Traumatology. International Association of Dental Traumatology guidelines for the management of traumatic dental injuries: 2. Avulsion of permanent teeth. *Dent Traumatol*. 2012. Apr;28(2):88-96.
- 2. Bae JH, Kim YK, Choi YH. Clinical characteristics of dental emergencies and prevalence of dental trauma at a university hospital emergency center in Korea. *Dent Traumatol.* 2011 Oct;27(5):374-8.
- 3. Stewart GB, Shields BJ, Fields S, Comstock RD, Smith GA. Consumer products and activities associated with dental injuries to children treated in United States emergency departments, 1990-2003. *Dent Traumatol.* 2009 Aug;25(4):399-405.
- 4. Dale RA. Dentoalveolar trauma. Emerg Med Clin North Am. 2000 Aug;18(3):521-38.
- 5. Armstrong BD. Lacerations of the mouth. *Emerg Med Clin North Am.* 2000 Aug;18(3):471-80, vi.





Approved 9/04/24, Effective 1/15/25, replaces all prior versions

#### 10D - CHEST/ABDOMEN/PELVIS INJURY **ADULT & PEDIATRIC**

#### TREATMENT PRIORITIES

- 1. Hemorrhage control
- 2. Assessment/Care for lifethreatening injuries/shock
- 3. Needle thoracostomy for tension peumothorax
- 4. Vital signs
- 5. Appropriate trauma care destination selection

#### **EMD**

DO NOT MOVE THE PATIENT UNLESS IN DANGER STABILIZE HEAD AND NECK IN POSITION FOUND OPEN AIRWAY IF NOT ALERT & INEFFECTIVE BREATHING CONTROL BLEEDING ONLY IF SERIOUS DO NOT ATTEMPT TO SPLINT INJURIES

#### EMERGENCY MEDICAL **DISPATCHER**

**EMERGENCY MEDICAL** RESPONDER

**EMT** 

**EMT-INTERMEDIATE 85** 

**ADVANCED EMT** 

**PARAMEDIC** 

**EMR EMT** 

TRAUMA AND HYPOVOLEMIC SHOCK SUPPORTIVE CARE SPINAL "STABILIZATION" - DO NOT APPLY SPINAL "TRACTION" DURING MOTION RESTRICTION OR IMMOBILIZATION (if applicable)

COVER SUCKING CHEST WOUNDS WITH VENTED SEALS STABILIZE IMPALED OBJECTS

STABILIZE SUSPECTED PELVIC FRACTURE WITH SHEET/BINDER TIED LOW AROUND PELVIS IF DISTAL FRACTURES SUSPECTED STABILIZE SUSPECTED PELVIC FRACTURE WITH INTERNAL ROTATION & TAPING OF LOWER EXTREMITIES IF NO DISTAL FRACTURES EVIDENT IF USING IRTOTLE TECHNIQUE, DO NOT CIRCUMFERENTIAL TAPE, DO NOT TAPE OVER BONY PROMINENCES. 4 INCH FOAM TAPE PREFERRED. COVER EVISCERATED ABDOMINAL/PELVIC ORGANS WITH STERILE, SALINE DAMPENED DRESSING PRIOR TO LAYERING WITH DRY DRESSINGS **OBTAIN VITAL SIGNS** 

O2 VIA NC, NRB, OR BVM AS APPROPRIATE APPLY CARDIAC MONITOR (when available)

#### **EMT OR HIGHER LICENSE:**

MEASURE END - TIDAL CO<sub>2</sub> & MONITOR WAVEFORM CAPNOGRAPHY (if equipped, \*\* Mandatory use if pt intubated) PLACE SUPRAGLOTTIC AIRWAY IF INDICATED & ONLY IF BVM VENTILATIONS INEFFECTIVE.

> **EMT-185 AEMT**

> > **ADULT: INTUBATE IF INDICATED**

IV ACCESS (IO IF INDICATED) (TWO LINES IF POSSIBLE) ADULT: IV NS TKO IF SYS BP ≥ 100 mmHg WITHOUT HYPOTENSIVE SYMPTOMS

ADULT: IV NS 250 mL BOLUS IF SYS BP <100 mmHg WITH HYPOTENSIVE SYMPTOMS & NO SIGNS OF PULMONARY EDEMA,

ADULT: REPEAT UP TO 2 LITERS NS IF SYS BP REMAINS < 100 mmHg WITH HYPOTENSIVE SYMPTOMS & NO SIGNS OF PULMONARY EDEMA PEDIATRIC: IV NS 20 mL/kg BOLUS IF SYS BP < (70 + 2x age in years) mmHg & NO SIGNS OF PULMONARY EDEMA PEDIATRIC: REPEAT UP TO 60 mL/kg IF SYS BP REMAINS < (70 + 2x age in years) mmHg & NO SIGNS OF PULMONARY EDEMA

#### **PARAMEDIC**

NEEDLE THORACOSTOMY FOR SUSPECTED TENSION PNEUMOTHORAX **ADULT: MEDICATION ASSISTED INTUBATION IF INDICATED** 

#### ANALGESIA (IF REQUIRED)

FOR OPIATE USE, ADULT MUST HAVE SYS BP ≥ 100 mmHg; PEDIATRIC MUST HAVE SYS BP ≥ (70 + 2x age in years) mmHg ADULT: FENTANYL 1 mcg/kg SLOW IVP/IM/IN, MAXIMUM DOSE 100 mcg. MAY REPEAT EVERY 10 MINUTES TO MAXIMUM CUMULATIVE DOSE OF 3 mcg/kg or 250 mcg WHICHEVER IS LESSER.

OR ADULT: MORPHINE SULFATE 2 - 4 mg SLOW IVP, MAY REPEAT 2 - 4 mg EVERY 5 MINUTES TO A TOTAL OF 10 mg. OR

ADULT: HYDROMORPHONE 0.5 - 1 mg SLOW IVP, MAY REPEAT EVERY 10 MINUTES TO MAXIMUM CUMULATIVE DOSE OF 2 mg.

PEDIATRIC: OLMCP ORDER ONLY

OLMCP CONSULT IF FURTHER ANALGESIA REQUIRED

CONTINUOUS ASSESSMENT & TREATMENT PER APPLICABLE PROTOCOL(S)





#### Medical Literature References 10D – Chest/Abdomen/Pelvis Injury – Adult & Pediatric

- 1. McMullan J, Rodriquez D, Hart KW, Lindsell CJ, Vonderschmidt K, Wayne B, Branson R. Prevalence of prehospital hypoxemia and oxygen use in trauma patients. *Mil Med.* 2013 Oct;178(10):1121-5.
- Hampton DA, Fabricant LJ, Differding J, Diggs B, Underwood S, De La Cruz D, Holcomb JB, Brasel KJ, Cohen MJ, Fox EE, Alarcon LH, Rahbar MH, Phelan HA, Bulger EM, Muskat P, Myers JG, del Junco DJ, Wade CE, Cotton BA, Schreiber MA; PROMMTT Study Group. Prehospital intravenous fluid is associated with increased survival in trauma patients. *J Trauma Acute Care Surg.* 2013 Jul;75(1 Suppl 1):S9-15.
- 3. Brown JB, Cohen MJ, Minei JP, Maier RV, West MA, Billiar TR, Peitzman AB, Moore EE, Cuschieri J, Sperry JL; Inflammation and the Host Response to Injury Investigators. Goal-directed resuscitation in the prehospital setting: a propensity-adjusted analysis. *J Trauma Acute Care Surg.* 2013 May;74(5):1207-12; discussion 1212-4.
- 4. McCoy CE, Menchine M, Sampson S, Anderson C, Kahn C. Emergency medical services out-of-hospital scene and transport times and their association with mortality in trauma patients presenting to an urban Level I trauma center. *Ann Emerg Med.* 2013 Feb;61(2):167-74.
- 5. Isbell CL, Batchinsky AI, Hetz KM, Baker WL, Cancio LC. Correlation between capnography and arterial carbon dioxide before, during, and after severe chest injury in swine. *Shock*. 2012 Jan;37(1):103-9.
- 6. Wigginton JG, Roppolo L, Pepe PE. Advances in resuscitative trauma care. *Minerva Anestesiol.* 2011 Oct;77(10):993-1002.
- 7. Kragh JF Jr, Murphy C, Dubick MA, Baer DG, Johnson J, Blackbourne LH. New tourniquet device concepts for battlefield hemorrhage control. *US Army Med Dep J*. 2011 Apr-Jun:38-48.
- 8. Tan EC, van Stigt SF, van Vugt AB. Effect of a new pelvic stabilizer (T-POD®) on reduction of pelvic volume and haemodynamic stability in unstable pelvic fractures. *Injury*. 2010 Dec;41(12):1239-43.
- 9. Williams-Johnson J, Williams E, Watson H. Management and treatment of pelvic and hip injuries. *Emerg Med Clin North Am.* 2010 Nov;28(4):841-59.
- 10. Gardner MJ, Parada S. Routt MLC Jr. Internal rotation and taping of the lower extremities for closed pelvic reduction. *J Orthop Trauma*. 2009 May-Jun;23(5):361-4.
- 11. Nabaweesi R, Arnold MA, Chang DC, Rossberg MI, Ziegfeld S, Sawaya DE, Bathurst MA, Colombani P, Abdullah F. Prehospital predictors of risk for pelvic fractures in pediatric trauma patients. *Pediatr Surg Int.* 2008 Sep;24(9):1053-6.
- 12. Yaghoubian A, Lewis RJ, Putnam B, De Virgilio C. Reanalysis of prehospital intravenous fluid administration in patients with penetrating truncal injury and field hypotension. *Am Surg.* 2007 Oct;73(10):1027-30.
- 13. Michetti CP, Hanna R, Crandall JR, Fakhry SM. Contemporary analysis of thoracic aortic injury: importance of screening based on crash characteristics. *J Trauma*. 2007 Jul:63(1):18-24.
- 14. Pediatr Surg Int. 2008 Sep;24(9):1053-6. The prehospital management of pelvic fractures. *Emerg Med J.* 2007 Feb;24(2):130-3.
- 15. Stockinger ZT, McSwain NE Jr. Prehospital endotracheal intubation for trauma does not improve survival over bag-valve-mask ventilation. *J Trauma*. 2004 Mar;56(3):531-6.
- 16. Shapiro NI, Kociszewski C, Harrison T, Chang Y, Wedel SK, Thomas SH. Isolated prehospital hypotension after traumatic injuries: a predictor of mortality? *J Emerg Med.* 2003 Aug;25(2):175-9.
- 17. Helm M, Schuster R, Hauke J, Lampl L. Tight control of prehospital ventilation by capnography in major trauma victims. *Br J Anaesth*. 2003 Mar;90(3):327-32.
- 18. Stafford PW, Blinman TA, Nance ML. Practical points in evaluation and resuscitation of the injured child. *Surg Clin North Am.* 2002 Apr;82(2):273-301.
- 19. Pepe PE, Mosesso VN Jr, Falk JL. Prehospital fluid resuscitation of the patient with major trauma. *Prehosp Emerg Care*. 2002 Jan-Mar;6(1):81-91.





Approved 9/04/24, Effective 1/15/25, replaces all prior versions

# 10E – NEEDLE THORACOSTOMY – TENSION PNEUMOTHORAX DECOMPRESSION ADULT & PEDIATRIC

PARAMEDIC

#### Indications:

Suspected tension pneumothorax

### Clinical signs of tension pneumothorax:

Increasing respiratory insufficiency in a susceptible patient:

- 1. Spontaneous pneumothorax
- 2. CPR with appearance of PEA, increased difficulty bagging patient
- 3. Sucking chest wound which has been covered and which has not responded to removal of the seal/dressing
- 4. Chest trauma with suspected pneumothorax AND

Adult systolic blood pressure less than 100 mmHg (or pediatric systolic blood pressure less than 70 + (2 x age in years) mmHg **AND** Three or more of the following:

- 1. "Air Hunger"
- 2. Cyanosis
- 3. Decreased breath sounds on affected side(s)
- 4. Jugular venous distension
- 5. Tracheal shift away from affected side extremely late sign do not wait as indication for needle thoracostomy if other signs are developing

Etiologies of tension pneumothorax include:

- 1. Trauma (blunt or penetrating) disruption of either visceral or parietal pleura; often associated with rib fractures (rib fractures not necessary for tension pneumothorax to occur)
- 2. Barotrauma secondary to positive-pressure ventilation, especially when using high amounts of positive end-expiratory pressure (PEEP)
- 3. Unsuccessful attempts to convert an open pneumothorax to a simple pneumothorax in which the occlusive dressing functions as a 1-way valve
- 4. Chest compressions during cardiopulmonary resuscitation

### Contraindications:

No absolute contraindications. Do not place a needle thoracostomy through an area of suspected cellulitis, using instead an approved alternative site.






Approved 9/04/24, Effective 1/15/25, replaces all prior versions PROTOCOL 10E: Needle Thoracostomy -Tension Pneumothorax Decompression - Adult & Pediatric, cont.

### Precautions:

- 1. A SIMPLE pneumothorax causes some degree of respiratory distress and chest pain, and MAY be associated with decreased or absent breath sounds on the side of the collapse and with subcutaneous air if the cause is traumatic. TENSION pneumothorax is associated with progressive respiratory distress, dropping BP, "drum-like" hyperexpanded chest, distended neck veins, and patient deterioration. Tracheal shift may be present but is a late sign and needle decompression should be accomplished before waiting for the appearance of tracheal shift.
- 2. Pneumothorax rarely presents with tension on initial assessment. Be particularly suspicious with deterioration during transport, and with patients requiring assisted ventilation.
- 3. In patients who are being ventilated by bag-valve mask or ventilator, caution should be exercised when performing needle decompression. If the presumptive diagnosis of a tension pneumothorax is incorrect, the insertion of the needle may create a pneumothorax, which may be converted into a tension pneumothorax by positive-pressure ventilation.
- 4. If a previously covered sucking chest wound is present, remove the seal and allow chest pressures to equilibrate. This should allow air to escape relieving the tension pneumothorax.

### Technique:

- A. Expose the entire chest.
- B. Locate landmark on affected side(s), (figure 1)
  - a. Adult: fourth or fifth intercostal space-anterior axillary just superior to the lower rib
  - b. Pediatric: second intercostal space-midclavicular just superior to third rib
- C. Clean area of insertion with ChloraPrep®, Betadine®, or alcohol prep.
- D. Attach 10 mL or larger syringe to a 15 gauge Cook pneumothorax catheter or use a 10-gauge SPEAR catheter (no syringe).
- E. Decisively locate the insertion point.
- F. Insert the needle at 90 degrees through the skin and advance until tip of the needle hits the top of the rib below the intercostal space penetrated by the needle. Continue to advance angling over the top of the rib to avoid the neurovascular bundle running horizontally under the rib above the intercostal space is penetrated.
- G. Advance of the needle tip into the pleural space. A slight "pop" is usually felt when the needle pierces the outside pleural membrane, or parietal pleura.







Approved 9/04/24, Effective 1/15/25, replaces all prior versions

PROTOCOL 10E: Needle Thoracostomy - Tension Pneumothorax Decompression - Adult
& Pediatric, cont.

### Technique, cont.:

- H. When tension is present, syringe plunger will typically dislodge back out of syringe, or an immediate hiss of air escaping will be heard.
- I. If using the 10-gauge SPEAR catheter the plastic catheter should be separated after signs of proper placement. This is achieved after the needle has been inserted to an estimated depth of:
  - **a.** <1 y.o. =  $\sim \frac{1}{2}$  cm past the rib
  - **b.** >1 y.o < 12 y.o.  $= \sim 1-3$  cm past the rib
  - **c.** 12 y.o Adult =  $\sim$ 3 cm past the rib
- J. Remove the syringe and needle and leave the catheter in the pleural space.
- K. If using the 10-gauge SPEAR catheter remove the one-way valve from the needle hub and attach it to the catheter hub.
- L. If recurrent decompensation of the patient occurs related to suspected redevelopment of tension pneumothorax, repeat the procedure next to the previously successful needle thoracostomy site.

### Complications:

- Creation of pneumothorax if none existed previously. This is an unfortunate occurrence if needle thoracostomy is done too aggressively. Do not hesitate to relieve a strongly suspected tension pneumothorax but perform an accurate assessment to validate the suspicion of tension pneumothorax.
- 2. Laceration of lung, which is rare, can cause significant pulmonary injury. Avoid excessive length needles.
- 3. Hemothorax from vascular injury. Avoid needle thoracostomy medial to the mid-clavicular line. Avoid needle thoracostomy just inferior to a rib, where the intercostal vessels run underneath the rib margin. Avoid needle thoracostomy inferior to the right 6<sup>th</sup> intercostal space to avoid the upper margin of the liver.
- 4. Infection. Minimize risk by clean insertion site and maintaining aseptic technique, using sterile catheters/needles.

### Note:

Both the 2<sup>nd</sup> Intercostal space-midclavicular line and the 4<sup>th</sup> or 5<sup>th</sup> Intercostal space-anterior axillary line are effective in the release of tension pneumothorax. Utilize this alternate location if the preferred site does not improve the respiratory or hemodynamic conditions of a patient with a strongly suspected tension pneumothorax.





### Medical Literature References 10E – Needle Thoracostomy (Tension Pneumonthorax Decompression) – Adult & Pediatric

- 1. Azizi, N., ter Avest, E., Hoek, A. E., Admiraal-van de Pas, Y., Buizert, P. J., Peijs, D. R., Berg, I., Rosendaal, A. v., Boeije, T., Rietveld, V., Olgers, T., & ter Maaten, J. C. (2021). Optimal anatomical location for needle chest decompression for tension pneumothorax: A multicenter prospective cohort study. *Injury*, *52*(2), 213–218. https://doi.org/10.1016/j.injury.2020.10.068
- 2. Clemency BM, Tanski CT, Rosenberg M, May PR, Consiglio JD, Lindstrom HA. Sufficient catheter length for pneumothorax needle decompression: a meta-analysis. *Prehosp Disaster Med.* 2015 Jun;30(3):249-53.
- 3. Akoglu H, Akoglu EU, Evman S, Akoglu T, Altinok AD, Guneysel O, Onur OE, Eroglu SE. Determination of the appropriate catheter length and place for needle thoracostomy by using computed tomography scans of pneumothorax patients. *Injury*. 2012 Oct 29.
- 4. Beckett A, Savage E, Pannell D, Acharya S, Kirkpatrick A, Tien HC. Needle decompression for tension pneumothorax in Tactical Combat Casualty Care: do catheters placed in the midaxillary line kink more often than those in the midclavicular line? *J Trauma*. 2011 Nov;71(5 Suppl 1):S408-12.
- 5. Blaivas M. Inadequate needle thoracostomy rate in the prehospital setting for presumed pneumothorax: an ultrasound study. *J Ultrasound Med.* 2010 Sep;29(9):1285-9.
- 6. Ball CG, Wyrzykowski AD, Kirkpatrick AW, Dente CJ, Nicholas JM, Salomone JP, Rozycki GS, Kortbeek JB, Feliciano DV. Thoracic needle decompression for tension pneumothorax: clinical correlation with catheter length. *Can J Surg.* 2010 Jun;53(3):184-8.
- 7. Mistry N, Bleetman A, Roberts KJ. Chest decompression during the resuscitation of patients in prehospital traumatic cardiac arrest. *Emerg Med J.* 2009 Oct;26(10):738-40.
- 8. Stevens RL, Rochester AA, Busko J, Blackwell T, Schwartz D, Argenta A, Sing RF. Needle thoracostomy for tension pneumothorax: failure predicted by chest computed tomography. *Prehosp Emerg Care*. 2009 Jan-Mar;13(1):14-7.
- 9. Warner KJ, Copass MK, Bulger EM. Paramedic use of needle thoracostomy in the prehospital environment. *Prehosp Emerg Care*. 2008 Apr-Jun;12(2):162-8.
- 10. Bushby N, Fitzgerald M, Cameron P, Marasco S, Bystrzycki A, Rosenfeld JV, Bailey M. Prehospital intubation and chest decompression is associated with unexpected survival in major thoracic blunt trauma. *Emerg Med Australas*. 2005 Oct-Dec;17(5-6):443-9.





Approved 9/04/24, Effective 1/15/25, replaces all prior versions

# 10F – CHEST TUBE MONITORING ADULT & PEDIATRIC

#### **PARAMEDIC**

### Indications:

Interfacility transfer of patient with chest tube thoracostomy.

### Technique:

The chest tube thoracostomy-related device(s) must be reviewed with either the transferring practitioner/physician or appropriate nursing personnel prior to conducting the interfacility transfer. Potential complications during transfer should be discussed, such as in the possibility of recurrent pneumothorax, and contingency plans reviewed, such as releasing the occlusive dressing around the chest tube or performing a needle thoracostomy per Protocol 10E – Needle Thoracostomy. If the Paramedic feels unable to safely monitor and maintain the chest tube, he or she is to request appropriate resources from the transferring hospital to accompany the patient during transfer.

Under these conditions, EMS personnel will not begin the transfer until such request is accommodated.

During packaging, patient movement, and throughout the interfacility transfer, perform periodic inspection and assessment of the chest tube.

The chest tube may be attached to a one-way valve (Heimlich valve) that allows for air or fluid passage from the chest to the outside, often contained within a simple bag container. If a Heimlich valve is present, keep it attached to the chest tube.

The chest tube may alternatively be attached to a multi-chamber container that can be attached to low suction. This container can be used for collection of blood drainage from the chest for auto-transfusion and/or to measure how much blood or other fluid is being drained from the chest tube. The chamber connecting to the chest tube is for fluid collection. The second chamber contains a small volume of water, establishing a water seal, creating a one-way flow of air from the chest, and keeping the pressure in the chest less than atmospheric pressure. The third chamber is a suction chamber, designed to limit excessive wall suction effect on the chest. Keep the container upright to keep fluid collection measurement accurate and avoid any loss in function of the device.

Persistent bubbling in the chamber(s) indicates an air leak in the chest tube system. This may be due to a loose connection in the tube/chamber/suction circuit or due to a perforation in the airway (e.g. bronchiole). Check the visible connections of the chest tube system. If bubbling prior to transfer, discuss with transferring practitioner/physician.





Medical Literature References 10F – Chest Tube Monitoring – Adult & Pediatric

- Joseph KT. Chapter 28. Tube Thoracostomy. In: Reichman EF, Simon RR, eds. Emergency Medicine Procedures. New York: McGraw-Hill; 2004. http://www.accessemergencymedicine.com/content.aspx?aID=48871. Accessed July 1, 2012.
- 2. Heimlich HJ. Heimlich valve for chest drainage. Med Instrum. 1983 Jan-Feb;17(1):29-31.





Approved 9/04/24, Effective 1/15/25, replaces all prior versions

## 10G - EXTREMITY/AMPUTATION INJURY **ADULT & PEDIATRIC**

#### TREATMENT PRIORITIES

- 1. Hemorrhage control
- 2. Assessment/Care for lifethreatening injuries/shock
- 3. Vital signs
- 4. Splint suspected fractures
- 5. Analgesia (if required)
- 6. Appropriate trauma care destination selection

# **EMD**

DO NOT MOVE THE PATIENT UNLESS IN DANGER STABILIZE HEAD AND NECK IN POSITION FOUND OPEN AIRWAY IF NOT ALERT & INEFFECTIVE BREATHING CONTROL BLEEDING ONLY IF SERIOUS DO NOT ATTEMPT TO SPLINT INJURIES

# **EMERGENCY MEDICAL DISPATCHER**

**EMERGENCY MEDICAL RESPONDER** 

**EMT** 

**EMT-INTERMEDIATE 85** 

**ADVANCED EMT** 

**PARAMEDIC** 

**EMR EMT** 

TRAUMA AND HYPOVOLEMIC SHOCK SUPPORTIVE CARE

SPINAL "STABILIZATION" - DO NOT APPLY SPINAL "TRACTION" DURING MOTION RESTRICTION OR IMMOBILIZATION (if applicable) APPLY TOURNIQUET FOR HEMORRHAGE UNCONTROLLED BY DIRECT PRESSURE PER PROTOCOL 10H - TOURNIQUET **OBTAIN VITAL SIGNS** 

O2 VIA NC, NRB AS APPROPRIATE

SPLINT SUSPECTED FRACTURES INCLUDING JOINT ABOVE AND BELOW AREA OF INJURY COVER AMPUTATED ANATOMY WITH SALINE-MOISTENED GAUZE

PLACE AMPUTATED ANATOMY IN A CLEAN PLASTIC BAG PLACE AMPUTATED ANATOMY OVER ICE, AVOIDING DIRECT CONTACT OF AMPUTATED ANATOMY WITH ICE STABILIZE IMPALED OBJECTS

APPLY CARDIAC MONITOR (if equipped)

**EMT-185 AEMT** 

IV ACCESS (IO IF INDICATED)

IV ACCESS (IO IF INDICATED) (TWO LINES IF POSSIBLE)

ADULT: IV NS TKO IF SYS BP ≥ 100 mmHg WITHOUT HYPOTENSIVE SYMPTOMS

ADULT: IV NS 250 mL BOLUS IF SYS BP < 100 mmHg WITH HYPOTENSIVE SYMPTOMS & NO SIGNS OF PULMONARY EDEMA, ADULT: REPEAT UP TO 2 LITERS NS IF SYS BP REMAINS < 100 mmHg WITH HYPOTENSIVE SYMPTOMS & NO SIGNS OF PULMONARY EDEMA

PEDIATRIC: IV NS 20 mL/kg BOLUS IF SYS BP < (70 + 2x age in years) mmHg & NO SIGNS OF PULMONARY EDEMA PEDIATRIC: REPEAT UP TO 60 mL/kg IF SYS BP REMAINS < (70 + 2x age in years) mmHg & NO SIGNS OF PULMONARY EDEMA

#### **PARAMEDIC**

ANALGESIA (IF REQUIRED)

FOR OPIATE USE, ADULT MUST HAVE SYS BP ≥ 100 mmHg; PEDIATRIC MUST HAVE SYS BP ≥ (70 + 2x age in years) mmHg

ADULT: FENTANYL 1 mcg/kg SLOW IVP/IM/IN, MAXIMUM DOSE 100 mcg. MAY REPEAT EVERY 10 MINUTES TO MAXIMUM CUMULATIVE DOSE OF 3 mcg/kg or 250 mcg WHICHEVER IS LESSER.

ADULT: MORPHINE SULFATE 2 - 4 mg SLOW IVP, MAY REPEAT 2 - 4 mg EVERY 5 MINUTES TO A TOTAL OF 10 mg. OR

ADULT: HYDROMORPHONE 0.5 - 1 mg SLOW IVP, MAY REPEAT EVERY 10 MINUTES TO MAXIMUM CUMULATIVE DOSE OF 2 mg.

PEDIATRIC: FENTANYL 1 mcg/kg SLOW IVP/IM/IN, MAXIMUM DOSE 50 mcg

OLMCP CONSULT IF FURTHER ANALGESIA REQUIRED

CONTINUOUS ASSESSMENT & TREATMENT PER APPLICABLE PROTOCOL(S)





### Medical Literature References 10G – Extremity/Amputation Injury – Adult & Pediatric


- 1. Kragh JF Jr, Beebe DF, O'Neill ML, Beekley AC, Dubick MA, Baer DG, Blackbourne LH. Performance improvement in emergency tourniquet use during the Baghdad surge. *Am J Emerg Med.* 2013 May;31(5):873-5.
- 2. Taylor DM, Vater GM, Parker PJ. An evaluation of two tourniquet systems for the control of prehospital lower limb hemorrhage. *J Trauma*. 2011 Sep;71(3):591-5.
- 3. Guo JY, Liu Y, Ma YL, Pi HY, Wang JR. Evaluation of emergency tourniquets for prehospital use in China. *Chin J Traumatol.* 2011 Jun 1;14(3):151-5.
- Kragh JF, O Neill ML, Beebe DF, Fox CJ, Beekley AC, Cain JS, Parsons DL, Mabry RL, Blackbourne LH. Survey of the indications for use of emergency tourniquets. *J Spec Oper Med*. 2011 Winter;11(1):30-8.
- 5. Kragh JF Jr, Littrel ML, Jones JA, Walters TJ, Baer DG, Wade CE, Holcomb JB. Battle casualty survival with emergency tourniquet use to stop limb bleeding. *J Emerg Med.* 2011 Dec;41(6):590-7.
- 6. Sambasivan CN, Schreiber MA. Emerging therapies in traumatic hemorrhage control. *Curr Opin Crit Care*. 2009 Dec;15(6):560-8.
- 7. Sharp CF, Mangram AJ, Lorenzo M, Dunn EL. A major metropolitan "field amputation" team: a call to arms ... and legs. *J Trauma*. 2009 Dec;67(6):1158-61.
- 8. Kragh JF Jr, Walters TJ, Baer DG, Fox CJ, Wade CE, Salinas J, Holcomb JB. Survival with emergency tourniquet use to stop bleeding in major limb trauma. *Ann Surg.* 2009 Jan;249(1):1-7.
- 9. Mabry R, McManus JG. Prehospital advances in the management of severe penetrating trauma. *Crit Care Med.* 2008 Jul;36(7 Suppl):S258-66.
- Beekley AC, Sebesta JA, Blackbourne LH, Herbert GS, Kauvar DS, Baer DG, Walters TJ, Mullenix PS, Holcomb JB; 31st Combat Support Hospital Research Group. Prehospital tourniquet use in Operation Iraqi Freedom: effect on hemorrhage control and outcomes. *J Trauma*. 2008 Feb;64(2 Suppl):S28-37.
- 11. Doyle GS, Taillac PP. Tourniquets: a review of current use with proposals for expanded prehospital use. *Prehosp Emerg Care*. 2008 Apr-Jun;12(2):241-56.
- 12. Lee C, Porter KM, Hodgetts TJ. Tourniquet use in the civilian prehospital setting. *Emerg Med J*. 2007 Aug;24(8):584-7.
- 13. Dorlac WC, DeBakey ME, Holcomb JB, Fagan SP, Kwong KL, Dorlac GR, Schreiber MA, Persse DE, Moore FA, Mattox KL. Mortality from isolated civilian penetrating extremity injury. *J Trauma*. 2005 Jul;59(1):217-22.
- 14. Wood SP, Vrahas M, Wedel SK. Femur fracture immobilization with traction splints in multisystem trauma patients. *Prehosp Emerg Care*. 2003 Apr-Jun;7(2):241-3.
- 15. Abarbanell NR. Prehospital mid thigh trauma and traction splint use: recommendations for treatment protocols. *Am J Emerg Med.* 2001 Mar;19(2):137-40.
- 16. Kampen KE, Krohmer JR, Jones JS, Dougherty JM, Bonness RK. In-field extremity amputation: prevalence and protocols in emergency medical services. *Prehosp Disaster Med.* 1996 Jan-Mar;11(1):63-6.





Approved 9/04/24, Effective 1/15/25, replaces all prior versions

10H – TOURNIQUET ADULT & PEDIATRIC



<u>Indication</u>: Life-threatening extremity hemorrhage unable to be controlled by direct pressure or immediately obvious that direct pressure alone will not provide control.


Contraindication: None

### Technique (Combat-Application-Tourniquet® - C-A-T®):

The <u>C-A-T®</u> (Figure 1) windlass uses a free moving internal band to provide circumferential pressure to an injured and uncontrollably bleeding extremity. Once placed, keep the tourniquet secure, but uncovered so that the bleeding site can be clearly monitored as well as the tourniquet itself. The time of tourniquet application (Figure 6, e.g. TK 0145) is to be written on a piece of adhesive tape and secured to the tourniquet. Conscious patients may experience pain related to tourniquet use. In such instances, follow the pain management protocol if the patient is hemodynamically stable.

Step 1 (Figure 2):

The <u>C-A-T®</u> is applied over the extremity proximal to the bleeding site routing the self – adhering band around the extremity. Feed the strap through the buckle.



Windlass Strap

Windlass

Self-Adhering

Band

Windlass Rod

10H.1

Figure 1





Approved 9/04/24, Effective 1/15/25, replaces all prior versions

## PROTOCOL 10H: Tourniquet, Adult & Pediatric, cont.

### Step 3 (Figure 3 & 4):

Pull the self - adhering band, through the buckle, tight and secure the band back on itself with the Velcro adhesive strap.



### Step 4 (Figure 4):

Twist the windlass until the bleeding has stopped. This will typically be at or less than 3 complete rotations of the windlass.



### Step 5 (Figure 5):

Lock the rod in place with the windlass clip.



## Step 6 (Figure 6):

Secure the rod with the strap by pulling it tight and adhering it to the opposite hook on the windlass hook. Indicate the time of tourniquet application on tape.







Approved 9/04/24, Effective 1/15/25, replaces all prior versions

### PROTOCOL 10H: Tourniquet, Adult & Pediatric, cont.

Using Generation 7 <u>C-A-T®</u> tourniquets, all applications are made passing the self-adhering band through the single slit of the buckle.

If one tourniquet correctly applied does not completely control hemorrhage, in addition to direct pressure, an additional tourniquet may be applied just proximal to the first tourniquet.

Once bleeding has been controlled by a tourniquet, the usual and customary practice is to leave the tourniquet in place throughout the remainder of scene care and transport to an emergency department. In infrequent circumstances, if pain control becomes an issue, the tourniquet may be loosened to see if bleeding will stay controlled. If bleeding resumes, promptly re-tighten the tourniquet to its effective tightness.

### Technique SWAT-T™

The SWAT-T<sup>TM</sup> (Figure 1) provides circumferential pressure to an injured and uncontrollably bleeding extremity. The SWAT-T<sup>TM</sup> can be used on children or adults with smaller extremities where the C-A-T<sup>®</sup> is too large to control the hemorrhage. Once placed, keep the SWAT-T<sup>TM</sup> secure, but uncovered so that the bleeding site can be clearly monitored as well as the SWAT-T<sup>TM</sup> itself. The time of application is to be written on a piece of adhesive tape and secured to the SWAT-T<sup>TM</sup>. Conscious patients may experience pain related to tourniquet use. In such instances, follow the pain management protocol if the patient is hemodynamically stable. (Stretch-Wrap-Tuck)



### Step 1 (Figure 2):

Wrap tightly while pulling tension (**Stretch**) on the  $\underline{SWAT-T^{TM}}$ 

### Step 2 (Figure 3):


Continue to **Wrap** while pulling tension on the SWAT-T™

### Step 3 (Figure 4):

After <u>SWAT-T™</u> is tight & bleeding is controlled **Tuck** the <u>SWAT-T™</u> up into itself making it secure.












### Medical Literature References 10H – Tourniquet– Adult & Pediatric

- Kragh JF Jr, Beebe DF, O'Neill ML, Beekley AC, Dubick MA, Baer DG, Blackbourne LH. Performance improvement in emergency tourniquet use during the Baghdad surge. Am J Emerg Med. 2013 May;31(5):873-5.
- 2. Taylor DM, Vater GM, Parker PJ. An evaluation of two tourniquet systems for the control of prehospital lower limb hemorrhage. *J Trauma*. 2011 Sep;71(3):591-5.
- 3. Guo JY, Liu Y, Ma YL, Pi HY, Wang JR. Evaluation of emergency tourniquets for prehospital use in China. *Chin J Traumatol.* 2011 Jun 1:14(3):151-5.
- 4. Kragh JF, O Neill ML, Beebe DF, Fox CJ, Beekley AC, Cain JS, Parsons DL, Mabry RL, Blackbourne LH. Survey of the indications for use of emergency tourniquets. *J Spec Oper Med.* 2011 Winter;11(1):30-8.
- 5. Kragh JF Jr, Littrel ML, Jones JA, Walters TJ, Baer DG, Wade CE, Holcomb JB. Battle casualty survival with emergency tourniquet use to stop limb bleeding. *J Emerg Med.* 2011 Dec;41(6):590-7.
- 6. Sambasivan CN, Schreiber MA. Emerging therapies in traumatic hemorrhage control. *Curr Opin Crit Care*. 2009 Dec;15(6):560-8.
- 7. Kragh JF Jr, Walters TJ, Baer DG, Fox CJ, Wade CE, Salinas J, Holcomb JB. Survival with emergency tourniquet use to stop bleeding in major limb trauma. *Ann Surg.* 2009 Jan;249(1):1-7.
- 8. Mabry R, McManus JG. Prehospital advances in the management of severe penetrating trauma. *Crit Care Med.* 2008 Jul;36(7 Suppl):S258-66.
- 9. Beekley AC, Sebesta JA, Blackbourne LH, Herbert GS, Kauvar DS, Baer DG, Walters TJ, Mullenix PS, Holcomb JB; 31st Combat Support Hospital Research Group. Prehospital tourniquet use in Operation Iraqi Freedom: effect on hemorrhage control and outcomes. *J Trauma*. 2008 Feb;64(2 Suppl):S28-37.
- 10. Doyle GS, Taillac PP. Tourniquets: a review of current use with proposals for expanded prehospital use. *Prehosp Emerg Care*. 2008 Apr-Jun;12(2):241-56.
- 11. Lee C, Porter KM, Hodgetts TJ. Tourniquet use in the civilian prehospital setting. *Emerg Med J*. 2007 Aug;24(8):584-7.
- 12. Dorlac WC, DeBakey ME, Holcomb JB, Fagan SP, Kwong KL, Dorlac GR, Schreiber MA, Persse DE, Moore FA, Mattox KL. Mortality from isolated civilian penetrating extremity injury. *J Trauma*. 2005 Jul;59(1):217-22.





Approved 9/04/24, Effective 1/15/25, replaces all prior versions



#### **PARAMEDIC**

ADULT & PEDIATRIC AGES 10 AND ABOVE: IN SETTING OF HEMORRHAGIC SHOCK FROM TRAUMA LESS THAN 3 HOURS OLD, WITH SUSPECTED NEED FOR MASSIVE BLOOD TRANSFUSION DUE TO MARKED INTERNAL OR EXTERNAL BLOOD LOSS

CRITERIA FOR TRANEXAMIC ACID ADMINISTRATION:

SUSTAINED TACHYCARDIA 110 BEATS PER MINUTE OR GREATER AND SUSTAINED HYPOTENSION SYSTOLIC BP 90 mmHg OR LESS

ADULT: TRANEXAMIC ACID (TXA) 1 GRAM IVPB OVER 10 MINS. ADMINISTER IN 100 mL or 250 mL NS. PEDIATRIC AGES 10 AND ABOVE: TRANEXAMIC ACID (TXA) 15 mg/kg UP TO 1 gram IVPB OVER 10 MINS. ADMINISTER IN 100mL or 250 mL NS.

CONTINUOUS ASSESSMENT & TREATMENT PER APPLICABLE PROTOCOL(S)





### Medical Literature References 10I – Hemostatic Agents– Adult & Pediatric

- Li, S. R., Guyette, F., Brown, J., Zenati, M., Reitz, K. M., Eastridge, B., Nirula, R., Vercruysse, G. A., O'Keeffe, T., Joseph, B., Neal, M. D., Zuckerbraun, B. S., & Sperry, J. L. (2021). Early Prehospital Tranexamic Acid Following Injury Is Associated With a 30-day Survival Benefit: A Secondary Analysis of a Randomized Clinical Trial. *Annals of Surgery*, 274(3), 419–426. https://doi.org/10.1097/SLA.000000000000000000
- 2. Roberts I, Prieto-Merino D, Merino D. Mechanism of action of tranexamic acid in bleeding trauma patients: an exploratory analysis of data from the CRASH-2 trial. Critical Care 2014. Dec 13:18(6):685.
- 3. Eckert MJ, Wertin TM, Tyner SD, Nelson DW, Izenberg S, Martin MJ. Tranexamic acid administration to pediatric trauma patients in a combat setting: the pediatric trauma and tranexamic acid study (PED-TRAX). *J Trauma Acute Care Surg.* 2014 Dec;77(6): 852-8.
- 4. Beno S, Ackery AD, Callum J, Rizoli S. Tranexamic acid in pediatric trauma: why not? *Critical Care*. 2014, 18:313.
- 5. Kunio NR, Riha GM, Watson KM, Differding JA, Schreiber MA, Watters JM. Chitosan based advanced hemostatic dressing is associated with decreased blood loss in a swine uncontrolled hemorrhage model. *Am J Surg.* 2013 May;205(5):505-10.
- 6. Napolitano LM, Cohen MJ, Cotton BA, Schreiber MA, Moore EE. Tranexamic acid in trauma: how should we use it? J Trauma Acute Care Surg. 2013. 74(6): 1575-1586
- 7. Satterly S, Nelson D, Zwintscher N, Oguntoye M, Causey W, Theis B, Huang R, Haque M, Martin M, Bickett G, Rush RM Jr. Hemostasis in a noncompressible hemorrhage model: an end-user evaluation of hemostatic agents in a proximal arterial injury. *J Surg Educ*. 2013 Mar-Apr;70(2):206-11.
- 8. Causey MW, McVay DP, Miller S, Beekley A, Martin M. The efficacy of Combat Gauze in extreme physiologic conditions. *J Surg Res.* 2012 Oct;177(2):301-5.
- 9. Morrison JJ, Dubose JJ, Rasmussen TE, Midwinter MJ. Military application of tranexamic acid in trauma emergency resuscitation (MATTERs) study. *Arch Surg.* 2012, 147:113-9.
- Schwartz RB, Reynolds BZ, Shiver SA, Lerner EB, Greenfield EM, Solis RA, Kimpel NA, Coule PL, McManus JG. Comparison of two packable hemostatic Gauze dressings in a porcine hemorrhage model. *Prehosp Emerg Care*. 2011 Oct-Dec;15(4):477-82.
- 11. Granville-Chapman J, Jacobs N, Midwinter MJ. Pre-hospital haemostatic dressings: a systematic review. *Injury*. 2011 May;42(5):447-59.
- 12. Littlejohn LF, Devlin JJ, Kircher SS, Lueken R, Melia MR, Johnson AS.Comparison of Celox-A, ChitoFlex, WoundStat, and combat gauze hemostatic agents versus standard gauze dressing in control of hemorrhage in a swine model of penetrating trauma. *Acad Emerg Med.* 2011 Apr;18(4):340-50.
- 13. CRASH-2 trial collaborators, Shakur H, Roberts I, Bautista R, Caballero J, Coats T, Dewan Y, El-Sayed H, Gogichaishvili T, Gupta S, Herrera J, Hunt B, Iribhogbe P, Izurieta M, Khamis H, Komolafe E, Marrero MA, Mejia-Mantilla J, Miranda J, Morales C, Olaomi O, Olldashi F, Perel P, Peto R, Ramana PV, Ravi RR, Yutthakasemsunt S. Effect of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial. *Lancet.* 2010, 376:23-32.
- 14. Achneck HE, Sileshi B, Jamiolkowski RM, Albala DM, Shapiro ML, Lawson JH. A comprehensive review of topical hemostatic agents: efficacy and recommendations for use. *Ann Surg.* 2010 Feb;251(2):217-28.
- 15. Cox ED, Schreiber MA, McManus J, Wade CE, Holcomb JB. New hemostatic agents in the combat setting. *Transfusion*. 2009 Dec;49Suppl 5:248S-55S.
- Kheirabadi BS, Scherer MR, Estep JS, Dubick MA, Holcomb JB. Determination of efficacy of new hemostatic dressings in a model of extremity arterial hemorrhage in swine. *J Trauma*. 2009 Sep;67(3):450-9; discussion 459-60.






- 17. Sohn VY, Eckert MJ, Martin MJ, Arthurs ZM, Perry JR, Beekley A, Rubel EJ, Adams RP, Bickett GL, Rush RM Jr. Efficacy of three topical hemostatic agents applied by medics in a lethal groin injury model. *J Surg Res.* 2009 Jun 15;154(2):258-61.
- 18. Mabry R, McManus JG. Prehospital advances in the management of severe penetrating trauma. *J Spec Oper Med.* 2009 Spring;9(2):93-101.
- 19. Kozen BG, Kircher SJ, Henao J, Godinez FS, Johnson AS. An alternative hemostatic dressing: comparison of CELOX, HemCon, and QuikClot. *Acad Emerg Med.* 2008 Jan;15(1):74-81.
- 20. Ward KR, Tiba MH, Holbert WH, Blocher CR, Draucker GT, Proffitt EK, Bowlin GL, Ivatury RR, Diegelmann RF. Comparison of a new hemostatic agent to current combat hemostatic agents in a Swine model of lethal extremity arterial hemorrhage. *J Trauma*. 2007 Aug;63(2):276-83; discussion 283-4.
- Nishijima, D. K., Kuppermann, N., Roberts, I., VanBuren, J. M., & Tancredi, D. J. (2019). The Effect of Tranexamic Acid on Functional Outcomes: An Exploratory Analysis of the CRASH-2 Randomized Controlled Trial. *Annals of Emergency Medicine*, 74(1), 79–87. https://doi.org/10.1016/j.annemergmed.2018.11.018





Approved 9/04/24, Effective 1/15/25, replaces all prior versions



ANALGESIA (IF REQUIRED)

FOR OPIATE USE, ADULT MUST HAVE SYS BP  $\geq$  100 mmHg; PEDIATRIC MUST HAVE SYS BP  $\geq$  (70 + 2x age in years) mmHg

ADULT: FENTANYL 1 mcg/kg SLOW IVP/IM/IN, MAXIMUM DOSE 100 mcg. MAY REPEAT EVERY 10 MINUTES TO MAXIMUM CUMULATIVE DOSE OF 3 mcg/kg or 250 mcg WHICHEVER IS LESSER.

OR

ADULT: MORPHINE SULFATE 2 - 4 mg SLOW IVP, MAY REPEAT 2 - 4 mg EVERY 5 MINUTES TO A TOTAL OF 10 mg. OR

ADULT: HYDROMORPHONE 0.5 - 1 mg SLOW IVP, MAY REPEAT EVERY 10 MINUTES TO MAXIMUM CUMULATIVE DOSE OF 2 mg.

PEDIATRIC: OLMCP ORDER ONLY

OLMCP CONSULT IF FURTHER ANALGESIA REQUIRED

CONTINUOUS ASSESSMENT & TREATMENT PER APPLICABLE PROTOCOL(S)





### Medical Literature References 10J – Compartment Syndrome– Adult & Pediatric

- 1. Taylor RM, Sullivan MP, Mehta S. Acute compartment syndrome: obtaining diagnosis, providing treatment, and minimizing medicolegal risk. *Curr Rev Musculoskelet Med.* 2012 September; 5(3): 206–213.
- 2. Mabvuure NT, Malahias M, Hindocha S, Khan W, Juma A. Acute compartment syndrome of the limbs: current concepts and management. *Open Orthop J.* 2012;6:535-43.
- 3. Tekwani K, Sikka R. High-risk chief complaints III: abdomen and extremities. *Emerg Med Clin North Am.* 2009 Nov;27(4):747-65, x.
- 4. Olson SA, Glasgow RR. Acute compartment syndrome in lower extremity musculoskeletal trauma. *J Am Acad Orthop Surg.* 2005 Nov;13(7):436-44.
- 5. Grottkau BE, Epps HR, Di Scala C. Compartment syndrome in children and adolescents. *J Pediatr Surg.* 2005 Apr;40(4):678-82.





Approved 9/04/24, Effective 1/15/25, replaces all prior versions

#### TREATMENT PRIORITIES

- 1 Personal safety
- 2. Patient safety
- 3. USAR (OK TF1) if needed
- 4. Vital signs
- Hospital notification of concern regarding trunk/ limb circulation compromise
- 6. OLMCP consult on treatment plan prior to crush release (if > 2hours crush)
- 7. Hyperkalemia prophylaxis (If required)

### 10K - CRUSH INJURY SYNDROME ADULT & PEDIATRIC

#### EMD

DO NOT MOVE THE PATIENT UNLESS IN DANGER CONTROL BLEEDING WITH DIRECT PRESSURE DO NOT ATTEMPT TO SPLINT INJURIES

# EMERGENCY MEDICAL DISPATCHER

EMERGENCY MEDICAL RESPONDER

**EMT** 

**EMT-INTERMEDIATE 85** 

**ADVANCED EMT** 

**PARAMEDIC** 

EMR EMT

#### PERSONAL & PATIENT SAFETY

MOBILIZATION OF LOCAL FIRE-RESCUE PROFESSIONALS FOR TRAPPED PATIENTS REQUIRING HEAVY/COMPLICATED EXTRICATION MOBILIZATION OF URBAN SEARCH & RESCUE SPECIALIST TEAM IF NUMEROUS TRAPPED PATIENTS/LARGE BUILDING OR TRENCH COLLAPSE (OKLAHOMA TASK FORCE 1 IS BASED & SUPPORTED AT OKLAHOMA CITY FIRE DEPARTMENT & TULSA FIRE DEPARTMENT)

TRAUMA AND HYPOVOLEMIC SHOCK SUPPORTIVE CARE OBTAIN VITAL SIGNS

HISTORY OF ONGOING AND/OR PROLONGED CRUSH MECHANISM ON TRUNK OR PROXIMAL EXTREMITY EVALUATE EXTREMITY FOR "5 Ps" OF COMPARTMENT SYNDROME PER PROTOCOL 10K ECG MONITOR (if equipped)

EMT-185 AEMT

IV ACCESS (IO IF INDICATED)

IF CRUSH ≥ 4 HRS IN DURATION:

ADULT: IV NS 1 LITER BOLUS THEN 250 mL/HR RATE IF NO SIGNS OF PULMONARY EDEMA

ADULT: REPEAT UP TO 2 LITERS NS IF SYS BP REMAINS < 100 mmHg WITH HYPOTENSIVE SYMPTOMS & NO SIGNS OF PULMONARY EDEMA

PEDIATRIC: IV NS 20 mL/kg BOLUS THEN 5 mL/kg/HR RATE IF NO SIGNS OF PULMONARY EDEMA

PEDIATRIC: REPEAT UP TO 60 mL/kg NS IF SYS BP REMAINS < (70 + 2x age in years) mmHg & NO SIGNS OF PULMONARY EDEMA

### PARAMEDIC

IF CRUSH ≥ 4 HRS IN DURATION:

JUST PRIOR TO CRUSH MECHANISM REMOVAL, ADMINISTER HYPERKALEMIA PROPHYLAXIS:

IV FLUID HYDRATION AS ABOVE

CALCIUM CHLORIDE 10 mg/kg IVP/IOP (MAX 1 gram)

SODIUM BICARBONATE 1 mEq/kg IVP/IOP (MAX 50 mEq)

### ANALGESIA (IF REQUIRED)

FOR OPIATE USE, ADULT MUST HAVE SYS BP ≥ 100 mmHg; PEDIATRIC MUST HAVE SYS BP ≥ (70 + 2x age in years) mmHg

ADULT: FENTANYL 1 mcg/kg SLOW IVP/IM/IN, MAXIMUM DOSE 100 mcg. MAY REPEAT EVERY 10 MINUTES TO

MAXIMUM CUMULATIVE DOSE OF 3 mcg/kg or 250 mcg WHICHEVER IS LESSER.

OR

ADULT: MORPHINE SULFATE 2 - 4 mg SLOW IVP, MAY REPEAT 2 - 4 mg EVERY 5 MINUTES TO A TOTAL OF 10 mg.

OR

ADULT: HYDROMORPHONE 0.5 - 1 mg SLOW IVP, MAY REPEAT EVERY 10 MINUTES TO MAXIMUM CUMULATIVE DOSE OF 2 mg.

PEDIATRIC: OLMCP ORDER ONLY

OLMCP CONSULT FOR TIMING/NEED FOR HYPERKALEMIA PROPHYLAXIS IF CRUSH  $\,<\,4$  HRS IN DURATION OR IF FURTHER ANALGESIA REQUIRED

CONTINUOUS ASSESSMENT & TREATMENT PER APPLICABLE PROTOCOL(S)





### Medical Literature References 10K – Crush Injury Syndrome– Adult & Pediatric

- 1. Burns K, Cone DC, Portereiko JV. Complex extrication and crush injury. *Prehosp Emerg Care*. 2010 Apr-Jun;14(2):240-4.
- 2. Newton EJ, Love J. Acute complications of extremity trauma. *Emerg Med Clin North Am.* 2007 Aug;25(3):751-61, iv.
- 3. Sever MS, Vanholder R, Lameire N. Management of crush-related injuries after disasters. *N Engl J Med.* 2006 Mar 9;354(10):1052-63.





Approved 9/04/24, Effective 1/15/25, replaces all prior versions

#### TREATMENT PRIORITIES

- . Thermal Burn
- Stop burning process
- · Flood with water only if flames not extinguished; smoldering present; significant heat being dissipated
- Determine possibility of smoke/toxic inhalation
- 2. Chemical Burn
  - Brush off dry chemicals
  - Flush with water for minimum of 15 minutes
- 3. Electrical Burn
- Evaluate airway and cardiac status
- 4. Do not delay transport for on scene IV fluids or medication

### **10L - BURNS ADULT & PEDIATRIC**

#### **EMD**

IF PT CLOTHES ARE BURNING OR SMOLDERING. DOUSE THEM WITH WATER IMMEDIATELY. IF WATER IS NOT AVAILABLE

THEN ROLL PT ON THE GROUND OR SMOTHER THE FIRE DO NOT TOUCH ANYTHING OR PICK UP DEBRIS

## **EMERGENCY MEDICAL DISPATCHER**

**EMERGENCY MEDICAL RESPONDER** 

**EMT** 

**EMT-INTERMEDIATE 85** 

**ADVANCED EMT** 

**PARAMEDIC** 

**EMR EMT** 

> TRAUMA AND HYPOVOLEMIC SHOCK SUPPORTIVE CARE STOP THE BURNING PROCESS

SPINAL "STABILIZATION" - DO NOT APPLY SPINAL "TRACTION" DURING IMMOBILIZATION (IF EXPLOSIVE MOI & if applicable) STABILIZE IMPALED OBJECTS (IF EXPLOSIVE MOI)

O2 VIA NC, NRB, OR BVM AS APPROPRIATE FOR RESPIRATORY SYMPTOMS COVER BURNED AREA WITH BURN DRESSING (if equipped) THEN APPLY DRY SHEET APPLY CARDIAC MONITOR (if equipped)

FOR RESPIRATORY SYMPTOMS,

MEASURE END - TIDAL CO2 & MONITOR WAVEFORM CAPNOGRAPHY (if equipped, \*\* Mandatory use if pt intubated) PLACE SUPRAGLOTTIC AIRWAY IF INDICATED & ONLY IF BVM VENTILATIONS INEFFECTIVE.

#### **EMT OR HIGHER LICENSE:**

**EMT-185 AEMT** 

**ADULT: INTUBATE IF INDICATED** 

IV/ IO ACCESS IF INDICATED

ADULT: IV NS; FOR MAJOR THERMAL BURNS, 500 mL BOLUS IF NO SIGNS OF PULMONARY EDEMA PEDIATRIC: IV NS 20 mL/kg BOLUS IF NO SIGNS OF PULMONARY EDEMA SEE WEIGHT BASED FLUID RESUSCITATION TABLE TO AVOID EXCESSIVE FLUID

#### **PARAMEDIC**

**ADULT: MEDICATION ASSISTED INTUBATION IF INDICATED** 

ANALGESIA (IF REQUIRED)

FOR OPIATE USE, ADULT MUST HAVE SYS BP ≥ 100 mmHg; PEDIATRIC MUST HAVE SYS BP ≥ (70 + 2x age in years) mmHg

ADULT: FENTANYL 1 mcg/kg SLOW IVP/IM/IN, MAXIMUM DOSE 100 mcg. MAY REPEAT EVERY 10 MINUTES TO MAXIMUM CUMULATIVE DOSE OF 3 mcg/kg or 250 mcg WHICHEVER IS LESSER.

OR

ADULT: MORPHINE SULFATE 2 - 4 mg SLOW IVP, MAY REPEAT 2 - 4 mg EVERY 5 MINUTES TO A TOTAL OF 10 mg. OR

ADULT: HYDROMORPHONE 0.5 - 1 mg SLOW IVP, MAY REPEAT EVERY 10 MINUTES TO MAXIMUM CUMULATIVE DOSE OF 2 mg.

PEDIATRIC: FENTANYL 1 mcg/kg SLOW IVP/IM/IN, MAXIMUM DOSE 50 mcg

OLMCP CONSULT IF FURTHER ANALGESIA REQUIRED

CONTINUOUS ASSESSMENT & TREATMENT PER APPLICABLE PROTOCOL(S)






Approved 9/04/24, Effective 1/15/25, replaces all prior versions **PROTOCOL 10L: Burns - Adult &Pediatric, cont,** 

## % Body Surface Area (BSA) Estimation Chart

Count only Second and Third Degree Burns when calculating estimated %BSA



An alternate method of calculating %BSA involvement is to use the size of the patient's entire hand equal to 1% of their BSA. This is a useful method when calculating smaller burn areas.





Approved 9/04/24, Effective 1/15/25, replaces all prior versions

Wt (Kg)	Burn Surface Area %												
	20	25	30	35	40	45	50	55	60	65	70	75	80
2	10	15	15	20	20	25	25	30	30	35	35	40	40
4	20	25	30	35	40	45	50	55	60	65	70	75	80
6	30	40	45	50	60	70	75	80	90	100	105	115	120
8	40	50	60	60	80	90	100	110	120	130	140	150	160
10	50	65	75	75	100	115	125	135	150	165	175	190	200
12	60	75	90	105	120	135	150	165	180	195	210	225	240
15	75	100	115	130	150	170	190	210	225	250	280	285	300
17	85	110	130	150	170	190	215	235	255	275	300	320	340
20	100	125	150	175	200	225	250	275	300	325	350	375	400
22	110	140	165	200	220	250	275	300	330	360	385	415	440
25	125	160	190	220	250	280	315	350	375	400	440	470	500
27	135	170	200	240	270	300	340	370	405	440	470	500	540
30	150	190	225	260	300	340	375	410	450	490	525	560	600
35	175	220	260	300	350	400	440	480	525	570	610	660	700
40	200	250	300	350	400	450	500	550	600	650	700	750	800
50	250	315	375	440	500	560	625	690	750	810	875	940	1000
60	300	375	450	525	600	675	750	825	900	975	1050	1125	1200
70	350	450	525	620	700	800	875	1000	1050	1150	1225	1325	1400
75	375	500	550	650	750	850	950	1050	1150	1200	1300	1400	1500
100	500	625	750	875	1000	1125	1250	1375	1500	1625	1750	1875	2000

Fluid resuscitation for 2nd and 3rd degree burns totalling greater than 20% BSA

Milliliters of fluid to be given during first hour based on Parkland Formula

4mL x kg x BSA% = Total Fuid over 24 Hrs

Half of total should be given over the first 8 Hrs





Medical Literature References 10L – Burns – Adult & Pediatric

- 1. Pham TN, Cancio LC, Gibran NS. American burn association practice guidelines burn shock resuscitation. J Burn Care Res. 2008;29(1):257-266. doi:10.1097/BCR.0b013e31815f3876.
- 2. ABLS Advisory Committee. Advanced Burn Life Support Course Provider Manual. 2015;60611(312). doi:10.1097/00004630-199901000-00006.
- 3. Hostler D. Scorched skin. A guide to prehospital burn management. J Emerg Med Serv. 2015;40(4):57-61.
- 4. Eastman AL, Arnoldo BA, Hunt JL, Purdue GF. Pre-burn center management of the burned airway: do we know enough? *J Burn Care Res.* 2010 Sep-Oct;31(5):701-5.
- 5. Singer AJ, Taira BR, Thode HC Jr, McCormack JE, Shapiro M, Aydin A, Lee C. The association between hypothermia, prehospital cooling, and mortality in burn victims. *Acad Emerg Med.* 2010 Apr;17(4):456-9.
- 6. Mlcak R, Cortiella J, Desai MH, Herndon DN. Emergency management of pediatric burn victims. *Pediatr Emerg Care*. 1998 Feb;14(1):51-4.
- 7. Nagel TR, Schunk JE. Using the hand to estimate the surface area of a burn in children. *Pediatr Emerg Care*. 1997 Aug;13(4):254-5.
- 8. Crawford ME, Rask H. Prehospital care of the burned patient. *Eur J Emerg Med.* 1996 Dec;3(4):247-51.





Approved 9/04/24, Effective 1/15/25, replaces all prior versions

# 10M - CONDUCTED ELECTRICAL WEAPON RELATED MANAGEMENT ADULT & PEDIATRIC

#### TREATMENT PRIORITIES

- 1. Personal safety
- 2. Patient safety
- 3. Physical Restraint
- 4. Chemical Restraint (if indicated)
- 5. Vital signs
- 6. Probe removal
- 7. Return probe to law enforcement

#### **EMD**

SUPPORT LAW ENFORCEMENT OPERATION

# EMERGENCY MEDICAL DISPATCHER

EMERGENCY MEDICAL RESPONDER

**EMT** 

**EMT-INTERMEDIATE 85** 

**ADVANCED EMT** 

**PARAMEDIC** 

EMR EMT-B

MAINTAIN PERSONAL AND PATIENT SAFETY
ENSURE LAW ENFORCEMENT OFFICER DISCONNECTS EMBEDDED PROBES FROM WEAPON
IF PROBE IS REMOVED DO NOT DISCARD, ENSURE SAFE RETURN TO LAW ENFORCEMENT FOR EVIDENCE
TREAT PER APPLICABLE SECTION 7 PROTOCOLS – PSYCHIATRIC/BEHAVIORAL DISORDERS

REMOVE PROBES UNLESS EMBEDDED IN FACE, NECK, GENITALS, SPINE APPLY CARDIAC MONITOR/OBTAIN 12-LEAD ECG (if equipped)
TRANSMIT 12-LEAD ECG TO RECEIVING EMERGENCY DEPARTMENT

#### **EMT OR HIGHER LICENSE:**

MEASURE END - TIDAL CO<sub>2</sub> & MONITOR WAVEFORM CAPNOGRAPHY (if equipped, \*\* Mandatory use if pt intubated)

#### **EMT-INTERMEDIATE 85**

### **ADVANCED EMT**

**ADULT: INTUBATE IF INDICATED** 

IV ACCESS

TREAT PER APPLICABLE SECTION 7 PROTOCOLS - PSYCHIATRIC/BEHAVIORAL DISORDERS

#### **PARAMEDIC**

**ADULT: MEDICATION ASSISTED INTUBATION IF INDICATED** 

CHEMICAL RESTRAINT IF INDICATED PER PROTOCOL 7C - CHEMICAL RESTRAINT

CONSULT OLMC IF UNCERTAIN OF ETIOLOGY AND TREATMENT PLAN FOR PSYCHIATRIC PROBLEM OR IF ADDITIONAL RESTRAINT MEASURES NEEDED

CONTINUOUS ASSESSMENT & TREATMENT PER APPLICABLE PROTOCOL(S)





Medical Literature References 10M – Conductive Energy Weapon Related Management– Adult & Pediatric

- 1. Bozeman WP, Teacher E, Winslow JE. Transcardiac Conducted Electrical Weapon (TASER) Probe Deployments: Incidence and Outcomes. *J Emerg Med.* 2012 Dec;43(6):970-5.
- Vilke GM, Debard ML, Chan TC, Ho JD, Dawes DM, Hall C, Curtis MD, Costello MW, Mash DC, Coffman SR, McMullen MJ, Metzger JC, Roberts JR, Sztajnkrcer MD, Henderson SO, Adler J, Czarnecki F, Heck J, Bozeman WP. Excited Delirium Syndrome (ExDS): Defining Based on a Review of the Literature. *J Emerg Med*. 2012 Nov;43(5):897-905.
- 3. Kunz SN, Grove N, Fischer F. Acute pathophysiological influences of conducted electrical weapons in humans: A review of current literature. *Forensic Sci Int.* 2012 Sep 10;221(1-3):1-4.
- 4. Vilke GM, Bozeman WP, Dawes DM, Demers G, Wilson MP. Excited delirium syndrome (ExDS): treatment options and considerations. *J Forensic Leg Med*. 2012 Apr;19(3):117-21.
- 5. Kroll MW, Lakkireddy D, Rahko PS, Panescu D. Ventricular fibrillation risk estimation for conducted electrical weapons: critical convolutions. *Conf Proc IEEE Eng Med Biol Soc.* 2011;2011:271-7.
- 6. Pasquier M, Carron PN, Vallotton L, Yersin B. Electronic control device exposure: a review of morbidity and mortality. *Ann Emerg Med.* 2011 Aug;58(2):178-88.
- 7. Vilke GM, Bozeman WP, Chan TC. Emergency department evaluation after conducted energy weapon use: review of the literature for the clinician. *J Emerg Med.* 2011 May;40(5):598-604.
- 8. Ho JD, Dawes DM, Nelson RS, Lundin EJ, Ryan FJ, Overton KG, Zeiders AJ, Miner JR. Acidosis and catecholamine evaluation following simulated law enforcement "use of force" encounters. *Acad Emerg Med.* 2010 Jul;17(7):e60-8.
- 9. Moscati R, Ho JD, Dawes DM, Miner JR. Physiologic effects of prolonged conducted electrical weapon discharge in ethanol-intoxicated adults. *Am J Emerg Med.* 2010 Jun;28(5):582-7.
- 10. Otahbachi M, Cevik C, Bagdure S, Nugent K. Excited delirium, restraints, and unexpected death: a review of pathogenesis. *Am J Forensic Med Pathol.* 2010 Jun;31(2):107-12.
- 11. Strote J, Verzemnieks E, Walsh M, Hutson HR. Use of force by law enforcement: an evaluation of safetyand injury. *J Trauma*. 2010 Nov:69(5):1288-93.
- 12. Brice JH, Pirrallo RG, Racht E, Zachariah BS, Krohmer J. Management of the violent patient. *Prehosp Emerg Care*. 2003 Jan-Mar;7(1):48-55.





**PARAMEDIC** 

Approved 9/04/24, Effective 1/15/25, replaces all prior versions

# 10N – "LESS LETHAL" WEAPON RELATED MANAGEMENT ADULT & PEDIATRIC

#### **EMERGENCY MEDICAL DISPATCHER** TREATMENT PRIORITIES **EMD EMERGENCY MEDICAL** 1. Personal safety **RESPONDER** SUPPORT LAW ENFORCEMENT OPERATION 2. Patient safety 3. Physical Restraint **EMT** 4. Chemical Restraint (if indicated) 5. Vital signs **EMT-INTERMEDIATE 85** 6. Appropriate trauma care destination selection **ADVANCED EMT**

EMR EMT


MAINTAIN PERSONAL AND PATIENT SAFETY
HISTORY FROM LAW ENFORCEMENT OFFICER(S) REGARDING WEAPON BALLISTICS
(eg. RUBBER BULLETS, BEAN BAG PROJECTILES)

TRAUMA AND HYPOVOLEMIC SHOCK SUPPORTIVE CARE
TREAT PER OTHER APPLICABLE SECTION 10 PROTOCOLS - TRAUMA
TREAT PER APPLICABLE SECTION 7 PROTOCOLS - PSYCHIATRIC/BEHAVIORAL DISORDERS

APPLY CARDIAC MONITOR/OBTAIN 12-LEAD ECG (if equipped)
TRANSMIT 12-LEAD ECG TO RECEIVING EMERGENCY DEPARTMENT

#### **EMT OR HIGHER LICENSE:**

MEASURE END – TIDAL CO<sub>2</sub> & MONITOR WAVEFORM CAPNOGRAPHY (if equipped, \*\* Mandatory use if pt intubated)







### Medical Literature References 10N – "Less Lethal" Weapon Weapon Related Management– Adult & Pediatric


- 1. Bozeman WP, Teacher E, Winslow JE. Transcardiac Conducted Electrical Weapon (TASER) Probe Deployments: Incidence and Outcomes. *J Emerg Med.* 2012 Dec;43(6):970-5
- 2. Vilke GM, Debard ML, Chan TC, Ho JD, Dawes DM, Hall C, Curtis MD, Costello MW, Mash DC, Coffman SR, McMullen MJ, Metzger JC, Roberts JR, Sztajnkrcer MD, Henderson SO, Adler J, Czarnecki F, Heck J, Bozeman WP. Excited Delirium Syndrome (ExDS): Defining Based on a Review of the Literature. *J Emerg Med.* 2012 Nov;43(5):897-905.
- 3. Vilke GM, Bozeman WP, Dawes DM, Demers G, Wilson MP. Excited delirium syndrome (ExDS): treatment options and considerations. *J Forensic Leg Med.* 2012 Apr;19(3):117-21.
- Kroll MW, Lakkireddy D, Rahko PS, Panescu D. Ventricular fibrillation risk estimation for conducted electrical weapons: critical convolutions. Conf Proc IEEE Eng Med Biol Soc. 2011;2011:271-7.
- 5. Pasquier M, Carron PN, Vallotton L, Yersin B. Electronic control device exposure: a review of morbidity and mortality. *Ann Emerg Med.* 2011 Aug;58(2):178-88.
- 6. Vilke GM, Bozeman WP, Chan TC. Emergency department evaluation after conducted energy weapon use: review of the literature for the clinician. *J Emerg Med*. 2011 May;40(5):598-604.
- 7. Strote J, Verzemnieks E, Walsh M, Hutson HR. Use of force by law enforcement: an evaluation of safetyand injury. *J Trauma*. 2010 Nov;69(5):1288-93.
- 8. Ho JD, Dawes DM, Nelson RS, Lundin EJ, Ryan FJ, Overton KG, Zeiders AJ, Miner JR. Acidosis and catecholamine evaluation following simulated law enforcement "use of force" encounters. *Acad Emerg Med.* 2010 Jul;17(7):e60-8.
- 9. Moscati R, Ho JD, Dawes DM, Miner JR. Physiologic effects of prolonged conducted electrical weapon discharge in ethanol-intoxicated adults. *Am J Emerg Med.* 2010 Jun;28(5):582-7.
- 10. Otahbachi M, Cevik C, Bagdure S, Nugent K. Excited delirium, restraints, and unexpected death: a review of pathogenesis. *Am J Forensic Med Pathol.* 2010 Jun;31(2):107-12.
- 11. Feier CC, Mallon W. Injury pattern of the stingball. J Emerg Med. 2010 May;38(4):444-8.
- 12. Rezende-Neto J, Silva FD, Porto LB, Teixeira LC, Tien H, Rizoli SB. Penetrating injury to the chest by an attenuated energy projectile: a case report and literature review of thoracic injuries caused by "less-lethal" munitions. *World J Emerg Surg.* 2009 Jun 26;4:26.
- 13. Maguire K, Hughes DM, Fitzpatrick MS, Dunn F, Rocke LG, Baird CJ. Injuries caused by the attenuated energy projectile: the latest less lethal option. *Emerg Med J.* 2007 Feb;24(2):103-5.
- 14. Brice JH, Pirrallo RG, Racht E, Zachariah BS, Krohmer J. Management of the violent patient. *Prehosp Emerg Care*. 2003 Jan-Mar;7(1):48-55.





Approved 9/04/24, Effective 1/15/25, replaces all prior versions

# 100 – SPLINTING OF INJURIES ADULT & PEDIATRIC



### 10Oa: Spinal Motion Restriction – Adult & Pediatric:

Many patients evaluated by EMS professionals are placed in a cervical collar and onto a long spine backboard based as much upon "tradition" that this practice is without risk and the benefit is without question. Like many medical practices scrutinized over time, evidence-based medicine reveals it is with risk (pain, tissue damage leading to pressure sores, and concerns about risks of aspiration and impaired breathing mechanics). Similarly, the benefit is not certain. Few "real" injuries are so unstable that the process of spinal motion restriction as performed in EMS is the difference-maker between paralysis and ambulation.

This protocol does not seek to avoid spinal motion restriction when clinically indicated. This protocol rather seeks to provide an evidence-based approach that directs the careful practice of spinal motion "restriction" in situations where history, exam findings, and/or patient interaction limitations make the possible benefit outweigh the risks. When the benefit does not outweigh the risks, patients should not incur clinically unnecessary collars and boards.

When applying spinal motion restriction, include the following:

- 1. Avoid traction being placed on the spine in any direction.
- 2. Correctly size the cervical collar to additionally avoid traction being placed on the spine.
- 3. Maintain the spinal column alignment integrity when rolling the patient onto a long back board, using a scoop stretcher, or placing/moving in any other spinal motion restriction device.
- 4. Secure the torso and extremities to the backboard first, the head/neck last.
- 5. Remove from the long spine backboard once on the stretcher, unless CPR is ongoing or anticipated during transport.

Documentation of spinal motion restriction should include a neurologic assessment before and after the process, which includes the application of a cervical collar, noting any movement using a backboard/scoop stretcher, and indicating prompt removal from the backboard/scoop stretcher unless CPR ongoing/anticipated. In the seated patient that is hemodynamically stable and requiring spinal motion restriction, assist the patient in pivoting and lying supine onto the stretcher and/or use a spinal motion restriction device to achieve the same, whichever involves less anticipated spinal motion.




EMERGENCY
MEDICINE
UNIVERSITY OF OKLAHOMA

\*\* EMS SECTION

Approved 9/04/24, Effective 1/15/25, replaces all prior versions

## PROTOCOL 100: Splinting of Injuries, cont. 100a - Spinal Motion Restriction – Adult & Pediatric, cont.

\*\*\*SPINAL "IMMOBILIZATION" INCLUDING BACKBOARD ONLY IF SPINAL INJURY EVIDENT (PARALYSIS, PRIAPISM, OR NEURO SHOCK)





EMERGENCY
MEDICINE
UNIVERSITY OF OKLAHOMA

EMS SECTION

Approved 9/04/24, Effective 1/15/25, replaces all prior versions

PROTOCOL 100: Splinting of Injuries, cont. 100a - Spinal Motion Restriction – Adult & Pediatric, cont.

Comments regarding the Selective Spinal Motion Restriction Process:

- 1. The process of EMS-performed selective spinal motion restriction constitutes a formal step-wise screening of individuals suffering from mechanisms of injury compatible with possible injury to the spine. This process, now increasingly widely adopted in EMS systems across the United States, is designed from research-verified assessments, identifying individuals that may be safely transported to an emergency department, without spinal immobilization, for further appropriate physician evaluation. IT DOES NOT CONSTITUTE FORMAL "CLEARING" OF THE SPINE.
- 2. When following the decision flowchart in this protocol, there is no validated benefit to applying a cervical collar to patients who do not have any indication for spinal motion restriction and risks of pain, skin trauma, and compromise of respiratory mechanics may result if placed and left on a long spine backboard.
- 3. The process of EMS-performed selective spinal motion restriction, while continuing to involve placement of a cervical collar, no longer requires continuous use of a long spine backboard. While the long spine backboard is one option to assist a patient supine onto a stretcher, in the absence of ongoing or imminent CPR, patients should be removed off the long spine backboard as soon after movement onto the stretcher as possible.
- 4. Patients with penetrating trauma have been shown to have worse outcomes with continuous use of the long spine backboard, in part due to prolonged scene times relating to extensive spinal motion restriction actions. Victims of penetrating trauma (stabbings, gunshot wounds) to the head, neck, and/or torso SHOULD NOT receive spinal motion restriction unless there is one or more of the following:
  - Obvious neurologic deficit to the extremities
  - Priapism
  - Neurogenic shock
  - Anatomic deformity to the spine secondary to injury
- 5. Patients with any form of trauma may experience reduction in pulmonary mechanics (ease of oxygenation/ventilation) when placed onto a long spine backboard. Continuous use of the long spine backboard should be limited to situations involving ongoing or imminent CPR.
- 6. Patients at age extremes are prone to unreliable history and physical assessments. Patients under the age of 12 years or over the age of 65 years, if they have suffered a mechanism of injury compatible with possible spinal injury, are to be placed in spinal motion restriction.
- 7. The designation of a Glasgow Coma Scale score of 15 includes an assessment that no neurological deficits exist. If a patient is complaining of motor and/or sensory loss following a mechanism of injury compatible with possible spinal injury, that patient is to be placed in a cervical collar with verbal reinforcement that they limit movement of their cervical spine, keeping the spine in natural/neutral alignment.



EMERGENCY
MEDICINE
UNIVERSITY OF OKLAHOMA

\*\* EMS Section

Approved 9/04/24, Effective 1/15/25, replaces all prior versions

# PROTOCOL 100: Splinting of Injuries, cont. 10Oa - Spinal Motion Restriction – Adult & Pediatric. cont.

Comments regarding the Selective Spinal Motion Restriction Process (cont):

- 8. At any point from sustaining an acute mechanism of injury compatible with possible spinal injury through EMS care, if the patient has a reported loss of consciousness or altered mental status, regardless of normal mental status upon EMS contact and assessment, that patient is to be placed in spinal motion restriction.
- 9. A language barrier exists if the EMS professional and the patient cannot fluently communicate. Fragmented communication ("broken" language) or the use of a family member or bystander to communicate with the patient does not constitute fluent communication. If the EMS professional has a language barrier with the patient following an injury involving a mechanism compatible with possible spinal injury, that patient is to be placed in spinal motion restriction.
- 10. Regardless of apparent "soberness" on assessment, if a patient has ingested ethanol or mental-status altering drugs (e.g. narcotics, benzodiazepines, barbiturates, marijuana, cocaine) within six hours prior to a mechanism of injury compatible with possible spinal injury, that patient is to be placed in spinal motion restriction.
- 11. Distracting pain or injury is best defined as an injury in which the patient is repetitively fixated upon to the extent the history and physical assessment is frequently interrupted to address that injury. The EMS professional must use his or her best judgment and anytime a concern exists that an injury may prove distracting to a patient with a mechanism of injury compatible with possible spinal injury, that patient is to be placed in spinal motion restriction.
- 12. In circumstances of acute vomiting and/or third trimester pregnancy, the patient is preferentially transported left lateral recumbent to reduce aspiration of emesis and when in advanced stages of pregnancy, to avoid compromising venous return to the chest.
- 13. If the supine positioning of the patient wearing a cervical collar is compromising respiratory mechanics and/or causing the patient to have dyspnea, the head of the stretcher may be elevated approx 15 degrees to assist respiratory status.
- 14. If a patient suffering a mechanism of injury compatible with possible spinal injury complains of pain in the spinal or paraspinal area anywhere from the base of the skull to the coccyx, that patient is to be placed in spinal motion restriction.
- 15. In the physical examination of a patient suffering a mechanism of injury compatible with possible spinal injury, if the EMS professional discovers spinal or paraspinal pain or deformity upon palpation or with patient flexion, extension, or lateral rotation of the neck or back, that patient is to be placed in spinal motion restriction.



EMERGENCY
MEDICINE
UNIVERSITY OF OKLAHOMA

EMS SECTION

Approved 9/04/24, Effective 1/15/25, replaces all prior versions

# PROTOCOL 100: Splinting of Injuries, cont. 10Oa - Spinal Motion Restriction – Adult & Pediatric. cont.

Comments regarding the Selective Spinal Motion Restriction Process (cont):

- 17. If the EMS professional judges a complicating factor (e.g. patient stress or anxiety, the energy or nature of the mechanism of injury) to be present or significantly concerning, that patient is to be placed in spinal motion restriction. If any doubt exists in the view of the EMS professional as to whether to spinal motion restrict the patient, that patient is to be placed in spinal motion restriction.
- 18. An instance may occur when a patient has been deemed safe for transport without spinal motion restriction using this protocol and the patient subsequently develops neck or back pain in the ambulance during transport to an emergency department. The EMS professional must use his or her best judgment factoring the degree of pain verbalized and the remaining transport route and time in deciding when to spinal motion restrict the patient. As a guideline, if the remaining route involves unusually rough highway or will be prolonged beyond several minutes duration, the EMS crew should temporarily stop transportation and apply spinal motion restriction to the patient in the ambulance unless the patient's condition is otherwise unstable and requires continued emergency transport. As a guideline, if the arrival at the destination emergency department is imminent, the patient may be spinal motion restricted upon hospital arrival. In each instance, the EMS professional should inform the receiving nurse or physician of the events and timing of spinal motion restriction and appropriately reflect the events in the patient care report.
- 19. Any utilization of the selective spinal motion restriction protocol should be clearly documented in the patient care report, with each requirement in this process denoted.
- 20. An instance may occur when a patient that is to be spinal motion restricted by this protocol absolutely refuses a cervical collar and other such movement limitations. These are, indeed, difficult circumstances. If repeated attempts to secure the cooperation of the patient fail, guidance from OLMC should be sought. If such a patient is transported without spinal motion restriction by the direction of the OLMC, detailed documentation of the spinal motion restriction attempts, OLMC consultation and direction, and subsequent actions is to be contained in the patient care report.
- 21. For pediatric patients found in car seats and involved in motor vehicle collisions, use the following if spinal motion restriction indicated:
  - Infants restrained in a rear-facing car seat may remain in and be extricated in the car seat if secure and his/her condition allows (no signs of respiratory distress or shock)
  - Children restrained in a car seat (with a high back) may remain in and be extricated in the car seat.
  - Children restrained in a booster seat (without a back) need to be extricated and cared for following standard spinal motion restriction procedures.





Approved 9/04/24, Effective 1/15/25, replaces all prior versions

## PROTOCOL 100: Splinting of Injuries, cont.

### <u>100b – Extremity – Adult & Pediatric:</u>

When applying extremity splinting, include the following:

- 1. Assess and document the assessment of distal vascular (pulse) and nerve (motor/sensation) function, before and after splinting.
- 2. In general, immobilize the joint on either side of the suspected fracture area.
- 3. Pad splints whenever possible to avoid tissue pressure from splints.
- 4. In the setting of that an extremity is pulseless distal to a markedly angulated fracture, make one gentle attempt to place the angulated extremity in near-normal alignment. Document the distal vascular and nerve function before and after any such maneuver.
- 5. Prioritize timely transport to an appropriate emergency department for extremity injuries with pulselessness distal to the suspected fracture/injury.





### Medical Literature References 100 – Splinting of Injuries– Adult & Pediatric

- Fischer, P. E., Perina, D. G., Delbridge, T. R., Fallat, M. E., Salomone, J. P., Dodd, J., ... Gestring, M. L. (2018). Spinal Motion Restriction in the Trauma Patient A Joint Position Statement. Prehospital Emergency Care, 3127, 1–3. https://doi.org/10.1080/10903127.2018.1481476
- 2. National Association of EMS Physicians and American College of Surgeons Committee on Trauma. Postion Statement: EMS spinal precautions and the use of the long backboard. *Prehosp Emerg Care*. 2013 Jul-Sep;17(3):392-3.
- 3. Kim EG, Brown KM, Leonard JC, Jaffe DM, Olsen CS, Kuppermann AN; C-Spine Study Group of the Pediatric Emergency Care Applied Research Network (PECARN). Variability of prehospital spinal immobilization in children at risk for cervical spine injury. *Pediatr Emerg Care*. 2013 Apr;29(4):413-8.
- 4. Stuke LE, Pons PT, Guy JS, Chapleau WP, Butler FK, McSwain NE. Prehospital spine immobilization for penetrating trauma--review and recommendations from the Prehospital Trauma Life Support Executive Committee. *J Trauma*. 2011 Sep;71(3):763-9; discussion 769-70.
- 5. Horodyski M, Conrad BP, Del Rossi G, DiPaola CP, Rechtine GR 2nd. Removing a patient from the spine board: is the lift and slide safer than the log roll? *J Trauma*. 2011 May;70(5):1282-5; discussion 1285.
- 6. Lador R, Ben-Galim P, Hipp JA. Motion within the unstable cervical spine during patient maneuvering: the neck pivot-shift phenomenon. *J Trauma*. 2011 Jan;70(1):247-50; discussion 250-1.
- 7. Del Rossi G, Rechtine GR, Conrad BP, Horodyski M. Are scoop stretchers suitable for use on spine-injured patients? *Am J Emerg Med.* 2010 Sep;28(7):751-6.
- 8. Ben-Galim P, Dreiangel N, Mattox KL, Reitman CA, Kalantar SB, Hipp JA. Extrication collars can result in abnormal separation between vertebrae in the presence of a dissociative injury. *J Trauma*. 2010 Aug;69(2):447-50.
- 9. Haut ER, Kalish BT, Efron DT, Haider AH, Stevens KA, Kieninger AN, Cornwell EE 3rd, Chang DC. Spine immobilization in penetrating trauma: more harm than good? *J Trauma*. 2010 Jan;68(1):115-20; discussion 120-1.
- 10. Burton JH, Dunn MG, Harmon NR, Hermanson TA, Bradshaw JR. A statewide, prehospital emergency medical service selective patient spine immobilization protocol. *J Trauma*. 2006 Jul;61(1):161-7.
- 11. Burton JH, Harmon NR, Dunn MG, Bradshaw JR. EMS provider findings and interventions with a statewide EMS spine-assessment protocol. *Prehosp Emerg Care*. 2005 Jul-Sep;9(3):303-9.
- 12. Del Rossi G, Horodyski M, Heffernan TP, Powers ME, Siders R, Brunt D, Rechtine GR. Spine-board transfer techniques and the unstable cervical spine. *Spine*. 2004 Apr 1;29(7):E134-8.
- 13. Stiell IG, Clement CM, McKnight RD, Brison R, Schull MJ, Rowe BH, Worthington JR, Eisenhauer MA, Cass D, Greenberg G, MacPhail I, Dreyer J, Lee JS, Bandiera G, Reardon M, Holroyd B, Lesiuk H, Wells GA. The Canadian C-spine rule versus the NEXUS low-risk criteria in patients with trauma. *N Engl J Med.* 2003 Dec 25;349(26):2510-8.
- 14. Domeier RM, Swor RA, Evans RW, Hancock JB, Fales W, Krohmer J, Frederiksen SM, Rivera-Rivera EJ, Schork MA. Multicenter prospective validation of prehospital clinical spinal clearance criteria. *J Trauma*. 2002 Oct;53(4):744-50.
- 15. Viccellio P, Simon H, Pressman BD, Shah MN, Mower WR, Hoffman JR; NEXUS Group. A prospective multicenter study of cervical spine injury in children. *Pediatrics*. 2001 Aug;108(2):E20.
- 16. Goldberg W, Mueller C, Panacek E, Tigges S, Hoffman JR, Mower WR; NEXUS Group. Distribution and patterns of blunt traumatic cervical spine injury. *Ann Emerg Med.* 2001 Jul;38(1):17-21.
- 17. Hauswald M, McNally T. Confusing extrication with immobilization: the inappropriate use of hard spine boards for interhospital transfers. *Air Med J.* 2000 Oct-Dec;19(4):126-7.
- 18. Perry SD, McLellan B, McIlroy WE, Maki BE, Schwartz M, Fernie GR. The efficacy of head immobilization techniques during simulated vehicle motion. *Spine*. 1999 Sep 1;24(17):1839-44.
- 19. McHugh TP, Taylor JP. Unnecessary out-of-hospital use of full spinal immobilization. *Acad Emerg Med.* 1998 Mar;5(3):278-80.
- 20. Chan D, Goldberg RM, Mason J, Chan L. Backboard versus mattress splint immobilization: a comparison of symptoms generated. *J Emerg Med.* 1996 May-Jun;14(3):293-8.





Approved 9/04/24, Effective 1/15/25, replaces all prior versions

10P - BLAST INJURY

# ADULT & PEDIATRIC

### TREATMENT PRIORITIES

- 1. SAFETY, SAFETY, SAFETY
- 2. Hemorrhage control
- 3. Assessment/Care for lifethreatening injuries/shock
- 4. Vital signs
- 5. Analgesia (if required)
- 6. Appropriate trauma care destination selection

### EMD

OBTAIN AVAILABLE SCENE HAZARD INFORMATION
FOR RESPONDER SAFETY
DO NOT MOVE PATIENTS UNLESS IN DANGER
STABILIZE HEAD AND NECK IN POSITION FOUND
OPEN AIRWAY IF NOT ALERT & INEFFECTIVE BREATHING
CONTROL BLEEDING BY DIRECT PRESSURE

# EMERGENCY MEDICAL DISPATCHER EMERGENCY MEDICAL

MERGENCY MEDICA RESPONDER

**EMT** 

**EMT-INTERMEDIATE 85** 

**ADVANCED EMT** 

**PARAMEDIC** 

### EMR EMT

SCENE SAFETY CONSIDERATIONS – FLAMMABLE ENVIRONMENT? TERRORISM CAUSE – SECONDARY DEVICES?

MASS CASUALTY INCIDENT MANAGEMENT/TRAUMA AND HYPOVOLEMIC SHOCK SUPPORTIVE CARE

EXPECT HEARING DIFFICULTY/DEAFNESS IN PATIENTS DUE TO PRIMARY BLAST INJURY OF RUPTURED EAR TYMPANUM

APPLY TOURNIQUET FOR HEMORRHAGE UNCONTROLLED BY DIRECT PRESSURE PER PROTOCOL 10H - TOURNIQUET

OBTAIN VITAL SIGNS

O<sub>2</sub> VIA NC, NRB AS APPROPRIATE

SPLINT SUSPECTED FRACTURES INCLUDING JOINT ABOVE AND BELOW AREA OF INJURY COVER AMPUTATED ANATOMY WITH SALINE-MOISTENED GAUZE

PLACE AMPUTATED ANATOMY IN A CLEAN PLASTIC BAG
PLACE AMPUTATED ANATOMY OVER ICE, AVOIDING DIRECT CONTACT OF AMPUTATED ANATOMY WITH ICE
STABILIZE IMPALED OBJECTS

APPLY CARDIAC MONITOR (if equipped)

**EMT-185** 

**AEMT** 

IV ACCESS (IO IF INDICATED)

IV ACCESS (IO IF INDICATED) (TWO LINES IF POSSIBLE)

ADULT: IV NS TKO IF SYS BP ≥ 100 mmHg WITHOUT HYPOTENSIVE SYMPTOMS

ADULT: IV NS 250 mL BOLUS IF SYS BP <100 mmHg WITH HYPOTENSIVE SYMPTOMS & NO SIGNS OF PULMONARY EDEMA,
ADULT: REPEAT UP TO 2 LITERS NS IF SYS BP REMAINS < 100 mmHg WITH HYPOTENSIVE SYMPTOMS & NO SIGNS OF PULMONARY EDEMA
PEDIATRIC: IV NS 20 mL/kg BOLUS IF SYS BP < (70 + 2x age in years) mmHg & NO SIGNS OF PULMONARY EDEMA

PEDIATRIC: REPEAT UP TO 60 mL/kg IF SYS BP REMAINS < (70 + 2x age in years) mmHg & NO SIGNS OF PULMONARY EDEMA

#### **PARAMEDIC**

ANALGESIA (IF REQUIRED)

FOR OPIATE USE, ADULT MUST HAVE SYS BP ≥ 100 mmHg; PEDIATRIC MUST HAVE SYS BP ≥ (70 + 2x age in years) mmHg

ADULT: FENTANYL 1 mcg/kg SLOW IVP/IM/IN, MAXIMUM DOSE 100 mcg. MAY REPEAT EVERY 10 MINUTES TO MAXIMUM CUMULATIVE DOSE OF 3 mcg/kg or 250 mcg WHICHEVER IS LESSER.

OR

ADULT: MORPHINE SULFATE 2 - 4 mg SLOW IVP, MAY REPEAT 2 - 4 mg EVERY 5 MINUTES TO A TOTAL OF 10 mg.

OR

 $\textbf{ADULT:} \ \ \text{HYDROMORPHONE 0.5-1 mg SLOW IVP, MAY REPEAT EVERY 10 MINUTES TO MAXIMUM CUMULATIVE DOSE OF 2 mg.$ 

PEDIATRIC: OLMCP ORDER ONLY

OLMCP CONSULT IF FURTHER ANALGESIA REQUIRED

CONTINUOUS ASSESSMENT & TREATMENT PER APPLICABLE PROTOCOL(S)





### Medical Literature References 10P – Blast Injury – Adult & Pediatric

- 1. Burnstein JL, ed. Best practices for management of explosive incidents: translating the US and Israeli military and civilian experience for use in the US civilians and military out-of-hospital and hospital health care. Supplement to Ann Emerg Med. 2017. 69(1).
- Yonekawa Y, Hacker HD, Lehman RE, Beal CJ, Veldman PB, Vyas NM, Shah AS, Wu D, Eliott D, Gardiner MF, Kuperwaser MC, Rosa RH Jr, Ramsey JE, Miller JW, Mazzoli RA, Lawrence MG, Arroyo JG. Ocular blast injuries in mass-casualty incidents: the marathon bombing in Boston, Massachusetts, and the fertilizer plant explosion in West, Texas. *Opthalmology*. 2014 Sep;121(9):1670-6.
- Biddinger PD, Baggish A, Harrington L, d'Hemecourt P, Hooley J, Jones J, Kue R, Troyanos C, Dyer KS. Be prepared--the Boston Marathon and mass-casualty events. NEJM. 2013 May 23:368(21):1958-60.
- 4. Kapur GB, Pillow MT, Nemeth I. Prehospital care algorithm for blast injuries due to bombing incidents. *Prehosp Disaster Med.* 2010 Nov-Dec;25(6):595-600.
- Cain JS. Lethal detonation: responding to scenes involving blast injuries. JEMS. 2010 Aug;35(8):64-68
- 6. Sambasivan CN, Schreiber MA. Emerging therapies in traumatic hemorrhage control. *Curr Opin Crit Care*. 2009 Dec;15(6):560-8.
- 7. Kragh JF Jr, Walters TJ, Baer DG, Fox CJ, Wade CE, Salinas J, Holcomb JB. Survival with emergency tourniquet use to stop bleeding in major limb trauma. *Ann Surg.* 2009 Jan;249(1):1-7.
- 8. Mabry R, McManus JG. Prehospital advances in the management of severe penetrating trauma. *Crit Care Med.* 2008 Jul;36(7 Suppl):S258-66.
- 9. Lerner EB, O'Connor RE, Schwartz R, Brinsfield K, Ashkenazi I, Degutis LC, Dionne JP, Hines S, Hunter S, O'Reilly G, Sattin RW. Blast-related injuries from terrorism: an international perspective. *Prehosp Emerg Care*. 2007 Apr-Jun;11(2):137-53.





Approved 9/04/24, Effective 1/15/25, replaced all prior versions

10Q - FIELD AMPUTATION

#### Operational Procedure:

- The Surgical Emergency Response Team (SERT OU Trauma) is a resource for metropolitan Oklahoma City that can be activated for patients with entrapped extremities requiring surgical amputation procedures which exceed the capabilities of EMS system professionals.
- SERT activation may occur when mutually agreed by the ranking fire officer and EMSA District Chief on-scene.
- 3. SERT activation is accomplished by contacting OUMC ED Trauma Side and requesting SERT mobilization to the indicated scene.
- 4. SERT transportation to and from the scene will be facilitated by the ranking fire officer and EMSA District Chief on-scene working together to determine the appropriate EMS system vehicle(s) to utilize for SERT members responding from OUMC.
- 5. SERT team composition may include trauma surgeon(s), orthopedic surgeon(s), surgical nurse(s), emergency nurse(s), surgical tech(s), and/or other deemed essential to specific patient care. SERT team composition is at the discretion of OU Trauma Services.

# SERT ACTIVATION ACCESS NUMBER OUMC ED - TRAUMA: 405-271-1623

## Contraindications:


- 1. Completed amputations
- 2. Near-complete amputations with only soft tissues needing incision to complete contact OMD for amputation completion orders if any questions remain about limb salvage/viability.
- 3. Ability to extricate the patient without need for further amputation

The instructions above apply only to metropolitan Oklahoma City. For metropolitan Tulsa, contact a Chief Medical Officer or OMD Division Chief for surgical team activation and mobilization assistance.





Approved 9/04/24, Effective 1/15/25, replaces all prior versions







Approved 9/04/24, Effective 1/15/25, replaces all prior versions

Protocol 11A: Heat Illness Adult & Pediatric (cont.)

## **Rapid Cooling for Heat Stroke**

## **PURPOSE**

Rapid, on-scene cooling is highly beneficial to survival from **environmental or exertional-induced heat stroke**. On-scene cooling is not intended for patients who have a non-environmental, non-exertional cause for elevated core temperature (such as fever from an infectious disease). The exact cooling method(s) chosen is often dependent upon scene location, available personnel, and available resources. The primary goal of rapid cooling for heat stroke is to provide **immersion cooling <u>before</u> transporting** to an emergency department. While on-scene cooling will involve extra minutes of care prior to transport, few if any destination hospitals have immersion cooling capabilities, particularly capabilities that can deployed as rapidly as within the EMS System for Metropolitan Oklahoma City and Tulsa. The extra time and effort in cooling before transporting can prove life-saving.

## **PROCEDURE**

In static settings, such as multi-hour fireground rehabs, and particularly in pre-planned static settings, such as summer outdoor football practices, cold water/ice bath immersion resources already on-scene should be identified and utilized.

For unplanned heat exposures leading to heat stroke, cold water deluge is the most practical application. As soon as potential heat stroke is identified, an emergency apparatus capable of establishing water supply from a fire hydrant should be dispatched. If a copious cold water supply or fire hydrant is not immediately available at the scene, it is acceptable to move the patient via ambulance to the nearest such copious cold water supply or fire hydrant to perform rapid cooling for heat stroke.

## **Cold Water Deluge:**

- 1. Place the patient in a cooling bag.
- 2. Place a minimum estimated 5 gallons of iced water on patient while fire hydrant source is established (if available/applicable).
- 3. Deluge water over the patient's chest and lower body continuously while protecting the patient's airway.
- 4. Deluge water until patient temperature is less than 102.2°F (39°C) or, if continuous temperature monitoring is not available, until the patient demonstrates improvement in mental status.
- 5. Do not initiate deluge while the patient is in an ambulance or on an ambulance stretcher due to electronics.
- 6. Unless hypotensive or other immediate need, prioritize rapid cooling in the setting of heat stroke, over IV access and other invasive procedures.





Approved 9/04/24, Effective 1/15/25, replaces all prior versions

## Protocol 11A: Heat Illness Adult & Pediatric (cont.)

## Static Setting Cold Water/Ice Bath Immersion:

- 1. Utilize a tub designed to manage weight of patient and water.
- 2. Fill tub with ice and water to a level that will cover the patient's chest.
- 3. Ice the water to reach a temperature near 50°F.
- 4. Utilize a tarp or similar device to lower and lift the patient.
- 5. Utilize a blanket roll or similar device looped under the axillae to keep the patient's head (airway) above water.
- 6. Agitate the water while patient is immersed.
- 7. Immerse until patient temperature is less than 102.2°F (39°C) or, if continuous temperature monitoring is not available, until the patient demonstrates improvement in mental status.
- 8. Unless hypotensive or other immediate need, prioritize immersion cooling in the setting of heat stroke, over IV access and other invasive procedures.

## **ADDITIONAL CONSIDERATIONS**

- Cooling bags should have handles to facilitate movement and oscillation of the patient during deluge or immersion. Webbing or sewed-on handles are preferred over less sturdy options. Handles cut into the material of the bag are more prone to leaks and failure.
- Rectal thermometers designed for continuous monitoring (if available) should be placed as soon as
  possible, even if after cold water deluge or cold water/ice bath immersion has been initiated.
- Fire hydrant water temperature may range between approximately 50°F to 70°F depending on time of year. Fire hydrant water is preferred over fire apparatus tank water due to more predictable temperature range.





## Medical Literature References 11A – Heat Illness – Adult & Pediatric

- 1. Belval, L. N., Casa, D. J., Adams, W. M., Chiampas, G. T., Holschen, J. C., Hosokawa, Y., ... Stearns, R. L. (2018). Consensus Statement- Prehospital Care of Exertional Heat Stroke. Prehospital Emergency Care, 22(3), 392–397. https://doi.org/10.1080/10903127.2017.1392666
- 2. Lipman GS, Eifling KP, Ellis MA, Gaudio FG, Otten EM, Grissom CK; Wilderness Medical Society. Wilderness Medical Society practice guidelines for the prevention and treatment of heat-related illness: 2014 update. *Wilderness Environ Med.* 2014 Dec;25(4 Suppl): S55-65.
- 3. Centers for Disease Control and Prevention (CDC). Nonfatal sports and recreation heat illness treated in hospital emergency departments--United States, 2001-2009. *MMWR Morb Mortal Wkly Rep.* 2011 Jul 29;60(29):977-80.
- 4. Zeller L, Novack V, Barski L, Jotkowitz A, Almog Y. Exertional heatstroke: clinical characteristics, diagnostic and therapeutic considerations. *Eur J Intern Med.* 2011 Jun;22(3):296-9.



TREATMENT PRIORITIES

1. Warming therapy


resuscitation (when applicable)

Vital signs
 Modified cardiac arrest

## EMS System for Metropolitan Oklahoma City and Tulsa 2025 Medical Control Board Treatment Protocols



Approved 9/04/24, Effective 1/15/25, replaces all prior versions



EMR EMT

GENERAL SUPPORTIVE CARE
REMOVE FROM COLD ENVIRONMENT
REMOVE WET/RESTRICTIVE CLOTHING
APPLY HEAT PACKS TO GROIN, NECK, AXILLA
COVER PATIENT WITH BLANKETS TO EXTENT CLINICALLY POSSIBLE
OBTAIN VITAL SIGNS
O<sub>2</sub> VIA NC, NRB, OR BVM AS APPROPRIATE (WARM & HUMIDIFIED O<sub>2</sub> if equipped)

/IA NC, NRB, OR BVM AS APPROPRIATE (WARM & HUMIDIFIED O₂ if equipped)
APPLY CARDIAC MONITOR (if equipped)

#### UNRESPONSIVE HYPOTHERMIA PATIENT STATUS?

ASSESS BREATHING/PULSE FOR UP TO 45 SECONDS
PERFORM CPR IF IN CARDIOPULMONARY ARREST
IF DEFIBRILLATION ADVISED BY AED, LIMIT TO ONE DEFIBRILLATION UNTIL WARMED

#### FROSTBITE?

APPLY LOOSE STERILE DRESSINGS AND SPLINT INVOLVED EXTREMITIES

#### **EMT OR HIGHER LICENSE:**

MEASURE END – TIDAL CO<sub>2</sub> & MONITOR WAVEFORM CAPNOGRAPHY (if equipped, \*\*Mandatory use if pt intubated)
PLACE SUPRAGLOTTIC AIRWAY IF INDICATED & ONLY IF BVM VENTILATIONS INEFFECTIVE

EMT-185 AEMT

ADULT: INTUBATE IF INDICATED

#### IV ACCESS

ADULT: IV NS (WARMED UP TO 43°C (109°F) if available) 500 mL BOLUS IF NO SIGNS OF PULMONARY EDEMA.

ADULT: REPEAT UP TO 2 LITERS NS IF PT TEMP <30°C (<86°F), ALTERED MENTAL STATUS, &/OR HYPOTENSION < 100 mmHg PERSISTS

IF NO SIGNS OF PULMONARY EDEMA

PEDIATRIC: IV NS 20 mL/kg BOLUS (WARMED AS PER ADULT if available) IF NO SIGNS OF PULMONARY EDEMA PEDIATRIC: REPEAT UP TO 60 mL/kg IF PT TEMP <30°C (<86°F), ALTERED MENTAL STATUS, &/OR HYPOTENSION < (70 + 2x age in years) mmHg PERSISTS IF NO SIGNS OF PULMONARY EDEMA

#### **PARAMEDIC**

ADULT: MEDICATION ASSISTED INTUBATION IF INDICATED

#### HYPOTHERMIC CARDIAC ARREST?

ADULT/PEDIATRIC: WITH BODY TEMPERATURE <30°C (<86°F)
CONTINUE CPR, WITHHOLD MEDICATIONS, LIMIT TO A SINGLE DEFIBRILLATION FOR VENTRICULAR FIBRILLATION/PULSELESS VT

ADULT/PEDIATRIC: WITH BODY TEMPERATURE ≥30°C (≥86°F)
CONTINUE CPR, ADMINISTER DYSRHYTHMIA APPLICABLE MEDICATIONS AT 10 MINUTE INTERVALS
AS CORE TEMPERATURE RISES, DEFIBRILLATE PER NORMAL BODY TEMPERATURE INTERVALS

CONTINUE REWARMING MEASURES UNTIL ROSC OR OLMCP AUTHORIZES TERMINATION OF RESUSCITATION

CONTINUOUS ASSESSMENT & TREATMENT PER APPLICABLE PROTOCOL(S)






## Medical Literature References 11B – Cold Illness/Injury – Adult & Pediatric

- Lavonas EJ, Drennan IR, Gabrielli A, Heffner AC, Hoyte CO, Orkin AM, Sawyer KN, Donnino MW. Part 10: Special Circumstances of Resuscitation: 2015 American Heart Association Guidelines Update for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. *Circulation*. 2015 Nov 3;132(18 Suppl 2):S501-18.
- Zafren K, Giesbrecht GG, Danzl DF, Brugger H, Sagalyn EB, Walpoth B, Weiss EA, Auerbach PS, McIntosh SE, Nemethy M, McDevitt M, Dow J, Schoene RB, Rodway GW, Hackett PH, Bennett BL, Grissom CK; Wilderness Medical Society. Wilderness Medical Society practice guidelines for the outof-hospital evaluation and treatment of accidental hypothermia: 2014 update. Wilderness Environ Med. 2014 Dec:25(4 Suppl):S66-85.
- 3. McIntosh SE, Opacic M, Freer L, Grissom CK, Auerbach PS, Rodway GW, Cochran A, Giesbrecht CG, McDevitt M, Imray CH, Johnson EL, Dow J, Hackett PH; Wilderness Medical Society. Wilderness Medical Society practice guidelines for the prevention and treatment of frostbite: 2014 update. *Wilderness Environ Med.* 2014 Dec;25(4 Suppl):S43-54.
- 4. Henriksson O, Lundgren JP, Kuklane K, Holmér I, Bjornstig U. Protection against cold in prehospital care-thermal insulation properties of blankets and rescue bags in different wind conditions. *Prehosp Disaster Med.* 2009 Sep-Oct;24(5):408-15.
- 5. Lundgren JP, Henriksson O, Pretorius T, Cahill F, Bristow G, Chochinov A, Pretorius A, Bjornstig U, Giesbrecht GG. Field torso-warming modalities: a comparative study using a human model. *Prehosp Emerg Care*. 2009 Jul-Sep;13(3):371-8.
- 6. Cagle A, Hubbard R. Cold-related cardiac mortality in King County, Washington, USA 1980-2001. *Ann Hum Biol.* 2005 Jul-Aug;32(4):525-37.
- 7. Ulrich AS, Rathlev NK. Hypothermia and localized cold injuries. *Emerg Med Clin North Am.* 2004 May;22(2):281-98.





Approved 9/04/24, Effective 1/15/25, replaces all prior versions








## Medical Literature References 11C – Lightning/Electrical Injury – Adult & Pediatric

- Lavonas EJ, Drennan IR, Gabrielli A, Heffner AC, Hoyte CO, Orkin AM, Sawyer KN, Donnino MW. Part 10: Special Circumstances of Resuscitation: 2015 American Heart Association Guidelines Update for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. *Circulation*. 2015 Nov 3;132(18 Suppl 2):S501-18.
- 2. Davis C, Engeln A, Johnson E, McIntosh SE, Zafren K, Islas AA, McStay C, Smith WR, Cushing T; Wilderness Medical Society. Wilderness medical society practice guidelines for the prevention and treatment of lightning injuries: 2014 update. *Wilderness Environ Med.* 2014 Dec;25(4 Suppl):S86-95.
- 3. Pfortmueller CA, Yikun Y, Haberkern M, Wuest E, Zimmermann H, Exadaktylos AK. Injuries, sequelae, and treatment of lightning-induced injuries: 10 years of experience at a swiss trauma center. *Emerg Med Int*. 2012;2012:167698. Epub 2012 May 13.
- 4. Ritenour AE, Morton MJ, McManus JG, Barillo DJ, Cancio LC. Lightning injury: a review. *Burns*. 2008 Aug;34(5):585-94.
- 5. Maghsoudi H, Adyani Y, Ahmadian N. Electrical and lightning injuries. *J Burn Care Res.* 2007 Mar-Apr;28(2):255-61.





Approved 9/04/24 Effective 1/15/25, replaces all prior versions







# Medical Literature References 11D – Water Submersion Events – Adult & Pediatric


- Lavonas EJ, Drennan IR, Gabrielli A, Heffner AC, Hoyte CO, Orkin AM, Sawyer KN, Donnino MW. Part 10: Special Circumstances of Resuscitation: 2015 American Heart Association Guidelines Update for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. *Circulation*. 2015 Nov 3;132(18 Suppl 2):S501-18.
- 2. Dyson K, Morgans A, Bray J, Matthews B, Smith K. Drowning related out-of-hospital cardiac arrests: Characteristics and outcomes. *Resuscitation*. 2013 Jan 29.
- 3. Ferguson JD, De Guzman J. Cardiac arrest in special populations. *Emerg Med Clin North Am.* 2012 Feb;30(1):169-78.
- 4. Diamond W, MacDonald RD. Submersion and early-onset acute respiratory distress syndrome: a case report. *Prehosp Emerg Care*. 2011 Apr-Jun;15(2):288-93.
- 5. Youn CS, Choi SP, Yim HW, Park KN. Out-of-hospital cardiac arrest due to drowning: An Utstein Style report of 10 years of experience from St. Mary's Hospital. *Resuscitation*. 2009 Jul;80(7):778
- 6. Layon AJ, Modell JH. Drowning: Update 2009. Anesthesiology. 2009 Jun;110(6):1390-401.
- 7. Szpilman D, Bierens JJLM, Handley A, Orlowski JP. Drowning. NEJM. 2012. 366 (22): 2102 2110
- 8. Quan L, Mack CD, Schiff MA. Association of water temperature and submersion duration and drowning outcome. Resuscitation. 2014. 85: 790 794
- 9. Wollenek G, Honarwar N, Golej J, Marx M. Cold water submersion and cardiac arrest in treatment of severe hypothermia with cardiopulmonary bypass. Resuscitation. 2002. 52: 255 263
- 10. Nordberg P, Ivert T, Dalen M, Forsberg S, Hedman A. Surviving two hours of ventricular fibrillation in accidental hypothermia. Prehosp Emerg Care. 2014. 18 (3): 446 449
- 11. Kulkarni RG, Thomas SH. Severe accidental hypothermia: the need for prolonged aggressive resuscitative efforts. Prehosp Emerg Care. 2009. 3 (3): 254 259
- 12. Lee CH, Gelder CV, Burns K, Cone DC. Advanced cardiac life support and defibrillation in severe hypothermic cardia arrest. Prehosp Emerg Care. 2009. 13 (1): 85 89





Approved 9/04/24, Effective 1/15/25, replaces all prior versions

# 11E – HEAT STROKE – ATHLETIC PARTICIPANTS WITH FIELD COOLING CAPABILITIES ON-SITE AT EVENT



<u>Indication</u>: Life-threatening heat stroke by clinical assessment requiring rapid cooling of core body temperature

Contraindication: Cardiac Arrest

Respiratory Arrest Unstable Airway

Inability to Maintain Normal Oxygenation

## Technique (Ice Bath Immersion or Commercially Produced Body Cooling Wraps):

Athletic trainers and sports medicine physicians most typically are able to identify athletes at increased risk of heat stroke, stopping their activity and initiating cooling measures before heat stroke occurs. Athletic trainers most typically know their assigned athletes well, work in consultation with sports medicine physicians, and are valuable resources on the scene of an athletic-related medical emergency.

Field cooling with ice bath immersion or using commercially produced body cooling wraps, typically performed in a training room area adjacent to the actual "field" of play, can lower core body temperature more rapidly than ice packs to the groin and axilla as traditionally used in EMS care or Emergency Department based care. The reality is that no local Emergency Department has measures that can lower core body temperature more rapidly than effective field cooling.

After initial Paramedic assessment of the patient, consult with an OMD physician (Dr. Goodloe or Dr. Knoles) or OMD paramedic (Duffy McAnallen, David Howerton, or Matt Cox) is mandatory to help guide efficient, effective patient management, including field cooling.

Essential steps in any field cooling include: rapid activation of 911-based EMS care, continuous attention to airway/breathing/circulation, organized ongoing assessment and care throughout cooling, ability to accurately and continuously measure core body temperature by rectal thermometry, and packaging/moving the patient for timely ambulance transport once field cooling has achieved core body temperature less than 103F (rectally).





Approved 9/04/24, Effective 1/15/25, replaces all prior versions

Heat Stroke - Athletic Participants with Field Cooling Capabilities On-Site at Event (cont.)

Appropriate hospital destinations for patients requiring emergent field cooling once cooled:

- Tulsa area: St. Johns Medical Center, Saint Francis Hospital, Hillcrest Medical Center, OSUMC
- Oklahoma City area: The Children's Hospital, Integris Baptist Medical Center, Integris
  Deaconess Hospital, Integris Southwest Medical Center, OU Medical Center, St. Anthony
  Hospital

## Step 1 (Figure 1):

The patient will most likely be encountered immersed in an ice bath or within the commercial cooling wrap device. Rectal thermometry should already be in place as well. Initial assessment includes confirmation of pulse – best practice would be to have continuous access to one wrist, and effective breathing. Any patient requiring active airway management beyond positioning the head above the ice bath should be removed from cooling and transported as quickly as possible.



## Step 2 (Figure 2):

The Paramedic should establish location near the patient's airway throughout cooling. Attach waveform capnography to continuously measure spontaneous circulation, respiratory rate, and ventilatory effects. Notify OMD for patient consultation of care.



## Step 3 (Figure 3):

Cooling impact should be rapid, being able to see decrease in core body temperature on the rectal thermometer screen. Be prepared for sudden alertness, and often vomiting, once the core temperature approaches 103F. If initial temperature shows 107.9F, realize the actual temperature is likely higher, as most available rectal thermometers will only read to 107.9F.







Approved 9/04/24, Effective 1/15/25, replaces all prior versions

Heat Stroke – Athletic Participants with Field Cooling Capabilities On-Site at Event (cont.)


## Step 4 (Figure 4):

Prior to patient alertness, pass a lifting tarp under the patient to assist in safely lifting the patient, particularly if immersed in an ice bath.



## Step 5 (Figure 5):

Once a core body temperature of 103F is achieved, the patient should be removed from ice immersion and packaged on the EMS stretcher for timely transport to a destination identified in this guidance document. Any patient with emergent field cooling mandates an Emergency Department evaluation.








Approved 9/04/24, Effective 1/15/25, replaces all prior versions

# 12A – FIREGROUND REHABILITATION CONCEPTS ADULT



#### Indications:

Active fireground operations in which physiologic stress is exerted upon firefighters.

## **Contraindications:**

None

## Clinical Pearls:

- 1. Fireground operations place significant physiologic stress upon firefighters. Even in seemingly "normal" weather (absence of temperature extremes, absence of precipitation) during operations on even terrain, conducted by ample numbers of firefighters, the elevated body temperatures and physical stress experienced from exertion while wearing heavy protective clothing should not be underestimated. Early and effective rehabilitation promotes desired firefighter safety on the fireground.
- 2. The "basics" of effective fireground rehabilitation include:
  - a. medical monitoring of fire fighters at rehab entry, during rehab, and at rehab release;
  - b. returning body temperatures to near normal (cooling in heat; warming in cold);
  - c. hydration and electrolyte replacement;
  - d. Incident Command support of preventing fire fighter return to fireground duty until medically appropriate.
- 3. Fireground rehabilitation operations conducted by EMS organizations should be performed in close cooperation with involved fire departments and with knowledge of the rehabilitation policies of those fire departments. Section 19 contains current fireground rehabilitation policies utilized by the Tulsa Fire Department as resource documents in assisting other EMS organizations and fire departments in Oklahoma (courtesy Tulsa Fire Department).





Approved 9/04/24, Effective 1/15/25, replaces all prior versions

## PROTOCOL 12A: Fireground Rehabilitation Concepts, cont.

4. In addition to the medical literature references for this protocol, additional fireground rehabilitation resources are available through the US Fire Administration, National Fire Protection Agency, International Association of Fire Chiefs, and International Association of Firefighters. Suggested resources that may prove helpful in designing and conducting effective fireground rehabilitation operations include:

U.S. Fire Administration, Emergency Incident Rehabilitation, February 2008 https://www.usfa.fema.gov/downloads/pdf/publications/fa\_314.pdf

NFPA 1584: Standard on the Rehabilitation Process for Members During Emergency Operations and Training Exercises, 2015 Edition

www.firerehab.com





Medical Literature References 12A – Fireground Rehabilitation Concepts - Adult

- 1. McEntire SJ, Suyama J, Hostler D. Mitigation and prevention of exertional heat stress in firefighters: a review of cooling strategies for structural firefighting and hazardous materials responders. *Prehosp Emerg Care*. 2013 Apr-Jun;17(2):241-60.
- 2. Pryor RR, Seitz JR, Morley J, Suyama J, Guyette FX, Reis SE, Hostler D. Estimating core temperature with external devices after exertional heat stress in thermal protective clothing. *Prehosp Emerg Care*. 2012 Jan;16(1):136-41.
- 3. Horn GP, Gutzmer S, Fahs CA, Petruzzello SJ, Goldstein E, Fahey GC, Fernhall B, Smith DL. Physiological recovery from firefighting activities in rehabilitation and beyond. *Prehosp Emerg Care*. 2011 Apr-Jun:15(2):214-25.
- 4. Hostler D, Reis SE, Bednez JC, Kerin S, Suyama J. Comparison of active cooling devices with passive cooling for rehabilitation of firefighters performing exercise in thermal protective clothing: a report from the Fireground Rehab Evaluation (FIRE) trial. *Prehosp Emerg Care*. 2010 Jul-Sep;14(3):300-9.
- 5. Hostler D, Bednez JC, Kerin S, Reis SE, Kong PW, Morley J, Gallagher M, Suyama J. Comparison of rehydration regimens for rehabilitation of firefighters performing heavy exercise in thermal protective clothing: a report from the fireground rehab evaluation (FIRE) trial. *Prehosp Emerg Care*. 2010 Apr-Jun;14(2):194-201.
- 6. Dickinson ET, Bevilacqua JJ, Hill JD, Sites FD, Wurster FW, Mechem CC. The utility of tympanic versus oral temperature measurements of firefighters in emergency incident rehabilitation operations. *Prehosp Emerg Care.* 2003 Jul-Sep;7(3):363-7.





Approved 9/04/24, Effective 1/15/25, replaces all prior versions

# 12B – SMOKE INHALATION ADULT & PEDIATRIC

#### TREATMENT PRIORITIES

- 1. Personal safety
- 2. Patient safety
- 3. Vital signs
  - (including EtCO2, if equipped)
- 4. Oxygenation support
  - O₂ by NC, NRB
  - BVM, Bi/CPAP, ETT if indicated
- 5. Ventilation support
  - BVM, Bi/CPAP, ETT if indicated
- 6. Nebulization therapy
  - Albuterol

#### **EMD**

DIRECT TO MOVE AWAY FROM SMOKE IF SAFE TO DO SO OPEN AIRWAY IF NOT ALERT & INEFFECTIVE BREATHING IF AWAKE, AVOID PHYSICAL EXERTION OR ENVIRONMENTAL STRESS (TEMP EXTREMES). ADVISE PT SELF-ADMINISTRATION OF MEDICATIONS (eg. ALBUTEROL INHALER)

IF PREVIOUSLY PRESCRIBED FOR SIMILAR SYMPTOMS

# EMERGENCY MEDICAL DISPATCHER

EMERGENCY MEDICAL RESPONDER

**EMT** 

**EMT-INTERMEDIATE 85** 

**ADVANCED EMT** 

**PARAMEDIC** 

EMR EMT

MAINTAIN PERSONAL & PATIENT SAFETY
GENERAL SUPPORTIVE CARE
OBTAIN VITAL SIGNS
O<sub>2</sub> VIA NC, NRB, OR BVM AS APPROPRIATE
APPLY CARDIAC MONITOR (if equipped)
ASSIST PT WITH PT'S OWN ALBUTEROL INHALER/NE BULIZER (when applicable)
TREAT PER 12C – CARBON MONOXIDE &/OR 12E – CYANIDE AS APPLICABLE

#### **EMT OR HIGHER LICENSE:**

MEASURE END-TIDAL CO<sub>2</sub> & MONITOR WAVEFORM CAPNOGRAPHY (if equipped)

ADULT: APPLY Bi/CPAP IF INDICATED (if equipped)

ADULT & PEDIATRIC WEIGHT ≥15 kg: NEBULIZED ALBUTEROL 5 mg OR LEVALBUTEROL 2.5 mg
PEDIATRIC WEIGHT <15 kg: NEBULIZED ALBUTEROL 2.5 mg OR LEVALBUTEROL 1.25 mg
MAY REPEAT ALBUTEROL OR LEVALBUTEROL ENROUTE X 1 AS NEEDED

PLACE SUPRAGLOTTIC AIRWAY IF INDICATED & ONLY IF BVM VENTILATIONS INEFFECTIVE

EMT-185 AEMT

**ADULT: INTUBATE IF INDICATED** 

#### IV ACCESS

ADULT: IV NS TKO IF SYS BP ≥ 100 mmHg WITHOUT HYPOTENSIVE SYMPTOMS

ADULT: IV NS 250 mL BOLUS IF SYS BP <100 mmHg WITH HYPOTENSIVE SYMPTOMS & NO SIGNS OF PULMONARY EDEMA,

ADULT: REPEAT UP TO 2 LITERS NS IF SYS BP REMAINS < 100 mmHg WITH HYPOTENSIVE SYMPTOMS & NO SIGNS OF PULMONARY EDEMA

PEDIATRIC: IV NS TKO IF SYS BP ≥ (70 + 2x age in years) mmHg

PEDIATRIC: IV NS 20 mL/kg BOLUS IF SYS BP < (70 + 2x age in years) mmHg IF NO SIGNS OF PULMONARY EDEMA

#### **PARAMEDIC**

ADULT: MEDICATION ASSISTED INTUBATION IF INDICATED CONTINUOUS ASSESSMENT & TREATMENT PER APPLICABLE PROTOCOL(S)





## Medical Literature References 12B – Smoke Inhalation - Adult & Pediatric

- Dries DJ, Endorf FW. Inhalation injury: epidemiology, pathology, treatment strategies. Scand J Trauma Resusc Emerg Med. 2013 Apr 19;21:31.
- 2. Bledsoe BE, Anderson E, Hodnick R, Johnson L, Johnson S, Dievendorf E. Low-fractional oxygen concentration continuous positive airway pressure is effective in the prehospital setting. *Prehosp Emerg Care*. 2012 Apr-Jun;16(2):217-21.
- 3. O'Brien DJ, Walsh DW, Terriff CM, Hall AH. Empiric management of cyanide toxicity associated with smoke inhalation. *Prehosp Disaster Med.* 2011 Oct;26(5):374-82.
- 4. Warner GS. Evaluation of the effect of prehospital application of continuous positive airway pressure therapy in acute respiratory distress. *Prehosp Disaster Med.* 2010 Jan-Feb; 25(1): 87-91.
- 5. Cone DC, MacMillan D, Parwani V, Van Gelder C. Threats to life in residential structure fires. *Prehosp Emerg Care*. 2008 Jul-Sep;12(3):297-301.
- 6. Borron SW, Baud FJ, Barriot P, Imbert M, Bismuth C. Prospective study of hydroxocobalamin for acute cyanide poisoning in smoke inhalation. *Ann Emerg Med.* 2007 Jun;49(6):794-801, 801.e12.
- 7. Hall AH, Dart R, Bogdan G. Sodium thiosulfate or hydroxocobalamin for the empiric treatment of cyanide poisoning? *Ann Emerg Med.* 2007 Jun;49(6):806-13.
- 8. Eckstein M, Maniscalco PM. Focus on smoke inhalation--the most common cause of acute cyanide poisoning. *Prehosp Disaster Med.* 2006 Mar-Apr;21(2):s49-55.
- 9. Guidotti T. Acute cyanide poisoning in prehospital care: new challenges, new tools for intervention. *Prehosp Disaster Med.* 2006 Mar-Apr;21(2):s40-8.
- 10. Madnani DD, Steele NP, de Vries E. Factors that predict the need for intubation in patients with smoke inhalation injury. *Ear Nose Throat J.* 2006 Apr;85(4):278-80.
- 11. Markenson D, Foltin G, Tunik M, Cooper A, Treiber M, Caravaglia K. Albuterol sulfate administration by EMT-basics: results of a demonstration project. *Prehosp Emerg Care*. 2004 Jan-Mar;8(1):34-40.
- 12. Kuo DC, Jerrard DA. Environmental insults: smoke inhalation, submersion, diving, and high altitude. *Emerg Med Clin North Am.* 2003 May;21(2):475-97.





Approved 9/04/24, Effective 1/15/25, replaces all prior versions

# 12C – CARBON MONOXIDE ADULT & PEDIATRIC

#### TREATMENT PRIORITIES

- 1. Personal safety
- 2. Patient safety
- 3. Vital signs
  - (including CO & EtCO2, if equipped)
- 4. Oxygenation support
  - → O₂ by NC, NRB
  - ➢ BVM, Bi/CPAP, ETT if indicated
- 5. Ventilation support
  - > BVM, Bi/CPAP, ETT if indicated
- 6. OLMC consult for hyperbaric oxygen use direction in serious exposures

#### **EMD**

DIRECT TO MOVE AWAY FROM SUSPECTED SOURCE IF SAFE TO DO SO

OPEN AIRWAY IF NOT ALERT & INEFFECTIVE BREATHING
IF AWAKE, AVOID PHYSICAL EXERTION
OR ENVIRONMENTAL STRESS (TEMP EXTREMES).

# EMERGENCY MEDICAL DISPATCHER

EMERGENCY MEDICAL RESPONDER

**EMT** 

**EMT-INTERMEDIATE 85** 

**ADVANCED EMT** 

**PARAMEDIC** 

EMR

**EMT-185** 

EMT

MAINTAIN PERSONAL & PATIENT SAFETY GENERAL SUPPORTIVE CARE OBTAIN VITAL SIGNS

 ${
m O_2}$  HIGH LITER PER MINUTE FLOW (15 LPM +) VIA NRB, OR BVM AS APPROPRIATE APPLY CARDIAC MONITOR (if equipped)

MEASURE CARBON MONOXIDE LEVEL – %spCO (if equipped)

IF %spCO NORMAL & NO SYMPTOMS, TREAT PER OTHER APPLICABLE PROTOCOL(S)

IF %spCO ABNORMAL, EVALUATE IF SYMPTOMS INCLUDE ALTERED MENTAL STATUS? PT PREGNANT?

OLMC CONSULT TO DISCUSS HYPERBARIC OXYGEN THERAPY FOR GCS ≤ 13 OR IF PREGNANT

#### **EMT OR HIGHER LICENSE:**

MEASURE END-TIDAL CO<sub>2</sub> & MONITOR WAVEFORM CAPNOGRAPHY (if equipped)

ADULT: APPLY Bi/CPAP IF INDICATED (if equipped)

PLACE SUPRAGLOTTIC AIRWAY IF INDICATED & ONLY IF BVM VENTILATIONS INEFFECTIVE

AEMT

**ADULT: INTUBATE IF INDICATED** 

IV ACCESS

**ADULT:** IV NS TKO IF SYS BP ≥ 100 mmHg WITHOUT HYPOTENSIVE SYMPTOMS

ADULT: IV NS 250 mL BOLUS IF SYS BP <100 mmHg WITH HYPOTENSIVE SYMPTOMS & NO SIGNS OF PULMONARY EDEMA,
ADULT: REPEAT UP TO 2 LITERS NS IF SYS BP REMAINS < 100 mmHg WITH HYPOTENSIVE SYMPTOMS & NO SIGNS OF PULMONARY EDEMA

PEDIATRIC: IV NS TKO IF SYS BP ≥ (70 + 2x age in years) mmHg

PEDIATRIC: IV NS 20 mL/kg BOLUS IF SYS BP < (70 + 2x age in years) mmHg IF NO SIGNS OF PULMONARY EDEMA

#### **PARAMEDIC**

ADULT: MEDICATION ASSISTED INTUBATION IF INDICATED CONTINUOUS ASSESSMENT & TREATMENT PER APPLICABLE PROTOCOL(S)





Approved 9/04/24, Effective 1/15/25, replaces all prior versions **PROTOCOL 12C: Carbon Monoxide, cont.** 

%SpCO	Expected Signs & Symptoms – * may not correlate w/ individual pt symptoms		
0-3%	None - Normal		
4-9%	Minor Headache (**Normal for Smokers)		
10-19%	Headache, Shortness of Breath		
20-29%	Headache, Nausea, Dizziness, Fatigue		
30-39%	Severe Headache, Vomiting, Vertigo, AMS		
40-49%	AMS, Syncope, Tachycardia		
50-59%	Seizures, Shock, Apnea, Coma		
60% +	Coma, Death		

## Technique (Masimo RAD-57<sup>™</sup> - see protocol Special Note):

## Fingertip Sensor Placement Using Light Shield:

- Using the light shield with correct placement of finger is VERY IMPORTANT for accuracy of reading.
- Clean and dry finger.
- · Orient equipment and finger to replicate diagram.
- When possible, use ring finger, non-dominant hand (using the dominant hand of smokers has been shown to result in higher level readings that do not correlate with bodywide levels of CO).
- Insert finger until the tip of finger hits the stop block.
- · Sensor should NOT rotate or move freely on finger.
- LED's (red light) should pass through mid-nail, not cuticle.
- Connecting cable should be on top (nail side).







Approved 9/04/24, Effective 1/15/25, replaces all prior versions

PROTOCOL 12C: Carbon Monoxide, cont.

## Startup Sequence:

- Place sensor on finger (clean/dry skin)
- Press "POWER" button
- Verify all LED's light up and a 1 second tone is heard
- Startup mode begins
- All preset configurations are displayed
- Scrolling zeroes 0 0 0 and flashes dashed lines
- May take up to 25 seconds
- Do not move sensor during startup
- When complete, reading is displayed
- Begin patient monitoring
- Defaults to pulse rate and oxygen saturation reading
- "PI" bar graph displays strength of arterial perfusion

Power Button. Press "ON", Hold for "OFF"

Each green LED window below Power Button that illuminates indicates 25% battery power

# Chicket III

## Operation / Pulse Oximetry & Pulse Rate:

- Displays after startup sequence described above
- Oxygen Saturation on top in red numbers
- Pulse Rate on bottom in green numbers
- Low Signal I.Q.<sup>®</sup> (SIQ) LED lit indicates poor pulse ox signal quality - evaluate finger/sensor, use alternate finger
- Press "DISPLAY" to display %spCO

Press "Bell" to silence alarms (if needed)







Approved 9/04/24, Effective 1/15/25, replaces all prior versions

PROTOCOL 12C: Carbon Monoxide, cont.

## Operation / Carbon Monoxide (Carboxyhemoglobin) Measurement:

- Press "DISPLAY" button as described above to toggle display to show %SpCO reading (to toggle back to pulse oximetry and pulse rate mode, press "DISPLAY" again).
- Carboxyhemoglobin displayed in % on top in numbers.
- "CO" displayed on bottom confirming mode.
- Real-time SpCO indicator continuously reads SpCO.
- Confirm abnormal readings by taking several measurements on different fingers and average the readings.



## Operation / Troubleshooting:

## Error Messages:

- "NO Cbl" = cable not seated properly into device or defective cable
- "SEN OFF" = sensor off finger or misaligned
- "bAd CbL" = defective cable (cable most likely needs replaced)
- "CbL" = incompatible cable (change to appropriate cable)
- "bAd SEN" = defective sensor (sensor most likely needs replaced)
- "SEN" = unrecognized sensor (change to appropriate sensor)
- "Err" = return for service

Will not power on = check battery compartment and replace batteries.

Continuously in startup mode (Scrolling zeroes 0 - 0 - 0 and flashes dashed lines) = shield sensor from flashing lights, strobes or high ambient light with Light Shield (best accurate practice is to always use the Light Shield); try another finger.

## Using Physio-Control LifePak® 15 with Masimo sensing to measure %SpCO:

- Power on, connect pulse oximetry cable to monitor/defibrillator and sensor, place sensor on patient...
- To display %SpCO, use the SPEED DIAL to select the pulse oximetry display area.
- Select PARAMETER from menu.
- Select SpCO. Selected value displays for 10 seconds. If %SpCO is elevated, an advisory event occurs and elevated value flashes and alarm tone sounds.





#### Medical Literature References 12C – Carbon Monoxide - Adult & Pediatric


- 1. Roth D, Bayer A, Schrattenbacher G, Malzer R, Herkner H, Schreiber W, Have C. Exposure to carbon monoxide for patients and providers in an urban emergency medical service. *Prehosp Emerg Care.* 2013 Jul-Sep;17(3):354-60.
- 2. Sebbane M, Claret PG, Mercier G, Lefebvre S, Théry R, Dumont R, Maillé M, Richard JP, Eledjam JJ, de La Coussaye JE. EMERGENCY DEPARTMENT MANAGEMENT OF SUSPECTED CARBON MONOXIDE POISONING: ROLE OF PULSE CO-OXIMETRY. *Respir Care*. 2013 Mar 19. [Epub ahead of print]
- 3. Weaver LK, Churchill SK, Deru K, Cooney D. False positive rate of carbon monoxide saturation by pulse oximetry of emergency department patients. *Respir Care*. 2013 Feb;58(2):232-40.
- 4. Hampson NB. Noninvasive pulse CO-oximetry expedites evaluation and management of patients with carbon monoxide poisoning. *Am J Emerg Med.* 2012 Nov;30(9):2021-4.
- Touger M, Birnbaum A, Wang J, Chou K, Pearson D, Bijur P. Performance of the RAD-57 pulse COoximeter compared with standard laboratory carboxyhemoglobin measurement. *Ann Emerg Med*. 2010 Oct;56(4):382-8.
- 6. Cone DC, MacMillan D, Parwani V, Van Gelder C. Threats to life in residential structure fires. *Prehosp Emerg Care*. 2008 Jul-Sep;12(3):297-301.
- 7. Wolf SJ, Lavonas EJ, Sloan EP, Jagoda AS; American College of Emergency Physicians. Clinical policy: Critical issues in the management of adult patients presenting to the emergency department with acute carbon monoxide poisoning. *Ann Emerg Med.* 2008 Feb;51(2):138-52.
- 8. Silver S, Smith C, Worster A; BEEM (Best Evidence in Emergency Medicine) Team. Should hyperbaric oxygen be used for carbon monoxide poisoning? *CJEM*. 2006 Jan;8(1):43-6.
- Kao LW, Nañagas KA. Toxicity associated with carbon monoxide. Clin Lab Med. 2006 Mar;26(1):99-125.
- 10. Kao LW, Nañagas KA. Carbon monoxide poisoning. Med Clin North Am. 2005 Nov;89(6):1161-94.
- 11. Gilmer B, Kilkenny J, Tomaszewski C, Watts JA. Hyperbaric oxygen does not prevent neurologic sequelae after carbon monoxide poisoning. *Acad Emerg Med.* 2002 Jan;9(1):1-8.





Approved 9/04/24, Effective 1/15/25, replaces all prior versions

# 12D – HYPERBARIC OXYGEN THERAPY CONSIDERATIONS ADULT & PEDIATRIC



## Indications:

Carbon monoxide (CO) toxicity (as determined through Protocol 12C – Carbon Monoxide).

#### Contraindications:

Absence of carbon monoxide toxicity.

## **Clinical Pearls**:

- 1. In the care of the suspected CO poisoned patient, exercise personal safety and avoid becoming CO poisoned.
- 2. The hallmarks of effective EMS care of the suspected CO poisoned patient include removal of the patient from the CO source and oxygenation with near 100% oxygen (via high flow through non-rebreather mask with good seal, non-invasive positive pressure ventilation, or through bag-valve-mask or bag-valve-artificial airway connected to an oxygen reservoir).
- 3. The vast majority (nearly all) of suspected CO poisoned patients may be appropriately transported to an emergency department that does not have direct access to hyperbaric oxygen (HBO) therapy.
- 4. Contact the nearest HBO capable facility's on-line medical control for EMS to discuss the advisability of transport for HBO therapy consideration if either of the following distinct clinical situations in which suspected/measured CO toxicity is the primary medical issue of concern:
  - a. Glasgow Coma Scale score ≤ 13
  - b. Pregnancy
- 5. Consultation and/or transport to a HBO-capable facility does not compel use of HBO therapy by the medical staff at that facility.
- 6. In Oklahoma, emergency facilities with direct access to HBO therapy (at least part-time) include:
  - a. Oklahoma City Integris Baptist Medical Center
  - b. Tulsa OSU Medical Center (cannot give HBO therapy to intubated patients)





# Medical Literature References 12D- Hyperbaric Oxygen Therapy Considerations - Adult & Pediatric

- Touger M, Birnbaum A, Wang J, Chou K, Pearson D, Bijur P. Performance of the RAD-57 pulse COoximeter compared with standard laboratory carboxyhemoglobin measurement. *Ann Emerg Med*. 2010 Oct;56(4):382-8.
- 2. Cone DC, MacMillan D, Parwani V, Van Gelder C. Threats to life in residential structure fires. *Prehosp Emerg Care*. 2008 Jul-Sep;12(3):297-301.
- 3. Wolf SJ, Lavonas EJ, Sloan EP, Jagoda AS; American College of Emergency Physicians. Clinical policy: Critical issues in the management of adult patients presenting to the emergency department with acute carbon monoxide poisoning. *Ann Emerg Med.* 2008 Feb;51(2):138-52.
- 4. Silver S, Smith C, Worster A; BEEM (Best Evidence in Emergency Medicine) Team. Should hyperbaric oxygen be used for carbon monoxide poisoning? *CJEM*. 2006 Jan;8(1):43-6.
- Kao LW, Nañagas KA. Toxicity associated with carbon monoxide. Clin Lab Med. 2006 Mar;26(1):99-125.
- 6. Kao LW, Nañagas KA. Carbon monoxide poisoning. Med Clin North Am. 2005 Nov;89(6):1161-94.
- 7. Gilmer B, Kilkenny J, Tomaszewski C, Watts JA. Hyperbaric oxygen does not prevent neurologic sequelae after carbon monoxide poisoning. *Acad Emerg Med.* 2002 Jan;9(1):1-8.





Approved 9/04/24, Effective 1/15/25, replaces all prior versions

## 12E - CYANIDE **ADULT & PEDIATRIC**

#### TREATMENT PRIORITIES

- 1. Personal safety
- 2. Patient safety
- 3. Cardiac arrest resuscitation (if applicable)
- 4. Oxygenation/Ventilation
- 5. Hydroxocobalamin administration Enclosed space? Soot in mouth/nose? Altered mental status?

#### **EMD**

DIRECT TO MOVE AWAY FROM SUSPECTED SOURCE IF SAFE TO DO SO CPR BY EMD INSTRUCTION (if applicable) IF AWAKE, AVOID PHYSICAL EXERTION OR ENVIRONMENTAL STRESS (TEMP EXTREMES).

## **EMERGENCY MEDICAL DISPATCHER**

**EMERGENCY MEDICAL RESPONDER** 

**EMT** 

**EMT-INTERMEDIATE 85** 

ADVANCED EMT

**PARAMEDIC** 

#### **EMR**

**EMT** 

**AEMT** 

MAINTAIN PERSONAL & PATIENT SAFETY RESUSCITATION PER SECTION 4 (CARDIAC ARREST) PROTOCOLS (if applicable) GENERAL SUPPORTIVE CARE **OBTAIN VITAL SIGNS** 

O<sub>2</sub> HIGH LITER PER MINUTE FLOW (15 LPM +) VIA NRB, OR BVM AS APPROPRIATE APPLY CARDIAC MONITOR (if equipped)

#### **EMT OR HIGHER LICENSE:**

MEASURE END-TIDAL CO<sub>2</sub> & MONITOR WAVEFORM CAPNOGRAPHY (if equipped) ADULT: APPLY Bi/CPAP IF INDICATED (if equipped)

PLACE SUPRAGLOTTIC AIRWAY IF INDICATED & ONLY IF BVM VENTILATIONS INEFFECTIVE

#### **EMT-185**

**ADULT:** INTUBATE IF INDICATED

IV/IO ACCESS - START TWO LINES

ADULT: IV NS TKO IF SYS BP ≥ 100 mmHg WITHOUT HYPOTENSIVE SYMPTOMS ADULT: IV NS 250 mL BOLUS IF SYS BP <100 mmHg WITH HYPOTENSIVE SYMPTOMS & NO SIGNS OF PULMONARY EDEMA,

ADULT: REPEAT UP TO 2 LITERS NS IF SYS BP REMAINS < 100 mmHg WITH HYPOTENSIVE SYMPTOMS & NO SIGNS OF PULMONARY EDEMA

PEDIATRIC: IV NS TKO IF SYS BP ≥ (70 + 2x age in years) mmHg
PEDIATRIC: IV NS 20 mL/kg BOLUS IF SYS BP < (70 + 2x age in years) mmHg IF NO SIGNS OF PULMONARY EDEMA

#### **AEMT or HIGHER LICENSE:**

FOR HYDROXOCOBALAMIN, USE SEPARATE LINE FROM ALL OTHER MEDICATIONS ADULT: HYDROXOCOBALAMIN 5 grams IVPB IN 15 MINS - ADMINISTER WITHOUT DELAY

PEDIATRIC: HYDROXOCOBALAMIN 70 mg/kg IVPB TO A MAX OF 5 grams IN 15 MINS - ADMINISTER WITHOUT DELAY

## **PARAMEDIC**

**ADULT: MEDICATION ASSISTED INTUBATION IF INDICATED** CONTINUOUS ASSESSMENT & TREATMENT PER APPLICABLE PROTOCOL(S)






## Medical Literature References 12E- Cyanide - Adult & Pediatric

- Holstege CP, Kirk MA. Cyanide and hydrogen sulfide. In: Hoffman RS, Howland M, Lewin NA, Nelson LS, Goldfrank LR, eds. Goldfrank's toxicologic emergencies. 10e ed. New York, NY: McGraw Hill;2015. http://accessemergencymedicine.mhmedical.com/content.aspx?bookid=1163& Section-id=65102837. Accessed 12/17/2015.
- 2. Desai S, Su M. Cyanide poisoning. UpToDate Website. www.uptodate.com. Published 9/29/2015. Updated 2015. Accessed 12/17/2015.
- 3. Anseeuw K, Delvau N, Burillo-Putze G, De Iaco F, Geldner G, Holmström P, Lambert Y, Sabbe M. Cyanide poisoning by fire smoke inhalation: a European expert consensus. *Eur J Emerg Med.* 2013 Feb;20(1):2-9.
- 4. Bebarta VS, Pitotti RL, Dixon P, Lairet JR, Bush A, Tanen DA. Hydroxocobalamin versus sodium thiosulfate for the treatment of acute cyanide toxicity in a swine (Sus scrofa) model. *Ann Emerg Med.* 2012 Jun;59(6):532-9.
- 5. O'Brien DJ, Walsh DW, Terriff CM, Hall AH. Empiric management of cyanide toxicity associated with smoke inhalation. *Prehosp Disaster Med.* 2011 Oct;26(5):374-82.
- 6. Cone DC, MacMillan D, Parwani V, Van Gelder C. Threats to life in residential structure fires. *Prehosp Emerg Care*. 2008 Jul-Sep;12(3):297-301.
- 7. Borron SW, Baud FJ, Barriot P, Imbert M, Bismuth C. Prospective study of hydroxocobalamin for acute cyanide poisoning in smoke inhalation. *Ann Emerg Med.* 2007 Jun;49(6):794-801, 801.e1-2.
- 8. Hall AH, Dart R, Bogdan G. Sodium thiosulfate or hydroxocobalamin for the empiric treatment of cyanide poisoning? *Ann Emerg Med.* 2007 Jun;49(6):806-13.
- 9. Eckstein M, Maniscalco PM. Focus on smoke inhalation--the most common cause of acute cyanide poisoning. *Prehosp Disaster Med.* 2006 Mar-Apr;21(2):s49-55.
- 10. Guidotti T. Acute cyanide poisoning in prehospital care: new challenges, new tools for intervention. *Prehosp Disaster Med.* 2006 Mar-Apr;21(2):s40-8.
- 11. Kuo DC, Jerrard DA. Environmental insults: smoke inhalation, submersion, diving, and high altitude. *Emerg Med Clin North Am.* 2003 May;21(2):475-97, x.





Approved 9/04/24, Effective 1/15/25, replaces all prior versions



APGAR SCORING (SIGN)	0	1	2
APPEARANCE	BLUE OR PALE	BODY PINK, EXTREMITIES BLUE	COMPLETELY PINK
HEART RATE (BPM)	ABSENT	≤100	>100
GRIMACE (REACTION TO CATHETER IN NARES)	NO RESPONSE	GRIMACE	COUGH OR SNEEZE
MUSCLE TONE	LIMP	SOME FLEXION	ACTIVE MOTION
RESPIRATORY RATE	ABSENT	SLOW/IRREGULAR	GOOD, CRYING





## Medical Literature References 13A – Childbirth - Routine

- Greenwald IB, Keady MT. Obstetric and Gynecologic Emergencies. In: Cone DC, O'Connor RE, Fowler RL, eds. Emergency Medical Services: Clinical Practice and Systems Oversight. Clinical Aspects of Prehospital Medicine. Dubuque, IA: Kendall Hunt Professional; 2009: 298-304.
- 2. Verdile VP, Tutsock G, Paris PM, Kennedy RA. Out-of-hospital deliveries: a five-year experience. *Prehosp Disaster Med.* 1995 Jan-Mar;10(1):10-3.





Approved 9/04/24, Effective 1/15/25, replaces all prior versions

#### 13B - CHILDBIRTH - COMPLICATED **EMERGENCY MEDICAL** TREATMENT PRIORITIES **EMD** DISPATCHER ADVISE TO NOT TRY TO PREVENT THE BIRTH ADVISE NOT TO SIT ON TOILET PATIENT TO ASSUME POSITION OF COMFORT ADVISE PATIENT TAKE DEEP BREATHS BETWEEN CONTRACTIONS Supportive Care Vital signs Transport left lat recumbent if prior to delivery OLMC consultation for cases of complicated delivery: • Cord prolapse **EMR EMT EMT-INTERMEDIATE 85** Limb presentationBreech delivery GENERAL SUPPORTIVE CARE ADVANCED EMT Neonatal resuscitation Transport directly to labor and CORD PROLAPSE: PLACE MOTHER IN TRENDELENBERG POSITION ELEVATE BUTTOCKS TO RELIEVE PRESSURE ON CORD delivery if directed/usual hospital destination practice **PARAMEDIC** PLACE GLOVED HAND INTO VAGINA PUSHING UP ON HEAD TO Post Delivery Infant Care Stimulate/dry/perform oral nasal suctioning RELIEVE COMPRESSION ON CORD MAINTAIN POSITION UNTIL RELIEVED BY ANOTHER HEALTH PROFESSIONAL OR DELIVERY OCCURS Prevent hypothermia O2 administration BREECH OR LIMB PRESENTATION: PLACE MOTHER IN TRENDELENBERG POSITION IMMEDIATE PRIORITY I TRANSPORT EARLY HOSPITAL NOTIFICATION CEPHALIC (HEAD FIRST) PRESENTATION: POSITION MOTHER SUPINE/KNEES WIDELY SEPARATED/ BUTTOCKS ELEVATED W/PILLOW/BLANKET PLACE STERILE PAD/SHEET UNDER AND AROUND VAGINA PLACE ONE HAND OVER FETAL HEAD APPLY MINIMAL STABILIZING PRESSURE TO PREVENT EXPLOSIVE BIRTH AS HEAD DELIVERED CHECK FOR NUCHAL CORD WRAPPED AROUND FETAL NECK – IF PRESENT, SLIP CORD EITHER OVER HEAD OR DOWN OVER SHOULDER OR CLAMP/CUT SUCTION MOUTH THEN EACH NOSTRIL WITH BULB SYRINGE IF NEEDED TO CLEAR AIRWAY ALLOW HEAD TO ROTATE NATURALLY DELIVER THE REST OF INFANT – MAY REQUIRE GENTLE DOWNWARD PRESSURE ON ANTERIOR (UPPER SHOULDER & GENTLE UPWARD PRESSURE ON POSTERIOR (LOWER) SHOULDER FOR EASIER DELIVERY CLAMP/CUT UMBILICAL CORD ASSESS INFANT/CALCULATE APGAR SCORE AT ONE AND FIVE MINUTES POST DELIVERY USING TABLE **EXCESSIVE POSTPARTUM BLEEDING** – MASSAGE UTERUS **EMT-185 AEMT**

IV ACCESS

IV NS TKO IF SYS BP ≥ 100 mmHg WITHOUT HYPOTENSIVE SYMPTOMS
IV NS 250 mL BOLUS IF SYS BP <100 mmHg WITH HYPOTENSIVE SYMPTOMS IF NO SIGNS OF PULMONARY EDEMA,
REPEAT UP TO 2 LITERS NS IF SYS BP REMAINS < 100 mmHg WITH HYPOTENSIVE SYMPTOMS IF NO SIGNS OF PULMONARY EDEMA

#### **PARAMEDIC**

ECLAMPSIA: MAGNESIUM SULFATE 1 gram IVP/IOP MAY REPEAT EVERY 2-3 MINUTES UNTIL SEIZURE ABATES MAXIMUM CUMULATIVE DOSE IS 4 grams CONTINUOUS ASSESSMENT & TREATMENT PER APPLICABLE PROTOCOL(S)

APGAR SCORING (SIGN)	0	1	2
APPEARANCE	BLUE OR PALE	BODY PINK, EXTREMITIES BLUE	COMPLETELY PINK
HEART RATE (BPM)	ABSENT	≤100	>100
GRIMACE (REACTION TO CATHETER IN NARES)	NO RESPONSE	GRIMACE	COUGH OR SNEEZE
MUSCLE TONE	LIMP	SOME FLEXION	ACTIVE MOTION
RESPIRATORY RATE	ABSENT	SLOW/IRREGULAR	GOOD, CRYING






Medical Literature References 13B – Childbirth - Complicated

- 1. Greenwald IB, Keady MT. Obstetric and Gynecologic Emergencies. In: Cone DC, O'Connor RE, Fowler RL, eds. Emergency Medical Services: Clinical Practice and Systems Oversight. Clinical Aspects of Prehospital Medicine. Dubuque, IA: Kendall Hunt Professional; 2009: 298-304.
- 2. Verdile VP, Tutsock G, Paris PM, Kennedy RA. Out-of-hospital deliveries: a five-year experience. *Prehosp Disaster Med.* 1995 Jan-Mar;10(1):10-3.





Approved 9/04/24, Effective 1/15/25, replaces all prior versions








Medical Literature References 13C – Vaginal Bleeding/Discharge – Adult & Pediatric

- 1. Schmitz G, Tibbles C. Genitourinary emergencies in the nonpregnant woman. *Emerg Med Clin North Am.* 2011 Aug;29(3):621-35.
- 2. Greenwald IB, Keady MT. Obstetric and Gynecologic Emergencies. In: Cone DC, O'Connor RE, Fowler RL, eds. Emergency Medical Services: Clinical Practice and Systems Oversight. Clinical Aspects of Prehospital Medicine. Dubuque, IA: Kendall Hunt Professional; 2009: 298-304.
- 3. Daniels RV, McCuskey C. Abnormal vaginal bleeding in the nonpregnant patient. *Emerg Med Clin North Am.* 2003 Aug;21(3):751-72.





Approved 9/04/24, Effective 1/15/25, replaces all prior versions








Medical Literature References 13D – Complications of Pregnancy – Adult

- 1. Marik PE, Rivera R. Hypertensive emergencies: an update. *Curr Opin Crit Care*. 2011 Dec;17(6):569-80.
- 2. Baumann BM, Cline DM, Pimenta E. Treatment of hypertension in the emergency department. *J Am Soc Hypertens*. 2011 Sep-Oct;5(5):366-77.
- 3. Greenwald IB, Keady MT. Obstetric and Gynecologic Emergencies. In: Cone DC, O'Connor RE, Fowler RL, eds. Emergency Medical Services: Clinical Practice and Systems Oversight. Clinical Aspects of Prehospital Medicine. Dubuque, IA: Kendall Hunt Professional; 2009: 298-304.
- 4. Mateos Rodriguez AA, Benito Vellisca MA. Management of eclampsia in the prehospital setting. *Emerg Med J.* 2007 Jul;24(7):504.





Approved 9/04/24, Effective 1/15/25, replaces all prior versions



ADULT: IV NS 250 ml BOLUS IF SYS BP < 100 mmHg WITH HYPOTENSIVE SYMPTOMS & NO SIGNS OF PULMONARY EDEMA. ADULT: REPEAT UP TO 2 LITERS NS IF SYS BP REMAINS < 100 mmHg WITH HYPOTENSIVE SYMPTOMS & NO SIGNS OF PULMONARY EDEMA PEDIATRIC: IV NS TKO IF SYS BP ≥ (70 + 2x age in years) mmHg

PEDIATRIC: IV NS 20 mL/kg BOLUS IF SYS BP < (70 + 2x age in years) mmHg & NO SIGNS OF PULMONARY EDEMA

#### **PARAMEDIC**

ANTIEMETIC (IF ACTIVELY VOMITING) ADULT: ONDANSETRON 4 mg IVP/ODT. MAY REPEAT ONCE IN 10 MINUTES

PEDIATRIC: ONDANSETRON 0.1 mg/kg IVP TO A MAXIMUM SINGLE DOSE OF 4 mg IF AGE >2 years, MAY GIVE ONDANSETRON 4 mg ODT

ANALGESIA (IF REQUIRED)

FOR OPIATE USE, ADULT MUST HAVE SYS BP ≥ 100 mmHg; PEDIATRIC MUST HAVE SYS BP ≥ (70 + 2x age in years) mmHg

ADULT: FENTANYL 1 mcg/kg SLOW IVP/IM/IN, MAXIMUM DOSE 100 mcg. MAY REPEAT EVERY 10 MINUTES TO MAXIMUM CUMULATIVE DOSE OF 3 mcg/kg or 250 mcg WHICHEVER IS LESSER. OR

ADULT: MORPHINE SULFATE 2 - 4 mg SLOW IVP, MAY REPEAT 2 - 4 mg EVERY 5 MINUTES TO A TOTAL OF 10 mg. OR

ADULT: HYDROMORPHONE 0.5 - 1 mg SLOW IVP MAY REPEAT EVERY 10 MINUTES TO MAXIMUM CUMULATIVE DOSE OF 2 mg.

PEDIATRIC: OLMCP ORDER ONLY

OLMCP CONSULT IF FURTHER ANALGESIA REQUIRED

CONTINUOUS ASSESSMENT & TREATMENT PER APPLICABLE PROTOCOL(S)






Medical Literature References 13E – Pelvic Pain – Adult& Pediatric

- 1. Schmitz G, Tibbles C. Genitourinary emergencies in the nonpregnant woman. *Emerg Med Clin North Am.* 2011 Aug;29(3):621-35.
- 2. Greenwald IB, Keady MT. Obstetric and Gynecologic Emergencies. In: Cone DC, O'Connor RE, Fowler RL, eds. Emergency Medical Services: Clinical Practice and Systems Oversight. Clinical Aspects of Prehospital Medicine. Dubuque, IA: Kendall Hunt Professional; 2009: 298-304.





Approved 9/04/24, Effective 1/15/25, replaces all prior versions







#### Medical Literature References 13F – Sexual Assault – Adult& Pediatric


- 1. Linden JA. Clinical practice. Care of the adult patient after sexual assault. *N Engl J Med.* 2011 Sep 1;365(9):834-41.
- 2. Greenwald IB, Keady MT. Obstetric and Gynecologic Emergencies. In: Cone DC, O'Connor RE, Fowler RL, eds. Emergency Medical Services: Clinical Practice and Systems Oversight. Clinical Aspects of Prehospital Medicine. Dubuque, IA: Kendall Hunt Professional; 2009: 298-304.
- 3. DeVore HK, Sachs CJ. Sexual assault. Emerg Med Clin North Am. 2011 Aug;29(3):605-20.





Approved 9/04/24, Effective 1/15/25; replaces all prior versions

14A - STAGING CONSIDERATIONS



The Medical Control Board firmly supports all appropriate operations designed to protect public safety professionals (law enforcement, fire, and EMS) from physical assault in the course of fulfilling their respective duties. While the vast majority of Medical Control Board Treatment Protocols focus upon patient care and beneficence, it is never their intent that public safety professionals purposefully compromise their personal safety in the commission of these protocols.

Enroute to a scene of threatened, alleged, or actual violence, non-law enforcement/tactical fire and EMS professionals are to stage an appropriately safe distance away and not to proceed to the patient(s) until the scene is declared safe by appropriate law enforcement professionals. In the event of structural fire, non-fire EMS professionals are to stage at a perimeter assigned by appropriate fire suppression professionals and to take further access as directed by fire suppression professionals when hazards are appropriately mitigated. In all cases involving staging pending hazard mitigation, dispatch should be notified when the scene has been declared safe to ensure timely information transmission to the assigned field professionals. Further specific details related to any hazard staging communication procedure should be the responsibility of centralized communications for each responding agency.

#### General Principles Regarding Threatened or Alleged Violent Scenes:

- A. While enroute to a scene where violence might be involved, check to see whether law enforcement officer(s) are also enroute to the scene. Responding EMS professionals should be advised by dispatch to stage when a known violent incident has not been declared safe for EMS entry by appropriate law enforcement professionals.
- B. While still an anticipated safe distance from the reported incident location, turn off all emergency warning devices if being used (emergency lights and sirens).
- C. Avoid crossing the line of sight of the reported incident address while responding and park out of sight of the address when staging.





Approved 9/04/24, Effective 1/15/25; replaces all prior versions **PROTOCOL 14A: Staging Considerations, cont.** 

- D. Advise dispatch of the staging location (exact address if known). First arriving unity should advise dispatch of an anticipated safe approach route to the area for all other incoming emergency responders.
- E. Anytime encountering a previously unidentified scene of threatened or alleged violence, rapidly promote personal safety and the safety of fellow emergency professionals. Advise dispatch for law enforcement assistance (emergency response/assistance if violence is ongoing). Withdraw to a position of safety until the scene can be appropriately secured by appropriate law enforcement. If the alleged assailant is reported to have left the scene use caution and gain access to the patient. If the patient condition is priority 1 begin transport without waiting for law enforcement to arrive. At all times use your best judgement for crew and patient safety, be constantly alert to the possibility of the assailant's return.





### Medical Literature References 14A – Staging Considerations

- 1. Brice JH, Studnek JR, Bigham BL, Martin-Gill C, Custalow CB, Hawkins E, Morrison LJ. EMS Provider and Patient Safety during Response and Transport: Proceedings of an Ambulance Safety Conference. *Prehosp Emerg Care*. 2012 Jan;16(1):3-19.
- 2. Lucas R. Violence in the prehospital setting. Emerg Med Clin North Am. 1999 Aug;17(3):679-83, vii.
- 3. Eckstein M, Cowen AR. Scene safety in the face of automatic weapons fire: a new dilemma for EMS? *Prehosp Emerg Care*. 1998 Apr-Jun;2(2):117-22.





Approved 9/04/24, Effective 1/15/25, replaces all prior versions

14B - ACTIONS TO PRESERVE CRIME SCENES



This protocol has been developed to promote proper emphasis on patient care while simultaneously promoting law enforcement ability to conduct effective and thorough crime scene investigation.

- A. Only assigned EMS units should respond. Excess numbers of EMS professionals on scene may lead to inadvertent evidence destruction.
- B. When approaching a crime scene protected by law enforcement, EMS professionals should request entry into the area to determine life status of the individual. The highest licensed EMS professional (eg. Paramedic if on scene) is to enter in cases of probable irreversible death to minimize scene disturbance. Attempt scene entry and exit by same route to minimize scene disturbance.
- C. If law enforcement professionals refuse EMS access into the crime scene, do not become confrontational. Follow applicable operational procedures in consulting with an appropriate Supervisor.
- D. Refer to Protocol 4K -"Do Not Resuscitate"/Advanced Directive Orders, Futility of Resuscitation Initiation & Termination of Resuscitation Adult & Pediatric for information regarding when to withhold resuscitation.
- E. To obtain an ECG tracing when the probable irreversibly dead patient is prone:

(If using a 4-lead cable) place the left arm electrode on the left arm or upper left back. Place the right arm electrode on the right arm or upper right back. Place the left leg electrode on the lower portion of the left back or on the left leg. Place the right leg electrode on the lower portion of the right back or on the right leg. Alternatively, use monitoring/defibrillation pads. Place the sternum electrode on the upper right back and the apex electrode on the lower left back.





Approved 9/04/24, Effective 1/15/25, replaces all prior versions PROTOCOL 14B: Actions to Preserve Crime Scenes, cont.

- F. If the patient has signs of life, aggressive resuscitative efforts should be initiated. During scene resuscitation:
  - 1. Keep EMS professionals and medical equipment close to the victim.
  - 2. Keep out of any blood that has pooled.
  - 3. Minimize destruction of the patient's clothing. If the patient's clothing has a puncture, do not use the hole to start cutting and do not cut "through" the hole.
- G. In crime victim resuscitation, work to move the victim to the ambulance expeditiously.
- H. If the patient relates any information relating to the crime, report this information to the appropriate law enforcement professionals.

### **Special Notes:**

- 1. **DO NOT** go through the victim's personal effects (if the victim has expired).
- 2. **DO NOT** cover the body with a sheet or other material (if the victim has expired).
- 3. **DO NOT** move or handle any object at the scene unless absolutely essential for lifesaving medical care. Inform law enforcement professionals of any such movement or handling, preferably before doing so.
- 4. **DO NOT** take any object from the scene unless absolutely essential for life-saving medical care (eg. impaled object).
- 5. **DO NOT** clean the body of blood, etc. (if the victim has expired)
- 6. **DO NOT** wander around the crime scene: return to the emergency vehicle.
- 7. **DO NOT** litter the crime scene with medical equipment, dressings, bandages, etc.





Medical Literature References 14B – Actions to Preserve Crime Scenes


- 1. Sharma BR. Clinical forensic medicine--management of crime victims from trauma to trial. *J Clin Forensic Med.* 2003 Dec;10(4):267-73.
- 2. Lucas R. Violence in the prehospital setting. Emerg Med Clin North Am. 1999 Aug;17(3):679-83, vii.





Approved 9/04/24, Effective 1/15/25, replaces all prior versions

14C – OTHER HEALTH PROFESSIONALS ON SCENES



Licensed EMS professionals must at all times act utilizing appropriate medical authority. Formats of appropriate medical authority include verbal physician medical orders, written physician medical orders, and standing orders in the form of the Medical Control Board Treatment Protocols. Licensed EMS professionals are authorized to accept medical directives from the following:

- 1. EMS System Chief Medical Officer.
- 2. Principles of accepted standard of care practice by EMS professionals, as defined by the Medical Control Board Treatment Protocols.
- 3. Verbal order from an On-Line Medical Control Physician (OLMCP) or approved designate (OLMC).
- 4. Verbal or written order signed by a physician (M.D. or D.O.) present with the patient in the medical office, clinic, or specialized treatment facility (eq. dialysis center).
- 5. Bystander physician that presents a valid M.D. or D.O. Oklahoma License Card.
- 6. Oklahoma Poison Control Center Specialists acting under the standing orders of the Physician Medical Director of the Oklahoma Poison Control Center.

### Compliance with Physician's Verbal or Written Orders:

- 1. Verbal or written orders that are signed by the physician are acceptable.
- If a physician (M.D. or D.O.) directs an EMS professional to provide treatment that is not clearly defined in the Medical Control Board Treatment Protocols that EMS professional may carry out the order to the best of his or her ability as long as the ordered treatment or procedure falls within his or her authorized scope of EMS practice.
- 3. If an EMS professional receives a physician order for care that he or she does not feel comfortable with, or feels the order does not represent the appropriate standard of care for the patient's assessed condition, he or she should advise the ordering physician of the Medical Control Board Treatment Protocols that he or she is required to uphold. Request to be allowed to continue further patient care under these standing orders. Should the ordering physician dissent to using these standing orders at that time, contact the appropriate OLMCP, brief the OLMCP on the situation, including the patient's assessed condition and the physician orders of





Approved 9/04/24, Effective 1/15/25, replaces all prior versions

#### PROTOCOL 14C: Other Health Care Professionals on Scene, cont.

### Compliance with Physician's Verbal or Written Orders, cont.:

concern and allow the physicians to directly discuss further treatment of the patient. At no time should critical patient care as specified in these standing medical orders be delayed while resolution of the situation is occurring.

4. Poison Control Center Specialists are authorized to direct medical care related to the medical toxicology and/or hazardous material exposure aspects of patient care if contacted for directives.

General Principles for Working with Other Health Care Professional(s) On-Scene

- 1. Conduct all conversations and operations with the standards of professional demeanor and respectful attitude.
- 2. Make every reasonable effort to carry out orders within appropriate standards of care given by on-scene physician(s).
- Orders by nurses, nurse practitioners, and physician assistants are not applicable to EMS professionals. Proceed with managing the patient according to established protocol.
- 4. If doubt exists as to whether the "physician" is indeed a validly licensed Oklahoma M.D. or D.O., ask to see the physician's registration card from the Oklahoma State Board of Medical Licensure and Supervision. If the physician cannot verify this status, EMS professionals are to proceed with managing the patient according to established protocol.





Medical Literature References 14C – Other Health Professionals on Scene

- 1. Barishansky RM, O'Connor KE, Perkins TJ. "Is there a doctor in the house?" Addressing bystander physician involvement on scene. *Emerg Med Serv.* 2005 Jan;34(1):87-90.
- 2. Benitez FL, Pepe PE. Role of the physician in prehospital management of trauma: North American perspective. *Curr Opin Crit Care*. 2002 Dec;8(6):551-8.
- 3. Rottman SJ, Schriger DL, Charlop G, Salas JH, Lee S. On-line medical control versus protocol-based prehospital care. *Ann Emerg Med.* 1997 Jul;30(1):62-8.





Approved 9/04/24, Effective 1/15/25, replaces all prior versions

14D - INFORMED PATIENT CONSENT/REFUSAL



- A. Competent adults are entitled to make decisions about their health care. They have the right to refuse medical care after they have been properly informed of the benefits, risks, and alternatives to the recommended care. This protocol defines the mechanisms by which a patient who summoned EMS care, or for whom EMS care was summoned, may refuse care and/or transport.
- B. To safely allow a patient (or their legal representatives) to exercise their rights while protecting yourself and your organization, you need to follow the following steps each and every time, with each patient who is ultimately not treated or transported:
  - 1. Perform a complete assessment, maintaining suspicion of serious illness or injury.
  - 2. Evaluate the differential of possible medical conditions. Avoid tunnel-vision on only one explanation for the patient's condition. Assume worst case possibilities. You should be thinking of "ruling in" rather than "trying to explain away" worrisome findings. These worst case possibilities must be communicated clearly to the patient (or their legal representatives).
  - 3. Ascertain the patient's mental status. The patient must be alert and oriented to time, place, and events. You must determine the patient's ability to make an informed refusal, dependent upon their ability to evaluate choices, understand risks and benefits of those choices, and have the capacity to make rational decisions. Factors that could impede or impair comprehension and decision making capacity include clinical, physical, and emotional disturbances. If a patient's legal representative is making a refusal request, similar evaluation of that person's mental status must be accomplished.
  - 4. The patient (or their legal representatives) must be offered transport in a polite and unqualified manner. Discouragement of EMS transport, intentional or not, may represent a breach of duty.





Approved 9/04/24, Effective 1/15/25, replaces all prior versions PROTOCOL 14D: Informed Patient Consent/Refusal, cont.

- C. For the purpose of this protocol, legal representatives of patients (by legal custody or Durable Power of Attorney for Health Care), or parents of minor patients may refuse medical care if they:
  - 1. Have capacity to make medical decisions = able to understand the nature of the potential injury or illness and the consequences of refusing medical care and/or transportation to an emergency department.

#### AND

- 2. At least one of the following:
  - Adult = 18 years of age or older.
  - An emancipated minor = <18 years of age but living away from parents or guardians and financially responsible for self.
  - Married minor.
  - Minor in the military.

Pregnant minors must still have adult consent (unless the emergency medical care being requested or refused is directly related to the pregnancy) if they do not meet one of the above minor exceptions.

- D. At no time may a spouse or relative who is not the legal representative of the patient make a decision to refuse evaluation, treatment, or transportation of the patient.
- E. The following patients may be considered **NOT** to have capacity to make medical decisions:
  - 1. Altered level of consciousness, including, but not limited to alcohol/drug use or head injury.
  - 2. Attempted or threatened suicide (verbally or otherwise) recently and related to the call.
  - 3. Suspected cerebral hypoxia due to, but not limited to, head injury or prolonged seizure(s).
  - 4. Adults with sustained severely altered vital signs (pulse >120 or <40; respirations >30 or <8 per min; pulse oximetry <85% if history of chronic respiratory illness or <90% if previously healthy; systolic BP >220mmHg or <90mmHg).





Approved 9/04/24, Effective 1/15/25, replaces all prior versions **PROTOCOL 14D: Informed Patient Consent/Refusal, cont.** 

- 5. Children with sustained severely altered vital signs (pulse >160 or <40; respirations >45 or <12 per min; pulse oximetry <90%; systolic BP >140 mmHg or < 70 + 2 x years of age).
- 6. Hypoglycemia defined as blood glucose <50 mg/dL.
- 7. Making largely irrational decisions in the presence of an obvious life or limb threatening condition (e.g. near amputation, ST elevation acute myocardial infarction), including persons who are emotionally unstable.
- 8. Under mental hold (Emergency Detention) which has been invoked by a person authorized to invoke such a hold.
- 9. Known mental retardation or deficiency to the degree of being unable to care for self without constant assistance or supervision.
- F. An appropriate Supervisor or OLMC must be contacted for all incidents when:
  - 1. EMS has been requested; AND
  - 2. Patient contact has been established (occurs when EMS personnel are physically with the patient and inquire to the patient's well-being), the patient has evidence of acute medical condition (verbalized symptoms or physical exam findings), but further EMS assessment, treatment, and/or transport has been refused; AND
  - 3. Any one of the following:
    - a) Patient may NOT have medical decision making capacity to refuse (see E 1-9 immediately above); **OR**
    - b) Age < 2 years or > 65 years; **OR**
    - c) Minors (unemancipated or not in military) without ability to contact parent/guardian; **OR**
    - d) Communication barrier (language or handicap) to extent patient's understanding of condition and recommended treatment/transport cannot be verified; OR
    - e) Refusal of further assessment, treatment, and/or transport in the EMS professional's judgment places the patient at significant risk.





Approved 9/04/24, Effective 1/15/25, replaces all prior versions PROTOCOL 14D: Informed Patient Consent/Refusal, cont.

- G. After the EMS Supervisor and/or OLMC has been informed of the situation, the EMS Supervisor and/or OLMC should communicate directly with the patient, on a recorded line, to establish the patient's intent. To validate the refusal, the EMS Supervisor and/or OLMC should inform the patient or patient's legal representative of:
  - 1. The patient's condition to the extent EMS assessment allows, specifically noting that EMS assessment is limited in scope and not a replacement for physician evaluation.
  - 2. Given the apparent patient condition, the corresponding potential risks of refusal.
  - 3. EMS will transport the patient to an appropriate emergency department for further assessment and care regardless of the financial status of the patient.
  - 4. Alternate forms of treatment or transport that can be offered.
  - 5. A clear statement that the patient (or patient's legal representative) is voluntarily assuming all health risks that may result from the refusal for care at this time.
  - 6. A clear statement that EMS can be recalled anytime if medical assistance is desired.
- H. If the EMS Supervisor and/or OLMC cannot successfully intervene to affect further assessment, treatment, and transport in an obvious life or limb threatening condition (e.g. near amputation, ST elevation acute myocardial infarction), AND on-scene personnel believe physically restraining the patient at this juncture to be unsafe or otherwise illadvised, the EMS Supervisor and/or OLMC should consult the EMS System Chief Medical Officer or his/her designee for further consultative directives.
- I. If a patient is determined to NOT have medical decision making capacity, the patient should be treated by implied consent. If this patient continues to refuse assessment, treatment, and/or transportation, all reasonable measures, including law enforcement assistance and/or appropriate use of physical restraint should be used to assess, treat, and transport the patient. The Medical Control Board does not expect EMS professionals to place themselves in physical danger in this process. If a physical threat is imminent, withdraw to a position of safety, requesting additional appropriate resources, while attempting to leave the patient in the care of a responsible adult.
- J. All patients (or their legal representatives) who are allowed to refuse further assessment, treatment, and/or transport must have the risks, benefits, and alternatives of their decisions explained to them by EMS personnel and demonstrate an understanding of this discussion. The reason(s) of refusal stated to EMS, benefits of recommended treatment and/or transport, alternatives to initially recommended care and/or transport, and risks of the refusal explained to the patient (or their legal representatives) and the reactions to this explanation must be documented in the patient care report in addition to the patient's chief complaint, vital signs and physical assessment.
- K. All patients (or their legal representatives) who are allowed to refuse further assessment, treatment, and/or transport must be advised to seek further medical examination and care by a licensed physician (M.D. or D.O.). The limitations of EMS scope of assessment and practice must be explained. Document this information as it was explained.





Approved 9/04/24, Effective 1/15/25, replaces all prior versions PROTOCOL 14D: Informed Patient Consent/Refusal, cont.

- L. All patients (or their legal representatives) who are allowed to refuse further assessment, treatment, and/or transport are to sign a refusal statement. A witness (preferably a friend or relative of the patient) is to countersign the refusal to verify its accuracy. The signature of release may or may not actually "release" an EMS professional or EMS organization from liability. One of the many purposes of using a release, however, is to further demonstrate good faith and diligence in meeting responsibilities to the patient. Together, with prudent actions, it helps to defend against assertions of abandonment. If the patient (or their legal representative) refuses to sign a valid refusal form, EMS professionals should also document the details of this encounter, including reasons for refusal to sign. EMS professionals should also document on the refusal form "Patient refused to sign." with at least one colleague signing as a witness.
- M. Leave the patient (or their legal representatives) any applicable medical care instruction sheets. Document in the patient care report what instruction sheet(s) were given.
- N. All dispatches not resulting in the transport of a patient require completion of the appropriate no transport information.

#### Additional Notes:

- DO NOT ignore clues to potentially serious injuries or illnesses, such as abnormal vital signs, unconsciousness which may be followed by a transient lucid stage (head injury with epidural hematoma), concern of family members or witnesses, or inconsistencies in information obtained from different sources.
- 2. A red flag needs to be raised anytime with thoughts such as "this patient is just a drunk", "it's not that bad, this patient can't afford an ambulance", or "an ambulance shouldn't be tied up on this type of call". These rationalizations encourage underestimating the patient's condition and treatment shortcuts, resulting in substandard patient care and patient endangerment.
- 3. Refusal of assessment, treatment, and/or transport situations are often emotionally and potentially legally charged situations. Maintain duty to act in the best interests of all patients by avoiding any potentially discouraging tone, language, or body positioning that conveys unwillingness to provide humane, compassionate patient care.
- 4. Every patient has a right to EMS full service and attention. While a perception of "system demands" may be commendable, it cannot supersede a patient's needs and rights unless in the most dire of disaster conditions. Take patients one at a time and give them the best care morally, ethically, and legally possible.





Approved 9/04/24, Effective 1/15/25, replaces all prior versions PROTOCOL 14D: Informed Patient Consent/Refusal, cont.

#### **Special Considerations in Care of Minors**

- A. If a minor aged patient presents with life or limb threatening condition, but no parent or guardian is present, do not delay indicated care. Provide treatment and transport per applicable protocol(s) and assign other public safety colleagues the task of notifying the child's parent/legal guardian of the incident, any obvious illness/injury, and hospital to which the child was transported.
- B. If a minor needs medical treatment, but no parent or guardian is present, EMS professionals may treat per applicable protocol(s) if the parent or guardian cannot be reached after reasonable attempts and the minor gives verbal and physical consent.
- C. IF THE PARENT/GUARDIAN CANNOT BE REACHED AFTER REASONABLE ATTEMPTS AND THE MINOR REFUSES TREATMENT:
  - 1. Consult an appropriate EMS Supervisor for advice, which may include, but is not limited to:
    - Police assistance, taking the minor into their protective custody.
    - Utilization of family members outside the immediate parents/legal guardians.
    - Utilization of reliable adults with prior knowledge of the minor.
    - As a last resort, allowing the minor refusal of service under the same requirements and procedures as listed above for adult patients (or their legal representatives).





#### Medical Literature References 14D – Informed Patient Consent Refusal


- Sinclair, J. E., Austin, M., Froats, M., Leduc, S., Maloney, J., Dionne, R., Reed, A., & Vaillancourt, C. (2019). Characteristics, Prehospital Management, and Outcomes in Patients Assessed for Hypoglycemia: Repeat Access to Prehospital or Emergency Care. *Prehospital Emergency Care*, 23(3), 364–376. https://doi.org/10.1080/10903127.2018.1504150
- Leggatt, L., Van Aarsen, K., Columbus, M., Dukelow, A., Lewell, M., Davis, M., & McLeod, S. (2017). Morbidity and Mortality Associated with Prehospital "Lift-assist" Calls. *Prehospital Emergency Care*. https://doi.org/10.1080/10903127.2017.1308607
- 3. Cone DC, Ahern J, Lee CH, Baker D, Murphy T, Bogucki S. A descriptive study of the "lift-assist" call. *Prehosp Emerg Care*. 2013 Jan-Mar;17(1):51-6.
- 4. Holder P, Arthur AO, Thiems G, Redmon T, Thomas M, Goodloe JM, Reginald TJ, Thomas SH. Patients refusing prehospital transport are increasingly likely to be geriatric. *Emerg Med Int.* 2012;2012:905976. Epub 2012 Feb 19.
- 5. Waldron R, Finalle C, Tsang J, Lesser M, Mogelof D. Effect of Gender on Prehospital Refusal of Medical Aid. J Emerg Med. 2012 Feb 9. [Epub ahead of print]
- 6. Maggiore WA. Legal Issues. In: Cone DC, O'Connor RE, Fowler RL, eds. Emergency Medical Services: Clinical Practice and Systems Oversight. Dubuque, IA: Kendall Hunt Professional; 2009: 69-94.
- 7. National Assoc of EMS Physicians/American College of Emergency Physicians. Patient Non-transport. Joint Position Paper. *Prehosp Emerg Care.* 2001;5:288. Reaffirmed by NAEMSP 1/07.
- 8. Cone DC, Kim DT, Davidson SJ. Patient-initiated refusals of prehospital care: ambulance call report documentation, patient outcome, and on-line medical command. *Prehosp Disaster Med.* 1995 Jan-Mar;10(1):3-9.
- Leggatt L, Van Aarsen K, Columbus M, et al. Morbidity and Mortality Associated with Prehospital "Lift-assist" Calls. *Prehospital Emergency Care*. 2017;21(5):556-562. doi:10.1080/10903127.2017.1308607
- 10. Brown LH. Researching Lift-Assists: Nebulous Complexity. *Prehospital Emergency Care*. 2017;21(5):670-672. doi:10.1080/10903127.2017.1317893





Approved 9/04/24, Effective 1/15/25, replaces all prior versions

14E - ON-LINE MEDICAL CONTROL PHYSICIANS



The Medical Control Board supports EMS professionals in the field having the availability of On-Line Medical Control Physicians (OLMCP). The OLMCP represents the Chief Medical Officer in "real-time" system operations.

The OLMCP is the resource available 24 hours per day for consultation contemporaneous with patient care.

OLMCP consultation, when desired or required, is to be made at the earliest appropriate point in the patient's assessment and treatment in order to facilitate appropriate patient care.

Radio reports to the OLMCP should follow Protocol 14H - Radio Report Communications. It is the responsibility of the consulting EMS professional to ensure a brief, yet pertinent report to meet the needs of the patient and the treating EMS professional(s). If the lead EMS professional is involved in performing critical interventions, other personnel may make the report under the guidance of the lead EMS professional as may be beneficial for accuracy. Communications should ideally be established via a recorded communication method.

Contact with OLMCP will be made in the following circumstances:

- All situations in which consultation is specifically required in these treatment protocols.
- Any situation in which the treating EMS professional(s) feel it is in the best interest
  of the patient to obtain physician consultation, ensuring the most accurate EMS
  care possible for the patient's condition.
- Any situation in which the EMS professional(s) feels extensive modification is required from the standard treatment and/or procedure protocols.
- All patients in whom a refusal of care and/or transport would, in the EMS
  professional's judgment, place the patient, the EMS professional, and/or the EMS
  system at risk after appropriate attempts fail to produce needed results..





Approved 9/04/24, Effective 1/15/25, replaces all prior versions

### PROTOCOL 14E: On-Line Medical Control Physicians, cont.

Acceptable modification to the sequence of drugs or procedures must be justified as being appropriate for field management of critically ill or injured patients in unusual circumstances and therefore, should be an uncommon event.

EMS providers complying with orders which exceed their level of licensure and/or authorized scope of EMS practice may be subject to disciplinary action by the Oklahoma State Department of Health (as well as locally applicable action) which may include, but is not limited to, indefinite suspension or permanent revocation of licensure and authorization to provide patient care.





### Medical Literature References 14E – On-Line Medical Control Physicians


- 1. Burstein JL, Hollander JE, Delagi R, Gold M, Henry MC, Alicandro JM. Refusal of out-of-hospital medical care: effect of medical-control physician assertiveness on transport rate. Acad Emerg Med. 1998 Jan;5(1):4-8.
- 2. Rottman SJ, Schriger DL, Charlop G, Salas JH, Lee S. On-line medical control versus protocol-based prehospital care. *Ann Emerg Med.* 1997 Jul;30(1):62-8.
- 3. Wuerz RC, Swope GE, Holliman CJ, Vazquez-de Miguel G. On-line medical direction: a prospective study. *Prehosp Disaster Med.* 1995 Jul-Sep;10(3):174-7.
- 4. Cone DC, Kim DT, Davidson SJ. Patient-initiated refusals of prehospital care: ambulance call report documentation, patient outcome, and on-line medical command. *Prehosp Disaster Med.* 1995 Jan-Mar;10(1):3-9.





Approved 9/04/24, Effective 1/15/25, replaces all prior versions

14F - HELICOPTER EMS (HEMS) CONSIDERATIONS



Medical literature to date demonstrates no significant survival benefit utilizing medical helicopter transport for patients in densely populated, urban settings. The Medical Control Board and the University of Oklahoma Department of Emergency Medicine EMS Section provide the following information regarding the clinically appropriate utilization of medical helicopters to maximize patient benefit and protect the safety of patients, aeromedical professionals, and ground EMS professionals.

### "No Fly" Patient Conditions

Medical helicopter utilization rarely affects outcome in already moribund patients or in the converse, stable patients without apparent serious illness/injury. A medical helicopter should NOT be utilized for the following patients:

- 1. Medical or Traumatic Cardiac Arrest without Return of Spontaneous Circulation;
- 2. Trauma Patients with minimal traumatic injury, without apparent risk of life/limb loss:
- 3. Patients with stable vital signs and without signs of serious illness/injury.

#### "No Fly" Zones

Medical helicopter utilization is very rarely indicated within an approximate 30 minute radius of an appropriate destination hospital unless there are extenuating circumstances. These "extenuating circumstances" include the following:

- 1. Hazardous or impassible road conditions resulting in significant ground transport delays for seriously injured or ill patients;
- Multiple casualty incidents with high numbers of red/priority 1 patients, overwhelming available ground EMS units;
- 3. A combination of lengthy extrication and extended ground transportation (traffic conditions, weather conditions) of a priority 1 or priority 2 patient at the lead EMS professional's careful discretion.





Approved 9/04/24, Effective 1/15/25, replaces all prior versions **PROTOCOL 14F: Helicopter EMS (HEMS) Considerations, cont.** 

### **Medical Helicopter Utilization:**

At incidents greater than 30 minutes from the appropriate destination hospital, the decision to activate a medical helicopter response should be based upon an EMS professional's assessment of the patient's clinical condition, factoring in apparent and/or suspected illness or injury, mechanisms of injury – if applicable, anticipated scene time, and anticipated ground transport time to an appropriate destination hospital (eg. cardiac catheterization capable hospital or trauma center). Medical helicopters should not be activated until an EMS professional or medically-trained law enforcement officer has assessed the patient. Further utilization concepts include:

- 1. EMS professionals on scene may elect to activate a medical helicopter if flight time to the incident, flight scene time, and return flight time would still allow a critical patient to arrive at an appropriate destination hospital significantly faster by air.
- 2. If ground EMS transport capability is not on scene and a decision is being factored as to ground or air transport, the on scene EMS professionals should first request an ETA for the ground transport unit. If the on scene EMS professionals then judge transport time by ground will be detrimental to the patient clinical condition, a medical helicopter response can be activated. This decision should be communicated to ground EMS agency to keep all responding apparatus crews aware of scene and patient dynamics.
- 3. If uncertain whether medical helicopter activation is in the best interest of the patient, contact OLMC at the anticipated destination hospital for consultation and determination of transport mode and destination.
- 4. The primary determinant of helicopter transport mode is to achieve getting the critical patient to the most appropriate definitive care hospital in the shortest amount of time. The medical helicopter to be utilized is the medical helicopter appropriate for the patient's needs and closest to the incident location.

#### **Cancellation of Medical Helicopter Activation:**

An EMS professional may cancel a medical helicopter response after being activated if patient condition significantly improves or deteriorates to meet "no fly" criteria. Keep in mind, though, that once a medical helicopter is responding to the scene, it is generally unwise to cancel that response. EMS professionals should avoid requesting a medical helicopter response, canceling the response, and then having to request the helicopter again. Such a situation prolongs scene time and helicopter response time in addition to conveying indecisive patient care.

#### **Landing Zone:**

Appropriate fire or law enforcement personnel will be responsible for establishing and maintaining a safe landing zone.





Approved 9/04/24, Effective 1/15/25, replaces all prior versions **PROTOCOL 14F: Helicopter EMS (HEMS) Consideration, cont.** 

### **Utilization Review:**

All medical helicopter activations may undergo utilization review by the Chief Medical Officer and/or his/her designee and by the medical director of the aeromedical organization. This is to specifically promote optimal medical helicopter utilization and not to be interpreted as discouraging appropriate medical helicopter utilization per this protocol.





#### Medical Literature References 14F – Helicopter (HEMS) Considerations


- Protocol expert consultant: Stephen H. Thomas, MD. Department of Emergency Medicine, University of Oklahoma School of Community Medicine, Tulsa. Board certified in emergency medicine by the American Board of Emergency Medicine.
- Galvagno SM Jr, Thomas S, Stephens C, Haut ER, Hirshon JM, Floccare D, Pronovost P. Helicopter emergency medical services for adults with major trauma. *Cochrane Database Syst Rev.* 2013 Mar 28;3:CD009228.
- 3. Brown BS, Pogue KA, Williams E, Hatfield J, Thomas M, Arthur A, Thomas SH. Helicopter EMS Transport Outcomes Literature: Annotated Review of Articles Published 2007-2011. *Emerg Med Int.* 2012;2012:876703. Epub 2012 Jan 11.
- 4. Stewart KE, Cowan LD, Thompson DM, Sacra JC, Albrecht R. Association of Direct Helicopter Versus Ground Transport and In-hospital Mortality in Trauma Patients: A Propensity Score Analysis. *Acad Emerg Med.* 2011;18:1208-16.
- 5. Garwe T, Cowan LD, Neas BR, Sacra JC, Albrecht RM. Directness of transport of major trauma patients to a level I trauma center: a propensity-adjusted survival analysis of the impact on short-term mortality. *J Trauma*. 2011;70:1118-27.
- 6. Stewart KE, Cowan LD, Thompson DM, Sacra JC. Factors at the scene of injury associated with air versus ground transport to definitive care in a state with a large rural population. *Prehosp Emerg Care*. 2011;15:193-202.
- Brown JB, Stassen NA, Bankey PE, Sangosanya AT, Cheng JD, Gestring ML. Helicopters improve survival in seriously injured patients requiring interfacility transfer for definitive care. *J Trauma*. 2011;70:310-4.
- 8. Thomas S, Judge T, Lowell MJ, et al. Airway management success and hypoxemia rates in air and ground critical care transport: a prospective multicenter study. *Prehosp Emerg Care*. 2010;14:283.
- 9. Brown JB, Stassen NA, Bankey PE, Sangosanya AT, Cheng JD, Gestring ML. Helicopters and the civilian trauma system: national utilization patterns demonstrate improved outcomes after traumatic injury. *J Trauma*. 2010;69:1030-4; discussion 4-6.
- Ringburg AN, Thomas SH, Steyerberg EW, van Lieshout EM, Patka P, Schipper IB. Lives saved by helicopter emergency medical services: an overview of literature. Air Med J. 2009;28:298-302.
- 11. MacDonald RD, Banks BA, Morrison M. Epidemiology of adverse events in air medical transport. *Acad Emerg Med.* 2008;15:923-31.
- 12. Thomas SH. Helicopter EMS transport outcomes literature: annotated review of articles published 2004-2006. *Prehosp Emerg Care*. 2007 Oct-Dec;11(4):477-88.
- 13. McGinnis KK, Judge T, Nemitz B, et al. Air Medical Services: Future Development as an Integrated Component of the Emergency Medical Services (EMS) System. *Prehosp Emerg Care*. 2007;11:353-68.
- Thomas S, Kociszewski C, Hyde R, Brennan P, Wedel SK. Prehospital EKG and early helicopter dispatch
  to expedite interfacility transfer for percutaneous coronary intervention. *Crit Pathways Cardiol*. 2006;5:155-
- 15. Bledsoe BE, Wesley AK, Eckstein M, Dunn TM, O'Keefe MF. Helicopter scene transport of trauma patients with nonlife-threatening injuries: a meta-analysis. J Trauma. 2006;60:1257-65; discussion 65-6.
- 16. Davis DP, Peay J, Sise MJ, et al. The impact of prehospital endotracheal intubation on outcome in moderate to severe traumatic brain injury. *J Trauma*. 2005;58:933-9.
- 17. Diaz M, Hendey G, Bivens H. When is the helicopter faster? A comparison of helicopter and ground ambulance transport times. *J Trauma*. 2005;58:148-53.
- 18. Thomson DP, Thomas SH. Guidelines for air medical dispatch. *Prehosp Emerg Care*. 2003;7:265-71.
- 19. Silliman S, Quinn B, Huggett V, Merino J. Use of a field-to-stroke-center helicopter transport program to extend thrombolytic therapy to rural residents. *Stroke*. 2003;34:729-33.
- 20. Amatangelo M, Thomas SH, Harrison T, Wedel SK. Analysis of patients discharged from receiving hospitals within 24 hours of air medical transport. *Air Med J.* 1997;16:44-6; discussion 7.
- 21. Thomas SH, Stone CK, Bryan-Berge D. The ability to perform closed chest compressions in helicopters. *Am J Emerg Med.* 1994;12:296-8.





Approved 9/04/24, Effective 1/15/25, replaces all prior versions

### **14G – PATIENT PRIORITIZATION**



While each patient will receive the best possible EMS care in a humane and ethical manner, proper patient prioritization ensures that patients most dependent upon rapid and critical medical interventions receive expeditious field treatment and that destination hospitals receive early notification.

#### **Adult Medical:**

Red/Priority I: Patient condition expected to require immediate intervention upon Emergency Department arrival. Examples include:

- Inability to successfully oxygenate and/or ventilate;
- Acute dyspnea in adults requiring NIPPV (use of red lights & sirens at paramedic discretion based upon patient stability and if markedly improving on NIPPV);
- Acute Myocardial Infarction with ST elevation on 12-Lead ECG;
- Acute Congestive Heart Failure with hypotension (Cardiogenic Shock);
- Acute Stroke with positive LAPSS with symptom onset < 23 hours in duration;</li>
- Status epilepticus;
- Deep penetrating trauma (e.g. gunshot wound) to head, neck, or trunk;
- Trauma in adults with systolic blood pressure <90 mmHg:</li>
- Trauma in pediatrics with systolic blood pressure < (70 + 2 X age in years) mmHg.

Red/Priority I patients are typically transported to the Emergency Department with red lights and sirens.

**Yellow/Priority II:** Patient condition expected to require intervention within 15 minutes upon Emergency Department arrival. Yellow/Priority II patients have potential time sensitive problems, are currently stable, but at risk for sudden deterioration. Examples include:

- Acute dyspnea in adults and pediatrics with normalizing vital signs;
- Acute non-traumatic chest pain in adults improving with protocol specified treatment;
- High force traumatic injuries with normal and stable vital signs.

Yellow/Priority II patients may be transported to the hospital red lights and sirens if time of transport would otherwise create marked risk to patient recovery. In most situations, though, the safety risk of red lights and sirens transport of these patients is unwarranted.





Approved 9/04/24, Effective 1/15/25, replaces all prior versions

PROTOCOL 14G: Patient Prioritization, cont.

Green/Priority III: Patient condition expected to require routine timeliness of intervention upon Emergency Department arrival. Green/Priority III patients do not appear to require further emergent medical intervention and do not appear to have life/organ threatening conditions. Examples include:

- Asthma exacerbation dyspnea resolved with bronchodilator nebulization;
- Nausea/non-bloody vomiting with normal and stable vital signs;
- Isolated orthopedic injury with intact neurovascular function.

Green/Priority III patients should be transported to the hospital without red lights and without sirens. The safety risk of red lights and sirens transport of these patients is unwarranted.

Black or Blue: Obvious death or illness/injury severity incompatible with successful resuscitation given concurrent system demands (such as in multiple casualty responses). **Pediatric Medical:** 

Pediatric (Age < 16 years of age) general medical patients are determined Red/Priority I to be if the following organ system dysfunction is evidenced by acute symptoms or physical exam signs:

#### Pulmonary System:

- Respiratory arrest;
- Respiratory distress and inability to maintain O<sub>2</sub> sat > 95% on 100% supplemental O<sub>2</sub>;
- Stridor with inability to phonate, weak cry, altered mental status, or pallor.

### Cardiovascular System:

- Cardiac arrest (or history of pre-arrival CPR) or bradycardia requiring chest compression;
- <u>Multiple</u> shock signs (pallor, cool, slow capillary refill, weak pulse, altered mental status):
- Persistent tachycardia > 200/min or bradycardia < 80/min (without athletic fitness level).

### Neurologic System

- Status epilepticus;
- Acute sustained altered mental status without apparent etiology;
- Acute focal neurological deficits.

#### Metabolic System/Toxicology (Overdose);

- Ingestion of a tricyclic antidepressant;
- Ingestion, inhalation, or contact exposure causing altered mental status, respiratory distress, or shock.

Pediatric (Age < 16 years of age) general medical patients are determined to be Green/Priority if there does not appear to be an acute medical problem of life/organ threatening severity.





Approved 9/04/24, Effective 1/15/25, replaces all prior versions

PROTOCOL 14G: Patient Prioritization, cont.

Adult Trauma: (15 years of age and older)

Adult trauma patients are determined to be Red/Priority by either vital signs and level of consciousness (systolic BP < 90 mmHg, sustained tachycardia, respiratory rate <10 or >29 breaths per minute, GCS ≤ 13, cool, diaphoretic skin) or any of the following anatomical injury:

- Penetrating injury of head, neck, torso, extremities proximal to elbow or knee;
- Amputation proximal to the wrist or ankle;
- Paralysis or suspected spinal fracture with neurological deficit;
- Flail chest;
- Two or more suspected proximal long bone fractures;
- Open or suspected depressed skull fracture;
- Unstable pelvis or suspected pelvic fracture;
- Abdominal rigidity;
- Burns associated with other Priority I Trauma;
- Crushed, degloved, or mangled extremity, proximal to the wrist or ankle;
- Pulseless extremity;
- · Active bleeding requiring a tourniquet.

Adult trauma patients are determined to be **Yellow/Priority II** from events with risk of severe injury despite <u>normal and stable vital signs</u> without change in usual mentation or usual neurologic function, or respiratory distress. Adult trauma patients may also be determined to be Yellow/Priority II if exhibiting a single system injury as noted:

- High risk auto crash (intrusion > 12 inches in occupant site; intrusion > 18 inches in any site; ejection (partial or complete) from automobile; death in same passenger compartment);
- Auto v. pedestrian/bicyclist thrown, run over, or with significant ( >20 mph) impact;
- Motorcycle crash > 20 mph;
- Rider separated from any mode of transport vehicle with significant impact (e.g., ejections motorcycle, ATV, horse, etc.)
- Falls > 20 feet in height (one building story is 10 feet in height);
- Significant force alleged assault;
- Isolated closed head trauma with resolved altered mental status (Neuro System);
- Positive seatbelt sign or handlebar mark;
- Fractures/dislocation; lacerations/avulsions with extensive tissue damage;
- High voltage electrical injury

Adult trauma patients are determined to be Yellow/Priority II from events with risk of severe injury despite <u>normal and stable vital signs</u> without change in usual mentation or usual neurologic function, or respiratory distress. Adult trauma patients may also be determined to be Yellow/Priority II if exhibiting a single system injury as noted:

- Pregnancy > 20 weeks.
- Facial lacerations; fractured facial bones; isolated orbit trauma; multiple avulsed teeth (Maxillofacial/Dental);





Approved 9/04/24, Effective 1/15/25, replaces all prior versions

PROTOCOL 14G: Patient Prioritization, cont.

Adult Trauma: (15 years of age and older), cont.

- Select & isolated hand injuries ("isolated" defined by the level of suspected injury involvement being no further proximal than the elbow).
  - Only certain hand injuries require rapid treatment to avoid unfavorable outcomes.
     These "select" Priority II injuries include:
    - Vascular injuries that involve significant arterial hemorrhage;
    - Nerve injuries that cause loss of motor function;
    - Amputations:
    - High-pressure injection injuries;
    - Flexor tendon injuries of hand.

Adult trauma patients <u>may</u> be determined to be <u>Discretionary Red/Priority I or Yellow/Priority I if clinical suspicion of significant injury <u>and</u> heightened by any single or particularly a combination of the following patient attributes:</u>

- Age > 65;
- Anticoagulation, bleeding disorders and/or significant comorbidities;
- Time sensitive extremity injury.

Discretionary Red/Priority I or Yellow/Priority II adult trauma patient radio and care reports should clearly indicate to the receiving Trauma Center personnel the rationale for the Discretionary Red/Priority I or Yellow/Priority II assignment.

Level III Trauma Centers are intended to receive adult patients at risk for severe injury with normal, stable vital signs or patients with no significant anatomical injuries.

Adult trauma patients are determined to be **Green/Priority III** from events with normal and stable vital signs, without change in usual mentation or usual neurologic function, and without new or significant organ system dysfunction. Green/Priority III adult trauma may include:

- Single proximal or distal long bone fractures without dislocation;
- Minor puncture wounds/lacerations/abrasions:
- · Isolated neck pain without new neurological deficit;
- Isolated extremity pain;
- Isolated abdominal pain.

Level IV Trauma Centers may receive adult patients <u>without</u> physiologic instability, altered mentation, neurological deficit or significant anatomical injuries and have also not been involved in a significant mechanism of injury incident for expected care at that facility. Patients in other categories (eg. with physiologic instability) should be expected to be transferred to a higher level trauma center after immediate care needs are addressed (eg. invasive airway management).





Approved 9/04/24, Effective 1/15/25, replaces all prior versions

PROTOCOL 14G: Patient Prioritization, cont.

### Pediatric Trauma; (<15 year of age):

Pediatric trauma patients are prioritized by either physiological compromise criteria Age 0-9: (systolic BP < (70 + 2 x) age of patient in years) mmHg, age 10-14 SBP <90mmHg & HR > SPB or signs that should be considered include: sustained tachycardia >160 bpm, cool diaphoretic skin, respiratory rate <12 or >40, pulse oximetry<95% without supplemental oxygen, or GCS  $\leq$  12)

- Penetrating injury of head, neck, torso, extremities proximal to elbow or knee;
- Amputation proximal to the wrist or ankle;
- Paralysis or suspected spinal fracture with neurological deficit;
- Flail chest;
- Unstable pelvis or suspected pelvic fracture;
- Crushed, degloved, or mangled extremity, proximal to the wrist or ankle;
- Pulseless extremity;
- Two or more open fractures.

Pediatric trauma patients are prioritized **Yellow/Priority II** from "high-energy" events with risk of severe injury despite <u>normal and stable vital signs</u> without change in usual mentation or usual neurologic function, or respiratory distress. Pediatric trauma patients may also be determined to be Yellow/Priority II if exhibiting any of the adult trauma priority II single system injury criteria.

Pediatric trauma patients <u>may</u> be determined to be <u>Discretionary Red/Priority I or</u> <u>Yellow/Priority II</u> if clinical suspicion of significant injury warrants <u>and</u> is heightened by any of the following patient attributes:

- GCS of 13-14;
- Extrication time > 20 mins, \*death in same vehicle, speed >40 mph, rollover mechanism, vehicle external intrusion >20" or compartment intrusion >12":
- Fall criteria for pediatric trauma Red/Priority I is >10 feet or 2 3 times the height of the child;
- Two or more suspected proximal long bone fractures;
- Open or suspected depressed skull fracture;
- Tender and/or distended abdomen/positive seatbelt sign or handlebar mark;
- Suspected or known Non-Accidental Trauma in pediatric patients;
- Tenderness to spine with palpation;
- Isolated open fracture (excluding hand);
- Significant laceration or soft tissue injury;
- High voltage electrical injury;
- Anticoagulation and bleeding disorders and/or significant comorbidities.





Approved 9/04/24, Effective 1/15/25, replaces all prior versions

PROTOCOL 14G: Patient Prioritization, cont.

Pediatric Trauma; (<15 year of age), cont.

Discretionary Red/Priority I or Yellow/Priority II pediatric trauma patient radio and care reports should clearly indicate to the receiving Trauma Center personnel the rationale for the Discretionary Red/Priority I or Yellow/Priority II assignment.

Pediatric trauma patients are determined to be Green/Priority III from events with normal and stable vital signs, without change in usual mentation or usual neurologic function, and without new or significant organ system dysfunction. Green/Priority III pediatric trauma may include any of the adult trauma Green/Priority III injury criteria as previously listed in this protocol.

- Single bone fractures from a same level fall;
- Minor puncture wounds/lacerations/abrasions;
- Isolated extremity pain;
- Abdominal pain without bruising;
- Back pain.

#### SEE ALSO SECTION 19 RESOURCE: OKLAHOMA MODEL TRAUMA TRIAGE ALGORITHM

### **Specialized Burn Care**

In Oklahoma, the following burn care specialty centers exist:

Oklahoma City:

Adult - Integris Baptist Medical Center

Adult up to 20% - OU Medical Center Pediatric - OU Medical Center Childrens

Tulsa: Adult/Pediatric - Hillcrest Medical Center

Patients with the following burn injuries (without additional trauma center criterion injuries) should either be transported directly to a burn care specialty center or be referred to such after initial emergency department evaluation:

- Partial thickness (second degree) burns >10% total body surface area (TBSA);
- Full thickness (third degree) burns:
- Partial or full thickness burns of the face, hands, feet, genitalia/perineum, or major joints;
- Electrical burns (includes lightning injury), inhalation burns, chemical burns;
- Burn injury in patients with preexisting medical disorders compromising healing and survival (cardiac disease, chronic respiratory illness, diabetes):
- Multisystem trauma with partial or full thickness burn as the predominant injury.

If the burn patient cannot be oxygenated or ventilated, transport the patient to the nearest appropriate emergency department for airway management.





#### Medical Literature References 14G – Patient Prioritization

- Kupas, D. F., Zavadsky, M., Burton, B., Baird, S., Clawson, J. J., Decker, C., Dworsky, P. I., Evans, B., Finger, D., Goodloe, J. M., LaCroix, B., Ludwig, G. G., McEvoy, M., Tan, D. K., Thornton, K. L., Smith, K., & Wilson, B. R. (2022). Joint Statement on Lights & Siren Vehicle Operations on Emergency Medical Services Responses. *Prehospital Emergency Care*, 26(3), 459–461. https://doi.org/10.1080/10903127.2022.2044417
- 2. Jarvis, J. L., Hamilton, V., Taigman, M., & Brown, L. H. (2021). Using Red Lights and Sirens for Emergency Ambulance Response: How Often Are Potentially Life-Saving Interventions Performed? *Prehospital Emergency Care*, 25(4), 549–555. https://doi.org/10.1080/10903127.2020.1797963
- 3. Lavonas EJ, Drennan IR, Gabrielli A, Heffner AC, Hoyte CO, Orkin AM, Sawyer KN, Donnino MW. Part 10: Special Circumstances of Resuscitation: 2015 American Heart Association Guidelines Update for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. *Circulation*. 2015 Nov 3;132(18 Suppl 2):S501-18.
- 4. Chenaitia H, Lefevre O, Ho V, Squarcioni C, Pradel V, Fournier M, Toesca R, Michelet P, Auffray JP. Emergency medical service in the stroke chain of survival. *Eur J Emerg Med.* 2013 Feb;20(1):39-44.
- 5. Sasser SM, Hunt RC, Faul M, Sugerman D, Pearson WS, Dulski T, Wald MM, Jurkovich GJ, Newgard CD, Lerner EB; Centers for Disease Control and Prevention (CDC). Guidelines for field triage of injured patients: recommendations of the National Expert Panel on Field Triage, 2011. *MMWR Recomm Rep.* 2012 Jan 13;61(RR-1):1-20.
- 6. National Association of EMS Physicians. Termination of resuscitation in nontraumatic cardiopulmonary arrest. *Prehosp Emerg Care*. 2011 Oct-Dec;15(4):542.
- 7. Millin MG, Khandker SR, Malki A. Termination of resuscitation of nontraumatic cardiopulmonary arrest: resource document for the National Association of EMS Physicians position statement. *Prehosp Emerg Care*. 2011 Oct-Dec;15(4):547-54.
- 8. Mayer SA, Kurtz P, Wyman A, Sung GY, Multz AS, Varon J, Granger CB, Kleinschmidt K, Lapointe M, Peacock WF, Katz JN, Gore JM, O'Neil B, Anderson FA; STAT Investigators. Clinical practices, complications, and mortality in neurological patients with acute severe hypertension: the Studying the Treatment of Acute hyperTension registry. *Crit Care Med.* 2011 Oct;39(10):2330-6.
- 9. Garwe T, Cowan LD, Neas BR, Sacra JC, Albrecht RM. Directness of transport of major trauma patients to a level I trauma center: a propensity-adjusted survival analysis of the impact on short-term mortality. *J Trauma*. 2011;70:1118-27.
- 10. Jauch ÉC, Cucchiara B, Adeoye O, Meurer W, Brice J, Chan Y-F, Gentile N, Hazinski MF. Part 11: adult stroke: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. *Circulation*. 2010;122(suppl 3):S818–S828.
- 11. Kushner FG, Hand M, Smith SC Jr, King SB 3rd, Anderson JL, Antman EM, Bailey SR, Bates ER, Blankenship JC, Casey DJ Jr, Green LA, Hochman JS, Jacobs AK, Krumholz HM, Morrison DA, Ornato JP, PearleDL, Peterson ED, Sloan MA, Whitlow PL, Williams DO. 2009 Focused updates: ACC/AHA guidelines for the management of patients with ST-elevationmyocardial infarction (updating the 2004 guideline and 2007 focused update) and ACC/AHA/SCAI guidelines on percutaneous coronary intervention(updating the 2005 guideline and 2007 focused update): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2009;120:2271–2306.
- 12. Bradley EH, Herrin J, Wang Y, Barton BA, Webster TR, Mattera JA, Roumanis SA, Curtis JP, Nallamothu BK, Magid DJ, McNamara RL, Parkosewich J, Loeb JM, Krumholz HM. Strategies for reducing the door-to-balloon time in acute myocardial infarction. *N Engl J Med.* 2006 Nov 30;355(22):2308-20.
- 13. Thomas S, Kociszewski C, Hyde R, Brennan P, Wedel SK. Prehospital EKG and early helicopter dispatch to expedite interfacility transfer for percutaneous coronary intervention. *Crit Pathways Cardiol.* 2006;5:155-9.Thomson DP, Thomas SH. Guid Medical Literature References elines for air medical dispatch. *Prehosp Emerg Care.* 2003; 7:265-71.





Medical Literature References 14G – Patient Prioritization (cont)


- 14. Silliman S, Quinn B, Huggett V, Merino J. Use of a field-to-stroke-center helicopter transport program to extend thrombolytic therapy to rural residents. *Stroke*. 2003;34:729-33.
- 15. Jauch EC, Cucchiara B, Adeoye O, Meurer W, Brice J, Chan Y-F, Gentile N, Hazinski MF. Part 11: adult stroke: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. *Circulation*. 2010;122(suppl 3):S818–S828.
- Watanabe, B. L., Patterson, G. S., Kempema, J. M., Magallanes, O., & Brown, L. H. (2019). Is Use of Warning Lights and Sirens Associated With Increased Risk of Ambulance Crashes? A Contemporary Analysis Using National EMS Information System (NEMSIS) Data. *Annals of Emergency Medicine*. https://doi.org/10.1016/j.annemergmed.2018.09.032





Approved 9/04/24, Effective 1/15/25, replaces all prior versions

14H - RADIO REPORT COMMUNICATIONS



#### Radio Report Format:

- A. Identification (Apparatus ID, Personnel Last Name & Licensure) & Estimated Time of Arrival;
- B. Patient Priority Red/Priority 1; Yellow/Priority 2; Green/Priority 3;
- C. Objective of communication Notification of transport only or request for on-line medical control. Be specific in what orders will be requested from on-line medical control so that the physician (or designate) will be oriented to the request as he/she is listening to the report;
- D. Patient Information Age/Sex/Chief Complaint or Condition/Pertinent Past Medical History;
- E. Patient Condition LOC/Vital Signs/Exam Findings/ECG Interpretation;
- F. Treatment and response to treatment.

#### Notes:

- A. All communications should be brief and orderly. Radio reports should rarely take longer than one or two minutes per patient and should be made on a recorded line.
- B. Describe the patient condition in enough detail to explain treatment initiated and rationale for any request(s). Remember while the patient's condition may be visually obvious, the nurse or physician on the radio or phone is completely dependent on the EMS professional's ability to verbally "paint the picture of the patient".
- C. It is critical to notify the receiving emergency department at the earliest opportunity to describe the patient's illness/injury and condition so that emergency department personnel can be appropriately prepared for the patient's arrival, including preparing resources to ensure continuity of care (eg. respiratory care, cardiac pacing, trauma surgery notification). In many instances, the earliest opportunity for a radio report will occur even before discovering the full extent of illness or injury in the critical patient. It is important that the "lead EMS professional" or his/her designee make the report at this time, especially to report a STEMI Alert, Stroke Alert, or Trauma Alert rather than wasting several minutes of hospital pre-arrival notification trying to make a "more complete" report.
- D. Particularly critical objective findings, (eg. cardiac arrest, critically abnormal vital signs, gunshot wound to chest) need to take precedence in a radio report and should be reported after the identification/ETA and patient priority statements.





#### Medical Literature References 14H – Radio Report Communications


- 1. Burstein JL, Hollander JE, Delagi R, Gold M, Henry MC, Alicandro JM. Refusal of out-of-hospital medical care: effect of medical-control physician assertiveness on transport rate. *Acad Emerg Med.* 1998 Jan;5(1):4-8.
- 2. Wuerz RC, Swope GE, Holliman CJ, Vazquez-de Miguel G. On-line medical direction: a prospective study. *Prehosp Disaster Med.* 1995 Jul-Sep;10(3):174-7.
- 3. Cone DC, Kim DT, Davidson SJ. Patient-initiated refusals of prehospital care: ambulance call report documentation, patient outcome, and on-line medical command. *Prehosp Disaster Med.* 1995 Jan-Mar;10(1):3-9.





Approved 9/04/24, Effective 1/15/25, replaces all prior versions

14I - INTERHOSPITAL TRANSFERS



A patient may require a transfer from one hospital to another hospital if:

- 1. Patient evaluation at the original hospital reveals care needs unavailable at that hospital.
- 2. Another hospital is preferred by the patient, the patient's legal representative, or the patient's established physician(s).

A hospital must agree to facilitate a patient transfer (regardless of patient's financial status) if the patient meets any of the above criteria.

Any interhospital transfer must be arranged as a practitioner/physician-to-physician transfer in accordance with Federal regulations.

Prior to any interhospital transfer, the EMS professional must receive appropriate transfer paperwork, including an adequate summary of the patient's condition, current treatment (including nursing and practitioner/physician evaluation notes, lab results, radiology results and films, possible complications that could occur during transfer, and any further medical information deemed necessary by the EMS professional or physician(s). Any anticipated interhospital transfer treatment orders are to be written and signed by the transfer initiating practitioner/physician.

Prior to any interhospital transfer, if the EMS professional is concerned that the patient is not stabilized to the extent possible for transport, the EMS professional shall review his /her concerns with the transferring practitioner/physician with a goal to ensure appropriate clinical care is performed to further stabilize the patient. In the **rare** instance in which the EMS professional and transferring practitioner/physician cannot agree on the stability of the patient and/ or further care necessary prior to the interhospital transfer, the EMS professional is to consult with the accepting physician at the receiving hospital to review these concerns. If in such situation the receiving hospital has automatically accepted the patient for care to the "emergency group/doctor", the EMS professional is to discuss concerns with the on-duty emergency physician at that hospital. If the EMS professional cannot rapidly resolve the situation with the transferring practitioner/physician and receiving physician, the EMS professional is to notify the Chief Medical Officer for intervention, ideally via a recorded line.





Approved 9/04/24, Effective 1/15/25, replaces all prior versions

#### PROTOCOL 14I: Interhospital Transfers, cont.

The overriding principle for all aspects of interhospital transfer is matching patient needs with adequate provider knowledge and skill, equipment and infrastructure that provide continued patient safety during transport.

It is the professional and ethical responsibility of an EMS professional as well as of an EMS organization to not accept or perform an interhospital transfer that involves monitoring and treatment exceeding their scope of authorized practice, training, and/or ability.

An EMS professional must be licensed as an EMT – I85 or higher to verify patency of vascular access. IV fluid type and flow rate must be specified in written practitioner/physician orders and verified prior to interhospital transfer. Any IV fluid bag supplied must contain enough solution to accommodate the expected interhospital transport time.

Any IV infusion medications must be specified in written practitioner/physician orders and verified prior to transfer. The paramedic must be comfortable managing all medications ordered or anticipated to be given during the interhospital transfer. Questions to the contrary should be routed to the supervisor, with subsequent physician consultation as needed. There is a limit of 4 concurrent IV infusion medications for paramedic-only accompanied interhospital transfers.

All interhospital transfer patients with IV infusion medications will be continuously cardiac monitored, including monitoring pulse oximetry during transport. Waveform capnography should be utilized as indicated by appropriate protocols. Blood pressure monitoring will be at least as frequently as every 10 minutes with a minimum of two blood pressure recordings. The interhospital transfer orders may specify more frequent measurements.

During interhospital transfer, should the patient experience signs or symptoms of intolerance (significant side effects) to the IV infusion medication(s) or the IV infusion pump indicates an error not easily addressed by the paramedic, stop the infusion and consult the transferring hospital's on-line medical control for direction.

Mechanical ventilation settings must be confirmed with either the transferring practitioner/physician or a respiratory therapist. The paramedic must review and confirm ventilation rate, tidal volume, FiO2 (50% or 100%), and positive-end expiratory pressure (PEEP) settings. If at any time during interhospital transfer mechanical ventilation malfunctions, institute bag-valve assisted ventilations with 100% O2 while troubleshooting the mechanical ventilator and airway circuit. Ensure the patient receives appropriate oxygenation and ventilation continuously.

All indwelling devices and lines (e.g. chest tube(s), naso/orogastric tube, PEG/G/J-tube, surgical drain(s), intra-aortic balloon pump (IABP), ventricular assist device (VAD), wound vacuum) must be reviewed with either the transferring practitioner/physician or appropriate nursing personnel. Potential complications during transfer should be discussed and contingency plans reviewed. If the paramedic feels unable to safely monitor and maintain any indwelling device, he or she is to request appropriate nursing or ancillary personnel from the transferring hospital to accompany the patient during transfer.





Approved 9/04/24, Effective 1/15/25, replaces all prior versions **PROTOCOL 14I: Interhospital Transfers, cont.** 

Under these conditions, EMS personnel will not begin the transfer until such request is accommodated.

\*\*\*For specialized patients not ordinarily transported by EMS professionals (e.g., high-risk obstetrical patients, neonates) or for any patient with a condition requiring interhospital assessment and/or treatment beyond expected EMS professional scope of practice, an appropriately trained healthcare professional is to accompany the transporting EMS professionals to best provide interhospital transfer care.

For acute stroke patients either having received alteplase (tPA®) just prior to interhospital transfer or that will be continuing to receive alteplase during interhospital transfer, specific documentation and treatment should include:

- 1. Vital signs prior to transport and every 10 minutes enroute. Verify that systolic blood pressure is less than 180 mmHg and diastolic blood pressure is less than 105 mmHg. If blood pressure exceeds these limits, the transferring hospital is to lower the blood pressure via antihypertensives for further vascular stabilization prior to transport.
- 2. Stroke neuro-exam at time of interhospital transfer, utilizing the Los Angeles Prehospital Stroke Screen.
- 3. Oxygen administration via NC or NRB if dyspnea or SpO2 <94% at room air.
- 4. Head of cot elevated at approximately 15 degrees if tolerated and low risk of aspiration.
- 5. Patient NPO status, including medications, to protect against aspiration.
- 6. Documentation of total dose and time of IV alteplase bolus (if dose is completed prior to transfer) and when infusion started (and completed, if applicable).
- 7. Infuse all alteplase from tubing by infusing saline through same tubing set following alteplase dose.
  - When bottle appears empty, there is still some alteplase left in the tubing which must be infused.
  - Remove the IV tubing connector from the bottle and attach it to a newly spiked bag of normal saline and re-start infusion at the previous rate used. This will ensure that the remainder of the alteplase is infused.
- 8. Anti-hypertensive therapy adjustment enroute:
  - If labetalol IV infusion started at sending facility: Increase infusion rate by 2 mg/min every 10 minutes (to maximum of 8 mg/min) until desired decrease in BP:
    - Sys BP <180 mmHg and Dia BP <105 mmHg
  - If nicardipine IV infusion started at sending facility: Increase infusion rate by 2.5 mg/hr every 10 minutes (to maximum of 15 mg/hr) until desired decrease in BP: Sys BP <180 mmHg and Dia BP <105 mmHg</li>
  - Discontinue anti-hypertensive infusion for any one of the following:
     Sys BP <140 mmHg, Dia BP <80 mmHg, or heart rate <50 per minute</li>





Approved 9/04/24, Effective 1/15/25, replaces all prior versions

PROTOCOL 14I: Interhospital Transfers, cont.

Common IV Medications During Interhospital Transfer (Infusions are continuation of infusions started at the transferring facility, not initiations)

Class of Medication Significant Side Effects

**Sedatives** 

Diazepam (Valium<sup>®</sup>) Diprivan (Propofol<sup>®</sup>) Lorazepam (Ativan<sup>®</sup>) Midazolam (Versed<sup>®</sup>) Respiratory depression, Hypotension

**Opiate Analgesics** 

Fentanyl (Sublimaze®)
Hydromorphone (Dilaudid®)
Meperidine (Demerol®)
Morphine
Nalbuphine (Nubain®)

Respiratory depression, Hypotension

**Hypertension Control Agents** 

Labetalol (Normodyne<sup>®</sup>, Trandate<sup>®</sup>) Nicardipine (Cardene<sup>®</sup>) Nitroprusside(Nipride<sup>®</sup>) Hypotension, Symptomatic bradycardia Symptomatic tachycardia, Ventricular dysrhythmias

**Acute Coronary Syndrome Agents** 

**Anti-platelet (Clot Inhibitors)** 

Abciximab (ReoPro®) Eptifibatide (Integrilin®) Bleeding

**Anti-coagulant (Clot Inhibitors)** 

Heparin Bleeding

**Thrombolytic ("Clot Buster")** 

Alteplase (tPA®) Reteplase (Retavase®) Tenectaplase (TNKase®) Bleeding

**Anti-anginal (Coronary Vasodilator)** 

Nitroglycerin (Tridil<sup>®</sup>) Hypotension





Approved 9/04/24, Effective 1/15/25, replaces all prior versions

PROTOCOL 14I: Interhospital Transfers, cont.

Common IV Medications during Interhospital Transfer, cont. (Infusions are continuation of infusions started at the transferring facility, not initiations)

**Class of Medication** 

**Significant Side Effects** 

**Cardiac Anti-arrhythmics** 

Amiodarone (Cordarone®, Pacerone®) Diltiazem (Cardizem®) Lidocaine Procainamide Hypotension, Symptomatic bradycardia Symptomatic tachycardia, Ventricular dysrhythmias

**Vasopressors (Hypotension Treatment)** 

Dobutamine (Dobutrex®)
Dopamine (Intropin®)
Epinephrine
Norepinephrine (Levophed®)
Phenylephrine (Neosynephrine®)

Hypertension, Symptomatic tachycardias Ventricular dysrhythmias

**Volume Expanders (Hypovolemia Treatment)** 

Albumin Dextran Hetastarch (Hespan®) Plasma protein fraction (Plasmanate®) Allergic reactions ranging from itching only to more serious reactions of hives, (urticaria), respiratory distress (typically bronchospasm), tachycardia, and hypotension (evidence of anaphylaxis).

#### **Blood Products (Anemia or Coagulopathy Treatment)**

Cryoprecipitate Frozen Plasma (FFP) Packed Red Blood Cells (PRBC) Platelets Whole Blood Allergic reactions ranging from itching only to more serious reactions of hives, (urticaria), respiratory distress (typically bronchospasm), tachycardia, and hypotension (evidence of anaphylaxis).

#### **Gastrointestinal Bleeding Control Agents**

Esomeprazole (Nexium® – acid reducer) Octreotide (Sandostatin® – varices constrictor) Pantoprazole (Protonix® – acid reducer) None

#### **Acid-Base Metabolism Agents**

Sodium Bicarbonate

None





Approved 9/04/24, Effective 1/15/25, replaces all prior versions

PROTOCOL 14I: Interhospital Transfers, cont.

Common IV Medications during Interhospital Transfer, cont. (Infusions are continuation of infusions started at the transferring facility, not initiations)

Class of Medication Significant Side Effects

**Hyperglycemia Control Agents** 

Insulin Hypoglycemia-related complications

**Electrolyte Replacement** 

Potassium chloride (KCL) Ventricular dysrhythmias

**Seizure Control Agent** 

Phenobarbital

Fosphenytoin (Cerebyx®)

Magnesium (for eclampsia)

Phenytoin (Dilantin®)

Respiratory depression, Hypotension,

Symptomatic bradycardia

**Bronchospasm Control Agents** 

Aminophylline (Theophylline<sup>®</sup>) Symptomatic tachycardias, Hypertension

**Pregnancy - Related Agents** 

Oxytocin (Pitocin®—stimulates uterine contraction Hypoter Inducing labor and controls uterine bleeding) tachyca

Hypotension (if rapid infusion), Symptomatic tachycardias, Hypertension

#### Antimicrobials/Antibiotics

Aminoglycosides (e.g. gentamicin)
Antifungals (e.g. fluconazole)
Anti-TB (e.g. isoniazid - INH)
Anti-viral (e.g. acyclovir)
Carbapenams (e.g. imipenem)
Cephalosporins (e.g. ceftriaxone)
Macrolides (e.g. azithromycin)
Penicillins (e.g. ampicillin; piperacillin)
Quinolones (e.g. levofloxacin)
Sulfonamides (e.g. TMP-SMX, Bactrim®)
Other categories (e.g. clindamycin, vancomycin)

Allergic reactions ranging from itching only to more serious reactions of hives (urticaria), respiratory distress (typically bronchospasm), tachycardia, and hypotension (evidence of anaphylaxis). In some cases, a localized phlebitis (pain at infusion site with redness of vein) may occur due to irritation cause by the infusion itself. While the infusion is to be stopped, this usually is not a true allergy.





Approved 9/04/24, Effective 1/15/25, replaces all prior versions

PROTOCOL 14I: Interhospital Transfers, cont.

**Priority and Timing for Interfacility Transfer Requests:** 

Priority 1 Clinical Condition – Immediate Life Critical Intervention at Receiving Hospital Facility Time Standard is 911 Call to Arrival = Response 10:59 or less with use of Red Lights & Sirens (RLS)

Once ambulance is assigned cannot be re-assigned unless closer unit and only one re-assignment total

Acute ST Elevation Myocardial Infarct

Transferring Facility – No Interventional Cardiology
Receiving Facility – Interventional Cardiology/Cardiac Cath Lab

Acute Thromboembolic Stroke

Transferring Facility – No Interventional Neurology Receiving Facility – Interventional Neurology & Procedure Imminent

Acute Aortic Dissection

Transferring Facility – No Vascular Surgery
Receiving Facility – Vascular Surgery & Surgery Imminent

Acute GI Bleeding with Hemodynamic Instability

Transferring Facility – No Gastrointestinal/Colorectal Capability
Receiving Facility – Gastrointestinal/Colorectal Capability and Endoscopy Imminent

Acute Amputation with Limb Salvage Attempt/Limb Ischemia/Arterial Occlusions

Transferring Facility – No Vascular Surgery/Interventional Radiology

Receiving Facility – Vascular Surgery/Interventional Radiology and Intervention Imminent

Suspected or Confirmed Ectopic Pregnancy with Hemodynamic Instability
Transferring Facility – No Obstetric Surgery
Receiving Facility – Obstetric Surgery & Surgery Imminent

Active Labor with Evidence for Complicated Delivery – Breech/Limb Position by Ultrasound Transferring Facility – No Obstetric Surgery Receiving Facility – Obstetric Surgery & Surgery Imminent

Acute Angle Closure Glaucoma/Acute Retinal Artery Occlusion/Acute Vision Loss Imminent Transferring Facility – No Ophthalmology Receiving Facility – Ophthalmology & Intervention Imminent

Level I/II Trauma with Hemodynamic Instability
Transferring Facility – No Trauma Surgery/Capability
Receiving Facility – Trauma Surgery/Capability





Approved 9/04/24, Effective 1/15/25, replaces all prior versions

PROTOCOL 14I: Interhospital Transfers, cont.

Priority 2 Clinical Condition – No Immediate Time Critical Intervention at Receiving Hospital Facility

Time Standard is 911 Call to Arrival = Response 24:59 or less without use of Red Lights & Sirens Once ambulance is assigned cannot be re-assigned unless Priority 1 Call and only one re-assignment total

Post Cardiac Arrest with Hemodynamic Stability

Transferring Facility – No ICU and/or Cardiology Services

Receiving Facility – ICU and Cardiology Services

Active Labor with Routine Delivery Planned
Transferring Facility – No Obstetric Surgery
Receiving Facility – Obstetric Surgery

Dialysis Required with Hemodynamic Stability

Transferring Facility – No Dialysis Capability

Receiving Facility – Dialysis Capability with Dialysis Imminent

Ground Component of Air Ambulance Transport Assist Estimated Landing Time 25 Mins or Less

Priority 3 Clinical Condition – No Immediate Time Critical Intervention at Receiving Hospital/Facility

Time Standard is 911/non-911 Call to Arrival = Response 59:59 or less without use of Red Lights & Sirens

Once ambulance is assigned cannot be re-assigned unless Priority 1 or 2 Call and only two re-assignments total

Hospital ED or Inpatient Transfer

Transferring Facility – Limit of Care Capabilities/Course of Treatment Reached Receiving Facility – Higher Care Capabilities/Ongoing Course of Treatment Possible

Hospital ED to Residence/Nursing Facility Post ED Evaluation and Treatment

Priority 4 Clinical/Logistic Condition – No Immediate Time Critical Intervention at Receiving Hospital/Facility

Time Standard is 911/non-911 Call to Arrival = 15 minutes within scheduled pick-up appointment time

Once ambulance is assigned cannot be re-assigned unless Priority 1, 2, or 3 Call and only four re-assignments total

Scheduled Outpatient Dialysis Care

Hospital Inpatient to Residence/Nursing Facility Post ED Evaluation and Treatment

Inpatient Bed Shortages and Hospital to Hospital or Facility to Facility Patient Movement Due to Bed Shortage






Approved 9/04/24, Effective 1/15/25, replaces all prior versions

#### PROTOCOL 14I: Interhospital Transfers, cont.

#### High Flow Nasal Cannula during Interhospital transfer

Nasal high flow creates breath and flow-dependent pressure, making inspiration easier and promoting slow, deep breathing on expiration, thereby increasing alveolar ventilation.



Any patient on High Flow Nasal Cannula (HFNC) requiring transfer to another facility or being discharged home with appropriate equipment in place may be transported utilizing the hospital's high flow system (if allowed by facility) or change out HFNC components as needed to allow for transport on the same settings.

Titrations can be made as needed during transport to maintain therapeutic oxygenation and ventilatory support.





#### Medical Literature References 14I – Interhospital Transfers

- 1. American College of Emergency Physicians. Appropriate Interhospital Patient Transfer. *Ann Emerg Med.* 2009;54:141.
- 2. Warren J, Fromm RE Jr, Orr RA, Rotello LC, Horst HM; American College of Critical Care Medicine. Guidelines for the inter- and intrahospital transport of critically ill patients. *Crit Care Med.* 2004 Jan;32(1):256-62.
- 3. National Assoc of EMS Physicians. Medical Direction of Interfacility Transport. *Prehosp Emerg Care*. 2000;4:361-4.





Approved 9/04/25, Effective 1/15/25, replaces all prior versions

#### 14J - SCENE COORDINATION

Emergency Medical Services in Metropolitan Oklahoma City and Tulsa are provided by several agencies that must interact cooperatively to achieve the goal of quality patient care. Interactions between on-scene personnel must be predictable and consistently professional. The following protocol has been developed to facilitate optimal scene coordination including transfer of care and timeliness of patient transport. Additional benefits include promoting a collaborative practice of EMS medicine and improved scene safety for patients and EMS professionals.

If a disagreement regarding patient care occurs, protocol, OMD or OLMC guidance is to be sought, avoiding any unnecessary delay in transport of critical patients.

The following guidelines are most commonly applicable to scenes involving a single or limited number of patients. Mass casualty incidents should be managed per Protocol 15A: Multiple Patient Scene/Mass Casualty Event Concepts.

- 1. The first arriving crew will bring all indicated mobile medical equipment to the patient side.
- The first arriving crew will relay information regarding current level of professional (EMT, EMT-I, AEMT, Paramedic), scene safety/staging, scene access, and equipment needs, as appropriate, to additional responding crews through 800 MHz radio systems, shared frequencies, or relay through respective communication centers.
- 3. The transporting agency crew will bring all indicated mobile medical equipment and the stretcher to the patient side, unless otherwise notified by crew(s) on-scene.
- 4. The first on duty OMD credentialed EMS professional on-scene will assume charge of and direct patient care. If a paramedic is not present and the call type and/or patient condition indicates need for paramedic assignment and scope of practice care, the on-scene officer or designated personnel in charge will brief the first arriving paramedic on assessment and treatment of the patient(s). The paramedic will verbally acknowledge receiving the patient-centered briefing, then assume charge of and direct patient care.
- 5. In the event there is a District Chief(s)/EMS Supervisor(s)/EMS Officer(s) on scene, care should then be coordinated through these supervisory paramedics. This does not mean the care interventions must all be personally performed by these supervisory paramedics if other OMD credentialed paramedics are on scene, but the care plan should be coordinated by these supervisory paramedics. In the event there is a differing opinion as to proper care among onscene supervisory paramedics, the transporting agency's on-scene supervisory paramedic is to take the lead. As per the highlighted statement above, OMD or OLMC guidance is to be sought if needed to further resolve any time-sensitive care disagreements.
- 6. On arrival of the transporting unit, the officer or designated person in charge will brief the transporting agency paramedic (if the call type and/or patient condition indicates need for paramedic assignment and scope of practice care) on assessment and treatment of the





Approved 9/04/25, Effective 1/15/25, replaces all prior versions

#### Protocol 14J: Scene Coordination, cont.

patient(s). The transporting agency paramedic will verbally acknowledge receiving the patient-centered briefing, then assume charge of and direct patient care. In the event the transporting agency paramedic and a non-transporting agency paramedic arrive on scene simultaneously, the transporting agency paramedic will assume charge of and direct patient care, though is expected to remain cognizant of clinical input from all relevant OMD credentialed providers on scene.

- 7. If the transporting agency paramedic (if the call type and/or patient condition indicates need for paramedic assignment and scope of practice care) is first on-scene, as soon as it is clinically practical, the transporting agency paramedic will brief subsequent arriving professionals on assessment and treatment of the patient(s) and assign tasks consistent with treatment protocols.
- 8. Avoid unnecessarily repeating questions to the patient that have been answered.
- 9. All personnel will assist each other in every possible way (i.e. moving/gathering of equipment, lifting and movement of stretcher).
- 10. Once charge of patient care is appropriately transferred, a confirmatory patient assessment by the transporting agency paramedic may be necessary. As a routine practice, such reassessments should not delay ongoing care and/or timely transport. Transport should not be delayed or interrupted for patient care documentation.
- 11. If a patient has been loaded into the ambulance prior to additional crew arrival(s), at least one additional crew will inquire with the transporting agency paramedic (if the call type and/or patient condition indicates need for paramedic assignment and scope of practice care) if they can be of assistance.
- 12. All personnel will work cooperatively and in a professional manner to ensure ongoing high quality of patient care. If any EMS personnel on-scene believes patient condition requires additional support, including accompanying the patient during transport, this shall be discussed with the transporting agency paramedic (if the call type and/or patient condition indicates need for paramedic assignment and scope of practice care)..
- 13. The transport agency crew will accept response cancellations from non-transport agency crew on-scene when clinically appropriate. Conversely if non-transport agency personnel are informed by the on-scene transporting agency crew that no clinical assistance is required the non-transporting agency units will cancel their response, unless non-clinical scene characteristics dictate a continued response.
- 14. In the case of a BLS 911 upgrade to an ALS/Paramedic level call, the paramedic who receives report will perform a physical examination and assessment prior to making decisions regarding final disposition. As a reminder, once a BLS 911 upgrade to ALS/Paramedic assignment has been made, the paramedic may not "downgrade" the call back to BLS 911 for non-paramedic transport or refusal of care by non-paramedic.
- 15. The EMS System for Metropolitan Oklahoma City and Tulsa supports the National Incident Management System guidelines, even in single patient encounters. Be familiar with NIMS (See Protocol 15A: Multiple Patient Scenes/Mass Casualty Event Concepts) and be able to utilize when indicated.





Approved 9/04/25, Effective 1/15/25, replaces all prior versions

Protocol 14J: Scene Coordination, cont.

#### Special Note: ALS First On-Scene at 911 BLS Assigned Response


In the rare instance that an OMD credentialed ALS professional is first on scene of a 911 BLS assigned response, they should assess all patients and determine if there is a need for the response to be upgraded to an ALS level call. If ALS care is needed, the ALS professional will assume charge of and direct patient care, until transitioning ALS care to an ALS transport unit-based paramedic (if applicable). If the ALS professional determines that no ALS-only scope of practice patient care is required, the ALS professional can transition care to the 911 BLS EMTs. The transporting EMTs shall verbally acknowledge receiving transition of care, then assume BLS scope of practice patient care.





Approved 9/04/24, Effective 1/15/25, replaces all prior versions

#### 15A – MULTIPLE PATIENT SCENES/ MASS CASUALTY EVENT CONCEPTS



A Multi-Patient Scene (MPS) occurs when an incident involves more than one patient, but less than 5 critical patients and less than 10 total patients.

A Mass Casualty Incident (MCI) occurs when an incident involves several patients, specifically including five or greater critical patients or ten or more total patients, regardless of patient priority composition.

Incident command at multiple patient scenes (MPS) or mass casualty incidents (MCI) will be assigned according to the National Incident Management System (NIMS) guidelines and a unified command team consisting of representatives of police, fire, and EMS should be rapidly assigned and coordinated to ensure safe, efficient, and effective operations.

#### Multi-Patient Scene Tasks:

- 1. Initial Size-up Actions: (these are the same for Mass Casualty Incidents)
  - a. Park initial arriving apparatus in safe location at scene perimeter to avoid loss of its availability/use.
  - b. Advise dispatch:
    - i. Incident location (if different from initial dispatch).
    - ii. Incident type (transportation accident, fire, etc. if different from initial dispatch).
    - iii. Estimated number of patients.
    - iv. Numbers & types of additional resources needed.
    - v. Any hazardous conditions (weather, electrical, structural, toxic chemicals, etc).
    - vi. Identify the "HOT ZONE/Direct Threat" or "Immediate Danger Zone" if applicable.
    - vii. Best route & access to scene (if appropriate).
    - viii. Staging area location (if staging indicated).





Approved 9/04/24, Effective 1/15/25, replaces all prior versions

PROTOCOL 15A: Multi-Patient Scenes/Mass Casualty Incident Concepts (cont.)

#### Multi-Patient Scene Tasks, cont.:

c. Check in with Incident Command to determine ICS role. The medical treatment and transport of injured patients will normally be done through the position of Medical Branch Director and subordinate positions headed by Group Supervisors. However, the Incident Commander will determine which positions, if any, he or she feels needs to be filled.

#### 2. Medical Branch Director:

- a. Reports to the Operations Section Chief.
- b. Don identification vest for position.
- c. Establishes Casualty Collection Point(s) and Ambulance Exchange Point (AEP)
  Transport Areas (if indicated) and assigns individuals to the role of Group Supervisors
  (Med Boss) for each area.
- d. Maintains adequate span of control within Medical Branch.
- e. Establish appropriate EMS communications with appropriate response elements (ie. Annex H, MERC, staging, logistics).
- f. Establish and maintains communications with assigned Group Supervisors (unit leader).
- g. Oversees the Casualty Collection Points (CCP) transportation and accountability of patients created by incident.
- h. Monitors the potential or actual effect of the incident on the existing medical infrastructure and communicates such with the Operations Section Chief, MERC, and/or Annex H.
- i. Determines resource requirements to meet the medical needs of the incident and communicates needs to Operations Section Chief or designated response element.
- j. Determines the need for specialized medical resources and processes requests for such elements through appropriate channels.
- k. Provides situation updates and reports to the Operations Section Chief, MERC, and/or Annex H.

#### 3. Group Supervisor (Unit Leader/Med Boss):

- a. Establishes Area to perform assigned tasks.
- b. Determine resource and staffing needs for Area of responsibility and communicates needs to Medical Branch Director.
- c. Follows assigned duties as outline in Agency Plan, Task Cards, or Job Action Sheets.
- d. Provides situational updates and reports to the Medical Branch Director.
- e. Establish communications with the Medical Branch Directors and other needed response elements.
- f. Monitors safety and welfare of patients and assigned personnel.
- g. Ensures patient tracking and accountability of injured patients in assigned Area.





Approved 9/04/24. Effective 1/15/25, replaces all prior versions

#### PROTOCOL 15A: Multi-Patient Scenes/Mass Casualty Incident Concepts (cont.)

#### Mass Casualty Incident Tasks, con't:

#### Casualty Collection Point Tasks:

- Initial triage is at casualty locations unless hazards indicate that rapid extrication or casualty self-extrication should occur to a designated area safe for triage operations. In some instances, the use of priority-specific colored tape (red, yellow, green, grey, black/white, orange for decontaminated patients) may be utilized to mark patients in the absence of readily usable triage tags.
- 2. Perform first pass (initial) triage. Implement life-saving interventions (i.e., bleeding control, mange chest trauma and open the airway by positioning). Move quickly to ensure all casualties are identified and triaged to minimize loss of life and limb.
- 3. First response units (non transport) will attach tape to patients directly on their body. The left extremities should be utilized unless extremely injured.
- 4. Triage Tags will be utilized by transport units/aircraft to properly identify and track patients.
- 5. Use a reliable method to count the number of patients in each category. This information will need to be relayed to the CCP Group Supervisor (Med Boss) officer, and in turn, the Medical Branch Director.
- 6. Direct ambulatory patients to the GREEN Casualty Collection (CCP) Area when it is established. Use discretion in allowing GREEN patients to assist in caring for the YELLOW and RED patients while those more serious casualties are awaiting extrication to the CCP areas. ALL persons involved in the incident are to be triaged, taped, and tagged those without apparent injuries should be tagged GREEN.
- 7. Report number of casualties in each category and in total to the Triage Group Supervisor (Med Boss).
- 8. Repeat triage sequence when possible and note changes in any casualty's condition. Perform a more detailed "MARCH" assessment, provide treatment, and write-in information on the tape while casualties are being extricated to the casualty collection point.





Approved 9/04/24, Effective 1/15/25, replaces all prior versions

PROTOCOL 15A: Multi-Patient Scenes/Mass Casualty Incident Concepts (cont.)

#### Mass Casualty Incident Tasks, con't:

#### Casualty Collection Point Tasks:

- 1. Establish CCP(s) area in consultation with the Medical Branch Director regarding location. Think BIG to allow adequate space to treat casualties. Ensure the location promotes relative ease of ambulance loading and egress.
- 2. Request, assign, utilize, and oversee appropriate clinical personnel caring for patients.
- 3. Assemble into crews of at least 2 personnel equipped with extraction equipment (mega movers or back board for assignment by the Med Boss to perform BASIC packaging and extrication of triaged casualties into the Red, Yellow, and Green CCP areas. The treatment officer (med boss) may choose to have separate personnel perform treatment once inside the CCP Area, depending on the logistics of the particular call. All persons involved in the incident triaged Green due to very minor or no apparent injury are to be kept in the Green CCP Area until more fully evaluated. These individuals will be released at an appropriate time by the Transport Group Supervisor (Unit Leader). Depending on the circumstances, the Green casualties may be transported early or in large groups using alternative transport means.
- 4. Transport teams on the clinical side of the triage tag, circle injuries on the body diagram (if present), note the BP, pulse, and respirations. Note any IM or IV medication given and the time it was given. On the administrative side of the tag, note the time, date, patient name, address, city, state, and past medical history and prescriptions. Record the primary EMS caregiver.
- 5. If a casualty's condition worsens (e.g. Yellow to Red; Green to Yellow) inside the CCP Area, apply a new triage tape/tag indicating the more serious condition (leaving the original tag in place to indicate a change in condition occurred) and move the patient to the appropriate location in the CCP Area. Notify the Treatment Group Supervisor (Med Boss) of any change in casualty condition so that this may be recorded for overall patient accountability and reported to the Medical Branch Director.





Approved 9/04/24, Effective 1/15/25, replaces all prior versions PROTOCOL 15A: Multi-Patient Scenes/Mass Casualty Incident Concepts (cont.)

#### Mass Casualty Incident Tasks, con't:

#### **Transportation Area Tasks:**

- 1. Establish ambulance exchange point (AEP) patient loading zone. Consider proximity to casualty collection point (CCP) area along with ambulance approach AND exit routes. Establish ambulance traffic routes that prevent ambulances from having to back-up to load patients. This makes for safer and more efficient transport operations. While multiple ambulances may be in staging, minimize the number of ambulances in the ambulance extraction point load zone. This makes for more accurate and efficient transport operations. Work with staging to ensure at least 1 ambulance is always available for the AEP zone. Ensure vehicle operators stay with their ambulances to ensure as soon as patients are loaded, the ambulance leaves.
- 2. Assign Unit Leaders to appropriate needed subordinate roles such as tracking and communications. The Transportation Area will likely require the coordinated effort of several people and can quickly overwhelm one individual. Loss of patient accountability can be the result of an inadequately staffed Transportation Area.
- 3. Communicate with CCP/Treatment Group Supervisor (Med Boss) when ambulances are available for transport. NO MORE THAN ONE CATEGORY RED PATIENT PER AMBULANCE. May take another patient if yellow/green in category.
- 4. Supervise the assignment and loading of patients into available transport.
- 5. Communicate with response elements (Annex H, MERC, Communications Center) to determine hospital capacity and appropriate destination of patients based upon clinical condition(s) and vehicle operator familiarity with destination.
- 6. Consider the use of alternate means of transportation if indicated (busses, specialty vans).
- 7. Before patient leaves the scene to destination, the accountability process should be completed by whatever means being used (triage tag identifier slip, patient log).
- 8. Notify the Medical Branch Director when all patients have been cleared from the scene and transported. Maintain and secure records for the Medical Branch Director and secure the patient loading area.





Approved 9/04/24, Effective 1/15/25, replaces all prior versions PROTOCOL 15A: Multi-Patient Scenes/Mass Casualty Incident Concepts (cont.)

#### Mass Casualty Incident Tasks, con't:

#### Staging Group Supervisor Tasks:

- If not already established and/or determined by Incident Command, establish staging area for medical transportation resources. Staging area should be an area large enough to contain numerous transportation assets, be far enough away so units don't get caught in incident, but close enough to ambulance exchange point (AEP) to allow for short drive times.
- 2. Select and communicate a desired travel route for resources assigned to the Staging Area. This route should allow for easy access but should take units away from the impacted area.
- Staging Area for medical assets may be co-located with staging for other response assets, or may be a stand-alone area, depending on the desire of the Incident Commander. If colocated with other response assets, ensure medical assets are grouped together for accountability and an accurate assessment of available resources.
- 4. The Staging Group Supervisor (Unit Leader) should coordinate an orderly arrangement of arriving apparatus to allow for ease of ambulance ingress to the transport loading zone. Medical equipment assets (cache, trailers) should also be organized to allow for rapid deployment upon request.
- 5. The Staging Group Supervisor (Unit Leader) or the officer's designee should maintain a log of available resources in staging and communicate with the Medical Branch Director resource levels as appropriate and as requested by the Medical Branch Director.
- 6. The Staging Officer or the officer's designee should assure ambulance or specialty transport crews stay with their assigned vehicles to assure rapid availability of the asset when requested at the transport loading zone.
- 7. Deliver equipment needed in the casualty collection point (CCP) that is requested from staging in an organized cache with a minimum of personnel leaving the staging area to deliver this equipment. Alternatively, all the requested equipment may be sent to the casualty collection point on one designated vehicle.
- 8. Assign and deploy transportation assets to the ambulance exchange point (AEP) per the request of the Medical Branch Director or the Transportation Group Supervisor depending on the established communication pathways.





Approved 9/04/24, Effective 1/15/25, replaces all prior versions

#### PROTOCOL 15A: Multi-Patient Scenes/Mass Casualty Incident Concepts (cont.)

#### Mass Casualty Incident Tasks, con't:

#### Mass Casualty Medical Communications:

- 1. Medical communications during a mass casualty incident, like all other incident communications, are of critical importance and often will determine the level of effectiveness and success of the operation. Basic communication principles should be used during an incident.
  - a. Use of interoperable radio channels so all agencies are able to communicate.
  - b. Following the overall incident communications plan established by the Incident Commander.
  - c. Establishing assigned, clear, and understood lines of communications; who will communicate with whom, for what reason, and by what method.
  - d. Use of multiple and redundant means of communications including, but not limited to, radio, data, phone, runners, face-to-face, and even hand signals.
  - e. Preparation for communications failure and immediately switching over to one of the established redundant communication means.
  - f. Ensuring communications sent receive a response of some manner to ensure the loop has been closed.
- 2. Medical communications from the scene of an MCI, depending on complexity and command structure, often involves up to three different levels of communications:
  - i. Communications (internal) with other Incident Command System elements
  - ii. Operations Section Chief or designee(s)
  - iii. Unified Command medical representatives
  - iv. Logistics, Planning, Admin/Finance if appropriate
  - b. Communications (internal) within the scene medical response infrastructure:
    - *i.* Casualty Collection Points (CCP), Transportation, Staging Group Supervisors
  - c. Communications (external) with local, county, or regional medical coordination entities:
    - i. Local Emergency Response Coordinator (LERC)
    - ii. County Public Health Annex H Representative
    - iii. Medical Emergency Response Center (MERC)





Approved 9/04/24, Effective 1/15/25, replaces all prior versions Mass Casualty Incident Tasks, con't:

#### Mass Casualty Medical Communications:

- 3. After assigning support positions, one of the first activities of the Medical Branch Director should be to establish redundant communications pathways with the ICS structure, subordinate Group Supervisors (Unit Leader), and other medical response elements by:
  - a. Obtaining the ICS Communication Plan (incident channels etc).
  - b. Determine reporting lines and redundant means of communication with Groups Supervisors (Unit Leader). Example: Transport requesting assets through Medical Branch or directly to Staging.
  - c. Establishing and communicating manner for all communications acknowledgments.
  - d. Establish communications via radio, e-mail, or phone with outside medical coordination entities.
  - e. Advise the ICS infrastructure of communication pathways for incorporation into updated ICS communication plan.





Medical Literature References 15A – Multiple Patient Scenes/Mass Casualty Event Concepts


 Klassen AB, Marshall M, Dai M, Mann NC, Sztajnkrycer MD. Emergency Medical Services Response to Mass Shooting and Active Shooter Incidents, United States, 2014–2015. Prehospital Emergency Care. 2019;23(2):159-166. doi:10.1080/10903127.2018.1484970





Approved 9/04/24, Effective 1/15/25, replaces all prior versions

15B - REGIONAL EMS SYSTEM (REMSS) ACTIVATION PROCEDURE



All requests for REMSS deployment will need to be validated through information provided on the request form contained within this protocol. The REMSS deployment request form can also be found within the Oklahoma REMSS Ambulance Strike Team (AST) Guidelines.

Medical Branch Request for REMSS Assistance is accomplished in the following sequence:

- 1. Before any REMSS assets can be requested, a functioning Incident Command Structure (ICS) with an identified Medical Branch will need to exist.
- 2. Depending upon local county emergency operational procedures, the Medical Branch can request REMSS assets through one of the following means:
  - a. through the ICS to the county Emergency Operations Center (EOC) and Annex H Health and Medical Representative (if EOC in operation)
  - b. through direct contact with Regional Medical Emergency Response Center (MERC) in Regions 1,3,5,6,7,8 or the Regional Multiple Agency Coordination Center (MACC) in Regions 2, 4
  - c. calling the Incident Resource Hotline at 1-800-800-2481 ("top down" method)
- 3. Any request for a REMSS team will need to be accompanied by:
  - a. Specific number/types of ambulances and trailers needed (Who/What needs to go?)
  - b. Reason for request (Why are they needed?)
  - c. Expected mission for REMSS team (What will they do?)
  - d. Staging location for REMSS team upon incident arrival (Where will they go?)
  - e. Known scene or access to scene hazards (What hazards do they need to expect?)
  - f. Contact name and phone number(s) for updates/requests for additional information (Who should be contacted during the REMSS response and upon arrival?)





Approved 9/04/24, Effective 1/15/25, replaces all prior versions

#### Protocol 15B: Regional EMS System (REMSS) Activation Procedure:

Once a valid request, containing the above information, is received for REMSS deployment, the following sequence of actions occurs to effect the deployment:


- Oklahoma State Office of Emergency Management (OEM) receives a call from the Incident Resource Hotline (1-800-800-2481) for REMSS assistance. An OEM representative will give the request to the Emergency Support Function 8 - Public Health and Medical Services (ESF-8) desk at the State Operations Center (Oklahoma State Department of Health) and notify the Regional Response Coordinator from the Oklahoma Office of Homeland Security.
- 2. ESF-8 personnel will contact MERC in regions 1,3,5,6,7,8, or the MACC in regions 2, 4 for validation.
- MERC/MACC professionals will contact the Medical Branch at the scene to validate the request for assets. That contact will also include the affected county's Annex H Representative if the county EOC has been activated.
- 4. Once the request is validated, MERC/MACC will contact REMSS regional representative in affected region to determine ability of REMSS team to respond based upon the parameters of a validated request.
- 5. If a REMSS team can be formed from within the affected region, it will respond to the validated request.
- 6. MERC/MACC will notify state ESF-8 personnel and state Regional Response Coordinator of intra-regional response. ESF-8 will notify Oklahoma State Department of Health EMS Division and the County Health Administrator for the affected area.
- 7. If the REMSS team from the affected region is already engaged or otherwise unavailable, ESF-8 personnel will be notified and will contact the MERC/MACC in the adjoining region.
- 8. The next involved MERC/MACC will repeat the contacting process and determination of an available team.
- 9. Once a REMSS team able to respond from another region has been identified, ESF-8 personnel will be notified, and in conjunction with the state Regional Response Coordinator, will dispatch that REMSS team as an inter-regional response asset. ESF-8 personnel will make notifications to Oklahoma State Department of Health EMS Division.





Approved 9/04/24, Effective 1/15/25, replaces all prior versions

15C - CHEMICAL WEAPONS



#### **Communication Center Principles:**

911 calls present the first opportunity to identify that a potential weapon of mass destruction (WMD) - chemical incident exists. Identifying the incident, relaying potential threat information, and advising precautionary measures to <u>all</u> of the responding public safety professionals may be a key to saving lives of responding public safety professionals.

#### Indicators of a Possible Chemical Weapons Incident:

- 1. Explosion with little or no structural damage;
- 2. Reports of a device that dispersed a mist or vapor;
- 3. Multiple casualties exhibiting similar symptoms (may be without apparent reason);
- 4. Reports of unusual odors, liquids, spray devices, or cylinders;
- 5. Dead animals:
- 6. Discarded personal protective equipment (PPE).

#### Potential Notifications (actual notification needed if chemical weapon event confirmed):

- 1. Local Law Enforcement
- 2. Local Federal Bureau of Investigation (FBI) office WMD Coordinator:
- 3. Local/State Office of Emergency Management (OEM);
- 4. Local Health Department

#### Initial Actions/On - Scene Arrival:

- 1. Approach upwind and uphill of the incident;
- 2. Stop at an apparent safe distance away from incident location;
- 3. Alert subsequent arriving responders;
- 4. Direct all personnel to use full PPE, including self-contained breathing apparatus (SCBA)
  - a. At a minimum, respiratory protection;
- 5. Be aware of possible secondary devices;
- 6. Treat as a crime scene/Consider that alleged perpetrator may still be on the scene;
- 7. Avoid contact with liquids;
- 8. Request appropriate resources (HazMat specialists, law enforcement officers, etc.).





Approved 9/04/24, Effective 1/15/25, replaces all prior versions **PROTOCOL 15C: Chemical Weapons, cont.:** 

#### **Establishing Incident Command: (Follow Specific Directives of Incident Commander)**

Follow National Incident Management System (NIMS) practices as reflected in local policies. Utilize a Unified Command structure, promoting effective and efficient multi-agency communications and operations.

Further information through NIMS courses can be accessed at this website: https://www.fema.gov/national-incident-management-system

#### **Casualty Rescue:** (Follow Specific Directives of Incident Commander)

As many ambulatory casualties as possible should be removed from the area without rescuers entering the incident site. It should be expected, though, that live, non-ambulatory casualties will be present at any chemical incident.

- 1. Use bull horns and vehicle public address (PA) system to give directions;
- 2. Be alert for secondary devices:
- 3. Determine if there are live victims in the contaminated area;
- 4. Use PPE appropriate for safe rescue PPE level most likely determined by HazMat specialists advising the Incident Commander (IC). The IC evaluates the chemical threat, potential to save lives, risk to responders, and time constraints to achieve each level of responder protection before determining what level of PPE to use to perform rescue operations;
- 5. When safe and appropriate, assist/direct all victims to decontamination and triage area.

#### **Decontamination: (Follow Specific Directives of Incident Commander)**

The theories and procedures referred to by the Chemical Weapons Improved Response Program (CWIRP) are based on decontaminating victims using large volumes of water.

#### Establish decontamination location(s) upwind and uphill of the incident:

- Decontamination personnel must wear appropriate PPE, likely to include SCBA;
- 2. Be alert for secondary devices, weapons, and perpetrators;
- 3. Avoid contact with unknown liquids;
- 4. Decontaminate (immediately) casualties with liquid contamination on their skin or clothing. For dry contamination, substance should be brushed off casualty immediately;
- 5. Clothing removal is often the most effective decontamination. Encourage victims to remove clothing at least down to their undergarments;
- 6. Prioritize asymptomatic, symptomatic, and non-ambulatory casualties:
  - a. Coordinate decontamination with EMS triage activities.
  - b. Establish separate technical decontamination for responders away from masscasualty decontamination.


The diagrams on the following page are provided to illustrate commonly recognized methods of mass "wet" decontamination. Follow the directives of the Incident Commander and HazMat specialists in charge of decontamination.






Approved 9/04/24, Effective 1/15/25, replaces all prior versions **PROTOCOL 15C: Chemical Weapons, cont.:** 

#### LADDER PIPE DECONTAMINATION SYSTEM (LDS)



#### EMERGENCY DECONTAMINATION CORRIDOR SYSTEM (EDCS)







Approved 9/04/24, Effective 1/15/25, replaces all prior versions **Protocol 15C: Chemical Weapons, cont.:** 

Types of Decontamination:

- a. Passive (clothing removal) often the simplest and effective method
- b. Dry agents
  - i. Dirt Flour
  - ii. Baking powder Sawdust
  - iii. Charcoal Silica gel
- c. Wet agents
  - i. Soap and water
  - ii. Water (only)
  - iii. Bleach (for equipment decontamination)
- d. Air decontamination (positive pressure ventilation [PPV]/portable fans)

#### **EMS Principles**: (Follow Specific Directives of Incident Commander)

One of the primary challenges facing EMS on a chemical weapons incident will be the number of casualties (eg. trauma and agent exposure) and segregating these casualties by severity of illness/injury as well as attempting to segregate the "worried well" from actual exposed victims.

Work with appropriate HazMat specialists to determine proper level of PPE and respiratory protection needed for EMS personnel and what areas are appropriate for EMS care activities.


- a. Be alert for secondary devices and perpetrators;
- b. Avoid contact with liquids other than non-contaminated water:
- c. Rapid prioritization of number of patients;
- d. Triage victims based on medical necessity, using MCI protocols;
- e. Establish patient identification and tracking.
- f. Establish:
- i. Communications with command post and hospitals;
- ii. Staging for EMS personnel, ambulances, supplies, and resources;
- iii. Transportation area avoid transporting any contaminated patient(s).





Approved 9/04/24, Effective 1/15/25, replaces all prior versions

15D – CHEMPACK DEPLOYMENT ACTIVATION PROCEDURE



If an incident appears to have the possibility of a nerve agent, organophosphate or radiological incident, the Incident Commander on the scene should notify the Oklahoma Poison Control Center (OPCC).

To contact the Oklahoma Poison Control Center in Oklahoma City:

## Healthcare Professional Access Number: 1-877-271-6998

When calling, identify yourself by name, EMS certification level, and agency/apparatus identification. Have as much patient information and substance information possible (may be limited in early phase of potential mass casualty incident) readily available to share with the poison center specialist.

Based on the outcome of the call, if it is a plausible chemical or radiological event, OPCC will activate the nearest CHEMPACK site and notify the appropriate Regional Medical Emergency Response Center (MERC) (also referred to as the Regional CHEMPACK Coordinator).

The Regional CHEMPACK Coordinator will assume coordination and determine additional support facilities, transport modes if needed (coordinating with local Emergency Management, medical facilities, the nearest CHEMPACK site and Oklahoma Highway Patrol), and contact the facilities to determine their level.

The selected site(s) can be placed on three (3) different levels: *Standby* - Level 1, *Alert* - Level 2 and *Activation* - Level 3. During *Activation* - Level 3, the cache site will open the container and access the material. If pre-defined at the time of container receipt from the CDC, the container contents will be separated and prepared for delivery to hospital emergency departments and/or EMS.


CHEMPACK assets are to be utilized as a second line of defense. It is expected that existing supplies of nerve agent antidotes will be utilized before opening CHEMPACK containers unless EMS and/or hospitals anticipate exhausting their existing cache of these agents, at which time CHEMPACK containers may be opened.





Approved 9/04/24, Effective 1/15/25, replaces all prior versions

**15E - NERVE AGENTS** 



#### **NERVE AGENT EXPOSURES**

#### Comments

- Nerve agent exposure should be considered at multiple causality incidents in which
  patients are exhibiting the DUMBELS constellation of symptoms and signs. In particular,
  nerve agent exposure should be considered while responding to any reports of multiple
  casualties at a location of high occupancy (should malls, stadiums, etc), high visibility
  (crowds gathered for public speeches, protests, etc), or high political symbolism (places of
  worship, governmental offices, etc).
- 2. Immediate countermeasures to nerve agent exposure with developing DUMBELS symptoms and signs are administration of the DuoDote® auto-injectors, auto-injector-as indicated and evacuation from the exposure are for decontamination.
- 3. Any personnel exposed to a nerve agent and requiring treatment with the DuoDote<sup>®</sup> autoinjectors is restricted from providing patient care and should be promptly transported for emergency physician evaluation.
- 4. Atropine is utilized in nerve agent exposure treatment to dry secretions, reduce bronchospasm, and decrease gastrointestinal motility. If significant bronchorrhea continues after three DuoDote® auto-injector have been administered in the adult patient, further atropine may be given by paramedic as follows until the bronchorrhea subsides:

Adult – 1 mg atropine IVP every 3-5 minutes Adult – 2 mg atropine IM every 5 minutes

5. In the case of nerve agent exposure with bronchorhea, there is no maximum atropine dosing in the adult patient, though atropine should be withheld in the case of developing ventricular tachydysrhythmias. In this case, treat the ventricular tachydysrhythmia according to 5G Tachycardia – Unstable – Adult & Pediatric or 4G Ventricular Fibrillation/Pulseless Ventricular Tachycardia – Adult & Pediatric as applicable.





Approved 9/04/24, Effective 1/15/25, replaces all prior versions

PROTOCOL 15E: Nerve Agents, cont.

- 6. DuoDote® is utilized in nerve agent exposure to reverse the nerve agent effect on acetylcholinesterase, the enzyme responsible for neurotransmitter regulation. Refer also to Protocol 16M for self/buddy care using DuoDote®.
- 7. Patients contaminated by vapor-only nerve agent exposures should be decontaminated by clothing removal (dry decon). Patients contaminated by liquid nerve agent exposures should be decontaminated by clothing removal and thoroughly washed with soap and water (wet decon).
- 8. In the absence of DUMBELS symptoms and signs, nerve agent exposure has not occurred. The DuoDote® auto-injectors are not authorized for patients not exhibiting DUMBELS symptoms and signs.
- Pediatric patients (<25 kg) with DUMBELS symptoms and signs in the setting of suspected nerve agent exposures should be treated with one DuoDote® auto-injector kit and OLMCP should be contacted for further direction in relation to any further atropine and/or 2-PAM usage.
- 10. Patients treated with DuoDote® auto-injector kits should either have the auto-injector hooked to their clothing or a prominent vertical mark on their forehead for each kit administered to indicate to further healthcare providers the number of DuoDote® auto-injector kits the patient has received.


# OMD

### EMS System for Metropolitan Oklahoma City and Tulsa 2025 Medical Control Board Treatment Protocols



Approved 9/04/24, Effective 1/15/25, replaces all prior versions

PROTOCOL 15E: Nerve Agents, cont.



#### LOOK FOR "DUMBELS" SIGNS AND SYMPTOMS

D: DIARRHEA

U: URINATION

M: MIOSIS (PINPOINT PUPILS)

B: BRONCHOSPASM, BRONCHORRHEA (COPIOUS RESPIRATORY SECRETIONS)

E: EMESIS (NAUSEA/VOMITING)

L: LACRIMATION (TEARING)

S: SALIVATION

Additional resources regarding nerve agents can primarily be accessed through the Centers for Disease Control at www.bt.cdc.gov/agent/nerve.

National Disaster Life Support training also includes nerve agent education in:

Basic Disaster Life Support (one day classroom course)


Advanced Disaster Life Support (two day classroom/practical exercise course)





Approved 9/04/24, Effective 1/15/25, replaces all prior versions

#### 15F - BIOLOGICAL WEAPONS



While a multitude of biological agents exist that have possibility in weapon use, the Centers for Disease Control categorizes these agents into priority of concern and probable use. Category A agents include organisms that pose a risk to national security due to easy dissemination or person to person transmission, high mortality rates, high impact upon public health, ability to cause public panic and social disruption, and require special action for public health preparedness.

Category A agents and their diseases include:

Bacillus anthracis – Anthrax
Clostridium botulinum toxin – Botulism
Yersinia pestis – Plague
variola major – Smallpox
Francisella tularensis – Tularemia
filoviruses (eg. Ebola, Marburg); arenaviruses (eg. Lassa, Machupo) – Viral hemorrhagic fevers

Of particular concern among these agents is anthrax. While anthrax is a naturally occurring disease among animal skin handlers, the bacteria has already been successfully used in domestic terrorism in the United States. Concern about anthrax prompts responses by public safety agencies, including EMS in some locales, to investigate these concerns and in some cases, acute onset of symptoms, in response to exposure to "suspicious white powder". The following information serves as one resource in preplanning responses to such substances in efforts to protect EMS and other safety professionals.

Additional resources regarding biologic weapons can primarily be accessed through the Centers for Disease Control at www.bt.cdc.gov/bioterrorism.





Approved 9/04/24, Effective 1/15/25, replaces all prior versions

#### PROTOCOL 15F: Biological Weapons, cont.

Suspicious Powder Response Model Procedure – Follow Local HazMat Directives

#### **Definitions:**

Isolation Perimeter – The designated crowd control line surrounding the Hazard Control Zones. The isolation perimeter is always the line between the general public and the Cold Zone.

Field Test – A procedure that will be determined by on-scene FD Hazmat and PD personnel to check the presence of radiological, biological, chemical, and volatility (flammability) in or around a package.

ID Test – FD procedure to obtain information to identify a specific substance (i.e., salt, sugar, flour, etc) or chemical compound. Testing to identify a substance is more geared toward dry product or liquids without water content. The test signature of water overrides/masks the graph spikes preventing identification.

#### Procedures:

The following actions should be taken at incidents involving a package suspicious for anthrax:


- 1. Once law enforcement (LE) arrives on scene and decides that FD is needed, HazMat resource mobilization should be considered.
- 2. If the first arriving FD company is not a Hazmat Unit and receives information that the incident may be a potential chemical or biological threat, the OIC should:
  - a. Not make entry or attempt to mitigate the incident
  - b. Establish an isolation perimeter of at least 100 feet
  - c. Should keep all citizens on the outside of the isolation perimeter
  - d. Call for the Hazmat Team
  - e. Wait upwind until arrival of Hazmat Team
  - f. Operate in a support role for the Hazmat Team upon their arrival
- 3. The Hazardous Materials Team OIC will be either Command or Hazmat Branch as appropriate.





Approved 9/04/24, Effective 1/15/25, replaces all prior versions

#### PROTOCOL 15F: Suspicious Power Response Procedure, cont.








Approved 9/04/24, Effective 1/15/25, replaces all prior versions

#### 15G - RADIOLOGICAL WEAPONS



- 1. Potential radiologic weapon devices in the United States include:
  - a. Simple radiation emitting devices (example would be dumping radioactive waste in a water supply typically NOT a significant threat due to dilution effect of large amount of water).
  - b. Conventional explosive device containing radiation ("dirty bomb") typically NOT a significant threat due to the fact that explosions are very inefficient in producing radioactive particles of a size that are easily inhaled.
- 2. Either of the above devices may be utilizing radioactive isotopes initially manufactured for medical use (eq. nuclear imaging).
- 3. Radiation types include the following:
  - a. Irradiation = gamma radiation passing through a body
  - b. External contamination = radioactive "dust" particles falling on a body
  - c. Internal contamination = radioactive "dust" particles being ingested or inhaled
- 4. Protection takes the simple format of:
  - a. Reducing time of exposure.
  - b. Increasing distance from exposure source biggest factor in protection. Radiation does not travel far, but contamination can.
  - c. Shielding device use to minimize exposure uptake. Airborne illness PPE protection is excellent for radiation protection as well). Think of radioactive particles as "dirt" that shouldn't be inhaled (wear N95 masks) and shouldn't be in contact with skin.
- 5. Three **myths** that can paralyze medical response:
  - a. "Radioactive contamination is highly dangerous & requires extraordinary protective measures." (see above)
  - b. "Decon is highest medical priority." Decon is actual very simple = remove clothing and shower. Most of radiation goes away with removal of clothing.
  - c. "Special skills are needed to handle radioactive patients." (see above)





Approved 9/04/24, Effective 1/15/25, replaces all prior versions

#### PROTOCOL 15G: Radiological Weapons, cont.

6. Multiple resources exist to aid in the understanding and response planning for radiological weapons. The following are suggested resources:

Radiation Emergency Medical Management www.remm.nlm.gov

National Alliance for Radiation Readiness (NARR) www.radiationready.org

Society of Nuclear Medicine and Molecular Imaging www.snmmi.org

Health Physics Society www.hps.org

National Disaster Life Support training

Basic Disaster Life Support (one day classroom course)

Advanced Disaster Life Support (two day classroom/practical exercise course)


Special acknowledgement to John C. White, CNMT, Radiation Safety Officer, The University of Texas Southwestern Medical Center at Dallas for material integral to this protocol's preparation.





Approved 9/04/24, Effective 1/15/25, replaces all prior versions

#### 15H - NUCLEAR WEAPONS



- 1. Potential nuclear weapon devices impacting the United States include:
  - a. Improvised nuclear device.
  - b. 1 kiloTon "suitcase nuke."
  - c. Tactical weapons of 5-50 kiloTons.
  - d. Electromagnetic pulse detonation = nuclear weapon detonation in atmosphere wherein gamma waves hit radio waves, causing phones, pagers, radios, etc go down.
  - e. Ballistic missile attack.
  - f. 250 kiloTon nuclear bomb = "city killer."
- 2. Nuclear detonation = 50% blast effect; 35% thermal effect; 10% fallout; 5% ionizing radiation effect.
- 3. Mass blindness is a concern due to retinal burns (non-thermal) from viewing detonation.
- 4. Radiation types include the following:
  - a. Irradiation = gamma radiation passing through a body.
  - b. External contamination = radioactive "dust" particles falling on a body.
  - c. Internal contamination = radioactive "dust" particles being ingested or inhaled.
- 5. Protection takes the simple format of:
  - a. Reducing time of exposure.
  - b. Increasing distance from exposure source biggest factor in protection. Radiation does not travel far, but contamination can.
  - c. Shielding device use to minimize exposure uptake. Airborne illness PPE protection is excellent for radiation protection as well). Think of radioactive particles as "dirt" that shouldn't be inhaled (wear N95 masks) and shouldn't be in contact with skin.





Approved 9/04/24, Effective 1/15/25, replaces all prior versions

PROTOCOL 15H: Nuclear Weapons, cont.

- 6. Three **myths** that can paralyze medical response:
  - a. "Radioactive contamination is highly dangerous & requires extraordinary protective measures." (see above)
  - b. "Decon is highest medical priority." Decon is actual very simple = remove clothing and shower. Most of radiation goes away with removal of clothing.
  - c. "Special skills are needed to handle radioactive patients." (see above)
- 7. Multiple resources exist to aid in the understanding and response planning for nuclear weapons. The following are suggested resources:

Radiation Emergency Medical Management www.remm.nlm.gov

National Alliance for Radiation Readiness (NARR) www.radiationready.org

Nuclear Regulatory Commission www.nrc.gov

Society of Nuclear Medicine and Molecular Imaging www.snmmi.org

Health Physics Society www.hps.org

Planning Guidance for Response to a Nuclear Detonation June 2010 – Second Edition www.remm.nlm.gov/PlanningGuidanceNuclearDetonation.pdf

National Disaster Life Support training

Basic Disaster Life Support (one day classroom course)

Advanced Disaster Life Support (two day classroom/practical exercise course)


Special acknowledgement to John C. White, CNMT, Radiation Safety Officer, The University of Texas Southwestern Medical Center at Dallas for material integral to this protocol's preparation.





Approved 9/04/24, Effective 1/15/25, replaces all prior versions

16A - ACTIVATED CHARCOAL



Class: Adsorbant

Actions/Pharmacodynamics: Activated charcoal is a liquid suspension that adsorbs many drugs and chemicals. It acts by binding / adsorbing toxic substances, thereby inhibiting their GI absorption, uptake into the liver, and thus, their presence in the bloodstream for action, also called "bioavailability". Activated charcoal has a tremendous surface area, allowing for a large amount of adsorption. The combined complex formed by the adsorption process is excreted from the body in the feces. It is a general purpose emergency treatment of poisoning by most drugs and chemicals, e.g., acetaminophen, aspirin, atropine, barbiturates, digitalis, glycosides, phenytoin, propoxyphene, strychnine, and tricyclic antidepressants, among many others.

**Indications:** Poisonings - General Management (8A)

**Contraindications:** Activated charcoal is contraindicated for treatment of poisoning by cyanide, mineral acids, caustic alkalis, organic solvents, iron, ethanol, and methanol. Activated charcoal may not be administered in patients with current or suspected imminent altered mental status, dysphagia, or vomiting to prevent elevated risk of aspiration of charcoal.

**Pharmacokinetics:** Nonabsorbed; onset immediate; peak, duration, and half – life: unknown.

**Side Effects:** GI: vomiting following rapid ingestion of high doses, abdominal cramping, abdominal bloating, constipation (diarrhea from sorbitol additive).

Dosage: Poisonings - General Management - Adult & Pediatric (8A)

1 gram/kg PO (**OLMC or OK Poison Center order required**; Consult for order

only if transport time estimated to exceed 30 mins)

**How Supplied:** 25 grams of activated charcoal in aqueous suspension in bottle.

(Always check concentration and dose per container at time of patient

medication administration)

**Special Comment:** Activated charcoal, while historically often administered in the setting of ingested poisonings, is no longer utilized with frequency. The American Board of Medical Toxicology does not recommend administering activated charcoal to all suspected ingested poisonings. The purpose of OLMC or OK Poison Center order requirement is to prevent unnecessary use of activated charcoal and the side effects its use can create - especially vomiting and aspiration.





Approved 9/04/24, Effective 1/15/25, replaces all prior versions

16B - ADENOSINE (ADENOCARD®)

#### **PARAMEDIC**

Class: Anti-Tachydysrhythmic (Purine Nucleoside)

**Actions/Pharmacodynamics:** Slows electrical conduction through the cardiac atrioventricular (AV) node, with ability to interrupt reentry pathways through the AV and sinoatrial (SA) nodes. Adenosine is administered to convert paroxysmal supraventricular tachycardia (PSVT) to normal sinus rhythm.

**Indications:** Tachycardia - Stable (5F)

PSVT (sustained regular, narrow-complex tachycardia >150 bpm in adults) & systolic BP ≥ 100mmHg, failed valsalva maneuver.

**Contraindications:** 2<sup>nd</sup>/3<sup>rd</sup> degree AV Blocks (may induce asystole)

Known Wolff-Parkinson-White Syndrome (may increase heart rate)

Known Sick Sinus Syndrome (may induce asystole) Bradycardia (may induce symptomatic hypotension)

**Pharmacokinetics:** Onset of action within 10-20 seconds after IV administration. Very rapid metabolism (and duration of effect) within 10-20 seconds after IV administration.

**Side Effects:** Common, though transient, symptoms include chest pain, palpitations of irregular bradycardia, dyspnea, lightheadedness, numbness, and sweating. A constellation of these side effects may produce significant patient apprehension and/or sense of impending doom. The patient should be advised of these possibilities prior to adenosine administration and given reassurance such symptoms will be short-lived in duration of seconds. Transient asystolic or profound, irregular bradycardic rhythms may be observed on ECG monitoring.

**Dosage:** Tachycardia - Stable - Adult (5F) (PSVT as described above)

12 mg rapid IVP (1 - 2 seconds) followed rapidly by 10 mL saline flush.

May repeat once at 12 mg.

\*\*OLMC Order Only for use in pediatric patients.

OLMC may direct use of adenosine in evaluating etiology of regular, monomorphic wide complex tachycardia.

**How Supplied:** 12 mg/4 mL in prefilled syringe.


(Always check concentration and dose per container at time of patient





Approved 9/04/24, Effective 1/15/25, replaces all prior versions

16C - ALBUTEROL (PROVENTIL®, VENTOLIN®)



Self-Administration Phone Directive - 3B 3C 3D 12B

Assist Pt with Self Administration - 3B 3C 3D 12B

Class: Sympathomimetic Bronchodilator

**Actions/Pharmacodynamics:** Albuterol is a relatively selective beta<sub>2</sub> adrenergic stimulant. Albuterol causes relaxation of the smooth muscles of the bronchial tree thus decreasing airway resistance, facilitating mucus drainage, and increasing vital capacity. It exerts mild effects on beta<sub>1</sub> (heart) or alpha (peripheral vasculature) receptors. In therapeutic doses, albuterol, by inhibiting histamine release from mast cells, also reduces the mucus secretion, capillary leaking, and mucosal edema caused by an allergic response in the lungs.

**Indications:** Dyspnea - Uncertain Etiology (3B)

Dyspnea - Asthma (3C)

Dyspnea - Chronic Obstructive Pulmonary Disease (3D)

Acute Allergic Reactions (8D)

Bee/Wasp Stings (8F) Smoke Inhalation (12B)

**Contraindications:** Known hypersensitivity to albuterol. Albuterol should not be used if the sole etiology of dyspnea is strongly suspected to be CHF, as albuterol-induced tachycardia may worsen the compromised cardiac output in CHF.

**Pharmacokinetics:** Onset within 5-15 minutes; peak effect in 1-1.5 hours; duration of effect is up to 3-6 hours; half – life is less than 3 hours. Distribution: When inhaled, albuterol is distributed to muscle cells along the bronchial tree. Very little is systemically absorbed and distributed.

**Side Effects:** Tremors, anxiety, dizziness, headache, cough, reflex bronchospasm, palpitations, tachycardia, and hypertension.





Approved 9/04/24, Effective 1/15/25, replaces all prior versions

PROTOCOL 16C: Albuterol (Proventil®, Ventolin®)

Dosage: Dyspnea - Uncertain Etiology - Adult & Pediatric Weight ≥ 15kg (3B)

Smoke Inhalation - Adult & Pediatric Weight ≥ 15kg (12B)

5 mg nebulized, may repeat once

Dyspnea - Uncertain Etiology - Pediatric Weight < 15kg (3B)

Smoke Inhalation - Pediatric Weight < 15kg (12B)

2.5 mg nebulized, may repeat once

Dyspnea - Asthma - Adult & Pediatric Weight ≥ 15kg (3C)

Dyspnea - Chronic Obstructive Pulmonary Disease - Adult (3D) Acute Allergic Reactions - Adult & Pediatric Weight ≥ 15kg (8D)

Bee/Wasp Stings - Adult & Pediatric Weight ≥ 15kg (8F)

5 mg nebulized (with ipratropium bromide 0.5 mg), may repeat twice

Dyspnea - Asthma - Pediatric Weight < 15kg (3C)

Acute Allergic Reactions - Pediatric Weight < 15kg (8D)

Bee/Wasp Stings - Pediatric Weight < 15kg (8F)

2.5 mg nebulized (with ipratropium bromide 0.25 mg), may repeat twice

**How Supplied:** 2.5 mg/3 mL (0.083%) in nebulizer vials.

(Always check concentration and dose per container at time of patient





Approved 9/04/24, Effective 1/15/25, replaces all prior versions

16D – AMIODARONE (CORDARONE®, NEXTERONE®)

#### **PARAMEDIC**

Class: Class III Anti-Dysrhythmic (Vaughn William Classification)

**Actions/Pharmacodynamics:** Prolongs the cardiac action potential's refractory period, slowing conduction through the heart. Amiodarone also has secondary actions in the other three classifications of anti-dysrhythmics. Amiodarone blocks sodium channels (class I) which can prevent cardiac action potentials. It is a non-competitive anti-sympathetic (class II) which slows cardiac action potentials. Amiodarone also slows conduction through the cardiac atrioventricular (AV) node (class IV). In sum, all of these actions lead to slowing of conduction and prolongation of refractoriness in the cardiac conduction system.

Indications: Ventricular Fibrillation/Pulseless Ventricular Tachycardia (4G)

Tachycardia - Stable (5F)

Wide-Complex Tachycardia of Uncertain Type or

Monomorphic VentricularTachycardia (if heart rate ≥ 150 beats

per minute with systolic BP ≥ 100 mmHg in adults)

Narrow-Complex Tachycardia (if heart rate ≥ 150 beats per minute with

systolic BP ≥ 100 mmHg in adults) \*\*OLMC Order Only

Tachycardia - Unstable (5G)

Post-Cardioverion of Ventricular Tachycardia

Premature Ventricular Contractions (5K)

Symptomatic Premature Ventricular Contractions (with BP < 100mmHg in adults due to frequent non-conducted ventricular impulses and in

absence of 2nd/3rd degree AV blocks)

**Contraindications:** 2nd/3rd degree AV blocks (may induce asystole)

Bradycardia (may induce symptomatic hypotension)

**Pharmacokinetics:** Onset of action within 60 seconds after IV administration, with effects lasting up to 20-25 minutes.

**Side Effects:** Hypotension is the most common side effect, requiring treatment in less than 20% of patients (transient effect). Bradycardia and AV Block may also result, requiring treatment in less than 10% of patients (transient effect). In a very rare circumstance, as with all anti-dysrythmics which can have pro-dysrhythmic effects, torsades may result from excessive prolongation of the cardiac action potential. When indicated by protocol, the benefits of amiodarone administration exceed these risks of side effects.





Approved 9/04/24, Effective 1/15/25, replaces all prior versions

PROTOCOL 16D: Amiodarone (Cordarone®, Nexterone®), cont.

Dosage:

#### Ventricular Fibrillation/Pulseless Ventricular Tachycardia - Adult (4G) (refractory to initial defibrillation attempt)

300 mg IVP/IOP. Repeat at 150 mg IVP/IOP in 5 minutes to maximum cumulative dose of 450 mg. Epinephrine 1 mg (1:10,000) IVP/IOP is to be given with every amiodarone administration.

#### Ventricular Fibrillation/Pulseless Ventricular Tachycardia - Pediatric (4G) (refractory to initial defibrillation attempts)

5 mg/kg IVP/IOP in single dose. Epinephrine 0.01 mg/kg (1:10,000, 0.1 mL/kg) IVP/IOP is to be given with every amiodarone administration.

#### Ventricular Fibrillation/Pulseless Ventricular Tachycardia - Adult (4G) (Successful conversion to sustained pulsatile rhythm)

150 mg (add to 100 ml NS and infuse over 10 minutes). If unable to establish IV access, then add 150 mg to 50 ml NS in a syringe and administer via IO over 10 minutes. IF maximum cumulative dose of 450 mg has not been achieved.

#### Ventricular Fibrillation/Pulseless Ventricular Tachycardia - Pediatric (4G) (post return of sustained spontaneous circulation)

Tachycardia - Stable - Pediatric (5F)

(wide-complex tachycardia of uncertain type or monomorphic ventricular tachycardia; narrow-complex tachycardia)

Tachycardia - Unstable - Pediatric (5G)

**Premature Ventricular Contractions - Pediatric (5K)** 

\*\*OLMC Consult & Order Only

#### Tachycardia - Stable - Adult (5F)

(wide-complex tachycardia of uncertain type - standing order; monomorphic ventricular tachycardia - standing order; narrow complex - \*\*OLMC order only)

Tachycardia - Unstable - Adult (5G)

(post cardioversion of ventricular tachycardia)

#### **Premature Ventricular Contractions - Adult (5K)**

150 mg (add to 100 ml NS and infuse over 10 minutes). If unable to establish IV access, then add 150 mg to 50 ml NS in a syringe and administer via IO over 10 minutes.

**How Supplied:** 

150 mg/3 mL in vial, ampule, or pre-filled syringe.

150 mg/100 mL pre-mixed infusion.

(Always check concentration and dose per container at time of patient





Approved 9/04/24, Effective 1/15/25, replaces all prior versions

16E - ASPIRIN

# EMERGENCY MEDICAL DISPATCHER EMERGENCY MEDICAL RESPONDER EMT EMT EMT-INTERMEDIATE 85 ADVANCED EMT PARAMEDIC

Self-Administration Phone Directive - 5A 5C

Assist Pt with Self Administration - 5A 5C

Class: Anti-Platelet

**Actions/Pharmacodynamics:** Inhibits platelet aggregation (and thereby, further clot formation). This action results in an overall increase in survival from acute myocardial infarction.

Indications: Chest Pain - Uncertain Etiology (5A) > 35 years of age

Acute Coronary Syndrome (5C)

**Contraindications:** Active gastrointestinal bleeding

History of aspirin allergy including angioedema and/or anaphylaxis

History of asthma with aspirin-induced exacerbation

**Pharmacokinetics:** Absorption in stomach and small intestine, with onset of action within 30 minutes and duration of action for several hours.

**Side Effects:** Typically, none from single EMS dosing. Rare instances of nausea or allergic reaction could be encountered. Treat allergic reaction per Protocol 8D - Acute Allergic Reactions.

Dosage: Chest Pain - Uncertain Etiology - Adult (5A)

**Acute Coronary Syndrome - Adult (5C)** 

324 OR 325 mg chewed by patient (hold if taken 324+mg within 6 hours)

**How Supplied:** 81 mg tablets

325 mg tablets

(Always check concentration and dose per container at time of patient

medication administration)

**Special Comment:** Aspirin is indicated even if the patient is taking warfarin sodium (Coumadin®), clopidogrel (Plavix®), or other anticoagulant or antiplatelet agents on a daily basis.





Approved 9/04/24, Effective 1/15/25, replaces all prior versions

**16F – ATROPINE SULFATE** 

#### **PARAMEDIC**

Class: Parasympatholytic

Actions/Pharmacodynamics: Blocks parasympathetic impulses to the heart via the vagus nerve. Atropine increases the rate of cardiac sinoatrial (SA) node discharges, enhances conduction through the atrioventricular (AV) node, and by increasing heart rate, increases the cardiac output and blood pressure. Additionally, in the treatment of indicated poisonings (organophosphates) atropine reverses muscarinic effects of acetylcholine, including diaphoresis, diarrhea, urination, bronchorrhea (secretions from the lower respiratory tract), emesis, lacrimation (tearing), and salivation. Atropine produces dilation of pupils by blocking stimulation of the ciliary muscle surrounding the pupils.

**Indications:** Bradycardia (5D)

Poisonings – General Management (Organophosphate) (8A)

**Contraindications:** None absolute in indicated situations.

Pharmacokinetics: Typical onset within 60 seconds given IV. Effects can persist in excess of

1 hour.

**Side Effects:** Tachycardia (either supraventricular or ventricular), hypertension, palpitations, blurred vision due to pupillary dilation, photophobia, dry mouth.

**Adult organophospate poisoning:** 2 mg IVP/IOP/IM. Use IVP for more severe presentations. May repeat as often as every 3-5 minutes if symptoms progressive or persistent.

Dosage: Bradycardia – Symptomatic & Systolic BP < 100 mmHg

(Sinus First Dograp 2nd Dograp Type I) - Adult (5D)

(Sinus, First Degree, 2nd Degree Type I) - Adult (5D)

In Non-Acute Coronary Syndrome, 0.5 mg IVP/IOP.

May repeat every 5 minutes to cumulative maximum dose of 3 mg

Bradycardia - Symptomatic & Systolic BP < 70 + (2 x age in years) mmHg (Sinus, First Degree, 2nd Degree Type I) - Pediatric (5D)

Unresponsive to Epinephrine, 0.02 mg/kg IVP/IOP; minimum dose 0.1 mg Max. single dose 0.5 mg May repeat once.

Poisonings – General Management (Organophosphate) – Adult (8A)

2 mg IVP/IOP/IM. Use IVP for more severe presentation.

Repeat every 3-5 minutes if symptoms progressive.





Approved 9/04/24, Effective 1/15/25, replaces all prior versions

PROTOCOL 16F: Atropine Sulfate, cont.

Dosage, cont:

Poisonings – General Management (Organophosphate) – Pediatric (8A)

0.05 mg/kg IVP/IOP/IM. Use IVP for more severe presentation.

Minimum dose 0.1 mg.

Consult with OLMCP for repeat dosing needs.

**How Supplied:** 1 mg/10 mL prefilled syringe

1 mg/1 mL vial

0.25 mg/5 mL prefilled syringe for pediatric use

(Always check concentration and dose per container at time of patient





Approved 9/04/24, Effective 1/15/25, replaces all prior versions

16G - CALCIUM CHLORIDE

#### **PARAMEDIC**

Class: Electrolyte

**Actions/Pharmacodynamics:** Calcium causes a significant increase in myocardial contractility and in ventricular automaticity. It is used as an antidote for some electrolyte imbalances (eg. stabilizing cardiac rhythm in the setting of hyperkalemia) and to minimize the side effects from calcium channel blocker overdose. The actions of calcium chloride are similar to those of calcium gluconate but, since it ionizes more readily, it is more potent than calcium gluconate.

**Indications:** Specific Causes of Cardiac Arrest (Hyperkalemia) (4I)

Poisonings - General Management (Calcium Channel Blocker Overdose) (8A)

Dialysis-Related Issues (Hyperkalemia) (9E)

Crush Injury Syndrome (Hyperkalemia Prophylaxis) (10K)

**Contraindications:** Calcium chloride is contraindicated in ventricular fibrillation unless known hyperkalemia, in known hypercalcemia, and in suspected digitalis toxicity. It should be used with caution in patients taking digoxin as it may precipitate toxicity. Safe use in pregnancy and in children has not been established, though in indicated conditions, benefits outweigh risks.

**Pharmacokinetics:** Onset nearly immediate when given IVP/IOP. The peak effect time frame and duration of effect is not well established.

**Side Effects:** Paresthesias (tingling), syncope, sensations of heat waves (peripheral vasodilation), pain and burning at IV site, <u>skin necrosis and sloughing (with extravasation)</u>, hypotension, bradycardia, cardiac dysrhythmias, cardiac arrest.

Dosage: Specific Causes of Cardiac Arrest (Hyperkalemia) - Adult & Pediatric (4I)

Poisonings - General Management (Calcium Channel Blocker Overdose) - Adult &

Pediatric (8A)

Dialysis-Related Issues (Hyperkalemia) - Adult & Pediatric (9E)

Crush Injury Syndrome (Hyperkalemia Prophylaxis) - Adult & Pediatric (10K)

10 mg/kg (10% solution) IVP/IOP, maximum dose of 1 gram

**How Supplied:** 1 gram in a 10 mL prefilled syringe (100 mg/mL)

(Always check concentration and dose per container at time of patient

medication administration)

**Special Comments:** Calcium chloride will interact with sodium bicarbonate and form a precipitate. Do not give both medications via the same vascular access line unless giving a copious flush of NS - approximately 50+ mL - between medications. In general, use an 18-20 gauge angiocatheter in a proximal IV site or use an IO line and test line patency before administration. In non-cardiac arrest or non-impending cardiac arrest settings, administer at 0.5 -1.0 mL per minute to reduce chances of venous irritation and extravasation.





Approved 9/04/24, Effective 1/15/25, replaces all prior versions

16H DEXTROSE (50% as D50; 25% as D25; 10% as D10)

EMT-INTERMEDIATE 85

ADVANCED EMT

PARAMEDIC

Class: Carbohydrate

Actions/Pharmacodynamics: Dextrose is the principal form of glucose (sugar) used by the body to create energy and support critical metabolic processes. Since serious brain injury can occur in prolonged hypoglycemia, the timely administration of glucose is essential in treating hypoglycemia (blood glucose < 50 mg/dL). Dextrose 10% IVPB is the treatment of choice for hypoglycemic patients. Medical literature shows speed of hypoglycemia reversal to be near clinically equivalent when comparing D10 infusion wide open with D50 IVP. The lower concentration of D10 results in less extravasation tissue damage than D50. Dextrose 25% IV/IO should be considered second line treatment for hypoglycemic patients and Dextrose 50% IV/IO should be considered the third line treatment of choice for hypoglycemic patients with weight at or exceeding 25 kg.

**Indications:** Respiratory Arrest (3A)

Specific Cause of Cardiac Arrest (4I)

Altered Mental Status (6B)

Seizure (6D) Syncope (6E)

Dystonic Reaction (6F)
Behavioral Disorder (7A)
Dialysis -Related Issues (9E)
Complications of Pregnancy (13D)

For all listed situations, indication is hypoglycemia (blood glucose < 50 mg/dL).

**Contraindications:** Hyperglycemia (blood glucose > 100 mg/dL)

Normoglycemia in the setting of suspected cerebral ischemia.

**Pharmacokinetics:** Onset within 60 seconds after IVP with peak effect and duration of action dependent upon degree and cause of hypoglycemia. Usual effective duration is more than 30 minutes. Medical literature shows speed of hypoglycemia reversal to be near clinically equivalent when comparing D10 infusion wide open with D50 IVP.

**Side Effects:** Warmth, pain, or burning at the injection site. D50 extravasation can cause tissue necrosis (requiring skin graft surgery), phlebitis, sclerosis, or thrombosis at the injection site.





Approved 9/04/24, Effective 1/15/25, replaces all prior versions

PROTOCOL 16H: Dextrose (50% as D50; 25% as D25; 10% as D10)

Dosage:

#### **Adult and Pediatric**

Dextrose 10% (D10) 5 mL/kg IVPB up to 250 mL Dextrose 25% (D25) 2 mL/kg IV/IO up to 100 mL (must be  $\geq$  1 year of age) Dextrose 50% (D50) 1 mL/kg IV/IO up to 50 mL (must be  $\geq$  25 kg)

#### **How Supplied:**

D10 - Premixed using 25 grams dextrose in 250 mL normal saline (0.1 gram/mL)

D25 - Discard 25 mL of prefilled syringe of D50 - Draw up 25 mL of NS for a total of 50 mL (0.5 gram/mL)

D50 - Prefilled syringes of D50 - 25 grams dextrose in 50 mL of water (0.5 gram/mL)

**Special Comments:** D50 should be administered using an infusing IV, **NOT** a saline lock. The tissue caustic nature of D50 can be decreased by performing a slow and non-forceful IV push through the side port of an IV line that is flowing with normal saline into the patient's vein. Because of the risk of extravasation and the consequences of local tissue damage from extravasation, neither D50 nor D25 should be administered through an external jugular IV. High concentrations of dextrose can lead to cerebral edema in younger/smaller pediatric patients. A repeat determination of blood glucose level is to be performed post D10, D25, or D50 administration

Given markedly low perfusing pressures, such as in cardiac arrest, utilize Dextrose 50% IV/IO.





Medical Literature References 16H – Dextrose (50% as D50; 25% as D25; 10% as D10)

1. Weant, K. A., Deloney, L., Elsey, G., Combs, D., & French, D. (2019). A Comparison of 10% Dextrose and 50% Dextrose for the Treatment of Hypoglycemia in the Prehospital Setting. Journal of Pharmacy Practice. https://doi.org/10.1177/0897190019889444





Approved 9/04/24, Effective 1/15/25, replaces all prior versions

16I – DIAZEPAM (VALIUM®)

#### **PARAMEDIC**

Class: Sedative; Anticonvulsant; Muscle Relaxant; Anxiolytic (Benzodiazepine)

**Actions/Pharmacodynamics:** Intermediate - acting benzodiazepine with central nervous system depressant, anticonvulsant, muscle relaxant, and anxiolytic effects. Like the other benzodiazepines, it has no effect on pain. Diazepam has considerably more muscle relaxant properties than midazolam, though no substantial amnestic effects as with midazolam.

**Indications:** Medication Assisted Intubation (2G)

Post-intubation sedation - onset delay does not favor pre-intubation use

Seizure (6D)

(Midazolam preferred benzodiazepine due to faster onset of action)

Dystonic Reactions (6F) Chemical Restraint (7C)

(Midazolam preferred benzodiazepine due to faster onset of action)

Poisonings - General Management (8A)

Suspected stimulant toxicity = severe agitation, HTN, tachycardia, diaphoresis

Head/Neck/Spine Injury (10A)

Heat Illness (11A)

**Contraindications:** Patients with intolerance to benzodiazepines, acute narrow - angle glaucoma, shock, or coma. Caution with use in patients with COPD, chronic hepatic or renal failure, CHF, acute alcohol intoxication, and the elderly due to increased risk of respiratory depression.

**Pharmacokinetics:** Onset is 3-5 minutes, IVP/IOP; 15-30 minutes IM with erratic absorption, mandating IM dosing only utilized as a last option in adults; peak effects in 15-45 minutes. Duration is 2+ hours IVP/IOP/IM; half – life can reach 20 – 50 hours.

**Side Effects:** Headache, euphoria, drowsiness, excessive sedation, confusion, dizziness, blurred vision, diplopia, nystagmus, respiratory arrest, hypotension, nausea, vomiting.

Dosage: Medication Assisted Intubation (Post Intubation Sedation) - Adult (2G)

0.1 mg/kg to max 5 mg IVP/IOP, may repeat once if systolic BP > 100 mmHg

Seizure - Adult (6D)
Head/Neck/Spine Injury - Adult (10A)
Heat Illness - Adult (11A)
5 mg IVP/IOP or 10 mg IM for active seizure

May repeat once in 5 minutes if still seizing.





Approved 9/04/24, Effective 1/15/25, replaces all prior versions

PROTOCOL 16I: Diazepam (Valium®), cont.

#### Dosage, cont.:

Seizure - Pediatric (6D)
Head/Neck/Spine Injury - Pediatric (10A)
Heat Illness - Pediatric (11A)
0.1 mg/kg to max 5 mg IVP/IOP/IM for active seizure
May repeat once in 5 minutes if still seizing.

**Dystonic Reactions - Adult (6F)** 5 mg IVP

**Dystonic Reactions - Pediatric (6F)** 0.1 mg/kg to max 5 mg IVP/IM

Chemical Restraint - Adult (7C) 5 mg IVP/IOP or 10 mg IM

Chemical Restraint - Pediatric (7C) 0.1 mg/kg to max 5 mg IVP/IOP/IM

**Poisoning - General Management (Suspected Stimulant Toxic) - Adult (8A)** 2.5 mg - 5 mg IVP

Poisoning - General Management (Suspected Stimulant Toxic) - Pediatric (8A) \*\*OLMC Order Only

**How Supplied:** 10 mg/2 mL in vials, ampules, or pre-filled syringes.

(Always check concentration and dose per container at time of patient





Approved 9/04/24, Effective 1/15/25, replaces all prior versions

16J – DILTIAZEM (CARDIZEM®)

#### **PARAMEDIC**

Class: Calcium Channel Blocker

Actions/Pharmacodynamics: Diltiazem is a slow calcium channel blocker with pharmacologic actions similar to those of verapamil. It inhibits calcium ion influx through slow channels into cells of myocardial and arterial smooth muscle (both coronary and peripheral blood vessels). As a result, intracellular calcium remains at sub-threshold levels insufficient to stimulate cell excitation and contraction. Diltiazem slows SA and AV node conduction (antidyshythmic effect) without affecting normal atrial action potential or intraventricular conduction.

**Indications:** Tachycardia - Stable (5F)

Sustained narrow-complex tachycardia > 150 bpm in adults

with systolic BP ≥ 100 mmHg

\*\*OLMC Order Only

**Contraindications:** Known hypersensitivity to diltiazem

2nd/3rd degree AV Blocks (may induce asystole)

Known Wolff-Parkinson-White Syndrome (may increase heart rate)

Known Sick Sinus Syndrome (may induce asystole)

Hypotension Bradycardia

Safe use in pregnancy and in children has not been established. Use with caution in CHF (especially if patient is also receiving a beta-blocker), conduction abnormalities, renal or hepatic impairment and the elderly due to exaggerated degree of effect.

**Pharmacokinetics:** Onset is 3 minutes; peak effect in 7 minutes; duration is 1-3 hours; half-life is 2 hours.

**Side Effects:** Headache, fatigue, dizziness, dysrhythmias, 2nd/3rd degree AV block, bradycardia, CHF, hypotension, syncope, palpitations.

Dosage: Tachycardia - Stable - Adult (5F)

Sustained narrow-complex tachycardia > 150 bpm in adults

with systolic BP ≥ 100mmHg

\*\*OLMC Order Only

Usual adult dose is 0.25 mg/kg slow IVP over 2 minutes

**How Supplied:** 25 mg in 5 mL vial (5 mg/mL)

(Always check concentration and dose per container at time of patient





Approved 9/04/24, Effective 1/15/25, replaces all prior versions

16K - DIPHENHYDRAMINE (BENADRYL®)

#### **PARAMEDIC**

Class: Antihistamine, Anticholinergic

Actions/Pharmacodynamics: Diphenhydramine competes for H1 – histamine receptor sites on effector cells, thus blocking histamine release. Histamine release creates some of the common signs and symptoms of an allergic response: pruritis (itching), mucus secretion, and capillary leaking, which contributes to the formation of urticaria (hives), erythematous skin, and mucosal edema. In the setting of a dystonic reaction, the balance of dopamine and choline must be changed within the brain. The most clinically feasible method of reversing a dystonic reaction, though inhibiting the enzyme acetylcholinesterase, is through the anti-cholinergic effect of a medication like diphenhydramine.

**Indications:** Dystonic Reactions (6F)

Acute Allergic Reactions (8D)

Bee/Wasp Stings (8F)

**Contraindications:** Known hypersensitivity to diphenhydramine. While rare, allergic reaction to diphenhydramine is possible and should be considered valid if stated or documented in a patient's medical history.

**Pharmacokinetics:** Onset within 15 – 30 minutes; duration is approximately 6 hours.

**Side Effects:** Drowsiness, dizziness, disturbed coordination.

Dosage: Dystonic Reactions - Adult (6F)

Acute Allergic Reactions- Adult (8D)

Bee/Wasp Stings - Adult (8F)

50 mg IM/IVP

Dystonic Reactions - Pediatric (6F)
Acute Allergic Reactions- Pediatric (8D)
Bee/Wasp Stings - Pediatric (8F)
1 mg/kg IM/IVP to maximum of 50 mg

**How Supplied:** 50 mg/1 mL in vial, ampule, or pre-filled syringe.

(Always check concentration and dose per container at time of patient





Approved 9/04/24, Effective 1/15/25, replaces all prior versions

16L – DOPAMINE (INTROPIN®)

#### **PARAMEDIC**

Class: Vasoconstrictor

Actions/Pharmacodynamics: Dose dependent. Higher doses (5+ mcg/kg/min) increasingly stimulate alpha receptors in the peripheral vasculature, producing vasoconstriction-related increases in system blood pressure. Concurrent beta receptor stimulation may produce increases in heart rate and mild bronchodilation. Lower doses (<5 mcg/kg/min), as may be encountered infrequently in interhospital transfers, produce mesenteric (intestinal) and renal vascular dilation to ensure continued perfusion to these organ systems in complicated medical illness that would otherwise sacrifice such circulation.

Indications: Dyspnea - Congestive Heart Failure (Cardiogenic Shock) (3E)

Post Cardiac Arrest Treatment (Cardiogenic Shock) (4J) Acute Coronary Syndrome (Cardiogenic Shock) (5C)

Sepsis (Septic Shock) (9B) Dialysis-Related Issues (9E)

For all listed situations, indication is hypotension (adult = systolic < 100 mmHg) due to cardiogenic, septic, or neurogenic shock either refractory to intravascular fluid boluses or in which intravascular fluid bolusing is

contraindicated (eg. pulmonary edema).

Contraindications: Hypertension

**Pharmacokinetics:** Onset of action within 5 minutes after IV/IO infusion initiated. Rapid metabolism, requiring ongoing IV/IO infusion to maintain clinical effects.

**Side Effects:** Palpitations, tachycardia, chest pain, and hypertension if not titrated.

Dosage: Dyspnea - Congestive Heart Failure (Cardiogenic Shock) - Adult (3E)

Post Cardiac Arrest Treatment (Cardiogenic Shock) - Adult (4J) Acute Coronary Syndrome (Cardiogenic Shock) - Adult (5C)

Sepsis (Septic Shock) - Adult (9B) Dialysis-Related Issues - Adult (9E)

For hypotension (shock) refractory to fluids or fluids contraindicated 5-20 mcg/kg/minute - see dosage chart - titrate to a sys B/P  $\geq 100 \text{ mmHg}$ .

Dyspnea - Congestive Heart Failure (Cardiogenic Shock) - Pediatric (3E) Post Cardiac Arrest Treatment (Cardiogenic Shock) - Pediatric (4J)

Sepsis (Septic Shock) - Pediatric (9B) Dialysis-Related Issues - Pediatric (9E)

For hypotension (shock) refractory to fluids or fluids contraindicated

\*\*OLMC Order Only.





Approved 9/04/24, Effective 1/15/25, replaces all prior versions

PROTOCOL 16L: Dopamine (Intropin®), cont

#### **Dopamine Infusion Adult Dosage Chart**

Dopamine		Dose in mcg				
		5	10	15	20	
Patient Weight in Kilograms	40	8	15	23	30	
	50	9	19	28	38	nly)
	60	11	23	34	45	
	70	13	26	39	53	0 =
	80	15	30	45	60	tio
	90	17	34	51	68	mL/hr or drips/minute (for 1600 mcg concentration only)
	100	19	38	56	75	
	110	21	41	62	83	
	120	23	45	68	90	
	130	24	49	73	98	
	140	26	53	79	105	
	150	28	56	84	113	
	160	30	60	90	120	Ę.
	170	32	64	96	128	ţ.
	180	34	68	101	135	n DC
	190	36	71	107	143	m/a
	200	38	75	113	150	sdi
	210	39	79	118	158	ㅎ
	220	41	83	124	165	ō
	230	43	86	129	173	h.
	240	45	90	135	180	a L
	250	47	94	141	188	_

How Supplied: 400 mg/10 mL vial to be mixed into 250 mL D5W. (1600 mcg/mL concentration) OR pre-mixed dopamine infusion at 1600 mcg/mL concentration. (Always check concentration and dose per container at time of patient medication administration)


Special Comments: Relative caution should be exercised prior to use in the setting of marked tachydysrhythmias, due to the potential for further increase in heart rates. In the setting of tachydysrhythmia-induced cardiogenic shock, treat per Protocol 5G - Tachycardia - Unstable. Ensure aggressive fluid resuscitation is accomplished (unless contraindicated) prior to dopamine use.





Approved 9/04/24, Effective 1/15/25, replaces all prior versions

16M - DUODOTE® AUTOINJECTOR



Class: Parasympatholytic & Cholinesterase Reactivator

#### **Actions/Pharmacodynamics:**

**Atropine** Blocks parasympathetic impulses to the heart via the vagus nerve. Atropine increases the rate of cardiac sinoatrial (SA) node discharges, enhances conduction through the atrioventricular (AV) node, and by increasing heart rate, increases the cardiac output and blood pressure. Additionally, in the treatment of indicated poisonings (organophosphates, nerve agents), atropine reverses muscarinic effects of acetylcholine, including diaphoresis, diarrhea, urination, bronchorrhea (secretions from the lower respiratory tract), emesis, lacrimation (tearing), and salivation. Atropine produces dilation of pupils by blocking stimulation of the ciliary muscle surrounding the pupils.

**Pralidoxime chloride** reactivates cholinesterase (mainly outside the central nervous system) which has been inactivated by an organophosphate pesticide. The destruction of accumulated acetylcholine can then proceed and neuromuscular junctions will regain function. Pralidoxime chloride has its most critical effect in reversing paralysis of the muscles of respiration. Because Pralidoxime Chloride is less effective in relieving depression of the respiratory center, atropine is always required concomitantly to block the effect of accumulated acetylcholine at the site. Pralidoxime Chloride is short acting and repeated doses may be needed, especially when there is evidence of continuing toxicity.

Indications: Nerve Agents (15E)

Contraindications: None

**Pharmacokinetics:** With IM autoinjector use in nerve agent poisoning, effects may not be observed for 3-5+ minutes. Beneficial effects can persist in excess of 1 hour.

**Side Effects:** Headache, dizziness, vision changes (blurry vision and photophobia) due to papillary dilation, loss of coordination, laryngospam, tachycardia, hypertension, palpitations, dry mouth.





Approved 9/04/24, Effective 1/15/25, replaces all prior versions

PROTOCOL 16M: DuoDote® Autoinjector, cont.

Dosage: Nerve Agents - Adult & Pediatric > 12 years of age (15E)

2.1 mg atropine/ 600 mg pralidoxime IM

May repeat every 5-15 minutes to cumulative maximum dose of 6.3 mg/1800 mg. In the setting of serious symptoms (cardiopulmonary distress), repeat doses in rapid succession.

Nerve Agents - Pediatric ≤ 12 years of age (15E)

\*\*OLMC Order Only

Typical pediatric dose is 0.05 mg/kg atropine & 15 mg/kg pralidoxime IM per dose, max single dose of 2.1 mg atropine/600 mg pralidoxime

How Supplied: DuoDote® autoinjector

(Always check concentration and dose per container at time of

patient medication administration)

**Special Comments:** Ideally, every public safety professional should have ready access to three DuoDote® autoinjectors for self/buddy use should emergent conditions warrant. In the setting of suspected/actual nerve agent exposure, administration of the DuoDote® autoinjector(s) must occur within minutes of exposure for clinically effective results.





Approved 9/04/24, Effective 1/15/25, replaces all prior versions

16N – EPINEPHRINE 1mg/mL (1:1000) & 0.1mg/mL (1:10,000)

EMT
EMT-INTERMEDIATE 85
ADVANCED EMT
PARAMEDIC

IM Administration 1mg/mL (1:1000) Only - 8D 8E 8F

IM Administration 1mg/mL (1:1000) Only – 8D 8E 8F

IM Administration 1mg/mL (1:1000) Only – 3C 8D 8E 8F

Class: Vasoconstrictor, Bronchodilator (Catecholamine)

**Actions/Pharmacodynamics:** Stimulates alpha receptors in the peripheral vasculature, producing vasoconstriction-related increases in systemic blood pressure. Stimulates beta-1 receptors in the myocardium, producing increases in heart rate, myocardial contraction, and as a result, cardiac output. Stimulates beta-2 receptors in the lower respiratory tract smooth musculature, producing bronchodilation.

Indications: Dyspnea - Asthma (Severe & Refractory to Nebulization) (3C)

Dyspnea – Croup (3C)

Asystole (4F)

Ventricular Fibrillation/Pulseless Ventricular Tachycardia (4G)

Pulseless Electrical Activity (4H) Bradycardia (Pediatric) (5D)

Acute Allergic Reactions (Anaphylaxis) (8D)

Snakebites (Anaphylaxis) (8E) Bee/Wasp Stings (Anaphylaxis) (8F)

**Contraindications:** None absolute in indications above.

Safety in pregnancy not firmly established, though when clinically indicated the benefits outweigh risks.

**Pharmacokinetics:** Onset of action within 2 minutes after IVP/IOP; within 5-10 minutes after IM. Duration of effect ranges from 3-5 minutes after IVP/IOP to upwards of 30 minutes after IM.

**Side Effects:** Restlessness, anxiety, generalized tremors, headache, dizziness, chest pain, palpitations, hypertension, premature ventricular contractions, tachycardia.

Dosage: Dyspnea - Asthma (Severe & Refractory to Nebulization) - Adult (3C)

1mg/mL (1:1000) 0.3 mg IM

\*\*OLMC Order Required if pt ≥ 50 years old, heart illness history, or blood pressure > 140/90 mmHg.

Dyspnea - Asthma (Severe & Refractory to Nebulization) - Pediatric (3C) 1mg/mL (1:1000) 0.01 mg/kg (0.01 mL/kg) not to exceed 0.3 mg (0.3 mL) IM

\*\*OLMC Order required if heart illness history or blood pressure > 140/90 mmHg.





Approved 9/04/24, Effective 1/15/25, replaces all prior versions

PROTOCOL 16N: Epinephrine 1mg/mL (1:1000) & 0.1mg/mL (1:10,000), cont

Dosage, cont:

Dyspnea - Croup - Pediatric (3M)

1mg/mL (1:1000) 3mg/3mL via nebulizer

Asystole - Adult (4F)

Ventricular Fibrillation/Pulseless Ventricular Tachycardia - Adult (4G)

Pulseless Electrical Activity - Adult (4H)

0.1mg/mL (1:10,000) 1 mg IVP/IOP

Repeat every 3 - 5 minutes while resuscitating cardiac arrest

Ventricular Fibrillation/Pulseless Ventricular Tachycardia - Adult (4G)

0.1mg/mL (1:10,000) 1 mg IVP/IOP

Repeat every 3 - 5 minutes while resuscitating cardiac arrest, cumulative maximum 3mg

Asystole - Pediatric (4F)

Ventricular Fibrillation/Pulseless Ventricular Tachycardia - Pediatric (4G)

Pulseless Electrical Activity - Pediatric (4H)

0.1mg/mL (1:10,000) 0.01 mg/kg (0.1 mL/kg) IVP/IOP

Repeat every 3 - 5 minutes while resuscitating cardiac arrest

Bradycardia - Symptomatic & Systolic BP < 70 + (2 x age in years) mmHg (Sinus, First Degree, 2nd Degree Type I) - Pediatric (5D)

0.1mg/mL (1:10,000) 0.01 mg/kg (0.1 mL/kg) IVP/IOP

May repeat once.

Acute Allergic Reactions (Anaphylaxis) - Adult (8D)

Snakebites (Anaphylaxis) - Adult (8E)

Bee/Wasp Stings (Anaphylaxis) - Adult (8F)

1mg/mL (1:1000) 0.5 mg IM

If anaphylaxis refractory to above IM dose:

0.1mg/mL (1:10,000) 1 mg slow IVP/IOP over 3 minutes

Acute Allergic Reactions (Anaphylaxis) - Pediatric (8D)

Snakebites (Anaphylaxis) - Pediatric (8E)

Bee/Wasp Stings (Anaphylaxis) - Pediatric (8F)

1mg/mL (1:1000) 0.15 mg IM dose for EMT

1mg/mL (1:1000) 0.01 mg/kg (0.01 mL/kg) not to exceed 0.3 mg (0.3 mL) IM

If anaphylaxis refractory to above IM dose:

0.1mg/mL (1:10,000) 0.01 mg/kg slow IVP/IOP over 3 minutes

How Supplied: Epinephrine 1mg/mL (1:1000) in 1 mg/1mL ampules or 30 mg/30 mL vial

(Always check concentration and dose per container at time of patient

medication administration)

Epinephrine 0.1mg/mL (1:10,000) in 1 mg/10 mL prefilled syringes

(Always check concentration and dose per container at time of patient

medication administration)


**Special Comments:** Be sure to administer correct concentration. Pulsatile patients ages 35 years or greater, particularly those with known coronary artery disease, receiving epinephrine should have ECG monitoring initiated and continued as soon as an ECG monitor is available.





Approved 9/04/24, Effective 1/15/25, replaces all prior versions

160 – EPINEPHRINE AUTOINJECTOR (EPIPEN®, Auvi-Q®)



Class: Vasoconstrictor, Bronchodilator (Catecholamine)

**Actions/Pharmacodynamics:** Stimulates alpha receptors in the peripheral vasculature, producing vasoconstriction-related increases in systemic blood pressure. Stimulates beta-1 receptors in the myocardium, producing increases in heart rate, myocardial contraction, and as a result, cardiac output. Stimulates beta-2 receptors in the lower respiratory tract smooth musculature, producing bronchodilation.

Indications: Dyspnea - Asthma (Severe - Refractory to Inhaler/Nebulization) (3C)

Acute Allergic Reactions (Anaphylaxis) (8D)

Snakebites (Anaphylaxis) (8E)

Bee/Wasp Stings (Anaphylaxis) (8F)

**Contraindications:** None in indications above.

**Pharmacokinetics:** Onset of action within 5-10 minutes after IM administration. Duration of effect may range upwards of 30 minutes intramuscularly.

Adverse/Side Effects: Restlessness, anxiety, generalized tremors, headache, dizziness, chest pain, palpitations, hypertension, premature ventricular contractions, tachycardia. Pulsatile patients ages 35 years or greater, particularly those with known coronary artery disease, receiving epinephrine should have ECG monitoring initiated and continued as soon as an ECG monitor is available. Safety in pregnancy not firmly established, though when clinically indicated the benefits outweigh risks and should not deter clinically necessary usage.

Dosage: Dyspnea - Asthma (Severe - Refractory to Inhaler/Nebulization) - Adult (3C)

**Acute Allergic Reactions (Anaphylaxis) - Adult (8D)** 

Snakebites (Anaphylaxis) - Adult (8E)

Bee/Wasp Stings (Anaphylaxis) - Adult (8F)

Adult Epinephrine Autoinjector (0.3 mg of Epinephrine 1mg/mL 1:1000) IM lateral

thigh

\*\*OLMC Order required if pt ≥ 50 years old, heart illness history, or blood pressure > 140/90 mmHg.





Approved 9/04/24, Effective 1/15/25, replaces all prior versions

PROTOCOL 160: Epinephrine Autoinjector (EpiPen®, Auvi-Q®)

Dosage, cont.:

Dyspnea- Asthma (Severe-Refractory to Inhaler/Nebulization)-Pediatric (3C) Acute Allergic Reactions (Anaphylaxis) - Pediatric (8D) Snakebites (Anaphylaxis) - Pediatric (8E) Bee/Wasp Stings (Anaphylaxis) - Pediatric (8F)

Pediatric Epinephrine Autoinjector (0.15 mg of Epinephrine 1mg/mL 1:1000) IM lateral thigh

\*\*OLMC Order required if heart illness history or blood pressure > 140/90 mmHg.

**How Supplied:** 0.3 mg Adult Epinephrine Autoinjector

0.15 mg Pediatric Epinephrine Autoinjector

(Always check concentration and dose per container at time of patient medication administration)

**Special Comment:** For autoinjector medication administration, expose and wipe the midlateral thigh with ChloraPrep<sup>®</sup>, Betadine<sup>®</sup>, or an alcohol wipe. When handling the autoinjector for dosing, grasp the autoinjector with a fist, and remove the trigger safety cap. DO NOT place fingers or hand over the injection tip once the trigger safety cap is being removed.

Place the injection tip on the desired injection skin area and push the entire autoinjector into the thigh, using firm and continuous pressure, until a click is heard (patient will exhibit evidence of feeling spring-loaded needle activation) and hold in place for 10 seconds while medication is being delivered intramuscular.

Use caution when withdrawing the autoinjector to avoid needlestick injury. Dispose of whole autoinjector in a sharps container.

After autoinjector is complete, massage injection site for 15 to 30 seconds to improve epinephrine absorption.





Approved 9/04/24, Effective 1/15/25, replaces all prior versions

16P – ETOMIDATE (AMIDATE®)

#### PARAMEDIC

**Class:** Sedative - Hypnotic (non-narcotic/opiate; non-benzodiazepine; non-barbiturate)

**Actions/Pharmacodynamics:** Etomidate is an intravenous hypnotic drug without analgesia. Etomidate is safe to use in patients with cardiac illness and patients with traumatic injuries. Etomidate has little to no effect upon myocardial metabolism, cardiac output, or peripheral circulation. Etomidate has been shown to reduce cerebral blood flow, cerebral oxygen consumption, and intracranial pressure – helpful in head injury situations.

**Indications:** Medication Assisted Intubation (2G)

**Contraindications:** Known hypersensitivity to etomidate.

**Pharmacokinetics:** Rapid onset of action, seen as desired sedation within as little as 10-15 seconds, but nearly always within less than 1 minute. Duration of action, based upon a standard dose of 0.3 mg/kg (70 kg adult dose of 20 mg) is 5-15 minutes.

**Side Effects:** 1) Transient skeletal muscle movements, called myoclonus, have been reported in 10-80% of patients. Most of these movements are mild to moderate in severity. Rarely, these movements are severe in motion and force, though transient. Most movements are bilateral and can involve any part of the body. Results of electroencephalographic studies taken during periods when these muscle movements were observed have failed to reveal true seizure activity. 2) Transient venous pain at injection site, due to propylene glycol, a solvent in Etomidate preparations. 3) Nausea and/or vomiting. 4) Very rarely, hypoventilation and apnea, though Etomidate generally preserves the baseline respiratory activity. 5) Very rarely, hypotension and when seen, usually is due to too rapid IVP administration.

Dosage: Medication Assisted Intubation - Adult (2G)

0.3 mg/kg IVP/IOP over 15-30 seconds, given just prior to intubation.

**How Supplied:** 40 mg/20 mL (2 mg/mL) vial or pre-filled syringe

(Always check concentration and dose per container at time of patient

medication administration)

**Special Comment:** Repeated doses of Etomidate should be avoided to minimize its effect upon adrenal function. Repeated doses and continuous infusions of etomidate have been linked to adrenal suppression.





Approved 9/04/24, Effective 1/15/25, replaces all prior versions

16Q - FENTANYL (SUBLIMAZE®)

#### **PARAMEDIC**

Class: Narcotic analgesic

**Actions/Pharmacodynamics:** Stimulates central nervous system opiate receptors, producing systemic analgesia. On a milligram weight basis, fentanyl is 50-100 times more potent than morphine. Its duration of action is shorter than morphine or hydromorphone. An IV dose of 100 mcg of fentanyl is roughly equivalent to an IV dose of 10 mg of morphine. Fentanyl has less emetic effects than other narcotic analgesics.

Indications: Chest Pain – Uncertain Etiology (5A)

Acute Coronary Syndrome (5C)

Snakebites (8E)

Abdominal Pain/Nausea/Vomiting/Diarrhea (9A)
Pain Management (Acute Onset & Chronic Type) (9D)

Eye Injury (10B)

Dental Injury/Pain (10C)

Chest/Abdomen/Pelvis Injury (10D) Extremity injury/Amputation Injury (10G)

Compartment Syndrome (10J) Crush Injury Syndrome (10K)

Burns (10L)

Lightning/Electrical Injury (11C)

Pelvic Pain (13E)

For all listed situations, indication is acute pain control in alert,

hemodynamically stable patient.

Contraindications: Hypotension

Respiratory Depression
Minor Degrees of Pain
Pain Assessed as Factitious

**Side Effects:** Hypotension, respiratory depression, euphoria, dizziness. Nausea and/or vomiting are rarely seen if administration is slow IVP.

**Pharmacokinetics:** Onset of action nearly immediate after IV administration. Peak effects occur within 3 – 5 minutes. Duration of effect is 30 - 60 minutes, with a half-life of 6 – 8 hours.





Approved 9/04/24, Effective 1/15/25, replaces all prior versions

PROTOCOL 16Q: Fentanyl (Sublimaze®), cont.

Dosage: Chest Pain – Uncertain Etiology – Adult (5A)

Acute Coronary Syndrome – Adult (5C)

0.5 mcg/kg slow IVP/IM/IN, maximum single dose of 50 mcg

May repeat every 10 minutes to a maximum cumulative dose of 1.5 mcg/kg or 125 mcg, whichever is lesser

Snakebites – Adult (8E)

Abdominal Pain/Nausea/Vomiting/Diarrhea – Adult (9A)

Pain Management (Acute Onset & Chronic Type) - Adult (9D)

Eye Injury - Adult (10B)

Dental Injury/Pain – Adult (10C)

Chest/Abdomen/Pelvis Injury - Adult (10D)

Extremity/Amputation Injury – Adult (10G)

**Compartment Syndrome – Adult (10J)** 

Crush Injury Syndrome – Adult (10K)

Burns - Adult (10L)

**Lightning/Electrical Injury – Adult (11C)** 

Pelvic Pain - Adult (13E)

For all listed situations, indication is acute pain control in alert, hemodynamically stable patient.

1 mcg/kg slow IVP/IM/IN, maximum single dose of 100 mcg

May repeat every 10 minutes to a maximum cumulative dose of 3 mcg/kg or 250 mcg, whichever is lesser

Extremity/Amputation Injury – Pediatric (10G)

Burns - Pediatric (10L)

1mcg/kg up to 50 mcg per dose. Repeat dose(s) requires OLMC order.

Chest Pain – Uncertain Etiology – Pediatric (5A)

Snakebites – Pediatric (8E)

Abdominal Pain/Nausea/Vomiting/Diarrhea – Pediatric (9A)

Pain Management (Acute Onset & Chronic Type) – Pediatric (9D)

Eye Injury – Pediatric (10B)

Dental Injury/Pain – Pediatric (10C)

Chest/Abdomen/Pelvis Injury – Pediatric (10D)

**Compartment Syndrome – Pediatric (10J)** 

Crush Injury Syndrome – Pediatric (10K)

**Lightning/Electrical Injury – Pediatric (11C)** 

Pelvic Pain - Pediatric (13E)

For all listed situations, indication is acute pain control in alert, hemodynamically stable patient

\*\*OLMC Order Only - Typical dose is 1 mcg/kg up to 50 mcg per dose.

**How Supplied:** 100 mcg/2 mL (50 mcg/mL) ampule, vial, or pre-filled syringe

250 mcg/5 mL (50 mcg/mL) ampule or vial

500 mcg/10 mL (50 mcg/mL) vial

(Always check concentration and dose per container at time of patient





Approved 9/04/24, Effective 1/15/25, replaces all prior versions

16R - GLUCAGON

**EMT-INTERMEDIATE 85** 

ADVANCED EMT

**PARAMEDIC** 

Intramuscular use only – 3A 4I 6B 6D 6E 6F 7A 8A 13D

Intramuscular use only – 3A 4I 6B 6D 6E 6F 7A 8A 13D

Class: Hormone

Actions/Pharmacodynamics: Glucagon is a hormone produced in the pancreas. When released in times of hypoglycemia, it causes a breakdown of glycogen (stored in the liver) to glucose and inhibits the subsequent synthesis of glycogen from circulating glucose. Both actions increase the blood levels of glucose. Given via the IM route, it is a useful drug in hypoglycemia when IV access is unsuccessful. Glucagon also increases heart rate, myocardial contractility and improves AV conduction in a manner similar to that produced by catecholamines. Its actions are independent of beta blockade and therefore may be useful via IV/IO administration by paramedics for reversing cardiovascular collapse effects of suspected beta blocker toxicity.

**Indications:** Respiratory Arrest (3A)

Specific Causes of Cardiac Arrest (4I)

Altered Mental Status (6B)

Seizure (6D) Syncope (6E)

Dystonic Reactions (6F) Behavioral Disorder (7A)

Poisonings – General Management (8A)

Complications of Pregnancy (13D)

For all listed situations, indication is hypoglycemia (blood glucose <50 mg/dL) without ability to safely administer oral glucose (due to aspiration concern) and without ability to establish IV access in EMT-I85, AEMT, and Paramedic Scopes of Practice.

Additional indication for beta blocker toxicity with hypotension and bradycardia in Paramedic Scope of Practice.

Contraindications: None

**Pharmacokinetics:** Onset 5 – 20 minutes; peak effects in 30 minutes; duration is 1 – 1.5

hours.

**Side Effects:** Dizziness, headache, nausea/vomiting, hyperglycemia.





Approved 9/04/24, Effective 1/15/25, replaces all prior versions

PROTOCOL 16R: Glucagon, cont.

Respiratory Arrest – Adult & Pediatric weight ≥ 25 kg (3A) Dosage:

Specific Causes of Cardiac Arrest - Adult& Pediatric weight ≥ 25 kg (4I)

Altered Mental Status – Adult & Pediatric weight ≥ 25 kg (6B)

Seizure – Adult & Pediatric weight ≥ 25 kg (6D) Syncope - Adult & Pediatric weight ≥ 25 kg (6E)

Dystonic Reactions – Adult & Pediatric weight ≥ 25 kg (6F) Behavioral Disorder – Adult & Pediatric weight ≥ 25 kg (7A)

Poisonings – General Management – Adult & Pediatric weight ≥ 25 kg (8A)

Complications of Pregnancy – Adult & Pediatric weight ≥ 25 kg(13D) All indicate hypoglycemia without safe PO access and without IV access

1 mg IM

Respiratory Arrest – Pediatric weight < 25 kg (3A)

Specific Causes of Cardiac Arrest–Pediatric weight < 25 kg (4I)

Altered Mental Status – Pediatric weight < 25 kg (6B)

Seizure – Pediatric weight < 25 kg (6D)

Syncope – Pediatric weight < 25 kg (6E)

Dystonic Reactions – Pediatric weight < 25 kg (6F)

Behavioral Disorder – Pediatric weight < 25 kg (7A)

Poisonings – General Management – Pediatric weight < 25 kg (8A)

Complications of Pregnancy – Pediatric weight < 25 kg (13D)

All indicate hypoglycemia without safe PO access and without IV access

0.5 mg IM

Specific Causes of Cardiac Arrest - Adult (4I)

Poisonings – General Management - Adult(8A)

Suspected beta blocker toxicity with arrest or hypotension/bradycardia (Paramedic only)

1 mg IVP/IOP; May be given IM if no IV access obtainable

Specific Causes of Cardiac Arrest - Pediatric (4I)

Poisonings – General Management – Pediatric (8A)

Suspected beta blocker toxicity with arrest or hypotension/bradycardia (Paramedic only)

0.5 mg IVP/IOP: May be given IM if no IV access obtainable

**How Supplied:** 1 mg dry powder in vial with 1 mL of diluting solute for reconstitution


(Always check concentration and dose per container at time of patient





Approved 9/04/24, Effective 1/15/25, replaces all prior versions

16S - GLUCOSE (ORAL)



Class: Carbohydrate

Actions/Pharmacodynamics: Increases blood sugar level.

**Indications:** Altered Mental Status (Hypoglycemia) (6B)

Syncope (Hypoglycemia) (6E)

Dystonic Reaction (Hypoglycemia) (6F) Behavioral Disorder (Hypoglycemia) (7A) Dialysis-Related Issues (Hypoglycemia) (9E) Complications of Pregnancy (Hypoglycemia) (13D)

**Contraindications:** Unconscious or semi–conscious and unable to follow simple commands. Care should be taken to prevent choking or aspiration of medication in semi–conscious patient.

**Pharmacokinetics:** Rapid oral absorption uptake to increase circulating blood sugar levels. Onset of effect within several minutes of oral dosing. Duration of effect up to 30+ minutes, but patient should be advised to consume complex carbohydrates within minutes of restoration of normal blood sugar, unless otherwise contraindicated.

Side Effects: None

Dosage: Altered Mental Status (Hypoglycemia) - Adult & Pediatric Weight ≥ 25 kg (6B)

Syncope (Hypoglycemia) - Adult & Pediatric Weight ≥ 25 kg (6E)

Dystonic Reaction (Hypoglycemia) - Adult & Pediatric Weight ≥ 25 kg (6F) Behavioral Disorder (Hypoglycemia) - Adult & Pediatric Weight ≥ 25 kg (7A) Dialysis-Related Issues (Hypoglycemia) - Adult & Pediatric Weight ≥ 25 kg (9E)

Complications of Pregnancy (Hypoglycemia) - Adult (13D) 15 grams (1 tube) PO or SL for blood glucose < 50 mg/dL





Approved 9/04/24, Effective 1/15/25, replaces all prior versions

PROTOCOL16S: Glucose (Oral), cont.

Dosage, cont.

Altered Mental Status (Hypoglycemia) - Pediatric Weight < 25 kg (6B) Syncope (Hypoglycemia) - Pediatric Weight < 25 kg (6E) Dystonic Reaction (Hypoglycemia) - Pediatric Weight < 25 kg (6F) Behavioral Disorder (Hypoglycemia) - Pediatric Weight < 25 kg (7A) Dialysis-Related Issues (Hypoglycemia) - Pediatric Weight < 25 kg (9E) 7.5 grams (1/2 tube) PO or SL for blood glucose < 50 mg/dL

**How Supplied:** 15 grams of glucose for oral administration in a squeeze tube container.

(Always check concentration and dose per container at time of patient

medication administration)

**Special Comment:** Medical grade glucose should be utilized in place of sodas, candy, and other carbohydrate-heavy solid food. In many cases, the carbohydrate grams cannot be measured.





Approved 9/04/24, Effective 1/15/25, replaces all prior versions

16T - HALOPERIDOL (HALDOL®)

### **PARAMEDIC**

Class: Antipsychotic

**Therapeutic Action/Pharmacodynamics:** Haloperidol is a potent, long – acting antipsychotic agent. While its exact mechanism is unclear, it appears to block the dopamine receptors in the brain associated with mood and behavior. It exerts strong antiemetic effects and impairs central thermoregulation. It also produces weak central anticholinergic effects and transient orthostatic hypotension

**Indications:** Chemical Restraint (7C)

**Contraindications:** Known hypersensitivity

Behavioral disorder etiology easily reversed (eg. hypoglycemia)

Minor degrees of agitation Parkinson's disease

Known seizure disorders (lowers seizure threshold)

CNS depressants, opiates, and alcohol may increase the CNS depression effect of haloperidol. Use with caution in elderly or debilitated patients due to exaggerated effect. Safe use in pregnancy has not been established, though in the indicated setting, benefit outweighs risks.

**Pharmacokinetics:** Onset is within 10-20 minutes IM; peak effect in 30-45 minutes; duration is 3+ hours, reported up to 35 hours.

**Side Effects:** CNS depression, seizure, dystonic reactions, dry mouth, blurry vision, bronchospasm, tachycardia, hypertension, hypotension, dysrhythmias, hyperpyrexia, diaphoresis, urinary retention.

Dosage: Chemical Restraint - Adult (7C)

5 mg IM (use deep IM injection in large muscle - lateral thigh if possible)

Chemical Restraint - Pediatric (7C)

\*\* OLMC Order Only

**How Supplied:** 5 mg/1 mL vial.

(Always check concentration and dose per container at time of patient

medication administration)

**Special Comments:** In emergency situations where the patient's behavior poses an immediate risk to rescuers and bystanders, the IM injection may be given through the patient's clothing to minimize risk of needlestick injuries to rescuers. Dystonic reactions are common with haloperidol; diphenhydramine should be readily available - see Protocol 6F - Dystonic Reactions.





16U – HYDRALAZINE (APRESOLINE®)

Protocol removed by the Medical Control Board





Approved 9/04/24, Effective 1/15/25 replaces all prior versions

### 16V - HYDROMORPHONE (DILAUDID®)

### **PARAMEDIC**

Class: Narcotic analgesic

**Actions/Pharmacodynamics:** Stimulates central nervous system opiate receptors, producing systemic analgesia. Modest vasodilation effects increase peripheral venous capacitance, and reduce venous return, myocardial workload, and myocardial oxygen demand. Hydromorphone is roughly 10 times more potent than morphine. An IV dose of 1 mg of hydromorphone is equivalent to an IV dose of 10 mg of morphine.

Indications: Snakebites (8E)

Abdominal Pain/Nausea/Vomiting/Diarrhea (9A)
Pain Management (Acute Onset & Chronic Type) (9D)

Eye Injury (10B)

Dental Injury/Pain (10C)

Chest/Abdomen/Pelvis Injury (10D) Extremity/Amputation Injury (10G) Compartment Syndrome (10J) Crush Injury Syndrome (10K)

Burns (10L)

Lightning/Electrical Injury (11C)

Pelvic Pain (13E)

For all listed situations, indication is acute pain control in alert,

hemodynamically stable patient.

Contraindications: Hypotension

Respiratory Depression Minor Degrees of Pain Pain Assessed as Factitious

**Side Effects:** Hypotension, respiratory depression, euphoria, dizziness. Nausea and/or vomiting are rarely seen if administration is slow IVP. Rapid IVP will lead to an accompanying histamine release, producing the nausea and/or vomiting often erroneously attributed to hydromorphone itself.

**Pharmacokinetics:** Onset of action within 5-10 minutes after IV administration. Duration of effect can reach 4 - 6 hours depending upon end-organ function.





Approved 9/04/24, Effective 1/15/25 replaces all prior versions

PROTOCOL 16V: Hydromorphone (Dilaudid®), cont.

Dosage: Snakebites – Adult (8E)

Abdominal Pain/Nausea/Vomiting/Diarrhea – Adult (9A)
Pain Management (Acute Onset & Chronic Type) – Adult (9D)

Eye Injury – Adult (10B)

**Dental Injury/Pain – Adult (10C)** 

Chest/Abdomen/Pelvis Injury – Adult (10D) Extremity/Amputation Injury – Adult (10G) Compartment Syndrome – Adult (10J) Crush Injury Syndrome – Adult (10K)

Burns - Adult (10L)

**Lightning/Electrical Injury – Adult (11C)** 

Pelvic Pain – Adult (13E)

For all listed situations, indication is acute pain control in alert, hemodynamically stable patient.

0.5 - 1 mg slow IVP

May repeat every 10 minutes to a maximum cumulative dose of 2 mg

Snakebites - Pediatric (8E)

Abdominal Pain/Nausea/Vomiting/Diarrhea – Pediatric (9A)

Pain Management (Acute Onset & Chronic Type) – Pediatric (9D)

Eye Injury – Pediatric (10B)

Dental Injury/Pain - Pediatric (10C)

Chest/Abdomen/Pelvis Injury – Pediatric (10D)

Extremity/Amputation Injury – Pediatric (10G)

Compartment Syndrome – Pediatric (10J)

**Crush Injury Syndrome – Pediatric (10K)** 

Burns - Pediatric (10L)

**Lightning/Electrical Injury – Pediatric (11C)** 

Pelvic Pain – Pediatric (13E)

For all listed situations, indication is acute pain control in alert,

hemodynamically stable patient

\*\*OLMC Order Only - Typical dose is 0.01 mg/kg up to 0.5 mg per dose.

**How Supplied:** 2 mg/1 mL vial or pre-filled syringe

(Always check concentration and dose per container at time of patient





Approved 9/04/24, Effective 1/15/25, replaces all prior versions

### 16W - HYDROXOCOBALAMIN (CYANOKIT®)

#### **ADVANCED EMT**

**PARAMEDIC** 

Class: Cyanide Antidote

Actions/Pharmacodynamics: Hydroxocobalamin binds cyanide, forming cyanocobalamin for

urinary excretion.

**Indications:** Cyanide (12E)

**Contraindications:** None in the setting of suspected cyanide toxicity.

**Pharmacokinetics:** Near immediate onset of action following IVPB initiation. Effect is seen for hours, with duration of action seen predominantly in the first 24 hours following administration, but measurable for days.

**Side Effects:** Redness of skin and mucous membranes may be prominently noted. Additional side effects include headache, dizziness, restlessness, eye irritation, throat irritation, dyspnea, pulmonary edema, chest tightness, hypertension, tachycardia, palpitations, nausea, vomiting, diarrhea, abdominal pain, dysphagia, red urine, and hives.

Dosage: Cyanide - Adult (12E)

5 grams IVPB in 15 minutes

### Cyanide - Pediatric (12E)

The pediatric dose is 70 mg/kg IVPB administered over 15 minutes. Safe use of CYANOKIT® has not been well established in children. However, if clinically indicated the benefits likely outweigh the risk.

**How Supplied:** CYANOKIT <sup>®</sup> preparations include either one glass vial containing 5

grams of hydroxocobalamin as a dark red crystalline powder for reconstitution with 200 mL normal saline or a set of two glass vials, each containing 2.5 grams of hydroxocobalamin as a dark red crystalline

powder for reconstitution with 100 mL normal saline per vial.

Follow full instructions accompanying CYANOKIT® for preparation and administration, including use of transfer spike for normal saline addition to the vial(s), rocking, but not shaking the vial for 60 seconds prior to

administration, and administering the infusion from the vial(s). (Always check concentration and dose per container at time of patient

medication administration)


**Special Comment:** Multiple drug-drug incompatibilities exist with hydroxocobalamin. Use a separate IV line for the administration of hydroxocobalamin.





Approved 9/04/24, Effective 1/15/25, replaces all prior versions

### 16X - IPRATROPIUM BROMIDE (ATROVENT®)



Class: Parasympatholytic Bronchodilator

**Actions/Pharmacodynamics:** Atrovent is an anticholinergic agent, chemically related to atropine. Given in a nebulized form, it acts directly on the smooth muscle of the bronchial tree by inhibiting acetylcholine at receptor sites. By blocking parasympathetic action, it dilates the bronchial smooth muscle and decreases secretions. It also abolishes the vagally mediated reflex bronchospasm caused by inhaled irritants such as smoke, dust, and cold air and by a range of inflammatory mediators such as histamine.

Indications: Dyspnea - Asthma (3C)

Dyspnea - Chronic Obstructive Pulmonary Disease (3D)

Acute Allergic Reactions (8D)

Bee/Wasp Stings (8F)

**Contraindications and Precautions:** Atrovent is contraindicated in patients with hypersensitivity to atropine. It should not be used as the sole pharmacologic treatment for acute bronchospasm. By protocol, atrovent is always administered in conjunction with albuterol.

**Pharmacokinetics:** Absorption: 10% of inhaled dose reaches lower airway; approximately 0.5% of dose is systemically absorbed; onset within 5-15 minutes; peak effect in 1.5 - 2 hours; duration of effect is up to 4 - 6 hours; half - life is 1.5 - 2 hours.

Side Effects: Cough, reflex bronchospasm, hoarseness, nasal/oral dryness, bitter taste.

Dosage: Dyspnea - Asthma - Adult & Pediatric weight ≥ 15 kg (3C)

Acute Allergic Reactions - Adult & Pediatric weight ≥ 15 kg (8D)

Bee/Wasp Stings - Adult & Pediatric weight ≥ 15 kg (8F)

0.5 mg nebulized (with albuterol 5 mg)

**Dyspnea - Chronic Obstructive Pulmonary Disease - Adult (3D)** 

0.5 mg nebulized (with albuterol 5 mg), may repeat twice





Approved 9/04/24, Effective 1/15/25, replaces all prior versions

PROTOCOL 16X: Ipratropium bromide (Atrovent®)

Dosage, cont.:

Dyspnea - Asthma - Pediatric weight < 15 kg (3C)
Acute Allergic Reactions - Pediatric weight < 15 kg (8D)
Bee/Wasp Stings - Pediatric weight < 15 kg (8F)
0.25 mg nebulized (with albuterol 2.5 mg)

0.25 mg nebulized (with abuterol 2.5 mg)

**How Supplied:** 0.5 mg/2.5 mL nebulizer solution vials.

(Always check concentration and dose per container at time of patient





16Y - LABETALOL (NORMODYNE®, TRANDATE®)

Protocol removed by the Medical Control Board





Approved 9/04/24, Effective 1/15/25, replaces all prior versions

### 16Z - LIDOCAINE 2% INTRAVASCULAR (XYLOCAINE®)

**EMT-INTERMEDIATE 85** 

ADVANCED EMT

**PARAMEDIC** 

Intraosseous local anesthetic use only - 91

Intraosseous local anesthetic use only - 9I

Class: Intraosseous Local Anesthetic & Antidysrhythmic

**Therapeutic Actions/Pharmacodynamics:** As a local anesthetic, reduces nerve activation that carries painful stimulus from intraosseous fluid and/or medication administration. As an antidysrhythmic, suppresses ventricular automaticity, chemically converting ventricular tachycardia.

Indications: Tachycardia - Stable (5F)

Wide complex tachycardia, refractory to amiodarone

\*\*OLMC Order Only

Vascular Access - Intraosseous (9I)

Contraindications: Narrow complex tachycardia

Second degree AV Block-Type II (Classic Type) Third degree AV Block (Complete Heart Block)

Premature ventricular contractions with underlying bradycardias

No indication for IO anesthetic (unresponsive patients)

Pharmacokinetics: Onset of action within 3 minutes IVP/IOP. Duration for 10-20 minutes.

**Side Effects:** None expected in indicated dosing. Erroneous use in high degree heart blocks can lead to complete ventricular suppression/cardiac arrest.

Dosage: Tachycardia - Stable - Wide Complex Tachycardia - Adult (5F)

**Refactory to Amiodarone** 

Up to 1 mg/kg, slow IVP/IOP at < 50 mg/minute

\*\*OLMC Order Only

Tachycardia - Stable - Pediatric (5F)
Consult with OLMCP for use and dosing.

Vascular Access - Intraosseous (Local Anesthetic) - Adult & Pediatric (91)

1 mg/kg up to 40 mg IOP

How Supplied: 100 mg/5 mL (20 mg/mL of 2% lidocaine) prefilled syringe.


(Always check concentration and dose per container at time of patient





Approved 9/04/24, Effective 1/15/25, replaces all prior versions

16AA – LIDOCAINE VISCOUS GEL (XYLOCAINE®)



Class: Topical Anesthetic

**Actions/Pharmacodynamics:** Lidocaine stabilizes the neuronal membrane by inhibiting the ionic fluxes required for the initiation and conduction of impulses, thereby effecting local anesthetic action. In gel formulation, additional lubricant effect is possible.

**Indications:** Nasotracheal Intubation (2H).

**Contraindications:** Known hypersensitivity to local anesthetics, amide type.

Pharmacokinetics: Onset of action within 3 - 5 minutes.

**Side Effects:** None expected unless amide anesthetic allergy. In this specific setting, adverse experiences are generally systemic in nature. Cardiovascular manifestations are usually depressant and are characterized by bradycardia, hypotension, and cardiovascular collapse.

Dosage: Nasotracheal Intubation - Adult (2H)

Apply gel to the external surface of the endotracheal tube, primarily the distal parts near the balloon cuff and the balloon cuff itself just prior to intubation. Typical use is 1-2 mL of gel.

How Supplied: 2% Viscous Gel (20 mg/mL) - available in foil packs, tubes, pre-filled

syringes for topical application, and bottles.

(Always check concentration and dose per container at time of patient

medication administration)

**Special Comments:** Care should be taken to avoid partially occluding the lumen of the endotracheal tube with gel. Do not use the gel to lubricate the endotracheal stylette. Avoid large bottles of lidocaine viscous gel. Attempts to use over multiple patients can result in gel contamination.





Approved 9/04/24, Effective 1/15/25, replaces all prior versions

16BB - LORAZEPAM (ATIVAN®)

#### **PARAMEDIC**

Class: Sedative; Anticonvulsant; Muscle Relaxant; Anxiolytic (Benzodiazepine)

**Actions/Pharmacodynamics:** Long - acting benzodiazepine with central nervous system depressant, anticonvulsant, muscle relaxant, and anxiolytic effects. Like the other benzodiazepines, it has no effect on pain. Ativan has less muscle relaxant properties than diazepam, though no substantial amnestic effects as with midazolam.

**Indications:** Medication Assisted Intubation (2G)

Post-intubation sedation - onset delay does not favor pre-intubation use

Seizure (6D)

(Midazolam preferred benzodiazepine due to faster onset of action)

Dystonic Reactions (6F) Chemical Restraint (7C)

(Midazolam preferred benzodiazepine due to faster onset of action)

Poisonings - General Management (8A)

Suspected stimulant toxicity = severe agitation, HTN, tachycardia, diaphoresis

Head/Neck/Spine Injury (10A)

(Midazolam preferred benzodiazepine due to faster onset of action)

Heat Illness (11A)

(Midazolam preferred benzodiazepine due to faster onset of action)

**Contraindications:** Patients with intolerance to benzodiazepines, acute narrow - angle glaucoma, shock, or coma. Caution with use in patients with COPD, chronic hepatic or renal failure, CHF, acute alcohol intoxication, and the elderly due to increased risk of respiratory depression.

**Pharmacokinetics:** Onset is 5-10 minutes, IVP/IOP; up to 30 minutes IM; peak effects in 2-3 hours. Duration is 3-6+ hours IVP/IOP/IM; half – life can reach 20 – 50 hours.

**Side Effects:** Headache, euphoria, drowsiness, excessive sedation, confusion, dizziness, blurred vision, diplopia, nystagmus, respiratory arrest, hypotension, nausea, vomiting.

Dosage: Medication Assisted Intubation (Post Intubation Sedation) - Adult (2G)

0.1 mg/kg to max 2 mg IVP/IOP, may repeat once if systolic BP > 100 mmHg

Seizure - Adult (6D) Heat Illness - Adult (11A)

2 mg IVP/IOP/IM for active seizure

May repeat once in 10 minutes if still seizing.





Approved 9/04/24, Effective 1/15/25, replaces all prior versions

PROTOCOL 16BB: Lorazepam (Ativan®), cont.

### Dosage, cont.:

Seizure - Pediatric (6D)
Heat Illness - Pediatric (11A)
0.1 mg/kg to max 2 mg IVP/IOP/IM for active seizure
May repeat once in 5 minutes if still seizing.

**Dystonic Reactions - Adult (6F)** 2 mg IVP/IM

**Dystonic Reactions - Pediatric (6F)** 0.1 mg/kg to max 2 mg IVP/IM

Chemical Restraint - Adult (7C) 2 mg IVP/IOP/IM May repeat once.

Chemical Restraint - Pediatric (7C) 0.1 mg/kg to max 2 mg IVP/IOP/IM

**Poisoning - General Management (Suspected Stimulant Toxic) - Adult (8A)** 1 -2 mg IVP/IM

Poisoning - General Management (Suspected Stimulant Toxic) - Pediatric (8A) \*\*OLMC Order Only

Head/Neck/Spine Injury - Adult (10A)

1 mg IVP/IM/IOP for active seizure. May repeat once in 5 minutes if still seizing.

Head/Neck/Spine Injury - Pediatric (10A)

0.1 mg/kg IVP/IM/IOP for active seizure.

May repeat once in 5 minutes if still seizing.

**How Supplied:** 2 mg/1 mL or 4 mg/1 mL in vials, ampules, or pre-filled syringes.

(Always check concentration and dose per container at time of patient

medication administration)

**Special Comment:** Lorazepam must be kept refrigerated.





Approved 9/04/24, Effective 1/15/25, replaces all prior versions

16CC - MAGNESIUM SULFATE

### **PARAMEDIC**

Class: Electrolyte

**Therapeutic Actions/Pharmacodynamics:** As an antidysrhythmic, reverses low circulating magnesium levels associated with ventricular arrhythmias, particularly polymorphic ventricular tachycardia, commonly called Torsades de Pointes. It is the anticonvulsant of greatest benefit for eclampsia.

**Indications:** Dyspnea - Asthma (3C)

Ventricular Fibrillation/Pulseless Ventricular Tachycardia (Torsades) (4G)

Tachycardia - Stable (Torsades) (5F) Childbirth - Complicated (Eclampsia) (13B) Complications of Pregnancy (Eclampsia) (13D)

**Contraindications:** Hypotension or Known Renal Failure (when treating asthma)

**Pharmacokinetics:** Onset of action typically within 1-2 minutes after IVP/IOP. Effects persist for up to 30 minutes.

**Side Effects:** None expected in indicated dosing. High doses (exceeding 4-6 grams) may cause sedation, muscle weakness, depressed reflexes, hypotension, bradycardia, and respiratory depression.

Dosage: Dyspnea - Asthma - (Severe & Refractory to Nebulization) - Adult (3C)

1 gram (add to 100 ml NS and infuse over 10 minutes)

Ventricular Fibrillation/Pulseless Ventricular Tachycardia (Torsades) - Adult (4G) 1 gram IVP/IOP

Tachycardia - Stable (Torsades) - Adult (5F)

1 gram slow IVP/IOP over 1 minute.

May repeat once.

Tachycardia - Stable (Torsades) - Pediatric (5F)

Consult with OLMCP for use and dosing.

Childbirth - Complicated (Eclampsia) (13B) Complications of Pregnancy (Eclampsia) (13D)

1 gram IVP/IOP/IM. Reconstitute 1 gram with 2 ml NS and administer 1 mL IM via two unique injection sites if unable to establish IV/IO access. May repeat every 2-3 mins until seizure abates. Maximum cumulative dose is 4 grams.





Approved 9/04/24, Effective 1/15/25, replaces all prior versions

PROTOCOL 16CC: Magnesium Sulfate, cont.

**How Supplied:** 1 gram/2 mL (500 mg/mL in 50% solution) vials

5 grams/10 mL (500 mg/mL in a 50% solution) vials

5 grams/10 mL (500 mg/mL in a 50% solution) pre-filled syringes (Always check concentration and dose per container at time of patient





Approved 9/04/24, Effective 1/15/25, replaces all prior versions

### 16DD – METHYLPREDNISOLONE (SOLU-MEDROL®)

### **PARAMEDIC**

Class: Steroid

**Actions/Pharmacodynamics:** Methylprednisolone is an intermediate-acting synthetic adrenal corticosteroid with glucocorticoid activity. It exerts anti-inflammatory effects in the setting of inflammatory-mediated illness.

**Indications:** Dyspnea - Asthma (3C)

Dyspnea - Chronic Obstructive Pulmonary Disease (3D)

Dyspnea – Croup (3M) Acute Allergic Reactions (8D)

Bee/Wasp Stings (8F)

**Contraindications and Precautions:** Known hypersensitivity to methylprednisolone. In the setting of anaphylaxis, the only true contraindication is prior severe allergy (anaphylaxis) caused by methylprednisolone.

**Pharmacokinetics:** Onset of action within 4 – 6 hours, may have effect in excess of 24 hours.

**Side Effects:** None expected immediately. May occasionally see any of the following effects with onset of action: euphoria, insomnia, confusion, psychosis, edema, hypertension, nausea/vomiting, hyperglycemia.

Dosage: Dyspnea - Asthma - Adult (3C)

Dyspnea - Chronic Obstructive Pulmonary Disease - Adult (3D)

Acute Allergic Reactions - Adult (8D)

Bee/Wasp Stings - Adult (8F)

125 mg IVP. Give IM if no IV access obtainable.

Dyspnea - Asthma - Pediatric (3C) Dyspnea - Croup - Pediatric (3M)

Acute Allergic Reactions - Pediatric (8D)

Bee/Wasp Stings - Pediatric (8F)

2 mg/kg not to exceed 125 mg IVP. Give IM if no IV access obtainable.

**How Supplied:** 125 mg Act-O-Vial™ System (Single Dose Vial)

(Always check concentration and dose per container at time of patient





Approved 9/04/24, Effective 1/15/25, replaces all prior versions

16EE - MIDAZOLAM (VERSED®)

### **PARAMEDIC**

Class: Sedative; Anticonvulsant; Amnestic; Muscle Relaxant, Anxiolytic (Benzodiazepine)

**Actions/Pharmacodynamics:** Short - acting benzodiazepine with central nervous system depressant, anticonvulsant, anterograde amnestic, muscle relaxant, and anxiolytic effects. Like the other benzodiazepines, it has no effect on pain.

Indications: Medication Assisted Intubation (Pre & Post Intubation Sedation) (2G)

Post Cardiac Arrest Treatment (Hypothermia Induced Shivering Control) (4J)

Transcutaneous Pacing (Sedation) (5E) Synchronized Cardioversion (Sedation) (5G)

Seizure (6D)

Dystonic Reactions (6F) Chemical Restraint (7C)

Poisonings - General Management (8A)

Suspected stimulant toxicity = severe agitation, HTN, tachycardia, diaphoresis

Head/Neck/Spine Injury (10A)

Heat Illness (11A)

**Contraindications:** Patients with intolerance to benzodiazepines, acute narrow - angle glaucoma, shock, or coma. Caution with use in patients with COPD, chronic hepatic or renal failure, CHF, acute alcohol intoxication, and the elderly due to increased risk of respiratory depression.

**Pharmacokinetics:** Onset is 3-5 minutes, IVP/IOP; 6-14 minutes IN; up to 15 minutes IM (though clinically evident much faster); peak effects in 20-60 minutes. Duration is 2 hours IVP/IOP/IN; 1-6 hours IM; half – life is 1-4 hours.

**Side Effects:** Retrograde amnesia, headache, euphoria, drowsiness, weakness, excessive sedation, confusion, dizziness, blurred vision, diplopia, nystagmus, respiratory arrest, tachypnea, hypotension, nausea, vomiting.

Dosage: Medication Assisted Intubation (Pre & Post Intubation Sedation) - Adult (2G)

0.1 mg/kg to max 5 mg IVP/IOP, may repeat once if systolic BP > 100 mmHg

Post Cardiac Arrest Treatment (Hypothermia Induced Shivering Control) - Adult & Pediatric (4J)

0.1 mg/kg to max 5 mg IVP/IOP

Transcutaneous Pacing (Sedation) - Adult (5E)

2 - 5 mg IVP based upon weight and hemodynamics (0.1 mg/kg to max 5 mg)





Approved 9/04/24, Effective 1/15/25, replaces all prior versions

PROTOCOL 16EE: Midazolam (Versed®), cont.

### Dosage, cont.:

### Synchronized Cardioversion (Sedation) - Adult (5G)

0.1 mg/kg to max 5 mg IVP/IOP/INP

Seizure - Adult (6D) Heat Illness - Adult (11A)

0.1 mg/kg to max 5 mg IM/IVP/IN/IOP for active seizure. May repeat once in 5 minutes if still seizing.

Seizure - Pediatric (6D)
Head/Neck/Spine Injury - Pediatric (10A)
Heat Illness - Pediatric (11A)

0.1 mg/kg to max 5 mg IM/IVP/IN/IOP for active seizure May repeat once in 5 minutes if still seizing.

**Dystonic Reactions - Adult (6F)** 

2.5 mg IVP/IM/IN

**Dystonic Reactions - Pediatric (6F)** 

0.1 mg/kg to max 2.5 mg IM/IVP/IN

**Chemical Restraint - Adult (7C)** 

0.1 mg/kg to max 5 mg IM/IVP/IN/IOP. May repeat once.

**Chemical Restraint - Pediatric (7C)** 

0.1 mg/kg to max 5 mg IM/IVP/IN/IOP

Poisoning - General Management (Suspected Stimulant Toxic) - Adult (8A) 0.1 mg/kg to max 5 mg IVP/IN/IM

Poisoning - General Management (Suspected Stimulant Toxic) - Pediatric (8A) \*\*OLMC Order Only

Head/Neck/Spine Injury - Adult (10A)

5 mg IM/IVP/IN/IOP for active seizure. May repeat once in 5 minutes if still seizing.

**How Supplied:** 5 mg/1 mL in vials, ampules, or pre-filled syringes.

(Always check concentration and dose per container at time of patient





Approved 9/04/24, Effective 1/15/25, replaces all prior versions

### 16FF - MORPHINE SULFATE

### **PARAMEDIC**

Class: Narcotic analgesic

**Actions/Pharmacodynamics:** Stimulates central nervous system opiate receptors, producing systemic analgesia. Modest vasodilation effects increase peripheral venous capacitance, and reduce venous return, myocardial workload, and myocardial oxygen demand.

Indications: Snakebites (8E)

Abdominal Pain/Nausea/Vomiting/Diarrhea (9A)
Pain Management (Acute Onset & Chronic Type) (9D)

Eye Injury (10B)

Dental Injury/Pain (10C)

Chest/Abdomen/Pelvis Injury (10D) Extremity/Amputation Injury (10G) Compartment Syndrome (10J) Crush Injury Syndrome (10K)

Burns (10L)

Lightning/Electrical Injury (11C)

Pelvic Pain (13E)

For all listed situations, indication is acute pain control in alert,

hemodynamically stable patient.

Contraindications: Hypotension

Respiratory Depression Minor Degrees of Pain Pain Assessed as Factitious

**Side Effects:** Hypotension, respiratory depression, euphoria, dizziness. Nausea and/or vomiting are rarely seen if administration is slow IVP. Rapid IVP will lead to an accompanying histamine release, producing the nausea and/or vomiting often erroneously attributed to morphine itself.

**Pharmacokinetics:** Onset of action within 3-5 minutes after IV administration. Duration of effect can reach 4 hours depending upon end-organ function.





Approved 9/04/24, Effective 1/15/25, replaces all prior versions

PROTOCOL 16FF: Morphine Sulfate, cont.

Dosage: Snakebites – Adult (8E)

Abdominal Pain/Nausea/Vomiting/Diarrhea – Adult (9A)
Pain Management (Acute Onset & Chronic Type) – Adult (9D)

Eye Injury – Adult (10B)

Dental Injury/Pain - Adult (10C)

Chest/Abdomen/Pelvis Injury – Adult (10D) Extremity/Amputation Injury – Adult (10G) Compartment Syndrome – Adult (10J) Crush Injury Syndrome – Adult (10K)

Burns - Adult (10L)

**Lightning/Electrical Injury – Adult (11C)** 

Pelvic Pain - Adult (13E)

For all listed situations, indication is acute pain control in alert,

hemodynamically stable patient.

2 - 4 mg slow IVP

May repeat every 5 minutes to a maximum cumulative dose of 10 mg

Snakebites - Pediatric (8E)

Abdominal Pain/Nausea/Vomiting/Diarrhea – Pediatric (9A)

Pain Management (Acute Onset & Chronic Type) – Pediatric (9D)

Eye Injury – Pediatric (10B)

Dental Injury/Pain – Pediatric (10C)

Chest/Abdomen/Pelvis Injury – Pediatric (10D)

Extremity/Amputation Injury – Pediatric (10G)

**Compartment Syndrome – Pediatric (10J)** 

**Crush Injury Syndrome – Pediatric (10K)** 

**Burns – Pediatric (10L)** 

Lightning/Electrical Injury – Pediatric (11C)

Pelvic Pain – Pediatric (13E)

For all listed situations, indication is acute pain control in alert,

hemodynamically stable patient

\*\*OLMC Order Only – Typical dose is 0.1 mg/kg up to 2 mg per dose.

**How Supplied:** 2 mg/1 mL pre-filled syringe

4 mg/1 mL vial, ampule, or pre-filled syringe

8 mg/1 mL pre-filled syringe

10 mg/1 mL vial 10 mg/10 mL vial

(Always check concentration and dose per container at time of patient





Approved 9/04/24, Effective 1/15/25, replaces all prior versions

16GG - NALOXONE (NARCAN®)



IN Administration via MPDS Phone Directive - 3A, 4I, 6B, 6E, 8A

IN Administration Only – 3A, 4I, 6B, 6E, 8A

IN Administration Only – 3A, 4I, 6B, 6E, 8A

IN Administration Only – 3A, 4I, 6B, 6E, 8A

Class: Narcotic antagonist

**Actions/Pharmacodynamics:** The primary action of interest is reversal of respiratory depression associated with narcotic agents. Naloxone competes with and displaces narcotic substances from opiate receptors.

**Indications:** Respiratory Arrest (3A)

Specific Causes of Cardiac Arrest (4I)

Altered Mental Status (6B)

Syncope (6E)

Poisonings – General Management (8A)

**Contraindications:** Known or suspected narcotic substance use or abuse without cardiopulmonary compromise. Post-intubation in known or suspected narcotic substance use or abuse situations. Avoid whenever possible in known or suspected narcotic addicts. In these patients, use the smallest clinically effective dose possible (titrating administration slowly) to avoid acute narcotic withdrawal.

**Pharmacokinetics:** Onset of action within 2 minutes after IVP/IOP/IN administration with duration of effect up to 2 hours.

**Side Effects:** Agitation, anxiety, diaphoresis, tachycardia, nausea, vomiting, headache, hypertension, hypotension, seizures.





Approved 9/04/24, Effective 1/15/25, replaces all prior versions

PROTOCOL 16GG: Naloxone (Narcan®), cont.

Dosage: Respiratory Arrest - Adult (3A)

Specific Causes of Cardiac Arrest - Adult (41)

Altered Mental Status – Adult (6B)

Syncope - Adult (6E)

Poisonings – General Management – Adult (8A) In Apnea/Agonal Breathing, 2 mg IVP/IOP/IN.

May repeat once to maximum cumulative dose of 4 mg.

In Ineffective Breathing Activity, 0.5 mg IVP/IOP/IN. May repeat to a maximum cumulative dose of 4 mg.

Respiratory Arrest - Pediatric (3A)

**Specific Causes of Cardiac Arrest - Pediatric (4I)** 

Altered Mental Status – Pediatric (6B)

Syncope – Pediatric (6E)

Poisonings – General Management – Pediatric (8A)

In Apnea/Agonal Breathing, 0.5 mg IVP/IOP/IN. May repeat to a maximum cumulative dose of 2 mg.

In Ineffective Breathing Activity, 0.5 mg IVP/IOP/IN. May repeat to a maximum cumulative dose of 2 mg.

**How Supplied:** 0.4 mg/1 mL vial

0.4 mg/1 mL prefilled syringe 2 mg/2 mL prefilled syringe

4 mg/10 mL vial

(Always check concentration and dose per container at time of patient

medication administration)

**Special Comment:** In non-respiratory arrest or non-cardiac arrest situations, always titrate administration slowly, using the lowest clinically effective amount of naloxone possible to avoid inadvertent acute narcotic withdrawal and/or other side effects.

Naloxone should not be administered unless there is a known or suspected narcotic substance use or abuse.





Approved 9/04/24, Effective 1/15/25, replaces all prior versions

16HH – NITROGLYCERIN (NITROLINGUAL®, NITROMIST®, NITROSTAT®, NITROQUICK®, TRIDIL (IV INFUSION), NITRO-BID® - DERMAL)

EMERGENCY MEDICAL
DISPATCHER
EMERGENCY MEDICAL
RESPONDER
EMT
EMT
EMT-INTERMEDIATE 85
ADVANCED EMT
PARAMEDIC

Sublingual Dosing - Own Self-Administration Phone Directive - 3E 5A 5C

Sublingual Dosing - Assist Pt with Own Self-Administration - 3E 5A 5C

Sublingual Dosing - Assist Pt with Own Self-Administration - 3E 5A 5C

Sublingual Dosing - Assist Pt with Own Self-Administration - 3E 5A 5C

Sublingual Dosing - Assist Pt with Own Self-Administration - 3E 5A 5C

Class: Anti-Anginal, Vasodilator, Anti-Hypertensive (Nitrate)

**Actions/Pharmacodynamics:** Arterial and venous vasodilator through relaxing vascular smooth muscle. Reduces cardiac afterload resistance and cardiac preload volume respectively. Myocardial oxygen consumption/demand is decreased. Systemic blood pressure is decreased.

**Indications:** Dyspnea - Congestive Heart Failure (3E)

Chest Pain - Uncertain Etiology (5A) Acute Coronary Syndrome (5C)

Contraindications: Hypotension

Asymptomatic Hypertension

Erectile Dysfunction Medications (\*\*Requires OLMC Order Only)
Sildenafil (Viagra®) or Vardenafil (Levitra®) use within 24 hours

Tadafil (Cialis®) use within 48 hours

**Pharmacokinetics:** Rapid vascular uptake within 3 minutes of sublingual dosing, with duration of effect up to 30 minutes. Rapid vascular effect within 1-3 minutes of intravenous dosing, with ongoing effect while continuous infusion. Vascular effect within 15-30 minutes of transdermal dosing, with ongoing effect while continued transdermal absorption.

**Side Effects:** The most serious side effect is hypotension, usually transient and responsive to supine positioning and intravenous fluid bolusing. Common, though non-serious, symptoms include: headache due to vasodilation, blurred vision, and dizziness. Paramedics should exercise caution when applying transdermal nitroglycerin ointment, avoiding contact with bare hands to avoid experiencing personal side effects, typically headache and dizziness.





Approved 9/04/24, Effective 1/15/25, replaces all prior versions

PROTOCOL 16HH: Nitroglycerin (Nitrolingual®, NitroMist®, NitroStat®, NitroQuick®, Tridil - Intravenous, Nitro-BID® - Transdermal), cont.

Dosage: Dyspnea - Congestive Heart Failure - Adult (3E)

Acute Coronary Syndrome - Adult (5C)

0.4 mg sublingual spray or tablet if systolic BP > 100 mmHg. Single dose unless by Paramedic. May repeat 0.4 mg sublingual spray or tablet every 5 minutes if systolic BP >100 mmHg until chest pain and/or respiratory distress resolves.

Following initial sublingual use, may utilize intravenous infusion start at 10 mcg/min, titrate slowly to effect. Maximum infusion rate without OLMC consult is 50 mcg/min.

Following initial sublingual use, may utilize transdermal application of 1½ inches ointment to chest wall.

### Chest Pain - Uncertain Etiology - Adult (5A)

0.4 mg sublingual spray or tablet if systolic BP >100 mmHg. Single dose unless by Paramedic. If chest pain improved with initial dose, 0.4 mg sublingual spray or tablet every 5 minutes until chest pain and/or respiratory distress resolves.

Following initial sublingual use, may utilize intravenous infusion start at 10 mcg/min, titrate slowly to effect. Maximum infusion rate without OLMC consult is 50 mcg/min.

Following initial sublingual use, may utilize transdermal application of 1½ inches ointment to chest wall.

**How Supplied:** Metered dose spray 0.4 mg/spray.

Tablets for sublingual absorption 0.4 mg.

Intravenous infusion - Mix 50 mg into 250 mL D5W (200 mcg/mL) 10 mcg/min using microdrip infusion set is 3 mL/hour rate 20 mcg/min using microdrip infusion set is 6 mL/hour rate

Transdermal ointment in 2% nitroglycerin concentration

1½ inches = 22.5 mg of nitroglycerin

(Always check concentration and dose per container at time of patient medication administration)

16HH.2





Approved 9/04/24, Effective 1/15/25, replaces all prior versions

### 16II – NOREPINEPHRINE (LEVOPHED®)

### **PARAMEDIC**

Class: Vasoconstrictor

**Actions/Pharmacodynamics:** Stimulates alpha receptors in the peripheral vasculature, producing vasoconstriction-related increase in systemic blood pressure. Concurrent beta receptor stimulation may produce increases in heart rate and mild bronchodilation, though norepinephrine is a weaker beta stimulator than dopamine.

Indications: Dyspnea – Congestive Heart Failure (Cardiogenic Shock) (3E)

Post Cardiac Arrest Treatment (Cardiogenic Shock) (4J) Acute Coronary Syndrome (Cardiogenic Shock) (5C)

Sepsis (Septic Shock) (9B) Dialysis-Related Issues (9E)

For all listed situations, indication is hypotension (adult = systolic < 100 mmHg) due to cardiogenic, septic, or neurogenic shock either refractory to

intravascular fluid boluses or in which intravascular fluid bolusing is

contraindicated (eg. pulmonary edema).

Contraindications: Hypertension

**Pharmacokinetics:** Onset of action within 5 minutes after IV/IO infusion initiated. Rapid metabolism, requiring ongoing IV/IO infusion to maintain clinical effects.

**Side Effects:** Few, though at higher doses, symptoms may include headache, palpitations, tachycardia, chest pain, and eventual hypertension. Bradycardia can result reflexively from an increase in blood pressure.

Dosage: Dyspnea – Congestive Heart Failure (CHF) – Adult (3E)

Post Cardiac Arrest Treatment - Cardiogenic Shock - Adult (4J)

Acute Coronary Syndrome – Adult (5C) Sepsis - Septic Shock - Adult (9B) Dialysis-Related Issues - Adult (9E)

For hypotension (shock) refractory to fluids or fluids contraindicated

Start at 2-4 mcg/minute - see dosage chart - titrated to a systolic B/P ≥

100 mmHg. Maximum infusion rate is 12 mcg/minute.

Norepinephrine Infusion Adult Dosage Chart rates reflect using a microdrip (60 drops/mL) set:

mcg/min	2	3	4	5	6	7	8	9	10	11	12
drops/min	15	22	30	37	45	52	60	67	75	82	90



EMERGENCY
MEDICINE
UNIVERSITY OF ORLAHOMA

EMS SECTION

Approved 9/04/24, Effective 1/15/25, replaces all prior versions

PROTOCOL 16II: Norepinephrine (Levophed®), cont.

Dosage, cont.: Dyspnea – Congestive Heart Failure (CHF) - Pediatric (3E)

Post Cardiac Arrest Treatment - Cardiogenic Shock - Pediatric (4J)

Sepsis - Septic Shock - Pediatric (9B) Dialysis-Related Issues - Pediatric (9E)

For hypotension (shock) refractory to fluids or fluids contraindicated

\*\*OLMC Order Only

**How Supplied:** 4 mg/4 mL ampule or vial.

Use only 2 mL in a 250 mL bag of D5W.

(8 mcg/mL concentration)

(Always check concentration and dose per container at time of patient

medication administration)

Special Comments: In the setting of tachydysrhythmia-induced cardiogenic shock, treat per

Protocol 5G – Tachycardia - Unstable. Ensure aggressive fluid resuscitation

is accomplished (unless contraindicated) prior to norepinephrine use.

Norepinephrine should be given into a large, patent vein. The vein of choice for EMS use is the antecubital vein, as this will decrease the risk of overlying skin

necrosis. Do not administer norepinephrine through an IV

in the hand or leg. These veins are more likely to be affected by vaso-

occlusive diseases and more prone to ischemic complications.

Administration through IO in the proximal tibia or humeral head is permitted.

If local extravasation occurs, notify the receiving physician of the following FDA advisement of antidote to extravasation ischemia:

"To prevent sloughing/necrosis in peripheral ischemic areas promptly use syringe w/ fine hypodermic needle to liberally infiltrate area w/ 10-15 mL saline solution containing 5-10 mg phentolamine; sympathetic blockade causes immediate conspicuous local hyperemic changes if area infiltrated within 12 hours."

Safety in pregnancy not firmly established, though when clinically indicated the benefits outweigh risks. Safety in pediatrics not firmly established and OLMC is to be consulted prior to pediatric usage.

Avoid mixing in normal saline, as NS promotes loss of potency through oxidation of norepinephrine.





Medical Literature References 16II – Norepinephrine (Levophed)

1. Tran, Q. K., Mester, G., Bzhilyanskaya, V., Afridi, L. Z., Andhavarapu, S., Alam, Z., Widjaja, A., Andersen, B., Matta, A., & Pourmand, A. (2020). Complication of vasopressor infusion through peripheral venous catheter: A systematic review and meta-analysis. In *American Journal of Emergency Medicine* (Vol. 38, Issue 11, pp. 2434–2443). W.B. Saunders





Approved 9/04/24, Effective 1/15/25, replaces all prior versions

### 16JJ – ONDANSETRON (ZOFRAN®)

### **PARAMEDIC**

Class: Antiemetic

**Actions/Pharmacodynamics:** Ondansetron reduces the activity of the vagus nerve, which activates the vomiting center in the medulla oblongata, and also blocks serotonin receptors in the chemoreceptor trigger zone. It has little effect on vomiting caused by motion sickness.

Indications: Snakebites (8E)

Abdominal Pain/Nausea/Vomiting/Diarrhea (9A)

Sepsis (9B) Pelvic Pain (13E)

For all listed situations, indication is for active vomiting.

**Contraindications:** Known hypersensitivity to ondansetron

Current use of Apomorphine (Apokyn®), an anti – parkinsonian drug

Use with caution with patients currently using medications which effect QT interval (eg. procainamide, amiodarone, tricyclic antidepressants, haloperidol)

**Side Effects:** Sedation, dystonic reactions (rare), hypotension, tachycardia, angina, torsades (rare).

Dosage: Snakebites - Adult (8E)

Abdominal Pain/Nausea/Vomiting/Diarrhea - Adult (9A)

Sepsis - Adult (9B) Pelvic Pain - Adult (13E)

For all listed situations, indication is for active vomiting.

4 mg oral dissolving tablet on tongue, may repeat once in 10 minutes 4 mg slow IVP over 60 seconds, may repeat once in 10 minutes

**Snakebites - Pediatric (8E)** 

Abdominal Pain/Nausea/Vomiting/Diarrhea - Pediatric (9A)

Sepsis - Pediatric (9B) Pelvic Pain - Pediatric (13E)

For all listed situations, indication is for active vomiting. If age > 2 years, 4 mg oral dissolving tablet on tongue

0.1 mg/kg to max of 4 mg slow IVP over 60 seconds

How Supplied: 4 mg/2 mL (2 mg/mL) vial.

4 mg rapid oral dissolving tablet (ODT)

(Always check concentration and dose per container at time of patient





Medical Literature References 16JJ – Ondansetron (Zofran)


1. April MD, Oliver JJ, Davis WT, et al. Aromatherapy Versus Oral Ondansetron for Antiemetic Therapy Among Adult Emergency Department Patients: A Randomized Controlled Trial. *Annals of Emergency Medicine*. 2018;72(2):184-193. doi:10.1016/j.annemergmed.2018.01.016





Approved 9/04/24, Effective 1/15/25, replaces all prior versions

### 16KK – PHENYLEPHRINE 2% (NEOSYNEPHRINE®)



Active epistaxis only - 9C

Class: Topical Nasal Vasoconstrictor

**Actions/Pharmacodynamics:** Phenylephrine is a direct-acting sympathomimetic amine. It stimulates alpha receptors in the blood vessels of the nasal mucosa which causes their constriction, thereby decreasing the risk of subsequent nasal bleeding.

Indications: Nasal Intubation (2H)

Epistaxis (9C)

**Contraindications:** None in the indicated settings.

Pharmacokinetics: Onset of action is within seconds.

**Side Effects:** Rare with single dose. It is rarely absorbed systemically from nasal instillation.

Dosage: Nasal Intubation - Adult (2H)

2 sprays in each nostril

**Epistaxis - Adult & Pediatric (9C)** 

2 - 4 sprays in affected nostril(s) for control of epistaxis (with compression

of nose immediately after administration)

**How Supplied:** Phenylephrine Nasal Spray 1% solution, 15 mL squeeze bottle for single

patient use only.

(Always check concentration and dose per container at time of patient





Approved 9/04/24, Effective 1/15/25, replaces all prior versions

16LL - PRALIDOXIME CHLORIDE (2PAM)

#### **PARAMEDIC**

Class: Cholinesterase Reactivator

Actions/Pharmacodynamics: Pralidoxime chloride reactivates cholinesterase (mainly outside the central nervous system) which has been inactivated by an organophosphate pesticide. The destruction of accumulated acetylcholine can then proceed and neuromuscular junctions will regain function. Pralidoxime chloride has its most critical effect in reversing paralysis of the muscles of respiration. Because Pralidoxime Chloride is less effective in relieving depression of the respiratory center, atropine is always required concomitantly to block the effect of accumulated acetylcholine at the site. Pralidoxime Chloride is short acting and repeated doses may be needed, especially when there is evidence of continuing toxicity.

**Indications:** Poisonings – General Management (8A)

Contraindications: None

**Pharmacokinetics:** With IM autoinjector use, effects may not be observed for up to 15 minutes. Beneficial effects can persist in excess of 1 hour.

**Side Effects:** Headache, dizziness, vision changes, loss of coordination, laryngospam, tachycardia, palpitations.

Dosage: Poisonings – General Management - Adult & Pediatric > 12 years of age (8A)

600 ma IM

May repeat every 15 minutes to cumulative maximum dose of 1800 mg. In the setting of serious symptoms (cardiopulmonary distress), repeat doses in rapid succession.

Poisonings – General Management - Pediatric ≤ 12 years of age (8A) \*\*OLMC Order Only

Typical pediatric dose is 15 mg/kg IM per dose, max single dose 600 mg

**How Supplied:** 600 mg/2 mL autoinjector

(Always check concentration and dose per container at time of

patient medication administration)





Approved 9/04/24, Effective 1/15/25, replaces all prior versions

### 16MM - SODIUM BICARBONATE

### **PARAMEDIC**

Class: Alkalinizing agent

**Actions/Pharmacodynamics:** Raises the pH of blood by buffering excess hydrogen ions that are present in acidotic states. The role of sodium bicarbonate is limited in cardiac arrest. Because ventilation is an effective tool in managing respiratory acidosis, sodium bicarbonate should rarely be administered for cardiac arrest, unless the arrest is suspected to be secondary to hyperkalemia or a tricyclic antidepressant over ingestion.

Indications: Specific Causes of Cardiac Arrest (Hyperkalemia) (4I)

Poisonings – General Management (Tricyclic Antidepressant) (8A)

Dialysis-Related Issues (Hyperkalemia) (9E)

Crush Injury Syndrome (Hyperkalemia Prophylaxis) (10K)

**Contraindications:** Known metabolic alkalosis.

Pharmacokinetics: Onset of effect is observed within 3-5 minutes after IVP/IOP administration.

**Side Effects:** Sodium bicarbonate may inhibit oxygen release secondary to a shift in oxyhemoglobin saturation. It also may produce a paradoxical acidosis that can depress cerebral and cardiac function. Severe soft tissue damage can occur in extravasated administrations.

Dosage: Specific Causes of Cardiac Arrest – Hyperkalemia - Adult & Pediatric (4I)

Poisonings – General Management – Tricyclic Antidepressants - Adult &

Pediatric (8A)

Dialysis-Related Issues - Hyperkalemia - Adult & Pediatric (9E)

Crush Injury Syndrome – Hyperkalemia Prophylaxis - Adult & Pediatric (10K)

1 mEg/kg IVP/IOP with maximum dose of 50mEg

**How Supplied:** 50 mEq/50 mL (1 mEq/mL) prefilled syringe.

(Always check concentration and dose per container at time of patient

medication administration)


**Special Comment:** Do not administer with calcium chloride. A precipitate will form and obstruct the vascular access being utilized.





Approved 9/04/24, Effective 1/15/25, replaces all prior versions

### 16NN - CALCIUM GLUCONATE



Administration Phone Directive - 8H

Class: Elemental metabolite – calcium is the active component

**Actions/Pharmacodynamics:** In the setting of hydrofluoric acid burns, calcium gluconate topically applied to affected skin will allow for calcium to bind up the free fluoride ions, reducing pain caused by such ions. Binding the free fluoride ions reduces their impacts, specifically those associated with causing hyperkalemia, hypocalcemia, and hypomagnesemia.

**Indications:** Hydrofluoric Acid (8H)

**Contraindications:** Known hypercalcemia; effectively none in setting of hydrofluoric acid burn

**Pharmacokinetics:** Absorption transdermally, with onset of action within several minutes and duration of action up to several hours.

**Side Effects:** Typically none from EMS dosing.

Dosage: Hydrofluoric Acid – Adult & Pediatric (8H)

Apply topically to exposed/affected burn on skin

**How Supplied:** 2.5% gel in 25 gram tube

(Always check concentration and dose per container at time of patient

medication administration)

**Special Comment:** To monitor pain relief from calcium gluconate gel absorption, paramedics should avoid concurrent administration of opiate/narcotic medications. When hand(s) are involved, a best practice is to place a liberal amount of the calcium gluconate gel in exam glove(s), placing the gel in the spaces for any affected fingers too, and then pulling the glove(s) onto the affected hand(s). Weaker concentrations of hydrofluoric acid may result in time lag of several hours from exposure to onset of burn pain. High concentrations of hydrofluoric acid will cause immediate burn pain.





Approved 9/04/24, Effective 1/15/25, replaces all prior versions

### 1600 - DEXAMETHASONE

### **PARAMEDIC**

Class: Steroid

**Actions/Pharmacodynamics:** Dexamethasone is a long-acting synthetic adrenal corticosteroid with glucocorticoid activity. It exerts anti-inflammatory effects in the setting of inflammatory-mediated illness.

**Indications**: Dyspnea - Asthma (3C)

Dyspnea - Chronic Obstructive Pulmonary Disease (3D)

Dyspnea – Croup (3M) Acute Allergic Reactions (8D)

Bee/Wasp Stings (8F)

**Contraindications and Precautions:** Known hypersensitivity to dexamethasone. In the setting of anaphylaxis, the only true contraindication is prior severe allergy (anaphylaxis) caused by dexamethasone.

**Pharmacokinetics:** Onset of action within 4-6 hours, may have effect for 4-5 days and reportedly up to as long as 10 days.

**Side Effects:** None expected immediately. May occasionally see any of the following effects with onset of action: euphoria, insomnia, confusion, psychosis, edema, hypertension, nausea/vomiting, hyperglycemia.

Dosage: Dyspnea - Asthma - Adult (3C)

Dyspnea - Chronic Obstructive Pulmonary Disease - Adult (3D)

Acute Allergic Reactions - Adult (8D)

Bee/Wasp Stings - Adult (8F)

10 mg IVP. Give IM if no IV access obtainable.

Dyspnea - Asthma - Pediatric (3C) Dyspnea - Croup - Pediatric (3M)

**Acute Allergic Reactions - Pediatric (8D)** 

Bee/Wasp Stings - Pediatric (8F)

0.6 mg/kg not to exceed 10 mg IVP. Give IM if no IV access obtainable.

**How Supplied:** 10 mg/mL in a 1mL single-use vial.


(Always check concentration and dose per container at time of patient





Approved 9/04/24, Effective 1/15/25, replaces all prior versions

### 16PP - LEVALBUTEROL (XOPENEX®)



### Self-Administration Phone Directive - 3B 3C 3D 12B

Assist Pt with Self Administration - 3B 3C 3D 12B

Class: Sympathomimetic Bronchodilator

Actions/Pharmacodynamics: Levalbuterol is a relatively selective beta<sub>2</sub> adrenergic stimulant. Levalbuterol causes relaxation of the smooth muscles of the bronchial tree thus decreasing airway resistance, facilitating mucus drainage, and increasing vital capacity. As an isomer (a differing molecular structure of the same atoms) of albuterol, marketing of levalbuterol historically describes milder effects on beta<sub>1</sub> (heart) or alpha (peripheral vasculature) receptors than albuterol. This has not consistently been proven in clinical trials. In therapeutic doses, levalbuterol, by inhibiting histamine release from mast cells, also reduces the mucus secretion, capillary leaking, and mucosal edema caused by an allergic response in the lungs.

Indications: Dyspnea - Uncertain Etiology (3B)

Dyspnea - Asthma (3C)

Dyspnea - Chronic Obstructive Pulmonary Disease (3D)

Acute Allergic Reactions (8D)

Bee/Wasp Stings (8F) Smoke Inhalation (12B)

**Contraindications:** Known hypersensitivity to levalbuterol or albuterol. Levalbuterol should not be used if the sole etiology of dyspnea is strongly suspected to be CHF, as levalbuterol-induced tachycardia (even if milder than albuterol) may worsen the compromised cardiac output in CHF.

**Pharmacokinetics:** Onset within 5–15 minutes; peak effect in 1.5 hours; duration of effect is up to 5-8 hours; half-life is 3-4 hours. Distribution: When inhaled, levalbuterol is distributed to muscle cells along the bronchial tree. Very little is systemically absorbed and distributed.

**Side Effects:** Tremors, anxiety, dizziness, headache, cough, reflex bronchospasm, palpitations, tachycardia, and hypertension.





Approved 9/04/24, Effective 1/15/25, replaces all prior versions

PROTOCOL 16PP: Levalbuterol (Xopenex®)

Dosage: Dyspnea - Uncertain Etiology - Adult & Pediatric Weight ≥ 15kg (3B)

Smoke Inhalation - Adult & Pediatric Weight ≥ 15kg (12B)

2.5 mg nebulized, may repeat once.

Dyspnea - Uncertain Etiology - Pediatric Weight < 15kg (3B)

Smoke Inhalation - Pediatric Weight < 15kg (12B)

1.25 mg nebulized, may repeat once.

Dyspnea - Asthma - Adult & Pediatric Weight ≥ 15kg (3C)

Dyspnea - Chronic Obstructive Pulmonary Disease - Adult (3D)

Acute Allergic Reactions - Adult & Pediatric Weight ≥ 15kg (8D)

Bee/Wasp Stings - Adult & Pediatric Weight ≥ 15kg (8F)

2.5 mg nebulized (with ipratropium bromide 0.5 mg), may repeat twice.

Dyspnea - Asthma - Pediatric Weight < 15kg (3C)

Acute Allergic Reactions - Pediatric Weight < 15kg (8D)

Bee/Wasp Stings - Pediatric Weight < 15kg (8F)

1.25 mg nebulized (with ipratropium bromide 0.25 mg), may repeat twice.

**How Supplied:** 1.25 mg/3 mL or 1.25mg/0.5 mL in nebulizer vials.


(Always check concentration and dose per container at time of patient



Approved 9/04/24, Effective 1/15/25, replaces all prior versions

## PROTOCOL 17A: Destination Determination – Adult General Medical Patients


Adult General Medical Patients
Destination Determination
Four (4) Levels of General Medical Hospitals





Approved 9/04/24, Effective 1/15/25, replaces all prior versions PROTOCOL 17A: Destination Determination – Adult Cardiology Patients

Adult Cardiology Patients
Destination Determination
ST – Elevation Myocardial Infarction Patients
Three (3) Levels of Cardiology Hospitals



#### Cardiology Hospitals

#### Level I Cardiology Hospitals (PCI-Capable Hospital)

- Emergency Medical Services and Operative Procedures
- Physician/Nursing Staff trained in cardiac care 24 hours a day
- Capability of providing
  - ✓ Immediate diagnostic angiography
  - ✓ Reperfustion therapy by thrombolysis
  - ✓ Percutaneous coronary intervention
  - ✓ Coronary artery bypass graft
  - ✓ Capabilities of receiving 12 lead prehospital ECG

### Level II Cardiology Hospitals (Non- PCI Hospital)

- ☐ Emergency Medical Services with an organized Emergency Department
- Physician/Nursing Staff trained in cardiac care 24 hours a day
- ☐ Capability of providing
  - ✓ Reperfusion therapy by thrombolysis

### Level III Cardiology Hospital (Non-PCI Hospital)

- Emergency Medical Services twenty-four (24) hours a day with at least:
  - ✓ Mid-level practitioner
  - √ RN
  - ✓ LPN or
  - ✓ Paramedic or Intermediate Level EMT
- ☐ Level III Cardiology Hospitals may **ONLY** receive:
  - ✓ Assigned Priority II cardiac patients


#### **Definition of Adult Cardiology Patient**

- Priority I Adult Cardiology Patient
  - Examples:
    - ✓ Unstable Angina
    - ✓ Acute myocardial infarction / STEMI
    - Any complex of signs and symptoms consistent with acute coronary syndrome and cardiac decompensation, i.e., pulmonary edema, symptomatic cardiac dysrhythmia
- Priority II Adult Cardiology Patient
  - ☐ Example:
    - ✓ Cardiac patients with pre-existing condition requiring evaluation only



Approved 9/04/24, Effective 1/15/25, replaces all prior versions PROTOCOL 17A: Destination Determination – Adult Stroke Patients

Adult Stroke Patients
Destination Determination
Three (3) Levels of Stroke Hospitals




#### Definition of Adult Stroke Patient

- ☐ Priority I Adult Stroke Patient
  - ✓ Examples:
    - Patient with acute stroke symptoms within 23 hours of onset with abnormal Los Angeles Prehospital Stroke Screen
- ☐ Priority III Adult Stroke Patient
  - Examples:
    - Patient with acute stroke symptoms > 23 hours of onset or time indeterminate with abnormal Los Angeles Prehospital Stroke Screen



Approved 9/04/24, Effective 1/15/25, replaces all prior versions PROTOCOL 17A: Destination Determination - Adult Trauma Patients

> Adult Trauma Patients **Destination Determination**



## Pre - Hospital Triage Criteria

- Priority 1 Trauma Patient / Adult
  - Patients with high energy blunt or penetrating trauma with physiologic or anatomic abnormalities
- Priority 2 Trauma Patient / Adult
  - Patients who are involved in a high energy event with risk for severe injury despite stable or normal vital signs with no altered mentation or respiratory distress or patients with a single system injury
  - Select & Isolated hand injuries (Refer to I.1 Section 1)
- Priority 3 Trauma Patient / Adult
  - Patients without physiologic instability, altered mentation, neurological deficit, or significant anatomical or single system injuries and generally have been involved in low energy mechanism of injury incident.

- Emergency Medical Services with organized trauma services
- Physician/Nursing Staff with some specialties in trauma care available 24 hours a day Level III Trauma Centers are intended to receive patients at risk for
- severe injury with normal, stable vital signs or patients with single system injuries
- Level III Trauma Centers may receive Priority I Trauma Patients if the Level I or Level II Trauma Centers are on trauma services divert
- Level IV Trauma Centers Emergency Medical Services twenty-four (24) hours a day with at
  - Mid-level practitioner

  - RNI PN or


least:

- Paramedic or Intermediate Level FMT
- Level IV Trauma Centers may receive adult/pediatric patients without physiologic instability, altered mentation, neurologic deficit or significant anatomical injuries and have also not been involved in a significant mechanism of injury incident



Approved 9/04/24, Effective 1/15/25, replaces all prior versions **PROTOCOL 17A: Destination Determination**– **Pediatric General Medical Patients** 

Pediatric General Medical Patients
Destination Determination
Four (4) Levels of Pediatric General Medical Hospitals






Approved 9/04/24, Effective 1/15/25, replaces all prior versions

PROTOCOL 17A: Destination Determination – Pediatric Trauma Patients Pediatric Trauma Patients (< 15 years of age) **Destination Determination** Priority I Trauma / Pediatric Patient **Priority II Trauma / Pediatric Patient** Western Eastern Division Division Western Eastern Division Division P- II Trauma / Pediatric Patient Saint Francis **OU Medical** ☐ Saint Francis Hospital Hospital Center P- II Trauma / Pediatric Patient √ Whenever possible, ☐ The Children's Hospital transport injured adult and pediatric members of the □ OU Medical Center same family to the same ✓ Whenever possible, ☐ If the patient requires hospital. transport injured adult and immediate airway management pediatric members of the and paramedic attempts have same family to the same failed to maintain the airway hospital. with ETT or BVM, the patient should be transported to closest Level II or III Trauma Center **Priority III Trauma / Pediatric Patient Assigned Patient Unassigned Patient** Eastern Division Eastern Division Western Division Western Division Hospital of **Eastern Division** Patient's Choice Hospital Rotation within zone ■ Western Division Closest Hospital



Approved 9/04/24, Effective 1/15/25, replaces all prior versions PROTOCOL 17A: Destination Determination – Neonatal Medical Patients




## Neonatal Priority Determination

- Priority I Unstable
  - ☐ Cardiac or respiratory arrest
  - ☐ Less than 35 weeks gestation at time of birth(estimated)
  - APGAR ≤ 5 at 5 minutes
  - ☐ SpO2 less than 90% on oxygen
  - Diagnosed genetic disorders
- Priority II Stable
  - ☐ 35 weeks or later gestation at time of birth (estimated)
  - APGAR > 5 at 5 minutes
  - No immediate life threat identified



Approved 9/04/24, Effective 1/15/25, replaces all prior versions



### **Burn Determination**

- Determination Criteria
  - Burns with P1 or P2 trauma should be transported to the Trauma Center.
  - Burns with P3 trauma can be transported to IBMC-NWE if closest facility
  - ☐ In the Western Division burns should be transported to the closest appropriate burn capable destination.





## Medical Literature References 17A- Destination Determination

- 1. Elmer J, Callaway CW, Chang C-CH, et al. Long-Term Outcomes of Out-of-Hospital Cardiac Arrest Care at Regionalized Centers. *Annals of Emergency Medicine*. 2019;73(1):29-39. doi:10.1016/j.annemergmed.2018.05.018
- Panchal, A. R., Berg, K. M., Cabanãs, J. G., Kurz, M. C., Link, M. S., Del Rios, M., ... Kudenchuk, P. J. (2019). 2019 American Heart Association Focused Update on Systems of Care: Dispatcher-Assisted Cardiopulmonary Resuscitation and Cardiac Arrest Centers: An Update to the American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation, 140(24), E895–E903.



# PROTOCOL 17B, Table: Categorization of Hospitals Approved 9/04/24, Effective 1/15/25, replaces all prior versions

## Categorized Hospitals—Tulsa (Levels of Emergency Services)

Hospital	General Medical	Adult Stroke	Trauma	Neonatal	Ped. Medical	Ped. Trauma	Cardiology	Burns	Heli. Pad	Hyperbaric Chamber	Level I Cardiac Arrest Center
Bailey Medical Center	IV	IV	IV	N/A	IV	IV	III		Yes		No
Hillcrest Medical Center	1	1	III	II	II	III	1	*	Yes		Yes
Hillcrest Hospital South	II	II	III	N/A	III	III	I		Yes		Yes
OSUMC	1	Ш	Ш	N/A	III	III	ı		Yes	Yes	Yes
Saint Francis Hospital	I	I	II	I	I	II	I		Yes		Yes
Saint Francis South	III	III	III	П	III	III	III		Yes		No
Saint Francis Healthplex Glenpool	III	III	IV	N/A	IV	IV	III		No		No
St. John Medical Center	I	1	II	I	IV	III	I		Yes		Yes
St. John Broken Arrow	IV	IV	IV	N/A	IV	IV	III		Yes		No
St. John Owasso	IV	IV	IV	II	IV	IV	III		Yes		No
St. John Sapulpa	IV	IV	IV	N/A	IV	IV	III	_	Yes		No

## Categorized Hospitals--Oklahoma City (Levels of Emergency Services)

Hospital	General Medical	Adult Stroke	Trauma	Neonatal	Ped. Medical	Ped. Trauma	Cardiology	Burns	Heli. Pad	Hyperbaric Chamber	Level I Cardiac Arrest Center
SSM Health St. Anthony Hospital Midwest	II	III	III	N/A	III	III	II		Yes		Yes
The Children's Hospital	I	N/A	N/A	I	I	II	I	**	Yes		No
Community Hospital	IV	IV	IV	N/A	IV	IV	III		No		No
Integris Baptist Medical Center - Northwest Expressway (IBMC-NWE)	ļ	I	III	I	I	III	I	*	Yes	Yes	Yes
Integris Canadian Valley Hospital	II	III	III	II	III	III	II		No		No
Integris Community Hospitals	III	III	IV	N/A	IV	IV	III		No		No
Integris Baptist Medical Center -Portland Avenue (IBMC-PA)	ļ	II	III	N/A	III	III	П		No		No
Integris Health Edmond	II	III	III	N/A	III	III	I		Yes		Yes
Integris Southwest Medical Center	I	II	III	N/A	III	III	ļ		Yes		Yes
Mercy Hospital – Oklahoma City	II	1	III	II	III	III	П		Yes		No
Mercy I-35 (Free Standing ED)***	III	III	IV	N/A	IV	IV	III		No		No
Norman Regional Hospital	П	II	III	N/A	III	III	II		Yes		No
Norman Regional Moore	III	II	IV	N/A	III	III	П		No		No
OU Edmond	Ш	IV	III	N/A	III	III	П		Yes		No
OK Heart Hospital North	NA	NA	NA	N/A	NA	NA	I		Yes		Yes
OK Heart Hospital South	NA	NA	NA	N/A	NA	NA	I		Yes		Yes
OU Medical Center	I	I	I	N/A	III	I	I	*	Yes		Yes
St. Anthony Hospital	I	1	III	II	III	III	1		Yes		Yes
St. Anthony Healthplexes (Free Standing EDs)***	III	III	IV	N/A	IV	IV	III		No		No
OU Health ER + Urgent Care -South OKC (Free Standing ED)***	III	III	IV	N/A	IV	IV	III		No		No
OU Health ER + Urgent Care – Czech Hall (Free Standing ED)***	III	III	IV	N/A	IV	IV	III		No		No



## PROTOCOL 17B, Table: Categorization of Hospitals

Approved 9/04/24, Effective 1/15/25, replaces all prior versions

## Specialty Hospitals, Healthcare Facilities, and Additional Service Capabilities

Veterans Administration	Predominately a medical and surgical facility for the veteran population.
Hospital OKC	The Veterans Administration Hospital is capable of managing patients with complex medical illnesses and non-Priority 1 traumatic injuries.
Bone and Joint Hospital OKC	Predominately an orthopedic referral facility; Level IV Trauma Center
Oklahoma Heart Hospital (North & South Campus) OKC	Predominately a medical and surgical facility for Priority I and II assigned and unassigned patients with cardiac related symptoms.
OU Medical Center, (Dean McGee Eye Institute) OKC	OUMC is affiliated with Dean McGee Eye Institute. Adult Patients with isolated ocular trauma with loss of vision, change in the appearance of the eye, or severe ocular pain should be transported to OUMC for most expeditious access to ocular services.
OU Medical Center, OKC	Labor and Delivery Services should only receive pregnant women with an obstetrical complaint and a gestational period greater than 16 weeks.
McBride Clinic Orthopedic Hospital OKC	Predominately an orthopedic referral facility; Level IV Trauma Center
Level I Cardiac Arrest Center	Cardiac intervention capabilities including a Cardiac Cath Lab and an interventional cardiologist available 24 hours a day, seven days a week; a therapeutic hypothermia method to cool the patient for at least 12 hours after a cardiac arrest.
Center for Orthopedic Reconstruction & Excellence (CORE), Jenks	Predominately an orthopedic referral facility that should only receive surgical related patients with a chief complaint related to a scheduled surgery at CORE within the next 7 days or a surgery that was performed at CORE within the past 30 days. The patient's surgeon (or the call coverage surgeon) must be contacted and agree to accept the patient at CORE's "Emergency Department" prior to EMSA transport. The patient and/or patient representative (eg. family) has the responsibility to provide the treating EMS personnel the contact number for the surgeon/physician at CORE. The EMSA Communications Center will attempt to contact that surgeon/physician at CORE on a recorded line. If no answer from the surgeon/physician at CORE within 10 (TEN) minutes of attempted notification, an alternate destination shall be selected to promote efficient scene time.
Oklahoma Surgical Hospital (OSH) Tulsa	Predominately a surgical referral facility that should only receive surgical related patients with a chief complaint related to a scheduled surgery at OSH within the next 7 days or a surgery that was performed at OSH within the past 30 days. The patient's surgeon (or the call coverage specialist partner) must be contacted and agree to accept the patient at OSH's "Emergency Department" prior to EMSA transport. The patient and/or patient representative (eg. family) has the responsibility to provide the treating EMS personnel the contact number for the surgeon/physician at OSH. The EMSA Communications Center will attempt to contact that surgeon/physician at OSH on a recorded line. If no answer from the surgeon/physician at OSH within 10 (TEN) minutes of attempted notification, an alternate destination shall be selected to promote efficient scene time.



## PROTOCOL 17B, Table: Categorization of Hospitals

Approved 9/04/24, Effective 1/15/25, replaces all prior versions

Tulsa Spine & Specialty Hospital (TSSH)	Predominately an orthopedic & neurosurgical referral facility that should only receive surgical related patients with a chief complaint related to a scheduled surgery at Tulsa Spine & Select Specialty Hospital within the next 7 days or a surgery that was performed at Tulsa Spine & Select Specialty Hospital within the past 30 days. The patient's surgeon (or the call coverage surgeon) must be contacted and agree to accept the patient at Tulsa Spine & Select Specialty Hospital's "Emergency Department" prior to EMSA transport. The patient and/or patient representative (eg. family) has the responsibility to provide the treating EMS personnel the contact number for the surgeon/physician at TSSH. The EMSA Communications Center will attempt to contact that surgeon/physician at TSSH on a recorded line. If no answer from the surgeon/physician at TSSH within 10 (TEN) minutes of attempted notification, an alternate destination shall be selected to promote efficient scene time.
Norman Regional Hospital	Norman Regional Hospital has Labor and Delivery services for patients in labor.
Integris Lakeside Women's Hospital OKC	Predominately a labor and delivery hospital for assigned patients
St. Anthony Healthplex, Saint Francis Healthplex- Glenpool, Mercy I-35, Integris Portland Hospital, OU Health Emergency Room & Urgent Care – Czech Hall	Typical emergency department capabilities exist, though no postemergency department care (surgery, cardiac cath, inpatient care) is available on-site. These facilities should be bypassed for a hospital-based emergency department when the patient's symptoms, exam, and/or diagnostics such as 12-lead ECG indicate the patient most likely requires very urgent or emergent intervention by a specialty physician that is hospital-based (eg. cardiac cath, surgery). Examples of typical transports allowed include: minor head trauma with no or brief LOC; MVC or falls with low suspicion for internal injury and normal vital signs; minor isolated/closed orthopedic injury; epistaxis; respiratory infections; dental injury/illness; fever in pediatrics and young adult (without hypotension/suspected sepsis); chest pain in patients less than 35 years of age, without ST elevation or depression on 12-lead ECG, and without coronary disease history; HTN illness; abdominal pain with normal vital signs and suspected non-surgical cause; genitourinary illness (infections, kidney stones, vaginal bleeding non-pregnant), neurological illness (headaches, seizure (nonstatus) with seizure history), psychiatric illness, allergic reactions, minor burns, dermal rashes, and MCI "green" patients.



## PROTOCOL 17B, Table: Categorization of Hospitals

Approved 9/04/24, Effective 1/15/25, replaces all prior versions

	<del>-</del>
Integris Community Hospital- (EMERUS) Council Crossing, Del City, Moore, OKC West.	Typical emergency department capabilities exist, with very limited post-emergency department adult-only inpatient care (no ICU, no surgery, no cardiac cath) available on-site. These facilities should be bypassed for a hospital-based emergency department when the patient's symptoms, exam, and/or diagnostics such as 12-lead ECG indicate the patient most likely requires very urgent or emergent intervention by a specialty physician that is hospital-based (eg. cardiac cath, surgery). Examples of typical transports allowed include: minor head trauma with no or brief LOC; MVC or falls with low suspicion for internal injury and normal vital signs; minor isolated/closed orthopedic injury; epistaxis; respiratory infections, including COPD or pneumonia that could require short term admission but not NIPPV/ICU care; dental injury/illness; fever in pediatrics and young adult (without hypotension/suspected sepsis); chest pain in patients less than 35 years of age, without ST elevation or depression on 12-lead ECG, and without coronary disease history; HTN illness; abdominal pain with normal vital signs and suspected non-surgical cause; prominent vomiting/diarrhea with suspected dehydration; genitourinary illness (infections, kidney stones, vaginal bleeding non-pregnant), neurological illness (headaches, seizure (non-status) with seizure history), psychiatric illness, allergic reactions, minor burns, dermal rashes, and MCI "green" patients.
St. John Medical Center Pediatric Capabilities	Internal medicine and ICU physicians will only treat patients 18 years of age and older. So, almost anyone under 18 years of age that, in the judgement of on-scene EMTs and Paramedics, will most likely require hospital inpatient admission and care beyond the emergency department should be taken to an alternative hospital destination. Many pediatric patients are successfully cared for with safe discharge home after emergency department-based care. Examples of such patients include non-toxic appearing febrile illness, febrile seizures that have resolved, seizures resolved prior to EMS arrival or with EMS care with a past medical history of seizure disorder, minor abdominal symptoms such as nausea/vomiting/diarrhea, lacerations without suspected underlying fracture(s), closed orthopedic injuries (strains, sprains, suspected simple fractures), and lower speed blunt trauma – motor vehicular, non-motorized scooters/bikes, and falls). Of note, at least one pediatric general surgeon, experienced in pediatric trauma care, two urologists doing pediatric surgeries, and multiple ear, nose, & throat surgeons doing pediatric surgeries are on the medical staff. You may encounter pediatric patients established with these surgeons and their families may understandably wish to continue utilizing St. John Medical Center for their child's specific surgical care. St. John Medical Center is a Level II Trauma Center by a definition established by the American Collee of Surgeons Committee on Trauma, and will accept trauma patients 15 years and older.  When any doubt arises if St. John Medical Center is an appropriate hospital destination, immediately request an on-line clinical consult with an on-duty emergency physician at St. John Medical Center to review with them the current clinical situation.

## Special Considerations

Burn Center. Burns associated with Priority I Trauma should be transported to Level I or II Trauma Centers
Pediatric Burn Center. Burns associated with Priority I Trauma should be transported to Level I or II
Trauma Centers
See comments above for Freestanding EDs



Approved 9/04/24, Effective 1/15/25, replaces all prior versions

## **PROTOCOL 17C: EMS Diversion from Hospitals**

In the event that a hospital's capability to safely provide the standard of care becomes compromised, one <u>temporary</u> action may be the EMS system suspends transports to that hospital's emergency department for a limited amount of time. While EMS patient diversion may occur, the Medical Control Board believes hospitals must continually strive to minimize these occurrences in frequency and in duration. Specifically, hospitals should not expect patient divert continuously more than 2 hours and/or more than 6 hours in any 24 hour period. In return for this professional and civic commitment, hospitals directly contribute to efforts to ensure that all EMS patients receive efficient out-of-hospital emergency medical response and care, including efficient ambulance transport, and timely emergency department physician evaluation and stabilization.

Hospitals may request to be placed on divert status by contacting the EMSA Communications Center. Divert status may be granted depending on the entire system status at the time the request is made. Alternatively, an EMSA Field Operations Supervisor may designate a hospital on divert status due to operational impacts placed on the EMS system (eg. prolonged bed waits).

Hospitals on divert will utilize EMSystem.com to reflect their type and time on divert status, including timely updates of status. Specific types (and triggers) of hospital-initiated EMS patient diversion include:

- 1. Emergency Department Divert\* applies to all illness and injury conditions\*\* \*\*\*.
  - a) Overcrowding secondary to unpredicted, sudden influx of critical care patients
- \* ED divert is not granted to alleviate routine ED overcrowding and each hospital is expected to have a Divert Avoidance Policy when predictable levels of excess capacity need occur, including expeditious movement of admitted patients out of the ED, ancillary service optimization, and addressing crowding due to non-critical patients. The placement of a hospital on ED divert status is subject to the entire Regulated Service Area's system status at the time of hospital request.
- \*\* For OU Medical Center in Oklahoma City, emergency department divert may be specified as medical only, trauma only, or complete.
- \*\*\* For pediatric priority one trauma, those patients must go to OU Medical Center if in Oklahoma City or St. Francis Hospital if in Tulsa regardless of divert status. For pediatric priority one medical, those patients must go to a hospital with pediatric ICU capabilities, which includes OU Medical Center Children's or Baptist Medical Center if in Oklahoma City or St. Francis Hospital if in Tulsa.
- 2. Priority One Trauma Divert\* applies to priority 1 trauma conditions only\*\*.
  - a) ICU or recovery bed shortage creating an overload of critical surgical patients in surgery or the emergency department
  - b) Two or more active, unscheduled critical patients in surgery or emergency department
  - c) Loss of critical ancillary service (CT scanning, basic laboratory)



Approved 9/04/24, Effective 1/15/25, replaces all prior versions

### PROTOCOL 17C: EMS Diversion from Hospitals, cont.

\*Priority One Trauma divert is not granted to alleviate routine bed or nurse staffing shortages. Expedited patient transfers to free needed beds and/or nursing callbacks to achieve needed specialty unit staffing levels should be utilized.

In the event of multiple unscheduled critical patient resuscitations/surgeries, a time estimate of stabilization and return to normal receiving capacity is to be communicated to EMSA dispatch at the time of divert status request.

- \*\*For pediatric priority one trauma, those patients must go to OU Medical Center if in Oklahoma City or St. Francis Hospital if in Tulsa regardless of divert status.
- 3. CT Divert (Computerized Tomography Scanning Divert)
  - a) Loss of CT scanning ability (affecting trauma and medical receiving capability)
- \*\*\* CT divert is not routinely granted to accommodate scheduled maintenance. Immediate repairs are to be initiated and a time estimate of return to normal capacity is to be communicated to EMSA dispatch at the time of divert status request.
- 4. Cath Lab Divert (Cardiac Catheterization Lab Divert)
  - a) Loss of Cath Lab operations (affecting STEMI receiving capability)
- \*\*\* Cath Lab divert is not routinely granted to accommodate scheduled maintenance. Immediate repairs are to be initiated and a time estimate of return to normal capacity is to be communicated to EMSA dispatch at the time of divert status request.

#### Procedure:

- 1. Hospitals will request divert status by contacting the EMSA Communication Center.
- 2. Once divert conditions are met and approved, hospitals may enter their status in the EMSystem.com computer according to the following categories:
  - a) Tulsa:
    - 1) ED Divert
    - 2) Priority One Trauma
    - 3) CT Divert
    - 4) Cath Lab Divert
  - b) Oklahoma City:
    - 1) ED Divert
    - 2) Priority One Trauma
    - 3) CT Divert
    - 4) Cath Lab Divert



Approved 9/04/24, Effective 1/15/25, replaces all prior versions

### PROTOCOL 17C: EMS Diversion from Hospitals, cont.

- 3. The following information on hospital diverts shall be displayed on the EMSystem.com computer:
  - a) Current hospital status
  - b) Type of divert
  - c) Time on divert or most recent update
  - d) Special comments

In accordance with the American College of Emergency Physicians Policy Statement on Ambulance Diversion, if the Chief Medical Officer or Chief Medical Offier's designee determines the <a href="entire">entire</a> system to be overloaded, all hospitals will be opened to receive EMS patients in accordance with these protocols. If hospitals request divert to the point that a given geographic area is essentially without a receiving hospital, or overload is created for that area, then all facilities within that geographic region will be opened to receive EMS patients in accordance with these protocols. At the discretion of the Chief Medical Officer or Chief Medical Officer's designee, a temporary rotation of hospitals on divert may be utilized as conditions allow.

A hospital-initiated request for ED Divert shall automatically expire 1 hour after being initially granted unless extenuating circumstances continue and a diversion extension is granted for an additional 1 hour. A verbal report on divert avoidance action will be requested and forwarded to an EMSA Field Operations Supervisor for approval prior to any extension being granted. At EMSA, Chief Medical Officer, or Chief Medical Officer's designee's discretion, an EMSA Field Supervisor may conduct an on-site consultation to determine if an extension of the divert status is justified, factoring concurrent system needs.

A hospital-initiated request for Priority One Trauma or CT Divert shall automatically expire 2 hours after being initially granted unless extenuating circumstances continue to prevail and a diversion extension is granted for an additionally defined period of hours.

When a hospital is on an MCB approved divert as defined above, all on-duty field personnel are to be notified in an expeditious manner and are expected to honor the diversion hospital's status (see exception next paragraph). Diversion status will be explained to the patient (or appropriate patient's representative) in order to allow for an informed alternative hospital destination decision. In the event of encode to a hospital in the midst of diversion request with EMSA Dispatch, the EMT or paramedic may continue to that hospital if an alternative hospital destination represents a detriment to the patient's clinical condition. Even after a hospital is on MCB approved divert status, an EMT or paramedic may override the hospital's divert status if transport to that hospital is required for life-saving, immediately needed patient stabilization.

When a hospital is on ED divert status only, all stable patients will be delivered to that hospital if there exists an established relationship with that hospital or a member of its medical staff. Established relationships include, but are not limited to, a previous admission to that hospital and/or a pre-existing doctor-patient relationship with a doctor on that hospital's medical staff.



Approved 9/04/24, Effective 1/15/25, replaces all prior versions

## PROTOCOL 17C: EMS Diversion from Hospitals, cont.

Questions that will assist Paramedics in determining an established patient include:

- Which hospital do you want to be transported to?
- Who is your primary physician?
- Which hospital has your physician told you to use for your care?
- Have you been an inpatient in a hospital and do you still go there for care?
- Have you recently been seen in a hospital emergency department for this problem?


In any instance that an EMSA ambulance transports an unscheduled patient for emergency medical care and arrives on hospital property, that hospital's Emergency Department must perform an emergency medical screening examination, even if on divert status. If further indicated treatment cannot be provided, it shall be the responsibility of that hospital to make arrangements for transfer of the patient to a more appropriate healthcare facility.



Approved 9/04/24, Effective 1/15/25, replaces all prior versions

### PROTOCOL 17C: EMS Diversion from Hospitals, cont.

The following algorithm is to be used in conjunction with the preceding text of this protocol and not independently of the preceding text of this protocol.



#### Medical References:

"Ambulance Diversion. A Position Paper for the Standards and Clinical Practices Committee of the National Association of EMS Physicians." 1997; 1:100-3.





## Medical Literature References 17C- EMS Diversion from Hospitals


1. Li, M., Vanberkel, P., & Carter, A. J. E. (2019). A review on ambulance offload delay literature. Health Care Management Science, 22(4), 658–675. https://doi.org/10.1007/s10729-018-9450-x



Approved 9/04/24, Effective 1/15/25, replaces all prior versions

PROTOCOL 17D: "No Fly Zones"

### **Western Division**




• Service area within the boundaries of the red circle represents "No Fly" zone.



Approved 9/04/24, Effective 1/15/25, replaces all prior versions **PROTOCOL 17D:** "No Fly Zones," cont.

#### **Eastern Division**




• Service area within the boundaries of the red circle represents "No Fly" zone.



Approved 9/04/24, Effective 1/15/25, replaces all prior versions

### PROTOCOL 17E: Advanced Airway Management: Pediatric Oral Intubation



Orotracheal intubation authorized for pediatric patients utilizing same protocols for adult patients.

### **Technique Comments**:

- 1. Avoid hyperextension of neck during intubation attempts. This positioning compromises glottic visualization.
- Endotracheal tube size and laryngoscope blade sizes are listed in the Handtevy application. In the instance that the Handtevy application is not available endotracheal tube size can be determined using the formula 16 + age in years/4 or using a tube roughly the diameter of the patient's little finger, (5<sup>th</sup> digit).
- 3. The Flex-Guide is **NOT** compatible with pediatric endotracheal tubes.
- 4. Video laryngoscopy technique is in protocol 2F-Oral Intubation.




Approved 9/04/24, Effective 1/15/25, replaces all prior versions

## 17F - MEDICATION-ASSISTED INTUBATION PEDIATRIC

TREATMENT PRIORITIES

1. Oxygenation/Ventilation support



#### **PARAMEDIC**

MEDICATION-ASSISTED INTUBATION IF INDICATED FOLLOW PROTOCOL 2G-ORAL INTUBATION FOR TECHNIQUE & CONFIRMATION OF INTUBATION

#### FOR FACILITATING ORAL INTUBATION:

PEDIATRIC: ETOMIDATE 0.3 mg/kg IVP/IOP SINGLE DOSE OR

PEDIATRIC: MIDAZOLAM 0.1 mg/kg TO MAX OF 5 mg IVP/IOP

### FOR POST-ORAL INTUBATION SEDATION TO PREVENT EXTUBATION (IF INDICATED):

PEDIATRIC: MIDAZOLAM 0.1 mg/kg TO MAX OF 5 mg IVP/IOP

OR

**PEDIATRIC:** DIAZEPAM 0.1 mg/kg TO MAX OF 5 mg IVP/IOP

OR


PEDIATRIC: LORAZEPAM 0.1 mg/kg TO MAX OF 2 mg IVP/IOP

CONTINUOUS ASSESSMENT & TREATMENT PER APPLICABLE PROTOCOL(S)




Approved 9/04/24, Effective 1/15/25, replaces all prior versions


## 17G – CONFIRMATION OF ENDOTRACHEAL AIRWAY PLACEMENT PEDIATRIC



The following sequence is to be used (and its use documented) to verify and maintain correct endotracheal artificial airway placement without fail:

- 1. Visualization of endotracheal tube passage between vocal cords oral intubation only. (Figure 1)
- 2. Detection of End-tidal carbon dioxide. End-tidal carbon dioxide (EtCO<sub>2</sub>) detection shall be confirmed within 60 seconds of endotracheal tube placement. The capnography adaptor is to be placed at the bag-valve device-endotracheal tube interface for the first ventilation. The normal waveform indicating correct endotracheal placement reflects a rapid upstroke with the beginning of exhalation, the exhalation plateau ending at the point of EtCO<sub>2</sub> measurement, and a rapid downstroke with the beginning of inhalation. Any waveform that does not show rhythmic rise and fall correlating with assisted ventilations indicates incorrect tube placement and the tube must be withdrawn. To be perfectly clear, the use of an endotracheal tube for ongoing oxygenation and ventilation is dependent upon continuously measurable capnography waveforms. See Protocol 3H -Capnography for discussion of EtCO<sub>2</sub> values and waveforms. (Figure 2)
- 3. Auscultation. Auscultate the epigastrium. (Figure 3) If epigastric sounds are heard, intubation is to be reattempted. The endotracheal tube placed in the esophagus may be left in place, at the intubator's discretion, until another endotracheal tube is correctly placed and verified. If no epigastric sounds are heard, proceed to auscultation of the thorax bilaterally. Breath sounds are best auscultated in the anterior to midaxillary lines. If breath sounds are present on the right and absent on the left, this suggests a right mainstem intubation. Withdraw the endotracheal tube 1 cm and repeat breath sound auscultation. If necessary, the tube may be withdrawn an additional 1-2 cm.










Approved 9/04/24, Effective 1/15/25, replaces all prior versions

PROTOCOL 17G: Confirmation of Endotracheal Artificial Airway Placement -

### **Pediatric**

- 4. **Assessment of physiologic changes.** These include equal rise and fall of the chest, condensation in the endotracheal tube on exhalation, improvement in the patient's color, and improvement in the patient's respiratory distress/failure.
- 5. Secure the endotracheal tube with a tube holder and place a cervical collar. (Figure 4)



When intubated patients are moved during EMS care, waveform capnography must be rechecked for any change. If the waveform continues to show a normal pattern of rapid upstroke with exhalation, exhalation plateau, and rapid downstroke with inhalation, no further repeat confirmation is required. If at any time, the capnography waveform is abnormal, steps 2-5 must be rechecked and documented. If at any time during patient care there is doubt as to correct endotracheal placement of intubation, either re-verify by this sequence or reattempt correct endotracheal placement. While the intubator may delegate confirmation steps to his/her colleagues, he or she is ultimately responsible to ensure that a complete confirmation sequence is performed. If the intubator accompanies the patient to the hospital, he or she remains ultimately responsible for ongoing endotracheal tube placement confirmation. If the intubator does not accompany the patient to the hospital by ambulance or helicopter ambulance transport, the primary transporting/treating paramedic or RN assumes ultimate responsibility for ongoing endotracheal tube placement confirmation.

Upon delivery of the patient at treatment destination or at subsequent transport (eg. helicopter transport), a waveform capnograph will be obtained and documented after the patient has been physically transferred onto the destination's/subsequent transport's stretcher/bed/operating table to show confirmed, continued correct endotracheal tube placement at EMS transfer of patient care.




Approved 9/04/24, Effective 1/15/25, replaces all prior versions

PROTOCOL 17H: Helmet Removal



### **Motorcycle-style helmet comments:**

While helmets offer protection for the head, they have not proven to reduce spine injuries. While their use is encouraged, helmets prevent airway access and complicate spinal immobilization. Because most full helmets do not hold the head firmly and also prevent cervical collar application, spinally immobilizing a helmeted patient does not result in effective cervical immobilization. Helmets must be removed prior to spinal immobilization on a long board to assure airway access and adequate spinal immobilization. In motocross events, look for neck braces and chest protectors that are attached by clasps and hinges that will also need to be removed.





Approved 9/04/24, Effective 1/15/25, replaces all prior versions

PROTOCOL 17H: Helmet Removal, (cont.)

## MOTORCYCLE-STYLE HELMET REMOVAL PROCEDURE (continued)

Step 6: After helmet removal, first EMT replaces hands on both sides of the head, resuming manual stabilization.



Step 7: Maintain manual stabilization until complete spinal immobilization is achieved.



Football helmet and pad set comments:

When removing football helmets, shoulder pad sets must be also be removed to avoid immobilizing the neck in a hyperextended position. In some instances, the face mask alone may need to be removed first, either for immediate airway interventions or to facilitate helmet removal. In all cases, the coach or athletic trainer may prove a good source of information regarding the exact equipment needed for removal. For instance, many recently manufactured football helmets have air bladder systems designed so the helmet tightly fits the head; the coach or athletic trainer will be best able to release these air bladders.

### FOOTBALL HELMET FACE MASK REMOVAL PROCEDURE

Several different tools can be used to remove a football helmet face mask – the FM extractor, Trainer's Angel, knives, pruning shears, and PVC cutters. There are typically four plastic clips attached to the face mask and screwed into the helmet. A screwdriver should be utilized only as a last resort. Unscrewing these face mask clips may cause excessive head movement if the screws have been place for some time and are rusted. Medic shears and seatbelt cutters are not recommended as these tools have been shown to take excessive time to work.

Step 1: Manually stabilize the head and spine. Remove the mouthpiece.



Step 2: Second EMT cuts all clips that secure the face mask.



Step 3: Second EMT removes the face mask by lifting it straight off the helmet.





Approved 9/04/24, Effective 1/15/25, replaces all prior versions

PROTOCOL 17H: Helmet Removal, (cont.)

## FOOTBALL HELMET & PAD SET REMOVAL PROCEDURE

Step 1: Manually stabilize the head and spine. Remove the mouthpiece.



Step 2: Second EMT unfastens any straps while stabilization is maintained.



Step 3: Second EMT removes ear pads by unsnapping them from inside the shell.



Step 4: If fitted with air bladder system, deflate the liner through the valve as pictured by using the needle of the inflation system to release air pressure at inflation points.







Approved 9/04/24, Effective 1/15/25, replaces all prior versions

PROTOCOL 17H: Helmet Removal, (cont.)

## FOOTBALL HELMET & PAD SET REMOVAL PROCEDURE (continued)





Step 6: Maintain neutral alignment of the neck while the shoulder pads are removed.



Step 7: Cut jersey away. Unfasten or cut the shoulder pads straps and laces.





Approved 9/04/24, Effective 1/15/25, replaces all prior versions **PROTOCOL 17H: Helmet Removal, (cont.)** 

## FOOTBALL HELMET & PAD SET REMOVAL PROCEDURE (continued)

Step 8: Laterally unfold shoulder pads and slide out toward the first EMT. A third and even fourth EMT may be needed to support the back.



Step 9: Maintain manual stabilization until complete spinal immobilization







- Techniques of Helmet Removal from Injured Patients, American College of Surgeons, Committee on Trauma, April 1997
- Training Medical Personnel in Techniques for Proper Motorcycle Helmet Removal, The Motorcycle Riders Foundation, September 2001
- Techniques and Equipment for Helmet Removal; Professional Sports Training, Green Bay Packers, EMSED.Com; November 2005
- Prehospital Emergency Care, 8<sup>th</sup> Edition, Copyright, July 2008



Approved 9/04/24, Effective 1/15/25, replaces all prior versions

#### PROTOCOL 17I: Controlled Substance Handling & Documentation - Field Paramedics

#### **EMT-PARAMEDIC**

#### Indication:

Federal, State of Oklahoma, and Medical Control Board/Office of the Medical Director laws, regulations, and requirements for appropriate control of controlled substances. These procedures apply to all scheduled controlled substances: Class II - Fentanyl (Sublimaze) and Morphine Sulfate; Class IV - Diazepam (Valium) and Midazolam (Versed).

#### Authorized Handling, Inventory, & Custody:

- 1. While in field use inventory, only system-certified paramedics may access and handle controlled substances.
- 2. At the start and end of every shift and at any time of resupply of controlled substance, direct inspection of each controlled substance container (e.g. vial, ampule, pre-filled syringe or cartridge) will be conducted for any signs of damage to the individually numbered and/or letter tamper-evident seals and overall container, recording of controlled substance containers present and/or missing, and such inspection shall be signed by the oncoming paramedic with an appropriate witness signature as well (e.g. off going paramedic if at shift change, authorized materials agent if at EMSA, supervising officer). Expiration dates are to be noted at these inspections. All such inspection/inventory shall be recorded in an apparatus specific controlled substance log book, itself having secured access.
- 3. At the start and end of every shift, if the apparatus is dispatched to an incident prior to the proper transfer of controlled substances to the oncoming paramedic, the paramedic with current documented custody must respond on the incident. At no time will transfer of controlled substances delay apparatus response or occur during an incident response.
- 4. In the event of tampered/damaged and/or unaccounted controlled substances at any inspection, all involved personnel will remain on-duty and the last authorized personnel will retain custody of the controlled substances until all discrepancies are immediately reported to the supervising EMS officer and an OMD Division Chief with sufficient resolution acceptable to both the EMS officer and OMD Division Chief.
- 5. In the event of expired controlled substances, the expired controlled substance will be removed from immediate patient use stock, reflected in the apparatus specific controlled substance log book and be secured, using a clear chain of custody per specific agency policy, until the expired controlled substance is in the secured custody of the agency's Controlled Substance Officer.
- 6. All completed pages in the apparatus specific controlled substance log book will be retained by the agency's Controlled Substance Officer in compiling an agency specific master log of controlled substance use and inventory.



Approved 9/04/24, Effective 1/15/25, replaces all prior versions

## PROTOCOL 17I: Controlled Substance Handling & Documentation - Field Paramedics (cont.)

#### Storage for Immediate Patient Use:

- 1. All MCB-approved controlled substances will be maintained in locked, temperature-controlled locations on paramedic-staffed apparatus.
- 2. Securing of controlled substances will be primarily by mechanical lock.
- 3. Securing of controlled substances will be secondarily by consistent personal control of devices for accessing the controlled substance location on the apparatus. Paramedics are not to share individual access codes, keys, or other devices for access with anyone other than agency clinical leadership, Office of the Medical Director personnel, and/or law enforcement personnel conducting a formal inspection of controlled substances assigned to the individual paramedic/apparatus.
- 4. Securing of controlled substances will be by individually numbered and/or lettered tamper-evident seals (as approved and assigned by the Office of the Medical Director) that are uniquely assigned to each controlled substance container.
- 5. At any time the paramedic-staffed apparatus is taken out of service, the assigned paramedic at the time of such status change will maintain direct control of controlled substances until all assigned substances on that apparatus are secured within the station or central inventory as applicable based upon specific agency procedure.

#### Patient Administration

- 1. Paramedics may only administer a controlled substance in accordance with MCB treatment protocol(s) and/or a direct order from an on-line medical control physician.
- When a controlled substance is administered in patient care, the patient care record will contain at a
  minimum in relation to the controlled substance: date, time, incident number,
  medical condition being treated, patient name, physician ordering (if applicable), and
  name, dose, and route of controlled substance administered.
- 3. When a controlled substance is administered in patient care, the apparatus specific controlled substance log book will contain at a minimum in relation to the controlled substance: date, time, incident number, medical condition being treated, patient initials, physician ordering (if applicable), and name and dose of controlled substance administered. Additionally, any unused ("wasted") amount of controlled substance will be recorded by patient care incident.
- 4. Any partially unused amount of opened controlled substance will require the log book entry to bear the signature of two persons each attesting to the fact that the drug was properly disposed. One of two persons should be a physician, nurse, or the paramedic's partner (if unable to obtain nurse or physician's signature).
- 5. Any wholly unused amount of an opened controlled substance (e.g. vial seal opened but not administered to patient) will be denoted in both the apparatus specific controlled substance log book and an incident report that details the specifics of why the controlled substance was accessed but not administered to the patient (e.g. seizure abated prior to medication administration). The involved container of controlled substance will be transferred, maintaining a clear chain of custody, to the agency's Controlled Substance Officer or his/her designee.



Approved 9/04/24, Effective 1/15/25, replaces all prior versions

## PROTOCOL 17J: Seasonal Influenza Vaccine Administration

#### **EMT-PARAMEDIC**

### Indications:

- 1. Request from employee of EMS Agency and/or Fire Department administering the vaccine.
- 2. Request from employee of the city, county, and/or regional governmental authority providing oversight of the EMS Agency and/or Fire Department administering the vaccine.
- 3. Timing of request by indicated personnel in 1 or 2 above within the seasonal influenza vaccination time period as authorized by the Chief Medical Officer (timing authorized may change from year to year)

### Contraindications:

- 1. Known hypersensitivity, including allergic reactions, to past seasonal influenza vaccine administration.
- 2. History of Guillain Barré syndrome onset within 6 weeks of a past seasonal influenza vaccine administration.
- 3. Known hypersensitivity, including allergic reactions, to eggs.
- 4. Active infection.
- 5. Close contact with an immune suppressed person requiring protective isolation.
- 6. Do not administer <u>a live</u>, <u>attenuated seasonal influenza vaccination</u> (e.g. inhaled formulation) to patients with any of the following characteristics:
  - a. Age 50 years or greater
  - b. COPD, including asthma
  - c. Heart disease
  - d. Vascular disease (excluding hypertension)
  - e. Renal disease
  - f. Hepatic disease
  - g. Neurologic/Neuromuscular disease, including cognitive impairment
  - h. Hematologic disease
  - i. Metabolic/Endocrine disease, including diabetes
  - i. Immune dysfunction, including that caused by HIV and related medications
  - k. Pregnancy

Approved 9/04/24, Effective 1/15/25, replaces all prior versions PROTOCOL 17J: Seasonal Influenza Vaccine Administration (cont.)

### Procedure Comments:

- 1. Review all seasonal influenza vaccine manufacturer's instructions supplied with the vaccine.
- 2. The seasonal influenza vaccine must be stored per manufacturer's instructions.
- 3. Utilize a standardized seasonal influenza vaccination informed consent form.
- 4. Utilize a standardized seasonal influenza vaccination pre-screening questionnaire form.
- 5. Ensure appropriate medical equipment is present at the seasonal influenza vaccination site for treatment per protocol of allergic reaction.
- Administer seasonal influenza vaccine per manufacturer's instructions proper dose, deltoid IM route (or inhaled route if using inhaled formulation), etc.
- 7. Briefly monitor the patient for any immediate allergic reaction.
- 8. Prior to patient leaving seasonal influenza vaccination site, ensure the following information is obtained and documented on a seasonal influenza vaccination form for each patient:
  - a. Contact information: work mailing address, work email (if applicable), work phone
  - b. This information is necessary if the seasonal influenza vaccination lot is found problematic (e.g. defective in immunity function) and patient notification is required.
- 9. Provide the patient with a standardized seasonal influenza vaccination post-vaccination information form.
- 10. A standard EMS Agency and/or Fire Department patient care record does NOT need to be generated, but the seasonal influenza vaccinating organization must maintain a log of all patient contacts associated with a seasonal influenza vaccination program. For each patient receiving a seasonal influenza vaccine administration, the following must be recorded:
  - a. date of seasonal influenza vaccine administration
  - b. the manufacturer and lot number of seasonal influenza vaccine administered
  - c. vaccination site and route (e.g. left deltoid IM)
  - d. name of paramedic administering the vaccination
- 11. Any and all adverse medical reactions to the administration of a seasonal influenza vaccine must be reported to the Chief Medical Officer or his/her designee within 24 hours. Upon the Chief Medical Officer's review, further reporting may be directed to the federal Vaccine Adverse Event Reporting System (VAERS) at www.vaers.hhs.gov or (800) 822-7967.



Approved 9/04/24, Effective 1/15/25, replaces all prior versions

17K - TRANEXAMIC ACID (TXA, CYCLOKAPRON)

#### **PARAMEDIC**

Class: Anti-Fibrinolytic

**Actions/Pharmacodynamics:** Promotes clot formation in the setting of massive hemorrhage.

**Indications:** Hemostatic Agents (10I)

Traumatic hemorrhagic shock less than 3 hours from injury with suspected need for massive blood transfusion (clinical evidence of marked blood loss – internal or external, sustained tachycardia and hypotension, see Protocol 10I for exact VS parameters by age group)

Contraindications: Non-hemorrhagic shock

Non-traumatic hemorrhagic shock

Hemorrhagic shock stabilized with other hemostatic agents/measures

**Pharmacokinetics:** Onset of action within 4 hours after IV administration, exact time of onset unclear and variable. Delayed effects up to 48 hours consistent with anti-inflammatory actions.

**Side Effects:** While a theoretical concern, TXA has not been shown to cause significant increase in deep venous thrombosis, pulmonary embolism, myocardial infarction, or stroke in published trials to date.

Dosage: Hemostatic Agents – Adult (101)

(Hemorrhagic shock as described above)

1 gram IVPB over 10 minutes.

Administer in 100 mL or 250 mL NS.

Hemostatic Agents – Pediatric Ages 10 and Above (10I)

(Hemorrhagic shock as described above)
15 mg/kg up to 1 gram IVPB over 10 minutes.

Administer in 100 mL or 250 mL NS.

**How Supplied:** 1 gram/10 mL vial or ampule (100 mg/mL)

(Always check concentration and dose per container at time of patient

medication administration)





## Medical Literature References 17K- Tranexamic Acid (TXA, Cyclokrapron)

- Li, S. R., Guyette, F., Brown, J., Zenati, M., Reitz, K. M., Eastridge, B., Nirula, R., Vercruysse, G. A., O'Keeffe, T., Joseph, B., Neal, M. D., Zuckerbraun, B. S., & Sperry, J. L. (2021). Early Prehospital Tranexamic Acid Following Injury Is Associated With a 30-day Survival Benefit: A Secondary Analysis of a Randomized Clinical Trial. *Annals of Surgery*, 274(3), 419–426. https://doi.org/10.1097/SLA.000000000000000000
- 2. El-Menyar, A., Sathian, B., Wahlen, B. M., Abdelrahman, H., Peralta, R., Al-Thani, H., & Rizoli, S. (2019). Prehospital administration of tranexamic acid in trauma patients: A 1:1 matched comparative study from a level 1 trauma center. American Journal of Emergency Medicine, 38(2), 266–271. https://doi.org/10.1016/j.ajem.2019.04.051



Approved 9/04/24, Effective 1/15/25, replaces all prior versions

## 17L - POSITIVE END EXPIRATORY PRESSURE (PEEP)

A small amount of PEEP ranging between 5 and 10 cm/H<sub>2</sub>O prevents airway closure, increases the airway opening index and improves the efficiency of alveolar ventilation produced by chest compressions.

**Indication**: Any pediatric patient (Birth to 12 years of age) with an advanced airway.


**Contraindication**: Status Asthmaticus


Set PEEP device to 5 cm/ $H_2O$  (Figure 1) and attach PEEP device to the Bag Valve Mask exhaust port (Figure 2). Attach Bag Valve Mask to endotracheal tube or supraglottic airway and provide ventilations per protocol 3A - Respiratory Arrest or 4A - Cardiac Arrest as indicated.

Rotate PEEP valve to increase pressure by 1 cm/ $H_2O$  (clockwise ½ turn) every 2 minutes until SpO2  $\geq$  94%. Max PEEP 10 cm/ $H_2O$ .

Clinical Note: If patient has a congenital cardiac anomaly or other known medical condition with baseline SpO2 <94% set PEEP device to 5 cm/ $H_2O$  and titrate to upper limit of baseline SpO2.

Attach ResQPOD<sup>™</sup> to BVM if  $\geq$  12 years of age AND estimated patient wt  $\geq$  50 Kg.









## Medical Literature References 17L Positive End Expiratory Pressure (PEEP)

- 1. Nakashima, T., Kawazoe, Y., Iseri, T., Miyamoto, K., Fujimoto, Y., & Kato, S. (2020). The effect of positive end-expiratory pressure on stroke volume variation: an experimental study in dogs. *Clinical and Experimental Pharmacology and Physiology*, (January), 1–6. https://doi.org/10.1111/1440-1681.13262
- 2. Cordioli, R. L., Grieco, D. L., Charbonney, E., Richard, J. C., & Savary, D. (2019). New physiological insights in ventilation during cardiopulmonary resuscitation. *Current Opinion in Critical Care*. https://doi.org/10.1097/MCC.0000000000000573
- 3. Grieco, D. L., Brochard, L. J., Drouet, A., Telias, I., Delisle, S., Bronchti, G., ... Richard, J. C. M. (2019). Intrathoracic airway closure impacts CO 2 signal and delivered ventilation during cardiopulmonary resuscitation. *American Journal of Respiratory and Critical Care Medicine*. https://doi.org/10.1164/rccm.201806-1111OC
- 4. Upadhya R, K., Shenoy, L., & Venkateswaran, R. (2018). Effect of intravenous dexmedetomidine administered as bolus or as bolus-plus-infusion on subarachnoid anesthesia with hyperbaric bupivacaine. *Journal of Anaesthesiology Clinical Pharmacology*, *34*(3), 46–50. https://doi.org/10.4103/joacp.JOACP
- 5. Sutherasan, Y., Raimondo, P., & Pelosi, P. (2015). Ventilation and gas exchange management after cardiac arrest. *Best Practice and Research: Clinical Anaesthesiology*. https://doi.org/10.1016/j.bpa.2015.09.001



EMERGENCY MEDICINE
UNIVERSITY OF OKLAHOMA

\*\* EMS Section

Approved 11/08/23, Effective 1/15/24, replaces all prior versions

### 17M – BLOOD SAMPLE COLLECTION FOR LAW ENFORCEMENT ADULT & PEDIATRIC



### Indications:

Collection of evidentiary blood samples for assisting law enforcement officers in select situations where logistics would otherwise prove notably difficult (e.g. patient transport out of state, patient transport significant distance in state). Blood collected will be for the purpose of Blood Alcohol and/or Drug Content Analysis pursuant to Oklahoma Statutes Title 47. Motor Vehicle Chapter 67 - Chemical Tests Section 752 - Procedure for Blood Tests - Authorization - Liability for Withdrawal - Reports Cite as: 47 O.S. § 752 (OSCN 2022). 40 O.A.R 10-9-1 - Persons authorized to withdraw blood

### Procedure by EMS Personnel:

- At no time is patient care to be compromised for the purpose of blood sample collection for assisting law enforcement. Unstable patients may not have evidentiary blood samples drawn if treating EMS personnel believe such will compromise medical care. Unstable patients should be transported to the hospital, where blood collection can be performed by hospital-based personnel.
- 2. EMS personnel should not be requested for the sole purpose of collecting a blood sample under the Oklahoma Vehicle and Traffic Law if no obvious EMS medical care need exists. Any person contacted by EMS personnel under such circumstance is to be offered medical assessment, care, and transport. See also Protocol 14D: Informed Patient Consent/Refusal.
- 3. EMS personnel are allowed, but not required, to perform blood collection requested by a law enforcement officer and consented to by the patient. If on-scene disagreement occurs between EMS personnel and law enforcement officers specific to the immediacy of medical care and/or EMS transportation needs, provide care within MCB Treatment Protocols and contact OMD for on-line consultation. Such consultation may include discussion by OMD with the ranking law enforcement officer on scene and/or supervising an arrest (if applicable). Medical decisions are to be made by EMS personnel (which may include OMD consultation).
- 4. OMD/physician contact is not required for EMS personnel to collect a blood sample for the purpose of Blood Alcohol and/or Drug Content Analysis if requested by a law enforcement officer.
- 5. If a blood sample is collected by EMS personnel, it must be performed in the presence of a law enforcement officer. EMS personnel obtaining a blood sample must collect or immediately deposit the collected blood samples into 10 milliliter (mL) glass vacuum tubes labeled by the manufacturer as containing 100 milligrams (mg) of sodium fluoride and 20 milligrams (mg) of potassium oxalate. The vacuum tubes contained in the State of Oklahoma Blood Specimen Collection Kit meet these requirements.
- 6. In the process of obtaining a blood sample, do not use an alcohol containing skin prep over the venipuncture site. If starting an IV for fluids or medications, first obtain the blood samples in the tubes provided by the law enforcement officer before the IV line.



### EMS System for Metropolitan Oklahoma City and Tulsa Interim Guidance from the Chief Medical Officer

Approved 9/04/24, Effective 1/15/25, replaces all prior versions

### **COVID-19 Vaccine Administration**

PARAMEDIC

### Indications:

- 1. Vaccinating Paramedic has completed all required COVID-19 vaccination training requirements established by relevant public health authority (typically Oklahoma City County Health Department, Tulsa Health Department, or Oklahoma State Department of Health).
- 2. Request for COVID-19 vaccination by anyone authorized by the relevant public health authority (typically Oklahoma City County Health Department, Tulsa Health Department, or Oklahoma State Department of Health) to receive COVID-19 vaccination. At Interim Guidance new issuance, the Pfizer/BioNTech COVID-19 vaccine is approved by the U.S. Food and Drug Administration (FDA) for individuals age 16 years and older. For the Moderna COVID-19 vaccine, FDA approval is for individuals age 18 years and older.
- 3. Timing of request above within a time period authorized by the Chief Medical Officer (timing at issuance is without limitation).

### **Contraindications:**

Per the Centers for Disease Control (CDC), history of severe allergic reaction (anaphylaxis) to any
of the components of the vaccine. Check manufacturer listing of components of the specific
vaccine intended for administration. Most anaphylaxis observed to date from COVID-19 vaccine is
thought due to polyethylene glycol (PEG) which can be used as a thickener, softener, or moisture
carrier in products such as toothpaste, shampoo, and laxatives.

Current observation in the United States indicates that anaphylaxis to COVID-19 vaccines is very rare. During December 14–23, 2020, monitoring by the Vaccine Adverse Event Reporting System detected 21 cases of anaphylaxis after administration of a reported 1,893,360 first doses of the Pfizer-BioNTech COVID-19 vaccine (11.1 cases per million doses); 71% of these occurred within 15 minutes of vaccination. (source: Allergic Reactions Including Anaphylaxis After Receipt of the First Dose of Pfizer-BioNTech COVID-19 Vaccine — United States, December 14–23, 2020. MMWR Morb Mortal Wkly Rep. ePub: 6 January 2021.)

### Precaution Considerations that are NOT Contraindications:

- 1. Per the CDC, persons with moderate to severe acute illness (e.g., pneumonia with acute dyspnea) should be encouraged to recover from such illness and vaccination is recommended deferred until that time.
- 2. Per the CDC, history of severe allergic reaction (anaphylaxis) to another vaccine or injectable therapy.

Of note, the CDC vaccine safety team experts have shared that there are NO contraindications or precautions to getting the COVID-19 mRNA vaccines if allergic to food (including eggs or gelatin), pets, venoms, environmental agents, oral medications, or latex.



### EMS System for Metropolitan Oklahoma City and Tulsa Interim Guidance from the Chief Medical Officer

Approved 9/04/24, Effective 1/15/25, replaces all prior versions

### **COVID-19 Vaccine Administration (cont.)**

### Procedure Comments:

- 1. Review all COVID-19 vaccine manufacturer's instructions supplied with the vaccine.
- 2. The COVID-19 vaccine must be stored and handled per manufacturer's instructions.
- 3. Utilize a standardized COVID-19 vaccination informed consent form available from the relevant public health authority.
- 4. Utilize a standardized COVID-19 vaccination pre-screening questionnaire form AND provide the patient a standardized pre-vaccination information sheet specific to the COVID-19 vaccine, which are both available from the relevant public health authority. It is federal law that anyone being vaccinated (or the legal guardian of the person being vaccinated) receive pre-vaccination information, typically called a Vaccine Information Statement (VIS), specific to the vaccine describing its risks and benefits. Review this information with the patient (or legal guardian) and give a copy of such to them for their personal records. Specific to the COVID-19 vaccines, the VIS is called "Fact Sheet for Recipients and Caregivers Emergency Use Authorization (EUA)."
- 5. Ensure appropriate medical equipment is present at the COVID-19 vaccination site for treatment per protocol of allergic reaction.
- 6. Administer COVID-19 vaccine per manufacturer's instructions dose, deltoid IM route, etc.
- 7. Monitor the patient for any immediate allergic reaction for a minimum of 15 minutes if no precaution considerations present. If precaution considerations are present, increase the minimum monitoring time to 30 minutes post-vaccination.
- 8. Prior to patient leaving the COVID-19 vaccination site, ensure the following information is obtained and documented on the COVID-19 vaccination form for each patient:
  - a. Contact information: preferred mailing address, preferred email (if applicable), preferred phone
  - b. This information is necessary if the COVID-19 vaccination lot is found problematic (e.g., defective in immunity function) and patient notification is required.
- 9. Provide the patient with a standardized CDC COVID-19 vaccination record card that has been completed by the vaccination team so the patient has a record of when vaccinated, what vaccine they received to include the specific manufacturer of it, the lot number of the vaccine received, and when the second dose (if applicable) should be scheduled. At present, the second dose for the Pfizer/BioNTech COVID-19 vaccine is 21 days after the first dose; the second dose for the Moderna COVID-19 vaccine is 28 days after the first dose. Patients are also to receive a standardized COVID-19 vaccination post-vaccination information form, including information about enrolling in the V-safe after vaccination health checker smartphone app. These information forms are available from the relevant public health authority.
- 10. A standard EMS Agency and/or Fire Department patient care record does NOT need to be generated, but the COVID-19 vaccinating organization must maintain a log of all patient contacts associated with a COVID-19 vaccination program. For each patient receiving a COVID-19 vaccine administration, the following must be recorded for EMS system and MCB/OMD availability:
  - a. date of COVID-19 vaccine administration
  - b. the manufacturer and lot number of COVID-19 vaccine administered
  - c. vaccination site and route (e.g., left deltoid IM)
  - d. name of Paramedic administering the vaccination



### EMS System for Metropolitan Oklahoma City and Tulsa Interim Guidance from the Chief Medical Officer

Approved 9/04/24, Effective 1/15/25, replaces all prior versions

### **COVID-19 Vaccine Administration (cont.)**

### Procedure Comments (cont.):

- 11. For each patient receiving a COVID-19 vaccine administration, the vaccination information must also be recorded into the Oklahoma State Immunization Information System (OSIIS). Information about OSIIS and recording information into it should be coordinated with the relevant public health authority.
- 12. Any and all adverse medical reactions to the administration of a COVID-19 vaccine must be reported to the Chief Medical Officer or his/her designee within 24 hours. Upon the Chief Medical Officer's review, further reporting may be directed to the federal Vaccine Adverse Event Reporting System (VAERS) at www.vaers.hhs.gov or (800) 822-7967.





Approved 9/04/24, Effective 1/15/25, replaces all prior versions

### 170 - LOW TITER O+ WHOLE BLOOD(LTOWB)

### TREATMENT PRIORITIES

- 1. MARCH Assessment:
  - ➤ Massive bleeding control
  - ► Airway NPA/OPA/Crich
  - Respiratory decompress chest if tension pneumothorax, seal "sucking" chest wound(s)
  - ➤ Circulation IV/IO, wound packing
  - ≻Hypothermia care
- 2. Minimize scene time in critical case\*\*
- 3. Initiate Whole Blood transfusion
- 4. Enroute Care:
  - ➤ Reassess all primary care
  - ➤ Support oxygenation/ventilation
  - ➤ Vascular access
  - ➤ Secondary Survey (if able)
  - ▶Keep patient warm/avoid hypothermia
- 5. Hospital per destination protocol..

Class: Blood Products

**Purpose**: Increase survival from traumatic hemorrhagic shock, factoring trauma patients who receive whole blood vs component therapy have many advantages, one of the most important being a reduction in 30-day mortality per published studies.

### Actions/Pharmacodynamics:

Whole blood provides red cells, stable clotting factors, and volume in each unit that make it potentially beneficial in rapidly hemorrhaging patients.

### Indications: Hemorrhagic Shock in Priority 1 Trauma Patients

- Age ≥15 years old AND
- Systolic Blood Pressure < 70 mmHg OR</li>
- If age < 65 years old and Systolic Blood pressure ≤90 with Shock index (Heart Rate/Systolic Blood Pressure) > 1.0 <u>OR</u>
- If age ≥ 65 years old <u>AND</u> Systolic Blood Pressure ≤ 100 with Shock Index (Heart Rate/Systolic Blood Pressure) > 0.9
- Post traumatic arrest/ ROSC obtained

### **Contraindications and Precautions:**

- Ground level falls/found down
- Age less than 15 years old
- Isolated head injuries above the neck
- Burns
- Non-traumatic blood loss
- Religious objection to receiving whole blood

**PARAMEDIC** 





Approved 9/04/24, Effective 1/15/25, replaces all prior versions

### Protocol 170: Low Titer O+ Whole Blood (LTOWB) cont.'

**Side Effects:** Transfusion Reactions - Fever, chills, urticaria (hives), and itching. Respiratory distress, high fever, hypotension, and hemoglobinuria can indicate a more serious reaction.

Dosage: One unit of Low Titer O+ Whole Blood

**How Supplied:** One unit of Low Titer O+ Whole Blood contains approximately 500 ml of blood and is packaged by Our Blood Institute.

### **Infusion Site Considerations**

LTOWB requires an 18 gauge or larger IV/IO. IO transfusion is authorized but is less efficient than IV. The humeral neck is the most effective IO site if used for blood transfusion. If TXA is needed it should be administered through a separate IV. This IV should be established in a different extremity than the one in which LTOWB is transfusing.

### Procedure: Prepping Tubing and Disposable Unit for Whole Blood Administration

- Make certain that unused portion of the IV line is closed off.
- Attach the IV line to the disposable tubing unit.
- Attach the disposable tubing unit to the blood warmer.
- Attach disposable tubing unit to the saline lock.
- Spike the 100 mL NS bag to appropriate port on the blood tubing.
- Spike the whole blood bag to the appropriate port on the blood tubing.
- Prime the IV-line, disposable tubing unit, and saline lock with saline <u>prior to powering on</u> the blood warmer.
- Turn blood warmer ON.
- Start infusion of LTOWB (do not wait for the blood to warm).
- Place LTOWB in the pressure bag and pump up the pressure bag.
- Use the hand pump built into the blood tubing for rapidly administering LTOWB.
- Once LTOWB infusion is complete, flush line with remaining saline from 100 mL bag.

<sup>\*\*</sup>Avoid excessive delays related to availability of LTOWB. Scene times may be delayed while starting LTOWB. However, there should not be a significant delay waiting on LTOWB to arrive on-scene. Consider intercept enroute to transition LTOWB case to transporting unit if time allows.





Medical Literature References 17O – Low Titer O+ Whole Blood (LTOWB) – Metropolitan Oklahoma City

Ward, K. R. (2016). "blood failure" time to view blood as an organ: How oxygen debt contributes to blood failure and its implications for remote damage control resuscitation. In *Transfusion* (Vol. 56, pp. S182–S189). Blackwell Publishing Inc. https://doi.org/10.1111/trf.13500

Case Report Prehospital Whole Blood. (n.d.).

Chang, R., & Holcomb, J. B. (2017). Optimal Fluid Therapy for Traumatic Hemorrhagic Shock. In *Critical Care Clinics* (Vol. 33, Issue 1, pp. 15–36). W.B. Saunders. https://doi.org/10.1016/j.ccc.2016.08.007

Crombie, N., Doughty, H. A., Bishop, J. R. B., Desai, A., Dixon, E. F., Hancox, J. M., Herbert, M. J., Leech, C., Lewis, S. J., Nash, M. R., Naumann, D. N., Slinn, G., Smith, H., Smith, I. M., Wale, R. K., Wilson, A., Ives, N., & Perkins, G. D. (2022). Resuscitation with blood products in patients with trauma-related haemorrhagic shock receiving prehospital care (RePHILL): a multicentre, openlabel, randomised, controlled, phase 3 trial. *The Lancet Haematology*, *9*(4), e250–e261. https://doi.org/10.1016/S2352-3026(22)00040-0

Doughty, H., & Strandenes, G. (2019). Whole blood in disaster and major incident planning. *ISBT Science Series*, 14(3), 323–331. https://doi.org/10.1111/voxs.12503

Guyette, F. X., Sperry, J. L., Peitzman, A. B., Billiar, T. R., Daley, B. J., Miller, R. S., Harbrecht, B. G., Claridge, J. A., Putnam, T., Duane, T. M., Phelan, H. A., & Brown, J. B. (2021). Prehospital Blood Product and Crystalloid Resuscitation in the Severely Injured Patient: A Secondary Analysis of the Prehospital Air Medical Plasma Trial. *Annals of Surgery*, *273*(2), 358–364. https://doi.org/10.1097/SLA.0000000000003324

Harm, S. K., & Dunbar, N. M. (2019). Immunologic risks of whole blood: ABO compatibility, D alloimmunization, and transfusion-related acute lung injury. *Transfusion*, *59*(S2), 1507–1511. https://doi.org/10.1111/trf.15168

Hazelton, J. P., Cannon, J. W., Zatorski, C., Roman, J. S., Moore, S. A., Young, A. J., Subramanian, M., Guzman, J. F., Fogt, F., Moran, A., Gaughan, J., Seamon, M. J., & Porter, J. (2019). Cold-stored whole blood: A better method of trauma resuscitation? *Journal of Trauma and Acute Care Surgery*, 87(5), 1035–1041. https://doi.org/10.1097/TA.000000000002471

Huish, S., Green, L., Kempster, C., Smethurst, P., Wiltshire, M., Prajapati, C., Allen, E., & Cardigan, R. (2021). A comparison of platelet function in cold-stored whole blood and platelet concentrates. *Transfusion*, *61*(11), 3224–3235. https://doi.org/10.1111/trf.16657

Kristoffersen, E. K., & Apelseth, T. O. (2019). Platelet functionality in cold-stored whole blood. *ISBT Science Series*, 14(3), 308–314. https://doi.org/10.1111/voxs.12501





Medical Literature References

17O – Low Titer O+ Whole Blood (LTOWB) – Metropolitan Oklahoma City

Leeper, C. M., Yazer, M. H., Cladis, F. P., Saladino, R., Triulzi, D. J., & Gaines, B. A. (2018). Use of uncross matched cold-stored whole blood in injured children with hemorrhagic shock. In *JAMA Pediatrics* (Vol. 172, Issue 5, pp. 491–492). American Medical Association. https://doi.org/10.1001/jamapediatrics.2017.5238

Leeper, C. M., Yazer, M. H., Cladis, F. P., Saladino, R., Triulzi, D. J., & Gaines, B. A. (2019). Cold-stored whole blood platelet function is preserved in injured children with hemorrhagic shock. *Journal of Trauma and Acute Care Surgery*, 87(1), 49–53. https://doi.org/10.1097/TA.000000000002340

Leukocyte-Reduced Red Blood Cell Transfusions in Patients With Anemia and Human Immunodeficiency Virus Infection: The Vir... Leukocyte-Reduced Red Blood Cell Transfusions in Patients With Anemia and Human Immunodeficiency Virus Infection: The Viral Activation Transfusion Study A Randomized Controlled Trial. (n.d.). https://oce-ovid-com.webproxy2.ouhsc.edu/article/00005407-200103280-00032/HTML

Mapp, J. G., Bank, E. A., Osborn, L. A., Stringfellow, M. L., Reininger, D. W., & Winckler, C. J. (2020). Epidemiological and Accounting Analysis of Ground Ambulance Whole Blood Transfusion. *Prehospital and Disaster Medicine*, *35*(1), 98–103. https://doi.org/10.1017/S1049023X1900517X

McGinity, A. C., Zhu, C. S., Greebon, L., Xenakis, E., Waltman, E., Epley, E., Cobb, D., Jonas, R., Nicholson, S. E., Eastridge, B. J., Stewart, R. M., & Jenkins, D. H. (2018). Prehospital low-titer cold-stored whole blood: Philosophy for ubiquitous utilization of O-positive product for emergency use in hemorrhage due to injury. *Journal of Trauma and Acute Care Surgery*, *84*(6S), S115–S119. https://doi.org/10.1097/TA.00000000000001905

Meledeo, M. A., Peltier, G. C., McIntosh, C. S., Bynum, J. A., & Cap, A. P. (2019). Optimizing whole blood storage: hemostatic function of 35-day stored product in CPD, CP2D, and CPDA-1 anticoagulants. *Transfusion*, *59*(S2), 1549–1559. https://doi.org/10.1111/trf.15164

Parker, M. E., Khasawneh, M. A., Thiels, C. A., Berns, K. S., Stubbs, J. R., Jenkins, D. H., Zietlow, S. P., & Zielinski, M. D. (2017). Prehospital Transfusion for Gastrointestinal Bleeding. *Air Medical Journal*, *36*(6), 315–319. https://doi.org/10.1016/j.amj.2017.06.002

Pidcoke, H. F., McFaul, S. J., Ramasubramanian, A. K., Parida, B. K., Mora, A. G., Fedyk, C. G., Valdez-Delgado, K. K., Montgomery, R. K., Reddoch, K. M., Rodriguez, A. C., Aden, J. K., Jones, J. A., Bryant, R. S., Scherer, M. R., Reddy, H. L., Goodrich, R. P., & Cap, A. P. (2013). Primary hemostatic capacity of whole blood: A comprehensive analysis of pathogen reduction and refrigeration effects over time. *Transfusion*, *53*(SUPPL. 1). https://doi.org/10.1111/trf.12048

Pokorny, D. M., Braverman, M. A., Edmundson, P. M., Bittenbinder, D. M., Zhu, C. S., Winckler, C. J., Schaefer, R., McGinity, A. C., Epley, E., Eastridge, B. J., Nicholson, S. E., Stewart, R. M., & Jenkins, D. H. (2019). The use of prehospital blood products in the resuscitation of trauma patients: a review of prehospital transfusion practices and a description of our regional whole blood program in San Antonio, TX . *ISBT Science Series*, *14*(3), 332–342. https://doi.org/10.1111/voxs.12498





Medical Literature References

17O – Low Titer O+ Whole Blood (LTOWB) – Metropolitan Oklahoma City Reddoch-Cardenas, K. M., Bynum, J. A., Meledeo, M. A., Nair, P. M., Wu, X., Darlington, D. N., Ramasubramanian, A. K., & Cap, A. P. (2019). Cold-stored platelets: A product with function optimized for hemorrhage control. In *Transfusion and Apheresis Science* (Vol. 58, Issue 1, pp. 16–22). Elsevier Ltd. https://doi.org/10.1016/j.transci.2018.12.012

Seheult, J. N., Anto, V., Alarcon, L. H., Sperry, J. L., Triulzi, D. J., & Yazer, M. H. (2018). Clinical outcomes among low-titer group O whole blood recipients compared to recipients of conventional components in civilian trauma resuscitation. *Transfusion*, *58*(8), 1838–1845. https://doi.org/10.1111/trf.14779

Snyder, E. L., Kingsbury, P. W., Kingsbury, T., Miripol, J., & Tormey, C. A. (2010). In vitro and in vivo evaluation of a whole blood platelet-sparing leukoreduction filtration system. *Transfusion*, *50*(10), 2145–2151. https://doi.org/10.1111/j.1537-2995.2010.02701.x

Sperry, J. L., Guyette, F. X., Brown, J. B., Yazer, M. H., Triulzi, D. J., Early-Young, B. J., Adams, P. W., Daley, B. J., Miller, R. S., Harbrecht, B. G., Claridge, J. A., Phelan, H. A., Witham, W. R., Putnam, A. T., Duane, T. M., Alarcon, L. H., Callaway, C. W., Zuckerbraun, B. S., Neal, M. D., ... Zenati, M. S. (2018). Prehospital Plasma during Air Medical Transport in Trauma Patients at Risk for Hemorrhagic Shock. *New England Journal of Medicine*, *379*(4), 315–326. https://doi.org/10.1056/nejmoa1802345

Spinella, P. C., Gurney, J., & Yazer, M. H. (2019). Low titer group O whole blood for prehospital hemorrhagic shock: It is an offer we cannot refuse. In *Transfusion* (Vol. 59, Issue 7, pp. 2177–2179). Blackwell Publishing Inc. https://doi.org/10.1111/trf.15408

White, N. J., Ward, K. R., Pati, S., Strandenes, G., & Cap, A. P. (2017). Hemorrhagic blood failure: Oxygen debt, coagulopathy, and endothelial damage. In *Journal of Trauma and Acute Care Surgery* (Vol. 82, Issue 6, pp. S41–S49). Lippincott Williams and Wilkins. https://doi.org/10.1097/TA.0000000000001436

Williams, J., Merutka, N., Meyer, D., Bai, Y., Prater, S., Cabrera, R., Holcomb, J. B., Wade, C. E., Love, J. D., & Cotton, B. A. (2020). Safety profile and impact of low-titer group O whole blood for emergency use in trauma. *Journal of Trauma and Acute Care Surgery*, 88(1), 87–93. https://doi.org/10.1097/TA.00000000000002498

Yazer, M. H., Delaney, M., Doughty, H., Dunbar, N. M., Al-Riyami, A. Z., Triulzi, D. J., Watchko, J. F., Wood, E. M., Yahalom, V., & Emery, S. P. (2019). It is time to reconsider the risks of transfusing RhD negative females of childbearing potential with RhD positive red blood cells in bleeding emergencies. In *Transfusion* (Vol. 59, Issue 12, pp. 3794–3799). Blackwell Publishing Inc. https://doi.org/10.1111/trf.15569





Medical Literature References 17O – Low Titer O+ Whole Blood (LTOWB) – Metropolitan Oklahoma City

Yazer, M. H., & Spinella, P. C. (2018). The use of low-titer group O whole blood for the resuscitation of civilian trauma patients in 2018. In *Transfusion* (Vol. 58, Issue 11, pp. 2744–2746). Blackwell Publishing Inc. https://doi.org/10.1111/trf.14869

Yazer, M. H., Spinella, P. C., Allard, S., Roxby, D., So-Osman, C., Lozano, M., Gunn, K., Shih, A. W. Y., Stensballe, J., Johansson, P. I., Bagge Hansen, M., Maegele, M., Doughty, H., Crombie, N., Jenkins, D. H., McGinity, A., Schaefer, R. M., Martinaud, C., Shinar, E., ... Russcher, H. (2018). Vox Sanguinis International Forum on the use of prehospital blood products and pharmaceuticals in the treatment of patients with traumatic haemorrhage. *Vox Sanguinis*, *113*(7), 701–706. https://doi.org/10.1111/vox.12678

Young, P. P., & Borge, P. D. (2019). Making whole blood for trauma available (again): the AMERICAN Red Cross experience. In *Transfusion* (Vol. 59, Issue S2, pp. 1439–1445). Blackwell Publishing Inc. https://doi.org/10.1111/trf.15166

Zhu, C. S., Cobb, D., Jonas, R. B., Pokorny, D., Rani, M., Cotner-Pouncy, T., Oliver, J., Cap, A., Cestero, R., Nicholson, S. E., Eastridge, B. J., & Jenkins, D. H. (2019). Shock index and pulse pressure as triggers for massive transfusion. *Journal of Trauma and Acute Care Surgery*, 87(1S), S159–S164. https://doi.org/10.1097/TA.000000000000002333

Zhu, C. S., Pokorny, D. M., Eastridge, B. J., Nicholson, S. E., Epley, E., Forcum, J., Long, T., Miramontes, D., Schaefer, R., Shiels, M., Stewart, R. M., Stringfellow, M., Summers, R., Winckler, C. J., & Jenkins, D. H. (2019). Give the trauma patient what they bleed, when and where they need it: establishing a comprehensive regional system of resuscitation based on patient need utilizing cold-stored, low-titer O+ whole blood. *Transfusion*, *59*(S2), 1429–1438. https://doi.org/10.1111/trf.15264

Zielinski, M. D., Stubbs, J. R., Berns, K. S., Glassberg, E., Murdock, A. D., Shinar, E., Sunde, G. A., Williams, S., Yazer, M. H., Zietlow, S., & Jenkins, D. H. (2017). Prehospital blood transfusion programs: Capabilities and lessons learned. *Journal of Trauma and Acute Care Surgery*, 82(6), S70–S78. https://doi.org/10.1097/TA.0000000000001427





### **ABBREVIATIONS**

<u>A</u>

ABCs AIRWAY, BREATHING, AND CIRCULATION

Abd ABDOMEN

AC ASSIST CONTROL (Mechanical Ventilation mode)

ACS ACUTE CORONARY SYNDROME

AED AUTOMATED EXTERNAL DEFIBRILLATOR

AEMT ADVANCED EMERGENCY MEDICAL TECHNICIAN

AKA/BKA ABOVE-BELOW-KNEE AMPUTATION

ALTE APPARENT LIFE THREATENING EVENT

AMI ACUTE MYOCARDIAL INFARCTION

AMS ALTERED MENTAL STATUS

AOS ARRIVAL ON SCENE

ASA ASPIRIN

ASAP AS SOON AS POSSIBLE

AV ATRIOVENTRICULAR

<u>B</u>

BIPAP BI-LEVEL POSTIVE AIRWAY PRESSURE

BGL BLOOD GLUCOSE

BP BLOOD PRESSURE

BSA BODY SURFACE AREA

BVM BAG VALVE MASK





<u>C</u>

C CELSIUS

C-COLLAR CERVICAL COLLAR

CABS CIRCULATION, AIRWAY, AND BREATHING

CHF CONGESTIVE HEART FAILURE

CM CENTIMETER

CNS CENTRAL NERVOUS SYSTEM

CO CARBON MONOXIDE

CO2 CARBON DIOXIDE

COPD CHRONIC OBSTRUCTIVE PULMONARY DISEASE

CPAP CONTINUOUS POSITIVE AIRWAY PRESSURE

CPR CARDIOPULMONARY RESUSCITATION

CTA CLEAR TO AUSCULTATION

D

D10 DEXTROSE 10%

D25 DEXTROSE 25%

D50 DEXTROSE 50%

DC DISCHARGE

DCAPP-BLS DEFORMITIES, CONTUSIONS, ABRASIONS, PENETRATIONS,

PARADOXICAL MOVEMENTS, BURNS, LACERATIONS, SWELLING

DBP DIASYSTOLIC BLOOD PRESSURE

dL DECILITER

DNI DO NOT INTUBATE

DNR DO NOT RESUSCITATE





<u>D</u>

D.O. DOCTOR OF OSTEOPATHY

<u>E</u>

ECG ELECTROCARDIOGRAM

ED EMERGENCY DEPARTMENT

EMD EMERGENCY MEDICAL DISPATCHER

EMR EMERGENCY MEDICAL RESPONDER

EMS EMERGENCY MEDICAL SERVICES

EMSA EMERGENCY MEDICAL SERVICE AUTHORITY

EMT EMERGENCY MEDICAL TECHNICIAN

EMT-I 85 EMERGENCY MEDICAL TECHNICIAN-INTERMEDIATE 1985

EOC EMERGENCY OPERATIONS CENTER

ETA ESTIMATED TIME OF ARRIVAL

EtCO2 END-TIDAL CARBON DIOXIDE

ETOH ETHANOL

ETT ENDOTRACHEAL TUBE

<u>F</u>

F FAHRENHEIT

FD FIRE DEPARTMENT

FiO2 FRACTION OF INSPIRED OXYGEN

FOS FIELD OPERATIONS SUPERVISOR

FT FEET (in measurement)





<u>G</u>

GCS GLASGOW COMA SCALE

<u>H</u>

HBO HYPERBARIC OXYGEN

HEMS HELICOPTER EMERGENCY MEDICAL SERVICE

HIV HUMAN IMMUNODEFICIENCY VIRUS

HR HOUR

HTN HYPERTENSION

HX HISTORY

Ī

IABP INTRA-AORTIC BALLON PUMP

ICD IMPLANTABLE CARDIOVERTER DEFIBRILLATOR

ICS INCIDENT COMMAND STRUCTURE

ID IDENTIFICATION

I:E INSPIRATORY TO EXPIRATORY RATIO

IM INTRAMUSCULAR

IN INTRANASAL

IO INTRAOSSEOUS

IOP INTRAOSSEOUS PUSH

IOPB INTRAOSSEOUS PIGGYBACK

IV INTRAVENOUS

IVP INTRAVENOUS PUSH

IVPB INTRAVENOUS PIGGYBACK





<u>J</u>

J JOULES

<u>K</u>

KCL POTASSIUM CHLORIDE

kg KILOGRAM

L

L LITER

LA LEFT ARM

LAPSS LOS ANGELES PREHOSPITAL STROKE SCALE

LL LEFT LEG

LLE LEFT LOWER EXTREMITY

LLQ LEFT LOWER QUADRANT

LOC LOSS OF CONSCIOUSNESS

lpm LITERS PER MINUTE

LUE LEFT UPPER EXTREMEITY

LUQ LEFT UPPER QUADRANT

M

mA milliAmp

MAX MAXIMUM

mcg MICROGRAM

MCB MEDICAL CONTROL BOARD

MCI MASS CASUALTY INCIDENT

M.D. MEDICAL DOCTOR





<u>M</u>

mEq MILLIEQUIVALENT

MERC MEDICAL EMERGENCY RESPONSE CENTER

mg MILLIGRAM

MI MYOCARDIAL INFARCTION

MIN MINUTE

mL MILLILITER

mm MILLIMETER

mmHg MILLIMETERS OF MERCURY

MOI MECHANISM OF INJURY

mph MILES PER HOUR

Ν

NC NASAL CANULA

NIPPV NON-INVASIVE POSITIVE PRESSURE VENTILATION

NPA NASAL PHARYNGEAL AIRWAY

NPO NOTHING BY MOUTH

NRB NON REBREATHER MASK

NS NORMAL SALINE

NTG NITROGLYCERIN

NVD NAUSEA, VOMITING, DIARRHEA

0

O2 OXYGEN

OD OVERDOSE

ODT ORAL DISOLVING TABLET





0

OLMC ON-LINE MEDICAL CONTROL

OLMCP ON-LINE MEDICAL CONTROL PHYSICIAN

OMD OFFICE OF THE MEDICAL DIRECTOR

OPA ORAL PHARYNGEAL AIRWAY

OSDH OKLAHOMA STATE DEPARTMENT OF HEALTH

O2 SAT OXYGEN SATURATION

<u>P</u>

PD POLCIE DEPARTMENT

PEA PULSELESS ELECTRICAL ACTIVITY

PEEP POSITIVE END-EXPIRATORY PRESSURE

PEP POST-EXPOSURE PROPHYLAXIS

PICC PERIPHERLLY INSERTED CENTRAL CATHETER

PMS PULSE MOVEMENT SENSATION

PO BY MOUTH

PRN AS NEEDED

Psi Pounds per square inch

PS PRESSURE SUPPORT (Mechanical Ventilation mode)

PSVT PAROXYSMAL SUPRAVENTRICULAR TACHYCARDIA

Pt PATIENT

PTA PRIOR TO ARRIVAL

PVC PREMATURE VENTRICULAR CONTRACTION

PERRLA PUPILS EQUAL ROUND REACTIVE TO LIGHT ACCOMADATIONS





<u>R</u>

RA RIGHT ARM

REMSS REGIONAL EMERGENCY MEDICAL SERVICE SYSTEM

RESP RESPIRATIONS

RL RIGHT LEG

RLE RIGHT LOWER EXTREMITY

RLQ RIGHT LOWER QUADRANT

RN REGISTERED NURSE

ROSC RETURN OF SPONTANEOUS CIRCULATION

RUE RIGHT UPPER EXTREMITY

RUQ RIGHT UPPER QUADRANT

<u>S</u>

SA SINOATRIAL

SBP SYSTOLIC BLOOD PRESSURE

SL SUBLINGUAL

SOB SHORTNESS OF BREATH

SpCO CARBON MONOXIDE SATURATION OF ARTERIAL BLOOD

SpO2 OXYGEN SATURATION OF ARTERIAL BLOOD

STEMI ST SEGMENT ELEVATION MYOCARDIAL INFARCTION

SubQ SUBCUTANEOUS

SYS BP SYSTOLIC BLOOD PRESSURE

ST SINUS TACHYCARDIA





<u>T</u>

TB TUBERCULOSIS

TBSA TOTAL BODY SURFACE AREA

TCA TRICYCLIC ANTIDEPRESSANT

TEMP TEMPERATURE

THA TOTAL HIP ARTHROPLASTY

TKA TOTAL KNEE ARTHROPLASTY

TKO TO KEEP OPEN

TREC TRAUMA REFERRAL CENTER

TXA TRANEXAMIC ACID

<u>V</u>

VAD VENTRICULAR ASSIST DEVICE

VF VENTRICULAR FIBRILLATION

VS VITAL SIGNS

VT VENTRICULAR TACHYCARDIA

W

WO WIDE OPEN (FLOW RATE)

### **INSTRUCTIONS**

### Oklahoma State Department of Health Communicable Disease Risk Exposure Report

This report form was developed to initiate a system of notification for risk exposures occurring outside of a health care facility to health care workers, emergency responders, and funeral workers as specified by the Oklahoma State Department of Health OAC 310:555. This report and all information entered on it are to be held in strictest confidence to conform with 63 O.S. Supp. 2001, Section 1-502.1 et. seq.

Note: For questions regarding the handling of ODH Form 207, call 405/271-4636.

### **PART I: Exposed Worker Section**

Questions 1-13 are to be completed by the exposed worker, immediately following the injury.

- 11: Describe exposure in detail. Include information regarding type of exposure, body part affected, type of body fluid involved, duration of exposure, etc.
- 13: List the facility where the source patient was taken. This will be the facility that is responsible for testing the source patient.

Questions 14-19 are to be completed by Employer's Designee, immediately following the injury.

Questions 20-22 are to be completed by a Licensed Health Care Professional. (MD, DO, RN, PA,).

### Routing:

- A. If the Licensed Health Care Professional determines that the exposure does not have the potential for transmission of a communicable disease, the form should be returned to the Employer's Designee.
- B. If the exposure does have the potential for transmission of a communicable disease, the *Yellow* copy should be mailed *immediately* to the OSDH HIV/STD Service (use gray, self addressed, metered envelope).

The *Green* copy, a gray metered envelope and instruction page are to be delivered *immediately* to the designated person (usually the Infection Control Practitioner) at the health care facility to which the source patient was transported; to the attending physician, if the source patient was being cared for outside of a health care facility; to the health care provider who last had responsibility for the deceased source patient; or to the medical examiner.

### PART II: Source Patient Health Care Provider Section

Questions 23-38 are to be completed by the Health Care Provider who is responsible for testing the source patient.

32. Rapid HIV testing has become a valuable tool used to quickly determine the need for initiation and/or continuation of PEP meds for the exposed person. When a rapid HIV test is performed on the source patient, communication of these results should not be delayed. The results should be **immediately** communicated to the physician/provider who is providing post-exposure counseling and follow up and is listed on page 1, q. 17-19.

Please note that as other source results become available, these should be released to the Provider listed on page 1, q. 17-19.

### Routing:

A. The Health Care Provider should complete Part II and mail the completed green form to OSDH HIV/STD Service immediately using the gray, self-addressed, metered envelope.

### PART II: Source Patient Health Care Provider Section (Please Print) 23. Date and time Communicable Disease Risk Exposure Report received: (Mo./Day/Yr.) \_\_\_/\_\_\_/ Time: \_\_\_\_AM or PM (Circle One) 24. Person completing Part II: \_ (Title) (First) (Last) Business Phone: (\_\_\_\_)\_\_\_\_ 25. Institution (name): \_\_\_ Source Patient Information 26. Birth date: (Mo./Day/Yr.) / / 27. Sex: [] Male: [] Female 28. Primary Diagnoses: \_\_\_\_\_ 29. Was the source patient found to have any potentially communicable disease(s), such as hepatitis B, hepatitis C, IIIV, TB, meningococcal disease, or others? ☐ Yes 31. Does the source patient have clinical evidence of AIDS or symptoms of HIV infection or acute retroviral syndrome? IYes; I No; Unknown Source Patient Test Results ☐ Not Done Test Date: (Mo./Day/Yr.) \_\_\_\_\_/\_\_\_/ \_\_\_\_/ Note: IMMEDIATELY report Rapid HIV results by phone or fax to the Provider listed on page 1, q. 17-19. As other test results become available, these are also to be released to the Provider listed on page 1, q. 17-19. □ Not Done ☐Positive; ☐Negative 33. HBsAg: Test Date: (Mo/Day/Yr.) \_\_\_\_/\_\_\_\_ Not Done ☐ Positive; ☐ Negative 34. anti-HCV: ■Not Done Positive; Negative; Indeterminant Test Date: (Mo/Day/Yr.) \_\_\_\_ /\_\_\_\_/\_\_\_\_ 35. HIV: \_\_\_\_\_ Test Date: (Mo./Day/Yr.) \_\_\_ 36. Other: Name of Test:\_\_\_\_\_\_ \_\_\_\_ Test result: \_\_\_\_ Note: Source results may be released to the source patient; the exposed person; the exposed person's physician/provider or OSDH per OAC 37. Date results released to Provider: (Mo/Day/Yr) \_\_\_\_/\_\_\_\_ 38. Date mailed to OSDH: (Mo./Day/Yr.) \_\_\_\_\_/\_\_\_\_ When Part II is completed, mail immediately to the OSDH HIV/STD Service using the gray, self-addressed, metered envelope. Part III: OSDH Section (Please Print) Date Report Received: (Mo./Day/Yr.) \_\_\_\_/\_\_\_ Person Completing Part III: \_ (First) (Last) OSDH Division: Follow-Up Action: \_\_\_\_ \_\_\_\_\_

### Communicable Disease Risk Exposure Report

The filing of this report initiates a system of notification for risk exposures occurring outside of a health care facility to health care workers, emergency responders, and funeral workers as specified by the Oklahoma State Department of Health OAC 310:555. This report and all information entered on it are to be held in strictest confidence in conformance with 63 O.S. Supp. 2001, Section 1-502.1 et. seq.

l. Employee Name:			2. Birth date:	
(Last)	(First)	(MI)	Mo.	Day Yr.
3. Home Telephone: ( )	4. Professio	on/Job Title:		
i. Employer/Company Name:				· · · · · · · · · · · · · · · · · · ·
5. Work Address/Telephone:(Street)	(City)	(Zip)	()	
Number of hepatitis B vaccinations previous	-	□1; □2; □3	Тетерлопе	
B. Date of Exposure: (Mo./Day/Yr.)	_//9. Time of	Exposure:	AM or PM (Circi	de Onc)
0. Supervisor's Name/Telephone:			()	
1. Description of Exposure:			тетерпопе 	
				<del>.</del> .
12. Source Patient Name:				
(Last)		(First)	(M.L.)	
3. Location of Source Patient (include nam		number):		
The state of the s				
to Be Completed By Employer's Designed	e			
have reviewed the circumstances and mana Plan) is being attempted in order to identify exposure.	igement of this incident and veri or prevent the transmission of co	fy that the appropriate following that the appropriate following the following that the state of	low-up (according to our agen which the employee may be at	cy Exposure Control risk as a result of thi
4	15 Si		/	1
			Mo, Da	y Yr.
ost-exposure counseling and follow-up will	be provided to this employee by:			
7. Provider's Name		Felephone Number	Provider's Fax Number	 er
		PA		
To Be Completed by A Licensed Health Ca	are Professional (MD, DO, RN	1 12,7		
n my professional judgment, this 🔲 was	☐was not—a muçosal, percutar	neous or respiratory expos	ure that has the potential for tr	ransmission of a
To Be Completed by A Licensed Health Canny professional judgment, this was communicable disease, such as hepatitis B. b	Twas not a mucosal, percutar nepatitis C, HIV, TB or meningoo	neous or respiratory expos		ransmission of a

For consultation regarding exposures and PEP meds: PEP Hotline 1-888-448-4911

Note: If this exposure does not warrant medical follow-up, please return the form to the Employer's Designee and indicate to that individual why no follow-up is required.

If this is an exposure that warrants medical follow-up, the employer shall handle the report accordingly:

- A. Yellow copy to be mailed Immediately to the OSDH HIV/STD Service (use gray, self-addressed, metered envelope) at 1006 N.E. 10, OKC, Ok 73110
- B. Green copy, a gray metered envelope and instruction page to be delivered immediately to the designated person (usually the Infection Control Practitioner) at the location of the source patient.

### ADULT PRE-HOSPITAL

### TRIAGE AND TRANSPORT GUIDELINES

Oklahoma Model Trauma Triage Algorithm

Inability To Secure Airway

Traumatic Arrest

YES

YES

YES

Go Directly to Nearest Appropriate Facility

### PRIORITY 1

### Physiological Compromise Criteria

- Hemodynamic Compromisel-Systolic BP < 90mm/rg Or signs that should be considered include:
  - Sustained tachycardia
     Cool diaphoretic skin
- Cool disphoretic skin
   Respiratory Compromise2- RR < 10 or > 29 breaths/minute or < 20 in Infant < 1 vr</li>
- Altered Mentation of trauma etiology 3- GCS < 14</li>

### NO V

### Anatomical Injury

- Penetrating injury of head, neck, chest/abdomen, or extremities proximal to elbow or knee
- Combination of burns > 10% or significant burns involving face, airway, hands, feet or genitalia without significant trauma transport to regional Burn Center. Burns >10% with significant trauma transport to trauma center.
- · Amputation above west or ankle
- · Paralysis or suspected spinal fracture w/neurological deficit
- · Flail chest
- Two or more obvious proximal long bone fractures [upper arm or thigh]
- . Open or suspected depressed skull fracture
- Unstable pelvis or suspected unstable pelvic fracture
- Tender and/or distended abdomen
- · Crushed, degloved, or mangled extremity

### Initiate Trauma Treatment Protocol Activate Trauma System

RAPID transport to the designated Level I, II, or Regional Level III Trauma Center according to the Regional Trauma Plan but may be stabilized at a Level III or IV facility depending on location and time and distance to the higher level trauma center.

Air Rendezvous may be necessary considering time & distance constraints. If conditions do not permit air transport then consider ALS rendezvous. Stabilization may occur either in the field or at the nearest appropriate facility.

Combination of burns > 10% or significant burns involving face, airway, hands, feet or genitalia without significant trauma transport to regional Burn Center. Burns >10% with significant trauma transport to trauma center.

### PRIORITY 2

### NO

### Risk of Serious Injury - Single System Injury

Patients with potentially time sensitive injuries due to a high energy event (positive mechanism of injury) or with a less severe single system injury; but currently with no physiological abnormalties or significant anatomical injury.

- . Election of the patient from an enclosed vehicle
- Auto/pedestrian or auto/bike or motorcycle crash with significant impact (> 20 mph) with the patient thrown or run over by a vehicle
- Falls greater than 20 feet or distance 2-3 times height of patient
- Significant assault or altercations
- High risk auto crashli
- Neurology: isolated head trauma with transient loss of consciousness or altered mental status but currently alort and oriented.
- Orthopedic: Single proximes and distall extremity fractures (including open) from high energy event, soluted joint dislocations-knee, his, ebow, shoulder without neuroviscular deficits, and unstable joint (ligament) injuries without neuroviscular deficits.
- Maxillofacial brauma: Facial accrations; such as those requiring surgical repeir, isolated open facial fractures or isolated orbit trauma with or without entrapments, or avuised teeth.

## Protoc

YES

### Initiate Trauma Treatment Protocol

PROMPT transport to the designated Level III Trauma Center or higher depending on location according to the Regional Trauma Plan

PRIORITY 3 NO YES

- Consider<sup>e</sup>
- Co-morbid factors
- Gestalt-EMS clinical judgment

NO

TRANSPORT to either the closest Level IV
Trauma Center or higher depending on location
according to the Regional Trauma Plan or the facility of
the patient's choice.

### PEDIATRIC (≤ 16YEARS) PRE-HOSPITAL

### TRIAGE AND TRANSPORT GUIDELINES

Oklahoma Model Trauma Triage Algorithm



Traumatic Arrest

YES

/ES

/ES

Go Directly to Nearest Appropriate Facility

### PRIORITY 1

### Physiological Compromise Criteria

- Hemodynamic Compromise'-Systolic BP < 90mmHg</li>
  - or other signs such as:

     Sustained tachycardia

     Cool diaphoretic skin
- Respiratory Compromise's RR < 10 or > 29 breaths/ minute or < 20 in infant < 1 yr

Altered Mentation of trauma etiology\*- GCS < 14



### Anatomical Injury

- Penetrating injury of head, neck, chest/abdomen or
- Penetrating injury of head, neck, chestylaboriner or extremittes proximal to elbow or lorse
   Combination of turns > 10% or significant burns involving face, ainway, hands, feet or genitalia without significant trauma transport to Hillcrest Burn Center or OUMC Children's Hospital, Burns >10% with significant trauma transport to
- Amputation above wrist or aride Paralysis or suspected spinal fracture w/neurological deficit
- . Flail chest
- . Two or more obvious proximal long bone fractures (upper
- . Open or suspected depressed skull fracture
- instable pelvis or suspected unstable pelvis fracture.
- Tender and/or distended abdomen Crushed, degloved, or mangled extremity

Pediatric Trauma Score <5

### Initiate Trauma Treatment Protocol Activate Trauma System

RAPID transport to the designated Level I, II, or Regional Level III Trauma Center according to the Regional Trauma Plan but may be stabilized at a Level III or IV facility depending on location and time and distance to the higher level trauma center

Air Rendezvous may be necessary considering time & distance constraints. If conditions do not permit air transport consider ALS rendezvous. Stabilization may occur either in the field or at the nearest appropriate facility.

Combination of burns > 10% or significant burns involving face, airway, hands, feet or genitalia without significant trauma transport to Hillcrest Burn Center or OUMC Children's Hospital. Burns >10% with significant trauma transport to trauma center.

### PRIORITY 2

### Risk of Serious Injury - Single System Injury

Patients with potentially time sensitive injuries due to a high energy event (positive mechanism of injury) or with a less severe single system injury, but currently with no physiological abnormalities or significant anatomical injury

- . Election of the patient from an enclosed vehicle
- Auto/pedestrian or auto/bike or motorcycle crash with significant impact (> 20 moh) with the patient thrown or run over by a vehicle
- · Falls greater than 10 feet or distance 2-3 times height of patient
- · Significant assault or altercations
- High risk auto crash\*
- · Neurology: Isolated head traums with transient loss of consciousness or altered mental status but currently alert and oriented.
- Orthopedic: Single proximal and distal extremity fractures (including open) from high energy event, isolated joint dislocations-ionee. hip, elbow, shoulder without neurovascular deficits, and unstable joint (ligament) injuries without neurovescular deficits.
- · Maxillotacial trauma: Facial lecerations; such as those requiring surgical repair, isolated open facial fractures or isolated orbit. trauma with or without entraoments, or avuised teeth

Pediatric Trauma Score 6-8



Initiate Trauma Treatment Protocol

to the designated Level III Trauma Center or higher depending on location according to the Regional Trauma Plan





YES



Co-morbid factors and Gestalt-EMS clinical judgment.

Pediatric Trauma Score 9-12

NO

TRANSPORT to either the closest Level IV Trauma Center or higher depending on location according to the Regional Trauma Plan or the facility of the patient's choice



### Section 100 - Incident Command/Management

### 100.3.17 Incident Scene Rehabilitation: (Rehab)

### 100.3.17.1 General:

No member will be permitted to continue emergency operations beyond safe levels of physical or mental endurance. The intent of rehab is to lessen the risk of injury that may result from extended field operations under adverse conditions. Rehab is implemented during hot or cold environmental temperature extremes, but may be used anytime at the direction of the IC.

### 100.3.17.2 Work-to-Rest Ratio:

The basic work-to-rest ratios are listed below. These ratios are considered minimum guidelines and can be adjusted for incident conditions.

Work: After:

• One 30-minute SCBA cylinder

• 20 minutes of intense work without SCBA

Rest: 10 minutes of self-rehabilitation (rest with hydration)

Work: After:

Two 30-minute SCBA cylinders

• One 45/60-minute SCBA cylinder when encapsulating chemical protective clothing is worn

40 Minutes of intense work without SCBA

Rest: 20 minutes of rest (with hydration) in a rehabilitation area

### 100.3.17.3 Ongoing Hydration: (Water)

Minimum of 2-4 oz. of water for every:

- 20 minutes during any type of firefighting
- 20 minutes during major medical or mass casualty incidents
- 15-30 minutes during Hazmat/special operations

### 100.3.17.4 Long Term Incident Hydration: (Diluted Sports Drink)

When the on-scene time exceeds two hours, members will be provided with sports drink diluted to half strength with water in place of water at the intervals indicated above.



### Section 100 - Incident Command/Management

### 100.3.17.5 Rehab Levels and Functions:

## 100.3.17.5.1 Self-Rehabilitation (Company/Crew Level Rehabilitation):

Self-rehabilitation occurs after short duration incidents and/or between trips to the Rehab Area. Company officers should ensure that fluids are available on their apparatus so that members can replace fluids (while changing SCBA cylinders, taking short breaks, etc.).

### 100.3.17.5.2 Formal Rehab (Rehab Group):

The Rehab group will be used to evaluate and assist personnel who could be suffering from the effects of sustained physical or mental exertion during emergency operations.

The rehab group provides a specific area where personnel will assemble to receive:

- A physical assessment
- Rest, hydration, and refreshments
- Medical evaluation and treatment of minor injuries
- Continual monitoring of physical condition
- Transportation for those requiring treatment at medical facilities
- Initial stress support assessment
- Reassignment

### 100.3.17.5.2.1 Rehab Group Resources and Capabilities:

When the IC implements the Rehab Group, the group supervisor should utilize any of the following resources that he/she deems appropriate:

- EMSA
- TFD Apparatus with Rehab Equipment
  - "? Air & Light Units
  - "? Hazmat
  - "? TFD Bus
- TFD Training Staff: The TFD Training Center maintains a cache
  of towels, buckets, and sports drink for Rehab. Additionally, the
  staff can bring the TFD Bus.
- TFD EMS Staff
- TFD ALS Capabilities
- TFD Fitness Staff
- MTTA Bus
- Any other resource necessary

### Section 100 - Incident Command/Management

The IC has the discretion to assign an appropriate person to the position of Rehab Group Supervisor. When assigning this position, the IC should consider the following personnel:

- TFD EMS Officer
- TFD Training Officer
- TFD Exercise Physiologist
- TFD Chief Officer or Company Officer
- EMSA Supervisor

### 100.3.17.5.2.2 Check-In Point:

This is the initial entry point. Rehab staff will take a pulse rate on all crew members.

- Any member who has a pulse rate greater than 120 will report directly to medical rehab. These members will be treated by advanced life support personnel in accordance with EMS protocols.
- All other members will report to the hydration and replenishment area.

### 100.3.17.5.2.3 Hydration and Replenishment Area:

During warm weather conditions, all personnel will remove coats, helmets, gloves, and protective hoods. Turnout pants should be removed or at least rolled down over the boots. Fluid and electrolyte replacement will be provided.

The following requirements pertain to the physical area used for Rehab:

- A key concept to abide by when establishing a Rehab Area is to set it up as close as safely possible to where firefighters are working.
- During hot temperature extremes, avoid placing personnel directly
  in an air conditioned environment. Provide a shaded area with air
  movement. Air and Light Units and Hazmat have canopies, fans
  and misters for this purpose. Hazmat also has tent capabilities.
  Rehab supervisors may also be able to secure areas that are close to
  the incident.

# (a)

### **Tulsa Fire Department - Emergency Operating Guidelines**

### Section 100 - Incident Command/Management

The following other requirements pertain to personnel assigned to the hydration and replenishment area:

- All personnel should spend a minimum of 20 minutes resting in this area.
- Personnel should consume a minimum of 10 ounces of water or other approved beverages while in this area.
- Personnel should place their arms into cool (not cold) water as they are resting (See Rehab Group Resources).
- Smoking is not permitted in this area.

### 100.3.17.5.2.4 Medical Rehab and Transport Area:

This Section is staffed by an ALS crew and at least one EMS transport vehicle. Personnel reporting here will receive evaluation and treatment per EMS protocols. The ALS crew in this area will pay close attention to the following:

- Pulse
- Pulse-ox
- Respiratory rate
- Blood pressure
- Body temperature
- Obvious injuries or illness

Any firefighters who receive IV fluids are considered to be in medical rehab and fall under EMS protocols. Additionally, those receiving IV fluids will be taken to the appropriate medical facility to obtain laboratory blood testing to ensure appropriate levels of hydration, electrolytes, and renal function.

### 100.3.17.5.2.5 Reassignment Area:

After the prescribed rehabilitation (minimum of 20 minutes for an initial cool down and evaluation period) members will be re-evaluated. Upon evaluation, the members will be triaged into one of the following groups:

- Return to duty adequately rehabbed and medically sound.
- Remove from duty evidence of an illness or injury; including any person with a pulse rate greater than 100.
- Transported to an appropriate medical facility for further evaluation and treatment of illness or injury; including any member who has a temperature greater than 101 °F (38 °C) or a blood pressure less than 100 (systolic).

Members who are transported to a medical facility should be accompanied by a department representative.

### Section 100 - Incident Command/Management

Crews authorized to return to duty will be released as intact crews and report to the Reassignment Area.

The rehab group supervisor will update the IC throughout the operation with pertinent information including the identities of companies in Rehab, the companies available for reassignment, and the status of injured personnel.

Company officers must keep crews intact and report to the proper sections in Rehab. The rehab group supervisor will direct the crew to the proper areas; however, it is the company officer's responsibility to make sure crew members receive refreshments, rest, and a medical clearance.



### **Section 100 - Incident Command/Management**

## REHABILITATION ARM & HAND IMMERSION IN TAP WATER

A simple, safe and controlled method to reduce heat stress is hand and arm immersion into containers of standard tap water. Buckets for this procedure will be stored on Engines and specialized apparatus or staff positions.



### STEP 1

Removethehelmet, bunkercoat, hood, pants and boots when checked into Rehabilitation. The helmet, coat and hood tend to be naturally removed. Direction usually needs to be given to remove the pants and boots. The removal of all gear is essential to obtain the desired cooling.

<u>Filltwobucketswithtapwater</u> obtained from a garden hose, hose line from fire apparatus or connection to a fire hydrant. NOTE: If water is acquired through a fire pump, make certain that it has not been heated from the churn action of the fire pump.



DO NOT ADD ICE TO THE BUCKETS.



### STEP 2

Seat the person onto a bench type surface such as the tailboard of the apparatus or curb of the street. <u>Positionthebucketsoneithersideofthepersonatthesameelevationattheobjectusedasaseat.</u> Instruct the person to place both hands and arms into the water with the hands touching the bottom of the bucket. Ideally, the person should spread his/her fingers apart to maximize the exchange of heat.



### STEP 3

<u>Theimmersion process should be conducted forten</u> to twenty minutes. A similar process may be conducted with the feet for additional control of severe cases.

<u>Continuouslymonitorthemedicalconditionoftheperson</u> and frequently record vital signs. Provide medical care as needed.

<u>Also provide coolwater or partial strengths ports drinks. Do not provide hotor cold beverages</u> and avoid all fluids that contain caffeine.

No employee will operate at an emergency or non-emergency scene beyond a safe level of physical and mental endurance. These guidelines apply to all appropriate emergency incidents and training exercises where physical activity or exposure to extreme environmental conditions exists. Rehabilitation (Rehab) will be utilized to evaluate and assist personnel to avoid sustained physical exertion that can result in acute health detriments as well as to evaluate and assist personnel who may already be suffering from the effects of sustained physical exertion during emergency operations. Rehab will provide a specific area where personnel will assemble to receive:

- √ a physical assessment
- ✓ revitalization rest, refreshments, etc.
- ✓ treatment for physical and/or mental stress as well as physically induced injuries and/or illnesses
- ✓ close monitoring of physical condition
- ✓ transportation for those requiring treatment at medical facilities

### **RESPONSIBILITIES**

The Incident Commander (IC) will consider the circumstances of each Incident and make necessary arrangements early in the Incident for rehabilitation of all personnel operating at the scene.

All Company Officers will maintain an awareness of the condition of each Fire Crew (Crew) member operating within their span of control.

It is the responsibility of each firefighter to advise their Company Officer when they believe that their level of fatigue or exposure to heat or cold is approaching a level that could affect themselves or their Crew in the operation in which they are involved.

### **ESTABLISHMENT OF REHAB**

### Responsibility

The Incident Commander will establish Rehab when conditions indicate it will be needed at an Incident or training evolution scene and will assign a Rehab Supervisor who reports to the Logistics Section Chief (if filled).

### Location

The location for Rehab will normally be designated by the Incident Commander. If a specific location has not been designated, the Rehab Supervisor will select an appropriate location for the Rehab Area.

### **Rehab Area Site Characteristics**

- 1. The entry/exit will be marked with two traffic cones to indicate where all personnel will enter and exit Rehab Area.
- 2. Rehab Area should be far enough away from the scene that members may safely remove their Structural PPE and SCBA.
- 3. The Rehab Area should enable members to be free of exhaust fumes from fire apparatus, vehicles, or equipment
- 4. It should provide protection from the prevailing environmental conditions.
- 5. Misting and cooling equipment should be made available if heat stress could result from the incident operations and/or prevailing environmental conditions.
- 6. It should be large enough to accommodate multiple Crews.
- 7. It should be easily accessible to EMS personnel and Incident support agencies.
- 8. It should allow easy reentry into the emergency operation.
- 9. Rehab Area should be divided into four areas:
  - Rest Area (for immediate Rehab)
  - Ready Area (for rehabbed firefighters cleared by Rehab Supervisor)
  - Medical Evaluation Area
  - Medical Treatment Area

The staffing of Rehab Area will be determined by the Incident Commander taking into consideration the size and duration of the Incident/evolution.

### Staffing

Residential/Commercial Response: Rehab Area will be staffed using the initial responding Fire Companies unless in the judgment of the Incident Commander more resources are needed to adequately staff it.

Multiple Alarm: Rehab Area will be staffed by initial responding resources until such time as the additional Alarm support personnel arrive on the scene. The additional Alarm support personnel will report to the Incident Commander and could be assigned Rehab duties, if necessary, for existing personnel to be relieved.

### **REHAB GUIDELINES**

### **Establishment**

Rehab should be considered by the Incident Commander during the size-up phase of an Incident. Climatic and environmental conditions for the Incident scene should not be the sole justification for establishing the location of Rehab Area. Any training or Incident activity which is large in size, long in duration, and/or labor intensive, will rapidly deplete the energy and strength of personnel and therefore merits consideration for establishing Rehab. When established, the Rehab Medical Evaluation Form will be used to document personnel in the Rehab Area (on FDWEB Forms).

### **Accountability**

All Crew members reporting to Rehab Area will check in with the Rehab Supervisor at the entry/exit point. Personnel leaving Rehab Area must check out through the Rehab Supervisor. Personnel assigned to Rehab Area must remain in Rehab for at least 10 minutes. During this time, the firefighter will be medically evaluated and be provided hydration. No firefighter should be reassigned to return to duty until cleared by the Rehab Supervisor.

The Rehab Supervisor will update the Incident Commander (or Logistics Section Chief, if filled) throughout the operation with pertinent information including: the Fire Companies in Rehab, the Fire Companies available for reassignment, and the status of any injured or ill personnel.

### Resources

The Rehab Supervisor will secure all necessary resources to adequately staff and supply the Rehab Area. The supplies should include the following items but should be adjusted as necessary for the Incident.

- 1. Hydration: water, activity beverage and ice
- 2. Nourishment: Red Cross can be used as a resource for food and nourishing drinks
- 3. Medical: at least one trauma kit, oxygen administration equipment, defibrillator with CO monitoring capability, and other equipment as needed
- 4. Other (as deemed by the Incident): fans, tarps, heaters, floodlights, blankets, and traffic cones (to mark the entry/exit of Rehab Area)

### Hydration

A critical factor in the prevention of heat injury is the maintenance of water and electrolytes. Water must be replaced during exercise periods and at emergency incidents. Employees will rehydrate (at least eight ounces) while SCBA cylinders are being refilled. During heat stress, each employee should consume at least one quart (32 oz.) of water per hour. The rehydration fluid, if possible, should be an activity beverage administered cool. Rehydration is important even during cold weather operations where heat stress may occur during firefighting or other strenuous activity when Structural PPE is worn. Carbonated and caffeinated drinks should be avoided before and during emergency operations, because both interfere with the body's water conservation mechanisms.

### Nourishment

Food and nourishing drinks may be provided by the American Red Cross (or suitable alternative) at the scene of extended Incidents when units are engaged for three or more hours.

### Rest

Rest should not be less than ten minutes and may exceed an hour as determined by the Rehab Supervisor. Fire Companies released from the Rest Area of Rehab, will move to the Ready Area of Rehab to ensure that fatigued employees are not required to return to duty before they are rested, evaluated, and released by the Rehab Supervisor.

\*The Company Officer should additionally ensure that all personnel in the Fire Company appear fit to return to duty.

### MEDICAL TREATMENT AREA

All treatment should follow approved protocols. There is clear delineation between Medical Evaluation and Medical Treatment in Rehab. Documentation is to be kept separately. Although the same providers may do both, it makes logistical and operational sense to separate them into functional areas if possible.

If an employee has abnormal vital signs or if employee does not recover in a reasonable amount of time, contact the Incident Commander for possible transport to the hospital.

- Measure the SpCO% with RAD-57 or LifePak 15
- # If SpCO% > 3% with any of below signs or symptoms, treat per MCB protocol III.44 Monitoring of CO Poisoning.

### **CO Poisoning Symptoms**

Flu-like symptoms Abdominal pain

Fatigue Headache
Dyspnea Drowsiness
Chest pain Dizziness
Palpitations Weakness
Lethargy Confusion

Confusion Visual disturbances

Depression Syncope Impulsiveness Seizures

Distractibility Fecal incontinence
Hallucination Urinary incontinence
Confabulation Memory disturbances
Agitation Gait disturbances

Nausea Bizarre neurologic symptoms


Vomiting Coma

Diarrhea

### **Firefighter Headaches**

While CO should always be considered a possible cause of headaches in working firefighters, there are more common causes which includes:

- > Tight helmet ratchet
- > Too heavy a helmet (especially leather)
- Dehydration



### MEDICAL TREATMENT AREA

All treatment should follow MCB approved protocols. There is clear delineation between medical monitoring and emergency medical treatment in rehab. Documentation is to be kept separately. Although the same providers may do both, it makes logistical and operational sense to separate them into functional areas if possible.

If an employee has abnormal vital signs or if employee does not recover in a reasonable amount of time, contact the Medical Officer for possible transport to the hospital.

Attachment A - COMPANY CHECK IN / CHECK OUT SHEET (FRONT SIDE) Destination Transport Transport Ϋ́ Complaints Medical ф Cooling/ Heating Y/N Incident Number:\_ Temp Page\_ Incident Medical Surveillance Form Oklahoma City Fire Department CO Level Pulse Ox Resp. Heart Rate В Rehab Medic:\_ Time Vitals Taken \*\*\*Instructions for this form are on reverse of this page # SCBA Bottles Used Time in /Time Out in Rehab Times Incident Address: Name and Company Date: Destination Transport

### Attachment A - COMPANY CHECK IN / CHECK OUT SHEET (BACK SIDE)

- Enter name of medic in rehab at bottom of form
- Enter the name and company of each person entering rehab
- Each time personnel enter rehab, re-enter them on the form. Be sure to record the number of times the person is rehabilatated
- Once in the medical evaluation area, heart rate should be measured for 30 seconds as early as possible in the rest period
- If employee's heart rate exceeds 110 beats per minute, an oral temperature should be taken
- If temperature exceeds 100.6°, no PPE should be worn
- If temperature is below 100.6° and heart rate remains above 110 beats per minute, rehab time should be increased
- Vitals should be taken every 5-10 minutes
- If employees SpCO level is >3% with any of the below signs or symptoms, treat per MCB protocol III.44 Monitoring of CO Poisoning

Signs of CO Poisioning		Heat Stress Symptoms		Cold Stress Symptoms		
Flu like symptoms	Fatigue	Dyspnea	nausea	shortness of breath	headache	low or absent blood pressure
Chest Pain	Palpitations	Lethargy	flushed skin	weakness	mental confusion	slow pupil response
Confusion	Depression	Impulsiveness	cramping	exhaustion	numbness	muscle rigidity or stiff posture
Abd pain	Headache	Drowsiness	headache	seizures	waxy/pale skin	blistered skin
Weakness	Confusion	Visual Disturbances	mental confusion	sunburn	dehydration	
Syncope Agitation	Seizures Nausea	Hallucination Vomiting	rapid heartbeat	absence of sweating		
Diarrhea	Incontinence	Memory disturbances				
Gait disturbances	Neurologic symptoms	Coma				

### Work-to-Rest Ratio

	At least 10 minutes of self-rehabilitation (rest with hydration ) as a company or
Up to one 30 minute SCBA cylinder	crew
	At least 10 minutes of self-rehabilitation (rest with hydration ) as a company or
20 min of intense work without SCBA	crew

(When encapsulating chemical protective clothing is worn)


Up to two 30-minute SCBA cylinders	At least 20 minutes of rest (with hydration) in rehabilitation area
One 45-minute SCBA cylinder	At least 20 minutes of rest (with hydration) in rehabilitation area
One 60-minute SCBA cylinder	At least 20 minutes of rest (with hydration) in rehabilitation area
40 minutes of of work without SCBA	At least 20 minutes of rest (with hydration) in rehabilitation area

If an employee has abnormal vital signs or if employee does not recover in a reasonable amount of time, contact the Medical Officer for possible transport to the hospital

Office of the Medical Director – EMS System for Metropolitan Oklahoma City & Tulsa Approved by: Jeffrey M. Goodloe, MD, NREMT-P, FACEP, Medical Director Effective: 1/15/2025; CQI data collection procedure



## TRANSMITTING CARDIAC ARREST MONITOR DATA ADULT & PEDIATRIC



### Indications:

1. Cardiac Arrest, regardless of etiology.

### Contraindications:

None

### Technique (LifePak® 15):

To transmit the cardiac arrest data for resuscitation CQI:

- In the OPTIONS window select Patient, scroll down to Incident and place the last five digits of the RUN number of the cardiac arrest into the OPTIONS/PATIENT/INCIDENT window. (Figure 1)
- 2. In the **TRANSMIT** window, Report selection **MUST** be "**All**" when transmitting data from the LifePak to CodeSTAT or your Electronic Health Care Record. Any other selection will not transmit a complete data PCO file for analytics. (Figure 2)
- 3. In the **TRANSMIT** window, select **SITE**. (Figure 3)
- 4. In the **SITE** window, select **CODE STAT**. (Figure 4)
- 5. In the **TRANSMIT** window, select **SEND**. (Figure 5)
- 6. The LifePak®15 should connect to the selected destination.
- 7. Once the transmission is completed a transaction message is automatically printed.
- 8. If the transmission fails, make additional attempts at transmission until successful. If unsuccessful, contact the Clinical Officer of the Day or Supervisor.

